#0
0	Here	O	['N']	[0]
1	we	O	['N']	[1]
2	present	O	['N']	[2]
3	the	O	['N']	[3]
4	case	O	['N']	[4]
5	of	O	['N']	[5]
6	a	O	['N']	[6]
7	generalized	B	['N']	[7]
8	lichen	I	['N']	[8]
9	nitidus	I-Adverse_Effect	['N']	[9]
10	with	O	['N']	[10]
11	involvement	O	['N']	[11]
12	of	O	['N']	[12]
13	the	O	['N']	[13]
14	palms	O	['N']	[14]
15	in	O	['N']	[15]
16	a	O	['N']	[16]
17	patient	O	['N']	[17]
18	with	O	['N']	[18]
19	hepatitis	O	['N']	[19]
20	C	O	['N']	[20]
21	after	O	['N']	[21]
22	systemic	O	['N']	[22]
23	treatment	O	['N']	[23]
24	with	O	['N']	[24]
25	interferon	B	['N']	[25]
26	alpha	I-Drug	['Causes']	[9]
27	and	O	['N']	[27]
28	ribavirin	O	['N']	[28]
29	.	O	['N']	[29]
#1
0	A	O	['N']	[0]
1	young	O	['N']	[1]
2	woman	O	['N']	[2]
3	with	O	['N']	[3]
4	epilepsy	O	['N']	[4]
5	had	O	['N']	[5]
6	tonic	B	['N']	[6]
7	-	I	['N']	[7]
8	clonic	I	['N']	[8]
9	seizures	I-Adverse_Effect	['N']	[9]
10	during	O	['N']	[10]
11	antineoplastic	O	['N']	[11]
12	therapy	O	['N']	[12]
13	with	O	['N']	[13]
14	adriamycin	B-Drug	['Causes']	[9]
15	and	O	['N']	[15]
16	cisplatin	O	['N']	[16]
17	.	O	['N']	[17]
#2
0	Flutamide	O	['N']	[0]
1	withdrawal	O	['N']	[1]
2	syndrome	O	['N']	[2]
3	is	O	['N']	[3]
4	characterized	O	['N']	[4]
5	by	O	['N']	[5]
6	a	O	['N']	[6]
7	decrease	B	['N']	[7]
8	in	I	['N']	[8]
9	prostate	I	['N']	[9]
10	-	I	['N']	[10]
11	specific	I	['N']	[11]
12	antigen	I-Adverse_Effect	['N']	[12]
13	(	O	['N']	[13]
14	PSA	O	['N']	[14]
15	)	O	['N']	[15]
16	after	O	['N']	[16]
17	flutamide	B-Drug	['Causes']	[12]
18	withdrawal	O	['N']	[18]
19	in	O	['N']	[19]
20	a	O	['N']	[20]
21	subset	O	['N']	[21]
22	of	O	['N']	[22]
23	patients	O	['N']	[23]
24	with	O	['N']	[24]
25	progressing	O	['N']	[25]
26	metastatic	O	['N']	[26]
27	carcinoma	O	['N']	[27]
28	of	O	['N']	[28]
29	the	O	['N']	[29]
30	prostate	O	['N']	[30]
31	.	O	['N']	[31]
#3
0	Continuous	O	['N']	[0]
1	EEG	O	['N']	[1]
2	monitoring	O	['N']	[2]
3	is	O	['N']	[3]
4	helpful	O	['N']	[4]
5	in	O	['N']	[5]
6	managing	O	['N']	[6]
7	seizures	O	['N']	[7]
8	that	O	['N']	[8]
9	occur	O	['N']	[9]
10	as	O	['N']	[10]
11	a	O	['N']	[11]
12	complication	O	['N']	[12]
13	of	O	['N']	[13]
14	CBZ	B-Drug	['Dosage']	[15]
15	OD	B-Dose	['N']	[15]
16	,	O	['N']	[16]
17	after	O	['N']	[17]
18	the	O	['N']	[18]
19	course	O	['N']	[19]
20	of	O	['N']	[20]
21	recovery	O	['N']	[21]
22	or	O	['N']	[22]
23	worsening	O	['N']	[23]
24	,	O	['N']	[24]
25	and	O	['N']	[25]
26	in	O	['N']	[26]
27	providing	O	['N']	[27]
28	assistance	O	['N']	[28]
29	with	O	['N']	[29]
30	prognosis	O	['N']	[30]
31	.	O	['N']	[31]
#4
0	After	O	['N']	[0]
1	three	O	['N']	[1]
2	weeks	O	['N']	[2]
3	of	O	['N']	[3]
4	carbamazepine	B-Drug	['Causes']	[22]
5	therapy	O	['N']	[5]
6	,	O	['N']	[6]
7	the	O	['N']	[7]
8	patient	O	['N']	[8]
9	arrived	O	['N']	[9]
10	at	O	['N']	[10]
11	the	O	['N']	[11]
12	emergency	O	['N']	[12]
13	department	O	['N']	[13]
14	(	O	['N']	[14]
15	ED	O	['N']	[15]
16	)	O	['N']	[16]
17	with	O	['N']	[17]
18	severe	O	['N']	[18]
19	agitation	O	['N']	[19]
20	and	O	['N']	[20]
21	aggressive	B	['N']	[21]
22	behavior	I-Adverse_Effect	['N']	[22]
23	.	O	['N']	[23]
#5
0	Mitomycin	O	['N']	[0]
1	C	O	['N']	[1]
2	(	O	['N']	[2]
3	MMC	B-Drug	['Causes']	[21]
4	)	O	['N']	[4]
5	is	O	['N']	[5]
6	an	O	['N']	[6]
7	alkylating	O	['N']	[7]
8	agent	O	['N']	[8]
9	that	O	['N']	[9]
10	has	O	['N']	[10]
11	been	O	['N']	[11]
12	recently	O	['N']	[12]
13	associated	O	['N']	[13]
14	with	O	['N']	[14]
15	the	O	['N']	[15]
16	hemolytic	O	['N']	[16]
17	-	O	['N']	[17]
18	uremic	O	['N']	[18]
19	syndrome	O	['N']	[19]
20	(	O	['N']	[20]
21	HUS	B-Adverse_Effect	['N']	[21]
22	)	O	['N']	[22]
23	.	O	['N']	[23]
#6
0	Acute	B	['N']	[0]
1	neutrophilic	I	['N']	[1]
2	dermatosis	I-Adverse_Effect	['N']	[2]
3	induced	O	['N']	[3]
4	by	O	['N']	[4]
5	all	B	['N']	[5]
6	-	I	['N']	[6]
7	trans	I	['N']	[7]
8	-	I	['N']	[8]
9	retinoic	I	['N']	[9]
10	acid	I-Drug	['Causes']	[2]
11	treatment	O	['N']	[11]
12	for	O	['N']	[12]
13	acute	O	['N']	[13]
14	promyelocytic	O	['N']	[14]
15	leukemia	O	['N']	[15]
16	.	O	['N']	[16]
#7
0	Transient	B	['N']	[0]
1	asymptomatic	I	['N']	[1]
2	bradycardia	I-Adverse_Effect	['N']	[2]
3	in	O	['N']	[3]
4	patients	O	['N']	[4]
5	on	O	['N']	[5]
6	infusional	O	['N']	[6]
7	5-fluorouracil	B-Drug	['Causes']	[2]
8	.	O	['N']	[8]
#8
0	A	O	['N']	[0]
1	sixty	O	['N']	[1]
2	-	O	['N']	[2]
3	year	O	['N']	[3]
4	-	O	['N']	[4]
5	old	O	['N']	[5]
6	woman	O	['N']	[6]
7	with	O	['N']	[7]
8	advanced	O	['N']	[8]
9	breast	O	['N']	[9]
10	cancer	O	['N']	[10]
11	,	O	['N']	[11]
12	previously	O	['N']	[12]
13	treated	O	['N']	[13]
14	with	O	['N']	[14]
15	cisplatin	O	['N']	[15]
16	,	O	['N']	[16]
17	developed	O	['N']	[17]
18	an	O	['N']	[18]
19	irreversible	O	['N']	[19]
20	lethal	O	['N']	[20]
21	renal	O	['N']	[21]
22	failure	O	['N']	[22]
23	with	O	['N']	[23]
24	anuria	O	['N']	[24]
25	,	O	['N']	[25]
26	the	O	['N']	[26]
27	day	O	['N']	[27]
28	after	O	['N']	[28]
29	5	B	['N']	[29]
30	g	I	['N']	[30]
31	/	I	['N']	[31]
32	m2	I-Dose	['N']	[32]
33	bolus	O	['N']	[33]
34	ifosfamide	B-Drug	['Dosage']	[32]
35	.	O	['N']	[35]
#9
0	Methotrexate	B-Drug	['Causes']	[32]
1	(	O	['N']	[1]
2	MTX	O	['N']	[2]
3	)	O	['N']	[3]
4	is	O	['N']	[4]
5	a	O	['N']	[5]
6	commonly	O	['N']	[6]
7	used	O	['N']	[7]
8	second	O	['N']	[8]
9	line	O	['N']	[9]
10	agent	O	['N']	[10]
11	for	O	['N']	[11]
12	RA	O	['N']	[12]
13	,	O	['N']	[13]
14	and	O	['N']	[14]
15	there	O	['N']	[15]
16	have	O	['N']	[16]
17	been	O	['N']	[17]
18	several	O	['N']	[18]
19	recent	O	['N']	[19]
20	reports	O	['N']	[20]
21	of	O	['N']	[21]
22	Epstein	B	['N']	[22]
23	-	I	['N']	[23]
24	Barr	I	['N']	[24]
25	virus	I	['N']	[25]
26	(	I	['N']	[26]
27	EBV)-associated	I	['N']	[27]
28	polyclonal	I	['N']	[28]
29	B	I	['N']	[29]
30	cell	I	['N']	[30]
31	lymphoproliferative	I	['N']	[31]
32	disorder	I-Adverse_Effect	['N']	[32]
33	in	O	['N']	[33]
34	MTX	O	['N']	[34]
35	-	O	['N']	[35]
36	treated	O	['N']	[36]
37	RA	O	['N']	[37]
38	patients	O	['N']	[38]
39	.	O	['N']	[39]
#10
0	Ulcer	B	['N']	[0]
1	became	I	['N']	[1]
2	worse	I-Adverse_Effect	['N']	[2]
3	after	O	['N']	[3]
4	tobramycin	B-Drug	['Causes']	[2]
5	and	O	['N']	[5]
6	gentamycin	O	['N']	[6]
7	treatment	O	['N']	[7]
8	for	O	['N']	[8]
9	2	O	['N']	[9]
10	days	O	['N']	[10]
11	.	O	['N']	[11]
#11
0	Amphotericin	B	['N']	[0]
1	B	I-Drug	['Causes']	[17]
2	(	O	['N']	[2]
3	AmB	O	['N']	[3]
4	)	O	['N']	[4]
5	is	O	['N']	[5]
6	effective	O	['N']	[6]
7	,	O	['N']	[7]
8	but	O	['N']	[8]
9	its	O	['N']	[9]
10	use	O	['N']	[10]
11	is	O	['N']	[11]
12	limited	O	['N']	[12]
13	by	O	['N']	[13]
14	toxicity	O	['N']	[14]
15	:	O	['N']	[15]
16	renal	B	['N']	[16]
17	impairment	I-Adverse_Effect	['N']	[17]
18	,	O	['N']	[18]
19	anaemia	O	['N']	[19]
20	,	O	['N']	[20]
21	fever	O	['N']	[21]
22	,	O	['N']	[22]
23	malaise	O	['N']	[23]
24	,	O	['N']	[24]
25	and	O	['N']	[25]
26	hypokalaemia	O	['N']	[26]
27	are	O	['N']	[27]
28	common	O	['N']	[28]
29	.	O	['N']	[29]
#12
0	The	O	['N']	[0]
1	first	O	['N']	[1]
2	case	O	['N']	[2]
3	concerns	O	['N']	[3]
4	a	O	['N']	[4]
5	70-year	O	['N']	[5]
6	-	O	['N']	[6]
7	old	O	['N']	[7]
8	man	O	['N']	[8]
9	who	O	['N']	[9]
10	developed	O	['N']	[10]
11	severe	O	['N']	[11]
12	aplastic	O	['N']	[12]
13	anemia	O	['N']	[13]
14	7	O	['N']	[14]
15	weeks	O	['N']	[15]
16	after	O	['N']	[16]
17	treatment	O	['N']	[17]
18	with	O	['N']	[18]
19	500	B	['N']	[19]
20	mg	I-Dose	['N']	[20]
21	of	O	['N']	[21]
22	ticlopidine	B-Drug	['Dosage']	[20]
23	daily	O	['N']	[23]
24	.	O	['N']	[24]
#13
0	Peripheral	B	['N']	[0]
1	nervous	I	['N']	[1]
2	system	I	['N']	[2]
3	disturbances	I-Adverse_Effect	['N']	[3]
4	caused	O	['N']	[4]
5	by	O	['N']	[5]
6	cytosine	B	['N']	[6]
7	arabinoside	I-Drug	['Causes']	[3]
8	have	O	['N']	[8]
9	rarely	O	['N']	[9]
10	been	O	['N']	[10]
11	reported	O	['N']	[11]
12	.	O	['N']	[12]
#14
0	The	O	['N']	[0]
1	present	O	['N']	[1]
2	case	O	['N']	[2]
3	is	O	['N']	[3]
4	the	O	['N']	[4]
5	first	O	['N']	[5]
6	report	O	['N']	[6]
7	of	O	['N']	[7]
8	hypercalcemia	B-Adverse_Effect	['N']	[8]
9	induced	O	['N']	[9]
10	by	O	['N']	[10]
11	vitamin	O	['N']	[11]
12	D3	O	['N']	[12]
13	ointment	O	['N']	[13]
14	and	O	['N']	[14]
15	thiazide	B-Drug	['Causes']	[8]
16	simultaneously	O	['N']	[16]
17	.	O	['N']	[17]
#15
0	Two	O	['N']	[0]
1	of	O	['N']	[1]
2	the	O	['N']	[2]
3	five	O	['N']	[3]
4	patients	O	['N']	[4]
5	who	O	['N']	[5]
6	worsened	B	['N']	[6]
7	motorically	I-Adverse_Effect	['N']	[7]
8	also	O	['N']	[8]
9	developed	O	['N']	[9]
10	encephalopathy	O	['N']	[10]
11	during	O	['N']	[11]
12	risperidone	B-Drug	['Causes']	[7]
13	treatment	O	['N']	[13]
14	;	O	['N']	[14]
15	the	O	['N']	[15]
16	encephalopathy	O	['N']	[16]
17	resolved	O	['N']	[17]
18	when	O	['N']	[18]
19	the	O	['N']	[19]
20	patients	O	['N']	[20]
21	were	O	['N']	[21]
22	switched	O	['N']	[22]
23	to	O	['N']	[23]
24	clozapine	O	['N']	[24]
25	treatment	O	['N']	[25]
26	.	O	['N']	[26]
#16
0	The	O	['N']	[0]
1	patient	O	['N']	[1]
2	presented	O	['N']	[2]
3	with	O	['N']	[3]
4	fulminant	B	['N']	[4]
5	microangiopathic	I	['N']	[5]
6	hemolytic	I	['N']	[6]
7	anemia	I-Adverse_Effect	['N']	[7]
8	and	O	['N']	[8]
9	thrombocytopenia	O	['N']	[9]
10	within	O	['N']	[10]
11	48	O	['N']	[11]
12	hr	O	['N']	[12]
13	of	O	['N']	[13]
14	initiating	O	['N']	[14]
15	therapy	O	['N']	[15]
16	with	O	['N']	[16]
17	trimethoprim	O	['N']	[17]
18	-	O	['N']	[18]
19	sulfamethoxazole	B-Drug	['Causes']	[7]
20	.	O	['N']	[20]
#17
0	We	O	['N']	[0]
1	present	O	['N']	[1]
2	a	O	['N']	[2]
3	depressive	O	['N']	[3]
4	patient	O	['N']	[4]
5	who	O	['N']	[5]
6	developed	O	['N']	[6]
7	mild	O	['N']	[7]
8	parkinsonian	O	['N']	[8]
9	signs	O	['N']	[9]
10	and	O	['N']	[10]
11	camptocormia	B-Adverse_Effect	['N']	[11]
12	after	O	['N']	[12]
13	the	O	['N']	[13]
14	introduction	O	['N']	[14]
15	of	O	['N']	[15]
16	olanzapine	B-Drug	['Causes']	[11]
17	.	O	['N']	[17]
#18
0	After	O	['N']	[0]
1	initiation	O	['N']	[1]
2	of	O	['N']	[2]
3	topical	O	['N']	[3]
4	vitamin	B	['N']	[4]
5	D3	I-Drug	['Dosage']	[12]
6	ointment	O	['N']	[6]
7	(	O	['N']	[7]
8	20	B	['N']	[8]
9	micro	I	['N']	[9]
10	g	I	['N']	[10]
11	/	I	['N']	[11]
12	g	I-Dose	['N']	[12]
13	of	O	['N']	[13]
14	tacalcitol	O	['N']	[14]
15	)	O	['N']	[15]
16	10	O	['N']	[16]
17	g	O	['N']	[17]
18	/	O	['N']	[18]
19	day	O	['N']	[19]
20	for	O	['N']	[20]
21	the	O	['N']	[21]
22	skin	O	['N']	[22]
23	lesions	O	['N']	[23]
24	,	O	['N']	[24]
25	both	O	['N']	[25]
26	the	O	['N']	[26]
27	serum	O	['N']	[27]
28	level	O	['N']	[28]
29	of	O	['N']	[29]
30	calcium	O	['N']	[30]
31	and	O	['N']	[31]
32	urinary	O	['N']	[32]
33	excretion	O	['N']	[33]
34	of	O	['N']	[34]
35	calcium	O	['N']	[35]
36	increased	O	['N']	[36]
37	gradually	O	['N']	[37]
38	.	O	['N']	[38]
#19
0	A	O	['N']	[0]
1	combination	O	['N']	[1]
2	of	O	['N']	[2]
3	behavioural	O	['N']	[3]
4	and	O	['N']	[4]
5	cognitive	O	['N']	[5]
6	adverse	O	['N']	[6]
7	effects	O	['N']	[7]
8	is	O	['N']	[8]
9	illustrated	O	['N']	[9]
10	in	O	['N']	[10]
11	this	O	['N']	[11]
12	case	O	['N']	[12]
13	report	O	['N']	[13]
14	of	O	['N']	[14]
15	a	O	['N']	[15]
16	recurrent	O	['N']	[16]
17	triazolam	B-Drug	['Causes']	[21]
18	-	O	['N']	[18]
19	induced	O	['N']	[19]
20	eating	B	['N']	[20]
21	disorder	I-Adverse_Effect	['N']	[21]
22	.	O	['N']	[22]
#20
0	A	O	['N']	[0]
1	transient	B	['N']	[1]
2	tonic	I	['N']	[2]
3	pupillary	I	['N']	[3]
4	response	I-Adverse_Effect	['N']	[4]
5	,	O	['N']	[5]
6	denervation	O	['N']	[6]
7	supersensitivity	O	['N']	[7]
8	,	O	['N']	[8]
9	and	O	['N']	[9]
10	abnormal	O	['N']	[10]
11	visual	O	['N']	[11]
12	-	O	['N']	[12]
13	evoked	O	['N']	[13]
14	potentials	O	['N']	[14]
15	in	O	['N']	[15]
16	quinine	B-Drug	['Causes']	[4]
17	toxicity	O	['N']	[17]
18	,	O	['N']	[18]
19	to	O	['N']	[19]
20	our	O	['N']	[20]
21	knowledge	O	['N']	[21]
22	,	O	['N']	[22]
23	have	O	['N']	[23]
24	not	O	['N']	[24]
25	been	O	['N']	[25]
26	previously	O	['N']	[26]
27	reported	O	['N']	[27]
28	.	O	['N']	[28]
#21
0	OBJECTIVE	O	['N']	[0]
1	:	O	['N']	[1]
2	To	O	['N']	[2]
3	report	O	['N']	[3]
4	the	O	['N']	[4]
5	late	O	['N']	[5]
6	development	O	['N']	[6]
7	of	O	['N']	[7]
8	immune	B	['N']	[8]
9	-	I	['N']	[9]
10	mediated	I	['N']	[10]
11	diabetes	I	['N']	[11]
12	mellitus	I-Adverse_Effect	['N']	[12]
13	after	O	['N']	[13]
14	completion	O	['N']	[14]
15	of	O	['N']	[15]
16	alfa	B	['N']	[16]
17	-	I	['N']	[17]
18	interferon	I-Drug	['Causes']	[12]
19	therapy	O	['N']	[19]
20	for	O	['N']	[20]
21	hepatitis	O	['N']	[21]
22	C	O	['N']	[22]
23	in	O	['N']	[23]
24	an	O	['N']	[24]
25	Asian	O	['N']	[25]
26	patient	O	['N']	[26]
27	.	O	['N']	[27]
#22
0	A	O	['N']	[0]
1	patient	O	['N']	[1]
2	that	O	['N']	[2]
3	received	O	['N']	[3]
4	methadone	B-Drug	['Causes']	[11]
5	for	O	['N']	[5]
6	cancer	O	['N']	[6]
7	-	O	['N']	[7]
8	associated	O	['N']	[8]
9	pain	O	['N']	[9]
10	developed	O	['N']	[10]
11	myoclonus	B-Adverse_Effect	['N']	[11]
12	as	O	['N']	[12]
13	a	O	['N']	[13]
14	side	O	['N']	[14]
15	effect	O	['N']	[15]
16	.	O	['N']	[16]
#23
0	Herpes	B	['N']	[0]
1	simplex	I	['N']	[1]
2	esophagitis	I-Adverse_Effect	['N']	[2]
3	in	O	['N']	[3]
4	a	O	['N']	[4]
5	renal	O	['N']	[5]
6	transplant	O	['N']	[6]
7	patient	O	['N']	[7]
8	treated	O	['N']	[8]
9	with	O	['N']	[9]
10	cyclosporine	B	['N']	[10]
11	A	I-Drug	['Causes']	[2]
12	:	O	['N']	[12]
13	a	O	['N']	[13]
14	case	O	['N']	[14]
15	report	O	['N']	[15]
16	.	O	['N']	[16]
#24
0	A	O	['N']	[0]
1	62-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	Indian	O	['N']	[4]
5	with	O	['N']	[5]
6	diabetic	O	['N']	[6]
7	nephropathy	O	['N']	[7]
8	controlled	O	['N']	[8]
9	with	O	['N']	[9]
10	metformin	B-Drug	['Causes']	[14]
11	,	O	['N']	[11]
12	developed	O	['N']	[12]
13	miliary	B	['N']	[13]
14	tuberculosis	I-Adverse_Effect	['N']	[14]
15	for	O	['N']	[15]
16	which	O	['N']	[16]
17	he	O	['N']	[17]
18	was	O	['N']	[18]
19	treated	O	['N']	[19]
20	with	O	['N']	[20]
21	rifampicin	O	['N']	[21]
22	,	O	['N']	[22]
23	isoniazid	O	['N']	[23]
24	and	O	['N']	[24]
25	ethambutol	O	['N']	[25]
26	.	O	['N']	[26]
#25
0	Meperidine	B-Drug	['Causes']	[10]
1	-	O	['N']	[1]
2	associated	O	['N']	[2]
3	central	B	['N']	[3]
4	nervous	I	['N']	[4]
5	system	I	['N']	[5]
6	(	I	['N']	[6]
7	CNS	I	['N']	[7]
8	)	I	['N']	[8]
9	excitatory	I	['N']	[9]
10	toxicities	I-Adverse_Effect	['N']	[10]
11	are	O	['N']	[11]
12	believed	O	['N']	[12]
13	to	O	['N']	[13]
14	be	O	['N']	[14]
15	caused	O	['N']	[15]
16	by	O	['N']	[16]
17	accumulation	O	['N']	[17]
18	of	O	['N']	[18]
19	the	O	['N']	[19]
20	active	O	['N']	[20]
21	metabolite	O	['N']	[21]
22	normeperidine	O	['N']	[22]
23	.	O	['N']	[23]
#26
0	Transfusion	B	['N']	[0]
1	haemosiderosis	I-Adverse_Effect	['N']	[1]
2	inspite	O	['N']	[2]
3	of	O	['N']	[3]
4	regular	O	['N']	[4]
5	use	O	['N']	[5]
6	of	O	['N']	[6]
7	desferrioxamine	B-Drug	['Causes']	[1]
8	:	O	['N']	[8]
9	case	O	['N']	[9]
10	report	O	['N']	[10]
11	.	O	['N']	[11]
#27
0	Fatal	B	['N']	[0]
1	eosinophilia	I	['N']	[1]
2	myalgia	I	['N']	[2]
3	syndrome	I-Adverse_Effect	['N']	[3]
4	in	O	['N']	[4]
5	a	O	['N']	[5]
6	marrow	O	['N']	[6]
7	transplant	O	['N']	[7]
8	patient	O	['N']	[8]
9	attributed	O	['N']	[9]
10	to	O	['N']	[10]
11	total	O	['N']	[11]
12	parenteral	O	['N']	[12]
13	nutrition	O	['N']	[13]
14	with	O	['N']	[14]
15	a	O	['N']	[15]
16	solution	O	['N']	[16]
17	containing	O	['N']	[17]
18	tryptophan	B-Drug	['Causes']	[3]
19	.	O	['N']	[19]
#28
0	Aminoglutethimide	B-Drug	['Causes']	[10]
1	was	O	['N']	[1]
2	discontinued	O	['N']	[2]
3	until	O	['N']	[3]
4	completion	O	['N']	[4]
5	of	O	['N']	[5]
6	radiotherapy	O	['N']	[6]
7	,	O	['N']	[7]
8	and	O	['N']	[8]
9	the	O	['N']	[9]
10	rash	B-Adverse_Effect	['N']	[10]
11	resolved	O	['N']	[11]
12	.	O	['N']	[12]
#29
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	patient	O	['N']	[3]
4	who	O	['N']	[4]
5	developed	O	['N']	[5]
6	acute	B	['N']	[6]
7	pancreatitis	I-Adverse_Effect	['N']	[7]
8	during	O	['N']	[8]
9	amiodarone	B-Drug	['Causes']	[7]
10	therapy	O	['N']	[10]
11	.	O	['N']	[11]
#30
0	CASE	O	['N']	[0]
1	SUMMARIES	O	['N']	[1]
2	:	O	['N']	[2]
3	In	O	['N']	[3]
4	each	O	['N']	[4]
5	case	O	['N']	[5]
6	,	O	['N']	[6]
7	the	O	['N']	[7]
8	patients	O	['N']	[8]
9	were	O	['N']	[9]
10	treated	O	['N']	[10]
11	over	O	['N']	[11]
12	5	O	['N']	[12]
13	years	O	['N']	[13]
14	with	O	['N']	[14]
15	lovastatin	B-Drug	['Causes']	[18]
16	and	O	['N']	[16]
17	developed	O	['N']	[17]
18	rhabdomyolysis	B-Adverse_Effect	['N']	[18]
19	that	O	['N']	[19]
20	coincided	O	['N']	[20]
21	with	O	['N']	[21]
22	the	O	['N']	[22]
23	completion	O	['N']	[23]
24	of	O	['N']	[24]
25	a	O	['N']	[25]
26	prescribed	O	['N']	[26]
27	regimen	O	['N']	[27]
28	of	O	['N']	[28]
29	a	O	['N']	[29]
30	newer	O	['N']	[30]
31	macrolide	O	['N']	[31]
32	antibiotic	O	['N']	[32]
33	.	O	['N']	[33]
#31
0	DIAGNOSIS	O	['N']	[0]
1	:	O	['N']	[1]
2	Interferon	B	['N']	[2]
3	alpha-2b	I-Drug	['Causes']	[6]
4	-	O	['N']	[4]
5	induced	O	['N']	[5]
6	cardiomyopathy	B-Adverse_Effect	['N']	[6]
7	.	O	['N']	[7]
#32
0	Possible	O	['N']	[0]
1	interaction	O	['N']	[1]
2	between	O	['N']	[2]
3	lopinavir	O	['N']	[3]
4	/	O	['N']	[4]
5	ritonavir	O	['N']	[5]
6	and	O	['N']	[6]
7	valproic	B	['N']	[7]
8	Acid	I-Drug	['Causes']	[11]
9	exacerbates	O	['N']	[9]
10	bipolar	B	['N']	[10]
11	disorder	I-Adverse_Effect	['N']	[11]
12	.	O	['N']	[12]
#33
0	In	O	['N']	[0]
1	this	O	['N']	[1]
2	paper	O	['N']	[2]
3	,	O	['N']	[3]
4	we	O	['N']	[4]
5	report	O	['N']	[5]
6	a	O	['N']	[6]
7	case	O	['N']	[7]
8	of	O	['N']	[8]
9	severe	B	['N']	[9]
10	hypercalcemia	I-Adverse_Effect	['N']	[10]
11	of	O	['N']	[11]
12	immobilization	O	['N']	[12]
13	in	O	['N']	[13]
14	a	O	['N']	[14]
15	40-year	O	['N']	[15]
16	-	O	['N']	[16]
17	old	O	['N']	[17]
18	hemodialyzed	O	['N']	[18]
19	woman	O	['N']	[19]
20	treated	O	['N']	[20]
21	by	O	['N']	[21]
22	cinacalcet	B	['N']	[22]
23	HCl	I-Drug	['Causes']	[10]
24	for	O	['N']	[24]
25	a	O	['N']	[25]
26	severe	O	['N']	[26]
27	HPTH	O	['N']	[27]
28	-	O	['N']	[28]
29	II	O	['N']	[29]
30	(	O	['N']	[30]
31	PTH>1,000	O	['N']	[31]
32	pg	O	['N']	[32]
33	/	O	['N']	[33]
34	mL	O	['N']	[34]
35	)	O	['N']	[35]
36	.	O	['N']	[36]
#34
0	CONCLUSION	O	['N']	[0]
1	:	O	['N']	[1]
2	This	O	['N']	[2]
3	report	O	['N']	[3]
4	describes	O	['N']	[4]
5	a	O	['N']	[5]
6	case	O	['N']	[6]
7	of	O	['N']	[7]
8	a	O	['N']	[8]
9	probable	O	['N']	[9]
10	interaction	O	['N']	[10]
11	between	O	['N']	[11]
12	topical	O	['N']	[12]
13	econazole	O	['N']	[13]
14	lotion	O	['N']	[14]
15	1	O	['N']	[15]
16	%	O	['N']	[16]
17	and	O	['N']	[17]
18	acenocoumarol	B-Drug	['Causes']	[29]
19	that	O	['N']	[19]
20	resulted	O	['N']	[20]
21	in	O	['N']	[21]
22	overanticoagulation	O	['N']	[22]
23	and	O	['N']	[23]
24	a	O	['N']	[24]
25	life	O	['N']	[25]
26	-	O	['N']	[26]
27	threatening	O	['N']	[27]
28	laryngeal	B	['N']	[28]
29	hematoma	I-Adverse_Effect	['N']	[29]
30	in	O	['N']	[30]
31	this	O	['N']	[31]
32	elderly	O	['N']	[32]
33	patient	O	['N']	[33]
34	.	O	['N']	[34]
#35
0	Administration	O	['N']	[0]
1	of	O	['N']	[1]
2	pyridoxine	B-Drug	['Causes']	[16]
3	to	O	['N']	[3]
4	an	O	['N']	[4]
5	infant	O	['N']	[5]
6	after	O	['N']	[6]
7	a	O	['N']	[7]
8	long	O	['N']	[8]
9	period	O	['N']	[9]
10	of	O	['N']	[10]
11	convulsions	O	['N']	[11]
12	was	O	['N']	[12]
13	followed	O	['N']	[13]
14	by	O	['N']	[14]
15	acute	B	['N']	[15]
16	hypotonia	I-Adverse_Effect	['N']	[16]
17	.	O	['N']	[17]
#36
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	an	O	['N']	[2]
3	HIV	O	['N']	[3]
4	-	O	['N']	[4]
5	infected	O	['N']	[5]
6	woman	O	['N']	[6]
7	who	O	['N']	[7]
8	developed	O	['N']	[8]
9	mild	O	['N']	[9]
10	leukopenia	B-Adverse_Effect	['N']	[10]
11	as	O	['N']	[11]
12	the	O	['N']	[12]
13	first	O	['N']	[13]
14	sign	O	['N']	[14]
15	of	O	['N']	[15]
16	a	O	['N']	[16]
17	nevirapine	B-Drug	['Causes']	[10]
18	-	O	['N']	[18]
19	related	O	['N']	[19]
20	adverse	O	['N']	[20]
21	event	O	['N']	[21]
22	,	O	['N']	[22]
23	which	O	['N']	[23]
24	was	O	['N']	[24]
25	followed	O	['N']	[25]
26	by	O	['N']	[26]
27	skin	O	['N']	[27]
28	and	O	['N']	[28]
29	hepatic	O	['N']	[29]
30	toxicity	O	['N']	[30]
31	associated	O	['N']	[31]
32	with	O	['N']	[32]
33	a	O	['N']	[33]
34	more	O	['N']	[34]
35	severe	O	['N']	[35]
36	leukopenia	O	['N']	[36]
37	.	O	['N']	[37]
#37
0	This	O	['N']	[0]
1	case	O	['N']	[1]
2	of	O	['N']	[2]
3	linezolid	B-Drug	['Causes']	[20]
4	-	O	['N']	[4]
5	associated	O	['N']	[5]
6	acute	O	['N']	[6]
7	interstitial	O	['N']	[7]
8	nephritis	O	['N']	[8]
9	within	O	['N']	[9]
10	the	O	['N']	[10]
11	context	O	['N']	[11]
12	of	O	['N']	[12]
13	a	O	['N']	[13]
14	drug	B	['N']	[14]
15	rash	I	['N']	[15]
16	with	I	['N']	[16]
17	eosinophilia	I	['N']	[17]
18	and	I	['N']	[18]
19	systemic	I	['N']	[19]
20	symptoms	I-Adverse_Effect	['N']	[20]
21	(	O	['N']	[21]
22	DRESS	O	['N']	[22]
23	)	O	['N']	[23]
24	syndrome	O	['N']	[24]
25	in	O	['N']	[25]
26	a	O	['N']	[26]
27	patient	O	['N']	[27]
28	treated	O	['N']	[28]
29	with	O	['N']	[29]
30	linezolid	O	['N']	[30]
31	raises	O	['N']	[31]
32	concerns	O	['N']	[32]
33	about	O	['N']	[33]
34	the	O	['N']	[34]
35	presumed	O	['N']	[35]
36	renal	O	['N']	[36]
37	safety	O	['N']	[37]
38	of	O	['N']	[38]
39	this	O	['N']	[39]
40	drug	O	['N']	[40]
41	.	O	['N']	[41]
#38
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	with	O	['N']	[4]
5	chronic	O	['N']	[5]
6	hepatitis	O	['N']	[6]
7	C	O	['N']	[7]
8	(	O	['N']	[8]
9	CHC	O	['N']	[9]
10	)	O	['N']	[10]
11	who	O	['N']	[11]
12	developed	O	['N']	[12]
13	sarcoidosis	B-Adverse_Effect	['N']	[13]
14	after	O	['N']	[14]
15	the	O	['N']	[15]
16	treatment	O	['N']	[16]
17	by	O	['N']	[17]
18	interferon	B	['N']	[18]
19	alpha	I-Drug	['Causes']	[13]
20	and	O	['N']	[20]
21	ribavirin	O	['N']	[21]
22	.	O	['N']	[22]
#39
0	Controversy	O	['N']	[0]
1	concerning	O	['N']	[1]
2	the	O	['N']	[2]
3	nephrotoxicity	B-Adverse_Effect	['N']	[3]
4	of	O	['N']	[4]
5	lithium	B-Drug	['Causes']	[3]
6	is	O	['N']	[6]
7	discussed	O	['N']	[7]
8	,	O	['N']	[8]
9	and	O	['N']	[9]
10	recommendations	O	['N']	[10]
11	for	O	['N']	[11]
12	the	O	['N']	[12]
13	evaluation	O	['N']	[13]
14	of	O	['N']	[14]
15	renal	O	['N']	[15]
16	failure	O	['N']	[16]
17	during	O	['N']	[17]
18	lithium	O	['N']	[18]
19	therapy	O	['N']	[19]
20	are	O	['N']	[20]
21	provided	O	['N']	[21]
22	.	O	['N']	[22]
#40
0	Escape	O	['N']	[0]
1	atrial	O	['N']	[1]
2	complexes	O	['N']	[2]
3	,	O	['N']	[3]
4	which	O	['N']	[4]
5	occurred	O	['N']	[5]
6	following	O	['N']	[6]
7	junctional	O	['N']	[7]
8	premature	O	['N']	[8]
9	complexes	O	['N']	[9]
10	,	O	['N']	[10]
11	failed	O	['N']	[11]
12	to	O	['N']	[12]
13	initiate	O	['N']	[13]
14	tachycardia	B-Adverse_Effect	['N']	[14]
15	in	O	['N']	[15]
16	the	O	['N']	[16]
17	control	O	['N']	[17]
18	state	O	['N']	[18]
19	but	O	['N']	[19]
20	tachycardia	O	['N']	[20]
21	was	O	['N']	[21]
22	always	O	['N']	[22]
23	reinitiated	O	['N']	[23]
24	by	O	['N']	[24]
25	an	O	['N']	[25]
26	identical	O	['N']	[26]
27	escape	O	['N']	[27]
28	sequence	O	['N']	[28]
29	after	O	['N']	[29]
30	procainamide	B-Drug	['Causes']	[14]
31	.	O	['N']	[31]
#41
0	Acute	B	['N']	[0]
1	myeloid	I	['N']	[1]
2	leukemia	I-Adverse_Effect	['N']	[2]
3	evolving	O	['N']	[3]
4	from	O	['N']	[4]
5	essential	O	['N']	[5]
6	thrombocythemia	O	['N']	[6]
7	in	O	['N']	[7]
8	two	O	['N']	[8]
9	patients	O	['N']	[9]
10	treated	O	['N']	[10]
11	with	O	['N']	[11]
12	hydroxyurea	B-Drug	['Causes']	[2]
13	.	O	['N']	[13]
#42
0	Two	O	['N']	[0]
1	patients	O	['N']	[1]
2	treated	O	['N']	[2]
3	with	O	['N']	[3]
4	5-fluorouracil	B-Drug	['Causes']	[20]
5	(	O	['N']	[5]
6	5-FU	O	['N']	[6]
7	)	O	['N']	[7]
8	for	O	['N']	[8]
9	disseminated	O	['N']	[9]
10	adenocarcinoma	O	['N']	[10]
11	of	O	['N']	[11]
12	the	O	['N']	[12]
13	colon	O	['N']	[13]
14	developed	O	['N']	[14]
15	cerebellar	O	['N']	[15]
16	dysfunction	O	['N']	[16]
17	typical	O	['N']	[17]
18	of	O	['N']	[18]
19	5-FU	O	['N']	[19]
20	neurotoxicity	B-Adverse_Effect	['N']	[20]
21	.	O	['N']	[21]
#43
0	A	O	['N']	[0]
1	case	O	['N']	[1]
2	of	O	['N']	[2]
3	phenytoin	B-Drug	['Causes']	[8]
4	-	O	['N']	[4]
5	induced	O	['N']	[5]
6	hepatitis	O	['N']	[6]
7	with	O	['N']	[7]
8	mononucleosis	B-Adverse_Effect	['N']	[8]
9	is	O	['N']	[9]
10	reported	O	['N']	[10]
11	,	O	['N']	[11]
12	and	O	['N']	[12]
13	syndromes	O	['N']	[13]
14	associated	O	['N']	[14]
15	with	O	['N']	[15]
16	phenytoin	O	['N']	[16]
17	hypersensitivity	O	['N']	[17]
18	reactions	O	['N']	[18]
19	are	O	['N']	[19]
20	discussed	O	['N']	[20]
21	.	O	['N']	[21]
#44
0	The	O	['N']	[0]
1	association	O	['N']	[1]
2	of	O	['N']	[2]
3	phenothiazine	B-Drug	['Dosage']	[4]
4	overdose	B-Dose	['N']	[4]
5	and	O	['N']	[5]
6	respiratory	O	['N']	[6]
7	distress	O	['N']	[7]
8	syndrome	O	['N']	[8]
9	merits	O	['N']	[9]
10	consideration	O	['N']	[10]
11	.	O	['N']	[11]
#45
0	Bulbar	B-Adverse_Effect	['N']	[0]
1	and	O	['N']	[1]
2	pseudobulbar	O	['N']	[2]
3	palsy	O	['N']	[3]
4	complicating	O	['N']	[4]
5	therapy	O	['N']	[5]
6	with	O	['N']	[6]
7	high	O	['N']	[7]
8	-	O	['N']	[8]
9	dose	O	['N']	[9]
10	cytosine	B	['N']	[10]
11	arabinoside	I-Drug	['Causes']	[0]
12	in	O	['N']	[12]
13	children	O	['N']	[13]
14	with	O	['N']	[14]
15	leukemia	O	['N']	[15]
16	.	O	['N']	[16]
#46
0	DISCUSSION	O	['N']	[0]
1	:	O	['N']	[1]
2	No	O	['N']	[2]
3	published	O	['N']	[3]
4	clinical	O	['N']	[4]
5	studies	O	['N']	[5]
6	in	O	['N']	[6]
7	patients	O	['N']	[7]
8	receiving	O	['N']	[8]
9	clindamycin	B-Drug	['Causes']	[21]
10	vaginal	O	['N']	[10]
11	cream	O	['N']	[11]
12	for	O	['N']	[12]
13	bacterial	O	['N']	[13]
14	vaginosis	O	['N']	[14]
15	have	O	['N']	[15]
16	documented	O	['N']	[16]
17	C.	B	['N']	[17]
18	difficile	I	['N']	[18]
19	toxin	I	['N']	[19]
20	in	I	['N']	[20]
21	stool	I-Adverse_Effect	['N']	[21]
22	samples	O	['N']	[22]
23	of	O	['N']	[23]
24	patients	O	['N']	[24]
25	with	O	['N']	[25]
26	diarrhea	O	['N']	[26]
27	.	O	['N']	[27]
#47
0	Electro	O	['N']	[0]
1	-	O	['N']	[1]
2	oculography	O	['N']	[2]
3	,	O	['N']	[3]
4	electroretinography	O	['N']	[4]
5	,	O	['N']	[5]
6	visual	O	['N']	[6]
7	evoked	O	['N']	[7]
8	potentials	O	['N']	[8]
9	,	O	['N']	[9]
10	and	O	['N']	[10]
11	multifocal	O	['N']	[11]
12	electroretinography	O	['N']	[12]
13	in	O	['N']	[13]
14	patients	O	['N']	[14]
15	with	O	['N']	[15]
16	vigabatrin	B-Drug	['Causes']	[21]
17	-	O	['N']	[17]
18	attributed	O	['N']	[18]
19	visual	B	['N']	[19]
20	field	I	['N']	[20]
21	constriction	I-Adverse_Effect	['N']	[21]
22	.	O	['N']	[22]
#48
0	Fatal	O	['N']	[0]
1	gemcitabine	B-Drug	['Causes']	[5]
2	-	O	['N']	[2]
3	induced	O	['N']	[3]
4	pulmonary	B	['N']	[4]
5	toxicity	I-Adverse_Effect	['N']	[5]
6	in	O	['N']	[6]
7	metastatic	O	['N']	[7]
8	gallbladder	O	['N']	[8]
9	adenocarcinoma	O	['N']	[9]
10	.	O	['N']	[10]
#49
0	These	O	['N']	[0]
1	findings	O	['N']	[1]
2	are	O	['N']	[2]
3	consistent	O	['N']	[3]
4	with	O	['N']	[4]
5	an	O	['N']	[5]
6	immune	O	['N']	[6]
7	-	O	['N']	[7]
8	complex	O	['N']	[8]
9	form	O	['N']	[9]
10	of	O	['N']	[10]
11	glomerulopathy	O	['N']	[11]
12	in	O	['N']	[12]
13	which	O	['N']	[13]
14	gold	B-Drug	['Causes']	[50]
15	is	O	['N']	[15]
16	neither	O	['N']	[16]
17	the	O	['N']	[17]
18	antigen	O	['N']	[18]
19	nor	O	['N']	[19]
20	a	O	['N']	[20]
21	hapten	O	['N']	[21]
22	in	O	['N']	[22]
23	the	O	['N']	[23]
24	glomerular	O	['N']	[24]
25	deposits	O	['N']	[25]
26	,	O	['N']	[26]
27	and	O	['N']	[27]
28	they	O	['N']	[28]
29	suggest	O	['N']	[29]
30	the	O	['N']	[30]
31	hypothesis	O	['N']	[31]
32	that	O	['N']	[32]
33	antibodies	O	['N']	[33]
34	to	O	['N']	[34]
35	tubular	O	['N']	[35]
36	epithelial	O	['N']	[36]
37	antigens	O	['N']	[37]
38	induced	O	['N']	[38]
39	by	O	['N']	[39]
40	gold	O	['N']	[40]
41	therapy	O	['N']	[41]
42	may	O	['N']	[42]
43	be	O	['N']	[43]
44	a	O	['N']	[44]
45	causative	O	['N']	[45]
46	factor	O	['N']	[46]
47	in	O	['N']	[47]
48	the	O	['N']	[48]
49	renal	B	['N']	[49]
50	disease	I-Adverse_Effect	['N']	[50]
51	associated	O	['N']	[51]
52	with	O	['N']	[52]
53	gold	O	['N']	[53]
54	therapy	O	['N']	[54]
55	in	O	['N']	[55]
56	rheumatoid	O	['N']	[56]
57	arthritis	O	['N']	[57]
58	.	O	['N']	[58]
#50
0	INTERPRETATION	O	['N']	[0]
1	:	O	['N']	[1]
2	When	O	['N']	[2]
3	high	B-Dose	['N']	[3]
4	doses	O	['N']	[4]
5	of	O	['N']	[5]
6	fluticasone	B	['N']	[6]
7	propionate	I-Drug	['Dosage']	[3]
8	are	O	['N']	[8]
9	used	O	['N']	[9]
10	,	O	['N']	[10]
11	growth	O	['N']	[11]
12	may	O	['N']	[12]
13	be	O	['N']	[13]
14	retarded	O	['N']	[14]
15	and	O	['N']	[15]
16	adrenal	O	['N']	[16]
17	suppression	O	['N']	[17]
18	may	O	['N']	[18]
19	occur	O	['N']	[19]
20	.	O	['N']	[20]
#51
0	The	O	['N']	[0]
1	authors	O	['N']	[1]
2	report	O	['N']	[2]
3	one	O	['N']	[3]
4	case	O	['N']	[4]
5	of	O	['N']	[5]
6	incomplete	B	['N']	[6]
7	posterior	I	['N']	[7]
8	hyaloid	I	['N']	[8]
9	detachment	I-Adverse_Effect	['N']	[9]
10	(	O	['N']	[10]
11	PHD	O	['N']	[11]
12	)	O	['N']	[12]
13	following	O	['N']	[13]
14	intravitreal	O	['N']	[14]
15	pegaptanib	B-Drug	['Causes']	[9]
16	to	O	['N']	[16]
17	treat	O	['N']	[17]
18	DME	O	['N']	[18]
19	.	O	['N']	[19]
#52
0	A	O	['N']	[0]
1	wide	O	['N']	[1]
2	variety	O	['N']	[2]
3	of	O	['N']	[3]
4	adverse	B	['N']	[4]
5	central	I	['N']	[5]
6	nervous	I	['N']	[6]
7	system	I	['N']	[7]
8	effects	I-Adverse_Effect	['N']	[8]
9	have	O	['N']	[9]
10	been	O	['N']	[10]
11	reported	O	['N']	[11]
12	in	O	['N']	[12]
13	association	O	['N']	[13]
14	with	O	['N']	[14]
15	propafenone	B-Drug	['Causes']	[8]
16	;	O	['N']	[16]
17	dizziness	O	['N']	[17]
18	is	O	['N']	[18]
19	the	O	['N']	[19]
20	most	O	['N']	[20]
21	common	O	['N']	[21]
22	.	O	['N']	[22]
#53
0	The	O	['N']	[0]
1	intramuscular	O	['N']	[1]
2	challenge	O	['N']	[2]
3	test	O	['N']	[3]
4	with	O	['N']	[4]
5	25	B	['N']	[5]
6	UI	I-Dose	['N']	[6]
7	of	O	['N']	[7]
8	Miacalcic	B-Drug	['Dosage']	[6]
9	was	O	['N']	[9]
10	positive	O	['N']	[10]
11	with	O	['N']	[11]
12	an	O	['N']	[12]
13	immediate	O	['N']	[13]
14	anaphylactic	O	['N']	[14]
15	reaction	O	['N']	[15]
16	.	O	['N']	[16]
#54
0	Type	B	['N']	[0]
1	1	I	['N']	[1]
2	diabetes	I	['N']	[2]
3	mellitus	I-Adverse_Effect	['N']	[3]
4	provoked	O	['N']	[4]
5	by	O	['N']	[5]
6	peginterferon	B	['N']	[6]
7	alpha-2b	I-Drug	['Causes']	[3]
8	plus	O	['N']	[8]
9	ribavirin	O	['N']	[9]
10	treatment	O	['N']	[10]
11	for	O	['N']	[11]
12	chronic	O	['N']	[12]
13	hepatitis	O	['N']	[13]
14	C.	O	['N']	[14]
#55
0	This	O	['N']	[0]
1	latest	O	['N']	[1]
2	(	O	['N']	[2]
3	third	O	['N']	[3]
4	)	O	['N']	[4]
5	report	O	['N']	[5]
6	suggests	O	['N']	[6]
7	that	O	['N']	[7]
8	the	O	['N']	[8]
9	safety	O	['N']	[9]
10	profile	O	['N']	[10]
11	should	O	['N']	[11]
12	be	O	['N']	[12]
13	reexamined	O	['N']	[13]
14	and	O	['N']	[14]
15	at	O	['N']	[15]
16	least	O	['N']	[16]
17	raises	O	['N']	[17]
18	the	O	['N']	[18]
19	question	O	['N']	[19]
20	of	O	['N']	[20]
21	potential	O	['N']	[21]
22	renal	B	['N']	[22]
23	toxicity	I-Adverse_Effect	['N']	[23]
24	of	O	['N']	[24]
25	interferons	B-Drug	['Causes']	[23]
26	in	O	['N']	[26]
27	MS	O	['N']	[27]
28	.	O	['N']	[28]
#56
0	Three	O	['N']	[0]
1	patients	O	['N']	[1]
2	,	O	['N']	[2]
3	in	O	['N']	[3]
4	whom	O	['N']	[4]
5	tumour	O	['N']	[5]
6	overkill	O	['N']	[6]
7	by	O	['N']	[7]
8	cytotoxic	O	['N']	[8]
9	treatment	O	['N']	[9]
10	,	O	['N']	[10]
11	including	O	['N']	[11]
12	high	O	['N']	[12]
13	dose	O	['N']	[13]
14	methotrexate	B-Drug	['Causes']	[43]
15	with	O	['N']	[15]
16	folinic	O	['N']	[16]
17	acid	O	['N']	[17]
18	rescue	O	['N']	[18]
19	,	O	['N']	[19]
20	resulted	O	['N']	[20]
21	in	O	['N']	[21]
22	the	O	['N']	[22]
23	'	O	['N']	[23]
24	phosphate	O	['N']	[24]
25	shower	O	['N']	[25]
26	syndrome	O	['N']	[26]
27	'	O	['N']	[27]
28	(	O	['N']	[28]
29	hyper	O	['N']	[29]
30	-	O	['N']	[30]
31	uricaemia	O	['N']	[31]
32	,	O	['N']	[32]
33	hyperkalaemia	O	['N']	[33]
34	and	O	['N']	[34]
35	hyperphosphataemia	O	['N']	[35]
36	with	O	['N']	[36]
37	hypocalcaemia	O	['N']	[37]
38	and	O	['N']	[38]
39	tetany	O	['N']	[39]
40	,	O	['N']	[40]
41	with	O	['N']	[41]
42	metabolic	B	['N']	[42]
43	acidosis	I-Adverse_Effect	['N']	[43]
44	and	O	['N']	[44]
45	acute	O	['N']	[45]
46	renal	O	['N']	[46]
47	impairment	O	['N']	[47]
48	)	O	['N']	[48]
49	are	O	['N']	[49]
50	described	O	['N']	[50]
51	.	O	['N']	[51]
#57
0	She	O	['N']	[0]
1	was	O	['N']	[1]
2	receiving	O	['N']	[2]
3	phenytoin	O	['N']	[3]
4	sodium	O	['N']	[4]
5	300	O	['N']	[5]
6	mg	O	['N']	[6]
7	/	O	['N']	[7]
8	day	O	['N']	[8]
9	;	O	['N']	[9]
10	carbamazepine	B-Drug	['Dosage']	[12]
11	200	B	['N']	[11]
12	mg	I-Dose	['N']	[12]
13	four	O	['N']	[13]
14	times	O	['N']	[14]
15	daily	O	['N']	[15]
16	had	O	['N']	[16]
17	been	O	['N']	[17]
18	discontinued	O	['N']	[18]
19	four	O	['N']	[19]
20	days	O	['N']	[20]
21	before	O	['N']	[21]
22	admission	O	['N']	[22]
23	because	O	['N']	[23]
24	of	O	['N']	[24]
25	leukopenia	O	['N']	[25]
26	.	O	['N']	[26]
#58
0	On	O	['N']	[0]
1	the	O	['N']	[1]
2	fifth	O	['N']	[2]
3	day	O	['N']	[3]
4	after	O	['N']	[4]
5	administration	O	['N']	[5]
6	of	O	['N']	[6]
7	a	O	['N']	[7]
8	high	O	['N']	[8]
9	dose	O	['N']	[9]
10	of	O	['N']	[10]
11	ARA	B	['N']	[11]
12	-	I	['N']	[12]
13	C	I-Drug	['Dosage']	[22]
14	(	O	['N']	[14]
15	2	B	['N']	[15]
16	g	I	['N']	[16]
17	/	I	['N']	[17]
18	m2	I	['N']	[18]
19	intravenously	I	['N']	[19]
20	every	I	['N']	[20]
21	12	I	['N']	[21]
22	hours	I-Dose	['N']	[22]
23	)	O	['N']	[23]
24	,	O	['N']	[24]
25	she	O	['N']	[25]
26	developed	O	['N']	[26]
27	bullous	O	['N']	[27]
28	lesions	O	['N']	[28]
29	on	O	['N']	[29]
30	the	O	['N']	[30]
31	hands	O	['N']	[31]
32	and	O	['N']	[32]
33	soles	O	['N']	[33]
34	that	O	['N']	[34]
35	disseminated	O	['N']	[35]
36	,	O	['N']	[36]
37	evolving	O	['N']	[37]
38	to	O	['N']	[38]
39	necrosis	O	['N']	[39]
40	,	O	['N']	[40]
41	sepsis	O	['N']	[41]
42	,	O	['N']	[42]
43	and	O	['N']	[43]
44	death	O	['N']	[44]
45	on	O	['N']	[45]
46	the	O	['N']	[46]
47	22nd	O	['N']	[47]
48	day	O	['N']	[48]
49	.	O	['N']	[49]
#59
0	The	O	['N']	[0]
1	authors	O	['N']	[1]
2	describe	O	['N']	[2]
3	a	O	['N']	[3]
4	case	O	['N']	[4]
5	of	O	['N']	[5]
6	interstitial	B	['N']	[6]
7	granulomatous	I	['N']	[7]
8	dermatitis	I-Adverse_Effect	['N']	[8]
9	associated	O	['N']	[9]
10	with	O	['N']	[10]
11	darifenacin	B-Drug	['Causes']	[8]
12	.	O	['N']	[12]
#60
0	Masculinization	O	['N']	[0]
1	of	O	['N']	[1]
2	a	O	['N']	[2]
3	female	O	['N']	[3]
4	fetus	O	['N']	[4]
5	occurred	O	['N']	[5]
6	in	O	['N']	[6]
7	5	O	['N']	[7]
8	of	O	['N']	[8]
9	39	O	['N']	[9]
10	(	O	['N']	[10]
11	12.8	O	['N']	[11]
12	%	O	['N']	[12]
13	)	O	['N']	[13]
14	exposed	O	['N']	[14]
15	to	O	['N']	[15]
16	norethisterone	B-Drug	['Causes']	[23]
17	;	O	['N']	[17]
18	all	O	['N']	[18]
19	were	O	['N']	[19]
20	cases	O	['N']	[20]
21	of	O	['N']	[21]
22	clitoral	B	['N']	[22]
23	hypertrophy	I-Adverse_Effect	['N']	[23]
24	not	O	['N']	[24]
25	requiring	O	['N']	[25]
26	surgical	O	['N']	[26]
27	treatment	O	['N']	[27]
28	.	O	['N']	[28]
#61
0	Reversible	O	['N']	[0]
1	leukopenia	O	['N']	[1]
2	was	O	['N']	[2]
3	documented	O	['N']	[3]
4	in	O	['N']	[4]
5	an	O	['N']	[5]
6	81-year	O	['N']	[6]
7	-	O	['N']	[7]
8	old	O	['N']	[8]
9	woman	O	['N']	[9]
10	treated	O	['N']	[10]
11	with	O	['N']	[11]
12	adjunctive	O	['N']	[12]
13	ibopamine	B-Drug	['Dosage']	[15]
14	100	B	['N']	[14]
15	mg	I-Dose	['N']	[15]
16	t.i.d	O	['N']	[16]
17	.	O	['N']	[17]
18	for	O	['N']	[18]
19	chronic	O	['N']	[19]
20	congestive	O	['N']	[20]
21	heart	O	['N']	[21]
22	failure	O	['N']	[22]
23	.	O	['N']	[23]
#62
0	Common	O	['N']	[0]
1	adverse	O	['N']	[1]
2	events	O	['N']	[2]
3	(	O	['N']	[3]
4	frequency	O	['N']	[4]
5	10	O	['N']	[5]
6	%	O	['N']	[6]
7	)	O	['N']	[7]
8	of	O	['N']	[8]
9	lacosamide	B-Drug	['Causes']	[26]
10	doses	O	['N']	[10]
11	up	O	['N']	[11]
12	to	O	['N']	[12]
13	600	O	['N']	[13]
14	mg	O	['N']	[14]
15	/	O	['N']	[15]
16	day	O	['N']	[16]
17	include	O	['N']	[17]
18	nonspecific	O	['N']	[18]
19	central	O	['N']	[19]
20	nervous	O	['N']	[20]
21	system	O	['N']	[21]
22	effects	O	['N']	[22]
23	(	O	['N']	[23]
24	e.g.	O	['N']	[24]
25	,	O	['N']	[25]
26	dizziness	B-Adverse_Effect	['N']	[26]
27	,	O	['N']	[27]
28	ataxia	O	['N']	[28]
29	,	O	['N']	[29]
30	diplopia	O	['N']	[30]
31	,	O	['N']	[31]
32	and	O	['N']	[32]
33	somnolence	O	['N']	[33]
34	)	O	['N']	[34]
35	.	O	['N']	[35]
#63
0	The	O	['N']	[0]
1	patient	O	['N']	[1]
2	experienced	O	['N']	[2]
3	hallucinations	B-Adverse_Effect	['N']	[3]
4	,	O	['N']	[4]
5	agitation	O	['N']	[5]
6	,	O	['N']	[6]
7	vomiting	O	['N']	[7]
8	,	O	['N']	[8]
9	tachycardia	O	['N']	[9]
10	and	O	['N']	[10]
11	seizures	O	['N']	[11]
12	after	O	['N']	[12]
13	ingestion	O	['N']	[13]
14	of	O	['N']	[14]
15	1050	O	['N']	[15]
16	(	O	['N']	[16]
17	48	O	['N']	[17]
18	mg	O	['N']	[18]
19	/	O	['N']	[19]
20	kg	O	['N']	[20]
21	)	O	['N']	[21]
22	of	O	['N']	[22]
23	extended	O	['N']	[23]
24	-	O	['N']	[24]
25	release	O	['N']	[25]
26	bupropion	B-Drug	['Causes']	[3]
27	.	O	['N']	[27]
#64
0	We	O	['N']	[0]
1	conclude	O	['N']	[1]
2	that	O	['N']	[2]
3	while	O	['N']	[3]
4	thrombocytopenia	B-Adverse_Effect	['N']	[4]
5	and	O	['N']	[5]
6	schistocytosis	O	['N']	[6]
7	can	O	['N']	[7]
8	be	O	['N']	[8]
9	seen	O	['N']	[9]
10	in	O	['N']	[10]
11	quinine	B-Drug	['Causes']	[4]
12	-	O	['N']	[12]
13	associated	O	['N']	[13]
14	TTP	O	['N']	[14]
15	/	O	['N']	[15]
16	HUS	O	['N']	[16]
17	,	O	['N']	[17]
18	the	O	['N']	[18]
19	pathophysiology	O	['N']	[19]
20	seems	O	['N']	[20]
21	to	O	['N']	[21]
22	be	O	['N']	[22]
23	distinct	O	['N']	[23]
24	from	O	['N']	[24]
25	that	O	['N']	[25]
26	seen	O	['N']	[26]
27	in	O	['N']	[27]
28	most	O	['N']	[28]
29	cases	O	['N']	[29]
30	of	O	['N']	[30]
31	idiopathic	O	['N']	[31]
32	TTP	O	['N']	[32]
33	(	O	['N']	[33]
34	i.e.	O	['N']	[34]
35	,	O	['N']	[35]
36	severely	O	['N']	[36]
37	decreased	O	['N']	[37]
38	ADAMTS13	O	['N']	[38]
39	with	O	['N']	[39]
40	an	O	['N']	[40]
41	inhibitor	O	['N']	[41]
42	)	O	['N']	[42]
43	.	O	['N']	[43]
#65
0	This	O	['N']	[0]
1	is	O	['N']	[1]
2	a	O	['N']	[2]
3	unique	O	['N']	[3]
4	autopsy	O	['N']	[4]
5	case	O	['N']	[5]
6	of	O	['N']	[6]
7	hepatocellular	B	['N']	[7]
8	carcinoma	I-Adverse_Effect	['N']	[8]
9	closely	O	['N']	[9]
10	related	O	['N']	[10]
11	to	O	['N']	[11]
12	diethylstilbestrol	B-Drug	['Causes']	[8]
13	(	O	['N']	[13]
14	DES	O	['N']	[14]
15	)	O	['N']	[15]
16	therapy	O	['N']	[16]
17	for	O	['N']	[17]
18	prostatic	O	['N']	[18]
19	cancer	O	['N']	[19]
20	.	O	['N']	[20]
#66
0	This	O	['N']	[0]
1	is	O	['N']	[1]
2	,	O	['N']	[2]
3	to	O	['N']	[3]
4	the	O	['N']	[4]
5	best	O	['N']	[5]
6	of	O	['N']	[6]
7	our	O	['N']	[7]
8	knowledge	O	['N']	[8]
9	,	O	['N']	[9]
10	the	O	['N']	[10]
11	first	O	['N']	[11]
12	report	O	['N']	[12]
13	of	O	['N']	[13]
14	a	O	['N']	[14]
15	case	O	['N']	[15]
16	in	O	['N']	[16]
17	which	O	['N']	[17]
18	agranulocytosis	B-Adverse_Effect	['N']	[18]
19	followed	O	['N']	[19]
20	treatment	O	['N']	[20]
21	with	O	['N']	[21]
22	both	O	['N']	[22]
23	propylthiouracil	B-Drug	['Causes']	[18]
24	and	O	['N']	[24]
25	methimazole	O	['N']	[25]
26	in	O	['N']	[26]
27	the	O	['N']	[27]
28	same	O	['N']	[28]
29	patient	O	['N']	[29]
30	.	O	['N']	[30]
#67
0	The	O	['N']	[0]
1	noted	O	['N']	[1]
2	increase	B	['N']	[2]
3	in	I	['N']	[3]
4	the	I	['N']	[4]
5	theophylline	I	['N']	[5]
6	level	I-Adverse_Effect	['N']	[6]
7	after	O	['N']	[7]
8	zafirlukast	B-Drug	['Causes']	[6]
9	administration	O	['N']	[9]
10	is	O	['N']	[10]
11	in	O	['N']	[11]
12	contrast	O	['N']	[12]
13	to	O	['N']	[13]
14	the	O	['N']	[14]
15	original	O	['N']	[15]
16	reports	O	['N']	[16]
17	by	O	['N']	[17]
18	the	O	['N']	[18]
19	manufacturer	O	['N']	[19]
20	.	O	['N']	[20]
#68
0	Reversible	O	['N']	[0]
1	sirolimus	B-Drug	['Causes']	[4]
2	-	O	['N']	[2]
3	associated	O	['N']	[3]
4	pneumonitis	B-Adverse_Effect	['N']	[4]
5	after	O	['N']	[5]
6	heart	O	['N']	[6]
7	transplantation	O	['N']	[7]
8	.	O	['N']	[8]
#69
0	The	O	['N']	[0]
1	introduction	O	['N']	[1]
2	of	O	['N']	[2]
3	para	O	['N']	[3]
4	-	O	['N']	[4]
5	aminosalicylic	O	['N']	[5]
6	acid	O	['N']	[6]
7	(	O	['N']	[7]
8	PAS	B-Drug	['Causes']	[13]
9	)	O	['N']	[9]
10	led	O	['N']	[10]
11	to	O	['N']	[11]
12	hypoglycaemic	B	['N']	[12]
13	coma	I-Adverse_Effect	['N']	[13]
14	.	O	['N']	[14]
#70
0	We	O	['N']	[0]
1	present	O	['N']	[1]
2	two	O	['N']	[2]
3	cases	O	['N']	[3]
4	of	O	['N']	[4]
5	nitrofurantoin	B-Drug	['Causes']	[19]
6	-	O	['N']	[6]
7	induced	O	['N']	[7]
8	pulmonary	O	['N']	[8]
9	toxicity	O	['N']	[9]
10	in	O	['N']	[10]
11	which	O	['N']	[11]
12	the	O	['N']	[12]
13	initial	O	['N']	[13]
14	HRCT	O	['N']	[14]
15	showed	O	['N']	[15]
16	a	O	['N']	[16]
17	widespread	B	['N']	[17]
18	reticular	I	['N']	[18]
19	pattern	I-Adverse_Effect	['N']	[19]
20	and	O	['N']	[20]
21	associated	O	['N']	[21]
22	distortion	O	['N']	[22]
23	of	O	['N']	[23]
24	the	O	['N']	[24]
25	lung	O	['N']	[25]
26	parenchyma	O	['N']	[26]
27	,	O	['N']	[27]
28	thought	O	['N']	[28]
29	to	O	['N']	[29]
30	represent	O	['N']	[30]
31	established	O	['N']	[31]
32	fibrosis	O	['N']	[32]
33	.	O	['N']	[33]
#71
0	Transient	O	['N']	[0]
1	leucopenia	B-Adverse_Effect	['N']	[1]
2	and	O	['N']	[2]
3	thrombocytopenia	O	['N']	[3]
4	associated	O	['N']	[4]
5	with	O	['N']	[5]
6	sodium	B	['N']	[6]
7	nitroprusside	I-Drug	['Causes']	[1]
8	infusion	O	['N']	[8]
9	.	O	['N']	[9]
#72
0	We	O	['N']	[0]
1	describe	O	['N']	[1]
2	the	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	a	O	['N']	[5]
6	nonatopic	O	['N']	[6]
7	17-year	O	['N']	[7]
8	-	O	['N']	[8]
9	old	O	['N']	[9]
10	girl	O	['N']	[10]
11	with	O	['N']	[11]
12	bronchial	O	['N']	[12]
13	asthma	O	['N']	[13]
14	and	O	['N']	[14]
15	aspirin	O	['N']	[15]
16	intolerance	O	['N']	[16]
17	who	O	['N']	[17]
18	developed	O	['N']	[18]
19	a	O	['N']	[19]
20	dramatic	O	['N']	[20]
21	anaphylactic	B	['N']	[21]
22	reaction	I-Adverse_Effect	['N']	[22]
23	to	O	['N']	[23]
24	oral	O	['N']	[24]
25	prednisone	B-Drug	['Causes']	[22]
26	.	O	['N']	[26]
#73
0	Both	O	['N']	[0]
1	had	O	['N']	[1]
2	impaired	O	['N']	[2]
3	lung	O	['N']	[3]
4	function	O	['N']	[4]
5	and	O	['N']	[5]
6	abnormal	B	['N']	[6]
7	computed	I	['N']	[7]
8	tomographic	I	['N']	[8]
9	scans	I-Adverse_Effect	['N']	[9]
10	,	O	['N']	[10]
11	and	O	['N']	[11]
12	their	O	['N']	[12]
13	condition	O	['N']	[13]
14	improved	O	['N']	[14]
15	when	O	['N']	[15]
16	nitrofurantoin	B-Drug	['Causes']	[9]
17	was	O	['N']	[17]
18	withdrawn	O	['N']	[18]
19	and	O	['N']	[19]
20	corticosteroid	O	['N']	[20]
21	treatment	O	['N']	[21]
22	commenced	O	['N']	[22]
23	.	O	['N']	[23]
#74
0	Although	O	['N']	[0]
1	there	O	['N']	[1]
2	is	O	['N']	[2]
3	one	O	['N']	[3]
4	case	O	['N']	[4]
5	report	O	['N']	[5]
6	of	O	['N']	[6]
7	cholesterol	B	['N']	[7]
8	crystal	I	['N']	[8]
9	embolization	I-Adverse_Effect	['N']	[9]
10	following	O	['N']	[10]
11	t	B	['N']	[11]
12	-	I	['N']	[12]
13	PA	I-Drug	['Causes']	[9]
14	therapy	O	['N']	[14]
15	with	O	['N']	[15]
16	only	O	['N']	[16]
17	extrarenal	O	['N']	[17]
18	manifestations	O	['N']	[18]
19	(	O	['N']	[19]
20	N	O	['N']	[20]
21	Engl	O	['N']	[21]
22	J	O	['N']	[22]
23	Med	O	['N']	[23]
24	321:1270	O	['N']	[24]
25	,	O	['N']	[25]
26	1989	O	['N']	[26]
27	)	O	['N']	[27]
28	,	O	['N']	[28]
29	this	O	['N']	[29]
30	is	O	['N']	[30]
31	the	O	['N']	[31]
32	first	O	['N']	[32]
33	reported	O	['N']	[33]
34	case	O	['N']	[34]
35	of	O	['N']	[35]
36	atheroembolic	O	['N']	[36]
37	acute	O	['N']	[37]
38	renal	O	['N']	[38]
39	failure	O	['N']	[39]
40	following	O	['N']	[40]
41	t	O	['N']	[41]
42	-	O	['N']	[42]
43	PA	O	['N']	[43]
44	therapy	O	['N']	[44]
45	.	O	['N']	[45]
#75
0	Propafenone	B-Drug	['Causes']	[3]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	ataxia	B-Adverse_Effect	['N']	[3]
4	:	O	['N']	[4]
5	report	O	['N']	[5]
6	of	O	['N']	[6]
7	three	O	['N']	[7]
8	cases	O	['N']	[8]
9	.	O	['N']	[9]
#76
0	Ampicillin	B-Drug	['Causes']	[8]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	interstitial	O	['N']	[3]
4	nephritis	O	['N']	[4]
5	with	O	['N']	[5]
6	generalised	B	['N']	[6]
7	exfoliative	I	['N']	[7]
8	dermatitis	I-Adverse_Effect	['N']	[8]
9	.	O	['N']	[9]
#77
0	Acute	B	['N']	[0]
1	pulmonary	I	['N']	[1]
2	reactions	I-Adverse_Effect	['N']	[2]
3	to	O	['N']	[3]
4	nitrofurantoin	B-Drug	['Causes']	[2]
5	are	O	['N']	[5]
6	an	O	['N']	[6]
7	uncommon	O	['N']	[7]
8	side	O	['N']	[8]
9	effect	O	['N']	[9]
10	of	O	['N']	[10]
11	therapy	O	['N']	[11]
12	and	O	['N']	[12]
13	can	O	['N']	[13]
14	cause	O	['N']	[14]
15	minor	O	['N']	[15]
16	or	O	['N']	[16]
17	life	O	['N']	[17]
18	-	O	['N']	[18]
19	threatening	O	['N']	[19]
20	pulmonary	O	['N']	[20]
21	dysfunction	O	['N']	[21]
22	.	O	['N']	[22]
#78
0	Anterior	B	['N']	[0]
1	ischemic	I	['N']	[1]
2	optic	I	['N']	[2]
3	neuropathy	I-Adverse_Effect	['N']	[3]
4	secondary	O	['N']	[4]
5	to	O	['N']	[5]
6	interferon	B	['N']	[6]
7	alfa	I-Drug	['Causes']	[3]
8	.	O	['N']	[8]
#79
0	Localized	O	['N']	[0]
1	panniculitis	O	['N']	[1]
2	and	O	['N']	[2]
3	subsequent	O	['N']	[3]
4	lipoatrophy	B-Adverse_Effect	['N']	[4]
5	with	O	['N']	[5]
6	subcutaneous	O	['N']	[6]
7	glatiramer	B	['N']	[7]
8	acetate	I-Drug	['Causes']	[4]
9	(	O	['N']	[9]
10	Copaxone	O	['N']	[10]
11	)	O	['N']	[11]
12	injection	O	['N']	[12]
13	for	O	['N']	[13]
14	the	O	['N']	[14]
15	treatment	O	['N']	[15]
16	of	O	['N']	[16]
17	multiple	O	['N']	[17]
18	sclerosis	O	['N']	[18]
19	.	O	['N']	[19]
#80
0	Sulfasalazine	B-Drug	['Causes']	[4]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	hypersensitivity	B	['N']	[3]
4	syndrome	I-Adverse_Effect	['N']	[4]
5	and	O	['N']	[5]
6	hemophagocytic	O	['N']	[6]
7	syndrome	O	['N']	[7]
8	associated	O	['N']	[8]
9	with	O	['N']	[9]
10	reactivation	O	['N']	[10]
11	of	O	['N']	[11]
12	Epstein	O	['N']	[12]
13	-	O	['N']	[13]
14	Barr	O	['N']	[14]
15	virus	O	['N']	[15]
16	.	O	['N']	[16]
#81
0	Bowel	B	['N']	[0]
1	perforation	I-Adverse_Effect	['N']	[1]
2	associated	O	['N']	[2]
3	with	O	['N']	[3]
4	intraperitoneal	O	['N']	[4]
5	chromic	B	['N']	[5]
6	phosphate	I-Drug	['Causes']	[1]
7	instillation	O	['N']	[7]
8	.	O	['N']	[8]
#82
0	CONCLUSIONS	O	['N']	[0]
1	:	O	['N']	[1]
2	The	O	['N']	[2]
3	administration	O	['N']	[3]
4	of	O	['N']	[4]
5	prostaglandin	B	['N']	[5]
6	E1	I-Drug	['Causes']	[18]
7	to	O	['N']	[7]
8	neonates	O	['N']	[8]
9	can	O	['N']	[9]
10	cause	O	['N']	[10]
11	gastric	O	['N']	[11]
12	-	O	['N']	[12]
13	outlet	O	['N']	[13]
14	obstruction	O	['N']	[14]
15	due	O	['N']	[15]
16	to	O	['N']	[16]
17	antral	B	['N']	[17]
18	hyperplasia	I-Adverse_Effect	['N']	[18]
19	.	O	['N']	[19]
#83
0	BACKGROUND	O	['N']	[0]
1	:	O	['N']	[1]
2	Methotrexate	B-Drug	['Causes']	[20]
3	(	O	['N']	[3]
4	MTX	O	['N']	[4]
5	)	O	['N']	[5]
6	may	O	['N']	[6]
7	induce	O	['N']	[7]
8	liver	O	['N']	[8]
9	damage	O	['N']	[9]
10	,	O	['N']	[10]
11	which	O	['N']	[11]
12	in	O	['N']	[12]
13	some	O	['N']	[13]
14	psoriatics	O	['N']	[14]
15	will	O	['N']	[15]
16	lead	O	['N']	[16]
17	to	O	['N']	[17]
18	fibrosis	O	['N']	[18]
19	or	O	['N']	[19]
20	cirrhosis	B-Adverse_Effect	['N']	[20]
21	.	O	['N']	[21]
#84
0	Transient	O	['N']	[0]
1	phenytoin	B-Drug	['Causes']	[8]
2	induced	O	['N']	[2]
3	IgA	O	['N']	[3]
4	deficiency	O	['N']	[4]
5	and	O	['N']	[5]
6	permanent	O	['N']	[6]
7	IgE	B	['N']	[7]
8	increase	I-Adverse_Effect	['N']	[8]
9	.	O	['N']	[9]
#85
0	Indolent	O	['N']	[0]
1	aspergillus	B	['N']	[1]
2	arthritis	I-Adverse_Effect	['N']	[2]
3	complicating	O	['N']	[3]
4	fludarabine	B-Drug	['Causes']	[2]
5	-	O	['N']	[5]
6	based	O	['N']	[6]
7	non	O	['N']	[7]
8	-	O	['N']	[8]
9	myeloablative	O	['N']	[9]
10	stem	O	['N']	[10]
11	cell	O	['N']	[11]
12	transplantation	O	['N']	[12]
13	.	O	['N']	[13]
#86
0	OBJECTIVE	O	['N']	[0]
1	:	O	['N']	[1]
2	To	O	['N']	[2]
3	determine	O	['N']	[3]
4	the	O	['N']	[4]
5	frequency	O	['N']	[5]
6	of	O	['N']	[6]
7	weight	B	['N']	[7]
8	loss	I-Adverse_Effect	['N']	[8]
9	in	O	['N']	[9]
10	patients	O	['N']	[10]
11	treated	O	['N']	[11]
12	with	O	['N']	[12]
13	leflunomide	B-Drug	['Causes']	[8]
14	for	O	['N']	[14]
15	rheumatoid	O	['N']	[15]
16	arthritis	O	['N']	[16]
17	at	O	['N']	[17]
18	an	O	['N']	[18]
19	arthritis	O	['N']	[19]
20	referral	O	['N']	[20]
21	center	O	['N']	[21]
22	.	O	['N']	[22]
#87
0	Rifampin	B-Drug	['Causes']	[14]
1	can	O	['N']	[1]
2	be	O	['N']	[2]
3	associated	O	['N']	[3]
4	with	O	['N']	[4]
5	severe	O	['N']	[5]
6	adverse	O	['N']	[6]
7	effects	O	['N']	[7]
8	such	O	['N']	[8]
9	as	O	['N']	[9]
10	hepatitis	O	['N']	[10]
11	,	O	['N']	[11]
12	acute	B	['N']	[12]
13	renal	I	['N']	[13]
14	failure	I-Adverse_Effect	['N']	[14]
15	,	O	['N']	[15]
16	hemolytic	O	['N']	[16]
17	anemia	O	['N']	[17]
18	,	O	['N']	[18]
19	and	O	['N']	[19]
20	thrombocytopenia	O	['N']	[20]
21	.	O	['N']	[21]
#88
0	Of	O	['N']	[0]
1	particular	O	['N']	[1]
2	interest	O	['N']	[2]
3	in	O	['N']	[3]
4	this	O	['N']	[4]
5	patient	O	['N']	[5]
6	is	O	['N']	[6]
7	the	O	['N']	[7]
8	fluctuation	B	['N']	[8]
9	of	I	['N']	[9]
10	the	I	['N']	[10]
11	QT	I	['N']	[11]
12	interval	I-Adverse_Effect	['N']	[12]
13	at	O	['N']	[13]
14	a	O	['N']	[14]
15	stable	O	['N']	[15]
16	dose	O	['N']	[16]
17	of	O	['N']	[17]
18	methadone	B-Drug	['Causes']	[12]
19	,	O	['N']	[19]
20	suggesting	O	['N']	[20]
21	that	O	['N']	[21]
22	a	O	['N']	[22]
23	single	O	['N']	[23]
24	normal	O	['N']	[24]
25	electrocardiogram	O	['N']	[25]
26	(	O	['N']	[26]
27	ECG	O	['N']	[27]
28	)	O	['N']	[28]
29	does	O	['N']	[29]
30	not	O	['N']	[30]
31	guarantee	O	['N']	[31]
32	that	O	['N']	[32]
33	the	O	['N']	[33]
34	patient	O	['N']	[34]
35	is	O	['N']	[35]
36	not	O	['N']	[36]
37	at	O	['N']	[37]
38	risk	O	['N']	[38]
39	of	O	['N']	[39]
40	ventricular	O	['N']	[40]
41	arrhythmias	O	['N']	[41]
42	.	O	['N']	[42]
#89
0	A	O	['N']	[0]
1	patient	O	['N']	[1]
2	with	O	['N']	[2]
3	intracranial	O	['N']	[3]
4	osteosarcoma	O	['N']	[4]
5	that	O	['N']	[5]
6	arose	O	['N']	[6]
7	16	O	['N']	[7]
8	years	O	['N']	[8]
9	after	O	['N']	[9]
10	radiation	O	['N']	[10]
11	therapy	O	['N']	[11]
12	for	O	['N']	[12]
13	hereditary	O	['N']	[13]
14	retinoblastoma	O	['N']	[14]
15	developed	O	['N']	[15]
16	fatal	B	['N']	[16]
17	cerebral	I	['N']	[17]
18	edema	I-Adverse_Effect	['N']	[18]
19	and	O	['N']	[19]
20	brainstem	O	['N']	[20]
21	herniation	O	['N']	[21]
22	after	O	['N']	[22]
23	she	O	['N']	[23]
24	received	O	['N']	[24]
25	a	O	['N']	[25]
26	single	O	['N']	[26]
27	dose	O	['N']	[27]
28	of	O	['N']	[28]
29	intravenous	O	['N']	[29]
30	methotrexate	B-Drug	['Causes']	[18]
31	.	O	['N']	[31]
#90
0	The	O	['N']	[0]
1	patient	O	['N']	[1]
2	was	O	['N']	[2]
3	given	O	['N']	[3]
4	methimazole	B-Drug	['Causes']	[14]
5	instead	O	['N']	[5]
6	of	O	['N']	[6]
7	propylthiouracil	O	['N']	[7]
8	but	O	['N']	[8]
9	,	O	['N']	[9]
10	10	O	['N']	[10]
11	weeks	O	['N']	[11]
12	later	O	['N']	[12]
13	,	O	['N']	[13]
14	agranulocytosis	B-Adverse_Effect	['N']	[14]
15	again	O	['N']	[15]
16	occurred	O	['N']	[16]
17	.	O	['N']	[17]
#91
0	In	O	['N']	[0]
1	a	O	['N']	[1]
2	series	O	['N']	[2]
3	of	O	['N']	[3]
4	104	O	['N']	[4]
5	cases	O	['N']	[5]
6	of	O	['N']	[6]
7	intentional	O	['N']	[7]
8	or	O	['N']	[8]
9	inadvertent	O	['N']	[9]
10	use	O	['N']	[10]
11	of	O	['N']	[11]
12	zidovudine	B-Drug	['Causes']	[25]
13	at	O	['N']	[13]
14	differing	O	['N']	[14]
15	gestations	O	['N']	[15]
16	in	O	['N']	[16]
17	pregnancy	O	['N']	[17]
18	,	O	['N']	[18]
19	there	O	['N']	[19]
20	were	O	['N']	[20]
21	eight	O	['N']	[21]
22	spontaneous	O	['N']	[22]
23	first	B	['N']	[23]
24	trimester	I	['N']	[24]
25	abortions	I-Adverse_Effect	['N']	[25]
26	,	O	['N']	[26]
27	eight	O	['N']	[27]
28	therapeutic	O	['N']	[28]
29	terminations	O	['N']	[29]
30	,	O	['N']	[30]
31	and	O	['N']	[31]
32	eight	O	['N']	[32]
33	cases	O	['N']	[33]
34	of	O	['N']	[34]
35	fetal	O	['N']	[35]
36	abnormality	O	['N']	[36]
37	occurring	O	['N']	[37]
38	among	O	['N']	[38]
39	a	O	['N']	[39]
40	total	O	['N']	[40]
41	of	O	['N']	[41]
42	88	O	['N']	[42]
43	cases	O	['N']	[43]
44	where	O	['N']	[44]
45	the	O	['N']	[45]
46	pregnancy	O	['N']	[46]
47	progressed	O	['N']	[47]
48	.	O	['N']	[48]
#92
0	INTRODUCTION	O	['N']	[0]
1	-	O	['N']	[1]
2	The	O	['N']	[2]
3	aim	O	['N']	[3]
4	of	O	['N']	[4]
5	this	O	['N']	[5]
6	case	O	['N']	[6]
7	report	O	['N']	[7]
8	is	O	['N']	[8]
9	to	O	['N']	[9]
10	present	O	['N']	[10]
11	a	O	['N']	[11]
12	15-year	O	['N']	[12]
13	follow	O	['N']	[13]
14	-	O	['N']	[14]
15	up	O	['N']	[15]
16	of	O	['N']	[16]
17	a	O	['N']	[17]
18	patient	O	['N']	[18]
19	with	O	['N']	[19]
20	phenytoin	O	['N']	[20]
21	(	O	['N']	[21]
22	PHT	B-Drug	['Causes']	[28]
23	)	O	['N']	[23]
24	intoxication	O	['N']	[24]
25	with	O	['N']	[25]
26	unilateral	B	['N']	[26]
27	gingival	I	['N']	[27]
28	hyperplasia	I-Adverse_Effect	['N']	[28]
29	(	O	['N']	[29]
30	GH	O	['N']	[30]
31	)	O	['N']	[31]
32	.	O	['N']	[32]
#93
0	Metformin	B-Drug	['Causes']	[4]
1	-	O	['N']	[1]
2	associated	O	['N']	[2]
3	lactic	B	['N']	[3]
4	acidosis	I-Adverse_Effect	['N']	[4]
5	precipitated	O	['N']	[5]
6	by	O	['N']	[6]
7	diarrhea	O	['N']	[7]
8	.	O	['N']	[8]
#94
0	FINDINGS	O	['N']	[0]
1	:	O	['N']	[1]
2	Six	O	['N']	[2]
3	children	O	['N']	[3]
4	with	O	['N']	[4]
5	growth	O	['N']	[5]
6	retardation	O	['N']	[6]
7	noted	O	['N']	[7]
8	after	O	['N']	[8]
9	treatment	O	['N']	[9]
10	with	O	['N']	[10]
11	high	O	['N']	[11]
12	-	O	['N']	[12]
13	dose	O	['N']	[13]
14	fluticasone	B	['N']	[14]
15	propionate	I-Drug	['Causes']	[21]
16	were	O	['N']	[16]
17	found	O	['N']	[17]
18	to	O	['N']	[18]
19	have	O	['N']	[19]
20	adrenal	B	['N']	[20]
21	suppression	I-Adverse_Effect	['N']	[21]
22	.	O	['N']	[22]
#95
0	Spontaneous	B	['N']	[0]
1	nasal	I	['N']	[1]
2	septal	I	['N']	[2]
3	perforation	I-Adverse_Effect	['N']	[3]
4	with	O	['N']	[4]
5	antiangiogenic	O	['N']	[5]
6	bevacizumab	B-Drug	['Causes']	[3]
7	therapy	O	['N']	[7]
8	.	O	['N']	[8]
#96
0	Thrombocytosis	B-Adverse_Effect	['N']	[0]
1	associated	O	['N']	[1]
2	with	O	['N']	[2]
3	enoxaparin	B-Drug	['Causes']	[0]
4	:	O	['N']	[4]
5	A	O	['N']	[5]
6	very	O	['N']	[6]
7	rare	O	['N']	[7]
8	cause	O	['N']	[8]
9	in	O	['N']	[9]
10	newborns	O	['N']	[10]
11	.	O	['N']	[11]
#97
0	Development	O	['N']	[0]
1	of	O	['N']	[1]
2	tics	B-Adverse_Effect	['N']	[2]
3	in	O	['N']	[3]
4	a	O	['N']	[4]
5	thirteen	O	['N']	[5]
6	-	O	['N']	[6]
7	year	O	['N']	[7]
8	-	O	['N']	[8]
9	old	O	['N']	[9]
10	male	O	['N']	[10]
11	following	O	['N']	[11]
12	atomoxetine	B-Drug	['Causes']	[2]
13	use	O	['N']	[13]
14	.	O	['N']	[14]
#98
0	There	O	['N']	[0]
1	are	O	['N']	[1]
2	now	O	['N']	[2]
3	reports	O	['N']	[3]
4	of	O	['N']	[4]
5	liver	B	['N']	[5]
6	failure	I-Adverse_Effect	['N']	[6]
7	following	O	['N']	[7]
8	treatment	O	['N']	[8]
9	of	O	['N']	[9]
10	childhood	O	['N']	[10]
11	cancers	O	['N']	[11]
12	with	O	['N']	[12]
13	AMD	B-Drug	['Causes']	[6]
14	.	O	['N']	[14]
#99
0	We	O	['N']	[0]
1	describe	O	['N']	[1]
2	3	O	['N']	[2]
3	AS	O	['N']	[3]
4	patients	O	['N']	[4]
5	treated	O	['N']	[5]
6	with	O	['N']	[6]
7	etanercept	B-Drug	['Causes']	[16]
8	for	O	['N']	[8]
9	active	O	['N']	[9]
10	AS	O	['N']	[10]
11	who	O	['N']	[11]
12	developed	O	['N']	[12]
13	new	O	['N']	[13]
14	onset	O	['N']	[14]
15	of	O	['N']	[15]
16	CD	B-Adverse_Effect	['N']	[16]
17	while	O	['N']	[17]
18	AS	O	['N']	[18]
19	related	O	['N']	[19]
20	symptoms	O	['N']	[20]
21	responded	O	['N']	[21]
22	well	O	['N']	[22]
23	to	O	['N']	[23]
24	etanercept	O	['N']	[24]
25	.	O	['N']	[25]
#100
0	The	O	['N']	[0]
1	more	O	['N']	[1]
2	common	O	['N']	[2]
3	grade	O	['N']	[3]
4	3	O	['N']	[4]
5	or	O	['N']	[5]
6	4	O	['N']	[6]
7	adverse	O	['N']	[7]
8	effects	O	['N']	[8]
9	of	O	['N']	[9]
10	sunitinib	B-Drug	['Causes']	[19]
11	include	O	['N']	[11]
12	hypertension	O	['N']	[12]
13	,	O	['N']	[13]
14	fatigue	O	['N']	[14]
15	,	O	['N']	[15]
16	hand	B	['N']	[16]
17	-	I	['N']	[17]
18	foot	I	['N']	[18]
19	syndrome	I-Adverse_Effect	['N']	[19]
20	,	O	['N']	[20]
21	elevated	O	['N']	[21]
22	lipase	O	['N']	[22]
23	and	O	['N']	[23]
24	lymphopenia	O	['N']	[24]
25	.	O	['N']	[25]
#101
0	An	O	['N']	[0]
1	association	O	['N']	[1]
2	of	O	['N']	[2]
3	granulocytopenia	O	['N']	[3]
4	,	O	['N']	[4]
5	eosinophilia	B-Adverse_Effect	['N']	[5]
6	,	O	['N']	[6]
7	skin	O	['N']	[7]
8	reaction	O	['N']	[8]
9	and	O	['N']	[9]
10	hepatitis	O	['N']	[10]
11	during	O	['N']	[11]
12	propylthiouracil	B-Drug	['Causes']	[5]
13	(	O	['N']	[13]
14	PTU	O	['N']	[14]
15	)	O	['N']	[15]
16	therapy	O	['N']	[16]
17	for	O	['N']	[17]
18	thyrotoxicosis	O	['N']	[18]
19	in	O	['N']	[19]
20	a	O	['N']	[20]
21	47	O	['N']	[21]
22	year	O	['N']	[22]
23	old	O	['N']	[23]
24	black	O	['N']	[24]
25	female	O	['N']	[25]
26	is	O	['N']	[26]
27	reported	O	['N']	[27]
28	.	O	['N']	[28]
#102
0	Gemcitabine	B-Drug	['Causes']	[6]
1	-	O	['N']	[1]
2	associated	O	['N']	[2]
3	hemolytic	B	['N']	[3]
4	-	I	['N']	[4]
5	uremic	I	['N']	[5]
6	syndrome	I-Adverse_Effect	['N']	[6]
7	.	O	['N']	[7]
#103
0	The	O	['N']	[0]
1	first	O	['N']	[1]
2	patient	O	['N']	[2]
3	developed	O	['N']	[3]
4	mild	B	['N']	[4]
5	nitritoid	I	['N']	[5]
6	symptoms	I-Adverse_Effect	['N']	[6]
7	and	O	['N']	[7]
8	pain	O	['N']	[8]
9	in	O	['N']	[9]
10	a	O	['N']	[10]
11	band	O	['N']	[11]
12	-	O	['N']	[12]
13	like	O	['N']	[13]
14	distribution	O	['N']	[14]
15	,	O	['N']	[15]
16	corresponding	O	['N']	[16]
17	to	O	['N']	[17]
18	T10-T12	O	['N']	[18]
19	dermatomes	O	['N']	[19]
20	,	O	['N']	[20]
21	shortly	O	['N']	[21]
22	after	O	['N']	[22]
23	gold	B	['N']	[23]
24	sodium	I	['N']	[24]
25	thiomalate	I-Drug	['Causes']	[6]
26	(	O	['N']	[26]
27	GSTM	O	['N']	[27]
28	)	O	['N']	[28]
29	injection	O	['N']	[29]
30	.	O	['N']	[30]
#104
0	The	O	['N']	[0]
1	use	O	['N']	[1]
2	of	O	['N']	[2]
3	methotrexate	O	['N']	[3]
4	(	O	['N']	[4]
5	MTX	B-Drug	['Causes']	[37]
6	)	O	['N']	[6]
7	has	O	['N']	[7]
8	been	O	['N']	[8]
9	contraindicated	O	['N']	[9]
10	for	O	['N']	[10]
11	treatment	O	['N']	[11]
12	of	O	['N']	[12]
13	severe	O	['N']	[13]
14	psoriasis	O	['N']	[14]
15	in	O	['N']	[15]
16	HIV	O	['N']	[16]
17	infection	O	['N']	[17]
18	on	O	['N']	[18]
19	the	O	['N']	[19]
20	basis	O	['N']	[20]
21	of	O	['N']	[21]
22	six	O	['N']	[22]
23	previously	O	['N']	[23]
24	reported	O	['N']	[24]
25	cases	O	['N']	[25]
26	in	O	['N']	[26]
27	which	O	['N']	[27]
28	MTX	O	['N']	[28]
29	appeared	O	['N']	[29]
30	to	O	['N']	[30]
31	potentiate	O	['N']	[31]
32	opportunistic	O	['N']	[32]
33	infections	O	['N']	[33]
34	and	O	['N']	[34]
35	accelerate	B	['N']	[35]
36	HIV	I	['N']	[36]
37	disease	I-Adverse_Effect	['N']	[37]
38	.	O	['N']	[38]
#105
0	Visceral	O	['N']	[0]
1	leishmaniasis	O	['N']	[1]
2	and	O	['N']	[2]
3	macrophagic	B	['N']	[3]
4	activation	I	['N']	[4]
5	syndrome	I-Adverse_Effect	['N']	[5]
6	in	O	['N']	[6]
7	a	O	['N']	[7]
8	patient	O	['N']	[8]
9	with	O	['N']	[9]
10	rheumatoid	O	['N']	[10]
11	arthritis	O	['N']	[11]
12	under	O	['N']	[12]
13	treatment	O	['N']	[13]
14	with	O	['N']	[14]
15	adalimumab	B-Drug	['Causes']	[5]
16	.	O	['N']	[16]
#106
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	fatal	O	['N']	[3]
4	case	O	['N']	[4]
5	of	O	['N']	[5]
6	toxic	O	['N']	[6]
7	epidermal	O	['N']	[7]
8	necrolysis	O	['N']	[8]
9	(	O	['N']	[9]
10	TEN	B-Adverse_Effect	['N']	[10]
11	)	O	['N']	[11]
12	resulting	O	['N']	[12]
13	from	O	['N']	[13]
14	a	O	['N']	[14]
15	high	O	['N']	[15]
16	dose	O	['N']	[16]
17	of	O	['N']	[17]
18	cytosine	O	['N']	[18]
19	arabinoside	O	['N']	[19]
20	(	O	['N']	[20]
21	ARA	B	['N']	[21]
22	-	I	['N']	[22]
23	C	I-Drug	['Causes']	[10]
24	)	O	['N']	[24]
25	.	O	['N']	[25]
#107
0	Methotrexate	B-Drug	['Causes']	[3]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	pneumonitis	B-Adverse_Effect	['N']	[3]
4	in	O	['N']	[4]
5	patients	O	['N']	[5]
6	with	O	['N']	[6]
7	rheumatoid	O	['N']	[7]
8	arthritis	O	['N']	[8]
9	and	O	['N']	[9]
10	psoriatic	O	['N']	[10]
11	arthritis	O	['N']	[11]
12	:	O	['N']	[12]
13	report	O	['N']	[13]
14	of	O	['N']	[14]
15	five	O	['N']	[15]
16	cases	O	['N']	[16]
17	and	O	['N']	[17]
18	review	O	['N']	[18]
19	of	O	['N']	[19]
20	the	O	['N']	[20]
21	literature	O	['N']	[21]
22	.	O	['N']	[22]
#108
0	Two	O	['N']	[0]
1	cases	O	['N']	[1]
2	of	O	['N']	[2]
3	childhood	O	['N']	[3]
4	-	O	['N']	[4]
5	onset	O	['N']	[5]
6	schizophrenia	O	['N']	[6]
7	associated	O	['N']	[7]
8	with	O	['N']	[8]
9	clozapine	B-Drug	['Causes']	[12]
10	-	O	['N']	[10]
11	induced	O	['N']	[11]
12	akathisia	B-Adverse_Effect	['N']	[12]
13	responsive	O	['N']	[13]
14	to	O	['N']	[14]
15	beta	O	['N']	[15]
16	-	O	['N']	[16]
17	blocker	O	['N']	[17]
18	treatment	O	['N']	[18]
19	are	O	['N']	[19]
20	described	O	['N']	[20]
21	.	O	['N']	[21]
#109
0	A	O	['N']	[0]
1	child	O	['N']	[1]
2	in	O	['N']	[2]
3	whom	O	['N']	[3]
4	a	O	['N']	[4]
5	phenobarbital	B-Drug	['Causes']	[23]
6	hypersensitivity	O	['N']	[6]
7	drug	O	['N']	[7]
8	reaction	O	['N']	[8]
9	developed	O	['N']	[9]
10	which	O	['N']	[10]
11	consisted	O	['N']	[11]
12	of	O	['N']	[12]
13	fever	O	['N']	[13]
14	,	O	['N']	[14]
15	a	O	['N']	[15]
16	pruritic	O	['N']	[16]
17	desquamating	O	['N']	[17]
18	erythrodermic	O	['N']	[18]
19	rash	O	['N']	[19]
20	,	O	['N']	[20]
21	alopecia	O	['N']	[21]
22	,	O	['N']	[22]
23	icterus	B-Adverse_Effect	['N']	[23]
24	,	O	['N']	[24]
25	protein	O	['N']	[25]
26	-	O	['N']	[26]
27	losing	O	['N']	[27]
28	enteropathy	O	['N']	[28]
29	,	O	['N']	[29]
30	myositis	O	['N']	[30]
31	,	O	['N']	[31]
32	and	O	['N']	[32]
33	nephritis	O	['N']	[33]
34	,	O	['N']	[34]
35	is	O	['N']	[35]
36	described	O	['N']	[36]
37	.	O	['N']	[37]
#110
0	Two	O	['N']	[0]
1	patients	O	['N']	[1]
2	are	O	['N']	[2]
3	described	O	['N']	[3]
4	who	O	['N']	[4]
5	developed	O	['N']	[5]
6	testicular	B	['N']	[6]
7	swelling	I-Adverse_Effect	['N']	[7]
8	and	O	['N']	[8]
9	pain	O	['N']	[9]
10	during	O	['N']	[10]
11	treatment	O	['N']	[11]
12	with	O	['N']	[12]
13	desipramine	B-Drug	['Causes']	[7]
14	.	O	['N']	[14]
#111
0	Seizures	B-Adverse_Effect	['N']	[0]
1	associated	O	['N']	[1]
2	with	O	['N']	[2]
3	fluoxetine	B-Drug	['Causes']	[0]
4	therapy	O	['N']	[4]
5	.	O	['N']	[5]
#112
0	Rupture	B	['N']	[0]
1	of	I	['N']	[1]
2	a	I	['N']	[2]
3	cerebral	I	['N']	[3]
4	aneurysm	I-Adverse_Effect	['N']	[4]
5	associated	O	['N']	[5]
6	with	O	['N']	[6]
7	nifedipine	B-Drug	['Causes']	[4]
8	treatment	O	['N']	[8]
9	.	O	['N']	[9]
#113
0	CONCLUSIONS	O	['N']	[0]
1	:	O	['N']	[1]
2	We	O	['N']	[2]
3	present	O	['N']	[3]
4	a	O	['N']	[4]
5	case	O	['N']	[5]
6	of	O	['N']	[6]
7	a	O	['N']	[7]
8	patient	O	['N']	[8]
9	with	O	['N']	[9]
10	CML	O	['N']	[10]
11	who	O	['N']	[11]
12	developed	O	['N']	[12]
13	KS	O	['N']	[13]
14	12	O	['N']	[14]
15	months	O	['N']	[15]
16	after	O	['N']	[16]
17	starting	O	['N']	[17]
18	treatment	O	['N']	[18]
19	with	O	['N']	[19]
20	imatinib	B-Drug	['Dosage']	[24]
21	400	B	['N']	[21]
22	mg	I	['N']	[22]
23	/	I	['N']	[23]
24	d	I-Dose	['N']	[24]
25	.	O	['N']	[25]
#114
0	Severe	O	['N']	[0]
1	dapsone	B-Drug	['Causes']	[3]
2	hypersensitivity	B	['N']	[2]
3	syndrome	I-Adverse_Effect	['N']	[3]
4	.	O	['N']	[4]
#115
0	A	O	['N']	[0]
1	44-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	woman	O	['N']	[4]
5	is	O	['N']	[5]
6	described	O	['N']	[6]
7	in	O	['N']	[7]
8	whom	O	['N']	[8]
9	amiodarone	O	['N']	[9]
10	,	O	['N']	[10]
11	disopyramide	B-Drug	['Causes']	[25]
12	,	O	['N']	[12]
13	and	O	['N']	[13]
14	quinidine	O	['N']	[14]
15	,	O	['N']	[15]
16	administered	O	['N']	[16]
17	alone	O	['N']	[17]
18	separately	O	['N']	[18]
19	,	O	['N']	[19]
20	induced	O	['N']	[20]
21	atypical	O	['N']	[21]
22	ventricular	O	['N']	[22]
23	tachycardia	O	['N']	[23]
24	(	O	['N']	[24]
25	AVT	B-Adverse_Effect	['N']	[25]
26	,	O	['N']	[26]
27	torsade	O	['N']	[27]
28	de	O	['N']	[28]
29	pointes	O	['N']	[29]
30	)	O	['N']	[30]
31	.	O	['N']	[31]
#116
0	These	O	['N']	[0]
1	cases	O	['N']	[1]
2	were	O	['N']	[2]
3	considered	O	['N']	[3]
4	unusual	O	['N']	[4]
5	in	O	['N']	[5]
6	light	O	['N']	[6]
7	of	O	['N']	[7]
8	the	O	['N']	[8]
9	short	O	['N']	[9]
10	delay	O	['N']	[10]
11	of	O	['N']	[11]
12	their	O	['N']	[12]
13	onset	O	['N']	[13]
14	after	O	['N']	[14]
15	initiation	O	['N']	[15]
16	of	O	['N']	[16]
17	immunosuppressive	O	['N']	[17]
18	therapy	O	['N']	[18]
19	and	O	['N']	[19]
20	their	O	['N']	[20]
21	fulminant	O	['N']	[21]
22	course	O	['N']	[22]
23	:	O	['N']	[23]
24	3	O	['N']	[24]
25	of	O	['N']	[25]
26	these	O	['N']	[26]
27	patients	O	['N']	[27]
28	died	B-Adverse_Effect	['N']	[28]
29	of	O	['N']	[29]
30	PCP	O	['N']	[30]
31	occurring	O	['N']	[31]
32	during	O	['N']	[32]
33	the	O	['N']	[33]
34	first	O	['N']	[34]
35	month	O	['N']	[35]
36	of	O	['N']	[36]
37	treatment	O	['N']	[37]
38	with	O	['N']	[38]
39	prednisone	B-Drug	['Causes']	[28]
40	.	O	['N']	[40]
#117
0	Linezolid	B-Drug	['Causes']	[15]
1	-	O	['N']	[1]
2	associated	O	['N']	[2]
3	acute	O	['N']	[3]
4	interstitial	O	['N']	[4]
5	nephritis	O	['N']	[5]
6	and	O	['N']	[6]
7	drug	O	['N']	[7]
8	rash	O	['N']	[8]
9	with	O	['N']	[9]
10	eosinophilia	O	['N']	[10]
11	and	O	['N']	[11]
12	systemic	O	['N']	[12]
13	symptoms	O	['N']	[13]
14	(	O	['N']	[14]
15	DRESS	B-Adverse_Effect	['N']	[15]
16	)	O	['N']	[16]
17	syndrome	O	['N']	[17]
18	.	O	['N']	[18]
#118
0	A	O	['N']	[0]
1	50-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	diabetic	O	['N']	[4]
5	and	O	['N']	[5]
6	hypertensive	O	['N']	[6]
7	male	O	['N']	[7]
8	patient	O	['N']	[8]
9	is	O	['N']	[9]
10	reported	O	['N']	[10]
11	who	O	['N']	[11]
12	had	O	['N']	[12]
13	ticlopidine	B-Drug	['Causes']	[17]
14	-	O	['N']	[14]
15	induced	O	['N']	[15]
16	marrow	B	['N']	[16]
17	aplasia	I-Adverse_Effect	['N']	[17]
18	partially	O	['N']	[18]
19	responsive	O	['N']	[19]
20	to	O	['N']	[20]
21	colony	O	['N']	[21]
22	-	O	['N']	[22]
23	stimulating	O	['N']	[23]
24	factors	O	['N']	[24]
25	and	O	['N']	[25]
26	corticosteroids	O	['N']	[26]
27	,	O	['N']	[27]
28	but	O	['N']	[28]
29	experienced	O	['N']	[29]
30	complete	O	['N']	[30]
31	recovery	O	['N']	[31]
32	with	O	['N']	[32]
33	cyclosporine	O	['N']	[33]
34	.	O	['N']	[34]
#119
0	OBJECTIVE	O	['N']	[0]
1	:	O	['N']	[1]
2	To	O	['N']	[2]
3	report	O	['N']	[3]
4	2	O	['N']	[4]
5	cases	O	['N']	[5]
6	of	O	['N']	[6]
7	nonconvulsive	B	['N']	[7]
8	status	I	['N']	[8]
9	epilepticus	I-Adverse_Effect	['N']	[9]
10	(	O	['N']	[10]
11	NCSE	O	['N']	[11]
12	)	O	['N']	[12]
13	following	O	['N']	[13]
14	infusion	O	['N']	[14]
15	of	O	['N']	[15]
16	ifosfamide	B-Drug	['Causes']	[9]
17	.	O	['N']	[17]
#120
0	Risperidone	B-Drug	['Causes']	[46]
1	is	O	['N']	[1]
2	a	O	['N']	[2]
3	frequently	O	['N']	[3]
4	used	O	['N']	[4]
5	member	O	['N']	[5]
6	of	O	['N']	[6]
7	a	O	['N']	[7]
8	new	O	['N']	[8]
9	class	O	['N']	[9]
10	of	O	['N']	[10]
11	atypical	O	['N']	[11]
12	antipsychotics	O	['N']	[12]
13	-	O	['N']	[13]
14	the	O	['N']	[14]
15	serotonin	O	['N']	[15]
16	-	O	['N']	[16]
17	dopamine	O	['N']	[17]
18	antagonists	O	['N']	[18]
19	(	O	['N']	[19]
20	SDAs)-due	O	['N']	[20]
21	to	O	['N']	[21]
22	its	O	['N']	[22]
23	comparatively	O	['N']	[23]
24	high	O	['N']	[24]
25	efficacy	O	['N']	[25]
26	and	O	['N']	[26]
27	low	O	['N']	[27]
28	D2/5HT2	O	['N']	[28]
29	binding	O	['N']	[29]
30	ratio	O	['N']	[30]
31	,	O	['N']	[31]
32	which	O	['N']	[32]
33	results	O	['N']	[33]
34	in	O	['N']	[34]
35	a	O	['N']	[35]
36	low	O	['N']	[36]
37	incidence	O	['N']	[37]
38	of	O	['N']	[38]
39	extrapyramidal	O	['N']	[39]
40	side	O	['N']	[40]
41	effects	O	['N']	[41]
42	including	O	['N']	[42]
43	tardive	O	['N']	[43]
44	dyskinesia	O	['N']	[44]
45	(	O	['N']	[45]
46	TD	B-Adverse_Effect	['N']	[46]
47	)	O	['N']	[47]
48	.	O	['N']	[48]
#121
0	CONCLUSIONS	O	['N']	[0]
1	:	O	['N']	[1]
2	In	O	['N']	[2]
3	our	O	['N']	[3]
4	reported	O	['N']	[4]
5	case	O	['N']	[5]
6	,	O	['N']	[6]
7	a	O	['N']	[7]
8	local	O	['N']	[8]
9	hyperproduction	B	['N']	[9]
10	of	I	['N']	[10]
11	TNF	I	['N']	[11]
12	-	I	['N']	[12]
13	alpha	I-Adverse_Effect	['N']	[13]
14	from	O	['N']	[14]
15	macrophages	O	['N']	[15]
16	that	O	['N']	[16]
17	was	O	['N']	[17]
18	induced	O	['N']	[18]
19	by	O	['N']	[19]
20	the	O	['N']	[20]
21	injected	O	['N']	[21]
22	insulin	B-Drug	['Causes']	[13]
23	could	O	['N']	[23]
24	explain	O	['N']	[24]
25	the	O	['N']	[25]
26	dedifferentiation	O	['N']	[26]
27	of	O	['N']	[27]
28	the	O	['N']	[28]
29	adipocytes	O	['N']	[29]
30	of	O	['N']	[30]
31	the	O	['N']	[31]
32	subcutaneous	O	['N']	[32]
33	tissue	O	['N']	[33]
34	and	O	['N']	[34]
35	the	O	['N']	[35]
36	reversion	O	['N']	[36]
37	that	O	['N']	[37]
38	was	O	['N']	[38]
39	induced	O	['N']	[39]
40	by	O	['N']	[40]
41	the	O	['N']	[41]
42	local	O	['N']	[42]
43	injection	O	['N']	[43]
44	of	O	['N']	[44]
45	dexamethasone	O	['N']	[45]
46	.	O	['N']	[46]
#122
0	STUDY	O	['N']	[0]
1	DESIGN	O	['N']	[1]
2	:	O	['N']	[2]
3	Case	O	['N']	[3]
4	reports	O	['N']	[4]
5	are	O	['N']	[5]
6	presented	O	['N']	[6]
7	of	O	['N']	[7]
8	three	O	['N']	[8]
9	premature	O	['N']	[9]
10	infants	O	['N']	[10]
11	(	O	['N']	[11]
12	mean	O	['N']	[12]
13	gestational	O	['N']	[13]
14	age	O	['N']	[14]
15	27	O	['N']	[15]
16	weeks	O	['N']	[16]
17	)	O	['N']	[17]
18	cared	O	['N']	[18]
19	for	O	['N']	[19]
20	in	O	['N']	[20]
21	the	O	['N']	[21]
22	intensive	O	['N']	[22]
23	care	O	['N']	[23]
24	nursery	O	['N']	[24]
25	in	O	['N']	[25]
26	whom	O	['N']	[26]
27	clinically	O	['N']	[27]
28	significant	O	['N']	[28]
29	septal	B	['N']	[29]
30	hypertrophy	I-Adverse_Effect	['N']	[30]
31	and	O	['N']	[31]
32	left	O	['N']	[32]
33	ventricular	O	['N']	[33]
34	outflow	O	['N']	[34]
35	tract	O	['N']	[35]
36	obstruction	O	['N']	[36]
37	developed	O	['N']	[37]
38	during	O	['N']	[38]
39	dexamethasone	B-Drug	['Causes']	[30]
40	treatment	O	['N']	[40]
41	for	O	['N']	[41]
42	bronchopulmonary	O	['N']	[42]
43	dysplasia	O	['N']	[43]
44	.	O	['N']	[44]
#123
0	Amiodarone	B-Drug	['Causes']	[4]
1	induced	O	['N']	[1]
2	torsades	B	['N']	[2]
3	de	I	['N']	[3]
4	pointe	I-Adverse_Effect	['N']	[4]
5	.	O	['N']	[5]
#124
0	The	O	['N']	[0]
1	patient	O	['N']	[1]
2	presented	O	['N']	[2]
3	with	O	['N']	[3]
4	fulminant	O	['N']	[4]
5	microangiopathic	O	['N']	[5]
6	hemolytic	O	['N']	[6]
7	anemia	O	['N']	[7]
8	and	O	['N']	[8]
9	thrombocytopenia	B-Adverse_Effect	['N']	[9]
10	within	O	['N']	[10]
11	48	O	['N']	[11]
12	hr	O	['N']	[12]
13	of	O	['N']	[13]
14	initiating	O	['N']	[14]
15	therapy	O	['N']	[15]
16	with	O	['N']	[16]
17	trimethoprim	O	['N']	[17]
18	-	O	['N']	[18]
19	sulfamethoxazole	B-Drug	['Causes']	[9]
20	.	O	['N']	[20]
#125
0	Aseptic	O	['N']	[0]
1	meningitis	O	['N']	[1]
2	,	O	['N']	[2]
3	hemolytic	O	['N']	[3]
4	anemia	O	['N']	[4]
5	,	O	['N']	[5]
6	hepatitis	B-Adverse_Effect	['N']	[6]
7	,	O	['N']	[7]
8	and	O	['N']	[8]
9	orthostatic	O	['N']	[9]
10	hypotension	O	['N']	[10]
11	in	O	['N']	[11]
12	a	O	['N']	[12]
13	patient	O	['N']	[13]
14	treated	O	['N']	[14]
15	with	O	['N']	[15]
16	trimethoprim	B-Drug	['Causes']	[6]
17	-	O	['N']	[17]
18	sulfamethoxazole	O	['N']	[18]
19	.	O	['N']	[19]
#126
0	Abrupt	O	['N']	[0]
1	,	O	['N']	[1]
2	accidental	O	['N']	[2]
3	withdrawal	O	['N']	[3]
4	of	O	['N']	[4]
5	trihexyphenidyl	B-Drug	['Causes']	[20]
6	triggered	O	['N']	[6]
7	severe	O	['N']	[7]
8	exacerbation	O	['N']	[8]
9	of	O	['N']	[9]
10	the	O	['N']	[10]
11	cranial	O	['N']	[11]
12	dystonia	O	['N']	[12]
13	associated	O	['N']	[13]
14	with	O	['N']	[14]
15	inspiratory	O	['N']	[15]
16	stridor	O	['N']	[16]
17	and	O	['N']	[17]
18	acute	B	['N']	[18]
19	respiratory	I	['N']	[19]
20	difficulties	I-Adverse_Effect	['N']	[20]
21	,	O	['N']	[21]
22	prompting	O	['N']	[22]
23	emergency	O	['N']	[23]
24	admission	O	['N']	[24]
25	.	O	['N']	[25]
#127
0	A	O	['N']	[0]
1	toxic	O	['N']	[1]
2	encephalopathy	O	['N']	[2]
3	characterized	O	['N']	[3]
4	by	O	['N']	[4]
5	depressed	O	['N']	[5]
6	level	O	['N']	[6]
7	of	O	['N']	[7]
8	consciousness	O	['N']	[8]
9	,	O	['N']	[9]
10	marked	B	['N']	[10]
11	irritability	I-Adverse_Effect	['N']	[11]
12	,	O	['N']	[12]
13	and	O	['N']	[13]
14	ataxia	O	['N']	[14]
15	developed	O	['N']	[15]
16	in	O	['N']	[16]
17	seven	O	['N']	[17]
18	children	O	['N']	[18]
19	,	O	['N']	[19]
20	5	O	['N']	[20]
21	years	O	['N']	[21]
22	of	O	['N']	[22]
23	age	O	['N']	[23]
24	and	O	['N']	[24]
25	younger	O	['N']	[25]
26	,	O	['N']	[26]
27	following	O	['N']	[27]
28	administration	O	['N']	[28]
29	of	O	['N']	[29]
30	an	O	['N']	[30]
31	antiemetic	O	['N']	[31]
32	combination	O	['N']	[32]
33	of	O	['N']	[33]
34	pentobarbital	O	['N']	[34]
35	and	O	['N']	[35]
36	pyrilamine	B	['N']	[36]
37	maleate	I-Drug	['Causes']	[11]
38	.	O	['N']	[38]
#128
0	We	O	['N']	[0]
1	cared	O	['N']	[1]
2	for	O	['N']	[2]
3	a	O	['N']	[3]
4	patient	O	['N']	[4]
5	with	O	['N']	[5]
6	progressive	O	['N']	[6]
7	renal	O	['N']	[7]
8	impairment	O	['N']	[8]
9	who	O	['N']	[9]
10	presented	O	['N']	[10]
11	with	O	['N']	[11]
12	blurred	B	['N']	[12]
13	vision	I-Adverse_Effect	['N']	[13]
14	,	O	['N']	[14]
15	QRS	O	['N']	[15]
16	broadening	O	['N']	[16]
17	and	O	['N']	[17]
18	cardiac	O	['N']	[18]
19	failure	O	['N']	[19]
20	due	O	['N']	[20]
21	to	O	['N']	[21]
22	chronic	O	['N']	[22]
23	cibenzoline	B-Drug	['Causes']	[13]
24	intoxication	O	['N']	[24]
25	.	O	['N']	[25]
#129
0	A	O	['N']	[0]
1	review	O	['N']	[1]
2	of	O	['N']	[2]
3	the	O	['N']	[3]
4	literature	O	['N']	[4]
5	found	O	['N']	[5]
6	11	O	['N']	[6]
7	children	O	['N']	[7]
8	and	O	['N']	[8]
9	2	O	['N']	[9]
10	adults	O	['N']	[10]
11	in	O	['N']	[11]
12	whom	O	['N']	[12]
13	intranasal	O	['N']	[13]
14	desmopressin	B-Drug	['Causes']	[24]
15	was	O	['N']	[15]
16	associated	O	['N']	[16]
17	with	O	['N']	[17]
18	hyponatremia	O	['N']	[18]
19	,	O	['N']	[19]
20	all	O	['N']	[20]
21	of	O	['N']	[21]
22	whom	O	['N']	[22]
23	experienced	O	['N']	[23]
24	seizures	B-Adverse_Effect	['N']	[24]
25	or	O	['N']	[25]
26	altered	O	['N']	[26]
27	mental	O	['N']	[27]
28	status	O	['N']	[28]
29	.	O	['N']	[29]
#130
0	Cutaneous	B	['N']	[0]
1	rashes	I-Adverse_Effect	['N']	[1]
2	and	O	['N']	[2]
3	eruptions	O	['N']	[3]
4	can	O	['N']	[4]
5	be	O	['N']	[5]
6	caused	O	['N']	[6]
7	by	O	['N']	[7]
8	many	O	['N']	[8]
9	medications	O	['N']	[9]
10	,	O	['N']	[10]
11	including	O	['N']	[11]
12	carbamazepine	B-Drug	['Causes']	[1]
13	.	O	['N']	[13]
#131
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	patient	O	['N']	[3]
4	who	O	['N']	[4]
5	developed	O	['N']	[5]
6	heparin	B-Drug	['Causes']	[8]
7	associated	O	['N']	[7]
8	thrombocytopenia	B-Adverse_Effect	['N']	[8]
9	during	O	['N']	[9]
10	continuous	O	['N']	[10]
11	arteriovenous	O	['N']	[11]
12	haemofiltration	O	['N']	[12]
13	and	O	['N']	[13]
14	discuss	O	['N']	[14]
15	its	O	['N']	[15]
16	implications	O	['N']	[16]
17	and	O	['N']	[17]
18	alternative	O	['N']	[18]
19	anticoagulant	O	['N']	[19]
20	treatment	O	['N']	[20]
21	.	O	['N']	[21]
#132
0	Bleomycin	B-Drug	['Causes']	[2]
1	induced	O	['N']	[1]
2	hyperpigmentation	B-Adverse_Effect	['N']	[2]
3	with	O	['N']	[3]
4	yolk	O	['N']	[4]
5	sac	O	['N']	[5]
6	tumor	O	['N']	[6]
7	.	O	['N']	[7]
#133
0	In	O	['N']	[0]
1	this	O	['N']	[1]
2	case	O	['N']	[2]
3	,	O	['N']	[3]
4	interferon	B	['N']	[4]
5	alpha	I-Drug	['Causes']	[9]
6	induced	O	['N']	[6]
7	polymyositis	O	['N']	[7]
8	and	O	['N']	[8]
9	cardiomyopathy	B-Adverse_Effect	['N']	[9]
10	is	O	['N']	[10]
11	diagnosed	O	['N']	[11]
12	in	O	['N']	[12]
13	a	O	['N']	[13]
14	33-yr	O	['N']	[14]
15	-	O	['N']	[15]
16	old	O	['N']	[16]
17	male	O	['N']	[17]
18	patient	O	['N']	[18]
19	with	O	['N']	[19]
20	history	O	['N']	[20]
21	of	O	['N']	[21]
22	chronic	O	['N']	[22]
23	hepatitis	O	['N']	[23]
24	B.	O	['N']	[24]
#134
0	Here	O	['N']	[0]
1	,	O	['N']	[1]
2	we	O	['N']	[2]
3	report	O	['N']	[3]
4	a	O	['N']	[4]
5	case	O	['N']	[5]
6	of	O	['N']	[6]
7	angio	B	['N']	[7]
8	-	I	['N']	[8]
9	oedema	I-Adverse_Effect	['N']	[9]
10	associated	O	['N']	[10]
11	with	O	['N']	[11]
12	VRC	B-Drug	['Causes']	[9]
13	therapy	O	['N']	[13]
14	.	O	['N']	[14]
#135
0	CASE	O	['N']	[0]
1	SUMMARY	O	['N']	[1]
2	:	O	['N']	[2]
3	A	O	['N']	[3]
4	65-year	O	['N']	[4]
5	-	O	['N']	[5]
6	old	O	['N']	[6]
7	patient	O	['N']	[7]
8	chronically	O	['N']	[8]
9	treated	O	['N']	[9]
10	with	O	['N']	[10]
11	the	O	['N']	[11]
12	selective	O	['N']	[12]
13	serotonin	O	['N']	[13]
14	reuptake	O	['N']	[14]
15	inhibitor	O	['N']	[15]
16	(	O	['N']	[16]
17	SSRI	O	['N']	[17]
18	)	O	['N']	[18]
19	citalopram	O	['N']	[19]
20	developed	O	['N']	[20]
21	confusion	O	['N']	[21]
22	,	O	['N']	[22]
23	agitation	O	['N']	[23]
24	,	O	['N']	[24]
25	tachycardia	O	['N']	[25]
26	,	O	['N']	[26]
27	tremors	B-Adverse_Effect	['N']	[27]
28	,	O	['N']	[28]
29	myoclonic	O	['N']	[29]
30	jerks	O	['N']	[30]
31	and	O	['N']	[31]
32	unsteady	O	['N']	[32]
33	gait	O	['N']	[33]
34	,	O	['N']	[34]
35	consistent	O	['N']	[35]
36	with	O	['N']	[36]
37	serotonin	O	['N']	[37]
38	syndrome	O	['N']	[38]
39	,	O	['N']	[39]
40	following	O	['N']	[40]
41	initiation	O	['N']	[41]
42	of	O	['N']	[42]
43	fentanyl	B-Drug	['Causes']	[27]
44	,	O	['N']	[44]
45	and	O	['N']	[45]
46	all	O	['N']	[46]
47	symptoms	O	['N']	[47]
48	and	O	['N']	[48]
49	signs	O	['N']	[49]
50	resolved	O	['N']	[50]
51	following	O	['N']	[51]
52	discontinuation	O	['N']	[52]
53	of	O	['N']	[53]
54	fentanyl	O	['N']	[54]
55	.	O	['N']	[55]
#136
0	Thus	O	['N']	[0]
1	cabergoline	B-Drug	['Causes']	[6]
2	may	O	['N']	[2]
3	cause	O	['N']	[3]
4	similar	O	['N']	[4]
5	pleuropulmonary	B	['N']	[5]
6	abnormalities	I-Adverse_Effect	['N']	[6]
7	to	O	['N']	[7]
8	bromocriptine	O	['N']	[8]
9	.	O	['N']	[9]
#137
0	Methylphenidate	B-Drug	['Causes']	[5]
1	(	O	['N']	[1]
2	Ritalin)-associated	O	['N']	[2]
3	cataract	O	['N']	[3]
4	and	O	['N']	[4]
5	glaucoma	B-Adverse_Effect	['N']	[5]
6	.	O	['N']	[6]
#138
0	Fatal	B	['N']	[0]
1	acute	I	['N']	[1]
2	encephalomyelitis	I-Adverse_Effect	['N']	[2]
3	after	O	['N']	[3]
4	a	O	['N']	[4]
5	single	O	['N']	[5]
6	dose	O	['N']	[6]
7	of	O	['N']	[7]
8	intrathecal	O	['N']	[8]
9	methotrexate	B-Drug	['Causes']	[2]
10	.	O	['N']	[10]
#139
0	Osteonecrosis	B-Adverse_Effect	['N']	[0]
1	is	O	['N']	[1]
2	a	O	['N']	[2]
3	serious	O	['N']	[3]
4	side	O	['N']	[4]
5	effect	O	['N']	[5]
6	of	O	['N']	[6]
7	antiemetic	O	['N']	[7]
8	treatment	O	['N']	[8]
9	with	O	['N']	[9]
10	dexamethasone	B-Drug	['Causes']	[0]
11	and	O	['N']	[11]
12	this	O	['N']	[12]
13	serious	O	['N']	[13]
14	complication	O	['N']	[14]
15	should	O	['N']	[15]
16	be	O	['N']	[16]
17	incorporated	O	['N']	[17]
18	in	O	['N']	[18]
19	the	O	['N']	[19]
20	current	O	['N']	[20]
21	guidelines	O	['N']	[21]
22	.	O	['N']	[22]
#140
0	In	O	['N']	[0]
1	this	O	['N']	[1]
2	case	O	['N']	[2]
3	,	O	['N']	[3]
4	unlike	O	['N']	[4]
5	those	O	['N']	[5]
6	previously	O	['N']	[6]
7	reported	O	['N']	[7]
8	,	O	['N']	[8]
9	hyponatremia	B-Adverse_Effect	['N']	[9]
10	recurred	O	['N']	[10]
11	5	O	['N']	[11]
12	months	O	['N']	[12]
13	after	O	['N']	[13]
14	switching	O	['N']	[14]
15	from	O	['N']	[15]
16	citalopram	O	['N']	[16]
17	to	O	['N']	[17]
18	mirtazapine	B-Drug	['Causes']	[9]
19	,	O	['N']	[19]
20	which	O	['N']	[20]
21	is	O	['N']	[21]
22	believed	O	['N']	[22]
23	to	O	['N']	[23]
24	be	O	['N']	[24]
25	a	O	['N']	[25]
26	safe	O	['N']	[26]
27	antidepressant	O	['N']	[27]
28	.	O	['N']	[28]
#141
0	Although	O	['N']	[0]
1	the	O	['N']	[1]
2	existence	O	['N']	[2]
3	of	O	['N']	[3]
4	an	O	['N']	[4]
5	acute	O	['N']	[5]
6	pericarditis	O	['N']	[6]
7	or	O	['N']	[7]
8	an	O	['N']	[8]
9	acute	O	['N']	[9]
10	myocarditis	O	['N']	[10]
11	as	O	['N']	[11]
12	possible	O	['N']	[12]
13	causes	O	['N']	[13]
14	of	O	['N']	[14]
15	the	O	['N']	[15]
16	ST	O	['N']	[16]
17	elevation	O	['N']	[17]
18	can	O	['N']	[18]
19	not	O	['N']	[19]
20	be	O	['N']	[20]
21	fully	O	['N']	[21]
22	ruled	O	['N']	[22]
23	out	O	['N']	[23]
24	,	O	['N']	[24]
25	the	O	['N']	[25]
26	sudden	O	['N']	[26]
27	onset	O	['N']	[27]
28	,	O	['N']	[28]
29	prominent	O	['N']	[29]
30	magnitude	O	['N']	[30]
31	,	O	['N']	[31]
32	and	O	['N']	[32]
33	brief	O	['N']	[33]
34	duration	O	['N']	[34]
35	of	O	['N']	[35]
36	the	O	['N']	[36]
37	ST	O	['N']	[37]
38	elevation	O	['N']	[38]
39	are	O	['N']	[39]
40	perhaps	O	['N']	[40]
41	more	O	['N']	[41]
42	indicative	O	['N']	[42]
43	of	O	['N']	[43]
44	an	O	['N']	[44]
45	acute	O	['N']	[45]
46	ischemic	O	['N']	[46]
47	event	O	['N']	[47]
48	,	O	['N']	[48]
49	possibly	O	['N']	[49]
50	related	O	['N']	[50]
51	to	O	['N']	[51]
52	a	O	['N']	[52]
53	transient	O	['N']	[53]
54	coronary	B	['N']	[54]
55	vasoconstriction	I-Adverse_Effect	['N']	[55]
56	induced	O	['N']	[56]
57	by	O	['N']	[57]
58	the	O	['N']	[58]
59	dopamine	B-Drug	['Causes']	[55]
60	infusion	O	['N']	[60]
61	.	O	['N']	[61]
#142
0	Priapism	B-Adverse_Effect	['N']	[0]
1	associated	O	['N']	[1]
2	with	O	['N']	[2]
3	olanzapine	B-Drug	['Causes']	[0]
4	.	O	['N']	[4]
#143
0	Ritonavir	B-Drug	['Causes']	[9]
1	acted	O	['N']	[1]
2	as	O	['N']	[2]
3	a	O	['N']	[3]
4	CYP3A4	O	['N']	[4]
5	inhibitor	O	['N']	[5]
6	,	O	['N']	[6]
7	diminishing	B	['N']	[7]
8	carbamazepine	I	['N']	[8]
9	metabolism	I-Adverse_Effect	['N']	[9]
10	and	O	['N']	[10]
11	provoking	O	['N']	[11]
12	an	O	['N']	[12]
13	increase	O	['N']	[13]
14	in	O	['N']	[14]
15	serum	O	['N']	[15]
16	levels	O	['N']	[16]
17	and	O	['N']	[17]
18	clinical	O	['N']	[18]
19	toxicity	O	['N']	[19]
20	.	O	['N']	[20]
#144
0	Severe	O	['N']	[0]
1	serotonin	B	['N']	[1]
2	syndrome	I-Adverse_Effect	['N']	[2]
3	induced	O	['N']	[3]
4	by	O	['N']	[4]
5	mirtazapine	B-Drug	['Causes']	[2]
6	monotherapy	O	['N']	[6]
7	.	O	['N']	[7]
#145
0	We	O	['N']	[0]
1	conclude	O	['N']	[1]
2	that	O	['N']	[2]
3	myocardial	O	['N']	[3]
4	infarction	O	['N']	[4]
5	may	O	['N']	[5]
6	develop	O	['N']	[6]
7	in	O	['N']	[7]
8	patients	O	['N']	[8]
9	treated	O	['N']	[9]
10	with	O	['N']	[10]
11	high	B	['N']	[11]
12	-	I	['N']	[12]
13	dose	I-Dose	['N']	[13]
14	glucocorticoids	B-Drug	['Dosage']	[13]
15	for	O	['N']	[15]
16	Graves	O	['N']	[16]
17	'	O	['N']	[17]
18	ophthalmopathy	O	['N']	[18]
19	,	O	['N']	[19]
20	and	O	['N']	[20]
21	increased	O	['N']	[21]
22	blood	O	['N']	[22]
23	pressure	O	['N']	[23]
24	may	O	['N']	[24]
25	herald	O	['N']	[25]
26	this	O	['N']	[26]
27	complication	O	['N']	[27]
28	.	O	['N']	[28]
#146
0	The	O	['N']	[0]
1	induction	O	['N']	[1]
2	of	O	['N']	[2]
3	hypoglycaemia	B-Adverse_Effect	['N']	[3]
4	with	O	['N']	[4]
5	PAS	B-Drug	['Causes']	[3]
6	in	O	['N']	[6]
7	this	O	['N']	[7]
8	patient	O	['N']	[8]
9	suggests	O	['N']	[9]
10	a	O	['N']	[10]
11	potential	O	['N']	[11]
12	role	O	['N']	[12]
13	for	O	['N']	[13]
14	PAS	O	['N']	[14]
15	in	O	['N']	[15]
16	the	O	['N']	[16]
17	treatment	O	['N']	[17]
18	of	O	['N']	[18]
19	diabetes	O	['N']	[19]
20	mellitus	O	['N']	[20]
21	.	O	['N']	[21]
#147
0	We	O	['N']	[0]
1	describe	O	['N']	[1]
2	2	O	['N']	[2]
3	patients	O	['N']	[3]
4	with	O	['N']	[4]
5	severe	O	['N']	[5]
6	erosive	O	['N']	[6]
7	rheumatoid	O	['N']	[7]
8	arthritis	O	['N']	[8]
9	and	O	['N']	[9]
10	rheumatoid	O	['N']	[10]
11	vasculitis	O	['N']	[11]
12	,	O	['N']	[12]
13	respectively	O	['N']	[13]
14	,	O	['N']	[14]
15	in	O	['N']	[15]
16	whom	O	['N']	[16]
17	infliximab	B-Drug	['Causes']	[27]
18	therapy	O	['N']	[18]
19	was	O	['N']	[19]
20	associated	O	['N']	[20]
21	with	O	['N']	[21]
22	peripheral	O	['N']	[22]
23	neuropathy	O	['N']	[23]
24	due	O	['N']	[24]
25	to	O	['N']	[25]
26	necrotizing	B	['N']	[26]
27	vasculitis	I-Adverse_Effect	['N']	[27]
28	in	O	['N']	[28]
29	one	O	['N']	[29]
30	patient	O	['N']	[30]
31	and	O	['N']	[31]
32	to	O	['N']	[32]
33	progression	O	['N']	[33]
34	of	O	['N']	[34]
35	preexisting	O	['N']	[35]
36	mononeuritis	O	['N']	[36]
37	multiplex	O	['N']	[37]
38	in	O	['N']	[38]
39	the	O	['N']	[39]
40	other	O	['N']	[40]
41	.	O	['N']	[41]
#148
0	We	O	['N']	[0]
1	have	O	['N']	[1]
2	described	O	['N']	[2]
3	three	O	['N']	[3]
4	patients	O	['N']	[4]
5	with	O	['N']	[5]
6	hepatitis	O	['N']	[6]
7	C	O	['N']	[7]
8	for	O	['N']	[8]
9	whom	O	['N']	[9]
10	IFN	O	['N']	[10]
11	-	O	['N']	[11]
12	alpha	O	['N']	[12]
13	and	O	['N']	[13]
14	ribavirin	B-Drug	['Causes']	[25]
15	were	O	['N']	[15]
16	prescribed	O	['N']	[16]
17	and	O	['N']	[17]
18	who	O	['N']	[18]
19	developed	O	['N']	[19]
20	two	O	['N']	[20]
21	successive	O	['N']	[21]
22	phases	O	['N']	[22]
23	of	O	['N']	[23]
24	silent	O	['N']	[24]
25	thyroiditis	B-Adverse_Effect	['N']	[25]
26	followed	O	['N']	[26]
27	by	O	['N']	[27]
28	hyperthryroidism	O	['N']	[28]
29	relapse	O	['N']	[29]
30	due	O	['N']	[30]
31	to	O	['N']	[31]
32	Graves	O	['N']	[32]
33	'	O	['N']	[33]
34	disease	O	['N']	[34]
35	.	O	['N']	[35]
#149
0	This	O	['N']	[0]
1	case	O	['N']	[1]
2	highlights	O	['N']	[2]
3	the	O	['N']	[3]
4	need	O	['N']	[4]
5	to	O	['N']	[5]
6	monitor	O	['N']	[6]
7	liver	O	['N']	[7]
8	enzymes	O	['N']	[8]
9	in	O	['N']	[9]
10	patients	O	['N']	[10]
11	treated	O	['N']	[11]
12	with	O	['N']	[12]
13	6-TG	O	['N']	[13]
14	and	O	['N']	[14]
15	identifies	O	['N']	[15]
16	the	O	['N']	[16]
17	need	O	['N']	[17]
18	for	O	['N']	[18]
19	additional	O	['N']	[19]
20	research	O	['N']	[20]
21	focused	O	['N']	[21]
22	on	O	['N']	[22]
23	the	O	['N']	[23]
24	mechanism	O	['N']	[24]
25	of	O	['N']	[25]
26	thiopurine	B-Drug	['Causes']	[30]
27	-	O	['N']	[27]
28	induced	O	['N']	[28]
29	hepatic	B	['N']	[29]
30	injury	I-Adverse_Effect	['N']	[30]
31	.	O	['N']	[31]
#150
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	48-year	O	['N']	[5]
6	-	O	['N']	[6]
7	old	O	['N']	[7]
8	woman	O	['N']	[8]
9	with	O	['N']	[9]
10	seizure	O	['N']	[10]
11	disorder	O	['N']	[11]
12	on	O	['N']	[12]
13	divalproex	O	['N']	[13]
14	sodium	O	['N']	[14]
15	(	O	['N']	[15]
16	Depakote	B-Drug	['Causes']	[21]
17	)	O	['N']	[17]
18	who	O	['N']	[18]
19	presented	O	['N']	[19]
20	with	O	['N']	[20]
21	dyspnea	B-Adverse_Effect	['N']	[21]
22	.	O	['N']	[22]
#151
0	Haemolytic	B	['N']	[0]
1	-	I	['N']	[1]
2	uraemic	I	['N']	[2]
3	syndrome	I-Adverse_Effect	['N']	[3]
4	complicating	O	['N']	[4]
5	long	O	['N']	[5]
6	-	O	['N']	[6]
7	term	O	['N']	[7]
8	mitomycin	B	['N']	[8]
9	C	I-Drug	['Causes']	[3]
10	and	O	['N']	[10]
11	5-fluorouracil	O	['N']	[11]
12	therapy	O	['N']	[12]
13	for	O	['N']	[13]
14	gastric	O	['N']	[14]
15	carcinoma	O	['N']	[15]
16	.	O	['N']	[16]
#152
0	Here	O	['N']	[0]
1	,	O	['N']	[1]
2	we	O	['N']	[2]
3	describe	O	['N']	[3]
4	a	O	['N']	[4]
5	case	O	['N']	[5]
6	of	O	['N']	[6]
7	Vogt	B	['N']	[7]
8	-	I	['N']	[8]
9	Koyanagi	I	['N']	[9]
10	-	I	['N']	[10]
11	Harada	I	['N']	[11]
12	disease	I-Adverse_Effect	['N']	[12]
13	occurring	O	['N']	[13]
14	4	O	['N']	[14]
15	months	O	['N']	[15]
16	after	O	['N']	[16]
17	the	O	['N']	[17]
18	start	O	['N']	[18]
19	of	O	['N']	[19]
20	interferon	B	['N']	[20]
21	alpha	I-Drug	['Causes']	[12]
22	treatment	O	['N']	[22]
23	,	O	['N']	[23]
24	probably	O	['N']	[24]
25	induced	O	['N']	[25]
26	by	O	['N']	[26]
27	the	O	['N']	[27]
28	immunomodulatory	O	['N']	[28]
29	effects	O	['N']	[29]
30	of	O	['N']	[30]
31	interferon	O	['N']	[31]
32	.	O	['N']	[32]
#153
0	Autopsy	O	['N']	[0]
1	evidence	O	['N']	[1]
2	of	O	['N']	[2]
3	herpesvirus	B	['N']	[3]
4	infection	I-Adverse_Effect	['N']	[4]
5	was	O	['N']	[5]
6	found	O	['N']	[6]
7	in	O	['N']	[7]
8	visceral	O	['N']	[8]
9	organs	O	['N']	[9]
10	of	O	['N']	[10]
11	four	O	['N']	[11]
12	leukemic	O	['N']	[12]
13	patients	O	['N']	[13]
14	who	O	['N']	[14]
15	had	O	['N']	[15]
16	received	O	['N']	[16]
17	large	O	['N']	[17]
18	doses	O	['N']	[18]
19	of	O	['N']	[19]
20	cytarabine	B-Drug	['Causes']	[4]
21	(	O	['N']	[21]
22	cytosine	O	['N']	[22]
23	arabinoside	O	['N']	[23]
24	;	O	['N']	[24]
25	Ara	O	['N']	[25]
26	-	O	['N']	[26]
27	C	O	['N']	[27]
28	)	O	['N']	[28]
29	shortly	O	['N']	[29]
30	before	O	['N']	[30]
31	their	O	['N']	[31]
32	death	O	['N']	[32]
33	.	O	['N']	[33]
#154
0	The	O	['N']	[0]
1	first	O	['N']	[1]
2	patient	O	['N']	[2]
3	developed	O	['N']	[3]
4	mild	O	['N']	[4]
5	nitritoid	O	['N']	[5]
6	symptoms	O	['N']	[6]
7	and	O	['N']	[7]
8	pain	O	['N']	[8]
9	in	O	['N']	[9]
10	a	O	['N']	[10]
11	band	O	['N']	[11]
12	-	O	['N']	[12]
13	like	O	['N']	[13]
14	distribution	O	['N']	[14]
15	,	O	['N']	[15]
16	corresponding	O	['N']	[16]
17	to	O	['N']	[17]
18	T10-T12	B	['N']	[18]
19	dermatomes	I-Adverse_Effect	['N']	[19]
20	,	O	['N']	[20]
21	shortly	O	['N']	[21]
22	after	O	['N']	[22]
23	gold	B	['N']	[23]
24	sodium	I	['N']	[24]
25	thiomalate	I-Drug	['Causes']	[19]
26	(	O	['N']	[26]
27	GSTM	O	['N']	[27]
28	)	O	['N']	[28]
29	injection	O	['N']	[29]
30	.	O	['N']	[30]
#155
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	31-year	O	['N']	[3]
4	-	O	['N']	[4]
5	old	O	['N']	[5]
6	women	O	['N']	[6]
7	with	O	['N']	[7]
8	recurrent	O	['N']	[8]
9	Hodgkin	O	['N']	[9]
10	's	O	['N']	[10]
11	lymphoma	O	['N']	[11]
12	and	O	['N']	[12]
13	unrecognized	O	['N']	[13]
14	HMSN-1	O	['N']	[14]
15	who	O	['N']	[15]
16	developed	O	['N']	[16]
17	severe	B	['N']	[17]
18	motor	I	['N']	[18]
19	neuropathy	I-Adverse_Effect	['N']	[19]
20	3	O	['N']	[20]
21	weeks	O	['N']	[21]
22	after	O	['N']	[22]
23	the	O	['N']	[23]
24	first	O	['N']	[24]
25	cycle	O	['N']	[25]
26	of	O	['N']	[26]
27	treatment	O	['N']	[27]
28	including	O	['N']	[28]
29	2	O	['N']	[29]
30	mg	O	['N']	[30]
31	of	O	['N']	[31]
32	vincristine	B-Drug	['Causes']	[19]
33	.	O	['N']	[33]
#156
0	In	O	['N']	[0]
1	this	O	['N']	[1]
2	article	O	['N']	[2]
3	,	O	['N']	[3]
4	we	O	['N']	[4]
5	present	O	['N']	[5]
6	the	O	['N']	[6]
7	case	O	['N']	[7]
8	of	O	['N']	[8]
9	a	O	['N']	[9]
10	vitiligo	O	['N']	[10]
11	patient	O	['N']	[11]
12	who	O	['N']	[12]
13	was	O	['N']	[13]
14	admitted	O	['N']	[14]
15	to	O	['N']	[15]
16	our	O	['N']	[16]
17	facility	O	['N']	[17]
18	with	O	['N']	[18]
19	an	O	['N']	[19]
20	intense	B	['N']	[20]
21	burn	I-Adverse_Effect	['N']	[21]
22	after	O	['N']	[22]
23	the	O	['N']	[23]
24	topical	O	['N']	[24]
25	use	O	['N']	[25]
26	of	O	['N']	[26]
27	8-methoxypsoralen	B-Drug	['Causes']	[21]
28	solution	O	['N']	[28]
29	as	O	['N']	[29]
30	a	O	['N']	[30]
31	suntanning	O	['N']	[31]
32	agent	O	['N']	[32]
33	.	O	['N']	[33]
#157
0	OBJECTIVE	O	['N']	[0]
1	:	O	['N']	[1]
2	To	O	['N']	[2]
3	describe	O	['N']	[3]
4	onset	O	['N']	[4]
5	of	O	['N']	[5]
6	syndrome	O	['N']	[6]
7	of	O	['N']	[7]
8	inappropriate	O	['N']	[8]
9	antidiuretic	O	['N']	[9]
10	hormone	O	['N']	[10]
11	(	O	['N']	[11]
12	SIADH	B-Adverse_Effect	['N']	[12]
13	)	O	['N']	[13]
14	associated	O	['N']	[14]
15	with	O	['N']	[15]
16	vinorelbine	B-Drug	['Causes']	[12]
17	therapy	O	['N']	[17]
18	for	O	['N']	[18]
19	advanced	O	['N']	[19]
20	breast	O	['N']	[20]
21	cancer	O	['N']	[21]
22	.	O	['N']	[22]
#158
0	Severe	O	['N']	[0]
1	heparin	B-Drug	['Causes']	[3]
2	associated	O	['N']	[2]
3	thrombocytopenia	B-Adverse_Effect	['N']	[3]
4	is	O	['N']	[4]
5	a	O	['N']	[5]
6	rare	O	['N']	[6]
7	complication	O	['N']	[7]
8	of	O	['N']	[8]
9	heparin	O	['N']	[9]
10	therapy	O	['N']	[10]
11	.	O	['N']	[11]
#159
0	Easily	O	['N']	[0]
1	reversible	O	['N']	[1]
2	hypoxemia	B-Adverse_Effect	['N']	[2]
3	and	O	['N']	[3]
4	hypotension	O	['N']	[4]
5	induced	O	['N']	[5]
6	by	O	['N']	[6]
7	nimodipine	B-Drug	['Causes']	[2]
8	.	O	['N']	[8]
#160
0	CASE	O	['N']	[0]
1	REPORT	O	['N']	[1]
2	:	O	['N']	[2]
3	We	O	['N']	[3]
4	hereby	O	['N']	[4]
5	report	O	['N']	[5]
6	a	O	['N']	[6]
7	case	O	['N']	[7]
8	of	O	['N']	[8]
9	radiation	O	['N']	[9]
10	recall	O	['N']	[10]
11	dermatitis	O	['N']	[11]
12	and	O	['N']	[12]
13	myositis	B-Adverse_Effect	['N']	[13]
14	occurring	O	['N']	[14]
15	on	O	['N']	[15]
16	gemcitabine	B-Drug	['Causes']	[13]
17	monotherapy	O	['N']	[17]
18	,	O	['N']	[18]
19	five	O	['N']	[19]
20	months	O	['N']	[20]
21	after	O	['N']	[21]
22	completing	O	['N']	[22]
23	chemoradiation	O	['N']	[23]
24	for	O	['N']	[24]
25	locally	O	['N']	[25]
26	advanced	O	['N']	[26]
27	pancreatic	O	['N']	[27]
28	cancer	O	['N']	[28]
29	.	O	['N']	[29]
#161
0	A	O	['N']	[0]
1	case	O	['N']	[1]
2	is	O	['N']	[2]
3	presented	O	['N']	[3]
4	of	O	['N']	[4]
5	a	O	['N']	[5]
6	patient	O	['N']	[6]
7	who	O	['N']	[7]
8	experienced	O	['N']	[8]
9	benzodiazepine	B	['N']	[9]
10	withdrawal	I	['N']	[10]
11	symptoms	I-Adverse_Effect	['N']	[11]
12	on	O	['N']	[12]
13	discontinuation	O	['N']	[13]
14	of	O	['N']	[14]
15	nefazodone	B-Drug	['Causes']	[11]
16	,	O	['N']	[16]
17	an	O	['N']	[17]
18	antidepressant	O	['N']	[18]
19	that	O	['N']	[19]
20	inhibits	O	['N']	[20]
21	the	O	['N']	[21]
22	cytochrome	O	['N']	[22]
23	P450	O	['N']	[23]
24	3A4	O	['N']	[24]
25	isoenzyme	O	['N']	[25]
26	.	O	['N']	[26]
#162
0	CASE	O	['N']	[0]
1	SUMMARY	O	['N']	[1]
2	:	O	['N']	[2]
3	A	O	['N']	[3]
4	65-year	O	['N']	[4]
5	-	O	['N']	[5]
6	old	O	['N']	[6]
7	patient	O	['N']	[7]
8	chronically	O	['N']	[8]
9	treated	O	['N']	[9]
10	with	O	['N']	[10]
11	the	O	['N']	[11]
12	selective	O	['N']	[12]
13	serotonin	O	['N']	[13]
14	reuptake	O	['N']	[14]
15	inhibitor	O	['N']	[15]
16	(	O	['N']	[16]
17	SSRI	O	['N']	[17]
18	)	O	['N']	[18]
19	citalopram	B-Drug	['Causes']	[27]
20	developed	O	['N']	[20]
21	confusion	O	['N']	[21]
22	,	O	['N']	[22]
23	agitation	O	['N']	[23]
24	,	O	['N']	[24]
25	tachycardia	O	['N']	[25]
26	,	O	['N']	[26]
27	tremors	B-Adverse_Effect	['N']	[27]
28	,	O	['N']	[28]
29	myoclonic	O	['N']	[29]
30	jerks	O	['N']	[30]
31	and	O	['N']	[31]
32	unsteady	O	['N']	[32]
33	gait	O	['N']	[33]
34	,	O	['N']	[34]
35	consistent	O	['N']	[35]
36	with	O	['N']	[36]
37	serotonin	O	['N']	[37]
38	syndrome	O	['N']	[38]
39	,	O	['N']	[39]
40	following	O	['N']	[40]
41	initiation	O	['N']	[41]
42	of	O	['N']	[42]
43	fentanyl	O	['N']	[43]
44	,	O	['N']	[44]
45	and	O	['N']	[45]
46	all	O	['N']	[46]
47	symptoms	O	['N']	[47]
48	and	O	['N']	[48]
49	signs	O	['N']	[49]
50	resolved	O	['N']	[50]
51	following	O	['N']	[51]
52	discontinuation	O	['N']	[52]
53	of	O	['N']	[53]
54	fentanyl	O	['N']	[54]
55	.	O	['N']	[55]
#163
0	After	O	['N']	[0]
1	the	O	['N']	[1]
2	addition	O	['N']	[2]
3	of	O	['N']	[3]
4	citalopram	B-Drug	['Causes']	[10]
5	,	O	['N']	[5]
6	a	O	['N']	[6]
7	desmethylclomipramine	B	['N']	[7]
8	plasma	I	['N']	[8]
9	level	I	['N']	[9]
10	increase	I-Adverse_Effect	['N']	[10]
11	and	O	['N']	[11]
12	an	O	['N']	[12]
13	8-hydroacy	O	['N']	[13]
14	-	O	['N']	[14]
15	desmethylclomipramine	O	['N']	[15]
16	plasma	O	['N']	[16]
17	level	O	['N']	[17]
18	decrease	O	['N']	[18]
19	were	O	['N']	[19]
20	observed	O	['N']	[20]
21	.	O	['N']	[21]
#164
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	4	O	['N']	[2]
3	patients	O	['N']	[3]
4	,	O	['N']	[4]
5	2	O	['N']	[5]
6	on	O	['N']	[6]
7	methylphenidate	O	['N']	[7]
8	and	O	['N']	[8]
9	2	O	['N']	[9]
10	on	O	['N']	[10]
11	dextroamphetamine	B-Drug	['Causes']	[23]
12	who	O	['N']	[12]
13	presented	O	['N']	[13]
14	with	O	['N']	[14]
15	acral	O	['N']	[15]
16	cyanosis	O	['N']	[16]
17	,	O	['N']	[17]
18	livedo	O	['N']	[18]
19	reticularis	O	['N']	[19]
20	,	O	['N']	[20]
21	or	O	['N']	[21]
22	Raynaud	B	['N']	[22]
23	phenomenon	I-Adverse_Effect	['N']	[23]
24	.	O	['N']	[24]
#165
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	four	O	['N']	[2]
3	cases	O	['N']	[3]
4	of	O	['N']	[4]
5	encephalopathy	B-Adverse_Effect	['N']	[5]
6	coincident	O	['N']	[6]
7	with	O	['N']	[7]
8	elevated	O	['N']	[8]
9	aluminum	-	['N']	[9]
10	levels	O	['N']	[10]
11	as	O	['N']	[11]
12	well	O	['N']	[12]
13	as	O	['N']	[13]
14	one	O	['N']	[14]
15	patient	O	['N']	[15]
16	who	O	['N']	[16]
17	developed	O	['N']	[17]
18	seizures	O	['N']	[18]
19	while	O	['N']	[19]
20	receiving	O	['N']	[20]
21	continuous	O	['N']	[21]
22	bladder	O	['N']	[22]
23	irrigations	O	['N']	[23]
24	with	O	['N']	[24]
25	alum	O	['N']	[25]
26	.	O	['N']	[26]
#166
0	Two	O	['N']	[0]
1	patients	O	['N']	[1]
2	with	O	['N']	[2]
3	osteomyelitis	O	['N']	[3]
4	who	O	['N']	[4]
5	developed	O	['N']	[5]
6	reversible	B	['N']	[6]
7	cholestatic	I	['N']	[7]
8	jaundice	I-Adverse_Effect	['N']	[8]
9	during	O	['N']	[9]
10	treatment	O	['N']	[10]
11	with	O	['N']	[11]
12	oxacillin	B-Drug	['Causes']	[8]
13	derivatives	O	['N']	[13]
14	are	O	['N']	[14]
15	described	O	['N']	[15]
16	.	O	['N']	[16]
#167
0	Concomitant	O	['N']	[0]
1	administration	O	['N']	[1]
2	of	O	['N']	[2]
3	lithium	O	['N']	[3]
4	with	O	['N']	[4]
5	olanzapine	B-Drug	['Causes']	[12]
6	may	O	['N']	[6]
7	place	O	['N']	[7]
8	patients	O	['N']	[8]
9	at	O	['N']	[9]
10	risk	O	['N']	[10]
11	for	O	['N']	[11]
12	NMS	B-Adverse_Effect	['N']	[12]
13	.	O	['N']	[13]
#168
0	She	O	['N']	[0]
1	had	O	['N']	[1]
2	been	O	['N']	[2]
3	on	O	['N']	[3]
4	Copaxone	B-Drug	['Dosage']	[8]
5	20	B	['N']	[5]
6	mg	I	['N']	[6]
7	/	I	['N']	[7]
8	day	I-Dose	['N']	[8]
9	treatment	O	['N']	[9]
10	for	O	['N']	[10]
11	2	O	['N']	[11]
12	years	O	['N']	[12]
13	when	O	['N']	[13]
14	she	O	['N']	[14]
15	first	O	['N']	[15]
16	exhibited	O	['N']	[16]
17	gastrointestinal	O	['N']	[17]
18	symptoms	O	['N']	[18]
19	.	O	['N']	[19]
#169
0	On	O	['N']	[0]
1	the	O	['N']	[1]
2	second	O	['N']	[2]
3	day	O	['N']	[3]
4	of	O	['N']	[4]
5	hospitalization	O	['N']	[5]
6	,	O	['N']	[6]
7	it	O	['N']	[7]
8	was	O	['N']	[8]
9	noted	O	['N']	[9]
10	that	O	['N']	[10]
11	the	O	['N']	[11]
12	patient	O	['N']	[12]
13	's	O	['N']	[13]
14	dyspnea	B-Adverse_Effect	['N']	[14]
15	and	O	['N']	[15]
16	sinus	O	['N']	[16]
17	bradycardia	O	['N']	[17]
18	could	O	['N']	[18]
19	be	O	['N']	[19]
20	related	O	['N']	[20]
21	to	O	['N']	[21]
22	a	O	['N']	[22]
23	recent	O	['N']	[23]
24	increase	O	['N']	[24]
25	in	O	['N']	[25]
26	his	O	['N']	[26]
27	timolol	B-Drug	['Causes']	[14]
28	dosage	O	['N']	[28]
29	.	O	['N']	[29]
#170
0	The	O	['N']	[0]
1	chemotherapeutics	O	['N']	[1]
2	,	O	['N']	[2]
3	including	O	['N']	[3]
4	vincristine	B-Drug	['Causes']	[27]
5	,	O	['N']	[5]
6	actinomycin	O	['N']	[6]
7	D	O	['N']	[7]
8	,	O	['N']	[8]
9	and	O	['N']	[9]
10	epirubicin	O	['N']	[10]
11	in	O	['N']	[11]
12	case	O	['N']	[12]
13	1	O	['N']	[13]
14	and	O	['N']	[14]
15	vincristine	O	['N']	[15]
16	and	O	['N']	[16]
17	actinomycin	O	['N']	[17]
18	D	O	['N']	[18]
19	in	O	['N']	[19]
20	case	O	['N']	[20]
21	2	O	['N']	[21]
22	,	O	['N']	[22]
23	were	O	['N']	[23]
24	given	O	['N']	[24]
25	before	O	['N']	[25]
26	the	O	['N']	[26]
27	hepatotoxicity	B-Adverse_Effect	['N']	[27]
28	developed	O	['N']	[28]
29	.	O	['N']	[29]
#171
0	Transient	O	['N']	[0]
1	neurological	O	['N']	[1]
2	disturbances	O	['N']	[2]
3	induced	O	['N']	[3]
4	by	O	['N']	[4]
5	the	O	['N']	[5]
6	chemotherapy	O	['N']	[6]
7	of	O	['N']	[7]
8	high	B	['N']	[8]
9	-	I	['N']	[9]
10	dose	I-Dose	['N']	[10]
11	methotrexate	B-Drug	['Dosage']	[10]
12	for	O	['N']	[12]
13	osteogenic	O	['N']	[13]
14	sarcoma	O	['N']	[14]
15	.	O	['N']	[15]
#172
0	Rapamycin	O	['N']	[0]
1	/	O	['N']	[1]
2	sirolimus	O	['N']	[2]
3	(	O	['N']	[3]
4	SR	B-Drug	['Causes']	[34]
5	)	O	['N']	[5]
6	,	O	['N']	[6]
7	trade	O	['N']	[7]
8	named	O	['N']	[8]
9	Rapammune	O	['N']	[9]
10	(	O	['N']	[10]
11	Wyeth	O	['N']	[11]
12	-	O	['N']	[12]
13	Ayerst	O	['N']	[13]
14	,	O	['N']	[14]
15	Sydney	O	['N']	[15]
16	,	O	['N']	[16]
17	Australia	O	['N']	[17]
18	)	O	['N']	[18]
19	,	O	['N']	[19]
20	is	O	['N']	[20]
21	a	O	['N']	[21]
22	potent	O	['N']	[22]
23	immunosuppressive	O	['N']	[23]
24	drug	O	['N']	[24]
25	associated	O	['N']	[25]
26	with	O	['N']	[26]
27	myelosuppression	O	['N']	[27]
28	,	O	['N']	[28]
29	hypertension	O	['N']	[29]
30	,	O	['N']	[30]
31	hyperlipidemia	O	['N']	[31]
32	,	O	['N']	[32]
33	and	O	['N']	[33]
34	infection	B-Adverse_Effect	['N']	[34]
35	.	O	['N']	[35]
#173
0	Adverse	O	['N']	[0]
1	reaction	O	['N']	[1]
2	in	O	['N']	[2]
3	a	O	['N']	[3]
4	patient	O	['N']	[4]
5	with	O	['N']	[5]
6	aspirin	B-Drug	['Causes']	[9]
7	-	O	['N']	[7]
8	induced	O	['N']	[8]
9	asthma	B-Adverse_Effect	['N']	[9]
10	treated	O	['N']	[10]
11	with	O	['N']	[11]
12	zafirlukast	O	['N']	[12]
13	.	O	['N']	[13]
#174
0	An	O	['N']	[0]
1	association	O	['N']	[1]
2	of	O	['N']	[2]
3	granulocytopenia	B-Adverse_Effect	['N']	[3]
4	,	O	['N']	[4]
5	eosinophilia	O	['N']	[5]
6	,	O	['N']	[6]
7	skin	O	['N']	[7]
8	reaction	O	['N']	[8]
9	and	O	['N']	[9]
10	hepatitis	O	['N']	[10]
11	during	O	['N']	[11]
12	propylthiouracil	B-Drug	['Causes']	[3]
13	(	O	['N']	[13]
14	PTU	O	['N']	[14]
15	)	O	['N']	[15]
16	therapy	O	['N']	[16]
17	for	O	['N']	[17]
18	thyrotoxicosis	O	['N']	[18]
19	in	O	['N']	[19]
20	a	O	['N']	[20]
21	47	O	['N']	[21]
22	year	O	['N']	[22]
23	old	O	['N']	[23]
24	black	O	['N']	[24]
25	female	O	['N']	[25]
26	is	O	['N']	[26]
27	reported	O	['N']	[27]
28	.	O	['N']	[28]
#175
0	Beginning	O	['N']	[0]
1	ductopenia	O	['N']	[1]
2	was	O	['N']	[2]
3	present	O	['N']	[3]
4	in	O	['N']	[4]
5	two	O	['N']	[5]
6	,	O	['N']	[6]
7	suggesting	O	['N']	[7]
8	that	O	['N']	[8]
9	itraconazole	B-Drug	['Causes']	[21]
10	might	O	['N']	[10]
11	be	O	['N']	[11]
12	responsible	O	['N']	[12]
13	for	O	['N']	[13]
14	the	O	['N']	[14]
15	occurrence	O	['N']	[15]
16	of	O	['N']	[16]
17	prolonged	O	['N']	[17]
18	drug	O	['N']	[18]
19	-	O	['N']	[19]
20	induced	O	['N']	[20]
21	cholangiopathy	B-Adverse_Effect	['N']	[21]
22	.	O	['N']	[22]
#176
0	The	O	['N']	[0]
1	former	O	['N']	[1]
2	patient	O	['N']	[2]
3	had	O	['N']	[3]
4	complained	O	['N']	[4]
5	once	O	['N']	[5]
6	that	O	['N']	[6]
7	his	O	['N']	[7]
8	visual	B	['N']	[8]
9	acuity	I	['N']	[9]
10	had	I	['N']	[10]
11	decreased	I-Adverse_Effect	['N']	[11]
12	after	O	['N']	[12]
13	the	O	['N']	[13]
14	termination	O	['N']	[14]
15	of	O	['N']	[15]
16	IFN	B-Drug	['Causes']	[11]
17	therapy	O	['N']	[17]
18	,	O	['N']	[18]
19	and	O	['N']	[19]
20	the	O	['N']	[20]
21	latter	O	['N']	[21]
22	patient	O	['N']	[22]
23	complained	O	['N']	[23]
24	twice	O	['N']	[24]
25	during	O	['N']	[25]
26	IFN	O	['N']	[26]
27	therapy	O	['N']	[27]
28	that	O	['N']	[28]
29	his	O	['N']	[29]
30	visual	O	['N']	[30]
31	acuity	O	['N']	[31]
32	had	O	['N']	[32]
33	decreased	O	['N']	[33]
34	.	O	['N']	[34]
#177
0	Three	O	['N']	[0]
1	of	O	['N']	[1]
2	these	O	['N']	[2]
3	patients	O	['N']	[3]
4	had	O	['N']	[4]
5	convulsions	O	['N']	[5]
6	attributed	O	['N']	[6]
7	to	O	['N']	[7]
8	imipenem	B-Drug	['Causes']	[18]
9	/	O	['N']	[9]
10	cilastatin	O	['N']	[10]
11	;	O	['N']	[11]
12	3.6	O	['N']	[12]
13	%	O	['N']	[13]
14	of	O	['N']	[14]
15	the	O	['N']	[15]
16	patients	O	['N']	[16]
17	had	O	['N']	[17]
18	seizure	B-Adverse_Effect	['N']	[18]
19	,	O	['N']	[19]
20	or	O	['N']	[20]
21	2	O	['N']	[21]
22	%	O	['N']	[22]
23	of	O	['N']	[23]
24	imipenem	O	['N']	[24]
25	/	O	['N']	[25]
26	cilastatin	O	['N']	[26]
27	administrations	O	['N']	[27]
28	was	O	['N']	[28]
29	followed	O	['N']	[29]
30	by	O	['N']	[30]
31	a	O	['N']	[31]
32	seizure	O	['N']	[32]
33	attack	O	['N']	[33]
34	.	O	['N']	[34]
#178
0	Slow	O	['N']	[0]
1	acetylator	O	['N']	[1]
2	genotypes	O	['N']	[2]
3	as	O	['N']	[3]
4	a	O	['N']	[4]
5	possible	O	['N']	[5]
6	risk	O	['N']	[6]
7	factor	O	['N']	[7]
8	for	O	['N']	[8]
9	infectious	B	['N']	[9]
10	mononucleosis	I	['N']	[10]
11	-	I	['N']	[11]
12	like	I	['N']	[12]
13	syndrome	I-Adverse_Effect	['N']	[13]
14	induced	O	['N']	[14]
15	by	O	['N']	[15]
16	salazosulfapyridine	B-Drug	['Causes']	[13]
17	.	O	['N']	[17]
#179
0	Polymyositis	B-Adverse_Effect	['N']	[0]
1	after	O	['N']	[1]
2	propylthiouracil	B-Drug	['Causes']	[0]
3	treatment	O	['N']	[3]
4	for	O	['N']	[4]
5	hyperthyroidism	O	['N']	[5]
6	.	O	['N']	[6]
#180
0	Listeria	O	['N']	[0]
1	brain	O	['N']	[1]
2	abscess	O	['N']	[2]
3	,	O	['N']	[3]
4	Pneumocystis	B	['N']	[4]
5	pneumonia	I-Adverse_Effect	['N']	[5]
6	and	O	['N']	[6]
7	Kaposi	O	['N']	[7]
8	's	O	['N']	[8]
9	sarcoma	O	['N']	[9]
10	after	O	['N']	[10]
11	temozolomide	B-Drug	['Causes']	[5]
12	.	O	['N']	[12]
#181
0	A	O	['N']	[0]
1	7-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	with	O	['N']	[4]
5	congenital	O	['N']	[5]
6	toxoplasmosis	O	['N']	[6]
7	who	O	['N']	[7]
8	took	O	['N']	[8]
9	pyrimethamine	O	['N']	[9]
10	and	O	['N']	[10]
11	sulfadiazine	B-Drug	['Causes']	[22]
12	for	O	['N']	[12]
13	reactivated	O	['N']	[13]
14	chorioretinitis	O	['N']	[14]
15	developed	O	['N']	[15]
16	fever	O	['N']	[16]
17	,	O	['N']	[17]
18	severe	O	['N']	[18]
19	cutaneous	O	['N']	[19]
20	involvement	O	['N']	[20]
21	,	O	['N']	[21]
22	swelling	B-Adverse_Effect	['N']	[22]
23	,	O	['N']	[23]
24	abdominal	O	['N']	[24]
25	pain	O	['N']	[25]
26	and	O	['N']	[26]
27	transaminitis	O	['N']	[27]
28	,	O	['N']	[28]
29	persisting	O	['N']	[29]
30	weeks	O	['N']	[30]
31	after	O	['N']	[31]
32	withholding	O	['N']	[32]
33	medicines	O	['N']	[33]
34	.	O	['N']	[34]
#182
0	Myoclonus	B-Adverse_Effect	['N']	[0]
1	was	O	['N']	[1]
2	induced	O	['N']	[2]
3	and	O	['N']	[3]
4	enhanced	O	['N']	[4]
5	by	O	['N']	[5]
6	L	B	['N']	[6]
7	-	I	['N']	[7]
8	dopa	I-Drug	['Causes']	[0]
9	,	O	['N']	[9]
10	developing	O	['N']	[10]
11	into	O	['N']	[11]
12	generalized	O	['N']	[12]
13	seizures	O	['N']	[13]
14	.	O	['N']	[14]
#183
0	We	O	['N']	[0]
1	suggest	O	['N']	[1]
2	that	O	['N']	[2]
3	sarcoidosis	B-Adverse_Effect	['N']	[3]
4	may	O	['N']	[4]
5	develop	O	['N']	[5]
6	in	O	['N']	[6]
7	chronic	O	['N']	[7]
8	hepatitis	O	['N']	[8]
9	C	O	['N']	[9]
10	patients	O	['N']	[10]
11	during	O	['N']	[11]
12	interferon	B	['N']	[12]
13	alpha	I-Drug	['Causes']	[3]
14	and/or	O	['N']	[14]
15	ribavirin	O	['N']	[15]
16	treatment	O	['N']	[16]
17	,	O	['N']	[17]
18	and	O	['N']	[18]
19	diagnostic	O	['N']	[19]
20	tests	O	['N']	[20]
21	for	O	['N']	[21]
22	this	O	['N']	[22]
23	adverse	O	['N']	[23]
24	effect	O	['N']	[24]
25	should	O	['N']	[25]
26	be	O	['N']	[26]
27	performed	O	['N']	[27]
28	during	O	['N']	[28]
29	the	O	['N']	[29]
30	follow	O	['N']	[30]
31	-	O	['N']	[31]
32	ups	O	['N']	[32]
33	.	O	['N']	[33]
#184
0	PURPOSE	O	['N']	[0]
1	:	O	['N']	[1]
2	To	O	['N']	[2]
3	report	O	['N']	[3]
4	that	O	['N']	[4]
5	acute	O	['N']	[5]
6	lamotrigine	B-Drug	['Causes']	[12]
7	poisoning	O	['N']	[7]
8	may	O	['N']	[8]
9	result	O	['N']	[9]
10	in	O	['N']	[10]
11	severe	O	['N']	[11]
12	encephalopathy	B-Adverse_Effect	['N']	[12]
13	.	O	['N']	[13]
#185
0	An	O	['N']	[0]
1	evaluation	O	['N']	[1]
2	of	O	['N']	[2]
3	ovarian	O	['N']	[3]
4	structure	O	['N']	[4]
5	and	O	['N']	[5]
6	function	O	['N']	[6]
7	should	O	['N']	[7]
8	be	O	['N']	[8]
9	considered	O	['N']	[9]
10	in	O	['N']	[10]
11	women	O	['N']	[11]
12	of	O	['N']	[12]
13	reproductive	O	['N']	[13]
14	age	O	['N']	[14]
15	being	O	['N']	[15]
16	treated	O	['N']	[16]
17	with	O	['N']	[17]
18	valproate	B-Drug	['Causes']	[28]
19	for	O	['N']	[19]
20	epilepsy	O	['N']	[20]
21	,	O	['N']	[21]
22	especially	O	['N']	[22]
23	if	O	['N']	[23]
24	they	O	['N']	[24]
25	develop	O	['N']	[25]
26	menstrual	B	['N']	[26]
27	cycle	I	['N']	[27]
28	disturbances	I-Adverse_Effect	['N']	[28]
29	during	O	['N']	[29]
30	treatment	O	['N']	[30]
31	.	O	['N']	[31]
#186
0	Hypokalemia	B-Adverse_Effect	['N']	[0]
1	after	O	['N']	[1]
2	normal	O	['N']	[2]
3	doses	O	['N']	[3]
4	of	O	['N']	[4]
5	neubulized	O	['N']	[5]
6	albuterol	B-Drug	['Causes']	[0]
7	(	O	['N']	[7]
8	salbutamol	O	['N']	[8]
9	)	O	['N']	[9]
10	.	O	['N']	[10]
#187
0	PURPOSE	O	['N']	[0]
1	:	O	['N']	[1]
2	To	O	['N']	[2]
3	report	O	['N']	[3]
4	a	O	['N']	[4]
5	case	O	['N']	[5]
6	of	O	['N']	[6]
7	nodular	B	['N']	[7]
8	scleritis	I-Adverse_Effect	['N']	[8]
9	following	O	['N']	[9]
10	alendronate	B	['N']	[10]
11	sodium	I-Drug	['Causes']	[8]
12	.	O	['N']	[12]
#188
0	Nephrotic	B	['N']	[0]
1	syndrome	I-Adverse_Effect	['N']	[1]
2	associated	O	['N']	[2]
3	with	O	['N']	[3]
4	interferon	B	['N']	[4]
5	-	I	['N']	[5]
6	beta-1b	I-Drug	['Causes']	[1]
7	therapy	O	['N']	[7]
8	for	O	['N']	[8]
9	multiple	O	['N']	[9]
10	sclerosis	O	['N']	[10]
11	.	O	['N']	[11]
#189
0	A	O	['N']	[0]
1	10-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	asthmatic	O	['N']	[4]
5	boy	O	['N']	[5]
6	began	O	['N']	[6]
7	to	O	['N']	[7]
8	suffer	O	['N']	[8]
9	from	O	['N']	[9]
10	urticarial	B	['N']	[10]
11	rash	I-Adverse_Effect	['N']	[11]
12	and	O	['N']	[12]
13	moderately	O	['N']	[13]
14	severe	O	['N']	[14]
15	bronchospasm	O	['N']	[15]
16	after	O	['N']	[16]
17	8	O	['N']	[17]
18	weeks	O	['N']	[18]
19	'	O	['N']	[19]
20	treatment	O	['N']	[20]
21	with	O	['N']	[21]
22	disodium	B	['N']	[22]
23	cromoglycate	I-Drug	['Causes']	[11]
24	.	O	['N']	[24]
#190
0	Administration	O	['N']	[0]
1	of	O	['N']	[1]
2	excessive	O	['N']	[2]
3	insulin	B-Drug	['Causes']	[15]
4	induced	O	['N']	[4]
5	hypoglycemia	O	['N']	[5]
6	within	O	['N']	[6]
7	4	O	['N']	[7]
8	to	O	['N']	[8]
9	8	O	['N']	[9]
10	hours	O	['N']	[10]
11	,	O	['N']	[11]
12	followed	O	['N']	[12]
13	by	O	['N']	[13]
14	rebound	B	['N']	[14]
15	hyperglycemia	I-Adverse_Effect	['N']	[15]
16	.	O	['N']	[16]
#191
0	Therefore	O	['N']	[0]
1	,	O	['N']	[1]
2	we	O	['N']	[2]
3	diagnosed	O	['N']	[3]
4	her	O	['N']	[4]
5	eruption	O	['N']	[5]
6	as	O	['N']	[6]
7	contact	B	['N']	[7]
8	dermatitis	I-Adverse_Effect	['N']	[8]
9	due	O	['N']	[9]
10	to	O	['N']	[10]
11	sodium	B	['N']	[11]
12	bisulfite	I-Drug	['Causes']	[8]
13	.	O	['N']	[13]
#192
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	a	O	['N']	[5]
6	women	O	['N']	[6]
7	in	O	['N']	[7]
8	whom	O	['N']	[8]
9	a	O	['N']	[9]
10	malignant	B	['N']	[10]
11	mixed	I	['N']	[11]
12	mesodermal	I	['N']	[12]
13	tumor	I-Adverse_Effect	['N']	[13]
14	was	O	['N']	[14]
15	diagnosed	O	['N']	[15]
16	while	O	['N']	[16]
17	she	O	['N']	[17]
18	was	O	['N']	[18]
19	taking	O	['N']	[19]
20	raloxifene	B-Drug	['Causes']	[13]
21	,	O	['N']	[21]
22	which	O	['N']	[22]
23	is	O	['N']	[23]
24	also	O	['N']	[24]
25	a	O	['N']	[25]
26	selective	O	['N']	[26]
27	estrogen	O	['N']	[27]
28	receptor	O	['N']	[28]
29	modulator	O	['N']	[29]
30	.	O	['N']	[30]
#193
0	CONCLUSIONS	O	['N']	[0]
1	:	O	['N']	[1]
2	This	O	['N']	[2]
3	case	O	['N']	[3]
4	describes	O	['N']	[4]
5	the	O	['N']	[5]
6	clinically	O	['N']	[6]
7	significant	O	['N']	[7]
8	increase	B	['N']	[8]
9	of	I	['N']	[9]
10	INR	I-Adverse_Effect	['N']	[10]
11	in	O	['N']	[11]
12	an	O	['N']	[12]
13	elderly	O	['N']	[13]
14	patient	O	['N']	[14]
15	after	O	['N']	[15]
16	adding	O	['N']	[16]
17	a	O	['N']	[17]
18	chemotherapy	O	['N']	[18]
19	regimen	O	['N']	[19]
20	of	O	['N']	[20]
21	levamisole	O	['N']	[21]
22	and	O	['N']	[22]
23	5-FU	O	['N']	[23]
24	to	O	['N']	[24]
25	a	O	['N']	[25]
26	previous	O	['N']	[26]
27	regimen	O	['N']	[27]
28	of	O	['N']	[28]
29	warfarin	B-Drug	['Causes']	[10]
30	alone	O	['N']	[30]
31	.	O	['N']	[31]
#194
0	This	O	['N']	[0]
1	article	O	['N']	[1]
2	describes	O	['N']	[2]
3	two	O	['N']	[3]
4	cases	O	['N']	[4]
5	of	O	['N']	[5]
6	aplastic	B	['N']	[6]
7	anemia	I-Adverse_Effect	['N']	[7]
8	,	O	['N']	[8]
9	at	O	['N']	[9]
10	least	O	['N']	[10]
11	one	O	['N']	[11]
12	of	O	['N']	[12]
13	which	O	['N']	[13]
14	was	O	['N']	[14]
15	almost	O	['N']	[15]
16	certainly	O	['N']	[16]
17	induced	O	['N']	[17]
18	by	O	['N']	[18]
19	the	O	['N']	[19]
20	use	O	['N']	[20]
21	of	O	['N']	[21]
22	methazolamide	B-Drug	['Causes']	[7]
23	,	O	['N']	[23]
24	and	O	['N']	[24]
25	one	O	['N']	[25]
26	case	O	['N']	[26]
27	of	O	['N']	[27]
28	agranulocytosis	O	['N']	[28]
29	related	O	['N']	[29]
30	to	O	['N']	[30]
31	the	O	['N']	[31]
32	use	O	['N']	[32]
33	of	O	['N']	[33]
34	methazolamide	O	['N']	[34]
35	.	O	['N']	[35]
#195
0	CASE	O	['N']	[0]
1	DESCRIPTION	O	['N']	[1]
2	:	O	['N']	[2]
3	A	O	['N']	[3]
4	59-year	O	['N']	[4]
5	-	O	['N']	[5]
6	old	O	['N']	[6]
7	man	O	['N']	[7]
8	with	O	['N']	[8]
9	known	O	['N']	[9]
10	neurocysticercosis	O	['N']	[10]
11	developed	O	['N']	[11]
12	a	O	['N']	[12]
13	large	B	['N']	[13]
14	cerebral	I	['N']	[14]
15	infarction	I-Adverse_Effect	['N']	[15]
16	during	O	['N']	[16]
17	praziquantel	B-Drug	['Causes']	[15]
18	therapy	O	['N']	[18]
19	.	O	['N']	[19]
#196
0	Post	O	['N']	[0]
1	marketing	O	['N']	[1]
2	studies	O	['N']	[2]
3	of	O	['N']	[3]
4	Interferon	O	['N']	[4]
5	-	O	['N']	[5]
6	beta	O	['N']	[6]
7	(	O	['N']	[7]
8	IFN	B	['N']	[8]
9	beta	I-Drug	['Causes']	[24]
10	)	O	['N']	[10]
11	therapy	O	['N']	[11]
12	in	O	['N']	[12]
13	multiple	O	['N']	[13]
14	sclerosis	O	['N']	[14]
15	(	O	['N']	[15]
16	MS	O	['N']	[16]
17	)	O	['N']	[17]
18	have	O	['N']	[18]
19	demonstrated	O	['N']	[19]
20	surprisingly	O	['N']	[20]
21	high	O	['N']	[21]
22	rates	O	['N']	[22]
23	of	O	['N']	[23]
24	hepatotoxicity	B-Adverse_Effect	['N']	[24]
25	.	O	['N']	[25]
#197
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	acne	B	['N']	[5]
6	fulminans	I-Adverse_Effect	['N']	[6]
7	occurring	O	['N']	[7]
8	during	O	['N']	[8]
9	treatment	O	['N']	[9]
10	with	O	['N']	[10]
11	13-cis	B	['N']	[11]
12	-	I	['N']	[12]
13	retinoic	I	['N']	[13]
14	acid	I-Drug	['Causes']	[6]
15	for	O	['N']	[15]
16	cystic	O	['N']	[16]
17	acne	O	['N']	[17]
18	.	O	['N']	[18]
#198
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	the	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	intoxication	B-Adverse_Effect	['N']	[5]
6	of	O	['N']	[6]
7	a	O	['N']	[7]
8	41-year	O	['N']	[8]
9	-	O	['N']	[9]
10	old	O	['N']	[10]
11	female	O	['N']	[11]
12	patient	O	['N']	[12]
13	suffering	O	['N']	[13]
14	from	O	['N']	[14]
15	major	O	['N']	[15]
16	depression	O	['N']	[16]
17	with	O	['N']	[17]
18	mirtazapine	B-Drug	['Causes']	[5]
19	complicated	O	['N']	[19]
20	by	O	['N']	[20]
21	severe	O	['N']	[21]
22	hypothermia	O	['N']	[22]
23	.	O	['N']	[23]
#199
0	Intracranial	B	['N']	[0]
1	hemorrhage	I-Adverse_Effect	['N']	[1]
2	and	O	['N']	[2]
3	focal	O	['N']	[3]
4	seizures	O	['N']	[4]
5	secondary	O	['N']	[5]
6	to	O	['N']	[6]
7	use	O	['N']	[7]
8	of	O	['N']	[8]
9	L	B	['N']	[9]
10	-	I	['N']	[10]
11	asparaginase	I-Drug	['Causes']	[1]
12	during	O	['N']	[12]
13	induction	O	['N']	[13]
14	therapy	O	['N']	[14]
15	of	O	['N']	[15]
16	acute	O	['N']	[16]
17	lymphocytic	O	['N']	[17]
18	leukemia	O	['N']	[18]
19	.	O	['N']	[19]
#200
0	Nevertheless	O	['N']	[0]
1	,	O	['N']	[1]
2	the	O	['N']	[2]
3	coagulopathy	B-Adverse_Effect	['N']	[3]
4	seemed	O	['N']	[4]
5	to	O	['N']	[5]
6	be	O	['N']	[6]
7	most	O	['N']	[7]
8	closely	O	['N']	[8]
9	associated	O	['N']	[9]
10	with	O	['N']	[10]
11	the	O	['N']	[11]
12	administration	O	['N']	[12]
13	of	O	['N']	[13]
14	the	O	['N']	[14]
15	cephalosporin	B-Drug	['Causes']	[3]
16	.	O	['N']	[16]
#201
0	A	O	['N']	[0]
1	66-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	Japanese	O	['N']	[4]
5	woman	O	['N']	[5]
6	with	O	['N']	[6]
7	severe	O	['N']	[7]
8	scleroderma	O	['N']	[8]
9	developed	O	['N']	[9]
10	anemia	O	['N']	[10]
11	and	O	['N']	[11]
12	thrombocytopenia	B-Adverse_Effect	['N']	[12]
13	due	O	['N']	[13]
14	to	O	['N']	[14]
15	D	B	['N']	[15]
16	-	I	['N']	[16]
17	penicillamine	I-Drug	['Causes']	[12]
18	(	O	['N']	[18]
19	D	O	['N']	[19]
20	-	O	['N']	[20]
21	Pen	O	['N']	[21]
22	)	O	['N']	[22]
23	treatment	O	['N']	[23]
24	,	O	['N']	[24]
25	although	O	['N']	[25]
26	the	O	['N']	[26]
27	leukopenia	O	['N']	[27]
28	was	O	['N']	[28]
29	not	O	['N']	[29]
30	markedly	O	['N']	[30]
31	severe	O	['N']	[31]
32	.	O	['N']	[32]
#202
0	The	O	['N']	[0]
1	cause	O	['N']	[1]
2	of	O	['N']	[2]
3	these	O	['N']	[3]
4	previously	O	['N']	[4]
5	unreported	O	['N']	[5]
6	side	O	['N']	[6]
7	effects	O	['N']	[7]
8	of	O	['N']	[8]
9	niacin	B-Drug	['Causes']	[21]
10	therapy	O	['N']	[10]
11	is	O	['N']	[11]
12	uncertain	O	['N']	[12]
13	but	O	['N']	[13]
14	may	O	['N']	[14]
15	be	O	['N']	[15]
16	related	O	['N']	[16]
17	to	O	['N']	[17]
18	prostaglandin	B	['N']	[18]
19	-	I	['N']	[19]
20	mediated	I	['N']	[20]
21	vasodilatation	I-Adverse_Effect	['N']	[21]
22	,	O	['N']	[22]
23	hyperalgesia	O	['N']	[23]
24	of	O	['N']	[24]
25	sensory	O	['N']	[25]
26	nerve	O	['N']	[26]
27	receptors	O	['N']	[27]
28	,	O	['N']	[28]
29	and	O	['N']	[29]
30	potentiation	O	['N']	[30]
31	of	O	['N']	[31]
32	inflammation	O	['N']	[32]
33	in	O	['N']	[33]
34	the	O	['N']	[34]
35	gingiva	O	['N']	[35]
36	with	O	['N']	[36]
37	referral	O	['N']	[37]
38	of	O	['N']	[38]
39	pain	O	['N']	[39]
40	to	O	['N']	[40]
41	the	O	['N']	[41]
42	teeth	O	['N']	[42]
43	.	O	['N']	[43]
#203
0	Pheripheral	O	['N']	[0]
1	edema	O	['N']	[1]
2	was	O	['N']	[2]
3	observed	O	['N']	[3]
4	in	O	['N']	[4]
5	five	O	['N']	[5]
6	female	O	['N']	[6]
7	patients	O	['N']	[7]
8	after	O	['N']	[8]
9	taking	O	['N']	[9]
10	proton	O	['N']	[10]
11	pump	O	['N']	[11]
12	inhibitors	O	['N']	[12]
13	omeprazole	O	['N']	[13]
14	,	O	['N']	[14]
15	lansoprazole	B-Drug	['Dosage']	[30]
16	,	O	['N']	[16]
17	or	O	['N']	[17]
18	pantoprazole	O	['N']	[18]
19	for	O	['N']	[19]
20	7	O	['N']	[20]
21	-	O	['N']	[21]
22	15	O	['N']	[22]
23	days	O	['N']	[23]
24	for	O	['N']	[24]
25	peptic	O	['N']	[25]
26	acid	O	['N']	[26]
27	diseases	O	['N']	[27]
28	in	O	['N']	[28]
29	recommended	O	['N']	[29]
30	standard	B-Dose	['N']	[30]
31	doses	O	['N']	[31]
32	.	O	['N']	[32]
#204
0	CONCLUSIONS	O	['N']	[0]
1	:	O	['N']	[1]
2	These	O	['N']	[2]
3	results	O	['N']	[3]
4	suggest	O	['N']	[4]
5	that	O	['N']	[5]
6	clozapine	B-Drug	['Causes']	[31]
7	may	O	['N']	[7]
8	cause	O	['N']	[8]
9	TD	O	['N']	[9]
10	;	O	['N']	[10]
11	however	O	['N']	[11]
12	,	O	['N']	[12]
13	the	O	['N']	[13]
14	prevalence	O	['N']	[14]
15	is	O	['N']	[15]
16	low	O	['N']	[16]
17	and	O	['N']	[17]
18	the	O	['N']	[18]
19	severity	O	['N']	[19]
20	is	O	['N']	[20]
21	relatively	O	['N']	[21]
22	mild	O	['N']	[22]
23	,	O	['N']	[23]
24	with	O	['N']	[24]
25	no	O	['N']	[25]
26	or	O	['N']	[26]
27	mild	O	['N']	[27]
28	self	O	['N']	[28]
29	-	O	['N']	[29]
30	reported	O	['N']	[30]
31	discomfort	B-Adverse_Effect	['N']	[31]
32	.	O	['N']	[32]
#205
0	Pemphigus	B	['N']	[0]
1	foliaceus	I-Adverse_Effect	['N']	[1]
2	was	O	['N']	[2]
3	seen	O	['N']	[3]
4	in	O	['N']	[4]
5	a	O	['N']	[5]
6	patient	O	['N']	[6]
7	with	O	['N']	[7]
8	pulmonary	O	['N']	[8]
9	tuberculosis	O	['N']	[9]
10	during	O	['N']	[10]
11	rifampicin	B-Drug	['Causes']	[1]
12	therapy	O	['N']	[12]
13	.	O	['N']	[13]
#206
0	CONCLUSIONS	O	['N']	[0]
1	:	O	['N']	[1]
2	Clinicians	O	['N']	[2]
3	should	O	['N']	[3]
4	be	O	['N']	[4]
5	aware	O	['N']	[5]
6	of	O	['N']	[6]
7	a	O	['N']	[7]
8	risk	O	['N']	[8]
9	of	O	['N']	[9]
10	serotonin	O	['N']	[10]
11	syndrome	O	['N']	[11]
12	with	O	['N']	[12]
13	serious	O	['N']	[13]
14	extrapyramidal	B	['N']	[14]
15	reactions	I-Adverse_Effect	['N']	[15]
16	in	O	['N']	[16]
17	patients	O	['N']	[17]
18	receiving	O	['N']	[18]
19	sertraline	B-Drug	['Causes']	[15]
20	or	O	['N']	[20]
21	venlafaxine	O	['N']	[21]
22	when	O	['N']	[22]
23	metoclopramide	O	['N']	[23]
24	is	O	['N']	[24]
25	coadministered	O	['N']	[25]
26	even	O	['N']	[26]
27	in	O	['N']	[27]
28	a	O	['N']	[28]
29	single	O	['N']	[29]
30	,	O	['N']	[30]
31	conventional	O	['N']	[31]
32	dose	O	['N']	[32]
33	.	O	['N']	[33]
#207
0	To	O	['N']	[0]
1	our	O	['N']	[1]
2	knowledge	O	['N']	[2]
3	this	O	['N']	[3]
4	is	O	['N']	[4]
5	the	O	['N']	[5]
6	first	O	['N']	[6]
7	report	O	['N']	[7]
8	that	O	['N']	[8]
9	demonstrates	O	['N']	[9]
10	histological	B	['N']	[10]
11	abnormalities	I	['N']	[11]
12	of	I	['N']	[12]
13	the	I	['N']	[13]
14	glomerulus	I-Adverse_Effect	['N']	[14]
15	associated	O	['N']	[15]
16	with	O	['N']	[16]
17	postoperative	O	['N']	[17]
18	IFN	B	['N']	[18]
19	-	I	['N']	[19]
20	beta	I-Drug	['Causes']	[14]
21	therapy	O	['N']	[21]
22	for	O	['N']	[22]
23	the	O	['N']	[23]
24	malignant	O	['N']	[24]
25	melanoma	O	['N']	[25]
26	.	O	['N']	[26]
#208
0	The	O	['N']	[0]
1	renal	O	['N']	[1]
2	biopsy	O	['N']	[2]
3	showed	O	['N']	[3]
4	focal	B	['N']	[4]
5	segmental	I	['N']	[5]
6	glomerulosclerosis	I-Adverse_Effect	['N']	[6]
7	,	O	['N']	[7]
8	which	O	['N']	[8]
9	has	O	['N']	[9]
10	only	O	['N']	[10]
11	been	O	['N']	[11]
12	previously	O	['N']	[12]
13	reported	O	['N']	[13]
14	in	O	['N']	[14]
15	two	O	['N']	[15]
16	cases	O	['N']	[16]
17	of	O	['N']	[17]
18	CML	O	['N']	[18]
19	treated	O	['N']	[19]
20	with	O	['N']	[20]
21	IFNalpha	B-Drug	['Causes']	[6]
22	.	O	['N']	[22]
#209
0	During	O	['N']	[0]
1	clarithromycin	O	['N']	[1]
2	coadministration	O	['N']	[2]
3	,	O	['N']	[3]
4	four	O	['N']	[4]
5	out	O	['N']	[5]
6	of	O	['N']	[6]
7	the	O	['N']	[7]
8	seven	O	['N']	[8]
9	patients	O	['N']	[9]
10	developed	O	['N']	[10]
11	moderate	O	['N']	[11]
12	-	O	['N']	[12]
13	to	O	['N']	[13]
14	-	O	['N']	[14]
15	severe	O	['N']	[15]
16	toxic	O	['N']	[16]
17	symptoms	O	['N']	[17]
18	of	O	['N']	[18]
19	carbamazepine	B-Drug	['Causes']	[25]
20	,	O	['N']	[20]
21	such	O	['N']	[21]
22	as	O	['N']	[22]
23	drowsiness	O	['N']	[23]
24	,	O	['N']	[24]
25	dizziness	B-Adverse_Effect	['N']	[25]
26	,	O	['N']	[26]
27	and	O	['N']	[27]
28	ataxia	O	['N']	[28]
29	,	O	['N']	[29]
30	which	O	['N']	[30]
31	resolved	O	['N']	[31]
32	within	O	['N']	[32]
33	5	O	['N']	[33]
34	days	O	['N']	[34]
35	after	O	['N']	[35]
36	clarithromycin	O	['N']	[36]
37	discontinuation	O	['N']	[37]
38	.	O	['N']	[38]
#210
0	Purple	O	['N']	[0]
1	glove	O	['N']	[1]
2	syndrome	O	['N']	[2]
3	,	O	['N']	[3]
4	named	O	['N']	[4]
5	for	O	['N']	[5]
6	its	O	['N']	[6]
7	distinctive	O	['N']	[7]
8	purple	O	['N']	[8]
9	discoloration	O	['N']	[9]
10	and	O	['N']	[10]
11	swelling	B	['N']	[11]
12	of	I	['N']	[12]
13	the	I	['N']	[13]
14	hands	I-Adverse_Effect	['N']	[14]
15	in	O	['N']	[15]
16	the	O	['N']	[16]
17	distribution	O	['N']	[17]
18	of	O	['N']	[18]
19	a	O	['N']	[19]
20	glove	O	['N']	[20]
21	,	O	['N']	[21]
22	is	O	['N']	[22]
23	an	O	['N']	[23]
24	uncommon	O	['N']	[24]
25	complication	O	['N']	[25]
26	of	O	['N']	[26]
27	intravenous	O	['N']	[27]
28	phenytoin	B-Drug	['Causes']	[14]
29	administration	O	['N']	[29]
30	through	O	['N']	[30]
31	small	O	['N']	[31]
32	dorsal	O	['N']	[32]
33	veins	O	['N']	[33]
34	of	O	['N']	[34]
35	the	O	['N']	[35]
36	hands	O	['N']	[36]
37	.	O	['N']	[37]
#211
0	The	O	['N']	[0]
1	increased	B	['N']	[1]
2	libido	I-Adverse_Effect	['N']	[2]
3	disappeared	O	['N']	[3]
4	after	O	['N']	[4]
5	fluvoxamine	B-Drug	['Causes']	[2]
6	was	O	['N']	[6]
7	discontinued	O	['N']	[7]
8	.	O	['N']	[8]
#212
0	Chlormadinone	B	['N']	[0]
1	acetate	I-Drug	['Causes']	[3]
2	withdrawal	B	['N']	[2]
3	syndrome	I-Adverse_Effect	['N']	[3]
4	under	O	['N']	[4]
5	combined	O	['N']	[5]
6	androgen	O	['N']	[6]
7	blockade	O	['N']	[7]
8	for	O	['N']	[8]
9	advanced	O	['N']	[9]
10	prostate	O	['N']	[10]
11	cancer	O	['N']	[11]
12	.	O	['N']	[12]
#213
0	Nonspecific	O	['N']	[0]
1	but	O	['N']	[1]
2	significant	B	['N']	[2]
3	abnormalities	I-Adverse_Effect	['N']	[3]
4	have	O	['N']	[4]
5	been	O	['N']	[5]
6	described	O	['N']	[6]
7	in	O	['N']	[7]
8	the	O	['N']	[8]
9	infants	O	['N']	[9]
10	of	O	['N']	[10]
11	women	O	['N']	[11]
12	treated	O	['N']	[12]
13	with	O	['N']	[13]
14	disulfiram	B-Drug	['Causes']	[3]
15	in	O	['N']	[15]
16	the	O	['N']	[16]
17	first	O	['N']	[17]
18	trimester	O	['N']	[18]
19	of	O	['N']	[19]
20	their	O	['N']	[20]
21	pregnancies	O	['N']	[21]
22	.	O	['N']	[22]
#214
0	Our	O	['N']	[0]
1	report	O	['N']	[1]
2	suggested	O	['N']	[2]
3	that	O	['N']	[3]
4	CBDCA	B-Drug	['Dosage']	[50]
5	hypersensitivity	O	['N']	[5]
6	was	O	['N']	[6]
7	correlated	O	['N']	[7]
8	with	O	['N']	[8]
9	the	O	['N']	[9]
10	total	O	['N']	[10]
11	dose	O	['N']	[11]
12	of	O	['N']	[12]
13	previously	O	['N']	[13]
14	administered	O	['N']	[14]
15	platinum	O	['N']	[15]
16	agents	O	['N']	[16]
17	and	O	['N']	[17]
18	that	O	['N']	[18]
19	CBDCA	O	['N']	[19]
20	should	O	['N']	[20]
21	be	O	['N']	[21]
22	excluded	O	['N']	[22]
23	in	O	['N']	[23]
24	patients	O	['N']	[24]
25	who	O	['N']	[25]
26	have	O	['N']	[26]
27	received	O	['N']	[27]
28	multiple	O	['N']	[28]
29	platinum	O	['N']	[29]
30	-	O	['N']	[30]
31	based	O	['N']	[31]
32	chemotherapy	O	['N']	[32]
33	,	O	['N']	[33]
34	even	O	['N']	[34]
35	in	O	['N']	[35]
36	platinum	O	['N']	[36]
37	-	O	['N']	[37]
38	sensitive	O	['N']	[38]
39	cases	O	['N']	[39]
40	,	O	['N']	[40]
41	because	O	['N']	[41]
42	CBDCA	O	['N']	[42]
43	hypersensitivity	O	['N']	[43]
44	can	O	['N']	[44]
45	occur	O	['N']	[45]
46	even	O	['N']	[46]
47	with	O	['N']	[47]
48	low	B	['N']	[48]
49	-	I	['N']	[49]
50	dose	I-Dose	['N']	[50]
51	CBDCA	O	['N']	[51]
52	administration	O	['N']	[52]
53	.	O	['N']	[53]
#215
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	the	O	['N']	[2]
3	first	O	['N']	[3]
4	case	O	['N']	[4]
5	of	O	['N']	[5]
6	an	O	['N']	[6]
7	acute	O	['N']	[7]
8	flare	O	['N']	[8]
9	of	O	['N']	[9]
10	eosinophilic	B	['N']	[10]
11	cystitis	I-Adverse_Effect	['N']	[11]
12	in	O	['N']	[12]
13	a	O	['N']	[13]
14	51-year	O	['N']	[14]
15	-	O	['N']	[15]
16	old	O	['N']	[16]
17	woman	O	['N']	[17]
18	after	O	['N']	[18]
19	bladder	O	['N']	[19]
20	instillation	O	['N']	[20]
21	with	O	['N']	[21]
22	dimethyl	B	['N']	[22]
23	sulfoxide	I-Drug	['Causes']	[11]
24	(	O	['N']	[24]
25	DMSO	O	['N']	[25]
26	)	O	['N']	[26]
27	for	O	['N']	[27]
28	presumed	O	['N']	[28]
29	interstitial	O	['N']	[29]
30	cystitis	O	['N']	[30]
31	.	O	['N']	[31]
#216
0	Unexpected	O	['N']	[0]
1	severe	O	['N']	[1]
2	reversible	O	['N']	[2]
3	cyclosporine	B	['N']	[3]
4	A	I-Drug	['Causes']	[7]
5	-	O	['N']	[5]
6	induced	O	['N']	[6]
7	nephrotoxicity	B-Adverse_Effect	['N']	[7]
8	in	O	['N']	[8]
9	a	O	['N']	[9]
10	patient	O	['N']	[10]
11	with	O	['N']	[11]
12	systemic	O	['N']	[12]
13	lupus	O	['N']	[13]
14	erythematosus	O	['N']	[14]
15	and	O	['N']	[15]
16	tubulointerstitial	O	['N']	[16]
17	renal	O	['N']	[17]
18	disease	O	['N']	[18]
19	.	O	['N']	[19]
#217
0	Since	O	['N']	[0]
1	amiodarone	B-Drug	['Causes']	[18]
2	was	O	['N']	[2]
3	first	O	['N']	[3]
4	marketed	O	['N']	[4]
5	in	O	['N']	[5]
6	1992	O	['N']	[6]
7	in	O	['N']	[7]
8	Japan	O	['N']	[8]
9	,	O	['N']	[9]
10	the	O	['N']	[10]
11	incidence	O	['N']	[11]
12	of	O	['N']	[12]
13	amiodarone	O	['N']	[13]
14	-	O	['N']	[14]
15	induced	O	['N']	[15]
16	thyrotoxicosis	O	['N']	[16]
17	(	O	['N']	[17]
18	AIT	B-Adverse_Effect	['N']	[18]
19	)	O	['N']	[19]
20	has	O	['N']	[20]
21	been	O	['N']	[21]
22	increasing	O	['N']	[22]
23	.	O	['N']	[23]
#218
0	OBJECTIVE	O	['N']	[0]
1	:	O	['N']	[1]
2	To	O	['N']	[2]
3	report	O	['N']	[3]
4	a	O	['N']	[4]
5	case	O	['N']	[5]
6	of	O	['N']	[6]
7	reversible	O	['N']	[7]
8	nonthrombocytopenic	B	['N']	[8]
9	palpable	I	['N']	[9]
10	purpura	I-Adverse_Effect	['N']	[10]
11	associated	O	['N']	[11]
12	with	O	['N']	[12]
13	metoclopramide	B-Drug	['Causes']	[10]
14	.	O	['N']	[14]
#219
0	The	O	['N']	[0]
1	literature	O	['N']	[1]
2	on	O	['N']	[2]
3	thiabendazole	B-Drug	['Causes']	[12]
4	-	O	['N']	[4]
5	induced	O	['N']	[5]
6	cholestasis	O	['N']	[6]
7	and	O	['N']	[7]
8	its	O	['N']	[8]
9	association	O	['N']	[9]
10	with	O	['N']	[10]
11	sicca	B	['N']	[11]
12	complex	I-Adverse_Effect	['N']	[12]
13	is	O	['N']	[13]
14	reviewed	O	['N']	[14]
15	.	O	['N']	[15]
#220
0	Progressive	B	['N']	[0]
1	hypoxemia	I-Adverse_Effect	['N']	[1]
2	mandated	O	['N']	[2]
3	endotracheal	O	['N']	[3]
4	intubation	O	['N']	[4]
5	1	O	['N']	[5]
6	week	O	['N']	[6]
7	after	O	['N']	[7]
8	rituximab	B-Drug	['Causes']	[1]
9	administration	O	['N']	[9]
10	and	O	['N']	[10]
11	led	O	['N']	[11]
12	to	O	['N']	[12]
13	death	O	['N']	[13]
14	4	O	['N']	[14]
15	weeks	O	['N']	[15]
16	after	O	['N']	[16]
17	admission	O	['N']	[17]
18	.	O	['N']	[18]
#221
0	A	O	['N']	[0]
1	7-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	with	O	['N']	[4]
5	congenital	O	['N']	[5]
6	toxoplasmosis	O	['N']	[6]
7	who	O	['N']	[7]
8	took	O	['N']	[8]
9	pyrimethamine	O	['N']	[9]
10	and	O	['N']	[10]
11	sulfadiazine	B-Drug	['Causes']	[16]
12	for	O	['N']	[12]
13	reactivated	O	['N']	[13]
14	chorioretinitis	O	['N']	[14]
15	developed	O	['N']	[15]
16	fever	B-Adverse_Effect	['N']	[16]
17	,	O	['N']	[17]
18	severe	O	['N']	[18]
19	cutaneous	O	['N']	[19]
20	involvement	O	['N']	[20]
21	,	O	['N']	[21]
22	swelling	O	['N']	[22]
23	,	O	['N']	[23]
24	abdominal	O	['N']	[24]
25	pain	O	['N']	[25]
26	and	O	['N']	[26]
27	transaminitis	O	['N']	[27]
28	,	O	['N']	[28]
29	persisting	O	['N']	[29]
30	weeks	O	['N']	[30]
31	after	O	['N']	[31]
32	withholding	O	['N']	[32]
33	medicines	O	['N']	[33]
34	.	O	['N']	[34]
#222
0	AIM	O	['N']	[0]
1	:	O	['N']	[1]
2	To	O	['N']	[2]
3	report	O	['N']	[3]
4	three	O	['N']	[4]
5	cases	O	['N']	[5]
6	of	O	['N']	[6]
7	extensive	O	['N']	[7]
8	skin	B	['N']	[8]
9	necrosis	I-Adverse_Effect	['N']	[9]
10	in	O	['N']	[10]
11	cirrhotic	O	['N']	[11]
12	patients	O	['N']	[12]
13	treated	O	['N']	[13]
14	with	O	['N']	[14]
15	the	O	['N']	[15]
16	vasoconstrictor	O	['N']	[16]
17	agent	O	['N']	[17]
18	terlipressin	O	['N']	[18]
19	(	O	['N']	[19]
20	Glypressin	B-Drug	['Causes']	[9]
21	)	O	['N']	[21]
22	.	O	['N']	[22]
#223
0	We	O	['N']	[0]
1	describe	O	['N']	[1]
2	a	O	['N']	[2]
3	premenopausal	O	['N']	[3]
4	woman	O	['N']	[4]
5	who	O	['N']	[5]
6	,	O	['N']	[6]
7	while	O	['N']	[7]
8	having	O	['N']	[8]
9	tamoxifen	B-Drug	['Causes']	[21]
10	due	O	['N']	[10]
11	to	O	['N']	[11]
12	a	O	['N']	[12]
13	diagnosis	O	['N']	[13]
14	of	O	['N']	[14]
15	in	O	['N']	[15]
16	situ	O	['N']	[16]
17	ductal	O	['N']	[17]
18	carcinoma	O	['N']	[18]
19	,	O	['N']	[19]
20	developed	O	['N']	[20]
21	endometriosis	B-Adverse_Effect	['N']	[21]
22	requiring	O	['N']	[22]
23	surgery	O	['N']	[23]
24	.	O	['N']	[24]
#224
0	A	O	['N']	[0]
1	fatal	B	['N']	[1]
2	pancytopenia	I-Adverse_Effect	['N']	[2]
3	occurred	O	['N']	[3]
4	in	O	['N']	[4]
5	a	O	['N']	[5]
6	patient	O	['N']	[6]
7	with	O	['N']	[7]
8	an	O	['N']	[8]
9	history	O	['N']	[9]
10	of	O	['N']	[10]
11	depression	O	['N']	[11]
12	with	O	['N']	[12]
13	hypomanic	O	['N']	[13]
14	rebounds	O	['N']	[14]
15	,	O	['N']	[15]
16	admitted	O	['N']	[16]
17	for	O	['N']	[17]
18	a	O	['N']	[18]
19	manic	O	['N']	[19]
20	episode	O	['N']	[20]
21	and	O	['N']	[21]
22	treated	O	['N']	[22]
23	with	O	['N']	[23]
24	levomepromazine	O	['N']	[24]
25	,	O	['N']	[25]
26	diazepam	O	['N']	[26]
27	and	O	['N']	[27]
28	lithium	B	['N']	[28]
29	carbonate	I-Drug	['Causes']	[2]
30	.	O	['N']	[30]
#225
0	k	O	['N']	[0]
1	bipolar	O	['N']	[1]
2	manic	O	['N']	[2]
3	-	O	['N']	[3]
4	depressive	O	['N']	[4]
5	patient	O	['N']	[5]
6	,	O	['N']	[6]
7	developed	O	['N']	[7]
8	while	O	['N']	[8]
9	on	O	['N']	[9]
10	lithium	B-Drug	['Causes']	[13]
11	prophylaxis	O	['N']	[11]
12	,	O	['N']	[12]
13	akathisia	B-Adverse_Effect	['N']	[13]
14	at	O	['N']	[14]
15	therapeutic	O	['N']	[15]
16	serum	O	['N']	[16]
17	lithium	O	['N']	[17]
18	levels	O	['N']	[18]
19	and	O	['N']	[19]
20	subsequently	O	['N']	[20]
21	bucco	O	['N']	[21]
22	-	O	['N']	[22]
23	linguo	O	['N']	[23]
24	-	O	['N']	[24]
25	masticatory	O	['N']	[25]
26	dyskinesia	O	['N']	[26]
27	.	O	['N']	[27]
#226
0	We	O	['N']	[0]
1	describe	O	['N']	[1]
2	the	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	a	O	['N']	[5]
6	50-year	O	['N']	[6]
7	-	O	['N']	[7]
8	old	O	['N']	[8]
9	woman	O	['N']	[9]
10	with	O	['N']	[10]
11	advanced	O	['N']	[11]
12	non	O	['N']	[12]
13	-	O	['N']	[13]
14	small	O	['N']	[14]
15	cell	O	['N']	[15]
16	lung	O	['N']	[16]
17	cancer	O	['N']	[17]
18	who	O	['N']	[18]
19	developed	O	['N']	[19]
20	status	B	['N']	[20]
21	epilepticus	I-Adverse_Effect	['N']	[21]
22	shortly	O	['N']	[22]
23	after	O	['N']	[23]
24	receiving	O	['N']	[24]
25	cisplatin	B-Drug	['Causes']	[21]
26	and	O	['N']	[26]
27	gemcitabine	O	['N']	[27]
28	chemotherapy	O	['N']	[28]
29	.	O	['N']	[29]
#227
0	Seizures	B-Adverse_Effect	['N']	[0]
1	and	O	['N']	[1]
2	extrapyramidal	O	['N']	[2]
3	symptoms	O	['N']	[3]
4	in	O	['N']	[4]
5	a	O	['N']	[5]
6	patient	O	['N']	[6]
7	with	O	['N']	[7]
8	Tourette	O	['N']	[8]
9	's	O	['N']	[9]
10	syndrome	O	['N']	[10]
11	,	O	['N']	[11]
12	Asperger	O	['N']	[12]
13	's	O	['N']	[13]
14	syndrome	O	['N']	[14]
15	,	O	['N']	[15]
16	and	O	['N']	[16]
17	multiple	O	['N']	[17]
18	sclerosis	O	['N']	[18]
19	treated	O	['N']	[19]
20	with	O	['N']	[20]
21	interferon	B	['N']	[21]
22	beta-1a	I-Drug	['Causes']	[0]
23	and	O	['N']	[23]
24	clomipramine	O	['N']	[24]
25	.	O	['N']	[25]
#228
0	Tumor	B	['N']	[0]
1	lysis	I	['N']	[1]
2	syndrome	I-Adverse_Effect	['N']	[2]
3	after	O	['N']	[3]
4	transcatheter	O	['N']	[4]
5	arterial	O	['N']	[5]
6	infusion	O	['N']	[6]
7	of	O	['N']	[7]
8	cisplatin	B-Drug	['Causes']	[2]
9	and	O	['N']	[9]
10	embolization	O	['N']	[10]
11	therapy	O	['N']	[11]
12	for	O	['N']	[12]
13	liver	O	['N']	[13]
14	metastases	O	['N']	[14]
15	of	O	['N']	[15]
16	melanoma	O	['N']	[16]
17	.	O	['N']	[17]
#229
0	The	O	['N']	[0]
1	purpose	O	['N']	[1]
2	of	O	['N']	[2]
3	this	O	['N']	[3]
4	study	O	['N']	[4]
5	was	O	['N']	[5]
6	to	O	['N']	[6]
7	examine	O	['N']	[7]
8	the	O	['N']	[8]
9	incidence	O	['N']	[9]
10	and	O	['N']	[10]
11	cause	O	['N']	[11]
12	of	O	['N']	[12]
13	Clostridium	B	['N']	[13]
14	difficile	I	['N']	[14]
15	colitis	I-Adverse_Effect	['N']	[15]
16	occurring	O	['N']	[16]
17	after	O	['N']	[17]
18	cisplatin	B-Drug	['Causes']	[15]
19	-	O	['N']	[19]
20	based	O	['N']	[20]
21	combination	O	['N']	[21]
22	chemotherapy	O	['N']	[22]
23	in	O	['N']	[23]
24	ovarian	O	['N']	[24]
25	cancer	O	['N']	[25]
26	patients	O	['N']	[26]
27	.	O	['N']	[27]
#230
0	Onset	O	['N']	[0]
1	of	O	['N']	[1]
2	male	O	['N']	[2]
3	gynaecomastia	B-Adverse_Effect	['N']	[3]
4	in	O	['N']	[4]
5	a	O	['N']	[5]
6	patient	O	['N']	[6]
7	treated	O	['N']	[7]
8	with	O	['N']	[8]
9	sunitinib	B-Drug	['Causes']	[3]
10	for	O	['N']	[10]
11	metastatic	O	['N']	[11]
12	renal	O	['N']	[12]
13	cell	O	['N']	[13]
14	carcinoma	O	['N']	[14]
15	.	O	['N']	[15]
#231
0	Ballistic	O	['N']	[0]
1	movements	O	['N']	[1]
2	due	O	['N']	[2]
3	to	O	['N']	[3]
4	ischemic	O	['N']	[4]
5	infarcts	O	['N']	[5]
6	after	O	['N']	[6]
7	intravenous	O	['N']	[7]
8	heroin	B-Drug	['Dosage']	[9]
9	overdose	B-Dose	['N']	[9]
10	:	O	['N']	[10]
11	report	O	['N']	[11]
12	of	O	['N']	[12]
13	two	O	['N']	[13]
14	cases	O	['N']	[14]
15	.	O	['N']	[15]
#232
0	Central	O	['N']	[0]
1	nervous	O	['N']	[1]
2	system	O	['N']	[2]
3	effects	O	['N']	[3]
4	secondary	O	['N']	[4]
5	to	O	['N']	[5]
6	ciprofloxacin	B-Drug	['Causes']	[25]
7	treatment	O	['N']	[7]
8	are	O	['N']	[8]
9	uncommon	O	['N']	[9]
10	and	O	['N']	[10]
11	usually	O	['N']	[11]
12	consist	O	['N']	[12]
13	only	O	['N']	[13]
14	of	O	['N']	[14]
15	minor	O	['N']	[15]
16	dizziness	O	['N']	[16]
17	or	O	['N']	[17]
18	mild	O	['N']	[18]
19	headache	O	['N']	[19]
20	,	O	['N']	[20]
21	although	O	['N']	[21]
22	rare	O	['N']	[22]
23	occurrences	O	['N']	[23]
24	of	O	['N']	[24]
25	seizures	B-Adverse_Effect	['N']	[25]
26	and	O	['N']	[26]
27	hallucinations	O	['N']	[27]
28	have	O	['N']	[28]
29	been	O	['N']	[29]
30	reported	O	['N']	[30]
31	.	O	['N']	[31]
#233
0	During	O	['N']	[0]
1	clarithromycin	B-Drug	['Causes']	[28]
2	coadministration	O	['N']	[2]
3	,	O	['N']	[3]
4	four	O	['N']	[4]
5	out	O	['N']	[5]
6	of	O	['N']	[6]
7	the	O	['N']	[7]
8	seven	O	['N']	[8]
9	patients	O	['N']	[9]
10	developed	O	['N']	[10]
11	moderate	O	['N']	[11]
12	-	O	['N']	[12]
13	to	O	['N']	[13]
14	-	O	['N']	[14]
15	severe	O	['N']	[15]
16	toxic	O	['N']	[16]
17	symptoms	O	['N']	[17]
18	of	O	['N']	[18]
19	carbamazepine	O	['N']	[19]
20	,	O	['N']	[20]
21	such	O	['N']	[21]
22	as	O	['N']	[22]
23	drowsiness	O	['N']	[23]
24	,	O	['N']	[24]
25	dizziness	O	['N']	[25]
26	,	O	['N']	[26]
27	and	O	['N']	[27]
28	ataxia	B-Adverse_Effect	['N']	[28]
29	,	O	['N']	[29]
30	which	O	['N']	[30]
31	resolved	O	['N']	[31]
32	within	O	['N']	[32]
33	5	O	['N']	[33]
34	days	O	['N']	[34]
35	after	O	['N']	[35]
36	clarithromycin	O	['N']	[36]
37	discontinuation	O	['N']	[37]
38	.	O	['N']	[38]
#234
0	BACKGROUND	O	['N']	[0]
1	:	O	['N']	[1]
2	Reproductive	O	['N']	[2]
3	endocrine	O	['N']	[3]
4	disorders	O	['N']	[4]
5	characterized	O	['N']	[5]
6	by	O	['N']	[6]
7	menstrual	B	['N']	[7]
8	disorders	I-Adverse_Effect	['N']	[8]
9	,	O	['N']	[9]
10	polycystic	O	['N']	[10]
11	ovaries	O	['N']	[11]
12	,	O	['N']	[12]
13	and	O	['N']	[13]
14	hyperandrogenism	O	['N']	[14]
15	seem	O	['N']	[15]
16	to	O	['N']	[16]
17	be	O	['N']	[17]
18	common	O	['N']	[18]
19	among	O	['N']	[19]
20	women	O	['N']	[20]
21	treated	O	['N']	[21]
22	with	O	['N']	[22]
23	sodium	B	['N']	[23]
24	valproate	I-Drug	['Causes']	[8]
25	for	O	['N']	[25]
26	epilepsy	O	['N']	[26]
27	.	O	['N']	[27]
#235
0	Hypersensitivity	O	['N']	[0]
1	to	O	['N']	[1]
2	aspirin	B-Drug	['Causes']	[10]
3	can	O	['N']	[3]
4	be	O	['N']	[4]
5	manifested	O	['N']	[5]
6	as	O	['N']	[6]
7	acute	O	['N']	[7]
8	asthma	O	['N']	[8]
9	,	O	['N']	[9]
10	urticaria	B-Adverse_Effect	['N']	[10]
11	and/or	O	['N']	[11]
12	angioedema	O	['N']	[12]
13	,	O	['N']	[13]
14	or	O	['N']	[14]
15	a	O	['N']	[15]
16	systemic	O	['N']	[16]
17	anaphylactoid	O	['N']	[17]
18	reaction	O	['N']	[18]
19	.	O	['N']	[19]
#236
0	The	O	['N']	[0]
1	second	O	['N']	[1]
2	patient	O	['N']	[2]
3	experienced	O	['N']	[3]
4	mild	B	['N']	[4]
5	nitritoid	I	['N']	[5]
6	symptoms	I-Adverse_Effect	['N']	[6]
7	following	O	['N']	[7]
8	several	O	['N']	[8]
9	GSTM	B-Drug	['Causes']	[6]
10	injections	O	['N']	[10]
11	prior	O	['N']	[11]
12	experiencing	O	['N']	[12]
13	a	O	['N']	[13]
14	cerebrovascular	O	['N']	[14]
15	accident	O	['N']	[15]
16	within	O	['N']	[16]
17	several	O	['N']	[17]
18	hours	O	['N']	[18]
19	of	O	['N']	[19]
20	her	O	['N']	[20]
21	next	O	['N']	[21]
22	injection	O	['N']	[22]
23	.	O	['N']	[23]
#237
0	Warfarin	B-Drug	['Causes']	[3]
1	-	O	['N']	[1]
2	associated	O	['N']	[2]
3	bleeding	B-Adverse_Effect	['N']	[3]
4	complication	O	['N']	[4]
5	saved	O	['N']	[5]
6	life	O	['N']	[6]
7	.	O	['N']	[7]
#238
0	Flucloxacillin	B-Drug	['Causes']	[7]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	aplastic	O	['N']	[3]
4	anaemia	O	['N']	[4]
5	and	O	['N']	[5]
6	liver	B	['N']	[6]
7	failure	I-Adverse_Effect	['N']	[7]
8	.	O	['N']	[8]
#239
0	After	O	['N']	[0]
1	infliximab	B-Drug	['Causes']	[18]
2	treatment	O	['N']	[2]
3	,	O	['N']	[3]
4	additional	O	['N']	[4]
5	sleep	O	['N']	[5]
6	studies	O	['N']	[6]
7	revealed	O	['N']	[7]
8	an	O	['N']	[8]
9	increase	O	['N']	[9]
10	in	O	['N']	[10]
11	the	O	['N']	[11]
12	number	O	['N']	[12]
13	of	O	['N']	[13]
14	apneic	O	['N']	[14]
15	events	O	['N']	[15]
16	and	O	['N']	[16]
17	SaO2	B	['N']	[17]
18	dips	I-Adverse_Effect	['N']	[18]
19	suggesting	O	['N']	[19]
20	that	O	['N']	[20]
21	TNFalpha	O	['N']	[21]
22	plays	O	['N']	[22]
23	an	O	['N']	[23]
24	important	O	['N']	[24]
25	role	O	['N']	[25]
26	in	O	['N']	[26]
27	the	O	['N']	[27]
28	pathophysiology	O	['N']	[28]
29	of	O	['N']	[29]
30	sleep	O	['N']	[30]
31	apnea	O	['N']	[31]
32	.	O	['N']	[32]
#240
0	After	O	['N']	[0]
1	seven	O	['N']	[1]
2	months	O	['N']	[2]
3	'	O	['N']	[3]
4	continuous	O	['N']	[4]
5	treatment	O	['N']	[5]
6	for	O	['N']	[6]
7	suspected	O	['N']	[7]
8	tuberculosis	O	['N']	[8]
9	with	O	['N']	[9]
10	rifampicin	O	['N']	[10]
11	and	O	['N']	[11]
12	ethambutol	B-Drug	['Causes']	[21]
13	a	O	['N']	[13]
14	nine	O	['N']	[14]
15	-	O	['N']	[15]
16	year	O	['N']	[16]
17	-	O	['N']	[17]
18	old	O	['N']	[18]
19	boy	O	['N']	[19]
20	developed	O	['N']	[20]
21	polyarthritis	B-Adverse_Effect	['N']	[21]
22	,	O	['N']	[22]
23	rash	O	['N']	[23]
24	and	O	['N']	[24]
25	hepatitis	O	['N']	[25]
26	in	O	['N']	[26]
27	association	O	['N']	[27]
28	with	O	['N']	[28]
29	anti	O	['N']	[29]
30	-	O	['N']	[30]
31	native	O	['N']	[31]
32	DNA	O	['N']	[32]
33	antibodies	O	['N']	[33]
34	and	O	['N']	[34]
35	positive	O	['N']	[35]
36	antinuclear	O	['N']	[36]
37	factor	O	['N']	[37]
38	.	O	['N']	[38]
#241
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	two	O	['N']	[2]
3	cases	O	['N']	[3]
4	that	O	['N']	[4]
5	developed	O	['N']	[5]
6	acute	O	['N']	[6]
7	myeloid	O	['N']	[7]
8	leukaemia	O	['N']	[8]
9	(	O	['N']	[9]
10	AML	B-Adverse_Effect	['N']	[10]
11	)	O	['N']	[11]
12	during	O	['N']	[12]
13	tamoxifen	B-Drug	['Causes']	[10]
14	therapy	O	['N']	[14]
15	for	O	['N']	[15]
16	breast	O	['N']	[16]
17	cancer	O	['N']	[17]
18	.	O	['N']	[18]
#242
0	A	O	['N']	[0]
1	patient	O	['N']	[1]
2	developed	O	['N']	[2]
3	cholestatic	B	['N']	[3]
4	hepatitis	I-Adverse_Effect	['N']	[4]
5	while	O	['N']	[5]
6	being	O	['N']	[6]
7	treated	O	['N']	[7]
8	with	O	['N']	[8]
9	nitrofurantoin	B-Drug	['Causes']	[4]
10	.	O	['N']	[10]
#243
0	Secretory	B	['N']	[0]
1	endometrial	I	['N']	[1]
2	adenocarcinoma	I-Adverse_Effect	['N']	[2]
3	in	O	['N']	[3]
4	a	O	['N']	[4]
5	patient	O	['N']	[5]
6	on	O	['N']	[6]
7	tamoxifen	B-Drug	['Causes']	[2]
8	for	O	['N']	[8]
9	breast	O	['N']	[9]
10	cancer	O	['N']	[10]
11	:	O	['N']	[11]
12	a	O	['N']	[12]
13	report	O	['N']	[13]
14	of	O	['N']	[14]
15	a	O	['N']	[15]
16	case	O	['N']	[16]
17	.	O	['N']	[17]
#244
0	Interstitial	O	['N']	[0]
1	pneumonitis	O	['N']	[1]
2	and	O	['N']	[2]
3	alveolar	B	['N']	[3]
4	hemorrhage	I-Adverse_Effect	['N']	[4]
5	complicating	O	['N']	[5]
6	use	O	['N']	[6]
7	of	O	['N']	[7]
8	rituximab	B-Drug	['Causes']	[4]
9	:	O	['N']	[9]
10	case	O	['N']	[10]
11	report	O	['N']	[11]
12	and	O	['N']	[12]
13	review	O	['N']	[13]
14	of	O	['N']	[14]
15	the	O	['N']	[15]
16	literature	O	['N']	[16]
17	.	O	['N']	[17]
#245
0	This	O	['N']	[0]
1	is	O	['N']	[1]
2	the	O	['N']	[2]
3	first	O	['N']	[3]
4	report	O	['N']	[4]
5	of	O	['N']	[5]
6	UFT	B-Drug	['Causes']	[12]
7	-	I	['N']	[7]
8	induced	I	['N']	[8]
9	scleroderma	I	['N']	[9]
10	-	I	['N']	[10]
11	like	I	['N']	[11]
12	reaction	I-Adverse_Effect	['N']	[12]
13	.	O	['N']	[13]
#246
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	the	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	a	O	['N']	[5]
6	child	O	['N']	[6]
7	with	O	['N']	[7]
8	metastatic	O	['N']	[8]
9	osteosarcoma	O	['N']	[9]
10	,	O	['N']	[10]
11	who	O	['N']	[11]
12	experienced	O	['N']	[12]
13	an	O	['N']	[13]
14	anaphylactic	B	['N']	[14]
15	/	I	['N']	[15]
16	anaphylactoid	I	['N']	[16]
17	reaction	I-Adverse_Effect	['N']	[17]
18	to	O	['N']	[18]
19	methotrexate	B-Drug	['Causes']	[17]
20	.	O	['N']	[20]
#247
0	Itch	O	['N']	[0]
1	and	O	['N']	[1]
2	skin	B	['N']	[2]
3	rash	I-Adverse_Effect	['N']	[3]
4	from	O	['N']	[4]
5	chocolate	O	['N']	[5]
6	during	O	['N']	[6]
7	fluoxetine	O	['N']	[7]
8	and	O	['N']	[8]
9	sertraline	B-Drug	['Causes']	[3]
10	treatment	O	['N']	[10]
11	:	O	['N']	[11]
12	case	O	['N']	[12]
13	report	O	['N']	[13]
14	.	O	['N']	[14]
#248
0	We	O	['N']	[0]
1	observed	O	['N']	[1]
2	2	O	['N']	[2]
3	cases	O	['N']	[3]
4	of	O	['N']	[4]
5	hepatotoxicity	O	['N']	[5]
6	after	O	['N']	[6]
7	a	O	['N']	[7]
8	high	B	['N']	[8]
9	-	I	['N']	[9]
10	dose	I-Dose	['N']	[10]
11	methylprednisolone	B-Drug	['Dosage']	[10]
12	treatment	O	['N']	[12]
13	of	O	['N']	[13]
14	a	O	['N']	[14]
15	demyelinating	O	['N']	[15]
16	disease	O	['N']	[16]
17	and	O	['N']	[17]
18	evaluated	O	['N']	[18]
19	the	O	['N']	[19]
20	potential	O	['N']	[20]
21	relationship	O	['N']	[21]
22	in	O	['N']	[22]
23	the	O	['N']	[23]
24	light	O	['N']	[24]
25	of	O	['N']	[25]
26	available	O	['N']	[26]
27	evidence	O	['N']	[27]
28	.	O	['N']	[28]
#249
0	Captopril	B-Drug	['Causes']	[6]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	pulmonary	B	['N']	[3]
4	infiltrates	I	['N']	[4]
5	with	I	['N']	[5]
6	eosinophilia	I-Adverse_Effect	['N']	[6]
7	in	O	['N']	[7]
8	an	O	['N']	[8]
9	infant	O	['N']	[9]
10	with	O	['N']	[10]
11	congenital	O	['N']	[11]
12	heart	O	['N']	[12]
13	disease	O	['N']	[13]
14	.	O	['N']	[14]
#250
0	Two	O	['N']	[0]
1	patients	O	['N']	[1]
2	developed	O	['N']	[2]
3	diabetic	B	['N']	[3]
4	coma	I-Adverse_Effect	['N']	[4]
5	when	O	['N']	[5]
6	taking	O	['N']	[6]
7	a	O	['N']	[7]
8	combination	O	['N']	[8]
9	of	O	['N']	[9]
10	a	O	['N']	[10]
11	thiazide	O	['N']	[11]
12	diuretic	O	['N']	[12]
13	and	O	['N']	[13]
14	propranolol	B-Drug	['Causes']	[4]
15	.	O	['N']	[15]
#251
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	45-year	O	['N']	[3]
4	-	O	['N']	[4]
5	old	O	['N']	[5]
6	Chinese	O	['N']	[6]
7	man	O	['N']	[7]
8	with	O	['N']	[8]
9	CML	O	['N']	[9]
10	and	O	['N']	[10]
11	chronic	O	['N']	[11]
12	hepatitis	O	['N']	[12]
13	B	O	['N']	[13]
14	virus	O	['N']	[14]
15	infection	O	['N']	[15]
16	,	O	['N']	[16]
17	on	O	['N']	[17]
18	imatinib	B-Drug	['Causes']	[24]
19	treatment	O	['N']	[19]
20	,	O	['N']	[20]
21	presenting	O	['N']	[21]
22	with	O	['N']	[22]
23	herpetic	B	['N']	[23]
24	rash	I-Adverse_Effect	['N']	[24]
25	and	O	['N']	[25]
26	acute	O	['N']	[26]
27	liver	O	['N']	[27]
28	failure	O	['N']	[28]
29	.	O	['N']	[29]
#252
0	Two	O	['N']	[0]
1	cases	O	['N']	[1]
2	are	O	['N']	[2]
3	reported	O	['N']	[3]
4	of	O	['N']	[4]
5	patients	O	['N']	[5]
6	who	O	['N']	[6]
7	developed	O	['N']	[7]
8	a	O	['N']	[8]
9	hematologic	B	['N']	[9]
10	malignancy	I-Adverse_Effect	['N']	[10]
11	several	O	['N']	[11]
12	years	O	['N']	[12]
13	after	O	['N']	[13]
14	intravesical	O	['N']	[14]
15	chemotherapy	O	['N']	[15]
16	of	O	['N']	[16]
17	superficial	O	['N']	[17]
18	bladder	O	['N']	[18]
19	cancer	O	['N']	[19]
20	with	O	['N']	[20]
21	etoglucid	O	['N']	[21]
22	,	O	['N']	[22]
23	doxorubicin	O	['N']	[23]
24	,	O	['N']	[24]
25	and	O	['N']	[25]
26	mitomycin	-	['N']	[26]
27	C.	-	['N']	[27]
#253
0	Barbiturate	B-Drug	['Causes']	[5]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	submassive	B	['N']	[3]
4	hepatic	I	['N']	[4]
5	necrosis	I-Adverse_Effect	['N']	[5]
6	.	O	['N']	[6]
#254
0	Bilateral	O	['N']	[0]
1	acoustic	O	['N']	[1]
2	(	O	['N']	[2]
3	VIII	O	['N']	[3]
4	)	O	['N']	[4]
5	nerve	O	['N']	[5]
6	palsy	O	['N']	[6]
7	in	O	['N']	[7]
8	this	O	['N']	[8]
9	patient	O	['N']	[9]
10	was	O	['N']	[10]
11	most	O	['N']	[11]
12	likely	O	['N']	[12]
13	a	O	['N']	[13]
14	manifestation	O	['N']	[14]
15	of	O	['N']	[15]
16	vincristine	B-Drug	['Causes']	[17]
17	neurotoxicity	B-Adverse_Effect	['N']	[17]
18	.	O	['N']	[18]
#255
0	Toxic	B	['N']	[0]
1	hepatitis	I-Adverse_Effect	['N']	[1]
2	due	O	['N']	[2]
3	to	O	['N']	[3]
4	combination	O	['N']	[4]
5	therapy	O	['N']	[5]
6	with	O	['N']	[6]
7	methotrexate	B-Drug	['Causes']	[1]
8	and	O	['N']	[8]
9	etretinate	O	['N']	[9]
10	in	O	['N']	[10]
11	psoriasis	O	['N']	[11]
12	.	O	['N']	[12]
#256
0	Tardive	B	['N']	[0]
1	dyskinesia	I-Adverse_Effect	['N']	[1]
2	in	O	['N']	[2]
3	2	O	['N']	[3]
4	patients	O	['N']	[4]
5	treated	O	['N']	[5]
6	with	O	['N']	[6]
7	ziprasidone	B-Drug	['Causes']	[1]
8	.	O	['N']	[8]
#257
0	Both	O	['N']	[0]
1	6-MP	O	['N']	[1]
2	and	O	['N']	[2]
3	AZA	B-Drug	['Causes']	[12]
4	are	O	['N']	[4]
5	widely	O	['N']	[5]
6	used	O	['N']	[6]
7	and	O	['N']	[7]
8	are	O	['N']	[8]
9	known	O	['N']	[9]
10	to	O	['N']	[10]
11	cause	O	['N']	[11]
12	hepatotoxicity	B-Adverse_Effect	['N']	[12]
13	in	O	['N']	[13]
14	a	O	['N']	[14]
15	proportion	O	['N']	[15]
16	of	O	['N']	[16]
17	patients	O	['N']	[17]
18	.	O	['N']	[18]
#258
0	An	O	['N']	[0]
1	11-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	boy	O	['N']	[4]
5	who	O	['N']	[5]
6	was	O	['N']	[6]
7	treated	O	['N']	[7]
8	with	O	['N']	[8]
9	a	O	['N']	[9]
10	relatively	O	['N']	[10]
11	high	B	['N']	[11]
12	dose	I-Dose	['N']	[12]
13	of	O	['N']	[13]
14	methotrimeprazine	B	['N']	[14]
15	meleate	I-Drug	['Dosage']	[12]
16	(	O	['N']	[16]
17	Levemepromazine	O	['N']	[17]
18	)	O	['N']	[18]
19	a	O	['N']	[19]
20	phenothiazine	O	['N']	[20]
21	antipsychotic	O	['N']	[21]
22	drug	O	['N']	[22]
23	,	O	['N']	[23]
24	was	O	['N']	[24]
25	admitted	O	['N']	[25]
26	to	O	['N']	[26]
27	the	O	['N']	[27]
28	pediatric	O	['N']	[28]
29	intensive	O	['N']	[29]
30	care	O	['N']	[30]
31	unit	O	['N']	[31]
32	suffering	O	['N']	[32]
33	from	O	['N']	[33]
34	respiratory	O	['N']	[34]
35	distress	O	['N']	[35]
36	syndrome	O	['N']	[36]
37	.	O	['N']	[37]
#259
0	Carbamazepine	B-Drug	['Causes']	[3]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	hyperammonemia	B-Adverse_Effect	['N']	[3]
4	.	O	['N']	[4]
#260
0	Zolpidem	O	['N']	[0]
1	tissue	O	['N']	[1]
2	concentrations	O	['N']	[2]
3	in	O	['N']	[3]
4	a	O	['N']	[4]
5	multiple	O	['N']	[5]
6	drug	O	['N']	[6]
7	related	O	['N']	[7]
8	death	B-Adverse_Effect	['N']	[8]
9	involving	O	['N']	[9]
10	Ambien	B-Drug	['Causes']	[8]
11	.	O	['N']	[11]
#261
0	A	O	['N']	[0]
1	32-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	man	O	['N']	[4]
5	with	O	['N']	[5]
6	a	O	['N']	[6]
7	family	O	['N']	[7]
8	history	O	['N']	[8]
9	of	O	['N']	[9]
10	type	O	['N']	[10]
11	2	O	['N']	[11]
12	diabetes	O	['N']	[12]
13	mellitus	O	['N']	[13]
14	presented	O	['N']	[14]
15	with	O	['N']	[15]
16	circulatory	O	['N']	[16]
17	collapse	O	['N']	[17]
18	and	O	['N']	[18]
19	deep	B	['N']	[19]
20	coma	I-Adverse_Effect	['N']	[20]
21	after	O	['N']	[21]
22	9	O	['N']	[22]
23	days	O	['N']	[23]
24	of	O	['N']	[24]
25	treatment	O	['N']	[25]
26	with	O	['N']	[26]
27	perospirone	B	['N']	[27]
28	hydrochloride	I-Drug	['Causes']	[20]
29	,	O	['N']	[29]
30	a	O	['N']	[30]
31	recently	O	['N']	[31]
32	developed	O	['N']	[32]
33	atypical	O	['N']	[33]
34	antipsychotic	O	['N']	[34]
35	agent	O	['N']	[35]
36	available	O	['N']	[36]
37	only	O	['N']	[37]
38	in	O	['N']	[38]
39	Japan	O	['N']	[39]
40	.	O	['N']	[40]
#262
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	53-year	O	['N']	[3]
4	-	O	['N']	[4]
5	old	O	['N']	[5]
6	-	O	['N']	[6]
7	man	O	['N']	[7]
8	who	O	['N']	[8]
9	developed	O	['N']	[9]
10	rippling	O	['N']	[10]
11	muscle	O	['N']	[11]
12	disease	O	['N']	[12]
13	(	O	['N']	[13]
14	RMD	B-Adverse_Effect	['N']	[14]
15	)	O	['N']	[15]
16	2	O	['N']	[16]
17	months	O	['N']	[17]
18	after	O	['N']	[18]
19	starting	O	['N']	[19]
20	simvastatin	B-Drug	['Causes']	[14]
21	therapy	O	['N']	[21]
22	for	O	['N']	[22]
23	hypercholesterolemia	O	['N']	[23]
24	.	O	['N']	[24]
#263
0	Sensorineural	B	['N']	[0]
1	hearing	I	['N']	[1]
2	loss	I-Adverse_Effect	['N']	[2]
3	due	O	['N']	[3]
4	to	O	['N']	[4]
5	quinine	B-Drug	['Causes']	[2]
6	therapy	O	['N']	[6]
7	for	O	['N']	[7]
8	malaria	O	['N']	[8]
9	has	O	['N']	[9]
10	frequently	O	['N']	[10]
11	been	O	['N']	[11]
12	mentioned	O	['N']	[12]
13	in	O	['N']	[13]
14	the	O	['N']	[14]
15	literature	O	['N']	[15]
16	but	O	['N']	[16]
17	has	O	['N']	[17]
18	not	O	['N']	[18]
19	been	O	['N']	[19]
20	a	O	['N']	[20]
21	subject	O	['N']	[21]
22	of	O	['N']	[22]
23	research	O	['N']	[23]
24	during	O	['N']	[24]
25	the	O	['N']	[25]
26	last	O	['N']	[26]
27	decades	O	['N']	[27]
28	.	O	['N']	[28]
#264
0	One	O	['N']	[0]
1	patient	O	['N']	[1]
2	had	O	['N']	[2]
3	a	O	['N']	[3]
4	lower	O	['N']	[4]
5	average	O	['N']	[5]
6	heart	O	['N']	[6]
7	rate	O	['N']	[7]
8	and	O	['N']	[8]
9	two	O	['N']	[9]
10	patients	O	['N']	[10]
11	had	O	['N']	[11]
12	lower	B	['N']	[12]
13	average	I	['N']	[13]
14	mean	I	['N']	[14]
15	blood	I	['N']	[15]
16	pressure	I-Adverse_Effect	['N']	[16]
17	values	O	['N']	[17]
18	during	O	['N']	[18]
19	propranolol	B-Drug	['Causes']	[16]
20	treatment	O	['N']	[20]
21	,	O	['N']	[21]
22	none	O	['N']	[22]
23	of	O	['N']	[23]
24	which	O	['N']	[24]
25	was	O	['N']	[25]
26	clinically	O	['N']	[26]
27	significant	O	['N']	[27]
28	.	O	['N']	[28]
#265
0	Rifampicin	B-Drug	['Causes']	[4]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	renal	B	['N']	[3]
4	failure	I-Adverse_Effect	['N']	[4]
5	.	O	['N']	[5]
#266
0	Fulminant	B	['N']	[0]
1	hepatitis	I-Adverse_Effect	['N']	[1]
2	with	O	['N']	[2]
3	severe	O	['N']	[3]
4	lactate	O	['N']	[4]
5	acidosis	O	['N']	[5]
6	in	O	['N']	[6]
7	HIV	O	['N']	[7]
8	-	O	['N']	[8]
9	infected	O	['N']	[9]
10	patients	O	['N']	[10]
11	on	O	['N']	[11]
12	didanosine	B-Drug	['Causes']	[1]
13	therapy	O	['N']	[13]
14	.	O	['N']	[14]
#267
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	pancytopenia	O	['N']	[5]
6	in	O	['N']	[6]
7	a	O	['N']	[7]
8	23-year	O	['N']	[8]
9	-	O	['N']	[9]
10	old	O	['N']	[10]
11	man	O	['N']	[11]
12	with	O	['N']	[12]
13	Crohn	O	['N']	[13]
14	's	O	['N']	[14]
15	disease	O	['N']	[15]
16	who	O	['N']	[16]
17	was	O	['N']	[17]
18	treated	O	['N']	[18]
19	with	O	['N']	[19]
20	5-aminosalicylic	B	['N']	[20]
21	acid	I-Drug	['Dosage']	[34]
22	(	O	['N']	[22]
23	Pentasa	O	['N']	[23]
24	;	O	['N']	[24]
25	Nisshin	O	['N']	[25]
26	,	O	['N']	[26]
27	Tokyo	O	['N']	[27]
28	,	O	['N']	[28]
29	Japan	O	['N']	[29]
30	)	O	['N']	[30]
31	3.0	B	['N']	[31]
32	g	I	['N']	[32]
33	/	I	['N']	[33]
34	day	I-Dose	['N']	[34]
35	.	O	['N']	[35]
#268
0	Severe	B	['N']	[0]
1	Raynaud	I	['N']	[1]
2	's	I	['N']	[2]
3	phenomenon	I-Adverse_Effect	['N']	[3]
4	with	O	['N']	[4]
5	yohimbine	B-Drug	['Causes']	[3]
6	therapy	O	['N']	[6]
7	for	O	['N']	[7]
8	erectile	O	['N']	[8]
9	dysfunction	O	['N']	[9]
10	.	O	['N']	[10]
#269
0	Aseptic	B	['N']	[0]
1	meningitis	I-Adverse_Effect	['N']	[1]
2	,	O	['N']	[2]
3	hemolytic	O	['N']	[3]
4	anemia	O	['N']	[4]
5	,	O	['N']	[5]
6	hepatitis	O	['N']	[6]
7	,	O	['N']	[7]
8	and	O	['N']	[8]
9	orthostatic	O	['N']	[9]
10	hypotension	O	['N']	[10]
11	in	O	['N']	[11]
12	a	O	['N']	[12]
13	patient	O	['N']	[13]
14	treated	O	['N']	[14]
15	with	O	['N']	[15]
16	trimethoprim	B-Drug	['Causes']	[1]
17	-	O	['N']	[17]
18	sulfamethoxazole	O	['N']	[18]
19	.	O	['N']	[19]
#270
0	In	O	['N']	[0]
1	eight	O	['N']	[1]
2	patients	O	['N']	[2]
3	,	O	['N']	[3]
4	a	O	['N']	[4]
5	mean	O	['N']	[5]
6	decrease	B	['N']	[6]
7	in	I	['N']	[7]
8	serum	I	['N']	[8]
9	Na+	I-Adverse_Effect	['N']	[9]
10	of	O	['N']	[10]
11	8.25	O	['N']	[11]
12	+	O	['N']	[12]
13	/-	O	['N']	[13]
14	3.2	O	['N']	[14]
15	mEq	O	['N']	[15]
16	/	O	['N']	[16]
17	L	O	['N']	[17]
18	was	O	['N']	[18]
19	observed	O	['N']	[19]
20	after	O	['N']	[20]
21	a	O	['N']	[21]
22	single	O	['N']	[22]
23	200	O	['N']	[23]
24	mg	O	['N']	[24]
25	intravenous	O	['N']	[25]
26	dose	O	['N']	[26]
27	of	O	['N']	[27]
28	lorcainide	B-Drug	['Causes']	[9]
29	.	O	['N']	[29]
#271
0	Since	O	['N']	[0]
1	its	O	['N']	[1]
2	FDA	O	['N']	[2]
3	approval	O	['N']	[3]
4	in	O	['N']	[4]
5	2002	O	['N']	[5]
6	,	O	['N']	[6]
7	there	O	['N']	[7]
8	are	O	['N']	[8]
9	no	O	['N']	[9]
10	known	O	['N']	[10]
11	citations	O	['N']	[11]
12	of	O	['N']	[12]
13	ezetimibe	B-Drug	['Causes']	[16]
14	-	O	['N']	[14]
15	induced	O	['N']	[15]
16	pancreatitis	B-Adverse_Effect	['N']	[16]
17	.	O	['N']	[17]
#272
0	BACKGROUND	O	['N']	[0]
1	:	O	['N']	[1]
2	Gemcitabine	B-Drug	['Causes']	[6]
3	has	O	['N']	[3]
4	mild	O	['N']	[4]
5	renal	B	['N']	[5]
6	toxicity	I-Adverse_Effect	['N']	[6]
7	,	O	['N']	[7]
8	but	O	['N']	[8]
9	cases	O	['N']	[9]
10	of	O	['N']	[10]
11	gemcitabine	O	['N']	[11]
12	-	O	['N']	[12]
13	associated	O	['N']	[13]
14	hemolytic	O	['N']	[14]
15	-	O	['N']	[15]
16	uremic	O	['N']	[16]
17	syndrome	O	['N']	[17]
18	(	O	['N']	[18]
19	HUS	O	['N']	[19]
20	)	O	['N']	[20]
21	have	O	['N']	[21]
22	been	O	['N']	[22]
23	reported	O	['N']	[23]
24	.	O	['N']	[24]
#273
0	BACKGROUND	O	['N']	[0]
1	:	O	['N']	[1]
2	Fluoxetine	B-Drug	['Causes']	[17]
3	,	O	['N']	[3]
4	a	O	['N']	[4]
5	highly	O	['N']	[5]
6	specific	O	['N']	[6]
7	serotonin	O	['N']	[7]
8	reuptake	O	['N']	[8]
9	inhibitor	O	['N']	[9]
10	,	O	['N']	[10]
11	has	O	['N']	[11]
12	been	O	['N']	[12]
13	reported	O	['N']	[13]
14	to	O	['N']	[14]
15	cause	O	['N']	[15]
16	sexual	B	['N']	[16]
17	dysfunction	I-Adverse_Effect	['N']	[17]
18	in	O	['N']	[18]
19	a	O	['N']	[19]
20	minority	O	['N']	[20]
21	of	O	['N']	[21]
22	patients	O	['N']	[22]
23	.	O	['N']	[23]
#274
0	Prior	O	['N']	[0]
1	neurologic	O	['N']	[1]
2	illness	O	['N']	[2]
3	or	O	['N']	[3]
4	CNS	O	['N']	[4]
5	insult	O	['N']	[5]
6	of	O	['N']	[6]
7	any	O	['N']	[7]
8	kind	O	['N']	[8]
9	is	O	['N']	[9]
10	known	O	['N']	[10]
11	to	O	['N']	[11]
12	increase	O	['N']	[12]
13	the	O	['N']	[13]
14	vulnerability	O	['N']	[14]
15	to	O	['N']	[15]
16	neurotoxicity	B-Adverse_Effect	['N']	[16]
17	of	O	['N']	[17]
18	lithium	B-Drug	['Causes']	[16]
19	.	O	['N']	[19]
#275
0	A	O	['N']	[0]
1	10-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	boy	O	['N']	[4]
5	with	O	['N']	[5]
6	osteosarcoma	O	['N']	[6]
7	and	O	['N']	[7]
8	normal	O	['N']	[8]
9	renal	O	['N']	[9]
10	function	O	['N']	[10]
11	manifested	O	['N']	[11]
12	laboratory	O	['N']	[12]
13	evidence	O	['N']	[13]
14	of	O	['N']	[14]
15	impending	O	['N']	[15]
16	renal	B	['N']	[16]
17	toxicity	I-Adverse_Effect	['N']	[17]
18	and	O	['N']	[18]
19	extreme	O	['N']	[19]
20	elevation	O	['N']	[20]
21	of	O	['N']	[21]
22	aspartate	O	['N']	[22]
23	aminotrasferase	O	['N']	[23]
24	and	O	['N']	[24]
25	alanine	O	['N']	[25]
26	aminotransferase	O	['N']	[26]
27	within	O	['N']	[27]
28	2	O	['N']	[28]
29	hours	O	['N']	[29]
30	after	O	['N']	[30]
31	the	O	['N']	[31]
32	completion	O	['N']	[32]
33	of	O	['N']	[33]
34	a	O	['N']	[34]
35	4-hour	O	['N']	[35]
36	infusion	O	['N']	[36]
37	of	O	['N']	[37]
38	high	O	['N']	[38]
39	-	O	['N']	[39]
40	dose	O	['N']	[40]
41	methotrexate	O	['N']	[41]
42	(	O	['N']	[42]
43	MTX	B-Drug	['Causes']	[17]
44	)	O	['N']	[44]
45	(	O	['N']	[45]
46	12	O	['N']	[46]
47	g	O	['N']	[47]
48	/	O	['N']	[48]
49	m2	O	['N']	[49]
50	)	O	['N']	[50]
51	,	O	['N']	[51]
52	and	O	['N']	[52]
53	went	O	['N']	[53]
54	on	O	['N']	[54]
55	to	O	['N']	[55]
56	develop	O	['N']	[56]
57	acute	O	['N']	[57]
58	renal	O	['N']	[58]
59	failure	O	['N']	[59]
60	with	O	['N']	[60]
61	life	O	['N']	[61]
62	-	O	['N']	[62]
63	threatening	O	['N']	[63]
64	hyperkalemia	O	['N']	[64]
65	29	O	['N']	[65]
66	hours	O	['N']	[66]
67	later	O	['N']	[67]
68	.	O	['N']	[68]
#276
0	We	O	['N']	[0]
1	describe	O	['N']	[1]
2	the	O	['N']	[2]
3	infectious	O	['N']	[3]
4	toxicities	O	['N']	[4]
5	experienced	O	['N']	[5]
6	by	O	['N']	[6]
7	the	O	['N']	[7]
8	first	O	['N']	[8]
9	two	O	['N']	[9]
10	patients	O	['N']	[10]
11	in	O	['N']	[11]
12	our	O	['N']	[12]
13	institution	O	['N']	[13]
14	treated	O	['N']	[14]
15	with	O	['N']	[15]
16	dexamethasone	B-Drug	['Causes']	[51]
17	(	O	['N']	[17]
18	10	O	['N']	[18]
19	mg	O	['N']	[19]
20	/	O	['N']	[20]
21	m(2)/day	O	['N']	[21]
22	for	O	['N']	[22]
23	4	O	['N']	[23]
24	weeks	O	['N']	[24]
25	with	O	['N']	[25]
26	gradual	O	['N']	[26]
27	tapering	O	['N']	[27]
28	)	O	['N']	[28]
29	during	O	['N']	[29]
30	induction	O	['N']	[30]
31	according	O	['N']	[31]
32	to	O	['N']	[32]
33	the	O	['N']	[33]
34	dexamethasone	O	['N']	[34]
35	arm	O	['N']	[35]
36	of	O	['N']	[36]
37	BFM	O	['N']	[37]
38	2000	O	['N']	[38]
39	and	O	['N']	[39]
40	review	O	['N']	[40]
41	the	O	['N']	[41]
42	relevant	O	['N']	[42]
43	literature	O	['N']	[43]
44	that	O	['N']	[44]
45	suggests	O	['N']	[45]
46	an	O	['N']	[46]
47	increased	O	['N']	[47]
48	risk	O	['N']	[48]
49	of	O	['N']	[49]
50	infectious	B	['N']	[50]
51	complications	I-Adverse_Effect	['N']	[51]
52	with	O	['N']	[52]
53	dexamethasone	O	['N']	[53]
54	.	O	['N']	[54]
#277
0	CASE	O	['N']	[0]
1	SUMMARY	O	['N']	[1]
2	:	O	['N']	[2]
3	A	O	['N']	[3]
4	25-year	O	['N']	[4]
5	-	O	['N']	[5]
6	old	O	['N']	[6]
7	postpartum	O	['N']	[7]
8	white	O	['N']	[8]
9	woman	O	['N']	[9]
10	developed	O	['N']	[10]
11	multiple	B	['N']	[11]
12	watery	I	['N']	[12]
13	stools	I-Adverse_Effect	['N']	[13]
14	and	O	['N']	[14]
15	abdominal	O	['N']	[15]
16	cramping	O	['N']	[16]
17	on	O	['N']	[17]
18	day	O	['N']	[18]
19	6	O	['N']	[19]
20	of	O	['N']	[20]
21	therapy	O	['N']	[21]
22	with	O	['N']	[22]
23	clindamycin	B-Drug	['Causes']	[13]
24	vaginal	O	['N']	[24]
25	cream	O	['N']	[25]
26	for	O	['N']	[26]
27	bacterial	O	['N']	[27]
28	vaginosis	O	['N']	[28]
29	.	O	['N']	[29]
#278
0	This	O	['N']	[0]
1	report	O	['N']	[1]
2	rules	O	['N']	[2]
3	out	O	['N']	[3]
4	other	O	['N']	[4]
5	causes	O	['N']	[5]
6	of	O	['N']	[6]
7	toxic	B	['N']	[7]
8	epidermal	I	['N']	[8]
9	necrolysis	I-Adverse_Effect	['N']	[9]
10	and	O	['N']	[10]
11	implicates	O	['N']	[11]
12	ofloxacin	B-Drug	['Causes']	[9]
13	in	O	['N']	[13]
14	what	O	['N']	[14]
15	appears	O	['N']	[15]
16	to	O	['N']	[16]
17	be	O	['N']	[17]
18	an	O	['N']	[18]
19	atypical	O	['N']	[19]
20	presentation	O	['N']	[20]
21	of	O	['N']	[21]
22	drug	O	['N']	[22]
23	-	O	['N']	[23]
24	induced	O	['N']	[24]
25	toxic	O	['N']	[25]
26	epidermal	O	['N']	[26]
27	necrolysis	O	['N']	[27]
28	.	O	['N']	[28]
#279
0	CASE	O	['N']	[0]
1	REPORT	O	['N']	[1]
2	:	O	['N']	[2]
3	We	O	['N']	[3]
4	describe	O	['N']	[4]
5	here	O	['N']	[5]
6	a	O	['N']	[6]
7	case	O	['N']	[7]
8	of	O	['N']	[8]
9	a	O	['N']	[9]
10	60	O	['N']	[10]
11	year	O	['N']	[11]
12	old	O	['N']	[12]
13	female	O	['N']	[13]
14	that	O	['N']	[14]
15	experienced	O	['N']	[15]
16	a	O	['N']	[16]
17	relapse	O	['N']	[17]
18	of	O	['N']	[18]
19	symptomatic	B	['N']	[19]
20	hyperlactatemia	I-Adverse_Effect	['N']	[20]
21	after	O	['N']	[21]
22	being	O	['N']	[22]
23	switched	O	['N']	[23]
24	from	O	['N']	[24]
25	stavudine	B-Drug	['Causes']	[20]
26	to	O	['N']	[26]
27	zidovudine	O	['N']	[27]
28	and	O	['N']	[28]
29	how	O	['N']	[29]
30	the	O	['N']	[30]
31	case	O	['N']	[31]
32	was	O	['N']	[32]
33	managed	O	['N']	[33]
34	at	O	['N']	[34]
35	the	O	['N']	[35]
36	Infectious	O	['N']	[36]
37	Diseases	O	['N']	[37]
38	Institute	O	['N']	[38]
39	,	O	['N']	[39]
40	Kampala	O	['N']	[40]
41	,	O	['N']	[41]
42	Uganda	O	['N']	[42]
43	.	O	['N']	[43]
#280
0	Livedo	B	['N']	[0]
1	reticularis	I-Adverse_Effect	['N']	[1]
2	associated	O	['N']	[2]
3	with	O	['N']	[3]
4	interferon	B	['N']	[4]
5	alpha	I-Drug	['Causes']	[1]
6	therapy	O	['N']	[6]
7	in	O	['N']	[7]
8	two	O	['N']	[8]
9	melanoma	O	['N']	[9]
10	patients	O	['N']	[10]
11	.	O	['N']	[11]
#281
0	Transient	B	['N']	[0]
1	acute	I	['N']	[1]
2	myopia	I-Adverse_Effect	['N']	[2]
3	resulting	O	['N']	[3]
4	from	O	['N']	[4]
5	isotretinoin	B-Drug	['Causes']	[2]
6	(	O	['N']	[6]
7	accutane	O	['N']	[7]
8	)	O	['N']	[8]
9	therapy	O	['N']	[9]
10	.	O	['N']	[10]
#282
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	interstitial	B	['N']	[5]
6	pneumonitis	I-Adverse_Effect	['N']	[6]
7	induced	O	['N']	[7]
8	by	O	['N']	[8]
9	bicalutamide	O	['N']	[9]
10	and/or	O	['N']	[10]
11	leuprorelin	B	['N']	[11]
12	acetate	I-Drug	['Causes']	[6]
13	given	O	['N']	[13]
14	as	O	['N']	[14]
15	therapy	O	['N']	[15]
16	for	O	['N']	[16]
17	prostate	O	['N']	[17]
18	cancer	O	['N']	[18]
19	,	O	['N']	[19]
20	in	O	['N']	[20]
21	which	O	['N']	[21]
22	the	O	['N']	[22]
23	pneumonitis	O	['N']	[23]
24	was	O	['N']	[24]
25	successfully	O	['N']	[25]
26	managed	O	['N']	[26]
27	by	O	['N']	[27]
28	steroid	O	['N']	[28]
29	treatment	O	['N']	[29]
30	.	O	['N']	[30]
#283
0	We	O	['N']	[0]
1	present	O	['N']	[1]
2	a	O	['N']	[2]
3	fatal	O	['N']	[3]
4	case	O	['N']	[4]
5	of	O	['N']	[5]
6	subacute	O	['N']	[6]
7	methanol	B-Drug	['Causes']	[8]
8	toxicity	I-Adverse_Effect	['N']	[8]
9	with	O	['N']	[9]
10	associated	O	['N']	[10]
11	diffuse	O	['N']	[11]
12	brain	O	['N']	[12]
13	involvement	O	['N']	[13]
14	,	O	['N']	[14]
15	including	O	['N']	[15]
16	bilateral	O	['N']	[16]
17	putaminal	O	['N']	[17]
18	necrosis	O	['N']	[18]
19	and	O	['N']	[19]
20	cerebral	O	['N']	[20]
21	edema	O	['N']	[21]
22	with	O	['N']	[22]
23	ventricular	O	['N']	[23]
24	compression	O	['N']	[24]
25	.	O	['N']	[25]
#284
0	Painful	B-Adverse_Effect	['N']	[0]
1	neutrophilic	O	['N']	[1]
2	skin	O	['N']	[2]
3	lesions	O	['N']	[3]
4	were	O	['N']	[4]
5	observed	O	['N']	[5]
6	in	O	['N']	[6]
7	two	O	['N']	[7]
8	children	O	['N']	[8]
9	receiving	O	['N']	[9]
10	granulocyte	B	['N']	[10]
11	colony	I	['N']	[11]
12	-	I	['N']	[12]
13	stimulating	I	['N']	[13]
14	factor	I-Drug	['Causes']	[0]
15	(	O	['N']	[15]
16	G	O	['N']	[16]
17	-	O	['N']	[17]
18	CSF	O	['N']	[18]
19	)	O	['N']	[19]
20	for	O	['N']	[20]
21	treatment	O	['N']	[21]
22	of	O	['N']	[22]
23	idiopathic	O	['N']	[23]
24	neutropenia	O	['N']	[24]
25	.	O	['N']	[25]
#285
0	OBJECTIVE	O	['N']	[0]
1	:	O	['N']	[1]
2	To	O	['N']	[2]
3	report	O	['N']	[3]
4	the	O	['N']	[4]
5	first	O	['N']	[5]
6	five	O	['N']	[6]
7	cases	O	['N']	[7]
8	of	O	['N']	[8]
9	amphotericin	B	['N']	[9]
10	B	I-Drug	['Dosage']	[11]
11	overdose	B-Dose	['N']	[11]
12	with	O	['N']	[12]
13	secondary	O	['N']	[13]
14	cardiac	O	['N']	[14]
15	complications	O	['N']	[15]
16	in	O	['N']	[16]
17	a	O	['N']	[17]
18	pediatric	O	['N']	[18]
19	population	O	['N']	[19]
20	.	O	['N']	[20]
#286
0	Bulbar	O	['N']	[0]
1	and	O	['N']	[1]
2	pseudobulbar	O	['N']	[2]
3	palsy	O	['N']	[3]
4	complicating	O	['N']	[4]
5	therapy	O	['N']	[5]
6	with	O	['N']	[6]
7	high	B	['N']	[7]
8	-	I	['N']	[8]
9	dose	I-Dose	['N']	[9]
10	cytosine	B	['N']	[10]
11	arabinoside	I-Drug	['Dosage']	[9]
12	in	O	['N']	[12]
13	children	O	['N']	[13]
14	with	O	['N']	[14]
15	leukemia	O	['N']	[15]
16	.	O	['N']	[16]
#287
0	The	O	['N']	[0]
1	epivodes	O	['N']	[1]
2	of	O	['N']	[2]
3	NMS	B-Adverse_Effect	['N']	[3]
4	occured	O	['N']	[4]
5	under	O	['N']	[5]
6	treatment	O	['N']	[6]
7	with	O	['N']	[7]
8	clozapine	O	['N']	[8]
9	,	O	['N']	[9]
10	risperidone	O	['N']	[10]
11	,	O	['N']	[11]
12	and	O	['N']	[12]
13	amisulpride	B-Drug	['Causes']	[3]
14	.	O	['N']	[14]
#288
0	CONCLUSION	O	['N']	[0]
1	:	O	['N']	[1]
2	The	O	['N']	[2]
3	new	O	['N']	[3]
4	quinolone	O	['N']	[4]
5	derivatives	O	['N']	[5]
6	(	O	['N']	[6]
7	levofloxacin	O	['N']	[7]
8	,	O	['N']	[8]
9	sparfloxacin	O	['N']	[9]
10	,	O	['N']	[10]
11	grepafloxacin	O	['N']	[11]
12	,	O	['N']	[12]
13	trovafloxacin	O	['N']	[13]
14	,	O	['N']	[14]
15	gatifloxacin	B-Drug	['Causes']	[45]
16	and	O	['N']	[16]
17	moxifloxacin	O	['N']	[17]
18	)	O	['N']	[18]
19	,	O	['N']	[19]
20	also	O	['N']	[20]
21	called	O	['N']	[21]
22	gyrase	O	['N']	[22]
23	inhibitors	O	['N']	[23]
24	,	O	['N']	[24]
25	are	O	['N']	[25]
26	known	O	['N']	[26]
27	for	O	['N']	[27]
28	their	O	['N']	[28]
29	potential	O	['N']	[29]
30	to	O	['N']	[30]
31	cause	O	['N']	[31]
32	central	O	['N']	[32]
33	nervous	O	['N']	[33]
34	system	O	['N']	[34]
35	-	O	['N']	[35]
36	related	O	['N']	[36]
37	adverse	O	['N']	[37]
38	effects	O	['N']	[38]
39	,	O	['N']	[39]
40	including	O	['N']	[40]
41	headache	O	['N']	[41]
42	,	O	['N']	[42]
43	dizziness	O	['N']	[43]
44	and	O	['N']	[44]
45	insomnia	B-Adverse_Effect	['N']	[45]
46	.	O	['N']	[46]
#289
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	71-year	O	['N']	[3]
4	male	O	['N']	[4]
5	with	O	['N']	[5]
6	castration	O	['N']	[6]
7	-	O	['N']	[7]
8	resistant	O	['N']	[8]
9	metastatic	O	['N']	[9]
10	prostate	O	['N']	[10]
11	cancer	O	['N']	[11]
12	who	O	['N']	[12]
13	was	O	['N']	[13]
14	treated	O	['N']	[14]
15	with	O	['N']	[15]
16	weekly	O	['N']	[16]
17	docetaxel	B-Drug	['Causes']	[27]
18	for	O	['N']	[18]
19	12	O	['N']	[19]
20	weeks	O	['N']	[20]
21	and	O	['N']	[21]
22	developed	O	['N']	[22]
23	significant	O	['N']	[23]
24	eye	B	['N']	[24]
25	irritation	I	['N']	[25]
26	and	I	['N']	[26]
27	dryness	I-Adverse_Effect	['N']	[27]
28	during	O	['N']	[28]
29	treatment	O	['N']	[29]
30	.	O	['N']	[30]
#290
0	The	O	['N']	[0]
1	authors	O	['N']	[1]
2	describe	O	['N']	[2]
3	a	O	['N']	[3]
4	case	O	['N']	[4]
5	of	O	['N']	[5]
6	combined	O	['N']	[6]
7	lithium	B-Drug	['Causes']	[25]
8	and	O	['N']	[8]
9	haloperidol	O	['N']	[9]
10	toxicity	O	['N']	[10]
11	characterized	O	['N']	[11]
12	by	O	['N']	[12]
13	hyperpyrexia	O	['N']	[13]
14	,	O	['N']	[14]
15	severe	O	['N']	[15]
16	rigidity	O	['N']	[16]
17	,	O	['N']	[17]
18	mutism	O	['N']	[18]
19	,	O	['N']	[19]
20	and	O	['N']	[20]
21	development	O	['N']	[21]
22	of	O	['N']	[22]
23	irreversible	B	['N']	[23]
24	tardive	I	['N']	[24]
25	dyskinesia	I-Adverse_Effect	['N']	[25]
26	.	O	['N']	[26]
#291
0	The	O	['N']	[0]
1	fourth	O	['N']	[1]
2	patient	O	['N']	[2]
3	showed	O	['N']	[3]
4	RLS	O	['N']	[4]
5	symptoms	O	['N']	[5]
6	that	O	['N']	[6]
7	were	O	['N']	[7]
8	initially	O	['N']	[8]
9	caused	O	['N']	[9]
10	by	O	['N']	[10]
11	a	O	['N']	[11]
12	20-mg	B	['N']	[12]
13	daily	I-Dose	['N']	[13]
14	olanzapine	B-Drug	['Dosage']	[13]
15	dosage	O	['N']	[15]
16	and	O	['N']	[16]
17	were	O	['N']	[17]
18	later	O	['N']	[18]
19	mitigated	O	['N']	[19]
20	when	O	['N']	[20]
21	olanzapine	O	['N']	[21]
22	was	O	['N']	[22]
23	reduced	O	['N']	[23]
24	and	O	['N']	[24]
25	ropinirole	O	['N']	[25]
26	was	O	['N']	[26]
27	administered	O	['N']	[27]
28	.	O	['N']	[28]
#292
0	Eleven	O	['N']	[0]
1	patients	O	['N']	[1]
2	developed	O	['N']	[2]
3	infection	O	['N']	[3]
4	requiring	O	['N']	[4]
5	hospitalization	O	['N']	[5]
6	while	O	['N']	[6]
7	taking	O	['N']	[7]
8	leflunomide	B-Drug	['Causes']	[33]
9	including	O	['N']	[9]
10	:	O	['N']	[10]
11	lower	O	['N']	[11]
12	respiratory	O	['N']	[12]
13	tract	O	['N']	[13]
14	infections	O	['N']	[14]
15	(	O	['N']	[15]
16	3	O	['N']	[16]
17	)	O	['N']	[17]
18	,	O	['N']	[18]
19	cellulitis	O	['N']	[19]
20	(	O	['N']	[20]
21	2	O	['N']	[21]
22	)	O	['N']	[22]
23	,	O	['N']	[23]
24	disseminated	O	['N']	[24]
25	herpes	O	['N']	[25]
26	zoster	O	['N']	[26]
27	(	O	['N']	[27]
28	2	O	['N']	[28]
29	)	O	['N']	[29]
30	,	O	['N']	[30]
31	probable	O	['N']	[31]
32	TB	B	['N']	[32]
33	liver	I-Adverse_Effect	['N']	[33]
34	(	O	['N']	[34]
35	1	O	['N']	[35]
36	)	O	['N']	[36]
37	,	O	['N']	[37]
38	abdominal	O	['N']	[38]
39	sepsis	O	['N']	[39]
40	(	O	['N']	[40]
41	1	O	['N']	[41]
42	)	O	['N']	[42]
43	,	O	['N']	[43]
44	mycotic	O	['N']	[44]
45	aneurysm	O	['N']	[45]
46	(	O	['N']	[46]
47	1	O	['N']	[47]
48	)	O	['N']	[48]
49	and	O	['N']	[49]
50	gastroenteritis	O	['N']	[50]
51	(	O	['N']	[51]
52	1	O	['N']	[52]
53	)	O	['N']	[53]
54	.	O	['N']	[54]
#293
0	A	O	['N']	[0]
1	17-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	boy	O	['N']	[4]
5	with	O	['N']	[5]
6	acute	O	['N']	[6]
7	lymphoblastic	O	['N']	[7]
8	leukemia	O	['N']	[8]
9	developed	O	['N']	[9]
10	acute	O	['N']	[10]
11	renal	O	['N']	[11]
12	failure	O	['N']	[12]
13	within	O	['N']	[13]
14	48	O	['N']	[14]
15	h	O	['N']	[15]
16	of	O	['N']	[16]
17	an	O	['N']	[17]
18	intravenous	O	['N']	[18]
19	high	B	['N']	[19]
20	-	I	['N']	[20]
21	dose	I-Dose	['N']	[21]
22	methotrexate	B-Drug	['Dosage']	[21]
23	(	O	['N']	[23]
24	5	O	['N']	[24]
25	g	O	['N']	[25]
26	/	O	['N']	[26]
27	m2	O	['N']	[27]
28	)	O	['N']	[28]
29	infusion	O	['N']	[29]
30	.	O	['N']	[30]
#294
0	He	O	['N']	[0]
1	developed	O	['N']	[1]
2	recurrent	O	['N']	[2]
3	skin	O	['N']	[3]
4	rash	O	['N']	[4]
5	,	O	['N']	[5]
6	fever	O	['N']	[6]
7	,	O	['N']	[7]
8	hypereosinophilia	O	['N']	[8]
9	,	O	['N']	[9]
10	and	O	['N']	[10]
11	acute	B	['N']	[11]
12	renal	I	['N']	[12]
13	failure	I-Adverse_Effect	['N']	[13]
14	after	O	['N']	[14]
15	rechallenge	O	['N']	[15]
16	with	O	['N']	[16]
17	chlorambucil	B-Drug	['Causes']	[13]
18	.	O	['N']	[18]
#295
0	This	O	['N']	[0]
1	panic	B	['N']	[1]
2	anxiety	I-Adverse_Effect	['N']	[2]
3	was	O	['N']	[3]
4	not	O	['N']	[4]
5	relieved	O	['N']	[5]
6	by	O	['N']	[6]
7	taking	O	['N']	[7]
8	etizolam	O	['N']	[8]
9	and	O	['N']	[9]
10	flunitrazepam	O	['N']	[10]
11	again	O	['N']	[11]
12	,	O	['N']	[12]
13	but	O	['N']	[13]
14	subsided	O	['N']	[14]
15	rapidly	O	['N']	[15]
16	by	O	['N']	[16]
17	the	O	['N']	[17]
18	re	O	['N']	[18]
19	-	O	['N']	[19]
20	administration	O	['N']	[20]
21	of	O	['N']	[21]
22	mianserin	B-Drug	['Causes']	[2]
23	30	O	['N']	[23]
24	mg	O	['N']	[24]
25	/	O	['N']	[25]
26	day	O	['N']	[26]
27	,	O	['N']	[27]
28	and	O	['N']	[28]
29	because	O	['N']	[29]
30	of	O	['N']	[30]
31	that	O	['N']	[31]
32	the	O	['N']	[32]
33	depressive	O	['N']	[33]
34	symptom	O	['N']	[34]
35	also	O	['N']	[35]
36	disappeared	O	['N']	[36]
37	.	O	['N']	[37]
#296
0	OBJECTIVE	O	['N']	[0]
1	:	O	['N']	[1]
2	To	O	['N']	[2]
3	report	O	['N']	[3]
4	a	O	['N']	[4]
5	case	O	['N']	[5]
6	of	O	['N']	[6]
7	phenolphthalein	B-Drug	['Causes']	[14]
8	-	O	['N']	[8]
9	induced	O	['N']	[9]
10	toxic	O	['N']	[10]
11	epidermal	O	['N']	[11]
12	necrolysis	O	['N']	[12]
13	(	O	['N']	[13]
14	TEN	B-Adverse_Effect	['N']	[14]
15	)	O	['N']	[15]
16	in	O	['N']	[16]
17	a	O	['N']	[17]
18	patient	O	['N']	[18]
19	maintained	O	['N']	[19]
20	on	O	['N']	[20]
21	several	O	['N']	[21]
22	other	O	['N']	[22]
23	medications	O	['N']	[23]
24	more	O	['N']	[24]
25	commonly	O	['N']	[25]
26	known	O	['N']	[26]
27	to	O	['N']	[27]
28	be	O	['N']	[28]
29	associated	O	['N']	[29]
30	with	O	['N']	[30]
31	TEN	O	['N']	[31]
32	.	O	['N']	[32]
#297
0	Mitomycin	B	['N']	[0]
1	-	I	['N']	[1]
2	C	I-Drug	['Causes']	[26]
3	is	O	['N']	[3]
4	used	O	['N']	[4]
5	widely	O	['N']	[5]
6	in	O	['N']	[6]
7	the	O	['N']	[7]
8	treatment	O	['N']	[8]
9	of	O	['N']	[9]
10	malignancies	O	['N']	[10]
11	and	O	['N']	[11]
12	is	O	['N']	[12]
13	associated	O	['N']	[13]
14	with	O	['N']	[14]
15	serious	O	['N']	[15]
16	dose	O	['N']	[16]
17	related	O	['N']	[17]
18	adverse	O	['N']	[18]
19	effects	O	['N']	[19]
20	including	O	['N']	[20]
21	the	O	['N']	[21]
22	occurrence	O	['N']	[22]
23	of	O	['N']	[23]
24	hemolytic	B	['N']	[24]
25	uremic	I	['N']	[25]
26	syndrome	I-Adverse_Effect	['N']	[26]
27	.	O	['N']	[27]
#298
0	We	O	['N']	[0]
1	describe	O	['N']	[1]
2	a	O	['N']	[2]
3	patient	O	['N']	[3]
4	with	O	['N']	[4]
5	androgen	O	['N']	[5]
6	-	O	['N']	[6]
7	independent	O	['N']	[7]
8	prostate	O	['N']	[8]
9	cancer	O	['N']	[9]
10	in	O	['N']	[10]
11	whom	O	['N']	[11]
12	PSA	B	['N']	[12]
13	continued	I	['N']	[13]
14	to	I	['N']	[14]
15	decrease	I-Adverse_Effect	['N']	[15]
16	for	O	['N']	[16]
17	a	O	['N']	[17]
18	period	O	['N']	[18]
19	of	O	['N']	[19]
20	15	O	['N']	[20]
21	months	O	['N']	[21]
22	after	O	['N']	[22]
23	flutamide	B-Drug	['Causes']	[15]
24	withdrawal	O	['N']	[24]
25	.	O	['N']	[25]
#299
0	Methylphenidate	O	['N']	[0]
1	and	O	['N']	[1]
2	dextroamphetamine	B-Drug	['Causes']	[6]
3	-	O	['N']	[3]
4	induced	O	['N']	[4]
5	peripheral	B	['N']	[5]
6	vasculopathy	I-Adverse_Effect	['N']	[6]
7	.	O	['N']	[7]
#300
0	A	O	['N']	[0]
1	case	O	['N']	[1]
2	of	O	['N']	[2]
3	fluoxetine	B-Drug	['Causes']	[5]
4	induced	O	['N']	[4]
5	seizures	B-Adverse_Effect	['N']	[5]
6	,	O	['N']	[6]
7	in	O	['N']	[7]
8	a	O	['N']	[8]
9	person	O	['N']	[9]
10	with	O	['N']	[10]
11	Down	O	['N']	[11]
12	syndrome	O	['N']	[12]
13	,	O	['N']	[13]
14	is	O	['N']	[14]
15	described	O	['N']	[15]
16	.	O	['N']	[16]
#301
0	Our	O	['N']	[0]
1	report	O	['N']	[1]
2	suggested	O	['N']	[2]
3	that	O	['N']	[3]
4	CBDCA	B-Drug	['Dosage']	[50]
5	hypersensitivity	O	['N']	[5]
6	was	O	['N']	[6]
7	correlated	O	['N']	[7]
8	with	O	['N']	[8]
9	the	O	['N']	[9]
10	total	O	['N']	[10]
11	dose	O	['N']	[11]
12	of	O	['N']	[12]
13	previously	O	['N']	[13]
14	administered	O	['N']	[14]
15	platinum	O	['N']	[15]
16	agents	O	['N']	[16]
17	and	O	['N']	[17]
18	that	O	['N']	[18]
19	CBDCA	O	['N']	[19]
20	should	O	['N']	[20]
21	be	O	['N']	[21]
22	excluded	O	['N']	[22]
23	in	O	['N']	[23]
24	patients	O	['N']	[24]
25	who	O	['N']	[25]
26	have	O	['N']	[26]
27	received	O	['N']	[27]
28	multiple	O	['N']	[28]
29	platinum	O	['N']	[29]
30	-	O	['N']	[30]
31	based	O	['N']	[31]
32	chemotherapy	O	['N']	[32]
33	,	O	['N']	[33]
34	even	O	['N']	[34]
35	in	O	['N']	[35]
36	platinum	O	['N']	[36]
37	-	O	['N']	[37]
38	sensitive	O	['N']	[38]
39	cases	O	['N']	[39]
40	,	O	['N']	[40]
41	because	O	['N']	[41]
42	CBDCA	O	['N']	[42]
43	hypersensitivity	O	['N']	[43]
44	can	O	['N']	[44]
45	occur	O	['N']	[45]
46	even	O	['N']	[46]
47	with	O	['N']	[47]
48	low	B	['N']	[48]
49	-	I	['N']	[49]
50	dose	I-Dose	['N']	[50]
51	CBDCA	O	['N']	[51]
52	administration	O	['N']	[52]
53	.	O	['N']	[53]
#302
0	Peripheral	O	['N']	[0]
1	nerve	O	['N']	[1]
2	dysfunction	O	['N']	[2]
3	is	O	['N']	[3]
4	a	O	['N']	[4]
5	potentially	O	['N']	[5]
6	serious	O	['N']	[6]
7	complication	O	['N']	[7]
8	of	O	['N']	[8]
9	high	B	['N']	[9]
10	-	I	['N']	[10]
11	dose	I-Dose	['N']	[11]
12	cytosine	B	['N']	[12]
13	arabinoside	I-Drug	['Dosage']	[11]
14	.	O	['N']	[14]
#303
0	Symptomatic	B	['N']	[0]
1	hypocalcaemia	I-Adverse_Effect	['N']	[1]
2	and	O	['N']	[2]
3	renal	O	['N']	[3]
4	impairment	O	['N']	[4]
5	associated	O	['N']	[5]
6	with	O	['N']	[6]
7	bisphosphonate	B-Drug	['Causes']	[1]
8	treatment	O	['N']	[8]
9	in	O	['N']	[9]
10	patients	O	['N']	[10]
11	with	O	['N']	[11]
12	multiple	O	['N']	[12]
13	myeloma	O	['N']	[13]
14	.	O	['N']	[14]
#304
0	Dorzolamide	B-Drug	['Causes']	[4]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	choroidal	B	['N']	[3]
4	detachment	I-Adverse_Effect	['N']	[4]
5	in	O	['N']	[5]
6	a	O	['N']	[6]
7	surgically	O	['N']	[7]
8	untreated	O	['N']	[8]
9	eye	O	['N']	[9]
10	.	O	['N']	[10]
#305
0	Dyspnea	O	['N']	[0]
1	,	O	['N']	[1]
2	hypoxemia	B-Adverse_Effect	['N']	[2]
3	,	O	['N']	[3]
4	and	O	['N']	[4]
5	pleuritic	O	['N']	[5]
6	chest	O	['N']	[6]
7	pain	O	['N']	[7]
8	occurred	O	['N']	[8]
9	within	O	['N']	[9]
10	24	O	['N']	[10]
11	hours	O	['N']	[11]
12	of	O	['N']	[12]
13	rituximab	B-Drug	['Causes']	[2]
14	administration	O	['N']	[14]
15	,	O	['N']	[15]
16	and	O	['N']	[16]
17	there	O	['N']	[17]
18	was	O	['N']	[18]
19	no	O	['N']	[19]
20	other	O	['N']	[20]
21	apparent	O	['N']	[21]
22	explanation	O	['N']	[22]
23	.	O	['N']	[23]
#306
0	Torsemide	B-Drug	['Causes']	[16]
1	appears	O	['N']	[1]
2	to	O	['N']	[2]
3	also	O	['N']	[3]
4	be	O	['N']	[4]
5	a	O	['N']	[5]
6	part	O	['N']	[6]
7	of	O	['N']	[7]
8	a	O	['N']	[8]
9	long	O	['N']	[9]
10	list	O	['N']	[10]
11	of	O	['N']	[11]
12	agents	O	['N']	[12]
13	that	O	['N']	[13]
14	can	O	['N']	[14]
15	cause	O	['N']	[15]
16	pancreatitis	B-Adverse_Effect	['N']	[16]
17	.	O	['N']	[17]
#307
0	A	O	['N']	[0]
1	25-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	man	O	['N']	[4]
5	with	O	['N']	[5]
6	a	O	['N']	[6]
7	history	O	['N']	[7]
8	of	O	['N']	[8]
9	mid	O	['N']	[9]
10	-	O	['N']	[10]
11	borderline	O	['N']	[11]
12	(	O	['N']	[12]
13	BB	O	['N']	[13]
14	)	O	['N']	[14]
15	Hansen	O	['N']	[15]
16	's	O	['N']	[16]
17	disease	O	['N']	[17]
18	developing	O	['N']	[18]
19	a	O	['N']	[19]
20	reversal	B	['N']	[20]
21	reaction	I-Adverse_Effect	['N']	[21]
22	after	O	['N']	[22]
23	starting	O	['N']	[23]
24	dapsone	B-Drug	['Causes']	[21]
25	and	O	['N']	[25]
26	rifampin	O	['N']	[26]
27	therapy	O	['N']	[27]
28	is	O	['N']	[28]
29	presented	O	['N']	[29]
30	.	O	['N']	[30]
#308
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	biopsy	O	['N']	[5]
6	proven	O	['N']	[6]
7	myositis	B-Adverse_Effect	['N']	[7]
8	whose	O	['N']	[8]
9	symptoms	O	['N']	[9]
10	began	O	['N']	[10]
11	within	O	['N']	[11]
12	10	O	['N']	[12]
13	days	O	['N']	[13]
14	of	O	['N']	[14]
15	receiving	O	['N']	[15]
16	leuprolide	B	['N']	[16]
17	acetate	I-Drug	['Causes']	[7]
18	therapy	O	['N']	[18]
19	for	O	['N']	[19]
20	prostate	O	['N']	[20]
21	cancer	O	['N']	[21]
22	.	O	['N']	[22]
#309
0	However	O	['N']	[0]
1	,	O	['N']	[1]
2	he	O	['N']	[2]
3	developed	O	['N']	[3]
4	acute	B	['N']	[4]
5	renal	I	['N']	[5]
6	failure	I-Adverse_Effect	['N']	[6]
7	,	O	['N']	[7]
8	hyperkalemia	O	['N']	[8]
9	,	O	['N']	[9]
10	and	O	['N']	[10]
11	hyperuricemia	O	['N']	[11]
12	30	O	['N']	[12]
13	d	O	['N']	[13]
14	after	O	['N']	[14]
15	receiving	O	['N']	[15]
16	the	O	['N']	[16]
17	sorafenib	B-Drug	['Causes']	[6]
18	treatment	O	['N']	[18]
19	.	O	['N']	[19]
#310
0	She	O	['N']	[0]
1	was	O	['N']	[1]
2	diagnosed	O	['N']	[2]
3	with	O	['N']	[3]
4	Epstein	B	['N']	[4]
5	-	I	['N']	[5]
6	Barr	I	['N']	[6]
7	virus	I	['N']	[7]
8	-	I	['N']	[8]
9	associated	I	['N']	[9]
10	polymorphic	I	['N']	[10]
11	lymphoproliferative	I	['N']	[11]
12	disorder	I-Adverse_Effect	['N']	[12]
13	(	O	['N']	[13]
14	LPD	O	['N']	[14]
15	)	O	['N']	[15]
16	due	O	['N']	[16]
17	to	O	['N']	[17]
18	immunodeficiency	O	['N']	[18]
19	caused	O	['N']	[19]
20	by	O	['N']	[20]
21	MTX	B-Drug	['Causes']	[12]
22	administration	O	['N']	[22]
23	.	O	['N']	[23]
#311
0	We	O	['N']	[0]
1	presented	O	['N']	[1]
2	the	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	a	O	['N']	[5]
6	patient	O	['N']	[6]
7	who	O	['N']	[7]
8	developed	O	['N']	[8]
9	a	O	['N']	[9]
10	cutaneous	B	['N']	[10]
11	reaction	I-Adverse_Effect	['N']	[11]
12	induced	O	['N']	[12]
13	by	O	['N']	[13]
14	captopril	B-Drug	['Causes']	[11]
15	with	O	['N']	[15]
16	positive	O	['N']	[16]
17	patch	O	['N']	[17]
18	test	O	['N']	[18]
19	.	O	['N']	[19]
#312
0	A	O	['N']	[0]
1	twelve	O	['N']	[1]
2	year	O	['N']	[2]
3	-	O	['N']	[3]
4	old	O	['N']	[4]
5	-	O	['N']	[5]
6	girl	O	['N']	[6]
7	with	O	['N']	[7]
8	idiopathic	O	['N']	[8]
9	partial	O	['N']	[9]
10	epilepsy	O	['N']	[10]
11	with	O	['N']	[11]
12	secondary	O	['N']	[12]
13	generalization	O	['N']	[13]
14	,	O	['N']	[14]
15	developed	O	['N']	[15]
16	acute	B	['N']	[16]
17	psychosis	I-Adverse_Effect	['N']	[17]
18	10	O	['N']	[18]
19	days	O	['N']	[19]
20	after	O	['N']	[20]
21	the	O	['N']	[21]
22	administration	O	['N']	[22]
23	of	O	['N']	[23]
24	levetiracetam	B-Drug	['Causes']	[17]
25	.	O	['N']	[25]
#313
0	Brugada	B	['N']	[0]
1	type	I	['N']	[1]
2	electrocardiographic	I	['N']	[2]
3	changes	I-Adverse_Effect	['N']	[3]
4	induced	O	['N']	[4]
5	by	O	['N']	[5]
6	concomitant	O	['N']	[6]
7	use	O	['N']	[7]
8	of	O	['N']	[8]
9	lithium	B-Drug	['Causes']	[3]
10	and	O	['N']	[10]
11	propafenone	O	['N']	[11]
12	in	O	['N']	[12]
13	patient	O	['N']	[13]
14	with	O	['N']	[14]
15	Wolff	O	['N']	[15]
16	-	O	['N']	[16]
17	Parkinson	O	['N']	[17]
18	-	O	['N']	[18]
19	White	O	['N']	[19]
20	syndrome	O	['N']	[20]
21	.	O	['N']	[21]
#314
0	CASE	O	['N']	[0]
1	REPORT	O	['N']	[1]
2	:	O	['N']	[2]
3	Soon	O	['N']	[3]
4	after	O	['N']	[4]
5	initiation	O	['N']	[5]
6	of	O	['N']	[6]
7	amiodarone	B	['N']	[7]
8	HCl	I-Drug	['Dosage']	[13]
9	(	O	['N']	[9]
10	200	B	['N']	[10]
11	mg	I	['N']	[11]
12	/	I	['N']	[12]
13	day	I-Dose	['N']	[13]
14	)	O	['N']	[14]
15	,	O	['N']	[15]
16	a	O	['N']	[16]
17	76-year	O	['N']	[17]
18	-	O	['N']	[18]
19	old	O	['N']	[19]
20	man	O	['N']	[20]
21	came	O	['N']	[21]
22	to	O	['N']	[22]
23	us	O	['N']	[23]
24	with	O	['N']	[24]
25	symptoms	O	['N']	[25]
26	of	O	['N']	[26]
27	visual	O	['N']	[27]
28	"	O	['N']	[28]
29	shining	O	['N']	[29]
30	,	O	['N']	[30]
31	"	O	['N']	[31]
32	glare	O	['N']	[32]
33	,	O	['N']	[33]
34	color	O	['N']	[34]
35	vision	O	['N']	[35]
36	anomalies	O	['N']	[36]
37	,	O	['N']	[37]
38	and	O	['N']	[38]
39	gradually	O	['N']	[39]
40	decreased	O	['N']	[40]
41	vision	O	['N']	[41]
42	.	O	['N']	[42]
#315
0	This	O	['N']	[0]
1	case	O	['N']	[1]
2	report	O	['N']	[2]
3	illustrates	O	['N']	[3]
4	the	O	['N']	[4]
5	neurotoxicity	B-Adverse_Effect	['N']	[5]
6	unique	O	['N']	[6]
7	to	O	['N']	[7]
8	HDARAC	B-Drug	['Causes']	[5]
9	.	O	['N']	[9]
#316
0	Goiter	O	['N']	[0]
1	and	O	['N']	[1]
2	hypothyroidism	B-Adverse_Effect	['N']	[2]
3	during	O	['N']	[3]
4	re	O	['N']	[4]
5	-	O	['N']	[5]
6	treatment	O	['N']	[6]
7	with	O	['N']	[7]
8	amiodarone	B-Drug	['Causes']	[2]
9	in	O	['N']	[9]
10	a	O	['N']	[10]
11	patient	O	['N']	[11]
12	who	O	['N']	[12]
13	previously	O	['N']	[13]
14	experienced	O	['N']	[14]
15	amiodarone	O	['N']	[15]
16	-	O	['N']	[16]
17	induced	O	['N']	[17]
18	thyrotoxicosis	O	['N']	[18]
19	.	O	['N']	[19]
#317
0	Based	O	['N']	[0]
1	on	O	['N']	[1]
2	the	O	['N']	[2]
3	clinical	O	['N']	[3]
4	status	O	['N']	[4]
5	of	O	['N']	[5]
6	the	O	['N']	[6]
7	patient	O	['N']	[7]
8	,	O	['N']	[8]
9	it	O	['N']	[9]
10	was	O	['N']	[10]
11	suspected	O	['N']	[11]
12	that	O	['N']	[12]
13	several	O	['N']	[13]
14	conditions	O	['N']	[14]
15	contributed	O	['N']	[15]
16	to	O	['N']	[16]
17	the	O	['N']	[17]
18	abnormal	B	['N']	[18]
19	hypersensitivity	I-Adverse_Effect	['N']	[19]
20	to	O	['N']	[20]
21	warfarin	B-Drug	['Causes']	[19]
22	.	O	['N']	[22]
#318
0	CONCLUSIONS	O	['N']	[0]
1	:	O	['N']	[1]
2	The	O	['N']	[2]
3	observation	O	['N']	[3]
4	that	O	['N']	[4]
5	neurotoxicity	B-Adverse_Effect	['N']	[5]
6	developed	O	['N']	[6]
7	with	O	['N']	[7]
8	a	O	['N']	[8]
9	delay	O	['N']	[9]
10	of	O	['N']	[10]
11	24	O	['N']	[11]
12	to	O	['N']	[12]
13	48	O	['N']	[13]
14	hours	O	['N']	[14]
15	after	O	['N']	[15]
16	acyclovir	B-Drug	['Causes']	[5]
17	peak	O	['N']	[17]
18	serum	O	['N']	[18]
19	concentrations	O	['N']	[19]
20	could	O	['N']	[20]
21	explain	O	['N']	[21]
22	the	O	['N']	[22]
23	wide	O	['N']	[23]
24	range	O	['N']	[24]
25	of	O	['N']	[25]
26	acyclovir	O	['N']	[26]
27	levels	O	['N']	[27]
28	reported	O	['N']	[28]
29	in	O	['N']	[29]
30	similar	O	['N']	[30]
31	cases	O	['N']	[31]
32	.	O	['N']	[32]
#319
0	Muscle	O	['N']	[0]
1	biopsy	O	['N']	[1]
2	revealed	O	['N']	[2]
3	variation	O	['N']	[3]
4	in	O	['N']	[4]
5	muscle	O	['N']	[5]
6	fiber	O	['N']	[6]
7	size	O	['N']	[7]
8	and	O	['N']	[8]
9	few	O	['N']	[9]
10	vacuolated	B	['N']	[10]
11	fibers	I-Adverse_Effect	['N']	[11]
12	which	O	['N']	[12]
13	were	O	['N']	[13]
14	features	O	['N']	[14]
15	of	O	['N']	[15]
16	colchicine	B-Drug	['Causes']	[11]
17	-	O	['N']	[17]
18	induced	O	['N']	[18]
19	myopathy	O	['N']	[19]
20	.	O	['N']	[20]
#320
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	the	O	['N']	[2]
3	development	O	['N']	[3]
4	of	O	['N']	[4]
5	squamous	B	['N']	[5]
6	-	I	['N']	[6]
7	cell	I	['N']	[7]
8	carcinoma	I-Adverse_Effect	['N']	[8]
9	within	O	['N']	[9]
10	a	O	['N']	[10]
11	basal	O	['N']	[11]
12	-	O	['N']	[12]
13	cell	O	['N']	[13]
14	epithelioma	O	['N']	[14]
15	that	O	['N']	[15]
16	was	O	['N']	[16]
17	treated	O	['N']	[17]
18	with	O	['N']	[18]
19	intralesional	O	['N']	[19]
20	injections	O	['N']	[20]
21	of	O	['N']	[21]
22	5-FU	B-Drug	['Causes']	[8]
23	.	O	['N']	[23]
#321
0	Although	O	['N']	[0]
1	the	O	['N']	[1]
2	literature	O	['N']	[2]
3	on	O	['N']	[3]
4	the	O	['N']	[4]
5	use	O	['N']	[5]
6	of	O	['N']	[6]
7	risperidone	B-Drug	['Causes']	[48]
8	in	O	['N']	[8]
9	elderly	O	['N']	[9]
10	patients	O	['N']	[10]
11	with	O	['N']	[11]
12	dementia	O	['N']	[12]
13	consists	O	['N']	[13]
14	largely	O	['N']	[14]
15	of	O	['N']	[15]
16	uncontrolled	O	['N']	[16]
17	trials	O	['N']	[17]
18	,	O	['N']	[18]
19	case	O	['N']	[19]
20	reports	O	['N']	[20]
21	,	O	['N']	[21]
22	and	O	['N']	[22]
23	chart	O	['N']	[23]
24	reviews	O	['N']	[24]
25	,	O	['N']	[25]
26	it	O	['N']	[26]
27	appears	O	['N']	[27]
28	that	O	['N']	[28]
29	this	O	['N']	[29]
30	agent	O	['N']	[30]
31	is	O	['N']	[31]
32	effective	O	['N']	[32]
33	for	O	['N']	[33]
34	managing	O	['N']	[34]
35	agitation	O	['N']	[35]
36	in	O	['N']	[36]
37	this	O	['N']	[37]
38	population	O	['N']	[38]
39	and	O	['N']	[39]
40	does	O	['N']	[40]
41	so	O	['N']	[41]
42	with	O	['N']	[42]
43	a	O	['N']	[43]
44	low	O	['N']	[44]
45	frequency	O	['N']	[45]
46	of	O	['N']	[46]
47	extrapyramidal	B	['N']	[47]
48	symptoms	I-Adverse_Effect	['N']	[48]
49	(	O	['N']	[49]
50	EPS	O	['N']	[50]
51	)	O	['N']	[51]
52	.	O	['N']	[52]
#322
0	Tiagabine	B-Drug	['Dosage']	[1]
1	overdose	B-Dose	['N']	[1]
2	causes	O	['N']	[2]
3	an	O	['N']	[3]
4	unusual	O	['N']	[4]
5	array	O	['N']	[5]
6	of	O	['N']	[6]
7	neurological	O	['N']	[7]
8	symptoms	O	['N']	[8]
9	,	O	['N']	[9]
10	many	O	['N']	[10]
11	similar	O	['N']	[11]
12	to	O	['N']	[12]
13	reported	O	['N']	[13]
14	adverse	O	['N']	[14]
15	effects	O	['N']	[15]
16	during	O	['N']	[16]
17	therapeutic	O	['N']	[17]
18	use	O	['N']	[18]
19	.	O	['N']	[19]
#323
0	DISCUSSION	O	['N']	[0]
1	:	O	['N']	[1]
2	The	O	['N']	[2]
3	main	O	['N']	[3]
4	adverse	O	['N']	[4]
5	effects	O	['N']	[5]
6	of	O	['N']	[6]
7	leflunomide	B-Drug	['Causes']	[20]
8	consist	O	['N']	[8]
9	of	O	['N']	[9]
10	diarrhea	O	['N']	[10]
11	,	O	['N']	[11]
12	nausea	O	['N']	[12]
13	,	O	['N']	[13]
14	liver	O	['N']	[14]
15	enzyme	O	['N']	[15]
16	elevation	O	['N']	[16]
17	,	O	['N']	[17]
18	hypertension	O	['N']	[18]
19	,	O	['N']	[19]
20	alopecia	B-Adverse_Effect	['N']	[20]
21	,	O	['N']	[21]
22	and	O	['N']	[22]
23	allergic	O	['N']	[23]
24	skin	O	['N']	[24]
25	reactions	O	['N']	[25]
26	.	O	['N']	[26]
#324
0	CONCLUSIONS	O	['N']	[0]
1	:	O	['N']	[1]
2	Hypersensitivity	B	['N']	[2]
3	reactions	I-Adverse_Effect	['N']	[3]
4	to	O	['N']	[4]
5	cyclosporine	O	['N']	[5]
6	are	O	['N']	[6]
7	due	O	['N']	[7]
8	to	O	['N']	[8]
9	Cremophor	B	['N']	[9]
10	EL	I-Drug	['Causes']	[3]
11	.	O	['N']	[11]
#325
0	We	O	['N']	[0]
1	have	O	['N']	[1]
2	successfully	O	['N']	[2]
3	overcome	O	['N']	[3]
4	severe	B	['N']	[4]
5	neutropenia	I-Adverse_Effect	['N']	[5]
6	in	O	['N']	[6]
7	an	O	['N']	[7]
8	RA	O	['N']	[8]
9	patient	O	['N']	[9]
10	treated	O	['N']	[10]
11	with	O	['N']	[11]
12	gold	B-Drug	['Causes']	[5]
13	salts	O	['N']	[13]
14	,	O	['N']	[14]
15	using	O	['N']	[15]
16	granulocyte	O	['N']	[16]
17	colony	O	['N']	[17]
18	-	O	['N']	[18]
19	stimulating	O	['N']	[19]
20	factor	O	['N']	[20]
21	(	O	['N']	[21]
22	G	O	['N']	[22]
23	-	O	['N']	[23]
24	CSF	O	['N']	[24]
25	)	O	['N']	[25]
26	,	O	['N']	[26]
27	reducing	O	['N']	[27]
28	the	O	['N']	[28]
29	duration	O	['N']	[29]
30	of	O	['N']	[30]
31	neutropenia	O	['N']	[31]
32	and	O	['N']	[32]
33	risk	O	['N']	[33]
34	of	O	['N']	[34]
35	infection	O	['N']	[35]
36	.	O	['N']	[36]
#326
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	a	O	['N']	[5]
6	previously	O	['N']	[6]
7	healthy	O	['N']	[7]
8	,	O	['N']	[8]
9	postmenopausal	O	['N']	[9]
10	woman	O	['N']	[10]
11	who	O	['N']	[11]
12	developed	O	['N']	[12]
13	anticonvulsant	B	['N']	[13]
14	hypersensitivity	I	['N']	[14]
15	syndrome	I-Adverse_Effect	['N']	[15]
16	while	O	['N']	[16]
17	taking	O	['N']	[17]
18	Bellamine	B	['N']	[18]
19	S	I-Drug	['Causes']	[15]
20	(	O	['N']	[20]
21	belladonna	O	['N']	[21]
22	alkaloids	O	['N']	[22]
23	;	O	['N']	[23]
24	ergotamine	O	['N']	[24]
25	;	O	['N']	[25]
26	phenobarbital	O	['N']	[26]
27	)	O	['N']	[27]
28	for	O	['N']	[28]
29	hot	O	['N']	[29]
30	flashes	O	['N']	[30]
31	.	O	['N']	[31]
#327
0	CASE	O	['N']	[0]
1	SUMMARY	O	['N']	[1]
2	:	O	['N']	[2]
3	A	O	['N']	[3]
4	10-year	O	['N']	[4]
5	-	O	['N']	[5]
6	old	O	['N']	[6]
7	white	O	['N']	[7]
8	girl	O	['N']	[8]
9	with	O	['N']	[9]
10	bilateral	O	['N']	[10]
11	optic	O	['N']	[11]
12	glioma	O	['N']	[12]
13	developed	O	['N']	[13]
14	a	O	['N']	[14]
15	hypersensitivity	B-Adverse_Effect	['N']	[15]
16	reaction	O	['N']	[16]
17	to	O	['N']	[17]
18	carboplatin	B-Drug	['Causes']	[15]
19	after	O	['N']	[19]
20	nine	O	['N']	[20]
21	courses	O	['N']	[21]
22	.	O	['N']	[22]
#328
0	We	O	['N']	[0]
1	describe	O	['N']	[1]
2	the	O	['N']	[2]
3	infectious	O	['N']	[3]
4	toxicities	O	['N']	[4]
5	experienced	O	['N']	[5]
6	by	O	['N']	[6]
7	the	O	['N']	[7]
8	first	O	['N']	[8]
9	two	O	['N']	[9]
10	patients	O	['N']	[10]
11	in	O	['N']	[11]
12	our	O	['N']	[12]
13	institution	O	['N']	[13]
14	treated	O	['N']	[14]
15	with	O	['N']	[15]
16	dexamethasone	B-Drug	['Dosage']	[21]
17	(	O	['N']	[17]
18	10	B	['N']	[18]
19	mg	I	['N']	[19]
20	/	I	['N']	[20]
21	m(2)/day	I-Dose	['N']	[21]
22	for	O	['N']	[22]
23	4	O	['N']	[23]
24	weeks	O	['N']	[24]
25	with	O	['N']	[25]
26	gradual	O	['N']	[26]
27	tapering	O	['N']	[27]
28	)	O	['N']	[28]
29	during	O	['N']	[29]
30	induction	O	['N']	[30]
31	according	O	['N']	[31]
32	to	O	['N']	[32]
33	the	O	['N']	[33]
34	dexamethasone	O	['N']	[34]
35	arm	O	['N']	[35]
36	of	O	['N']	[36]
37	BFM	O	['N']	[37]
38	2000	O	['N']	[38]
39	and	O	['N']	[39]
40	review	O	['N']	[40]
41	the	O	['N']	[41]
42	relevant	O	['N']	[42]
43	literature	O	['N']	[43]
44	that	O	['N']	[44]
45	suggests	O	['N']	[45]
46	an	O	['N']	[46]
47	increased	O	['N']	[47]
48	risk	O	['N']	[48]
49	of	O	['N']	[49]
50	infectious	O	['N']	[50]
51	complications	O	['N']	[51]
52	with	O	['N']	[52]
53	dexamethasone	O	['N']	[53]
54	.	O	['N']	[54]
#329
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	the	O	['N']	[2]
3	occurrence	O	['N']	[3]
4	of	O	['N']	[4]
5	renal	B	['N']	[5]
6	failure	I-Adverse_Effect	['N']	[6]
7	due	O	['N']	[7]
8	to	O	['N']	[8]
9	cholesterol	O	['N']	[9]
10	crystal	O	['N']	[10]
11	embolization	O	['N']	[11]
12	following	O	['N']	[12]
13	thrombolytic	O	['N']	[13]
14	therapy	O	['N']	[14]
15	with	O	['N']	[15]
16	intravenous	O	['N']	[16]
17	recombinant	B	['N']	[17]
18	tissue	I	['N']	[18]
19	-	I	['N']	[19]
20	type	I	['N']	[20]
21	plasminogen	I	['N']	[21]
22	activator	I-Drug	['Causes']	[6]
23	(	O	['N']	[23]
24	t	O	['N']	[24]
25	-	O	['N']	[25]
26	PA	O	['N']	[26]
27	)	O	['N']	[27]
28	.	O	['N']	[28]
#330
0	The	O	['N']	[0]
1	aim	O	['N']	[1]
2	of	O	['N']	[2]
3	this	O	['N']	[3]
4	paper	O	['N']	[4]
5	is	O	['N']	[5]
6	to	O	['N']	[6]
7	report	O	['N']	[7]
8	the	O	['N']	[8]
9	case	O	['N']	[9]
10	of	O	['N']	[10]
11	rosaceiform	B	['N']	[11]
12	eruption	I-Adverse_Effect	['N']	[12]
13	induced	O	['N']	[13]
14	by	O	['N']	[14]
15	erlotinib	B-Drug	['Causes']	[12]
16	in	O	['N']	[16]
17	an	O	['N']	[17]
18	81-year	O	['N']	[18]
19	-	O	['N']	[19]
20	old	O	['N']	[20]
21	-	O	['N']	[21]
22	man	O	['N']	[22]
23	and	O	['N']	[23]
24	to	O	['N']	[24]
25	discuss	O	['N']	[25]
26	the	O	['N']	[26]
27	pathogenetic	O	['N']	[27]
28	role	O	['N']	[28]
29	of	O	['N']	[29]
30	Demodex	O	['N']	[30]
31	folliculorum	O	['N']	[31]
32	mites	O	['N']	[32]
33	,	O	['N']	[33]
34	found	O	['N']	[34]
35	in	O	['N']	[35]
36	the	O	['N']	[36]
37	present	O	['N']	[37]
38	patient	O	['N']	[38]
39	,	O	['N']	[39]
40	using	O	['N']	[40]
41	skin	O	['N']	[41]
42	scraping	O	['N']	[42]
43	.	O	['N']	[43]
#331
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	on	O	['N']	[2]
3	three	O	['N']	[3]
4	patients	O	['N']	[4]
5	with	O	['N']	[5]
6	acute	O	['N']	[6]
7	schizophrenia	O	['N']	[7]
8	,	O	['N']	[8]
9	who	O	['N']	[9]
10	developed	O	['N']	[10]
11	severe	B	['N']	[11]
12	akathisia	I-Adverse_Effect	['N']	[12]
13	during	O	['N']	[13]
14	treatment	O	['N']	[14]
15	with	O	['N']	[15]
16	olanzapine	B-Drug	['Causes']	[12]
17	(	O	['N']	[17]
18	20	O	['N']	[18]
19	-	O	['N']	[19]
20	25	O	['N']	[20]
21	mg	O	['N']	[21]
22	/	O	['N']	[22]
23	d	O	['N']	[23]
24	)	O	['N']	[24]
25	.	O	['N']	[25]
#332
0	Serotonin	B	['N']	[0]
1	syndrome	I-Adverse_Effect	['N']	[1]
2	caused	O	['N']	[2]
3	by	O	['N']	[3]
4	interaction	O	['N']	[4]
5	between	O	['N']	[5]
6	citalopram	B-Drug	['Causes']	[1]
7	and	O	['N']	[7]
8	fentanyl	O	['N']	[8]
9	.	O	['N']	[9]
#333
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	5	O	['N']	[2]
3	patients	O	['N']	[3]
4	(	O	['N']	[4]
5	3	O	['N']	[5]
6	patients	O	['N']	[6]
7	with	O	['N']	[7]
8	chronic	O	['N']	[8]
9	hepatitis	O	['N']	[9]
10	C	O	['N']	[10]
11	treated	O	['N']	[11]
12	with	O	['N']	[12]
13	pegylated	B	['N']	[13]
14	interferon	I	['N']	[14]
15	alfa-2b	I-Drug	['Causes']	[33]
16	in	O	['N']	[16]
17	association	O	['N']	[17]
18	with	O	['N']	[18]
19	oral	O	['N']	[19]
20	ribavirin	O	['N']	[20]
21	and	O	['N']	[21]
22	two	O	['N']	[22]
23	patients	O	['N']	[23]
24	with	O	['N']	[24]
25	chronic	O	['N']	[25]
26	myelocytic	O	['N']	[26]
27	leukemia	O	['N']	[27]
28	)	O	['N']	[28]
29	who	O	['N']	[29]
30	developed	O	['N']	[30]
31	local	B	['N']	[31]
32	cutaneous	I	['N']	[32]
33	reactions	I-Adverse_Effect	['N']	[33]
34	at	O	['N']	[34]
35	sites	O	['N']	[35]
36	of	O	['N']	[36]
37	injection	O	['N']	[37]
38	after	O	['N']	[38]
39	the	O	['N']	[39]
40	administration	O	['N']	[40]
41	of	O	['N']	[41]
42	weekly	O	['N']	[42]
43	subcutaneous	O	['N']	[43]
44	injections	O	['N']	[44]
45	of	O	['N']	[45]
46	pegylated	O	['N']	[46]
47	interferon	O	['N']	[47]
48	alfa-2b	O	['N']	[48]
49	at	O	['N']	[49]
50	different	O	['N']	[50]
51	doses	O	['N']	[51]
52	.	O	['N']	[52]
#334
0	Prominent	O	['N']	[0]
1	positive	B	['N']	[1]
2	U	I	['N']	[2]
3	waves	I-Adverse_Effect	['N']	[3]
4	appearing	O	['N']	[4]
5	with	O	['N']	[5]
6	high	O	['N']	[6]
7	-	O	['N']	[7]
8	dose	O	['N']	[8]
9	intravenous	O	['N']	[9]
10	phenylephrine	B-Drug	['Causes']	[3]
11	.	O	['N']	[11]
#335
0	The	O	['N']	[0]
1	authors	O	['N']	[1]
2	present	O	['N']	[2]
3	an	O	['N']	[3]
4	elderly	O	['N']	[4]
5	patient	O	['N']	[5]
6	with	O	['N']	[6]
7	mixed	O	['N']	[7]
8	dementia	O	['N']	[8]
9	who	O	['N']	[9]
10	developed	O	['N']	[10]
11	TD	O	['N']	[11]
12	at	O	['N']	[12]
13	multiple	O	['N']	[13]
14	sites	O	['N']	[14]
15	,	O	['N']	[15]
16	(	O	['N']	[16]
17	including	O	['N']	[17]
18	respiratory	O	['N']	[18]
19	dyskinesia	O	['N']	[19]
20	[	O	['N']	[20]
21	RD	B-Adverse_Effect	['N']	[21]
22	]	O	['N']	[22]
23	,	O	['N']	[23]
24	limb	O	['N']	[24]
25	dyskinesia	O	['N']	[25]
26	,	O	['N']	[26]
27	and	O	['N']	[27]
28	orofacial	O	['N']	[28]
29	dyskinesia	O	['N']	[29]
30	)	O	['N']	[30]
31	following	O	['N']	[31]
32	abrupt	O	['N']	[32]
33	withdrawal	O	['N']	[33]
34	of	O	['N']	[34]
35	risperidone	B-Drug	['Causes']	[21]
36	therapy	O	['N']	[36]
37	.	O	['N']	[37]
#336
0	These	O	['N']	[0]
1	evolutional	O	['N']	[1]
2	changes	O	['N']	[2]
3	in	O	['N']	[3]
4	both	O	['N']	[4]
5	proteinuria	O	['N']	[5]
6	and	O	['N']	[6]
7	glomerular	O	['N']	[7]
8	histology	O	['N']	[8]
9	suggest	O	['N']	[9]
10	a	O	['N']	[10]
11	close	O	['N']	[11]
12	linkage	O	['N']	[12]
13	between	O	['N']	[13]
14	the	O	['N']	[14]
15	M	B	['N']	[15]
16	-	I	['N']	[16]
17	CSF	I-Drug	['Causes']	[24]
18	treatment	O	['N']	[18]
19	and	O	['N']	[19]
20	macrophage	B	['N']	[20]
21	-	I	['N']	[21]
22	related	I	['N']	[22]
23	glomerular	I	['N']	[23]
24	injury	I-Adverse_Effect	['N']	[24]
25	.	O	['N']	[25]
#337
0	We	O	['N']	[0]
1	believe	O	['N']	[1]
2	that	O	['N']	[2]
3	these	O	['N']	[3]
4	skin	B	['N']	[4]
5	eruptions	I-Adverse_Effect	['N']	[5]
6	belong	O	['N']	[6]
7	to	O	['N']	[7]
8	a	O	['N']	[8]
9	spectrum	O	['N']	[9]
10	of	O	['N']	[10]
11	neutrophilic	O	['N']	[11]
12	dermatoses	O	['N']	[12]
13	that	O	['N']	[13]
14	can	O	['N']	[14]
15	be	O	['N']	[15]
16	induced	O	['N']	[16]
17	or	O	['N']	[17]
18	aggravated	O	['N']	[18]
19	by	O	['N']	[19]
20	G	B	['N']	[20]
21	-	I	['N']	[21]
22	CSF	I-Drug	['Causes']	[5]
23	therapy	O	['N']	[23]
24	.	O	['N']	[24]
#338
0	The	O	['N']	[0]
1	authors	O	['N']	[1]
2	present	O	['N']	[2]
3	a	O	['N']	[3]
4	case	O	['N']	[4]
5	report	O	['N']	[5]
6	of	O	['N']	[6]
7	a	O	['N']	[7]
8	granulomatous	O	['N']	[8]
9	reaction	O	['N']	[9]
10	leading	O	['N']	[10]
11	to	O	['N']	[11]
12	urethral	B	['N']	[12]
13	prolapse	I-Adverse_Effect	['N']	[13]
14	,	O	['N']	[14]
15	3	O	['N']	[15]
16	months	O	['N']	[16]
17	after	O	['N']	[17]
18	the	O	['N']	[18]
19	transurethral	O	['N']	[19]
20	injection	O	['N']	[20]
21	of	O	['N']	[21]
22	calcium	B	['N']	[22]
23	hydroxylapatite	I-Drug	['Causes']	[13]
24	.	O	['N']	[24]
#339
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	patient	O	['N']	[3]
4	with	O	['N']	[4]
5	recurrent	O	['N']	[5]
6	,	O	['N']	[6]
7	increasingly	O	['N']	[7]
8	severe	O	['N']	[8]
9	episodes	O	['N']	[9]
10	of	O	['N']	[10]
11	PPE	O	['N']	[11]
12	,	O	['N']	[12]
13	ultimately	O	['N']	[13]
14	complicated	O	['N']	[14]
15	by	O	['N']	[15]
16	a	O	['N']	[16]
17	severe	O	['N']	[17]
18	bullous	B	['N']	[18]
19	eruption	I-Adverse_Effect	['N']	[19]
20	,	O	['N']	[20]
21	following	O	['N']	[21]
22	successive	O	['N']	[22]
23	cycles	O	['N']	[23]
24	of	O	['N']	[24]
25	high	O	['N']	[25]
26	-	O	['N']	[26]
27	dose	O	['N']	[27]
28	cytarabine	B-Drug	['Causes']	[19]
29	for	O	['N']	[29]
30	the	O	['N']	[30]
31	treatment	O	['N']	[31]
32	of	O	['N']	[32]
33	acute	O	['N']	[33]
34	lymphoblastic	O	['N']	[34]
35	leukaemia	O	['N']	[35]
36	.	O	['N']	[36]
#340
0	Temporary	O	['N']	[0]
1	neurologic	O	['N']	[1]
2	abnormalities	O	['N']	[2]
3	were	O	['N']	[3]
4	observed	O	['N']	[4]
5	in	O	['N']	[5]
6	one	O	['N']	[6]
7	out	O	['N']	[7]
8	of	O	['N']	[8]
9	23	O	['N']	[9]
10	patients	O	['N']	[10]
11	undergoing	O	['N']	[11]
12	chemotherapy	O	['N']	[12]
13	with	O	['N']	[13]
14	high	B	['N']	[14]
15	-	I	['N']	[15]
16	dose	I-Dose	['N']	[16]
17	methotrexate	B-Drug	['Dosage']	[16]
18	(	O	['N']	[18]
19	HD	O	['N']	[19]
20	-	O	['N']	[20]
21	MTX	O	['N']	[21]
22	)	O	['N']	[22]
23	for	O	['N']	[23]
24	osteogenic	O	['N']	[24]
25	sarcoma	O	['N']	[25]
26	.	O	['N']	[26]
#341
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	here	O	['N']	[2]
3	a	O	['N']	[3]
4	rare	O	['N']	[4]
5	case	O	['N']	[5]
6	of	O	['N']	[6]
7	ritodrine	B	['N']	[7]
8	-	I	['N']	[8]
9	hydrochloride	I-Drug	['Causes']	[12]
10	-	O	['N']	[10]
11	induced	O	['N']	[11]
12	rhabdomyolysis	B-Adverse_Effect	['N']	[12]
13	in	O	['N']	[13]
14	a	O	['N']	[14]
15	pregnant	O	['N']	[15]
16	patient	O	['N']	[16]
17	with	O	['N']	[17]
18	myotonic	O	['N']	[18]
19	dystrophy	O	['N']	[19]
20	.	O	['N']	[20]
#342
0	One	O	['N']	[0]
1	other	O	['N']	[1]
2	patient	O	['N']	[2]
3	on	O	['N']	[3]
4	digoxin	B-Drug	['Causes']	[10]
5	stopped	O	['N']	[5]
6	taking	O	['N']	[6]
7	it	O	['N']	[7]
8	and	O	['N']	[8]
9	developed	O	['N']	[9]
10	cardiomyopathy	B-Adverse_Effect	['N']	[10]
11	.	O	['N']	[11]
#343
0	A	O	['N']	[0]
1	case	O	['N']	[1]
2	of	O	['N']	[2]
3	acute	B	['N']	[3]
4	cardiomyopathy	I-Adverse_Effect	['N']	[4]
5	and	O	['N']	[5]
6	pericarditis	O	['N']	[6]
7	associated	O	['N']	[7]
8	with	O	['N']	[8]
9	methylphenidate	B-Drug	['Causes']	[4]
10	.	O	['N']	[10]
#344
0	METHODS	O	['N']	[0]
1	:	O	['N']	[1]
2	The	O	['N']	[2]
3	patient	O	['N']	[3]
4	required	O	['N']	[4]
5	insulin	B-Drug	['Causes']	[9]
6	desensitization	O	['N']	[6]
7	for	O	['N']	[7]
8	severe	B	['N']	[8]
9	urticaria	I-Adverse_Effect	['N']	[9]
10	,	O	['N']	[10]
11	angioedema	O	['N']	[11]
12	,	O	['N']	[12]
13	and	O	['N']	[13]
14	occasional	O	['N']	[14]
15	wheezing	O	['N']	[15]
16	resulting	O	['N']	[16]
17	from	O	['N']	[17]
18	her	O	['N']	[18]
19	insulin	O	['N']	[19]
20	dose	O	['N']	[20]
21	.	O	['N']	[21]
#345
0	We	O	['N']	[0]
1	describe	O	['N']	[1]
2	a	O	['N']	[2]
3	patient	O	['N']	[3]
4	with	O	['N']	[4]
5	M4	O	['N']	[5]
6	AML	O	['N']	[6]
7	treated	O	['N']	[7]
8	with	O	['N']	[8]
9	standard	O	['N']	[9]
10	chemotherapy	O	['N']	[10]
11	followed	O	['N']	[11]
12	by	O	['N']	[12]
13	G	B	['N']	[13]
14	-	I	['N']	[14]
15	CSF	I-Drug	['Causes']	[19]
16	who	O	['N']	[16]
17	developed	O	['N']	[17]
18	marked	O	['N']	[18]
19	monocytosis	B-Adverse_Effect	['N']	[19]
20	on	O	['N']	[20]
21	day	O	['N']	[21]
22	8	O	['N']	[22]
23	of	O	['N']	[23]
24	G	O	['N']	[24]
25	-	O	['N']	[25]
26	CSF	O	['N']	[26]
27	therapy	O	['N']	[27]
28	.	O	['N']	[28]
#346
0	The	O	['N']	[0]
1	clinical	O	['N']	[1]
2	course	O	['N']	[2]
3	suggests	O	['N']	[3]
4	that	O	['N']	[4]
5	caffeine	B-Drug	['Causes']	[24]
6	,	O	['N']	[6]
7	which	O	['N']	[7]
8	is	O	['N']	[8]
9	present	O	['N']	[9]
10	in	O	['N']	[10]
11	oolong	O	['N']	[11]
12	tea	O	['N']	[12]
13	,	O	['N']	[13]
14	was	O	['N']	[14]
15	mainly	O	['N']	[15]
16	responsible	O	['N']	[16]
17	for	O	['N']	[17]
18	the	O	['N']	[18]
19	rhabdomyolysis	O	['N']	[19]
20	as	O	['N']	[20]
21	well	O	['N']	[21]
22	as	O	['N']	[22]
23	the	O	['N']	[23]
24	delirium	B-Adverse_Effect	['N']	[24]
25	,	O	['N']	[25]
26	although	O	['N']	[26]
27	severe	O	['N']	[27]
28	hyponatremia	O	['N']	[28]
29	has	O	['N']	[29]
30	been	O	['N']	[30]
31	reported	O	['N']	[31]
32	to	O	['N']	[32]
33	cause	O	['N']	[33]
34	rhabdomyolysis	O	['N']	[34]
35	on	O	['N']	[35]
36	rare	O	['N']	[36]
37	occasions	O	['N']	[37]
38	.	O	['N']	[38]
#347
0	The	O	['N']	[0]
1	authors	O	['N']	[1]
2	describe	O	['N']	[2]
3	a	O	['N']	[3]
4	case	O	['N']	[4]
5	of	O	['N']	[5]
6	combined	O	['N']	[6]
7	lithium	B-Drug	['Causes']	[13]
8	and	O	['N']	[8]
9	haloperidol	O	['N']	[9]
10	toxicity	O	['N']	[10]
11	characterized	O	['N']	[11]
12	by	O	['N']	[12]
13	hyperpyrexia	B-Adverse_Effect	['N']	[13]
14	,	O	['N']	[14]
15	severe	O	['N']	[15]
16	rigidity	O	['N']	[16]
17	,	O	['N']	[17]
18	mutism	O	['N']	[18]
19	,	O	['N']	[19]
20	and	O	['N']	[20]
21	development	O	['N']	[21]
22	of	O	['N']	[22]
23	irreversible	O	['N']	[23]
24	tardive	O	['N']	[24]
25	dyskinesia	O	['N']	[25]
26	.	O	['N']	[26]
#348
0	Hypernatraemia	B-Adverse_Effect	['N']	[0]
1	induced	O	['N']	[1]
2	by	O	['N']	[2]
3	sodium	O	['N']	[3]
4	polystyrene	O	['N']	[4]
5	sulphonate	O	['N']	[5]
6	(	O	['N']	[6]
7	Kayexalate	B-Drug	['Causes']	[0]
8	)	O	['N']	[8]
9	in	O	['N']	[9]
10	two	O	['N']	[10]
11	extremely	O	['N']	[11]
12	low	O	['N']	[12]
13	birth	O	['N']	[13]
14	weight	O	['N']	[14]
15	newborns	O	['N']	[15]
16	.	O	['N']	[16]
#349
0	Protease	O	['N']	[0]
1	inhibitor	O	['N']	[1]
2	-	O	['N']	[2]
3	induced	O	['N']	[3]
4	carbamazepine	B-Drug	['Causes']	[5]
5	toxicity	I-Adverse_Effect	['N']	[5]
6	.	O	['N']	[6]
#350
0	A	O	['N']	[0]
1	case	O	['N']	[1]
2	of	O	['N']	[2]
3	severe	O	['N']	[3]
4	visual	O	['N']	[4]
5	loss	O	['N']	[5]
6	following	O	['N']	[6]
7	a	O	['N']	[7]
8	single	B	['N']	[8]
9	dose	I-Dose	['N']	[9]
10	of	O	['N']	[10]
11	vincristine	B-Drug	['Dosage']	[9]
12	is	O	['N']	[12]
13	described	O	['N']	[13]
14	.	O	['N']	[14]
#351
0	After	O	['N']	[0]
1	a	O	['N']	[1]
2	second	O	['N']	[2]
3	dose	O	['N']	[3]
4	of	O	['N']	[4]
5	metoclopramide	B-Drug	['Causes']	[20]
6	,	O	['N']	[6]
7	these	O	['N']	[7]
8	symptoms	O	['N']	[8]
9	recurred	O	['N']	[9]
10	and	O	['N']	[10]
11	were	O	['N']	[11]
12	associated	O	['N']	[12]
13	with	O	['N']	[13]
14	confusion	O	['N']	[14]
15	,	O	['N']	[15]
16	agitation	O	['N']	[16]
17	,	O	['N']	[17]
18	fever	O	['N']	[18]
19	,	O	['N']	[19]
20	diaphoresis	B-Adverse_Effect	['N']	[20]
21	,	O	['N']	[21]
22	tachypnea	O	['N']	[22]
23	,	O	['N']	[23]
24	tachycardia	O	['N']	[24]
25	,	O	['N']	[25]
26	and	O	['N']	[26]
27	hypertension	O	['N']	[27]
28	.	O	['N']	[28]
#352
0	In	O	['N']	[0]
1	this	O	['N']	[1]
2	article	O	['N']	[2]
3	,	O	['N']	[3]
4	we	O	['N']	[4]
5	describe	O	['N']	[5]
6	a	O	['N']	[6]
7	Japanese	O	['N']	[7]
8	patient	O	['N']	[8]
9	with	O	['N']	[9]
10	severe	B	['N']	[10]
11	interstitial	I	['N']	[11]
12	pneumonia	I-Adverse_Effect	['N']	[12]
13	probably	O	['N']	[13]
14	caused	O	['N']	[14]
15	by	O	['N']	[15]
16	sorafenib	B-Drug	['Causes']	[12]
17	treatment	O	['N']	[17]
18	for	O	['N']	[18]
19	metastatic	O	['N']	[19]
20	renal	O	['N']	[20]
21	cell	O	['N']	[21]
22	carcinoma	O	['N']	[22]
23	.	O	['N']	[23]
#353
0	CASE	O	['N']	[0]
1	:	O	['N']	[1]
2	We	O	['N']	[2]
3	report	O	['N']	[3]
4	a	O	['N']	[4]
5	case	O	['N']	[5]
6	of	O	['N']	[6]
7	a	O	['N']	[7]
8	woman	O	['N']	[8]
9	with	O	['N']	[9]
10	severe	O	['N']	[10]
11	human	B	['N']	[11]
12	insulin	I-Drug	['Causes']	[15]
13	-	O	['N']	[13]
14	induced	O	['N']	[14]
15	lipoatrophy	B-Adverse_Effect	['N']	[15]
16	who	O	['N']	[16]
17	has	O	['N']	[17]
18	been	O	['N']	[18]
19	treated	O	['N']	[19]
20	exclusively	O	['N']	[20]
21	with	O	['N']	[21]
22	recombinant	O	['N']	[22]
23	DNA	O	['N']	[23]
24	human	O	['N']	[24]
25	insulin	O	['N']	[25]
26	since	O	['N']	[26]
27	the	O	['N']	[27]
28	onset	O	['N']	[28]
29	of	O	['N']	[29]
30	IDDM	O	['N']	[30]
31	.	O	['N']	[31]
#354
0	To	O	['N']	[0]
1	date	O	['N']	[1]
2	,	O	['N']	[2]
3	only	O	['N']	[3]
4	three	O	['N']	[4]
5	cases	O	['N']	[5]
6	of	O	['N']	[6]
7	seizures	B-Adverse_Effect	['N']	[7]
8	associated	O	['N']	[8]
9	with	O	['N']	[9]
10	amphotericin	B	['N']	[10]
11	B	I-Drug	['Causes']	[7]
12	have	O	['N']	[12]
13	been	O	['N']	[13]
14	reported	O	['N']	[14]
15	in	O	['N']	[15]
16	the	O	['N']	[16]
17	literature	O	['N']	[17]
18	,	O	['N']	[18]
19	but	O	['N']	[19]
20	healthcare	O	['N']	[20]
21	providers	O	['N']	[21]
22	should	O	['N']	[22]
23	be	O	['N']	[23]
24	aware	O	['N']	[24]
25	of	O	['N']	[25]
26	the	O	['N']	[26]
27	potential	O	['N']	[27]
28	for	O	['N']	[28]
29	this	O	['N']	[29]
30	rare	O	['N']	[30]
31	adverse	O	['N']	[31]
32	effect	O	['N']	[32]
33	.	O	['N']	[33]
#355
0	While	O	['N']	[0]
1	undergoing	O	['N']	[1]
2	treatment	O	['N']	[2]
3	with	O	['N']	[3]
4	albendazole	B-Drug	['Causes']	[14]
5	,	O	['N']	[5]
6	he	O	['N']	[6]
7	developed	O	['N']	[7]
8	worsening	O	['N']	[8]
9	diarrhea	O	['N']	[9]
10	with	O	['N']	[10]
11	abdominal	O	['N']	[11]
12	pain	O	['N']	[12]
13	and	O	['N']	[13]
14	fever	B-Adverse_Effect	['N']	[14]
15	.	O	['N']	[15]
#356
0	Carbamazepine	B-Drug	['Causes']	[5]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	systemic	B	['N']	[3]
4	lupus	I	['N']	[4]
5	erythematosus	I-Adverse_Effect	['N']	[5]
6	.	O	['N']	[6]
#357
0	Methanol	B-Drug	['Causes']	[17]
1	toxicity	O	['N']	[1]
2	can	O	['N']	[2]
3	cause	O	['N']	[3]
4	severe	O	['N']	[4]
5	central	O	['N']	[5]
6	nervous	O	['N']	[6]
7	system	O	['N']	[7]
8	insult	O	['N']	[8]
9	in	O	['N']	[9]
10	which	O	['N']	[10]
11	a	O	['N']	[11]
12	characteristic	O	['N']	[12]
13	pattern	O	['N']	[13]
14	of	O	['N']	[14]
15	bilateral	B	['N']	[15]
16	putaminal	I	['N']	[16]
17	injury	I-Adverse_Effect	['N']	[17]
18	is	O	['N']	[18]
19	noted	O	['N']	[19]
20	on	O	['N']	[20]
21	brain	O	['N']	[21]
22	imaging	O	['N']	[22]
23	studies	O	['N']	[23]
24	.	O	['N']	[24]
#358
0	After	O	['N']	[0]
1	therapy	O	['N']	[1]
2	with	O	['N']	[2]
3	parenteral	O	['N']	[3]
4	amiodarone	B-Drug	['Causes']	[27]
5	(	O	['N']	[5]
6	2300	O	['N']	[6]
7	mg	O	['N']	[7]
8	in	O	['N']	[8]
9	3	O	['N']	[9]
10	days	O	['N']	[10]
11	)	O	['N']	[11]
12	and	O	['N']	[12]
13	other	O	['N']	[13]
14	measures	O	['N']	[14]
15	,	O	['N']	[15]
16	signs	O	['N']	[16]
17	of	O	['N']	[17]
18	congestive	O	['N']	[18]
19	heart	O	['N']	[19]
20	failure	O	['N']	[20]
21	disappeared	O	['N']	[21]
22	;	O	['N']	[22]
23	subsequently	O	['N']	[23]
24	the	O	['N']	[24]
25	patient	O	['N']	[25]
26	developed	O	['N']	[26]
27	jaundice	B-Adverse_Effect	['N']	[27]
28	,	O	['N']	[28]
29	marked	O	['N']	[29]
30	increase	O	['N']	[30]
31	in	O	['N']	[31]
32	serum	O	['N']	[32]
33	transaminase	O	['N']	[33]
34	levels	O	['N']	[34]
35	and	O	['N']	[35]
36	fall	O	['N']	[36]
37	in	O	['N']	[37]
38	prothrombin	O	['N']	[38]
39	time	O	['N']	[39]
40	,	O	['N']	[40]
41	and	O	['N']	[41]
42	histologic	O	['N']	[42]
43	changes	O	['N']	[43]
44	of	O	['N']	[44]
45	severe	O	['N']	[45]
46	centrilobular	O	['N']	[46]
47	necrosis	O	['N']	[47]
48	were	O	['N']	[48]
49	observed	O	['N']	[49]
50	in	O	['N']	[50]
51	hepatic	O	['N']	[51]
52	biopsy	O	['N']	[52]
53	.	O	['N']	[53]
#359
0	The	O	['N']	[0]
1	patient	O	['N']	[1]
2	had	O	['N']	[2]
3	recurrence	O	['N']	[3]
4	of	O	['N']	[4]
5	urticaria	B-Adverse_Effect	['N']	[5]
6	and	O	['N']	[6]
7	angioedema	O	['N']	[7]
8	a	O	['N']	[8]
9	year	O	['N']	[9]
10	and	O	['N']	[10]
11	a	O	['N']	[11]
12	half	O	['N']	[12]
13	later	O	['N']	[13]
14	,	O	['N']	[14]
15	at	O	['N']	[15]
16	which	O	['N']	[16]
17	point	O	['N']	[17]
18	the	O	['N']	[18]
19	NPH	O	['N']	[19]
20	was	O	['N']	[20]
21	stopped	O	['N']	[21]
22	and	O	['N']	[22]
23	she	O	['N']	[23]
24	was	O	['N']	[24]
25	desensitized	O	['N']	[25]
26	to	O	['N']	[26]
27	regular	O	['N']	[27]
28	insulin	B-Drug	['Causes']	[5]
29	.	O	['N']	[29]
#360
0	This	O	['N']	[0]
1	case	O	['N']	[1]
2	extends	O	['N']	[2]
3	the	O	['N']	[3]
4	spectrum	O	['N']	[4]
5	of	O	['N']	[5]
6	fludarabine	B-Drug	['Causes']	[12]
7	pulmonary	O	['N']	[7]
8	toxicity	O	['N']	[8]
9	to	O	['N']	[9]
10	include	O	['N']	[10]
11	pulmonary	B	['N']	[11]
12	nodules	I-Adverse_Effect	['N']	[12]
13	.	O	['N']	[13]
#361
0	CONCLUSIONS	O	['N']	[0]
1	:	O	['N']	[1]
2	This	O	['N']	[2]
3	observation	O	['N']	[3]
4	of	O	['N']	[4]
5	"	O	['N']	[5]
6	on	O	['N']	[6]
7	-	O	['N']	[7]
8	off	O	['N']	[8]
9	"	O	['N']	[9]
10	risperidone	B-Drug	['Causes']	[22]
11	treatment	O	['N']	[11]
12	suggests	O	['N']	[12]
13	that	O	['N']	[13]
14	risperidone	O	['N']	[14]
15	may	O	['N']	[15]
16	have	O	['N']	[16]
17	worsened	O	['N']	[17]
18	both	O	['N']	[18]
19	psychiatric	B	['N']	[19]
20	and	I	['N']	[20]
21	physical	I	['N']	[21]
22	manifestations	I-Adverse_Effect	['N']	[22]
23	of	O	['N']	[23]
24	the	O	['N']	[24]
25	mitochondrial	O	['N']	[25]
26	disorder	O	['N']	[26]
27	in	O	['N']	[27]
28	this	O	['N']	[28]
29	adolescent	O	['N']	[29]
30	.	O	['N']	[30]
#362
0	CONCLUSIONS	O	['N']	[0]
1	:	O	['N']	[1]
2	Among	O	['N']	[2]
3	the	O	['N']	[3]
4	many	O	['N']	[4]
5	presentations	O	['N']	[5]
6	of	O	['N']	[6]
7	ifosfamide	B-Drug	['Causes']	[8]
8	neurotoxicity	B-Adverse_Effect	['N']	[8]
9	,	O	['N']	[9]
10	clinicians	O	['N']	[10]
11	should	O	['N']	[11]
12	consider	O	['N']	[12]
13	NCSE	O	['N']	[13]
14	as	O	['N']	[14]
15	a	O	['N']	[15]
16	possible	O	['N']	[16]
17	explanation	O	['N']	[17]
18	for	O	['N']	[18]
19	changes	O	['N']	[19]
20	in	O	['N']	[20]
21	consciousness	O	['N']	[21]
22	in	O	['N']	[22]
23	a	O	['N']	[23]
24	patient	O	['N']	[24]
25	receiving	O	['N']	[25]
26	this	O	['N']	[26]
27	agent	O	['N']	[27]
28	.	O	['N']	[28]
#363
0	This	O	['N']	[0]
1	concerns	O	['N']	[1]
2	2	O	['N']	[2]
3	male	O	['N']	[3]
4	patients	O	['N']	[4]
5	who	O	['N']	[5]
6	experienced	O	['N']	[6]
7	incontinence	B-Adverse_Effect	['N']	[7]
8	while	O	['N']	[8]
9	taking	O	['N']	[9]
10	venlafaxine	B-Drug	['Causes']	[7]
11	.	O	['N']	[11]
#364
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	fulminant	O	['N']	[5]
6	neuroleptic	B	['N']	[6]
7	malignant	I	['N']	[7]
8	syndrome	I-Adverse_Effect	['N']	[8]
9	in	O	['N']	[9]
10	a	O	['N']	[10]
11	man	O	['N']	[11]
12	aged	O	['N']	[12]
13	70	O	['N']	[13]
14	developing	O	['N']	[14]
15	within	O	['N']	[15]
16	12	O	['N']	[16]
17	hours	O	['N']	[17]
18	of	O	['N']	[18]
19	starting	O	['N']	[19]
20	six	O	['N']	[20]
21	-	O	['N']	[21]
22	hourly	O	['N']	[22]
23	intravenous	O	['N']	[23]
24	metoclopramide	B-Drug	['Causes']	[8]
25	.	O	['N']	[25]
#365
0	Despite	O	['N']	[0]
1	administration	O	['N']	[1]
2	of	O	['N']	[2]
3	phenytoin	O	['N']	[3]
4	and	O	['N']	[4]
5	lorazepam	O	['N']	[5]
6	,	O	['N']	[6]
7	the	O	['N']	[7]
8	seizures	B-Adverse_Effect	['N']	[8]
9	persisted	O	['N']	[9]
10	and	O	['N']	[10]
11	occurred	O	['N']	[11]
12	only	O	['N']	[12]
13	during	O	['N']	[13]
14	amphotercin	B	['N']	[14]
15	B	I-Drug	['Causes']	[8]
16	administration	O	['N']	[16]
17	.	O	['N']	[17]
#366
0	A	O	['N']	[0]
1	toxic	O	['N']	[1]
2	encephalopathy	O	['N']	[2]
3	characterized	O	['N']	[3]
4	by	O	['N']	[4]
5	depressed	B	['N']	[5]
6	level	I	['N']	[6]
7	of	I	['N']	[7]
8	consciousness	I-Adverse_Effect	['N']	[8]
9	,	O	['N']	[9]
10	marked	O	['N']	[10]
11	irritability	O	['N']	[11]
12	,	O	['N']	[12]
13	and	O	['N']	[13]
14	ataxia	O	['N']	[14]
15	developed	O	['N']	[15]
16	in	O	['N']	[16]
17	seven	O	['N']	[17]
18	children	O	['N']	[18]
19	,	O	['N']	[19]
20	5	O	['N']	[20]
21	years	O	['N']	[21]
22	of	O	['N']	[22]
23	age	O	['N']	[23]
24	and	O	['N']	[24]
25	younger	O	['N']	[25]
26	,	O	['N']	[26]
27	following	O	['N']	[27]
28	administration	O	['N']	[28]
29	of	O	['N']	[29]
30	an	O	['N']	[30]
31	antiemetic	O	['N']	[31]
32	combination	O	['N']	[32]
33	of	O	['N']	[33]
34	pentobarbital	O	['N']	[34]
35	and	O	['N']	[35]
36	pyrilamine	B	['N']	[36]
37	maleate	I-Drug	['Causes']	[8]
38	.	O	['N']	[38]
#367
0	The	O	['N']	[0]
1	second	O	['N']	[1]
2	is	O	['N']	[2]
3	a	O	['N']	[3]
4	29-year	O	['N']	[4]
5	-	O	['N']	[5]
6	old	O	['N']	[6]
7	man	O	['N']	[7]
8	with	O	['N']	[8]
9	CD	O	['N']	[9]
10	in	O	['N']	[10]
11	whom	O	['N']	[11]
12	nodular	B	['N']	[12]
13	sclerosing	I	['N']	[13]
14	Hodgkin	I	['N']	[14]
15	's	I	['N']	[15]
16	lymphoma	I-Adverse_Effect	['N']	[16]
17	was	O	['N']	[17]
18	diagnosed	O	['N']	[18]
19	3	O	['N']	[19]
20	weeks	O	['N']	[20]
21	after	O	['N']	[21]
22	infusion	O	['N']	[22]
23	with	O	['N']	[23]
24	infliximab	B-Drug	['Causes']	[16]
25	.	O	['N']	[25]
#368
0	Exacerbation	O	['N']	[0]
1	of	O	['N']	[1]
2	5-FU	B-Drug	['Causes']	[4]
3	dermatologic	B	['N']	[3]
4	toxicities	I-Adverse_Effect	['N']	[4]
5	in	O	['N']	[5]
6	patients	O	['N']	[6]
7	with	O	['N']	[7]
8	preexisting	O	['N']	[8]
9	conditions	O	['N']	[9]
10	suggests	O	['N']	[10]
11	the	O	['N']	[11]
12	importance	O	['N']	[12]
13	of	O	['N']	[13]
14	aggressive	O	['N']	[14]
15	ocular	O	['N']	[15]
16	prophylaxis	O	['N']	[16]
17	,	O	['N']	[17]
18	using	O	['N']	[18]
19	frequent	O	['N']	[19]
20	ocular	O	['N']	[20]
21	lubrication	O	['N']	[21]
22	and	O	['N']	[22]
23	topical	O	['N']	[23]
24	steroid	O	['N']	[24]
25	preparations	O	['N']	[25]
26	with	O	['N']	[26]
27	concurrent	O	['N']	[27]
28	medical	O	['N']	[28]
29	management	O	['N']	[29]
30	of	O	['N']	[30]
31	pre	O	['N']	[31]
32	-	O	['N']	[32]
33	existing	O	['N']	[33]
34	dermatologic	O	['N']	[34]
35	conditions	O	['N']	[35]
36	.	O	['N']	[36]
#369
0	The	O	['N']	[0]
1	toxicity	B-Adverse_Effect	['N']	[1]
2	and	O	['N']	[2]
3	plasma	O	['N']	[3]
4	concentrations	O	['N']	[4]
5	of	O	['N']	[5]
6	ifosfamide	O	['N']	[6]
7	,	O	['N']	[7]
8	chloroacetaldehyde	O	['N']	[8]
9	,	O	['N']	[9]
10	and	O	['N']	[10]
11	4-hydroxyifosfamide	B-Drug	['Causes']	[1]
12	were	O	['N']	[12]
13	then	O	['N']	[13]
14	determined	O	['N']	[14]
15	over	O	['N']	[15]
16	24	O	['N']	[16]
17	h	O	['N']	[17]
18	after	O	['N']	[18]
19	a	O	['N']	[19]
20	single	O	['N']	[20]
21	1.6	O	['N']	[21]
22	g	O	['N']	[22]
23	/	O	['N']	[23]
24	m2	O	['N']	[24]
25	dose	O	['N']	[25]
26	of	O	['N']	[26]
27	ifosfamide	O	['N']	[27]
28	.	O	['N']	[28]
#370
0	OBJECTIVE	O	['N']	[0]
1	:	O	['N']	[1]
2	To	O	['N']	[2]
3	report	O	['N']	[3]
4	a	O	['N']	[4]
5	case	O	['N']	[5]
6	of	O	['N']	[6]
7	severe	B	['N']	[7]
8	chloroquine	B-Drug	['Causes']	[9]
9	toxicity	I-Adverse_Effect	['N']	[9]
10	in	O	['N']	[10]
11	the	O	['N']	[11]
12	presence	O	['N']	[12]
13	of	O	['N']	[13]
14	high	O	['N']	[14]
15	-	O	['N']	[15]
16	grade	O	['N']	[16]
17	chloroquine	O	['N']	[17]
18	-	O	['N']	[18]
19	resistant	O	['N']	[19]
20	Plasmodium	O	['N']	[20]
21	vivax	O	['N']	[21]
22	.	O	['N']	[22]
#371
0	Multiple	O	['N']	[0]
1	complications	O	['N']	[1]
2	of	O	['N']	[2]
3	propylthiouracil	B-Drug	['Causes']	[13]
4	treatment	O	['N']	[4]
5	:	O	['N']	[5]
6	granulocytopenia	O	['N']	[6]
7	,	O	['N']	[7]
8	eosinophilia	O	['N']	[8]
9	,	O	['N']	[9]
10	skin	O	['N']	[10]
11	reaction	O	['N']	[11]
12	and	O	['N']	[12]
13	hepatitis	B-Adverse_Effect	['N']	[13]
14	with	O	['N']	[14]
15	lymphocyte	O	['N']	[15]
16	sensitization	O	['N']	[16]
17	.	O	['N']	[17]
#372
0	Inadvertent	O	['N']	[0]
1	and	O	['N']	[1]
2	accidental	O	['N']	[2]
3	epinephrine	B-Drug	['Causes']	[10]
4	overdose	O	['N']	[4]
5	might	O	['N']	[5]
6	result	O	['N']	[6]
7	in	O	['N']	[7]
8	potentially	O	['N']	[8]
9	lethal	B	['N']	[9]
10	complications	I-Adverse_Effect	['N']	[10]
11	.	O	['N']	[11]
#373
0	We	O	['N']	[0]
1	describe	O	['N']	[1]
2	two	O	['N']	[2]
3	patients	O	['N']	[3]
4	in	O	['N']	[4]
5	whom	O	['N']	[5]
6	painful	B	['N']	[6]
7	erosions	I	['N']	[7]
8	of	I	['N']	[8]
9	their	I	['N']	[9]
10	psoriasis	I-Adverse_Effect	['N']	[10]
11	developed	O	['N']	[11]
12	as	O	['N']	[12]
13	the	O	['N']	[13]
14	presenting	O	['N']	[14]
15	sign	O	['N']	[15]
16	of	O	['N']	[16]
17	methotrexate	B-Drug	['Causes']	[10]
18	toxicity	O	['N']	[18]
19	and	O	['N']	[19]
20	review	O	['N']	[20]
21	the	O	['N']	[21]
22	literature	O	['N']	[22]
23	,	O	['N']	[23]
24	emphasizing	O	['N']	[24]
25	the	O	['N']	[25]
26	risk	O	['N']	[26]
27	factors	O	['N']	[27]
28	associated	O	['N']	[28]
29	with	O	['N']	[29]
30	this	O	['N']	[30]
31	manifestation	O	['N']	[31]
32	.	O	['N']	[32]
#374
0	A	O	['N']	[0]
1	dapsone	B-Drug	['Causes']	[7]
2	hypersensitivity	O	['N']	[2]
3	syndrome	O	['N']	[3]
4	,	O	['N']	[4]
5	consisting	O	['N']	[5]
6	of	O	['N']	[6]
7	fever	B-Adverse_Effect	['N']	[7]
8	,	O	['N']	[8]
9	headache	O	['N']	[9]
10	,	O	['N']	[10]
11	nausea	O	['N']	[11]
12	,	O	['N']	[12]
13	vomiting	O	['N']	[13]
14	,	O	['N']	[14]
15	lymphadenopathy	O	['N']	[15]
16	,	O	['N']	[16]
17	hepatitis	O	['N']	[17]
18	,	O	['N']	[18]
19	hemolysis	O	['N']	[19]
20	,	O	['N']	[20]
21	leukopenia	O	['N']	[21]
22	,	O	['N']	[22]
23	and	O	['N']	[23]
24	mononucleosis	O	['N']	[24]
25	,	O	['N']	[25]
26	has	O	['N']	[26]
27	been	O	['N']	[27]
28	described	O	['N']	[28]
29	in	O	['N']	[29]
30	patients	O	['N']	[30]
31	treated	O	['N']	[31]
32	with	O	['N']	[32]
33	the	O	['N']	[33]
34	drug	O	['N']	[34]
35	for	O	['N']	[35]
36	leprosy	O	['N']	[36]
37	.	O	['N']	[37]
#375
0	Ibuprofen	B-Drug	['Dosage']	[1]
1	overdose	B-Dose	['N']	[1]
2	is	O	['N']	[2]
3	usually	O	['N']	[3]
4	characterized	O	['N']	[4]
5	by	O	['N']	[5]
6	GI	O	['N']	[6]
7	upset	O	['N']	[7]
8	,	O	['N']	[8]
9	dizziness	O	['N']	[9]
10	,	O	['N']	[10]
11	and	O	['N']	[11]
12	mild	O	['N']	[12]
13	sedation	O	['N']	[13]
14	.	O	['N']	[14]
#376
0	Sweet	B	['N']	[0]
1	's	I	['N']	[1]
2	syndrome	I-Adverse_Effect	['N']	[2]
3	associated	O	['N']	[3]
4	with	O	['N']	[4]
5	sargramostim	B-Drug	['Causes']	[2]
6	(	O	['N']	[6]
7	granulocyte	O	['N']	[7]
8	-	O	['N']	[8]
9	macrophage	O	['N']	[9]
10	colony	O	['N']	[10]
11	stimulating	O	['N']	[11]
12	factor	O	['N']	[12]
13	)	O	['N']	[13]
14	treatment	O	['N']	[14]
15	.	O	['N']	[15]
#377
0	He	O	['N']	[0]
1	had	O	['N']	[1]
2	also	O	['N']	[2]
3	developed	O	['N']	[3]
4	elevated	B	['N']	[4]
5	serum	I	['N']	[5]
6	ammonia	I	['N']	[6]
7	levels	I-Adverse_Effect	['N']	[7]
8	while	O	['N']	[8]
9	on	O	['N']	[9]
10	valproic	B	['N']	[10]
11	acid	I-Drug	['Causes']	[7]
12	.	O	['N']	[12]
#378
0	Sixteen	O	['N']	[0]
1	of	O	['N']	[1]
2	33	O	['N']	[2]
3	patients	O	['N']	[3]
4	developed	O	['N']	[4]
5	significant	O	['N']	[5]
6	hyponatremia	O	['N']	[6]
7	and	O	['N']	[7]
8	hypoosmolality	B-Adverse_Effect	['N']	[8]
9	during	O	['N']	[9]
10	oral	O	['N']	[10]
11	treatment	O	['N']	[11]
12	with	O	['N']	[12]
13	lorcainide	B-Drug	['Causes']	[8]
14	.	O	['N']	[14]
#379
0	Persistent	B	['N']	[0]
1	light	I	['N']	[1]
2	reactivity	I-Adverse_Effect	['N']	[2]
3	from	O	['N']	[3]
4	systemic	O	['N']	[4]
5	quinine	B-Drug	['Causes']	[2]
6	.	O	['N']	[6]
#380
0	Rapamycin	B-Drug	['Causes']	[31]
1	/	O	['N']	[1]
2	sirolimus	O	['N']	[2]
3	(	O	['N']	[3]
4	SR	O	['N']	[4]
5	)	O	['N']	[5]
6	,	O	['N']	[6]
7	trade	O	['N']	[7]
8	named	O	['N']	[8]
9	Rapammune	O	['N']	[9]
10	(	O	['N']	[10]
11	Wyeth	O	['N']	[11]
12	-	O	['N']	[12]
13	Ayerst	O	['N']	[13]
14	,	O	['N']	[14]
15	Sydney	O	['N']	[15]
16	,	O	['N']	[16]
17	Australia	O	['N']	[17]
18	)	O	['N']	[18]
19	,	O	['N']	[19]
20	is	O	['N']	[20]
21	a	O	['N']	[21]
22	potent	O	['N']	[22]
23	immunosuppressive	O	['N']	[23]
24	drug	O	['N']	[24]
25	associated	O	['N']	[25]
26	with	O	['N']	[26]
27	myelosuppression	O	['N']	[27]
28	,	O	['N']	[28]
29	hypertension	O	['N']	[29]
30	,	O	['N']	[30]
31	hyperlipidemia	B-Adverse_Effect	['N']	[31]
32	,	O	['N']	[32]
33	and	O	['N']	[33]
34	infection	O	['N']	[34]
35	.	O	['N']	[35]
#381
0	Oxcarbazepine	B-Drug	['Causes']	[9]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	Drug	B	['N']	[3]
4	Reaction	I	['N']	[4]
5	with	I	['N']	[5]
6	Eosinophilia	I	['N']	[6]
7	and	I	['N']	[7]
8	Systemic	I	['N']	[8]
9	Symptoms	I-Adverse_Effect	['N']	[9]
10	(	O	['N']	[10]
11	DRESS	O	['N']	[11]
12	)	O	['N']	[12]
13	.	O	['N']	[13]
#382
0	We	O	['N']	[0]
1	describe	O	['N']	[1]
2	3	O	['N']	[2]
3	cases	O	['N']	[3]
4	of	O	['N']	[4]
5	diphenhydramine	B-Drug	['Causes']	[9]
6	-	O	['N']	[6]
7	induced	O	['N']	[7]
8	cardiac	B	['N']	[8]
9	toxicity	I-Adverse_Effect	['N']	[9]
10	that	O	['N']	[10]
11	were	O	['N']	[11]
12	responsive	O	['N']	[12]
13	to	O	['N']	[13]
14	bicarbonate	O	['N']	[14]
15	.	O	['N']	[15]
#383
0	We	O	['N']	[0]
1	suggest	O	['N']	[1]
2	adding	O	['N']	[2]
3	this	O	['N']	[3]
4	side	O	['N']	[4]
5	effect	O	['N']	[5]
6	to	O	['N']	[6]
7	the	O	['N']	[7]
8	list	O	['N']	[8]
9	of	O	['N']	[9]
10	untoward	O	['N']	[10]
11	effects	O	['N']	[11]
12	of	O	['N']	[12]
13	lidocaine	B-Drug	['Causes']	[22]
14	and	O	['N']	[14]
15	to	O	['N']	[15]
16	the	O	['N']	[16]
17	differential	O	['N']	[17]
18	diagnosis	O	['N']	[18]
19	of	O	['N']	[19]
20	fixed	O	['N']	[20]
21	dilated	B	['N']	[21]
22	pupils	I-Adverse_Effect	['N']	[22]
23	in	O	['N']	[23]
24	neonates	O	['N']	[24]
25	treated	O	['N']	[25]
26	with	O	['N']	[26]
27	lidocaine	O	['N']	[27]
28	.	O	['N']	[28]
#384
0	Palpable	B	['N']	[0]
1	purpuric	I	['N']	[1]
2	skin	I	['N']	[2]
3	lesions	I-Adverse_Effect	['N']	[3]
4	on	O	['N']	[4]
5	the	O	['N']	[5]
6	anterior	O	['N']	[6]
7	surface	O	['N']	[7]
8	of	O	['N']	[8]
9	both	O	['N']	[9]
10	legs	O	['N']	[10]
11	appeared	O	['N']	[11]
12	on	O	['N']	[12]
13	the	O	['N']	[13]
14	55th	O	['N']	[14]
15	day	O	['N']	[15]
16	of	O	['N']	[16]
17	amphotericin	B	['N']	[17]
18	B	I-Drug	['Causes']	[3]
19	treatment	O	['N']	[19]
20	.	O	['N']	[20]
#385
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	male	O	['N']	[3]
4	patient	O	['N']	[4]
5	with	O	['N']	[5]
6	advanced	O	['N']	[6]
7	AIDS	O	['N']	[7]
8	who	O	['N']	[8]
9	developed	O	['N']	[9]
10	hypercalcemia	B-Adverse_Effect	['N']	[10]
11	2	O	['N']	[11]
12	weeks	O	['N']	[12]
13	after	O	['N']	[13]
14	institution	O	['N']	[14]
15	of	O	['N']	[15]
16	rhGH	B-Drug	['Causes']	[10]
17	therapy	O	['N']	[17]
18	.	O	['N']	[18]
#386
0	OBSERVATIONS	O	['N']	[0]
1	:	O	['N']	[1]
2	A	O	['N']	[2]
3	48-year	O	['N']	[3]
4	-	O	['N']	[4]
5	old	O	['N']	[5]
6	woman	O	['N']	[6]
7	presented	O	['N']	[7]
8	with	O	['N']	[8]
9	disfiguring	B	['N']	[9]
10	facial	I	['N']	[10]
11	edema	I-Adverse_Effect	['N']	[11]
12	10	O	['N']	[12]
13	weeks	O	['N']	[13]
14	after	O	['N']	[14]
15	she	O	['N']	[15]
16	began	O	['N']	[16]
17	antiviral	O	['N']	[17]
18	therapy	O	['N']	[18]
19	with	O	['N']	[19]
20	peginterferon	B	['N']	[20]
21	alfa-2a	I-Drug	['Causes']	[11]
22	and	O	['N']	[22]
23	ribavirin	O	['N']	[23]
24	for	O	['N']	[24]
25	chronic	O	['N']	[25]
26	hepatitis	O	['N']	[26]
27	C	O	['N']	[27]
28	infection	O	['N']	[28]
29	.	O	['N']	[29]
#387
0	After	O	['N']	[0]
1	5-ASA	B-Drug	['Causes']	[6]
2	was	O	['N']	[2]
3	discontinued	O	['N']	[3]
4	,	O	['N']	[4]
5	the	O	['N']	[5]
6	polyneuropathy	B-Adverse_Effect	['N']	[6]
7	symptoms	O	['N']	[7]
8	recovered	O	['N']	[8]
9	gradually	O	['N']	[9]
10	.	O	['N']	[10]
#388
0	Gynecomastia	B-Adverse_Effect	['N']	[0]
1	developed	O	['N']	[1]
2	in	O	['N']	[2]
3	two	O	['N']	[3]
4	epileptic	O	['N']	[4]
5	patients	O	['N']	[5]
6	some	O	['N']	[6]
7	months	O	['N']	[7]
8	after	O	['N']	[8]
9	the	O	['N']	[9]
10	addition	O	['N']	[10]
11	of	O	['N']	[11]
12	oral	O	['N']	[12]
13	fluoresone	O	['N']	[13]
14	750	O	['N']	[14]
15	mg	O	['N']	[15]
16	daily	O	['N']	[16]
17	to	O	['N']	[17]
18	the	O	['N']	[18]
19	phenobarbital	O	['N']	[19]
20	and	O	['N']	[20]
21	phenytoin	B-Drug	['Causes']	[0]
22	already	O	['N']	[22]
23	being	O	['N']	[23]
24	administered	O	['N']	[24]
25	.	O	['N']	[25]
#389
0	We	O	['N']	[0]
1	describe	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	severe	O	['N']	[5]
6	aplastic	O	['N']	[6]
7	anemia	O	['N']	[7]
8	(	O	['N']	[8]
9	AA	B-Adverse_Effect	['N']	[9]
10	)	O	['N']	[10]
11	that	O	['N']	[11]
12	was	O	['N']	[12]
13	probably	O	['N']	[13]
14	induced	O	['N']	[14]
15	by	O	['N']	[15]
16	lenalidomide	B-Drug	['Causes']	[9]
17	.	O	['N']	[17]
#390
0	An	O	['N']	[0]
1	infertile	O	['N']	[1]
2	patient	O	['N']	[2]
3	with	O	['N']	[3]
4	amenorrhea	O	['N']	[4]
5	-	O	['N']	[5]
6	galactorrhea	O	['N']	[6]
7	syndrome	O	['N']	[7]
8	lost	B	['N']	[8]
9	vision	I-Adverse_Effect	['N']	[9]
10	during	O	['N']	[10]
11	a	O	['N']	[11]
12	pregnancy	O	['N']	[12]
13	occurring	O	['N']	[13]
14	after	O	['N']	[14]
15	Bromocryptine	B-Drug	['Causes']	[9]
16	treatment	O	['N']	[16]
17	.	O	['N']	[17]
#391
0	We	O	['N']	[0]
1	describe	O	['N']	[1]
2	a	O	['N']	[2]
3	continuous	O	['N']	[3]
4	ambulatory	O	['N']	[4]
5	peritoneal	O	['N']	[5]
6	dialysis	O	['N']	[6]
7	(	O	['N']	[7]
8	CAPD	O	['N']	[8]
9	)	O	['N']	[9]
10	patient	O	['N']	[10]
11	that	O	['N']	[11]
12	developed	O	['N']	[12]
13	vancomycin	B-Drug	['Causes']	[16]
14	-	O	['N']	[14]
15	induced	O	['N']	[15]
16	agranulocytosis	B-Adverse_Effect	['N']	[16]
17	during	O	['N']	[17]
18	treatment	O	['N']	[18]
19	for	O	['N']	[19]
20	methicillin	O	['N']	[20]
21	-	O	['N']	[21]
22	resistant	O	['N']	[22]
23	Staphylococcus	O	['N']	[23]
24	aureus	O	['N']	[24]
25	(	O	['N']	[25]
26	MRSA)-associated	O	['N']	[26]
27	external	O	['N']	[27]
28	cuff	O	['N']	[28]
29	infection	O	['N']	[29]
30	and	O	['N']	[30]
31	pneumonia	O	['N']	[31]
32	.	O	['N']	[32]
#392
0	Usefulness	O	['N']	[0]
1	of	O	['N']	[1]
2	antiplatelet	O	['N']	[2]
3	drugs	O	['N']	[3]
4	in	O	['N']	[4]
5	the	O	['N']	[5]
6	management	O	['N']	[6]
7	of	O	['N']	[7]
8	heparin	B-Drug	['Causes']	[13]
9	-	O	['N']	[9]
10	associated	O	['N']	[10]
11	thrombocytopenia	O	['N']	[11]
12	and	O	['N']	[12]
13	thrombosis	B-Adverse_Effect	['N']	[13]
14	.	O	['N']	[14]
#393
0	Mean	O	['N']	[0]
1	time	O	['N']	[1]
2	between	O	['N']	[2]
3	initiation	O	['N']	[3]
4	of	O	['N']	[4]
5	gemcitabine	B-Drug	['Dosage']	[22]
6	therapy	O	['N']	[6]
7	and	O	['N']	[7]
8	onset	O	['N']	[8]
9	of	O	['N']	[9]
10	HUS	O	['N']	[10]
11	was	O	['N']	[11]
12	7.4	O	['N']	[12]
13	+	O	['N']	[13]
14	/-	O	['N']	[14]
15	3.5	O	['N']	[15]
16	months	O	['N']	[16]
17	,	O	['N']	[17]
18	or	O	['N']	[18]
19	21.9	B	['N']	[19]
20	+	I	['N']	[20]
21	/-	I	['N']	[21]
22	10.9	I-Dose	['N']	[22]
23	doses	O	['N']	[23]
24	of	O	['N']	[24]
25	gemcitabine	O	['N']	[25]
26	.	O	['N']	[26]
#394
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	the	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	a	O	['N']	[5]
6	lung	O	['N']	[6]
7	cancer	O	['N']	[7]
8	patient	O	['N']	[8]
9	with	O	['N']	[9]
10	bronquiloalveolar	O	['N']	[10]
11	carcinoma	O	['N']	[11]
12	(	O	['N']	[12]
13	BAC	O	['N']	[13]
14	)	O	['N']	[14]
15	presenting	O	['N']	[15]
16	with	O	['N']	[16]
17	BOOP	O	['N']	[17]
18	after	O	['N']	[18]
19	chemotherapy	O	['N']	[19]
20	with	O	['N']	[20]
21	docetaxel	B-Drug	['Causes']	[35]
22	and	O	['N']	[22]
23	gemcitabine	O	['N']	[23]
24	producing	O	['N']	[24]
25	severe	O	['N']	[25]
26	respiratory	O	['N']	[26]
27	insufficiency	O	['N']	[27]
28	,	O	['N']	[28]
29	and	O	['N']	[29]
30	simulating	O	['N']	[30]
31	a	O	['N']	[31]
32	progression	B	['N']	[32]
33	of	I	['N']	[33]
34	the	I	['N']	[34]
35	tumor	I-Adverse_Effect	['N']	[35]
36	.	O	['N']	[36]
#395
0	Horner	B	['N']	[0]
1	's	I	['N']	[1]
2	syndrome	I-Adverse_Effect	['N']	[2]
3	and	O	['N']	[3]
4	demyelinating	O	['N']	[4]
5	peripheral	O	['N']	[5]
6	neuropathy	O	['N']	[6]
7	caused	O	['N']	[7]
8	by	O	['N']	[8]
9	high	O	['N']	[9]
10	-	O	['N']	[10]
11	dose	O	['N']	[11]
12	cytosine	B	['N']	[12]
13	arabinoside	I-Drug	['Causes']	[2]
14	.	O	['N']	[14]
#396
0	One	O	['N']	[0]
1	patient	O	['N']	[1]
2	developed	O	['N']	[2]
3	large	B	['N']	[3]
4	intramural	I	['N']	[4]
5	esophageal	I	['N']	[5]
6	hematoma	I-Adverse_Effect	['N']	[6]
7	as	O	['N']	[7]
8	a	O	['N']	[8]
9	complication	O	['N']	[9]
10	of	O	['N']	[10]
11	heparin	B-Drug	['Causes']	[6]
12	therapy	O	['N']	[12]
13	.	O	['N']	[13]
#397
0	Six	O	['N']	[0]
1	patients	O	['N']	[1]
2	with	O	['N']	[2]
3	no	O	['N']	[3]
4	previous	O	['N']	[4]
5	signs	O	['N']	[5]
6	or	O	['N']	[6]
7	symptoms	O	['N']	[7]
8	suggestive	O	['N']	[8]
9	of	O	['N']	[9]
10	coronary	O	['N']	[10]
11	artery	O	['N']	[11]
12	disease	O	['N']	[12]
13	developed	O	['N']	[13]
14	acute	B	['N']	[14]
15	coronary	I	['N']	[15]
16	ischemia	I-Adverse_Effect	['N']	[16]
17	/	O	['N']	[17]
18	infarction	O	['N']	[18]
19	shortly	O	['N']	[19]
20	after	O	['N']	[20]
21	cis	B	['N']	[21]
22	-	I	['N']	[22]
23	diamine	I	['N']	[23]
24	-	I	['N']	[24]
25	dichloroplatinum	I	['N']	[25]
26	II	I-Drug	['Causes']	[16]
27	(	O	['N']	[27]
28	cisplatin	O	['N']	[28]
29	)	O	['N']	[29]
30	-based	O	['N']	[30]
31	chemotherapy	O	['N']	[31]
32	.	O	['N']	[32]
#398
0	The	O	['N']	[0]
1	main	O	['N']	[1]
2	clinical	O	['N']	[2]
3	features	O	['N']	[3]
4	of	O	['N']	[4]
5	this	O	['N']	[5]
6	58-year	O	['N']	[6]
7	-	O	['N']	[7]
8	old	O	['N']	[8]
9	female	O	['N']	[9]
10	patient	O	['N']	[10]
11	were	O	['N']	[11]
12	laboratory	O	['N']	[12]
13	evidence	O	['N']	[13]
14	of	O	['N']	[14]
15	leucopenia	O	['N']	[15]
16	and	O	['N']	[16]
17	cholestasis	O	['N']	[17]
18	,	O	['N']	[18]
19	and	O	['N']	[19]
20	biopsy	O	['N']	[20]
21	features	O	['N']	[21]
22	of	O	['N']	[22]
23	fatty	O	['N']	[23]
24	liver	O	['N']	[24]
25	parenchyma	O	['N']	[25]
26	degeneration	O	['N']	[26]
27	with	O	['N']	[27]
28	granulocytic	O	['N']	[28]
29	portal	O	['N']	[29]
30	infiltration	O	['N']	[30]
31	and	O	['N']	[31]
32	bile	O	['N']	[32]
33	stasis	O	['N']	[33]
34	,	O	['N']	[34]
35	demonstrated	O	['N']	[35]
36	20	O	['N']	[36]
37	days	O	['N']	[37]
38	after	O	['N']	[38]
39	the	O	['N']	[39]
40	initiation	O	['N']	[40]
41	of	O	['N']	[41]
42	antithyroid	O	['N']	[42]
43	therapy	O	['N']	[43]
44	with	O	['N']	[44]
45	20	B	['N']	[45]
46	mg	I-Dose	['N']	[46]
47	methimazole	B-Drug	['Dosage']	[46]
48	daily	O	['N']	[48]
49	.	O	['N']	[49]
#399
0	A	O	['N']	[0]
1	31-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	female	O	['N']	[4]
5	developed	O	['N']	[5]
6	multiple	O	['N']	[6]
7	episodes	O	['N']	[7]
8	of	O	['N']	[8]
9	grand	B	['N']	[9]
10	mal	I	['N']	[10]
11	seizures	I-Adverse_Effect	['N']	[11]
12	after	O	['N']	[12]
13	combination	O	['N']	[13]
14	chemotherapy	O	['N']	[14]
15	with	O	['N']	[15]
16	cisplatin	B-Drug	['Causes']	[11]
17	,	O	['N']	[17]
18	vinblastine	O	['N']	[18]
19	and	O	['N']	[19]
20	bleomycin	O	['N']	[20]
21	for	O	['N']	[21]
22	germ	O	['N']	[22]
23	cell	O	['N']	[23]
24	ovarian	O	['N']	[24]
25	cancer	O	['N']	[25]
26	stage	O	['N']	[26]
27	Ic	O	['N']	[27]
28	.	O	['N']	[28]
#400
0	The	O	['N']	[0]
1	authors	O	['N']	[1]
2	report	O	['N']	[2]
3	five	O	['N']	[3]
4	cases	O	['N']	[4]
5	of	O	['N']	[5]
6	tremor	B-Adverse_Effect	['N']	[6]
7	related	O	['N']	[7]
8	to	O	['N']	[8]
9	itraconazole	B-Drug	['Causes']	[6]
10	therapy	O	['N']	[10]
11	,	O	['N']	[11]
12	which	O	['N']	[12]
13	occurred	O	['N']	[13]
14	within	O	['N']	[14]
15	1	O	['N']	[15]
16	-	O	['N']	[16]
17	12	O	['N']	[17]
18	months	O	['N']	[18]
19	of	O	['N']	[19]
20	initiating	O	['N']	[20]
21	treatment	O	['N']	[21]
22	and	O	['N']	[22]
23	resolved	O	['N']	[23]
24	gradually	O	['N']	[24]
25	following	O	['N']	[25]
26	itraconazole	O	['N']	[26]
27	withdrawal	O	['N']	[27]
28	.	O	['N']	[28]
#401
0	Nephrotic	O	['N']	[0]
1	syndrome	O	['N']	[1]
2	related	O	['N']	[2]
3	to	O	['N']	[3]
4	systemic	B	['N']	[4]
5	lupus	I	['N']	[5]
6	erythematosus	I-Adverse_Effect	['N']	[6]
7	after	O	['N']	[7]
8	griseofulvin	B-Drug	['Causes']	[6]
9	therapy	O	['N']	[9]
10	.	O	['N']	[10]
#402
0	Eleven	O	['N']	[0]
1	patients	O	['N']	[1]
2	developed	O	['N']	[2]
3	infection	O	['N']	[3]
4	requiring	O	['N']	[4]
5	hospitalization	O	['N']	[5]
6	while	O	['N']	[6]
7	taking	O	['N']	[7]
8	leflunomide	B-Drug	['Causes']	[50]
9	including	O	['N']	[9]
10	:	O	['N']	[10]
11	lower	O	['N']	[11]
12	respiratory	O	['N']	[12]
13	tract	O	['N']	[13]
14	infections	O	['N']	[14]
15	(	O	['N']	[15]
16	3	O	['N']	[16]
17	)	O	['N']	[17]
18	,	O	['N']	[18]
19	cellulitis	O	['N']	[19]
20	(	O	['N']	[20]
21	2	O	['N']	[21]
22	)	O	['N']	[22]
23	,	O	['N']	[23]
24	disseminated	O	['N']	[24]
25	herpes	O	['N']	[25]
26	zoster	O	['N']	[26]
27	(	O	['N']	[27]
28	2	O	['N']	[28]
29	)	O	['N']	[29]
30	,	O	['N']	[30]
31	probable	O	['N']	[31]
32	TB	O	['N']	[32]
33	liver	O	['N']	[33]
34	(	O	['N']	[34]
35	1	O	['N']	[35]
36	)	O	['N']	[36]
37	,	O	['N']	[37]
38	abdominal	O	['N']	[38]
39	sepsis	O	['N']	[39]
40	(	O	['N']	[40]
41	1	O	['N']	[41]
42	)	O	['N']	[42]
43	,	O	['N']	[43]
44	mycotic	O	['N']	[44]
45	aneurysm	O	['N']	[45]
46	(	O	['N']	[46]
47	1	O	['N']	[47]
48	)	O	['N']	[48]
49	and	O	['N']	[49]
50	gastroenteritis	B-Adverse_Effect	['N']	[50]
51	(	O	['N']	[51]
52	1	O	['N']	[52]
53	)	O	['N']	[53]
54	.	O	['N']	[54]
#403
0	Gynecomastia	B-Adverse_Effect	['N']	[0]
1	associated	O	['N']	[1]
2	with	O	['N']	[2]
3	theophylline	B-Drug	['Causes']	[0]
4	.	O	['N']	[4]
#404
0	Exfoliative	B	['N']	[0]
1	dermatitis	I-Adverse_Effect	['N']	[1]
2	secondary	O	['N']	[2]
3	to	O	['N']	[3]
4	tobramycin	B	['N']	[4]
5	sulfate	I-Drug	['Causes']	[1]
6	.	O	['N']	[6]
#405
0	Pulmonary	O	['N']	[0]
1	hemorrhage	O	['N']	[1]
2	is	O	['N']	[2]
3	an	O	['N']	[3]
4	uncommon	O	['N']	[4]
5	feature	O	['N']	[5]
6	in	O	['N']	[6]
7	the	O	['N']	[7]
8	HUS	B-Adverse_Effect	['N']	[8]
9	,	O	['N']	[9]
10	and	O	['N']	[10]
11	seems	O	['N']	[11]
12	to	O	['N']	[12]
13	appear	O	['N']	[13]
14	especially	O	['N']	[14]
15	in	O	['N']	[15]
16	the	O	['N']	[16]
17	HUS	O	['N']	[17]
18	associated	O	['N']	[18]
19	with	O	['N']	[19]
20	MMC	B-Drug	['Causes']	[8]
21	therapy	O	['N']	[21]
22	.	O	['N']	[22]
#406
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	a	O	['N']	[5]
6	patient	O	['N']	[6]
7	with	O	['N']	[7]
8	mild	O	['N']	[8]
9	chronic	O	['N']	[9]
10	renal	O	['N']	[10]
11	insufficiency	O	['N']	[11]
12	who	O	['N']	[12]
13	had	O	['N']	[13]
14	been	O	['N']	[14]
15	taking	O	['N']	[15]
16	simvastatin	O	['N']	[16]
17	for	O	['N']	[17]
18	over	O	['N']	[18]
19	a	O	['N']	[19]
20	year	O	['N']	[20]
21	and	O	['N']	[21]
22	developed	O	['N']	[22]
23	acute	B	['N']	[23]
24	weakness	I-Adverse_Effect	['N']	[24]
25	within	O	['N']	[25]
26	3	O	['N']	[26]
27	weeks	O	['N']	[27]
28	after	O	['N']	[28]
29	the	O	['N']	[29]
30	start	O	['N']	[30]
31	of	O	['N']	[31]
32	treatment	O	['N']	[32]
33	with	O	['N']	[33]
34	colchicine	B-Drug	['Causes']	[24]
35	for	O	['N']	[35]
36	acute	O	['N']	[36]
37	gouty	O	['N']	[37]
38	bursitis	O	['N']	[38]
39	.	O	['N']	[39]
#407
0	OBJECTIVE	O	['N']	[0]
1	:	O	['N']	[1]
2	To	O	['N']	[2]
3	describe	O	['N']	[3]
4	a	O	['N']	[4]
5	case	O	['N']	[5]
6	of	O	['N']	[6]
7	exacerbated	O	['N']	[7]
8	mania	B-Adverse_Effect	['N']	[8]
9	potentially	O	['N']	[9]
10	related	O	['N']	[10]
11	to	O	['N']	[11]
12	an	O	['N']	[12]
13	interaction	O	['N']	[13]
14	between	O	['N']	[14]
15	lopinavir	O	['N']	[15]
16	/	O	['N']	[16]
17	ritonavir	O	['N']	[17]
18	and	O	['N']	[18]
19	valproic	B	['N']	[19]
20	acid	I-Drug	['Causes']	[8]
21	(	O	['N']	[21]
22	VPA	O	['N']	[22]
23	)	O	['N']	[23]
24	and	O	['N']	[24]
25	propose	O	['N']	[25]
26	a	O	['N']	[26]
27	mechanism	O	['N']	[27]
28	of	O	['N']	[28]
29	action	O	['N']	[29]
30	for	O	['N']	[30]
31	this	O	['N']	[31]
32	interaction	O	['N']	[32]
33	.	O	['N']	[33]
#408
0	Alternating	B	['N']	[0]
1	sinus	I	['N']	[1]
2	rhythm	I-Adverse_Effect	['N']	[2]
3	and	O	['N']	[3]
4	intermittent	O	['N']	[4]
5	sinoatrial	O	['N']	[5]
6	(	O	['N']	[6]
7	S	O	['N']	[7]
8	-	O	['N']	[8]
9	A	O	['N']	[9]
10	)	O	['N']	[10]
11	block	O	['N']	[11]
12	was	O	['N']	[12]
13	observed	O	['N']	[13]
14	in	O	['N']	[14]
15	a	O	['N']	[15]
16	57-year	O	['N']	[16]
17	-	O	['N']	[17]
18	old	O	['N']	[18]
19	woman	O	['N']	[19]
20	,	O	['N']	[20]
21	under	O	['N']	[21]
22	treatment	O	['N']	[22]
23	for	O	['N']	[23]
24	angina	O	['N']	[24]
25	with	O	['N']	[25]
26	80	O	['N']	[26]
27	mg	O	['N']	[27]
28	propranolol	B-Drug	['Causes']	[2]
29	daily	O	['N']	[29]
30	.	O	['N']	[30]
#409
0	Syringotropic	B	['N']	[0]
1	hypersensitivity	I	['N']	[1]
2	reaction	I-Adverse_Effect	['N']	[2]
3	associated	O	['N']	[3]
4	with	O	['N']	[4]
5	infliximab	B-Drug	['Causes']	[2]
6	and	O	['N']	[6]
7	leflunomide	O	['N']	[7]
8	combination	O	['N']	[8]
9	therapy	O	['N']	[9]
10	in	O	['N']	[10]
11	a	O	['N']	[11]
12	child	O	['N']	[12]
13	with	O	['N']	[13]
14	psoriatic	O	['N']	[14]
15	arthritis	O	['N']	[15]
16	.	O	['N']	[16]
#410
0	Based	O	['N']	[0]
1	on	O	['N']	[1]
2	these	O	['N']	[2]
3	findings	O	['N']	[3]
4	,	O	['N']	[4]
5	the	O	['N']	[5]
6	patient	O	['N']	[6]
7	was	O	['N']	[7]
8	diagnosed	O	['N']	[8]
9	with	O	['N']	[9]
10	diabetes	B	['N']	[10]
11	insipidus	I-Adverse_Effect	['N']	[11]
12	secondary	O	['N']	[12]
13	to	O	['N']	[13]
14	lithium	B-Drug	['Causes']	[11]
15	therapy	O	['N']	[15]
16	and	O	['N']	[16]
17	was	O	['N']	[17]
18	treated	O	['N']	[18]
19	successfully	O	['N']	[19]
20	with	O	['N']	[20]
21	amiloride	O	['N']	[21]
22	.	O	['N']	[22]
#411
0	CONCLUSION	O	['N']	[0]
1	:	O	['N']	[1]
2	Alendronate	B-Drug	['Causes']	[6]
3	led	O	['N']	[3]
4	to	O	['N']	[4]
5	nodular	O	['N']	[5]
6	scleritis	B-Adverse_Effect	['N']	[6]
7	and	O	['N']	[7]
8	rechallenge	O	['N']	[8]
9	caused	O	['N']	[9]
10	recurrence	O	['N']	[10]
11	of	O	['N']	[11]
12	scleritis	O	['N']	[12]
13	.	O	['N']	[13]
#412
0	OBJECTIVE	O	['N']	[0]
1	:	O	['N']	[1]
2	To	O	['N']	[2]
3	report	O	['N']	[3]
4	teicoplanin	O	['N']	[4]
5	-	O	['N']	[5]
6	related	O	['N']	[6]
7	neutropenia	B-Adverse_Effect	['N']	[7]
8	that	O	['N']	[8]
9	developed	O	['N']	[9]
10	after	O	['N']	[10]
11	an	O	['N']	[11]
12	episode	O	['N']	[12]
13	of	O	['N']	[13]
14	neutropenia	O	['N']	[14]
15	induced	O	['N']	[15]
16	by	O	['N']	[16]
17	vancomycin	B-Drug	['Causes']	[7]
18	therapy	O	['N']	[18]
19	.	O	['N']	[19]
#413
0	Teicoplanin	O	['N']	[0]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	agranulocytosis	B-Adverse_Effect	['N']	[3]
4	that	O	['N']	[4]
5	followed	O	['N']	[5]
6	vancomycin	B-Drug	['Causes']	[3]
7	-	O	['N']	[7]
8	induced	O	['N']	[8]
9	agranulocytosis	O	['N']	[9]
10	suggests	O	['N']	[10]
11	a	O	['N']	[11]
12	possible	O	['N']	[12]
13	cross	O	['N']	[13]
14	-	O	['N']	[14]
15	reactivity	O	['N']	[15]
16	between	O	['N']	[16]
17	the	O	['N']	[17]
18	2	O	['N']	[18]
19	drugs	O	['N']	[19]
20	.	O	['N']	[20]
#414
0	CONCLUSIONS	O	['N']	[0]
1	:	O	['N']	[1]
2	Peripheral	O	['N']	[2]
3	administration	O	['N']	[3]
4	of	O	['N']	[4]
5	low	O	['N']	[5]
6	-	O	['N']	[6]
7	dose	O	['N']	[7]
8	vasopressin	B-Drug	['Causes']	[22]
9	for	O	['N']	[9]
10	septic	O	['N']	[10]
11	shock	O	['N']	[11]
12	should	O	['N']	[12]
13	be	O	['N']	[13]
14	discouraged	O	['N']	[14]
15	because	O	['N']	[15]
16	of	O	['N']	[16]
17	the	O	['N']	[17]
18	risk	O	['N']	[18]
19	of	O	['N']	[19]
20	ischemic	B	['N']	[20]
21	skin	I	['N']	[21]
22	complications	I-Adverse_Effect	['N']	[22]
23	.	O	['N']	[23]
#415
0	This	O	['N']	[0]
1	article	O	['N']	[1]
2	presents	O	['N']	[2]
3	a	O	['N']	[3]
4	patient	O	['N']	[4]
5	with	O	['N']	[5]
6	hypoparathyroidism	O	['N']	[6]
7	who	O	['N']	[7]
8	was	O	['N']	[8]
9	treated	O	['N']	[9]
10	with	O	['N']	[10]
11	calcium	O	['N']	[11]
12	carbonate	O	['N']	[12]
13	and	O	['N']	[13]
14	calcitriol	B-Drug	['Causes']	[26]
15	resulting	O	['N']	[15]
16	in	O	['N']	[16]
17	two	O	['N']	[17]
18	admissions	O	['N']	[18]
19	to	O	['N']	[19]
20	the	O	['N']	[20]
21	hospital	O	['N']	[21]
22	for	O	['N']	[22]
23	milk	B	['N']	[23]
24	-	I	['N']	[24]
25	alkali	I	['N']	[25]
26	syndrome	I-Adverse_Effect	['N']	[26]
27	.	O	['N']	[27]
#416
0	CONCLUSION	O	['N']	[0]
1	:	O	['N']	[1]
2	A	O	['N']	[2]
3	37-year	O	['N']	[3]
4	-	O	['N']	[4]
5	old	O	['N']	[5]
6	African-	O	['N']	[6]
7	American	O	['N']	[7]
8	man	O	['N']	[8]
9	with	O	['N']	[9]
10	G6PD	O	['N']	[10]
11	deficiency	O	['N']	[11]
12	developed	O	['N']	[12]
13	hemolytic	O	['N']	[13]
14	anemia	O	['N']	[14]
15	,	O	['N']	[15]
16	hepatitis	O	['N']	[16]
17	,	O	['N']	[17]
18	orthostatic	B	['N']	[18]
19	hypotension	I-Adverse_Effect	['N']	[19]
20	,	O	['N']	[20]
21	and	O	['N']	[21]
22	aseptic	O	['N']	[22]
23	meningitis	O	['N']	[23]
24	simultaneously	O	['N']	[24]
25	after	O	['N']	[25]
26	using	O	['N']	[26]
27	trimethoprim	B-Drug	['Causes']	[19]
28	-	O	['N']	[28]
29	sulfamethoxazole	O	['N']	[29]
30	.	O	['N']	[30]
#417
0	The	O	['N']	[0]
1	Naranjo	O	['N']	[1]
2	probability	O	['N']	[2]
3	scale	O	['N']	[3]
4	suggests	O	['N']	[4]
5	a	O	['N']	[5]
6	highly	O	['N']	[6]
7	probable	O	['N']	[7]
8	relationship	O	['N']	[8]
9	between	O	['N']	[9]
10	AIN	B-Adverse_Effect	['N']	[10]
11	and	O	['N']	[11]
12	pantoprazole	B-Drug	['Causes']	[10]
13	therapy	O	['N']	[13]
14	in	O	['N']	[14]
15	this	O	['N']	[15]
16	patient	O	['N']	[16]
17	.	O	['N']	[17]
#418
0	We	O	['N']	[0]
1	present	O	['N']	[1]
2	a	O	['N']	[2]
3	unique	O	['N']	[3]
4	case	O	['N']	[4]
5	of	O	['N']	[5]
6	GTBM	B-Adverse_Effect	['N']	[6]
7	in	O	['N']	[7]
8	a	O	['N']	[8]
9	patient	O	['N']	[9]
10	with	O	['N']	[10]
11	myeloma	O	['N']	[11]
12	following	O	['N']	[12]
13	treatment	O	['N']	[13]
14	with	O	['N']	[14]
15	Melphalan	B-Drug	['Causes']	[6]
16	.	O	['N']	[16]
#419
0	After	O	['N']	[0]
1	the	O	['N']	[1]
2	chlorambucil	B-Drug	['Causes']	[18]
3	was	O	['N']	[3]
4	discontinued	O	['N']	[4]
5	,	O	['N']	[5]
6	the	O	['N']	[6]
7	wbc	O	['N']	[7]
8	count	O	['N']	[8]
9	began	O	['N']	[9]
10	to	O	['N']	[10]
11	slowly	O	['N']	[11]
12	rise	O	['N']	[12]
13	and	O	['N']	[13]
14	the	O	['N']	[14]
15	patient	O	['N']	[15]
16	developed	O	['N']	[16]
17	clinical	O	['N']	[17]
18	AML	B-Adverse_Effect	['N']	[18]
19	.	O	['N']	[19]
#420
0	CASE	O	['N']	[0]
1	REPORT	O	['N']	[1]
2	:	O	['N']	[2]
3	A	O	['N']	[3]
4	six	O	['N']	[4]
5	-	O	['N']	[5]
6	year	O	['N']	[6]
7	-	O	['N']	[7]
8	old	O	['N']	[8]
9	boy	O	['N']	[9]
10	with	O	['N']	[10]
11	transfusion	O	['N']	[11]
12	-	O	['N']	[12]
13	dependent	O	['N']	[13]
14	beta	O	['N']	[14]
15	-	O	['N']	[15]
16	thalassaemia	O	['N']	[16]
17	developed	O	['N']	[17]
18	a	O	['N']	[18]
19	unilateral	B	['N']	[19]
20	hearing	I	['N']	[20]
21	loss	I-Adverse_Effect	['N']	[21]
22	shortly	O	['N']	[22]
23	after	O	['N']	[23]
24	commencing	O	['N']	[24]
25	desferrioxamine	B-Drug	['Causes']	[21]
26	therapy	O	['N']	[26]
27	.	O	['N']	[27]
#421
0	She	O	['N']	[0]
1	was	O	['N']	[1]
2	placed	O	['N']	[2]
3	on	O	['N']	[3]
4	adjuvant	O	['N']	[4]
5	Adriamycin	B-Drug	['Causes']	[18]
6	(	O	['N']	[6]
7	doxorubicin	O	['N']	[7]
8	)	O	['N']	[8]
9	chemotherapy	O	['N']	[9]
10	,	O	['N']	[10]
11	but	O	['N']	[11]
12	6	O	['N']	[12]
13	months	O	['N']	[13]
14	later	O	['N']	[14]
15	died	O	['N']	[15]
16	of	O	['N']	[16]
17	Adriamycin	B	['N']	[17]
18	toxicity	I-Adverse_Effect	['N']	[18]
19	.	O	['N']	[19]
#422
0	BACKGROUND	O	['N']	[0]
1	:	O	['N']	[1]
2	Gemcitabine	O	['N']	[2]
3	has	O	['N']	[3]
4	mild	O	['N']	[4]
5	renal	O	['N']	[5]
6	toxicity	O	['N']	[6]
7	,	O	['N']	[7]
8	but	O	['N']	[8]
9	cases	O	['N']	[9]
10	of	O	['N']	[10]
11	gemcitabine	B-Drug	['Causes']	[19]
12	-	O	['N']	[12]
13	associated	O	['N']	[13]
14	hemolytic	O	['N']	[14]
15	-	O	['N']	[15]
16	uremic	O	['N']	[16]
17	syndrome	O	['N']	[17]
18	(	O	['N']	[18]
19	HUS	B-Adverse_Effect	['N']	[19]
20	)	O	['N']	[20]
21	have	O	['N']	[21]
22	been	O	['N']	[22]
23	reported	O	['N']	[23]
24	.	O	['N']	[24]
#423
0	The	O	['N']	[0]
1	authors	O	['N']	[1]
2	report	O	['N']	[2]
3	a	O	['N']	[3]
4	case	O	['N']	[4]
5	of	O	['N']	[5]
6	focal	O	['N']	[6]
7	myocardial	O	['N']	[7]
8	necrosis	O	['N']	[8]
9	,	O	['N']	[9]
10	presenting	O	['N']	[10]
11	clinically	O	['N']	[11]
12	as	O	['N']	[12]
13	an	O	['N']	[13]
14	acute	B	['N']	[14]
15	myocardial	I	['N']	[15]
16	infarction	I-Adverse_Effect	['N']	[16]
17	during	O	['N']	[17]
18	the	O	['N']	[18]
19	administration	O	['N']	[19]
20	of	O	['N']	[20]
21	the	O	['N']	[21]
22	antineoplastic	O	['N']	[22]
23	drug	O	['N']	[23]
24	,	O	['N']	[24]
25	amsacrine	B-Drug	['Causes']	[16]
26	,	O	['N']	[26]
27	in	O	['N']	[27]
28	a	O	['N']	[28]
29	patient	O	['N']	[29]
30	without	O	['N']	[30]
31	coronary	O	['N']	[31]
32	artery	O	['N']	[32]
33	disease	O	['N']	[33]
34	.	O	['N']	[34]
#424
0	When	O	['N']	[0]
1	SASP	O	['N']	[1]
2	was	O	['N']	[2]
3	changed	O	['N']	[3]
4	to	O	['N']	[4]
5	5-aminosalicylic	O	['N']	[5]
6	acid	O	['N']	[6]
7	(	O	['N']	[7]
8	5-ASA	B-Drug	['Causes']	[23]
9	)	O	['N']	[9]
10	,	O	['N']	[10]
11	his	O	['N']	[11]
12	skin	O	['N']	[12]
13	eruptions	O	['N']	[13]
14	were	O	['N']	[14]
15	resolved	O	['N']	[15]
16	,	O	['N']	[16]
17	however	O	['N']	[17]
18	,	O	['N']	[18]
19	he	O	['N']	[19]
20	developed	O	['N']	[20]
21	weakness	O	['N']	[21]
22	and	O	['N']	[22]
23	atrophy	B-Adverse_Effect	['N']	[23]
24	in	O	['N']	[24]
25	his	O	['N']	[25]
26	right	O	['N']	[26]
27	arm	O	['N']	[27]
28	as	O	['N']	[28]
29	well	O	['N']	[29]
30	as	O	['N']	[30]
31	progressive	O	['N']	[31]
32	worsening	O	['N']	[32]
33	of	O	['N']	[33]
34	the	O	['N']	[34]
35	dysesthesia	O	['N']	[35]
36	in	O	['N']	[36]
37	his	O	['N']	[37]
38	legs	O	['N']	[38]
39	and	O	['N']	[39]
40	gait	O	['N']	[40]
41	disturbance	O	['N']	[41]
42	.	O	['N']	[42]
#425
0	Tuberculous	B	['N']	[0]
1	uveitis	I-Adverse_Effect	['N']	[1]
2	after	O	['N']	[2]
3	treatment	O	['N']	[3]
4	with	O	['N']	[4]
5	etanercept	B-Drug	['Causes']	[1]
6	.	O	['N']	[6]
#426
0	Glaucoma	B-Adverse_Effect	['N']	[0]
1	secondary	O	['N']	[1]
2	to	O	['N']	[2]
3	epithelial	O	['N']	[3]
4	downgrowth	O	['N']	[4]
5	and	O	['N']	[5]
6	5-fluorouracil	B-Drug	['Causes']	[0]
7	.	O	['N']	[7]
#427
0	CASE	O	['N']	[0]
1	SUMMARY	O	['N']	[1]
2	:	O	['N']	[2]
3	A	O	['N']	[3]
4	65-year	O	['N']	[4]
5	-	O	['N']	[5]
6	old	O	['N']	[6]
7	patient	O	['N']	[7]
8	chronically	O	['N']	[8]
9	treated	O	['N']	[9]
10	with	O	['N']	[10]
11	the	O	['N']	[11]
12	selective	O	['N']	[12]
13	serotonin	O	['N']	[13]
14	reuptake	O	['N']	[14]
15	inhibitor	O	['N']	[15]
16	(	O	['N']	[16]
17	SSRI	O	['N']	[17]
18	)	O	['N']	[18]
19	citalopram	O	['N']	[19]
20	developed	O	['N']	[20]
21	confusion	O	['N']	[21]
22	,	O	['N']	[22]
23	agitation	O	['N']	[23]
24	,	O	['N']	[24]
25	tachycardia	B-Adverse_Effect	['N']	[25]
26	,	O	['N']	[26]
27	tremors	O	['N']	[27]
28	,	O	['N']	[28]
29	myoclonic	O	['N']	[29]
30	jerks	O	['N']	[30]
31	and	O	['N']	[31]
32	unsteady	O	['N']	[32]
33	gait	O	['N']	[33]
34	,	O	['N']	[34]
35	consistent	O	['N']	[35]
36	with	O	['N']	[36]
37	serotonin	O	['N']	[37]
38	syndrome	O	['N']	[38]
39	,	O	['N']	[39]
40	following	O	['N']	[40]
41	initiation	O	['N']	[41]
42	of	O	['N']	[42]
43	fentanyl	B-Drug	['Causes']	[25]
44	,	O	['N']	[44]
45	and	O	['N']	[45]
46	all	O	['N']	[46]
47	symptoms	O	['N']	[47]
48	and	O	['N']	[48]
49	signs	O	['N']	[49]
50	resolved	O	['N']	[50]
51	following	O	['N']	[51]
52	discontinuation	O	['N']	[52]
53	of	O	['N']	[53]
54	fentanyl	O	['N']	[54]
55	.	O	['N']	[55]
#428
0	Chronic	O	['N']	[0]
1	myelogenous	O	['N']	[1]
2	leukemia	O	['N']	[2]
3	(	O	['N']	[3]
4	CML	O	['N']	[4]
5	)	O	['N']	[5]
6	,	O	['N']	[6]
7	hepatitis	O	['N']	[7]
8	C	O	['N']	[8]
9	,	O	['N']	[9]
10	and	O	['N']	[10]
11	interferon	O	['N']	[11]
12	alpha	O	['N']	[12]
13	(	O	['N']	[13]
14	IFNalpha	B-Drug	['Causes']	[22]
15	)	O	['N']	[15]
16	have	O	['N']	[16]
17	all	O	['N']	[17]
18	been	O	['N']	[18]
19	associated	O	['N']	[19]
20	with	O	['N']	[20]
21	renal	B	['N']	[21]
22	dysfunction	I-Adverse_Effect	['N']	[22]
23	.	O	['N']	[23]
#429
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	on	O	['N']	[2]
3	a	O	['N']	[3]
4	patient	O	['N']	[4]
5	with	O	['N']	[5]
6	an	O	['N']	[6]
7	embryonal	O	['N']	[7]
8	teratocarcinoma	O	['N']	[8]
9	of	O	['N']	[9]
10	the	O	['N']	[10]
11	testicle	O	['N']	[11]
12	who	O	['N']	[12]
13	had	O	['N']	[13]
14	the	O	['N']	[14]
15	syndrome	O	['N']	[15]
16	of	O	['N']	[16]
17	inappropriate	O	['N']	[17]
18	secretion	O	['N']	[18]
19	of	O	['N']	[19]
20	antidiuretic	O	['N']	[20]
21	hormone	O	['N']	[21]
22	after	O	['N']	[22]
23	receiving	O	['N']	[23]
24	a	O	['N']	[24]
25	high	B	['N']	[25]
26	dose	I-Dose	['N']	[26]
27	of	O	['N']	[27]
28	vinblastine	B-Drug	['Dosage']	[26]
29	.	O	['N']	[29]
#430
0	Further	O	['N']	[0]
1	studies	O	['N']	[1]
2	are	O	['N']	[2]
3	necessary	O	['N']	[3]
4	to	O	['N']	[4]
5	evaluate	O	['N']	[5]
6	whether	O	['N']	[6]
7	the	O	['N']	[7]
8	study	O	['N']	[8]
9	of	O	['N']	[9]
10	HLA	O	['N']	[10]
11	antigens	O	['N']	[11]
12	may	O	['N']	[12]
13	be	O	['N']	[13]
14	a	O	['N']	[14]
15	very	O	['N']	[15]
16	useful	O	['N']	[16]
17	tool	O	['N']	[17]
18	to	O	['N']	[18]
19	detect	O	['N']	[19]
20	the	O	['N']	[20]
21	patients	O	['N']	[21]
22	with	O	['N']	[22]
23	a	O	['N']	[23]
24	predisposition	O	['N']	[24]
25	to	O	['N']	[25]
26	develop	O	['N']	[26]
27	autoimmune	B	['N']	[27]
28	thyroiditis	I-Adverse_Effect	['N']	[28]
29	,	O	['N']	[29]
30	in	O	['N']	[30]
31	order	O	['N']	[31]
32	to	O	['N']	[32]
33	make	O	['N']	[33]
34	a	O	['N']	[34]
35	early	O	['N']	[35]
36	diagnosis	O	['N']	[36]
37	of	O	['N']	[37]
38	thyroid	O	['N']	[38]
39	disorders	O	['N']	[39]
40	during	O	['N']	[40]
41	the	O	['N']	[41]
42	IFN	B	['N']	[42]
43	-	I	['N']	[43]
44	alpha	I-Drug	['Causes']	[28]
45	treatment	O	['N']	[45]
46	.	O	['N']	[46]
#431
0	Renal	B	['N']	[0]
1	toxicities	I-Adverse_Effect	['N']	[1]
2	have	O	['N']	[2]
3	been	O	['N']	[3]
4	reported	O	['N']	[4]
5	in	O	['N']	[5]
6	less	O	['N']	[6]
7	than	O	['N']	[7]
8	one	O	['N']	[8]
9	percent	O	['N']	[9]
10	of	O	['N']	[10]
11	the	O	['N']	[11]
12	patients	O	['N']	[12]
13	receiving	O	['N']	[13]
14	ciprofloxacin	B-Drug	['Causes']	[1]
15	therapy	O	['N']	[15]
16	.	O	['N']	[16]
#432
0	A	O	['N']	[0]
1	27-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	man	O	['N']	[4]
5	who	O	['N']	[5]
6	had	O	['N']	[6]
7	a	O	['N']	[7]
8	history	O	['N']	[8]
9	of	O	['N']	[9]
10	bronchial	O	['N']	[10]
11	asthma	O	['N']	[11]
12	,	O	['N']	[12]
13	eosinophilic	O	['N']	[13]
14	enteritis	O	['N']	[14]
15	,	O	['N']	[15]
16	and	O	['N']	[16]
17	eosinophilic	O	['N']	[17]
18	pneumonia	O	['N']	[18]
19	presented	O	['N']	[19]
20	with	O	['N']	[20]
21	fever	O	['N']	[21]
22	,	O	['N']	[22]
23	skin	O	['N']	[23]
24	eruptions	O	['N']	[24]
25	,	O	['N']	[25]
26	cervical	B	['N']	[26]
27	lymphadenopathy	I-Adverse_Effect	['N']	[27]
28	,	O	['N']	[28]
29	hepatosplenomegaly	O	['N']	[29]
30	,	O	['N']	[30]
31	atypical	O	['N']	[31]
32	lymphocytosis	O	['N']	[32]
33	,	O	['N']	[33]
34	and	O	['N']	[34]
35	eosinophilia	O	['N']	[35]
36	two	O	['N']	[36]
37	weeks	O	['N']	[37]
38	after	O	['N']	[38]
39	receiving	O	['N']	[39]
40	trimethoprim	B-Drug	['Causes']	[27]
41	(	O	['N']	[41]
42	TMP)-sulfamethoxazole	O	['N']	[42]
43	(	O	['N']	[43]
44	SMX	O	['N']	[44]
45	)	O	['N']	[45]
46	treatment	O	['N']	[46]
47	.	O	['N']	[47]
#433
0	The	O	['N']	[0]
1	clinical	O	['N']	[1]
2	course	O	['N']	[2]
3	suggests	O	['N']	[3]
4	that	O	['N']	[4]
5	caffeine	B-Drug	['Causes']	[19]
6	,	O	['N']	[6]
7	which	O	['N']	[7]
8	is	O	['N']	[8]
9	present	O	['N']	[9]
10	in	O	['N']	[10]
11	oolong	O	['N']	[11]
12	tea	O	['N']	[12]
13	,	O	['N']	[13]
14	was	O	['N']	[14]
15	mainly	O	['N']	[15]
16	responsible	O	['N']	[16]
17	for	O	['N']	[17]
18	the	O	['N']	[18]
19	rhabdomyolysis	B-Adverse_Effect	['N']	[19]
20	as	O	['N']	[20]
21	well	O	['N']	[21]
22	as	O	['N']	[22]
23	the	O	['N']	[23]
24	delirium	O	['N']	[24]
25	,	O	['N']	[25]
26	although	O	['N']	[26]
27	severe	O	['N']	[27]
28	hyponatremia	O	['N']	[28]
29	has	O	['N']	[29]
30	been	O	['N']	[30]
31	reported	O	['N']	[31]
32	to	O	['N']	[32]
33	cause	O	['N']	[33]
34	rhabdomyolysis	O	['N']	[34]
35	on	O	['N']	[35]
36	rare	O	['N']	[36]
37	occasions	O	['N']	[37]
38	.	O	['N']	[38]
#434
0	Acne	B-Adverse_Effect	['N']	[0]
1	provoked	O	['N']	[1]
2	by	O	['N']	[2]
3	gold	B-Drug	['Causes']	[0]
4	seems	O	['N']	[4]
5	not	O	['N']	[5]
6	to	O	['N']	[6]
7	have	O	['N']	[7]
8	been	O	['N']	[8]
9	described	O	['N']	[9]
10	elsewhere	O	['N']	[10]
11	.	O	['N']	[11]
#435
0	A	O	['N']	[0]
1	generalized	B	['N']	[1]
2	tonic	I	['N']	[2]
3	-	I	['N']	[3]
4	clonic	I	['N']	[4]
5	seizure	I-Adverse_Effect	['N']	[5]
6	occurred	O	['N']	[6]
7	a	O	['N']	[7]
8	few	O	['N']	[8]
9	minutes	O	['N']	[9]
10	after	O	['N']	[10]
11	injection	O	['N']	[11]
12	of	O	['N']	[12]
13	the	O	['N']	[13]
14	morphine	O	['N']	[14]
15	antagonist	O	['N']	[15]
16	naloxone	B-Drug	['Causes']	[5]
17	.	O	['N']	[17]
#436
0	When	O	['N']	[0]
1	vague	O	['N']	[1]
2	symptoms	O	['N']	[2]
3	develop	O	['N']	[3]
4	during	O	['N']	[4]
5	desmopressin	B-Drug	['Causes']	[8]
6	therapy	O	['N']	[6]
7	,	O	['N']	[7]
8	hyponatremia	B-Adverse_Effect	['N']	[8]
9	must	O	['N']	[9]
10	be	O	['N']	[10]
11	considered	O	['N']	[11]
12	as	O	['N']	[12]
13	part	O	['N']	[13]
14	of	O	['N']	[14]
15	the	O	['N']	[15]
16	differential	O	['N']	[16]
17	diagnosis	O	['N']	[17]
18	.	O	['N']	[18]
#437
0	However	O	['N']	[0]
1	,	O	['N']	[1]
2	follow	O	['N']	[2]
3	-	O	['N']	[3]
4	up	O	['N']	[4]
5	revealed	O	['N']	[5]
6	that	O	['N']	[6]
7	gestational	O	['N']	[7]
8	diabetes	O	['N']	[8]
9	when	O	['N']	[9]
10	associated	O	['N']	[10]
11	with	O	['N']	[11]
12	norethisterone	B-Drug	['Causes']	[24]
13	had	O	['N']	[13]
14	a	O	['N']	[14]
15	lesser	O	['N']	[15]
16	risk	O	['N']	[16]
17	of	O	['N']	[17]
18	emerging	O	['N']	[18]
19	diabetes	O	['N']	[19]
20	mellitus	O	['N']	[20]
21	and	O	['N']	[21]
22	impaired	B	['N']	[22]
23	glucose	I	['N']	[23]
24	tolerance	I-Adverse_Effect	['N']	[24]
25	.	O	['N']	[25]
#438
0	Myoglobinuria	B-Adverse_Effect	['N']	[0]
1	and	O	['N']	[1]
2	acute	O	['N']	[2]
3	renal	O	['N']	[3]
4	failure	O	['N']	[4]
5	were	O	['N']	[5]
6	observed	O	['N']	[6]
7	in	O	['N']	[7]
8	two	O	['N']	[8]
9	patients	O	['N']	[9]
10	with	O	['N']	[10]
11	vasopressin	B-Drug	['Causes']	[0]
12	-	O	['N']	[12]
13	treated	O	['N']	[13]
14	gastrointestinal	O	['N']	[14]
15	hemorrhage	O	['N']	[15]
16	.	O	['N']	[16]
#439
0	Warfarin	O	['N']	[0]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	skin	O	['N']	[3]
4	necrosis	O	['N']	[4]
5	and	O	['N']	[5]
6	heparin	B-Drug	['Causes']	[9]
7	-	O	['N']	[7]
8	induced	O	['N']	[8]
9	thrombocytopenia	B-Adverse_Effect	['N']	[9]
10	following	O	['N']	[10]
11	mitral	O	['N']	[11]
12	valve	O	['N']	[12]
13	replacement	O	['N']	[13]
14	for	O	['N']	[14]
15	marantic	O	['N']	[15]
16	endocarditis	O	['N']	[16]
17	.	O	['N']	[17]
#440
0	Anaphylaxis	B-Adverse_Effect	['N']	[0]
1	to	O	['N']	[1]
2	intrathecal	O	['N']	[2]
3	diamorphine	B-Drug	['Causes']	[0]
4	.	O	['N']	[4]
#441
0	A	O	['N']	[0]
1	case	O	['N']	[1]
2	of	O	['N']	[2]
3	propranolol	B-Drug	['Dosage']	[4]
4	overdose	B-Dose	['N']	[4]
5	complicated	O	['N']	[5]
6	by	O	['N']	[6]
7	esophageal	O	['N']	[7]
8	spasm	O	['N']	[8]
9	preventing	O	['N']	[9]
10	extrication	O	['N']	[10]
11	of	O	['N']	[11]
12	an	O	['N']	[12]
13	orogastric	O	['N']	[13]
14	lavage	O	['N']	[14]
15	tube	O	['N']	[15]
16	and	O	['N']	[16]
17	relieved	O	['N']	[17]
18	by	O	['N']	[18]
19	intravenous	O	['N']	[19]
20	glucagon	O	['N']	[20]
21	is	O	['N']	[21]
22	presented	O	['N']	[22]
23	.	O	['N']	[23]
#442
0	Acute	B	['N']	[0]
1	ocular	I	['N']	[1]
2	ischemic	I	['N']	[2]
3	change	I-Adverse_Effect	['N']	[3]
4	may	O	['N']	[4]
5	be	O	['N']	[5]
6	associated	O	['N']	[6]
7	with	O	['N']	[7]
8	intravitreal	O	['N']	[8]
9	injection	O	['N']	[9]
10	of	O	['N']	[10]
11	bevacizumab	B-Drug	['Causes']	[3]
12	in	O	['N']	[12]
13	patients	O	['N']	[13]
14	with	O	['N']	[14]
15	vascular	O	['N']	[15]
16	compromised	O	['N']	[16]
17	diabetic	O	['N']	[17]
18	retinopathy	O	['N']	[18]
19	and/or	O	['N']	[19]
20	underlying	O	['N']	[20]
21	stenosis	O	['N']	[21]
22	of	O	['N']	[22]
23	the	O	['N']	[23]
24	carotid	O	['N']	[24]
25	artery	O	['N']	[25]
26	.	O	['N']	[26]
#443
0	A	O	['N']	[0]
1	49-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	man	O	['N']	[4]
5	with	O	['N']	[5]
6	Crohn	O	['N']	[6]
7	's	O	['N']	[7]
8	disease	O	['N']	[8]
9	treated	O	['N']	[9]
10	with	O	['N']	[10]
11	prednisone	B-Drug	['Causes']	[20]
12	and	O	['N']	[12]
13	mesalamine	O	['N']	[13]
14	(	O	['N']	[14]
15	5-ASA	O	['N']	[15]
16	)	O	['N']	[16]
17	developed	O	['N']	[17]
18	worsening	B	['N']	[18]
19	respiratory	I	['N']	[19]
20	distress	I-Adverse_Effect	['N']	[20]
21	and	O	['N']	[21]
22	fever	O	['N']	[22]
23	.	O	['N']	[23]
#444
0	However	O	['N']	[0]
1	,	O	['N']	[1]
2	as	O	['N']	[2]
3	illustrated	O	['N']	[3]
4	by	O	['N']	[4]
5	these	O	['N']	[5]
6	and	O	['N']	[6]
7	other	O	['N']	[7]
8	cases	O	['N']	[8]
9	reported	O	['N']	[9]
10	to	O	['N']	[10]
11	date	O	['N']	[11]
12	,	O	['N']	[12]
13	the	O	['N']	[13]
14	onset	O	['N']	[14]
15	of	O	['N']	[15]
16	troglitazone	B-Drug	['Causes']	[20]
17	-	O	['N']	[17]
18	induced	O	['N']	[18]
19	liver	B	['N']	[19]
20	injury	I-Adverse_Effect	['N']	[20]
21	is	O	['N']	[21]
22	insidious	O	['N']	[22]
23	and	O	['N']	[23]
24	temporally	O	['N']	[24]
25	variable	O	['N']	[25]
26	.	O	['N']	[26]
#445
0	L	B	['N']	[0]
1	-	I	['N']	[1]
2	asparaginase	I-Drug	['Causes']	[5]
3	-	O	['N']	[3]
4	induced	O	['N']	[4]
5	pancreatitis	B-Adverse_Effect	['N']	[5]
6	has	O	['N']	[6]
7	been	O	['N']	[7]
8	reported	O	['N']	[8]
9	during	O	['N']	[9]
10	or	O	['N']	[10]
11	closely	O	['N']	[11]
12	following	O	['N']	[12]
13	administration	O	['N']	[13]
14	of	O	['N']	[14]
15	the	O	['N']	[15]
16	drug	O	['N']	[16]
17	.	O	['N']	[17]
#446
0	Our	O	['N']	[0]
1	experience	O	['N']	[1]
2	supports	O	['N']	[2]
3	hemodialysis	O	['N']	[3]
4	for	O	['N']	[4]
5	ESRF	O	['N']	[5]
6	patients	O	['N']	[6]
7	with	O	['N']	[7]
8	atenolol	B-Drug	['Causes']	[9]
9	toxicity	I-Adverse_Effect	['N']	[9]
10	.	O	['N']	[10]
#447
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	penile	B	['N']	[5]
6	fibrosis	I-Adverse_Effect	['N']	[6]
7	after	O	['N']	[7]
8	intracavernous	O	['N']	[8]
9	self	O	['N']	[9]
10	-	O	['N']	[10]
11	injection	O	['N']	[11]
12	of	O	['N']	[12]
13	a	O	['N']	[13]
14	combination	O	['N']	[14]
15	of	O	['N']	[15]
16	phentolamine	B-Drug	['Causes']	[6]
17	and	O	['N']	[17]
18	papaverine	O	['N']	[18]
19	.	O	['N']	[19]
#448
0	This	O	['N']	[0]
1	case	O	['N']	[1]
2	suggests	O	['N']	[2]
3	that	O	['N']	[3]
4	acyclovir	O	['N']	[4]
5	when	O	['N']	[5]
6	given	O	['N']	[6]
7	intravenously	O	['N']	[7]
8	in	O	['N']	[8]
9	doses	O	['N']	[9]
10	of	O	['N']	[10]
11	10	O	['N']	[11]
12	mg	O	['N']	[12]
13	/	O	['N']	[13]
14	kg	O	['N']	[14]
15	may	O	['N']	[15]
16	result	O	['N']	[16]
17	in	O	['N']	[17]
18	increased	B	['N']	[18]
19	serum	I	['N']	[19]
20	lithium	B-Drug	['N']	[20]
21	concentrations	O	['N']	[21]
22	.	O	['N']	[22]
#449
0	Progressive	B	['N']	[0]
1	anemia	I-Adverse_Effect	['N']	[1]
2	following	O	['N']	[2]
3	combination	O	['N']	[3]
4	therapy	O	['N']	[4]
5	with	O	['N']	[5]
6	interferon	O	['N']	[6]
7	-	O	['N']	[7]
8	alpha	O	['N']	[8]
9	and	O	['N']	[9]
10	interleukin-2	B-Drug	['Causes']	[1]
11	in	O	['N']	[11]
12	a	O	['N']	[12]
13	patient	O	['N']	[13]
14	with	O	['N']	[14]
15	metastatic	O	['N']	[15]
16	renal	O	['N']	[16]
17	cell	O	['N']	[17]
18	carcinoma	O	['N']	[18]
19	.	O	['N']	[19]
#450
0	Pneumonitis	B-Adverse_Effect	['N']	[0]
1	with	O	['N']	[1]
2	pleural	O	['N']	[2]
3	and	O	['N']	[3]
4	pericardial	O	['N']	[4]
5	effusion	O	['N']	[5]
6	and	O	['N']	[6]
7	neuropathy	O	['N']	[7]
8	during	O	['N']	[8]
9	amiodarone	B-Drug	['Causes']	[0]
10	therapy	O	['N']	[10]
11	.	O	['N']	[11]
#451
0	Voriconazole	B-Drug	['Causes']	[13]
1	(	O	['N']	[1]
2	VRC	O	['N']	[2]
3	)	O	['N']	[3]
4	has	O	['N']	[4]
5	not	O	['N']	[5]
6	previously	O	['N']	[6]
7	been	O	['N']	[7]
8	reported	O	['N']	[8]
9	to	O	['N']	[9]
10	cause	O	['N']	[10]
11	angio	B	['N']	[11]
12	-	I	['N']	[12]
13	oedema	I-Adverse_Effect	['N']	[13]
14	.	O	['N']	[14]
#452
0	Sotalol	B-Drug	['Causes']	[3]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	bradycardia	B-Adverse_Effect	['N']	[3]
4	reversed	O	['N']	[4]
5	by	O	['N']	[5]
6	glucagon	O	['N']	[6]
7	.	O	['N']	[7]
#453
0	This	O	['N']	[0]
1	patient	O	['N']	[1]
2	developed	O	['N']	[2]
3	sequential	O	['N']	[3]
4	symptoms	O	['N']	[4]
5	including	O	['N']	[5]
6	alternative	O	['N']	[6]
7	hemiparesis	O	['N']	[7]
8	,	O	['N']	[8]
9	dysarthria	O	['N']	[9]
10	and	O	['N']	[10]
11	altered	B	['N']	[11]
12	consciousness	I-Adverse_Effect	['N']	[12]
13	5	O	['N']	[13]
14	days	O	['N']	[14]
15	after	O	['N']	[15]
16	the	O	['N']	[16]
17	second	O	['N']	[17]
18	course	O	['N']	[18]
19	of	O	['N']	[19]
20	HD	B	['N']	[20]
21	-	I	['N']	[21]
22	MTX	I-Drug	['Causes']	[12]
23	(	O	['N']	[23]
24	8	O	['N']	[24]
25	gm	O	['N']	[25]
26	/	O	['N']	[26]
27	m2	O	['N']	[27]
28	by	O	['N']	[28]
29	6	O	['N']	[29]
30	h	O	['N']	[30]
31	continuous	O	['N']	[31]
32	infusion	O	['N']	[32]
33	)	O	['N']	[33]
34	with	O	['N']	[34]
35	leucovorin	O	['N']	[35]
36	rescue	O	['N']	[36]
37	.	O	['N']	[37]
#454
0	Amphotericin	B	['N']	[0]
1	B	I-Drug	['Causes']	[26]
2	(	O	['N']	[2]
3	AmB	O	['N']	[3]
4	)	O	['N']	[4]
5	is	O	['N']	[5]
6	effective	O	['N']	[6]
7	,	O	['N']	[7]
8	but	O	['N']	[8]
9	its	O	['N']	[9]
10	use	O	['N']	[10]
11	is	O	['N']	[11]
12	limited	O	['N']	[12]
13	by	O	['N']	[13]
14	toxicity	O	['N']	[14]
15	:	O	['N']	[15]
16	renal	O	['N']	[16]
17	impairment	O	['N']	[17]
18	,	O	['N']	[18]
19	anaemia	O	['N']	[19]
20	,	O	['N']	[20]
21	fever	O	['N']	[21]
22	,	O	['N']	[22]
23	malaise	O	['N']	[23]
24	,	O	['N']	[24]
25	and	O	['N']	[25]
26	hypokalaemia	B-Adverse_Effect	['N']	[26]
27	are	O	['N']	[27]
28	common	O	['N']	[28]
29	.	O	['N']	[29]
#455
0	Widespread	O	['N']	[0]
1	cutaneous	B	['N']	[1]
2	vasculitis	I-Adverse_Effect	['N']	[2]
3	associated	O	['N']	[3]
4	with	O	['N']	[4]
5	diltiazem	B-Drug	['Causes']	[2]
6	.	O	['N']	[6]
#456
0	Taxane	B-Drug	['Causes']	[3]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	glaucoma	B-Adverse_Effect	['N']	[3]
4	.	O	['N']	[4]
#457
0	Three	O	['N']	[0]
1	of	O	['N']	[1]
2	these	O	['N']	[2]
3	patients	O	['N']	[3]
4	had	O	['N']	[4]
5	convulsions	B-Adverse_Effect	['N']	[5]
6	attributed	O	['N']	[6]
7	to	O	['N']	[7]
8	imipenem	B-Drug	['Causes']	[5]
9	/	O	['N']	[9]
10	cilastatin	O	['N']	[10]
11	;	O	['N']	[11]
12	3.6	O	['N']	[12]
13	%	O	['N']	[13]
14	of	O	['N']	[14]
15	the	O	['N']	[15]
16	patients	O	['N']	[16]
17	had	O	['N']	[17]
18	seizure	O	['N']	[18]
19	,	O	['N']	[19]
20	or	O	['N']	[20]
21	2	O	['N']	[21]
22	%	O	['N']	[22]
23	of	O	['N']	[23]
24	imipenem	O	['N']	[24]
25	/	O	['N']	[25]
26	cilastatin	O	['N']	[26]
27	administrations	O	['N']	[27]
28	was	O	['N']	[28]
29	followed	O	['N']	[29]
30	by	O	['N']	[30]
31	a	O	['N']	[31]
32	seizure	O	['N']	[32]
33	attack	O	['N']	[33]
34	.	O	['N']	[34]
#458
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	the	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	an	O	['N']	[5]
6	adult	O	['N']	[6]
7	patient	O	['N']	[7]
8	with	O	['N']	[8]
9	acute	O	['N']	[9]
10	lymphoblastic	O	['N']	[10]
11	leukemia	O	['N']	[11]
12	who	O	['N']	[12]
13	presented	O	['N']	[13]
14	with	O	['N']	[14]
15	repeated	O	['N']	[15]
16	transient	O	['N']	[16]
17	ischemic	O	['N']	[17]
18	attacks	O	['N']	[18]
19	followed	O	['N']	[19]
20	by	O	['N']	[20]
21	a	O	['N']	[21]
22	seizure	B-Adverse_Effect	['N']	[22]
23	during	O	['N']	[23]
24	consolidation	O	['N']	[24]
25	treatment	O	['N']	[25]
26	with	O	['N']	[26]
27	L	B	['N']	[27]
28	-	I	['N']	[28]
29	asparaginase	I-Drug	['Causes']	[22]
30	.	O	['N']	[30]
#459
0	Systemic	B	['N']	[0]
1	lupus	I	['N']	[1]
2	erythematosus	I-Adverse_Effect	['N']	[2]
3	during	O	['N']	[3]
4	penicillamine	B-Drug	['Causes']	[2]
5	therapy	O	['N']	[5]
6	for	O	['N']	[6]
7	rheumatoid	O	['N']	[7]
8	arthritis	O	['N']	[8]
9	.	O	['N']	[9]
#460
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	44-year	O	['N']	[3]
4	-	O	['N']	[4]
5	old	O	['N']	[5]
6	woman	O	['N']	[6]
7	with	O	['N']	[7]
8	t	O	['N']	[8]
9	-	O	['N']	[9]
10	MDS	O	['N']	[10]
11	(	O	['N']	[11]
12	refractory	B	['N']	[12]
13	anemia	I	['N']	[13]
14	with	I	['N']	[14]
15	excess	I	['N']	[15]
16	blasts	I-Adverse_Effect	['N']	[16]
17	)	O	['N']	[17]
18	following	O	['N']	[18]
19	treatment	O	['N']	[19]
20	of	O	['N']	[20]
21	recurrent	O	['N']	[21]
22	anaplastic	O	['N']	[22]
23	astrocytoma	O	['N']	[23]
24	with	O	['N']	[24]
25	temozolomide	O	['N']	[25]
26	(	O	['N']	[26]
27	TMZ	B-Drug	['Causes']	[16]
28	)	O	['N']	[28]
29	.	O	['N']	[29]
#461
0	Intravenous	O	['N']	[0]
1	verapamil	O	['N']	[1]
2	therapy	O	['N']	[2]
3	in	O	['N']	[3]
4	babies	O	['N']	[4]
5	may	O	['N']	[5]
6	cause	O	['N']	[6]
7	apnea	O	['N']	[7]
8	,	O	['N']	[8]
9	hypotension	O	['N']	[9]
10	,	O	['N']	[10]
11	and	O	['N']	[11]
12	bradycardia	O	['N']	[12]
13	;	O	['N']	[13]
14	continued	O	['N']	[14]
15	episodes	O	['N']	[15]
16	of	O	['N']	[16]
17	atrial	O	['N']	[17]
18	flutter	O	['N']	[18]
19	in	O	['N']	[19]
20	a	O	['N']	[20]
21	child	O	['N']	[21]
22	may	O	['N']	[22]
23	cause	O	['N']	[23]
24	sudden	O	['N']	[24]
25	death	O	['N']	[25]
26	;	O	['N']	[26]
27	quinidine	B-Drug	['Causes']	[50]
28	may	O	['N']	[28]
29	be	O	['N']	[29]
30	related	O	['N']	[30]
31	to	O	['N']	[31]
32	the	O	['N']	[32]
33	death	O	['N']	[33]
34	;	O	['N']	[34]
35	children	O	['N']	[35]
36	with	O	['N']	[36]
37	"	O	['N']	[37]
38	familial	O	['N']	[38]
39	seizure	O	['N']	[39]
40	disorders	O	['N']	[40]
41	"	O	['N']	[41]
42	may	O	['N']	[42]
43	in	O	['N']	[43]
44	fact	O	['N']	[44]
45	have	O	['N']	[45]
46	the	O	['N']	[46]
47	long	B	['N']	[47]
48	QT	I	['N']	[48]
49	interval	I	['N']	[49]
50	syndrome	I-Adverse_Effect	['N']	[50]
51	.	O	['N']	[51]
#462
0	Intravenous	O	['N']	[0]
1	haloperidol	B-Drug	['Causes']	[10]
2	is	O	['N']	[2]
3	generally	O	['N']	[3]
4	well	O	['N']	[4]
5	tolerated	O	['N']	[5]
6	,	O	['N']	[6]
7	but	O	['N']	[7]
8	multiform	B	['N']	[8]
9	ventricular	I	['N']	[9]
10	tachycardia	I-Adverse_Effect	['N']	[10]
11	has	O	['N']	[11]
12	been	O	['N']	[12]
13	reported	O	['N']	[13]
14	.	O	['N']	[14]
#463
0	Reflex	B	['N']	[0]
1	sympathetic	I	['N']	[1]
2	dystrophy	I	['N']	[2]
3	syndrome	I-Adverse_Effect	['N']	[3]
4	in	O	['N']	[4]
5	renal	O	['N']	[5]
6	transplanted	O	['N']	[6]
7	patients	O	['N']	[7]
8	under	O	['N']	[8]
9	immunosuppression	O	['N']	[9]
10	with	O	['N']	[10]
11	tacrolimus	B-Drug	['Causes']	[3]
12	.	O	['N']	[12]
#464
0	Paroxysmal	B	['N']	[0]
1	supraventricular	I	['N']	[1]
2	tachycardia	I-Adverse_Effect	['N']	[2]
3	during	O	['N']	[3]
4	treatment	O	['N']	[4]
5	with	O	['N']	[5]
6	cisplatin	O	['N']	[6]
7	and	O	['N']	[7]
8	etoposide	B-Drug	['Causes']	[2]
9	combination	O	['N']	[9]
10	.	O	['N']	[10]
#465
0	It	O	['N']	[0]
1	occasionally	O	['N']	[1]
2	accompanies	O	['N']	[2]
3	the	O	['N']	[3]
4	heparin	B-Drug	['Causes']	[10]
5	-	O	['N']	[5]
6	associated	O	['N']	[6]
7	thrombocytopenia	O	['N']	[7]
8	and	O	['N']	[8]
9	thrombosis	B	['N']	[9]
10	syndrome	I-Adverse_Effect	['N']	[10]
11	.	O	['N']	[11]
#466
0	Three	O	['N']	[0]
1	patients	O	['N']	[1]
2	who	O	['N']	[2]
3	had	O	['N']	[3]
4	experienced	O	['N']	[4]
5	neuroleptic	O	['N']	[5]
6	-	O	['N']	[6]
7	induced	O	['N']	[7]
8	akathisia	B-Adverse_Effect	['N']	[8]
9	in	O	['N']	[9]
10	the	O	['N']	[10]
11	past	O	['N']	[11]
12	reported	O	['N']	[12]
13	that	O	['N']	[13]
14	the	O	['N']	[14]
15	symptoms	O	['N']	[15]
16	of	O	['N']	[16]
17	fluoxetine	B-Drug	['Causes']	[8]
18	-	O	['N']	[18]
19	induced	O	['N']	[19]
20	akathisia	O	['N']	[20]
21	were	O	['N']	[21]
22	identical	O	['N']	[22]
23	,	O	['N']	[23]
24	although	O	['N']	[24]
25	somewhat	O	['N']	[25]
26	milder	O	['N']	[26]
27	.	O	['N']	[27]
#467
0	Acute	O	['N']	[0]
1	nitrite	B-Drug	['Causes']	[2]
2	toxicity	I-Adverse_Effect	['N']	[2]
3	results	O	['N']	[3]
4	from	O	['N']	[4]
5	industrial	O	['N']	[5]
6	exposure	O	['N']	[6]
7	,	O	['N']	[7]
8	accidental	O	['N']	[8]
9	ingestion	O	['N']	[9]
10	(	O	['N']	[10]
11	e.g.	O	['N']	[11]
12	,	O	['N']	[12]
13	abuse	O	['N']	[13]
14	of	O	['N']	[14]
15	organic	O	['N']	[15]
16	nitrites	O	['N']	[16]
17	as	O	['N']	[17]
18	an	O	['N']	[18]
19	aphrodisiac	O	['N']	[19]
20	,	O	['N']	[20]
21	especially	O	['N']	[21]
22	in	O	['N']	[22]
23	the	O	['N']	[23]
24	male	O	['N']	[24]
25	homosexual	O	['N']	[25]
26	population	O	['N']	[26]
27	)	O	['N']	[27]
28	,	O	['N']	[28]
29	and	O	['N']	[29]
30	suicidal	O	['N']	[30]
31	ingestion	O	['N']	[31]
32	.	O	['N']	[32]
#468
0	Severe	B	['N']	[0]
1	respiratory	I	['N']	[1]
2	syncytial	I	['N']	[2]
3	virus	I	['N']	[3]
4	pulmonary	I	['N']	[4]
5	infection	I-Adverse_Effect	['N']	[5]
6	in	O	['N']	[6]
7	a	O	['N']	[7]
8	patient	O	['N']	[8]
9	treated	O	['N']	[9]
10	with	O	['N']	[10]
11	fludarabine	B-Drug	['Causes']	[5]
12	for	O	['N']	[12]
13	chronic	O	['N']	[13]
14	lymphocytic	O	['N']	[14]
15	leukemia	O	['N']	[15]
16	.	O	['N']	[16]
#469
0	Amphotericin	B	['N']	[0]
1	B	I-Drug	['Dosage']	[2]
2	overdose	B-Dose	['N']	[2]
3	in	O	['N']	[3]
4	pediatric	O	['N']	[4]
5	patients	O	['N']	[5]
6	with	O	['N']	[6]
7	associated	O	['N']	[7]
8	cardiac	O	['N']	[8]
9	arrest	O	['N']	[9]
10	.	O	['N']	[10]
#470
0	The	O	['N']	[0]
1	current	O	['N']	[1]
2	report	O	['N']	[2]
3	describes	O	['N']	[3]
4	a	O	['N']	[4]
5	man	O	['N']	[5]
6	who	O	['N']	[6]
7	was	O	['N']	[7]
8	prescribed	O	['N']	[8]
9	zonisamide	B-Drug	['Causes']	[42]
10	for	O	['N']	[10]
11	epilepsy	O	['N']	[11]
12	and	O	['N']	[12]
13	subsequently	O	['N']	[13]
14	developed	O	['N']	[14]
15	widespread	O	['N']	[15]
16	skin	O	['N']	[16]
17	rash	O	['N']	[17]
18	,	O	['N']	[18]
19	acute	O	['N']	[19]
20	kidney	O	['N']	[20]
21	injury	O	['N']	[21]
22	,	O	['N']	[22]
23	high	O	['N']	[23]
24	-	O	['N']	[24]
25	grade	O	['N']	[25]
26	fever	O	['N']	[26]
27	,	O	['N']	[27]
28	eosinophilia	O	['N']	[28]
29	,	O	['N']	[29]
30	liver	O	['N']	[30]
31	dysfunction	O	['N']	[31]
32	,	O	['N']	[32]
33	lymphadenopathy	O	['N']	[33]
34	and	O	['N']	[34]
35	an	B	['N']	[35]
36	increase	I	['N']	[36]
37	in	I	['N']	[37]
38	antihuman	I	['N']	[38]
39	herpesvirus-6	I	['N']	[39]
40	immunoglobulin	I	['N']	[40]
41	G	I	['N']	[41]
42	titer	I-Adverse_Effect	['N']	[42]
43	.	O	['N']	[43]
#471
0	Minimal	B	['N']	[0]
1	change	I	['N']	[1]
2	disease	I-Adverse_Effect	['N']	[2]
3	in	O	['N']	[3]
4	a	O	['N']	[4]
5	patient	O	['N']	[5]
6	receiving	O	['N']	[6]
7	IFN	B	['N']	[7]
8	-	I	['N']	[8]
9	alpha	I-Drug	['Causes']	[2]
10	therapy	O	['N']	[10]
11	for	O	['N']	[11]
12	chronic	O	['N']	[12]
13	hepatitis	O	['N']	[13]
14	C	O	['N']	[14]
15	virus	O	['N']	[15]
16	infection	O	['N']	[16]
17	.	O	['N']	[17]
#472
0	A	O	['N']	[0]
1	44-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	woman	O	['N']	[4]
5	is	O	['N']	[5]
6	described	O	['N']	[6]
7	in	O	['N']	[7]
8	whom	O	['N']	[8]
9	amiodarone	B-Drug	['Causes']	[23]
10	,	O	['N']	[10]
11	disopyramide	O	['N']	[11]
12	,	O	['N']	[12]
13	and	O	['N']	[13]
14	quinidine	O	['N']	[14]
15	,	O	['N']	[15]
16	administered	O	['N']	[16]
17	alone	O	['N']	[17]
18	separately	O	['N']	[18]
19	,	O	['N']	[19]
20	induced	O	['N']	[20]
21	atypical	B	['N']	[21]
22	ventricular	I	['N']	[22]
23	tachycardia	I-Adverse_Effect	['N']	[23]
24	(	O	['N']	[24]
25	AVT	O	['N']	[25]
26	,	O	['N']	[26]
27	torsade	O	['N']	[27]
28	de	O	['N']	[28]
29	pointes	O	['N']	[29]
30	)	O	['N']	[30]
31	.	O	['N']	[31]
#473
0	When	O	['N']	[0]
1	tuberculosis	O	['N']	[1]
2	patients	O	['N']	[2]
3	on	O	['N']	[3]
4	isoniazid	B-Drug	['Causes']	[15]
5	eat	O	['N']	[5]
6	certain	O	['N']	[6]
7	varieties	O	['N']	[7]
8	of	O	['N']	[8]
9	fish	O	['N']	[9]
10	they	O	['N']	[10]
11	may	O	['N']	[11]
12	develop	O	['N']	[12]
13	a	O	['N']	[13]
14	histamine	B	['N']	[14]
15	reaction	I-Adverse_Effect	['N']	[15]
16	.	O	['N']	[16]
#474
0	The	O	['N']	[0]
1	authors	O	['N']	[1]
2	also	O	['N']	[2]
3	determined	O	['N']	[3]
4	that	O	['N']	[4]
5	their	O	['N']	[5]
6	case	O	['N']	[6]
7	of	O	['N']	[7]
8	myositis	B-Adverse_Effect	['N']	[8]
9	developing	O	['N']	[9]
10	in	O	['N']	[10]
11	the	O	['N']	[11]
12	rectus	O	['N']	[12]
13	abdominus	O	['N']	[13]
14	muscle	O	['N']	[14]
15	of	O	['N']	[15]
16	a	O	['N']	[16]
17	patient	O	['N']	[17]
18	with	O	['N']	[18]
19	pancreatic	O	['N']	[19]
20	adenocarcinoma	O	['N']	[20]
21	was	O	['N']	[21]
22	the	O	['N']	[22]
23	manifestation	O	['N']	[23]
24	of	O	['N']	[24]
25	radiation	O	['N']	[25]
26	recall	O	['N']	[26]
27	,	O	['N']	[27]
28	thereby	O	['N']	[28]
29	bringing	O	['N']	[29]
30	the	O	['N']	[30]
31	number	O	['N']	[31]
32	of	O	['N']	[32]
33	patients	O	['N']	[33]
34	who	O	['N']	[34]
35	developed	O	['N']	[35]
36	radiation	O	['N']	[36]
37	recall	O	['N']	[37]
38	to	O	['N']	[38]
39	gemcitabine	B-Drug	['Causes']	[8]
40	and	O	['N']	[40]
41	were	O	['N']	[41]
42	discussed	O	['N']	[42]
43	in	O	['N']	[43]
44	the	O	['N']	[44]
45	current	O	['N']	[45]
46	study	O	['N']	[46]
47	to	O	['N']	[47]
48	13	O	['N']	[48]
49	.	O	['N']	[49]
#475
0	We	O	['N']	[0]
1	hypothesize	O	['N']	[1]
2	that	O	['N']	[2]
3	caffeine	B-Drug	['Causes']	[29]
4	toxicity	O	['N']	[4]
5	injured	O	['N']	[5]
6	the	O	['N']	[6]
7	muscle	O	['N']	[7]
8	cells	O	['N']	[8]
9	,	O	['N']	[9]
10	which	O	['N']	[10]
11	were	O	['N']	[11]
12	fragile	O	['N']	[12]
13	due	O	['N']	[13]
14	to	O	['N']	[14]
15	the	O	['N']	[15]
16	potassium	O	['N']	[16]
17	depletion	O	['N']	[17]
18	induced	O	['N']	[18]
19	by	O	['N']	[19]
20	the	O	['N']	[20]
21	coexisting	O	['N']	[21]
22	hyponatremia	O	['N']	[22]
23	,	O	['N']	[23]
24	to	O	['N']	[24]
25	result	O	['N']	[25]
26	in	O	['N']	[26]
27	unusually	O	['N']	[27]
28	severe	O	['N']	[28]
29	rhabdomyolysis	B-Adverse_Effect	['N']	[29]
30	.	O	['N']	[30]
#476
0	The	O	['N']	[0]
1	clinical	O	['N']	[1]
2	picture	O	['N']	[2]
3	was	O	['N']	[3]
4	identical	O	['N']	[4]
5	to	O	['N']	[5]
6	that	O	['N']	[6]
7	of	O	['N']	[7]
8	chloroquine	O	['N']	[8]
9	and	O	['N']	[9]
10	hydroxychloroquine	B-Drug	['Causes']	[11]
11	maculopathy	B-Adverse_Effect	['N']	[11]
12	.	O	['N']	[12]
#477
0	Isoniazid	B-Drug	['Causes']	[3]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	anaphylaxis	B-Adverse_Effect	['N']	[3]
4	.	O	['N']	[4]
#478
0	RESULTS	O	['N']	[0]
1	:	O	['N']	[1]
2	A	O	['N']	[2]
3	44-year	O	['N']	[3]
4	-	O	['N']	[4]
5	old	O	['N']	[5]
6	man	O	['N']	[6]
7	taking	O	['N']	[7]
8	naproxen	B-Drug	['Causes']	[31]
9	for	O	['N']	[9]
10	chronic	O	['N']	[10]
11	low	O	['N']	[11]
12	back	O	['N']	[12]
13	pain	O	['N']	[13]
14	and	O	['N']	[14]
15	a	O	['N']	[15]
16	20-year	O	['N']	[16]
17	-	O	['N']	[17]
18	old	O	['N']	[18]
19	woman	O	['N']	[19]
20	on	O	['N']	[20]
21	oxaprozin	O	['N']	[21]
22	for	O	['N']	[22]
23	rheumatoid	O	['N']	[23]
24	arthritis	O	['N']	[24]
25	presented	O	['N']	[25]
26	with	O	['N']	[26]
27	tense	O	['N']	[27]
28	bullae	O	['N']	[28]
29	and	O	['N']	[29]
30	cutaneous	B	['N']	[30]
31	fragility	I-Adverse_Effect	['N']	[31]
32	on	O	['N']	[32]
33	the	O	['N']	[33]
34	face	O	['N']	[34]
35	and	O	['N']	[35]
36	the	O	['N']	[36]
37	back	O	['N']	[37]
38	of	O	['N']	[38]
39	the	O	['N']	[39]
40	hands	O	['N']	[40]
41	.	O	['N']	[41]
#479
0	In	O	['N']	[0]
1	a	O	['N']	[1]
2	phase	O	['N']	[2]
3	II	O	['N']	[3]
4	study	O	['N']	[4]
5	of	O	['N']	[5]
6	hycanthone	B-Drug	['Causes']	[17]
7	in	O	['N']	[7]
8	patients	O	['N']	[8]
9	with	O	['N']	[9]
10	breast	O	['N']	[10]
11	cancer	O	['N']	[11]
12	we	O	['N']	[12]
13	have	O	['N']	[13]
14	recently	O	['N']	[14]
15	observed	O	['N']	[15]
16	severe	B	['N']	[16]
17	hepatotoxicity	I-Adverse_Effect	['N']	[17]
18	,	O	['N']	[18]
19	even	O	['N']	[19]
20	at	O	['N']	[20]
21	lower	O	['N']	[21]
22	doses	O	['N']	[22]
23	,	O	['N']	[23]
24	which	O	['N']	[24]
25	resulted	O	['N']	[25]
26	in	O	['N']	[26]
27	two	O	['N']	[27]
28	drug	O	['N']	[28]
29	-	O	['N']	[29]
30	related	O	['N']	[30]
31	deaths	O	['N']	[31]
32	.	O	['N']	[32]
#480
0	Flucytosine	B-Drug	['Causes']	[3]
1	-	O	['N']	[1]
2	associated	O	['N']	[2]
3	diarrhea	B-Adverse_Effect	['N']	[3]
4	has	O	['N']	[4]
5	been	O	['N']	[5]
6	previously	O	['N']	[6]
7	described	O	['N']	[7]
8	in	O	['N']	[8]
9	6%-10	O	['N']	[9]
10	%	O	['N']	[10]
11	of	O	['N']	[11]
12	patients	O	['N']	[12]
13	receiving	O	['N']	[13]
14	the	O	['N']	[14]
15	drug	O	['N']	[15]
16	.	O	['N']	[16]
#481
0	A	O	['N']	[0]
1	62-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	woman	O	['N']	[4]
5	treated	O	['N']	[5]
6	with	O	['N']	[6]
7	pranlukast	B-Drug	['Causes']	[13]
8	for	O	['N']	[8]
9	2	O	['N']	[9]
10	months	O	['N']	[10]
11	developed	O	['N']	[11]
12	interstitial	B	['N']	[12]
13	pneumonitis	I-Adverse_Effect	['N']	[13]
14	with	O	['N']	[14]
15	a	O	['N']	[15]
16	high	O	['N']	[16]
17	fever	O	['N']	[17]
18	.	O	['N']	[18]
#482
0	Second	O	['N']	[0]
1	,	O	['N']	[1]
2	we	O	['N']	[2]
3	report	O	['N']	[3]
4	a	O	['N']	[4]
5	case	O	['N']	[5]
6	of	O	['N']	[6]
7	neutropenia	B-Adverse_Effect	['N']	[7]
8	,	O	['N']	[8]
9	which	O	['N']	[9]
10	proved	O	['N']	[10]
11	to	O	['N']	[11]
12	be	O	['N']	[12]
13	fatal	O	['N']	[13]
14	in	O	['N']	[14]
15	a	O	['N']	[15]
16	schizophrenia	O	['N']	[16]
17	patient	O	['N']	[17]
18	receiving	O	['N']	[18]
19	olanzapine	O	['N']	[19]
20	and	O	['N']	[20]
21	thiazide	B-Drug	['Causes']	[7]
22	.	O	['N']	[22]
#483
0	Flecainide	B-Drug	['Causes']	[7]
1	is	O	['N']	[1]
2	a	O	['N']	[2]
3	rare	O	['N']	[3]
4	cause	O	['N']	[4]
5	of	O	['N']	[5]
6	hypersensitivity	B	['N']	[6]
7	pneumonitis	I-Adverse_Effect	['N']	[7]
8	,	O	['N']	[8]
9	and	O	['N']	[9]
10	few	O	['N']	[10]
11	cases	O	['N']	[11]
12	have	O	['N']	[12]
13	been	O	['N']	[13]
14	reported	O	['N']	[14]
15	.	O	['N']	[15]
#484
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	here	O	['N']	[2]
3	two	O	['N']	[3]
4	cases	O	['N']	[4]
5	of	O	['N']	[5]
6	dyserythropoietic	B	['N']	[6]
7	anaemia	I-Adverse_Effect	['N']	[7]
8	associated	O	['N']	[8]
9	with	O	['N']	[9]
10	long	O	['N']	[10]
11	-	O	['N']	[11]
12	term	O	['N']	[12]
13	linezolid	B-Drug	['Causes']	[7]
14	use	O	['N']	[14]
15	that	O	['N']	[15]
16	share	O	['N']	[16]
17	striking	O	['N']	[17]
18	similarities	O	['N']	[18]
19	to	O	['N']	[19]
20	chloramphenicol	O	['N']	[20]
21	-	O	['N']	[21]
22	associated	O	['N']	[22]
23	myelotoxicity	O	['N']	[23]
24	.	O	['N']	[24]
#485
0	A	O	['N']	[0]
1	lethal	B	['N']	[1]
2	complication	I-Adverse_Effect	['N']	[2]
3	of	O	['N']	[3]
4	peripheral	O	['N']	[4]
5	vein	O	['N']	[5]
6	vasopressin	B-Drug	['Causes']	[2]
7	infusion	O	['N']	[7]
8	.	O	['N']	[8]
#486
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	the	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	an	O	['N']	[5]
6	87-year	O	['N']	[6]
7	-	O	['N']	[7]
8	old	O	['N']	[8]
9	white	O	['N']	[9]
10	woman	O	['N']	[10]
11	with	O	['N']	[11]
12	myasthenia	O	['N']	[12]
13	gravis	O	['N']	[13]
14	who	O	['N']	[14]
15	presented	O	['N']	[15]
16	with	O	['N']	[16]
17	nausea	O	['N']	[17]
18	,	O	['N']	[18]
19	shortness	O	['N']	[19]
20	of	O	['N']	[20]
21	breath	O	['N']	[21]
22	,	O	['N']	[22]
23	azotemia	B-Adverse_Effect	['N']	[23]
24	,	O	['N']	[24]
25	and	O	['N']	[25]
26	hyperkalemia	O	['N']	[26]
27	shortly	O	['N']	[27]
28	after	O	['N']	[28]
29	completing	O	['N']	[29]
30	a	O	['N']	[30]
31	course	O	['N']	[31]
32	of	O	['N']	[32]
33	intravenous	O	['N']	[33]
34	immunoglobulin	B-Drug	['Causes']	[23]
35	(	O	['N']	[35]
36	IVIG	O	['N']	[36]
37	)	O	['N']	[37]
38	.	O	['N']	[38]
#487
0	Anaphylactoid	B	['N']	[0]
1	reactions	I-Adverse_Effect	['N']	[1]
2	with	O	['N']	[2]
3	intraperitoneal	O	['N']	[3]
4	cisplatin	B-Drug	['Causes']	[1]
5	.	O	['N']	[5]
#488
0	METHOD	O	['N']	[0]
1	:	O	['N']	[1]
2	Case	O	['N']	[2]
3	analysis	O	['N']	[3]
4	of	O	['N']	[4]
5	a	O	['N']	[5]
6	poly	O	['N']	[6]
7	-	O	['N']	[7]
8	drug	O	['N']	[8]
9	overdose	O	['N']	[9]
10	(	O	['N']	[10]
11	venlafaxine	O	['N']	[11]
12	,	O	['N']	[12]
13	topiramate	O	['N']	[13]
14	,	O	['N']	[14]
15	divalproex	B	['N']	[15]
16	sodium	I-Drug	['Causes']	[28]
17	,	O	['N']	[17]
18	risperidone	O	['N']	[18]
19	,	O	['N']	[19]
20	and	O	['N']	[20]
21	carbamazepine	O	['N']	[21]
22	)	O	['N']	[22]
23	presenting	O	['N']	[23]
24	with	O	['N']	[24]
25	mixed	O	['N']	[25]
26	SS	O	['N']	[26]
27	/	O	['N']	[27]
28	NMS	B-Adverse_Effect	['N']	[28]
29	features	O	['N']	[29]
30	and	O	['N']	[30]
31	whose	O	['N']	[31]
32	clinical	O	['N']	[32]
33	management	O	['N']	[33]
34	suggests	O	['N']	[34]
35	a	O	['N']	[35]
36	practical	O	['N']	[36]
37	algorithm	O	['N']	[37]
38	for	O	['N']	[38]
39	treatment	O	['N']	[39]
40	of	O	['N']	[40]
41	undifferentiated	O	['N']	[41]
42	SS	O	['N']	[42]
43	/	O	['N']	[43]
44	NMS	O	['N']	[44]
45	in	O	['N']	[45]
46	critical	O	['N']	[46]
47	care	O	['N']	[47]
48	settings	O	['N']	[48]
49	.	O	['N']	[49]
#489
0	A	O	['N']	[0]
1	selective	O	['N']	[1]
2	association	O	['N']	[2]
3	between	O	['N']	[3]
4	fluoxetine	B-Drug	['Causes']	[18]
5	and	O	['N']	[5]
6	extensive	O	['N']	[6]
7	,	O	['N']	[7]
8	prominent	O	['N']	[8]
9	eye	B	['N']	[9]
10	movements	I	['N']	[10]
11	in	I	['N']	[11]
12	nonrapid	I	['N']	[12]
13	eye	I	['N']	[13]
14	movement	I	['N']	[14]
15	(	I	['N']	[15]
16	NREM	I	['N']	[16]
17	)	I	['N']	[17]
18	sleep	I-Adverse_Effect	['N']	[18]
19	was	O	['N']	[19]
20	detected	O	['N']	[20]
21	,	O	['N']	[21]
22	utilizing	O	['N']	[22]
23	Fisher	O	['N']	[23]
24	's	O	['N']	[24]
25	exact	O	['N']	[25]
26	one	O	['N']	[26]
27	-	O	['N']	[27]
28	tailed	O	['N']	[28]
29	statistic	O	['N']	[29]
30	(	O	['N']	[30]
31	p	O	['N']	[31]
32	less	O	['N']	[32]
33	than	O	['N']	[33]
34	0.00001	O	['N']	[34]
35	for	O	['N']	[35]
36	each	O	['N']	[36]
37	comparison	O	['N']	[37]
38	)	O	['N']	[38]
39	.	O	['N']	[39]
#490
0	Methanol	B-Drug	['Causes']	[8]
1	toxicity	O	['N']	[1]
2	can	O	['N']	[2]
3	cause	O	['N']	[3]
4	severe	B	['N']	[4]
5	central	I	['N']	[5]
6	nervous	I	['N']	[6]
7	system	I	['N']	[7]
8	insult	I-Adverse_Effect	['N']	[8]
9	in	O	['N']	[9]
10	which	O	['N']	[10]
11	a	O	['N']	[11]
12	characteristic	O	['N']	[12]
13	pattern	O	['N']	[13]
14	of	O	['N']	[14]
15	bilateral	O	['N']	[15]
16	putaminal	O	['N']	[16]
17	injury	O	['N']	[17]
18	is	O	['N']	[18]
19	noted	O	['N']	[19]
20	on	O	['N']	[20]
21	brain	O	['N']	[21]
22	imaging	O	['N']	[22]
23	studies	O	['N']	[23]
24	.	O	['N']	[24]
#491
0	Severe	O	['N']	[0]
1	visual	O	['N']	[1]
2	loss	O	['N']	[2]
3	after	O	['N']	[3]
4	a	O	['N']	[4]
5	single	B	['N']	[5]
6	dose	I-Dose	['N']	[6]
7	of	O	['N']	[7]
8	vincristine	B-Drug	['Dosage']	[6]
9	in	O	['N']	[9]
10	a	O	['N']	[10]
11	patient	O	['N']	[11]
12	with	O	['N']	[12]
13	spinal	O	['N']	[13]
14	cord	O	['N']	[14]
15	astrocytoma	O	['N']	[15]
16	.	O	['N']	[16]
#492
0	Carbamazepine	B-Drug	['Causes']	[5]
1	induced	O	['N']	[1]
2	right	B	['N']	[2]
3	bundle	I	['N']	[3]
4	branch	I	['N']	[4]
5	block	I-Adverse_Effect	['N']	[5]
6	in	O	['N']	[6]
7	a	O	['N']	[7]
8	Greenlandic	O	['N']	[8]
9	patient	O	['N']	[9]
10	.	O	['N']	[10]
#493
0	The	O	['N']	[0]
1	typical	O	['N']	[1]
2	fluoxetine	B-Drug	['Causes']	[10]
3	-	O	['N']	[3]
4	induced	O	['N']	[4]
5	symptoms	O	['N']	[5]
6	of	O	['N']	[6]
7	restlessness	O	['N']	[7]
8	,	O	['N']	[8]
9	constant	B	['N']	[9]
10	pacing	I-Adverse_Effect	['N']	[10]
11	,	O	['N']	[11]
12	purposeless	O	['N']	[12]
13	movements	O	['N']	[13]
14	of	O	['N']	[14]
15	the	O	['N']	[15]
16	feet	O	['N']	[16]
17	and	O	['N']	[17]
18	legs	O	['N']	[18]
19	,	O	['N']	[19]
20	and	O	['N']	[20]
21	marked	O	['N']	[21]
22	anxiety	O	['N']	[22]
23	were	O	['N']	[23]
24	indistinguishable	O	['N']	[24]
25	from	O	['N']	[25]
26	those	O	['N']	[26]
27	of	O	['N']	[27]
28	neuroleptic	O	['N']	[28]
29	-	O	['N']	[29]
30	induced	O	['N']	[30]
31	akathisia	O	['N']	[31]
32	.	O	['N']	[32]
#494
0	We	O	['N']	[0]
1	postulate	O	['N']	[1]
2	that	O	['N']	[2]
3	gastritis	B-Adverse_Effect	['N']	[3]
4	caused	O	['N']	[4]
5	by	O	['N']	[5]
6	dexamethasone	B-Drug	['Causes']	[3]
7	,	O	['N']	[7]
8	mucositis	O	['N']	[8]
9	caused	O	['N']	[9]
10	by	O	['N']	[10]
11	doxorubicin	O	['N']	[11]
12	,	O	['N']	[12]
13	and	O	['N']	[13]
14	the	O	['N']	[14]
15	unique	O	['N']	[15]
16	anatomic	O	['N']	[16]
17	nature	O	['N']	[17]
18	of	O	['N']	[18]
19	a	O	['N']	[19]
20	Meckel	O	['N']	[20]
21	diverticulum	O	['N']	[21]
22	may	O	['N']	[22]
23	have	O	['N']	[23]
24	contributed	O	['N']	[24]
25	to	O	['N']	[25]
26	this	O	['N']	[26]
27	extremely	O	['N']	[27]
28	unlikely	O	['N']	[28]
29	and	O	['N']	[29]
30	previously	O	['N']	[30]
31	unreported	O	['N']	[31]
32	event	O	['N']	[32]
33	.	O	['N']	[33]
#495
0	A	O	['N']	[0]
1	case	O	['N']	[1]
2	of	O	['N']	[2]
3	tuberculosis	B-Adverse_Effect	['N']	[3]
4	in	O	['N']	[4]
5	a	O	['N']	[5]
6	patient	O	['N']	[6]
7	on	O	['N']	[7]
8	Efalizumab	O	['N']	[8]
9	and	O	['N']	[9]
10	Etanercept	B-Drug	['Causes']	[3]
11	for	O	['N']	[11]
12	treatment	O	['N']	[12]
13	of	O	['N']	[13]
14	refractory	O	['N']	[14]
15	palmopustular	O	['N']	[15]
16	psoriasis	O	['N']	[16]
17	and	O	['N']	[17]
18	psoriatic	O	['N']	[18]
19	arthritis	O	['N']	[19]
20	.	O	['N']	[20]
#496
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	on	O	['N']	[2]
3	three	O	['N']	[3]
4	cases	O	['N']	[4]
5	wherein	O	['N']	[5]
6	treatment	O	['N']	[6]
7	of	O	['N']	[7]
8	dexmedetomidine	O	['N']	[8]
9	-	O	['N']	[9]
10	induced	O	['N']	[10]
11	bradycardia	O	['N']	[11]
12	with	O	['N']	[12]
13	i.v	O	['N']	[13]
14	.	O	['N']	[14]
15	glycopyrrolate	B-Drug	['Dosage']	[20]
16	(	O	['N']	[16]
17	5.0	B	['N']	[17]
18	microg	I	['N']	[18]
19	/	I	['N']	[19]
20	kg	I-Dose	['N']	[20]
21	)	O	['N']	[21]
22	not	O	['N']	[22]
23	only	O	['N']	[23]
24	resulting	O	['N']	[24]
25	in	O	['N']	[25]
26	resolution	O	['N']	[26]
27	of	O	['N']	[27]
28	bradycardia	O	['N']	[28]
29	but	O	['N']	[29]
30	also	O	['N']	[30]
31	resulting	O	['N']	[31]
32	in	O	['N']	[32]
33	an	O	['N']	[33]
34	exaggerated	O	['N']	[34]
35	increase	O	['N']	[35]
36	of	O	['N']	[36]
37	arterial	O	['N']	[37]
38	blood	O	['N']	[38]
39	pressure	O	['N']	[39]
40	.	O	['N']	[40]
#497
0	A	O	['N']	[0]
1	21-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	woman	O	['N']	[4]
5	suffering	O	['N']	[5]
6	from	O	['N']	[6]
7	bipolar	O	['N']	[7]
8	affective	O	['N']	[8]
9	disorder	O	['N']	[9]
10	developed	O	['N']	[10]
11	systemic	B	['N']	[11]
12	lupus	I	['N']	[12]
13	erythematosus	I-Adverse_Effect	['N']	[13]
14	(	O	['N']	[14]
15	SLE	O	['N']	[15]
16	)	O	['N']	[16]
17	with	O	['N']	[17]
18	characteristic	O	['N']	[18]
19	laboratory	O	['N']	[19]
20	findings	O	['N']	[20]
21	,	O	['N']	[21]
22	18	O	['N']	[22]
23	months	O	['N']	[23]
24	after	O	['N']	[24]
25	starting	O	['N']	[25]
26	carbamazepine	B-Drug	['Causes']	[13]
27	maintenance	O	['N']	[27]
28	treatment	O	['N']	[28]
29	.	O	['N']	[29]
#498
0	A	O	['N']	[0]
1	71-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	man	O	['N']	[4]
5	with	O	['N']	[5]
6	paroxysmal	O	['N']	[6]
7	atrial	O	['N']	[7]
8	fibrillation	O	['N']	[8]
9	who	O	['N']	[9]
10	had	O	['N']	[10]
11	a	O	['N']	[11]
12	previous	O	['N']	[12]
13	anterior	O	['N']	[13]
14	myocardial	O	['N']	[14]
15	infarction	O	['N']	[15]
16	exhibited	O	['N']	[16]
17	granulocytopenia	B-Adverse_Effect	['N']	[17]
18	8	O	['N']	[18]
19	days	O	['N']	[19]
20	following	O	['N']	[20]
21	the	O	['N']	[21]
22	administration	O	['N']	[22]
23	of	O	['N']	[23]
24	oral	O	['N']	[24]
25	sustained	O	['N']	[25]
26	-	O	['N']	[26]
27	release	O	['N']	[27]
28	procainamide	B-Drug	['Causes']	[17]
29	(	O	['N']	[29]
30	750	O	['N']	[30]
31	mg	O	['N']	[31]
32	/	O	['N']	[32]
33	day	O	['N']	[33]
34	)	O	['N']	[34]
35	.	O	['N']	[35]
#499
0	Charcoal	O	['N']	[0]
1	haemoperfusion	O	['N']	[1]
2	and	O	['N']	[2]
3	cysteamine	O	['N']	[3]
4	therapy	O	['N']	[4]
5	led	O	['N']	[5]
6	to	O	['N']	[6]
7	the	O	['N']	[7]
8	rapid	O	['N']	[8]
9	removal	O	['N']	[9]
10	of	O	['N']	[10]
11	the	O	['N']	[11]
12	paracetamol	B-Drug	['Causes']	[24]
13	from	O	['N']	[13]
14	the	O	['N']	[14]
15	body	O	['N']	[15]
16	and	O	['N']	[16]
17	consequently	O	['N']	[17]
18	prevented	O	['N']	[18]
19	the	O	['N']	[19]
20	development	O	['N']	[20]
21	of	O	['N']	[21]
22	severe	B	['N']	[22]
23	hepatic	I	['N']	[23]
24	necrosis	I-Adverse_Effect	['N']	[24]
25	.	O	['N']	[25]
#500
0	OBJECTIVE	O	['N']	[0]
1	:	O	['N']	[1]
2	To	O	['N']	[2]
3	study	O	['N']	[3]
4	therapy	O	['N']	[4]
5	with	O	['N']	[5]
6	indapamide	B-Drug	['Causes']	[9]
7	impairing	B	['N']	[7]
8	carbohydrate	I	['N']	[8]
9	metabolism	I-Adverse_Effect	['N']	[9]
10	in	O	['N']	[10]
11	essential	O	['N']	[11]
12	hypertension	O	['N']	[12]
13	patients	O	['N']	[13]
14	and	O	['N']	[14]
15	achieve	O	['N']	[15]
16	earlier	O	['N']	[16]
17	prevention	O	['N']	[17]
18	,	O	['N']	[18]
19	diagnoses	O	['N']	[19]
20	and	O	['N']	[20]
21	treatment	O	['N']	[21]
22	of	O	['N']	[22]
23	diabetes	O	['N']	[23]
24	induced	O	['N']	[24]
25	by	O	['N']	[25]
26	indapamide	O	['N']	[26]
27	.	O	['N']	[27]
#501
0	A	O	['N']	[0]
1	high	B-Dose	['N']	[1]
2	dose	O	['N']	[2]
3	of	O	['N']	[3]
4	cotrimoxazole	B-Drug	['Dosage']	[1]
5	induced	O	['N']	[5]
6	hyperkalaemia	O	['N']	[6]
7	with	O	['N']	[7]
8	the	O	['N']	[8]
9	elevation	O	['N']	[9]
10	of	O	['N']	[10]
11	serum	O	['N']	[11]
12	creatinine	O	['N']	[12]
13	and	O	['N']	[13]
14	blood	O	['N']	[14]
15	urea	O	['N']	[15]
16	,	O	['N']	[16]
17	and	O	['N']	[17]
18	increased	O	['N']	[18]
19	urinary	O	['N']	[19]
20	N	O	['N']	[20]
21	-	O	['N']	[21]
22	acetyl	O	['N']	[22]
23	glucosaminase	O	['N']	[23]
24	after	O	['N']	[24]
25	several	O	['N']	[25]
26	days	O	['N']	[26]
27	of	O	['N']	[27]
28	the	O	['N']	[28]
29	drug	O	['N']	[29]
30	administration	O	['N']	[30]
31	in	O	['N']	[31]
32	these	O	['N']	[32]
33	patients	O	['N']	[33]
34	;	O	['N']	[34]
35	one	O	['N']	[35]
36	patient	O	['N']	[36]
37	became	O	['N']	[37]
38	unconscious	O	['N']	[38]
39	.	O	['N']	[39]
#502
0	Acute	B	['N']	[0]
1	pancreatitis	I-Adverse_Effect	['N']	[1]
2	associated	O	['N']	[2]
3	with	O	['N']	[3]
4	danazol	B-Drug	['Causes']	[1]
5	treatment	O	['N']	[5]
6	for	O	['N']	[6]
7	endometriosis	O	['N']	[7]
8	.	O	['N']	[8]
#503
0	This	O	['N']	[0]
1	is	O	['N']	[1]
2	the	O	['N']	[2]
3	first	O	['N']	[3]
4	case	O	['N']	[4]
5	of	O	['N']	[5]
6	hydroxyurea	B-Drug	['Causes']	[11]
7	-	O	['N']	[7]
8	induced	O	['N']	[8]
9	acute	B	['N']	[9]
10	interstitial	I	['N']	[10]
11	pneumonitis	I-Adverse_Effect	['N']	[11]
12	reported	O	['N']	[12]
13	in	O	['N']	[13]
14	the	O	['N']	[14]
15	literature	O	['N']	[15]
16	.	O	['N']	[16]
#504
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	on	O	['N']	[2]
3	a	O	['N']	[3]
4	56-year	O	['N']	[4]
5	-	O	['N']	[5]
6	old	O	['N']	[6]
7	female	O	['N']	[7]
8	who	O	['N']	[8]
9	exhibited	O	['N']	[9]
10	drug	O	['N']	[10]
11	refractory	O	['N']	[11]
12	paroxysmal	O	['N']	[12]
13	atrial	O	['N']	[13]
14	fibrillation	O	['N']	[14]
15	,	O	['N']	[15]
16	in	O	['N']	[16]
17	which	O	['N']	[17]
18	marked	O	['N']	[18]
19	prolongation	O	['N']	[19]
20	of	O	['N']	[20]
21	the	O	['N']	[21]
22	QT	O	['N']	[22]
23	interval	O	['N']	[23]
24	and	O	['N']	[24]
25	T	B	['N']	[25]
26	wave	I	['N']	[26]
27	inversion	I-Adverse_Effect	['N']	[27]
28	on	O	['N']	[28]
29	electrocardiogram	O	['N']	[29]
30	was	O	['N']	[30]
31	demonstrated	O	['N']	[31]
32	reproducibly	O	['N']	[32]
33	shortly	O	['N']	[33]
34	after	O	['N']	[34]
35	the	O	['N']	[35]
36	administration	O	['N']	[36]
37	of	O	['N']	[37]
38	oral	O	['N']	[38]
39	pirmenol	B-Drug	['Causes']	[27]
40	therapy	O	['N']	[40]
41	.	O	['N']	[41]
#505
0	Two	O	['N']	[0]
1	cases	O	['N']	[1]
2	of	O	['N']	[2]
3	polymorphic	B	['N']	[3]
4	ventricular	I	['N']	[4]
5	tachycardia	I-Adverse_Effect	['N']	[5]
6	induced	O	['N']	[6]
7	by	O	['N']	[7]
8	the	O	['N']	[8]
9	administration	O	['N']	[9]
10	of	O	['N']	[10]
11	verapamil	B-Drug	['Causes']	[5]
12	against	O	['N']	[12]
13	paroxysmal	O	['N']	[13]
14	supraventricular	O	['N']	[14]
15	tachycardia	O	['N']	[15]
16	.	O	['N']	[16]
#506
0	Isotretinoin	B-Drug	['Causes']	[1]
1	teratogenicity	B-Adverse_Effect	['N']	[1]
2	.	O	['N']	[2]
#507
0	DATA	O	['N']	[0]
1	SYNTHESIS	O	['N']	[1]
2	:	O	['N']	[2]
3	A	O	['N']	[3]
4	49-year	O	['N']	[4]
5	-	O	['N']	[5]
6	old	O	['N']	[6]
7	man	O	['N']	[7]
8	developed	O	['N']	[8]
9	symptoms	O	['N']	[9]
10	of	O	['N']	[10]
11	severe	O	['N']	[11]
12	psychosis	O	['N']	[12]
13	concomitant	O	['N']	[13]
14	with	O	['N']	[14]
15	ciprofloxacin	B-Drug	['Dosage']	[19]
16	(	O	['N']	[16]
17	250	B	['N']	[17]
18	mg	I	['N']	[18]
19	bid	I-Dose	['N']	[19]
20	)	O	['N']	[20]
21	treatment	O	['N']	[21]
22	.	O	['N']	[22]
#508
0	An	O	['N']	[0]
1	11-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	boy	O	['N']	[4]
5	who	O	['N']	[5]
6	was	O	['N']	[6]
7	treated	O	['N']	[7]
8	with	O	['N']	[8]
9	a	O	['N']	[9]
10	relatively	O	['N']	[10]
11	high	B	['N']	[11]
12	dose	I-Dose	['N']	[12]
13	of	O	['N']	[13]
14	methotrimeprazine	O	['N']	[14]
15	meleate	O	['N']	[15]
16	(	O	['N']	[16]
17	Levemepromazine	B-Drug	['Dosage']	[12]
18	)	O	['N']	[18]
19	a	O	['N']	[19]
20	phenothiazine	O	['N']	[20]
21	antipsychotic	O	['N']	[21]
22	drug	O	['N']	[22]
23	,	O	['N']	[23]
24	was	O	['N']	[24]
25	admitted	O	['N']	[25]
26	to	O	['N']	[26]
27	the	O	['N']	[27]
28	pediatric	O	['N']	[28]
29	intensive	O	['N']	[29]
30	care	O	['N']	[30]
31	unit	O	['N']	[31]
32	suffering	O	['N']	[32]
33	from	O	['N']	[33]
34	respiratory	O	['N']	[34]
35	distress	O	['N']	[35]
36	syndrome	O	['N']	[36]
37	.	O	['N']	[37]
#509
0	A	O	['N']	[0]
1	14-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	female	O	['N']	[4]
5	developed	O	['N']	[5]
6	systemic	O	['N']	[6]
7	lupus	O	['N']	[7]
8	erythematosus	O	['N']	[8]
9	(	O	['N']	[9]
10	SLE)-like	O	['N']	[10]
11	symptoms	O	['N']	[11]
12	,	O	['N']	[12]
13	rash	B-Adverse_Effect	['N']	[13]
14	,	O	['N']	[14]
15	fever	O	['N']	[15]
16	,	O	['N']	[16]
17	leukopenia	O	['N']	[17]
18	and	O	['N']	[18]
19	positive	O	['N']	[19]
20	anti	O	['N']	[20]
21	-	O	['N']	[21]
22	nuclear	O	['N']	[22]
23	antibody	O	['N']	[23]
24	(	O	['N']	[24]
25	ANA	O	['N']	[25]
26	)	O	['N']	[26]
27	two	O	['N']	[27]
28	weeks	O	['N']	[28]
29	after	O	['N']	[29]
30	administration	O	['N']	[30]
31	of	O	['N']	[31]
32	carbamazepine	O	['N']	[32]
33	(	O	['N']	[33]
34	CBZ	B-Drug	['Causes']	[13]
35	;	O	['N']	[35]
36	Tegretol	O	['N']	[36]
37	)	O	['N']	[37]
38	used	O	['N']	[38]
39	against	O	['N']	[39]
40	benign	O	['N']	[40]
41	Rolandic	O	['N']	[41]
42	epilepsy	O	['N']	[42]
43	.	O	['N']	[43]
#510
0	However	O	['N']	[0]
1	,	O	['N']	[1]
2	continued	O	['N']	[2]
3	low	O	['N']	[3]
4	-	O	['N']	[4]
5	dose	O	['N']	[5]
6	MTX	B-Drug	['Causes']	[24]
7	led	O	['N']	[7]
8	,	O	['N']	[8]
9	in	O	['N']	[9]
10	spite	O	['N']	[10]
11	of	O	['N']	[11]
12	normal	O	['N']	[12]
13	liver	O	['N']	[13]
14	tests	O	['N']	[14]
15	,	O	['N']	[15]
16	8	O	['N']	[16]
17	years	O	['N']	[17]
18	after	O	['N']	[18]
19	the	O	['N']	[19]
20	last	O	['N']	[20]
21	biopsy	O	['N']	[21]
22	to	O	['N']	[22]
23	liver	B	['N']	[23]
24	failure	I-Adverse_Effect	['N']	[24]
25	and	O	['N']	[25]
26	death	O	['N']	[26]
27	in	O	['N']	[27]
28	1	O	['N']	[28]
29	of	O	['N']	[29]
30	our	O	['N']	[30]
31	patients	O	['N']	[31]
32	.	O	['N']	[32]
#511
0	A	O	['N']	[0]
1	42	O	['N']	[1]
2	year	O	['N']	[2]
3	old	O	['N']	[3]
4	man	O	['N']	[4]
5	,	O	['N']	[5]
6	treated	O	['N']	[6]
7	for	O	['N']	[7]
8	testicular	O	['N']	[8]
9	carcinoma	O	['N']	[9]
10	with	O	['N']	[10]
11	combination	O	['N']	[11]
12	chemotherapy	O	['N']	[12]
13	that	O	['N']	[13]
14	included	O	['N']	[14]
15	bleomycin	B-Drug	['Causes']	[21]
16	,	O	['N']	[16]
17	developed	O	['N']	[17]
18	life	O	['N']	[18]
19	threatening	O	['N']	[19]
20	interstitial	B	['N']	[20]
21	pneumonitis	I-Adverse_Effect	['N']	[21]
22	.	O	['N']	[22]
#512
0	Two	O	['N']	[0]
1	patients	O	['N']	[1]
2	treated	O	['N']	[2]
3	with	O	['N']	[3]
4	alprazolam	B-Drug	['Causes']	[18]
5	had	O	['N']	[5]
6	histories	O	['N']	[6]
7	suggestive	O	['N']	[7]
8	of	O	['N']	[8]
9	a	O	['N']	[9]
10	bipolar	O	['N']	[10]
11	disorder	O	['N']	[11]
12	and	O	['N']	[12]
13	developed	O	['N']	[13]
14	lithium	O	['N']	[14]
15	-	O	['N']	[15]
16	responsive	O	['N']	[16]
17	manic	B	['N']	[17]
18	episodes	I-Adverse_Effect	['N']	[18]
19	.	O	['N']	[19]
#513
0	Tamoxifen	B-Drug	['Causes']	[5]
1	is	O	['N']	[1]
2	suggested	O	['N']	[2]
3	to	O	['N']	[3]
4	be	O	['N']	[4]
5	carcinogenic	B-Adverse_Effect	['N']	[5]
6	both	O	['N']	[6]
7	through	O	['N']	[7]
8	direct	O	['N']	[8]
9	genotoxic	O	['N']	[9]
10	and	O	['N']	[10]
11	epigenetic	O	['N']	[11]
12	mechanisms	O	['N']	[12]
13	.	O	['N']	[13]
#514
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	intrathecal	O	['N']	[5]
6	methotrexate	B-Drug	['Causes']	[7]
7	neurotoxicity	B-Adverse_Effect	['N']	[7]
8	manifesting	O	['N']	[8]
9	as	O	['N']	[9]
10	left	O	['N']	[10]
11	arm	O	['N']	[11]
12	weakness	O	['N']	[12]
13	and	O	['N']	[13]
14	aphasia	O	['N']	[14]
15	.	O	['N']	[15]
#515
0	The	O	['N']	[0]
1	reported	O	['N']	[1]
2	cases	O	['N']	[2]
3	of	O	['N']	[3]
4	in	O	['N']	[4]
5	utero	O	['N']	[5]
6	exposure	O	['N']	[6]
7	to	O	['N']	[7]
8	cyclosposphamide	B-Drug	['Causes']	[37]
9	shared	O	['N']	[9]
10	the	O	['N']	[10]
11	following	O	['N']	[11]
12	manifestations	O	['N']	[12]
13	with	O	['N']	[13]
14	our	O	['N']	[14]
15	patient	O	['N']	[15]
16	:	O	['N']	[16]
17	growth	O	['N']	[17]
18	deficiency	O	['N']	[18]
19	,	O	['N']	[19]
20	developmental	O	['N']	[20]
21	delay	O	['N']	[21]
22	,	O	['N']	[22]
23	craniosynostosis	O	['N']	[23]
24	,	O	['N']	[24]
25	blepharophimosis	O	['N']	[25]
26	,	O	['N']	[26]
27	flat	O	['N']	[27]
28	nasal	O	['N']	[28]
29	bridge	O	['N']	[29]
30	,	O	['N']	[30]
31	abnormal	O	['N']	[31]
32	ears	O	['N']	[32]
33	,	O	['N']	[33]
34	and	O	['N']	[34]
35	distal	B	['N']	[35]
36	limb	I	['N']	[36]
37	defects	I-Adverse_Effect	['N']	[37]
38	including	O	['N']	[38]
39	hypoplastic	O	['N']	[39]
40	thumbs	O	['N']	[40]
41	and	O	['N']	[41]
42	oligodactyly	O	['N']	[42]
43	.	O	['N']	[43]
#516
0	The	O	['N']	[0]
1	ocular	O	['N']	[1]
2	toxicity	O	['N']	[2]
3	of	O	['N']	[3]
4	DCF	B-Drug	['Causes']	[9]
5	,	O	['N']	[5]
6	previously	O	['N']	[6]
7	described	O	['N']	[7]
8	as	O	['N']	[8]
9	conjunctivitis	B-Adverse_Effect	['N']	[9]
10	,	O	['N']	[10]
11	appears	O	['N']	[11]
12	to	O	['N']	[12]
13	be	O	['N']	[13]
14	a	O	['N']	[14]
15	keratitis	O	['N']	[15]
16	of	O	['N']	[16]
17	moderate	O	['N']	[17]
18	severity	O	['N']	[18]
19	which	O	['N']	[19]
20	requires	O	['N']	[20]
21	further	O	['N']	[21]
22	study	O	['N']	[22]
23	.	O	['N']	[23]
#517
0	We	O	['N']	[0]
1	describe	O	['N']	[1]
2	in	O	['N']	[2]
3	detail	O	['N']	[3]
4	the	O	['N']	[4]
5	first	O	['N']	[5]
6	U.S.	O	['N']	[6]
7	case	O	['N']	[7]
8	report	O	['N']	[8]
9	,	O	['N']	[9]
10	of	O	['N']	[10]
11	a	O	['N']	[11]
12	4(1/2)-year	O	['N']	[12]
13	-	O	['N']	[13]
14	old	O	['N']	[14]
15	boy	O	['N']	[15]
16	who	O	['N']	[16]
17	experienced	O	['N']	[17]
18	angioedema	B-Adverse_Effect	['N']	[18]
19	during	O	['N']	[19]
20	treatment	O	['N']	[20]
21	with	O	['N']	[21]
22	oxcarbazepine	B-Drug	['Causes']	[18]
23	.	O	['N']	[23]
#518
0	Adverse	O	['N']	[0]
1	effects	O	['N']	[1]
2	of	O	['N']	[2]
3	amiodarone	B-Drug	['Causes']	[8]
4	including	O	['N']	[4]
5	pulmonary	O	['N']	[5]
6	toxicity	O	['N']	[6]
7	,	O	['N']	[7]
8	hepatotoxicity	B-Adverse_Effect	['N']	[8]
9	,	O	['N']	[9]
10	aggravation	O	['N']	[10]
11	of	O	['N']	[11]
12	arrhythmia	O	['N']	[12]
13	,	O	['N']	[13]
14	and	O	['N']	[14]
15	thyroid	O	['N']	[15]
16	diseases	O	['N']	[16]
17	are	O	['N']	[17]
18	well	O	['N']	[18]
19	understood	O	['N']	[19]
20	.	O	['N']	[20]
#519
0	The	O	['N']	[0]
1	third	O	['N']	[1]
2	patient	O	['N']	[2]
3	had	O	['N']	[3]
4	been	O	['N']	[4]
5	suffering	O	['N']	[5]
6	from	O	['N']	[6]
7	serious	O	['N']	[7]
8	akathisia	O	['N']	[8]
9	while	O	['N']	[9]
10	on	O	['N']	[10]
11	risperidone	B-Drug	['Causes']	[27]
12	,	O	['N']	[12]
13	and	O	['N']	[13]
14	was	O	['N']	[14]
15	cured	O	['N']	[15]
16	after	O	['N']	[16]
17	switching	O	['N']	[17]
18	to	O	['N']	[18]
19	olanzapine	O	['N']	[19]
20	,	O	['N']	[20]
21	but	O	['N']	[21]
22	thereafter	O	['N']	[22]
23	the	O	['N']	[23]
24	patient	O	['N']	[24]
25	suffered	O	['N']	[25]
26	from	O	['N']	[26]
27	RLS	B-Adverse_Effect	['N']	[27]
28	at	O	['N']	[28]
29	nighttime	O	['N']	[29]
30	.	O	['N']	[30]
#520
0	Three	O	['N']	[0]
1	patients	O	['N']	[1]
2	,	O	['N']	[2]
3	in	O	['N']	[3]
4	whom	O	['N']	[4]
5	tumour	O	['N']	[5]
6	overkill	O	['N']	[6]
7	by	O	['N']	[7]
8	cytotoxic	O	['N']	[8]
9	treatment	O	['N']	[9]
10	,	O	['N']	[10]
11	including	O	['N']	[11]
12	high	O	['N']	[12]
13	dose	O	['N']	[13]
14	methotrexate	B-Drug	['Causes']	[35]
15	with	O	['N']	[15]
16	folinic	O	['N']	[16]
17	acid	O	['N']	[17]
18	rescue	O	['N']	[18]
19	,	O	['N']	[19]
20	resulted	O	['N']	[20]
21	in	O	['N']	[21]
22	the	O	['N']	[22]
23	'	O	['N']	[23]
24	phosphate	O	['N']	[24]
25	shower	O	['N']	[25]
26	syndrome	O	['N']	[26]
27	'	O	['N']	[27]
28	(	O	['N']	[28]
29	hyper	O	['N']	[29]
30	-	O	['N']	[30]
31	uricaemia	O	['N']	[31]
32	,	O	['N']	[32]
33	hyperkalaemia	O	['N']	[33]
34	and	O	['N']	[34]
35	hyperphosphataemia	B-Adverse_Effect	['N']	[35]
36	with	O	['N']	[36]
37	hypocalcaemia	O	['N']	[37]
38	and	O	['N']	[38]
39	tetany	O	['N']	[39]
40	,	O	['N']	[40]
41	with	O	['N']	[41]
42	metabolic	O	['N']	[42]
43	acidosis	O	['N']	[43]
44	and	O	['N']	[44]
45	acute	O	['N']	[45]
46	renal	O	['N']	[46]
47	impairment	O	['N']	[47]
48	)	O	['N']	[48]
49	are	O	['N']	[49]
50	described	O	['N']	[50]
51	.	O	['N']	[51]
#521
0	We	O	['N']	[0]
1	describe	O	['N']	[1]
2	a	O	['N']	[2]
3	patient	O	['N']	[3]
4	with	O	['N']	[4]
5	acute	O	['N']	[5]
6	leukemia	O	['N']	[6]
7	who	O	['N']	[7]
8	developed	O	['N']	[8]
9	Horner	O	['N']	[9]
10	's	O	['N']	[10]
11	syndrome	O	['N']	[11]
12	and	O	['N']	[12]
13	a	O	['N']	[13]
14	severe	O	['N']	[14]
15	demyelinating	O	['N']	[15]
16	peripheral	O	['N']	[16]
17	neuropathy	O	['N']	[17]
18	leading	O	['N']	[18]
19	to	O	['N']	[19]
20	death	O	['N']	[20]
21	after	O	['N']	[21]
22	receiving	O	['N']	[22]
23	high	B	['N']	[23]
24	-	I	['N']	[24]
25	dose	I-Dose	['N']	[25]
26	cytosine	B	['N']	[26]
27	arabinoside	I-Drug	['Dosage']	[25]
28	.	O	['N']	[28]
#522
0	Ziprasidone	B-Drug	['Causes']	[23]
1	is	O	['N']	[1]
2	an	O	['N']	[2]
3	atypical	O	['N']	[3]
4	antipsychotic	O	['N']	[4]
5	drug	O	['N']	[5]
6	that	O	['N']	[6]
7	is	O	['N']	[7]
8	believed	O	['N']	[8]
9	to	O	['N']	[9]
10	have	O	['N']	[10]
11	a	O	['N']	[11]
12	low	O	['N']	[12]
13	propensity	O	['N']	[13]
14	for	O	['N']	[14]
15	inducing	O	['N']	[15]
16	extrapyramidal	O	['N']	[16]
17	symptoms	O	['N']	[17]
18	,	O	['N']	[18]
19	including	O	['N']	[19]
20	tardive	O	['N']	[20]
21	dyskinesia	O	['N']	[21]
22	(	O	['N']	[22]
23	TD	B-Adverse_Effect	['N']	[23]
24	)	O	['N']	[24]
25	.	O	['N']	[25]
#523
0	Bortezomib	B-Drug	['Causes']	[10]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	paralytic	O	['N']	[3]
4	ileus	O	['N']	[4]
5	is	O	['N']	[5]
6	a	O	['N']	[6]
7	potential	O	['N']	[7]
8	gastrointestinal	B	['N']	[8]
9	side	I	['N']	[9]
10	effect	I-Adverse_Effect	['N']	[10]
11	of	O	['N']	[11]
12	this	O	['N']	[12]
13	first	O	['N']	[13]
14	-	O	['N']	[14]
15	in	O	['N']	[15]
16	-	O	['N']	[16]
17	class	O	['N']	[17]
18	anticancer	O	['N']	[18]
19	proteasome	O	['N']	[19]
20	inhibitor	O	['N']	[20]
21	.	O	['N']	[21]
#524
0	An	O	['N']	[0]
1	adolescent	O	['N']	[1]
2	male	O	['N']	[2]
3	developed	O	['N']	[3]
4	acute	O	['N']	[4]
5	pancreatitis	O	['N']	[5]
6	and	O	['N']	[6]
7	pseudocyst	B	['N']	[7]
8	of	I	['N']	[8]
9	the	I	['N']	[9]
10	pancreas	I-Adverse_Effect	['N']	[10]
11	16	O	['N']	[11]
12	weeks	O	['N']	[12]
13	after	O	['N']	[13]
14	cessation	O	['N']	[14]
15	of	O	['N']	[15]
16	intramuscular	O	['N']	[16]
17	L	B	['N']	[17]
18	-	I	['N']	[18]
19	asparaginase	I-Drug	['Causes']	[10]
20	.	O	['N']	[20]
#525
0	A	O	['N']	[0]
1	dapsone	B-Drug	['Causes']	[19]
2	hypersensitivity	O	['N']	[2]
3	syndrome	O	['N']	[3]
4	,	O	['N']	[4]
5	consisting	O	['N']	[5]
6	of	O	['N']	[6]
7	fever	O	['N']	[7]
8	,	O	['N']	[8]
9	headache	O	['N']	[9]
10	,	O	['N']	[10]
11	nausea	O	['N']	[11]
12	,	O	['N']	[12]
13	vomiting	O	['N']	[13]
14	,	O	['N']	[14]
15	lymphadenopathy	O	['N']	[15]
16	,	O	['N']	[16]
17	hepatitis	O	['N']	[17]
18	,	O	['N']	[18]
19	hemolysis	B-Adverse_Effect	['N']	[19]
20	,	O	['N']	[20]
21	leukopenia	O	['N']	[21]
22	,	O	['N']	[22]
23	and	O	['N']	[23]
24	mononucleosis	O	['N']	[24]
25	,	O	['N']	[25]
26	has	O	['N']	[26]
27	been	O	['N']	[27]
28	described	O	['N']	[28]
29	in	O	['N']	[29]
30	patients	O	['N']	[30]
31	treated	O	['N']	[31]
32	with	O	['N']	[32]
33	the	O	['N']	[33]
34	drug	O	['N']	[34]
35	for	O	['N']	[35]
36	leprosy	O	['N']	[36]
37	.	O	['N']	[37]
#526
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	the	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	an	O	['N']	[5]
6	87-year	O	['N']	[6]
7	-	O	['N']	[7]
8	old	O	['N']	[8]
9	white	O	['N']	[9]
10	woman	O	['N']	[10]
11	with	O	['N']	[11]
12	myasthenia	O	['N']	[12]
13	gravis	O	['N']	[13]
14	who	O	['N']	[14]
15	presented	O	['N']	[15]
16	with	O	['N']	[16]
17	nausea	O	['N']	[17]
18	,	O	['N']	[18]
19	shortness	B	['N']	[19]
20	of	I	['N']	[20]
21	breath	I-Adverse_Effect	['N']	[21]
22	,	O	['N']	[22]
23	azotemia	O	['N']	[23]
24	,	O	['N']	[24]
25	and	O	['N']	[25]
26	hyperkalemia	O	['N']	[26]
27	shortly	O	['N']	[27]
28	after	O	['N']	[28]
29	completing	O	['N']	[29]
30	a	O	['N']	[30]
31	course	O	['N']	[31]
32	of	O	['N']	[32]
33	intravenous	O	['N']	[33]
34	immunoglobulin	B-Drug	['Causes']	[21]
35	(	O	['N']	[35]
36	IVIG	O	['N']	[36]
37	)	O	['N']	[37]
38	.	O	['N']	[38]
#527
0	Carbamazepine	B	['N']	[0]
1	toxicity	I-Adverse_Effect	['N']	[1]
2	induced	O	['N']	[2]
3	by	O	['N']	[3]
4	clarithromycin	B-Drug	['Causes']	[1]
5	coadministration	O	['N']	[5]
6	in	O	['N']	[6]
7	psychiatric	O	['N']	[7]
8	patients	O	['N']	[8]
9	.	O	['N']	[9]
#528
0	Fatal	O	['N']	[0]
1	interstitial	O	['N']	[1]
2	pneumonitis	O	['N']	[2]
3	following	O	['N']	[3]
4	high	B	['N']	[4]
5	-	I	['N']	[5]
6	dose	I-Dose	['N']	[6]
7	intermittent	O	['N']	[7]
8	chlorambucil	B-Drug	['Dosage']	[6]
9	therapy	O	['N']	[9]
10	for	O	['N']	[10]
11	chronic	O	['N']	[11]
12	lymphocyte	O	['N']	[12]
13	leukemia	O	['N']	[13]
14	.	O	['N']	[14]
#529
0	Erosion	O	['N']	[0]
1	of	O	['N']	[1]
2	psoriatic	O	['N']	[2]
3	plaques	O	['N']	[3]
4	:	O	['N']	[4]
5	an	O	['N']	[5]
6	early	O	['N']	[6]
7	sign	O	['N']	[7]
8	of	O	['N']	[8]
9	methotrexate	B-Drug	['Causes']	[10]
10	toxicity	I-Adverse_Effect	['N']	[10]
11	.	O	['N']	[11]
#530
0	The	O	['N']	[0]
1	results	O	['N']	[1]
2	clearly	O	['N']	[2]
3	demonstrate	O	['N']	[3]
4	that	O	['N']	[4]
5	CPH82	B-Drug	['Causes']	[25]
6	was	O	['N']	[6]
7	associated	O	['N']	[7]
8	with	O	['N']	[8]
9	suppression	O	['N']	[9]
10	of	O	['N']	[10]
11	the	O	['N']	[11]
12	endogeneous	O	['N']	[12]
13	production	O	['N']	[13]
14	of	O	['N']	[14]
15	ACTH	O	['N']	[15]
16	and	O	['N']	[16]
17	cortisol	O	['N']	[17]
18	with	O	['N']	[18]
19	a	O	['N']	[19]
20	concomitant	O	['N']	[20]
21	paradoxical	O	['N']	[21]
22	picture	O	['N']	[22]
23	of	O	['N']	[23]
24	clinical	O	['N']	[24]
25	hypercortisolism	B-Adverse_Effect	['N']	[25]
26	.	O	['N']	[26]
#531
0	We	O	['N']	[0]
1	describe	O	['N']	[1]
2	the	O	['N']	[2]
3	development	O	['N']	[3]
4	of	O	['N']	[4]
5	ischemic	O	['N']	[5]
6	colitis	O	['N']	[6]
7	in	O	['N']	[7]
8	a	O	['N']	[8]
9	woman	O	['N']	[9]
10	who	O	['N']	[10]
11	was	O	['N']	[11]
12	treated	O	['N']	[12]
13	with	O	['N']	[13]
14	tegaserod	B-Drug	['Causes']	[29]
15	and	O	['N']	[15]
16	review	O	['N']	[16]
17	the	O	['N']	[17]
18	relationship	O	['N']	[18]
19	among	O	['N']	[19]
20	ischemic	O	['N']	[20]
21	colitis	O	['N']	[21]
22	,	O	['N']	[22]
23	tegaserod	O	['N']	[23]
24	use	O	['N']	[24]
25	,	O	['N']	[25]
26	and	O	['N']	[26]
27	irritable	B	['N']	[27]
28	bowel	I	['N']	[28]
29	syndrome	I-Adverse_Effect	['N']	[29]
30	.	O	['N']	[30]
#532
0	While	O	['N']	[0]
1	40	B	['N']	[1]
2	mg	I	['N']	[2]
3	/	I	['N']	[3]
4	day	I-Dose	['N']	[4]
5	of	O	['N']	[5]
6	prednisolone	B-Drug	['Dosage']	[4]
7	improved	O	['N']	[7]
8	hepatic	O	['N']	[8]
9	dysfunction	O	['N']	[9]
10	dramatically	O	['N']	[10]
11	,	O	['N']	[11]
12	her	O	['N']	[12]
13	diabetic	O	['N']	[13]
14	milieu	O	['N']	[14]
15	deteriorated	O	['N']	[15]
16	seriously	O	['N']	[16]
17	.	O	['N']	[17]
#533
0	Prolonged	O	['N']	[0]
1	severe	O	['N']	[1]
2	5-fluorouracil	B-Drug	['Causes']	[5]
3	-	O	['N']	[3]
4	associated	O	['N']	[4]
5	neurotoxicity	B-Adverse_Effect	['N']	[5]
6	in	O	['N']	[6]
7	a	O	['N']	[7]
8	patient	O	['N']	[8]
9	with	O	['N']	[9]
10	dihydropyrimidine	O	['N']	[10]
11	dehydrogenase	O	['N']	[11]
12	deficiency	O	['N']	[12]
13	.	O	['N']	[13]
#534
0	This	O	['N']	[0]
1	paper	O	['N']	[1]
2	reports	O	['N']	[2]
3	on	O	['N']	[3]
4	a	O	['N']	[4]
5	6.9-year	O	['N']	[5]
6	-	O	['N']	[6]
7	old	O	['N']	[7]
8	autistic	O	['N']	[8]
9	male	O	['N']	[9]
10	who	O	['N']	[10]
11	developed	O	['N']	[11]
12	repeated	O	['N']	[12]
13	episodes	O	['N']	[13]
14	of	O	['N']	[14]
15	acute	O	['N']	[15]
16	dystonic	O	['N']	[16]
17	reactions	O	['N']	[17]
18	associated	O	['N']	[18]
19	with	O	['N']	[19]
20	pimozide	B-Drug	['Dosage']	[31]
21	administration	O	['N']	[21]
22	at	O	['N']	[22]
23	the	O	['N']	[23]
24	doses	O	['N']	[24]
25	of	O	['N']	[25]
26	0.096	B	['N']	[26]
27	mg	I	['N']	[27]
28	/	I	['N']	[28]
29	kg	I	['N']	[29]
30	/	I	['N']	[30]
31	day	I-Dose	['N']	[31]
32	and	O	['N']	[32]
33	0.032	O	['N']	[33]
34	mg	O	['N']	[34]
35	/	O	['N']	[35]
36	kg	O	['N']	[36]
37	/	O	['N']	[37]
38	day	O	['N']	[38]
39	and	O	['N']	[39]
40	32	O	['N']	[40]
41	hours	O	['N']	[41]
42	following	O	['N']	[42]
43	pimozide	O	['N']	[43]
44	withdrawal	O	['N']	[44]
45	,	O	['N']	[45]
46	as	O	['N']	[46]
47	well	O	['N']	[47]
48	as	O	['N']	[48]
49	during	O	['N']	[49]
50	subsequent	O	['N']	[50]
51	thioridazine	O	['N']	[51]
52	administration	O	['N']	[52]
53	.	O	['N']	[53]
#535
0	Two	O	['N']	[0]
1	cases	O	['N']	[1]
2	of	O	['N']	[2]
3	hypothyroidism	B-Adverse_Effect	['N']	[3]
4	in	O	['N']	[4]
5	patients	O	['N']	[5]
6	with	O	['N']	[6]
7	chronic	O	['N']	[7]
8	hepatitis	O	['N']	[8]
9	C	O	['N']	[9]
10	treated	O	['N']	[10]
11	with	O	['N']	[11]
12	recombinant	B	['N']	[12]
13	alpha	I	['N']	[13]
14	interferon	I-Drug	['Causes']	[3]
15	are	O	['N']	[15]
16	reported	O	['N']	[16]
17	.	O	['N']	[17]
#536
0	Though	O	['N']	[0]
1	hypotension	O	['N']	[1]
2	,	O	['N']	[2]
3	dry	O	['N']	[3]
4	mouth	O	['N']	[4]
5	,	O	['N']	[5]
6	and	O	['N']	[6]
7	constipation	B-Adverse_Effect	['N']	[7]
8	are	O	['N']	[8]
9	well	O	['N']	[9]
10	-	O	['N']	[10]
11	documented	O	['N']	[11]
12	possible	O	['N']	[12]
13	adverse	O	['N']	[13]
14	effects	O	['N']	[14]
15	,	O	['N']	[15]
16	the	O	['N']	[16]
17	possibility	O	['N']	[17]
18	of	O	['N']	[18]
19	clonidine	B-Drug	['Causes']	[7]
20	-	O	['N']	[20]
21	induced	O	['N']	[21]
22	bradycardia	O	['N']	[22]
23	is	O	['N']	[23]
24	less	O	['N']	[24]
25	well	O	['N']	[25]
26	recognized	O	['N']	[26]
27	and	O	['N']	[27]
28	is	O	['N']	[28]
29	rare	O	['N']	[29]
30	.	O	['N']	[30]
#537
0	The	O	['N']	[0]
1	authors	O	['N']	[1]
2	describe	O	['N']	[2]
3	a	O	['N']	[3]
4	woman	O	['N']	[4]
5	with	O	['N']	[5]
6	chronic	O	['N']	[6]
7	schizophrenia	O	['N']	[7]
8	who	O	['N']	[8]
9	experienced	O	['N']	[9]
10	delirium	O	['N']	[10]
11	,	O	['N']	[11]
12	grand	O	['N']	[12]
13	mal	O	['N']	[13]
14	seizure	O	['N']	[14]
15	,	O	['N']	[15]
16	and	O	['N']	[16]
17	photosensitivity	B-Adverse_Effect	['N']	[17]
18	after	O	['N']	[18]
19	the	O	['N']	[19]
20	addition	O	['N']	[20]
21	of	O	['N']	[21]
22	propranolol	B-Drug	['Causes']	[17]
23	to	O	['N']	[23]
24	her	O	['N']	[24]
25	neuroleptic	O	['N']	[25]
26	regimen	O	['N']	[26]
27	.	O	['N']	[27]
#538
0	Gentamicin	B-Drug	['Causes']	[5]
1	-	O	['N']	[1]
2	associated	O	['N']	[2]
3	acute	B	['N']	[3]
4	renal	I	['N']	[4]
5	failure	I-Adverse_Effect	['N']	[5]
6	.	O	['N']	[6]
#539
0	METHOD	O	['N']	[0]
1	:	O	['N']	[1]
2	We	O	['N']	[2]
3	describe	O	['N']	[3]
4	two	O	['N']	[4]
5	patients	O	['N']	[5]
6	who	O	['N']	[6]
7	presented	O	['N']	[7]
8	with	O	['N']	[8]
9	diabetic	B	['N']	[9]
10	ketoacidosis	I-Adverse_Effect	['N']	[10]
11	after	O	['N']	[11]
12	treatment	O	['N']	[12]
13	with	O	['N']	[13]
14	quetiapine	O	['N']	[14]
15	and	O	['N']	[15]
16	risperidone	B-Drug	['Causes']	[10]
17	,	O	['N']	[17]
18	respectively	O	['N']	[18]
19	.	O	['N']	[19]
#540
0	METHODS	O	['N']	[0]
1	:	O	['N']	[1]
2	A	O	['N']	[2]
3	68-year	O	['N']	[3]
4	-	O	['N']	[4]
5	old	O	['N']	[5]
6	man	O	['N']	[6]
7	developed	O	['N']	[7]
8	intense	O	['N']	[8]
9	conjunctival	O	['N']	[9]
10	hyperemia	O	['N']	[10]
11	and	O	['N']	[11]
12	cystoid	B	['N']	[12]
13	macula	I	['N']	[13]
14	edema	I-Adverse_Effect	['N']	[14]
15	after	O	['N']	[15]
16	switching	O	['N']	[16]
17	from	O	['N']	[17]
18	latanoprost	B-Drug	['Causes']	[14]
19	to	O	['N']	[19]
20	bimatoprost	O	['N']	[20]
21	9	O	['N']	[21]
22	months	O	['N']	[22]
23	after	O	['N']	[23]
24	cataract	O	['N']	[24]
25	surgery	O	['N']	[25]
26	in	O	['N']	[26]
27	an	O	['N']	[27]
28	eye	O	['N']	[28]
29	at	O	['N']	[29]
30	low	O	['N']	[30]
31	-	O	['N']	[31]
32	risk	O	['N']	[32]
33	for	O	['N']	[33]
34	this	O	['N']	[34]
35	cystoid	O	['N']	[35]
36	macular	O	['N']	[36]
37	edema	O	['N']	[37]
38	.	O	['N']	[38]
#541
0	An	O	['N']	[0]
1	8-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	girl	O	['N']	[4]
5	,	O	['N']	[5]
6	who	O	['N']	[6]
7	had	O	['N']	[7]
8	been	O	['N']	[8]
9	vaccinated	O	['N']	[9]
10	with	O	['N']	[10]
11	BCG	B-Drug	['Causes']	[22]
12	without	O	['N']	[12]
13	subsequent	O	['N']	[13]
14	regional	O	['N']	[14]
15	reactions	O	['N']	[15]
16	,	O	['N']	[16]
17	developed	O	['N']	[17]
18	osteomyelitis	B	['N']	[18]
19	in	I	['N']	[19]
20	the	I	['N']	[20]
21	left	I	['N']	[21]
22	calcaneus	I-Adverse_Effect	['N']	[22]
23	7	O	['N']	[23]
24	months	O	['N']	[24]
25	later	O	['N']	[25]
26	.	O	['N']	[26]
#542
0	A	O	['N']	[0]
1	27-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	man	O	['N']	[4]
5	who	O	['N']	[5]
6	had	O	['N']	[6]
7	a	O	['N']	[7]
8	history	O	['N']	[8]
9	of	O	['N']	[9]
10	bronchial	O	['N']	[10]
11	asthma	O	['N']	[11]
12	,	O	['N']	[12]
13	eosinophilic	O	['N']	[13]
14	enteritis	O	['N']	[14]
15	,	O	['N']	[15]
16	and	O	['N']	[16]
17	eosinophilic	O	['N']	[17]
18	pneumonia	O	['N']	[18]
19	presented	O	['N']	[19]
20	with	O	['N']	[20]
21	fever	O	['N']	[21]
22	,	O	['N']	[22]
23	skin	O	['N']	[23]
24	eruptions	O	['N']	[24]
25	,	O	['N']	[25]
26	cervical	O	['N']	[26]
27	lymphadenopathy	O	['N']	[27]
28	,	O	['N']	[28]
29	hepatosplenomegaly	O	['N']	[29]
30	,	O	['N']	[30]
31	atypical	B	['N']	[31]
32	lymphocytosis	I-Adverse_Effect	['N']	[32]
33	,	O	['N']	[33]
34	and	O	['N']	[34]
35	eosinophilia	O	['N']	[35]
36	two	O	['N']	[36]
37	weeks	O	['N']	[37]
38	after	O	['N']	[38]
39	receiving	O	['N']	[39]
40	trimethoprim	B-Drug	['Causes']	[32]
41	(	O	['N']	[41]
42	TMP)-sulfamethoxazole	O	['N']	[42]
43	(	O	['N']	[43]
44	SMX	O	['N']	[44]
45	)	O	['N']	[45]
46	treatment	O	['N']	[46]
47	.	O	['N']	[47]
#543
0	Mycophenolate	B	['N']	[0]
1	mofetil	I-Drug	['Causes']	[4]
2	-	O	['N']	[2]
3	induced	O	['N']	[3]
4	neutropenia	B-Adverse_Effect	['N']	[4]
5	in	O	['N']	[5]
6	liver	O	['N']	[6]
7	transplantation	O	['N']	[7]
8	.	O	['N']	[8]
#544
0	Fenclofenac	B-Drug	['Causes']	[5]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	selective	O	['N']	[3]
4	IgA	B	['N']	[4]
5	deficiency	I-Adverse_Effect	['N']	[5]
6	in	O	['N']	[6]
7	rheumatoid	O	['N']	[7]
8	arthritis	O	['N']	[8]
9	.	O	['N']	[9]
#545
0	We	O	['N']	[0]
1	have	O	['N']	[1]
2	reported	O	['N']	[2]
3	six	O	['N']	[3]
4	cases	O	['N']	[4]
5	of	O	['N']	[5]
6	metoclopramide	B-Drug	['Causes']	[9]
7	-	O	['N']	[7]
8	induced	O	['N']	[8]
9	parkinsonism	B-Adverse_Effect	['N']	[9]
10	seen	O	['N']	[10]
11	in	O	['N']	[11]
12	consultation	O	['N']	[12]
13	over	O	['N']	[13]
14	a	O	['N']	[14]
15	two	O	['N']	[15]
16	-	O	['N']	[16]
17	year	O	['N']	[17]
18	period	O	['N']	[18]
19	.	O	['N']	[19]
#546
0	Rebound	B	['N']	[0]
1	hyperglycemia	I-Adverse_Effect	['N']	[1]
2	was	O	['N']	[2]
3	observed	O	['N']	[3]
4	with	O	['N']	[4]
5	both	O	['N']	[5]
6	intermediate	O	['N']	[6]
7	(	O	['N']	[7]
8	neutral	O	['N']	[8]
9	protamine	B	['N']	[9]
10	hagedorn	I-Drug	['Causes']	[1]
11	)	O	['N']	[11]
12	and	O	['N']	[12]
13	long	O	['N']	[13]
14	-	O	['N']	[14]
15	acting	O	['N']	[15]
16	(	O	['N']	[16]
17	protamine	O	['N']	[17]
18	zinc	O	['N']	[18]
19	iletin	O	['N']	[19]
20	)	O	['N']	[20]
21	insulins	O	['N']	[21]
22	,	O	['N']	[22]
23	and	O	['N']	[23]
24	the	O	['N']	[24]
25	range	O	['N']	[25]
26	of	O	['N']	[26]
27	insulin	O	['N']	[27]
28	doses	O	['N']	[28]
29	at	O	['N']	[29]
30	which	O	['N']	[30]
31	the	O	['N']	[31]
32	disorder	O	['N']	[32]
33	developed	O	['N']	[33]
34	overlapped	O	['N']	[34]
35	previously	O	['N']	[35]
36	determined	O	['N']	[36]
37	therapeutic	O	['N']	[37]
38	doses	O	['N']	[38]
39	for	O	['N']	[39]
40	these	O	['N']	[40]
41	insulins	O	['N']	[41]
42	in	O	['N']	[42]
43	the	O	['N']	[43]
44	cat	O	['N']	[44]
45	.	O	['N']	[45]
#547
0	This	O	['N']	[0]
1	case	O	['N']	[1]
2	of	O	['N']	[2]
3	linezolid	B-Drug	['Causes']	[22]
4	-	O	['N']	[4]
5	associated	O	['N']	[5]
6	acute	O	['N']	[6]
7	interstitial	O	['N']	[7]
8	nephritis	O	['N']	[8]
9	within	O	['N']	[9]
10	the	O	['N']	[10]
11	context	O	['N']	[11]
12	of	O	['N']	[12]
13	a	O	['N']	[13]
14	drug	O	['N']	[14]
15	rash	O	['N']	[15]
16	with	O	['N']	[16]
17	eosinophilia	O	['N']	[17]
18	and	O	['N']	[18]
19	systemic	O	['N']	[19]
20	symptoms	O	['N']	[20]
21	(	O	['N']	[21]
22	DRESS	B-Adverse_Effect	['N']	[22]
23	)	O	['N']	[23]
24	syndrome	O	['N']	[24]
25	in	O	['N']	[25]
26	a	O	['N']	[26]
27	patient	O	['N']	[27]
28	treated	O	['N']	[28]
29	with	O	['N']	[29]
30	linezolid	O	['N']	[30]
31	raises	O	['N']	[31]
32	concerns	O	['N']	[32]
33	about	O	['N']	[33]
34	the	O	['N']	[34]
35	presumed	O	['N']	[35]
36	renal	O	['N']	[36]
37	safety	O	['N']	[37]
38	of	O	['N']	[38]
39	this	O	['N']	[39]
40	drug	O	['N']	[40]
41	.	O	['N']	[41]
#548
0	Patients	O	['N']	[0]
1	treated	O	['N']	[1]
2	with	O	['N']	[2]
3	L	B	['N']	[3]
4	-	I	['N']	[4]
5	asparaginase	I-Drug	['Causes']	[9]
6	may	O	['N']	[6]
7	present	O	['N']	[7]
8	with	O	['N']	[8]
9	hemorrhagic	B-Adverse_Effect	['N']	[9]
10	and	O	['N']	[10]
11	thrombotic	O	['N']	[11]
12	cerebrovascular	O	['N']	[12]
13	events	O	['N']	[13]
14	.	O	['N']	[14]
#549
0	This	O	['N']	[0]
1	article	O	['N']	[1]
2	describes	O	['N']	[2]
3	a	O	['N']	[3]
4	patient	O	['N']	[4]
5	with	O	['N']	[5]
6	suspected	O	['N']	[6]
7	ciprofloxacin	B-Drug	['Causes']	[11]
8	-	O	['N']	[8]
9	induced	O	['N']	[9]
10	interstitial	B	['N']	[10]
11	nephritis	I-Adverse_Effect	['N']	[11]
12	.	O	['N']	[12]
#550
0	METHOD	O	['N']	[0]
1	:	O	['N']	[1]
2	Case	O	['N']	[2]
3	analysis	O	['N']	[3]
4	of	O	['N']	[4]
5	a	O	['N']	[5]
6	poly	O	['N']	[6]
7	-	O	['N']	[7]
8	drug	O	['N']	[8]
9	overdose	O	['N']	[9]
10	(	O	['N']	[10]
11	venlafaxine	O	['N']	[11]
12	,	O	['N']	[12]
13	topiramate	O	['N']	[13]
14	,	O	['N']	[14]
15	divalproex	O	['N']	[15]
16	sodium	O	['N']	[16]
17	,	O	['N']	[17]
18	risperidone	O	['N']	[18]
19	,	O	['N']	[19]
20	and	O	['N']	[20]
21	carbamazepine	B-Drug	['Causes']	[26]
22	)	O	['N']	[22]
23	presenting	O	['N']	[23]
24	with	O	['N']	[24]
25	mixed	O	['N']	[25]
26	SS	B-Adverse_Effect	['N']	[26]
27	/	O	['N']	[27]
28	NMS	O	['N']	[28]
29	features	O	['N']	[29]
30	and	O	['N']	[30]
31	whose	O	['N']	[31]
32	clinical	O	['N']	[32]
33	management	O	['N']	[33]
34	suggests	O	['N']	[34]
35	a	O	['N']	[35]
36	practical	O	['N']	[36]
37	algorithm	O	['N']	[37]
38	for	O	['N']	[38]
39	treatment	O	['N']	[39]
40	of	O	['N']	[40]
41	undifferentiated	O	['N']	[41]
42	SS	O	['N']	[42]
43	/	O	['N']	[43]
44	NMS	O	['N']	[44]
45	in	O	['N']	[45]
46	critical	O	['N']	[46]
47	care	O	['N']	[47]
48	settings	O	['N']	[48]
49	.	O	['N']	[49]
#551
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	an	O	['N']	[2]
3	unusual	O	['N']	[3]
4	case	O	['N']	[4]
5	of	O	['N']	[5]
6	massive	B-Dose	['N']	[6]
7	fluoxetine	B-Drug	['Dosage']	[6]
8	ingestion	O	['N']	[8]
9	resulting	O	['N']	[9]
10	in	O	['N']	[10]
11	neurological	O	['N']	[11]
12	and	O	['N']	[12]
13	cardiovascular	O	['N']	[13]
14	toxicity	O	['N']	[14]
15	resulting	O	['N']	[15]
16	in	O	['N']	[16]
17	death	O	['N']	[17]
18	.	O	['N']	[18]
#552
0	The	O	['N']	[0]
1	purpose	O	['N']	[1]
2	of	O	['N']	[2]
3	this	O	['N']	[3]
4	report	O	['N']	[4]
5	is	O	['N']	[5]
6	to	O	['N']	[6]
7	document	O	['N']	[7]
8	a	O	['N']	[8]
9	new	O	['N']	[9]
10	case	O	['N']	[10]
11	of	O	['N']	[11]
12	in	O	['N']	[12]
13	utero	O	['N']	[13]
14	CP	B-Drug	['Causes']	[19]
15	exposure	O	['N']	[15]
16	with	O	['N']	[16]
17	multiple	B	['N']	[17]
18	congenital	I	['N']	[18]
19	anomalies	I-Adverse_Effect	['N']	[19]
20	and	O	['N']	[20]
21	to	O	['N']	[21]
22	establish	O	['N']	[22]
23	an	O	['N']	[23]
24	apparent	O	['N']	[24]
25	CP	O	['N']	[25]
26	embryopathy	O	['N']	[26]
27	phenotype	O	['N']	[27]
28	.	O	['N']	[28]
#553
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	5-year	O	['N']	[3]
4	-	O	['N']	[4]
5	old	O	['N']	[5]
6	boy	O	['N']	[6]
7	with	O	['N']	[7]
8	CF	O	['N']	[8]
9	who	O	['N']	[9]
10	had	O	['N']	[10]
11	a	O	['N']	[11]
12	stricture	B	['N']	[12]
13	of	I	['N']	[13]
14	the	I	['N']	[14]
15	hepatic	I	['N']	[15]
16	flexure	I	['N']	[16]
17	region	I	['N']	[17]
18	with	I	['N']	[18]
19	associated	I	['N']	[19]
20	narrowing	I-Adverse_Effect	['N']	[20]
21	due	O	['N']	[21]
22	to	O	['N']	[22]
23	submucosal	O	['N']	[23]
24	fibrosis	O	['N']	[24]
25	of	O	['N']	[25]
26	the	O	['N']	[26]
27	transverse	O	['N']	[27]
28	colon	O	['N']	[28]
29	,	O	['N']	[29]
30	secondary	O	['N']	[30]
31	to	O	['N']	[31]
32	high	B	['N']	[32]
33	-	I	['N']	[33]
34	lipase	I	['N']	[34]
35	pancreatin	I-Drug	['Causes']	[20]
36	therapy	O	['N']	[36]
37	.	O	['N']	[37]
#554
0	Acute	O	['N']	[0]
1	vision	O	['N']	[1]
2	loss	O	['N']	[2]
3	after	O	['N']	[3]
4	intravitreal	O	['N']	[4]
5	injection	O	['N']	[5]
6	of	O	['N']	[6]
7	bevacizumab	B-Drug	['Causes']	[15]
8	(	O	['N']	[8]
9	avastin	O	['N']	[9]
10	)	O	['N']	[10]
11	associated	O	['N']	[11]
12	with	O	['N']	[12]
13	ocular	B	['N']	[13]
14	ischemic	I	['N']	[14]
15	syndrome	I-Adverse_Effect	['N']	[15]
16	.	O	['N']	[16]
#555
0	OBJECTIVE	O	['N']	[0]
1	:	O	['N']	[1]
2	To	O	['N']	[2]
3	report	O	['N']	[3]
4	2	O	['N']	[4]
5	cases	O	['N']	[5]
6	of	O	['N']	[6]
7	serotonin	O	['N']	[7]
8	syndrome	O	['N']	[8]
9	with	O	['N']	[9]
10	serious	O	['N']	[10]
11	extrapyramidal	B	['N']	[11]
12	movement	I	['N']	[12]
13	disorders	I-Adverse_Effect	['N']	[13]
14	occurring	O	['N']	[14]
15	when	O	['N']	[15]
16	metoclopramide	O	['N']	[16]
17	was	O	['N']	[17]
18	coadministered	O	['N']	[18]
19	with	O	['N']	[19]
20	sertraline	B-Drug	['Causes']	[13]
21	or	O	['N']	[21]
22	venlafaxine	O	['N']	[22]
23	.	O	['N']	[23]
#556
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	the	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	an	O	['N']	[5]
6	11-year	O	['N']	[6]
7	-	O	['N']	[7]
8	old	O	['N']	[8]
9	female	O	['N']	[9]
10	treated	O	['N']	[10]
11	for	O	['N']	[11]
12	mediastinal	O	['N']	[12]
13	T	O	['N']	[13]
14	-	O	['N']	[14]
15	cell	O	['N']	[15]
16	lymphoma	O	['N']	[16]
17	who	O	['N']	[17]
18	presented	O	['N']	[18]
19	renal	B	['N']	[19]
20	failure	I-Adverse_Effect	['N']	[20]
21	following	O	['N']	[21]
22	the	O	['N']	[22]
23	second	O	['N']	[23]
24	cycle	O	['N']	[24]
25	of	O	['N']	[25]
26	high	O	['N']	[26]
27	-	O	['N']	[27]
28	dose	O	['N']	[28]
29	methotrexate	B-Drug	['Causes']	[20]
30	(	O	['N']	[30]
31	HDMTX	O	['N']	[31]
32	)	O	['N']	[32]
33	.	O	['N']	[33]
#557
0	CONCLUSIONS	O	['N']	[0]
1	:	O	['N']	[1]
2	Although	O	['N']	[2]
3	budesonide	B-Drug	['Causes']	[25]
4	may	O	['N']	[4]
5	be	O	['N']	[5]
6	beneficial	O	['N']	[6]
7	because	O	['N']	[7]
8	of	O	['N']	[8]
9	its	O	['N']	[9]
10	anti	O	['N']	[10]
11	-	O	['N']	[11]
12	inflammatory	O	['N']	[12]
13	effects	O	['N']	[13]
14	,	O	['N']	[14]
15	clinicians	O	['N']	[15]
16	should	O	['N']	[16]
17	be	O	['N']	[17]
18	alert	O	['N']	[18]
19	to	O	['N']	[19]
20	its	O	['N']	[20]
21	potential	O	['N']	[21]
22	for	O	['N']	[22]
23	causing	O	['N']	[23]
24	contact	B	['N']	[24]
25	dermatitis	I-Adverse_Effect	['N']	[25]
26	.	O	['N']	[26]
#558
0	Herein	O	['N']	[0]
1	is	O	['N']	[1]
2	reported	O	['N']	[2]
3	an	O	['N']	[3]
4	unusual	O	['N']	[4]
5	case	O	['N']	[5]
6	of	O	['N']	[6]
7	coexistent	O	['N']	[7]
8	warfarin	O	['N']	[8]
9	-	O	['N']	[9]
10	induced	O	['N']	[10]
11	skin	O	['N']	[11]
12	necrosis	O	['N']	[12]
13	and	O	['N']	[13]
14	heparin	B-Drug	['Causes']	[17]
15	-	O	['N']	[15]
16	induced	O	['N']	[16]
17	thrombocytopenia	B-Adverse_Effect	['N']	[17]
18	following	O	['N']	[18]
19	mitral	O	['N']	[19]
20	valve	O	['N']	[20]
21	replacement	O	['N']	[21]
22	for	O	['N']	[22]
23	thromboembolic	O	['N']	[23]
24	phenomena	O	['N']	[24]
25	associated	O	['N']	[25]
26	with	O	['N']	[26]
27	marantic	O	['N']	[27]
28	endocarditis	O	['N']	[28]
29	and	O	['N']	[29]
30	bronchial	O	['N']	[30]
31	adenocarcinoma	O	['N']	[31]
32	.	O	['N']	[32]
#559
0	Exacerbations	B	['N']	[0]
1	of	I	['N']	[1]
2	the	I	['N']	[2]
3	heart	I	['N']	[3]
4	failure	I-Adverse_Effect	['N']	[4]
5	were	O	['N']	[5]
6	temporally	O	['N']	[6]
7	related	O	['N']	[7]
8	to	O	['N']	[8]
9	the	O	['N']	[9]
10	administration	O	['N']	[10]
11	of	O	['N']	[11]
12	the	O	['N']	[12]
13	antitumor	O	['N']	[13]
14	antibiotics	O	['N']	[14]
15	actinomycin	O	['N']	[15]
16	-	O	['N']	[16]
17	D	O	['N']	[17]
18	(	O	['N']	[18]
19	NSC-3053	O	['N']	[19]
20	)	O	['N']	[20]
21	and	O	['N']	[21]
22	mithramycin	O	['N']	[22]
23	(	O	['N']	[23]
24	NSC-24559	B-Drug	['Causes']	[4]
25	)	O	['N']	[25]
26	.	O	['N']	[26]
#560
0	However	O	['N']	[0]
1	here	O	['N']	[1]
2	we	O	['N']	[2]
3	reported	O	['N']	[3]
4	two	O	['N']	[4]
5	patients	O	['N']	[5]
6	,	O	['N']	[6]
7	presenting	O	['N']	[7]
8	with	O	['N']	[8]
9	PD	O	['N']	[9]
10	during	O	['N']	[10]
11	high	B-Dose	['N']	[11]
12	dose	O	['N']	[12]
13	colchicine	B-Drug	['Dosage']	[11]
14	treatment	O	['N']	[14]
15	for	O	['N']	[15]
16	familiar	O	['N']	[16]
17	mediterranean	O	['N']	[17]
18	fever	O	['N']	[18]
19	(	O	['N']	[19]
20	FMF	O	['N']	[20]
21	)	O	['N']	[21]
22	.	O	['N']	[22]
#561
0	This	O	['N']	[0]
1	fourth	O	['N']	[1]
2	type	O	['N']	[2]
3	of	O	['N']	[3]
4	cutaneous	O	['N']	[4]
5	minocycline	B-Drug	['Causes']	[6]
6	hyperpigmentation	B-Adverse_Effect	['N']	[6]
7	may	O	['N']	[7]
8	be	O	['N']	[8]
9	a	O	['N']	[9]
10	variant	O	['N']	[10]
11	of	O	['N']	[11]
12	Type	O	['N']	[12]
13	I	O	['N']	[13]
14	,	O	['N']	[14]
15	but	O	['N']	[15]
16	based	O	['N']	[16]
17	on	O	['N']	[17]
18	clinical	O	['N']	[18]
19	,	O	['N']	[19]
20	pathological	O	['N']	[20]
21	and	O	['N']	[21]
22	microanalytical	O	['N']	[22]
23	differences	O	['N']	[23]
24	,	O	['N']	[24]
25	appears	O	['N']	[25]
26	to	O	['N']	[26]
27	be	O	['N']	[27]
28	a	O	['N']	[28]
29	new	O	['N']	[29]
30	entity	O	['N']	[30]
31	.	O	['N']	[31]
#562
0	Sulfasalazine	B-Drug	['Causes']	[17]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	lung	O	['N']	[3]
4	disorder	O	['N']	[4]
5	is	O	['N']	[5]
6	an	O	['N']	[6]
7	extremely	O	['N']	[7]
8	rare	O	['N']	[8]
9	entity	O	['N']	[9]
10	which	O	['N']	[10]
11	must	O	['N']	[11]
12	be	O	['N']	[12]
13	considered	O	['N']	[13]
14	in	O	['N']	[14]
15	all	O	['N']	[15]
16	ulcerative	B	['N']	[16]
17	colitis	I-Adverse_Effect	['N']	[17]
18	patients	O	['N']	[18]
19	while	O	['N']	[19]
20	on	O	['N']	[20]
21	sulfasalazine	O	['N']	[21]
22	therapy	O	['N']	[22]
23	,	O	['N']	[23]
24	despite	O	['N']	[24]
25	the	O	['N']	[25]
26	absence	O	['N']	[26]
27	of	O	['N']	[27]
28	pulmonary	O	['N']	[28]
29	symptomatology	O	['N']	[29]
30	.	O	['N']	[30]
#563
0	Treatment	O	['N']	[0]
1	of	O	['N']	[1]
2	chronic	O	['N']	[2]
3	hepatitis	O	['N']	[3]
4	C	O	['N']	[4]
5	with	O	['N']	[5]
6	interferon	B	['N']	[6]
7	alpha	I-Drug	['Causes']	[27]
8	(	O	['N']	[8]
9	IFN	O	['N']	[9]
10	-	O	['N']	[10]
11	alpha	O	['N']	[11]
12	)	O	['N']	[12]
13	is	O	['N']	[13]
14	relatively	O	['N']	[14]
15	contraindicated	O	['N']	[15]
16	in	O	['N']	[16]
17	patients	O	['N']	[17]
18	with	O	['N']	[18]
19	psychiatric	O	['N']	[19]
20	disorders	O	['N']	[20]
21	because	O	['N']	[21]
22	of	O	['N']	[22]
23	possible	O	['N']	[23]
24	severe	O	['N']	[24]
25	psychiatric	B	['N']	[25]
26	side	I	['N']	[26]
27	effects	I-Adverse_Effect	['N']	[27]
28	.	O	['N']	[28]
#564
0	With	O	['N']	[0]
1	the	O	['N']	[1]
2	first	O	['N']	[2]
3	cyclosporine	B-Drug	['Causes']	[11]
4	dose	O	['N']	[4]
5	,	O	['N']	[5]
6	the	O	['N']	[6]
7	patient	O	['N']	[7]
8	complained	O	['N']	[8]
9	of	O	['N']	[9]
10	leg	B	['N']	[10]
11	pain	I-Adverse_Effect	['N']	[11]
12	that	O	['N']	[12]
13	was	O	['N']	[13]
14	most	O	['N']	[14]
15	severe	O	['N']	[15]
16	during	O	['N']	[16]
17	the	O	['N']	[17]
18	cyclosporine	O	['N']	[18]
19	infusion	O	['N']	[19]
20	.	O	['N']	[20]
#565
0	Tardive	B	['N']	[0]
1	oculogyric	I	['N']	[1]
2	crisis	I-Adverse_Effect	['N']	[2]
3	during	O	['N']	[3]
4	treatment	O	['N']	[4]
5	with	O	['N']	[5]
6	clozapine	B-Drug	['Causes']	[2]
7	:	O	['N']	[7]
8	report	O	['N']	[8]
9	of	O	['N']	[9]
10	three	O	['N']	[10]
11	cases	O	['N']	[11]
12	.	O	['N']	[12]
#566
0	Psoriasis	B-Adverse_Effect	['N']	[0]
1	induced	O	['N']	[1]
2	by	O	['N']	[2]
3	interferon	B	['N']	[3]
4	-	I	['N']	[4]
5	alpha	I-Drug	['Causes']	[0]
6	.	O	['N']	[6]
#567
0	From	O	['N']	[0]
1	1996	O	['N']	[1]
2	to	O	['N']	[2]
3	2002	O	['N']	[3]
4	several	O	['N']	[4]
5	medications	O	['N']	[5]
6	were	O	['N']	[6]
7	changed	O	['N']	[7]
8	due	O	['N']	[8]
9	to	O	['N']	[9]
10	their	O	['N']	[10]
11	adverse	O	['N']	[11]
12	effects	O	['N']	[12]
13	:	O	['N']	[13]
14	indinavir	O	['N']	[14]
15	(	O	['N']	[15]
16	renal	O	['N']	[16]
17	colic	O	['N']	[17]
18	and	O	['N']	[18]
19	fever	O	['N']	[19]
20	)	O	['N']	[20]
21	,	O	['N']	[21]
22	nelfinavir	O	['N']	[22]
23	(	O	['N']	[23]
24	cutaneous	O	['N']	[24]
25	rash	O	['N']	[25]
26	)	O	['N']	[26]
27	,	O	['N']	[27]
28	and	O	['N']	[28]
29	efavirenz	B-Drug	['Causes']	[31]
30	(	O	['N']	[30]
31	nausea	B-Adverse_Effect	['N']	[31]
32	and	O	['N']	[32]
33	temporary	O	['N']	[33]
34	memory	O	['N']	[34]
35	loss	O	['N']	[35]
36	)	O	['N']	[36]
37	.	O	['N']	[37]
#568
0	A	O	['N']	[0]
1	65-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	woman	O	['N']	[4]
5	with	O	['N']	[5]
6	angina	O	['N']	[6]
7	pectoris	O	['N']	[7]
8	presented	O	['N']	[8]
9	with	O	['N']	[9]
10	syncope	O	['N']	[10]
11	after	O	['N']	[11]
12	sublingual	O	['N']	[12]
13	ingestion	O	['N']	[13]
14	of	O	['N']	[14]
15	isosorbide	B	['N']	[15]
16	dinitrate	I-Drug	['Dosage']	[19]
17	(	O	['N']	[17]
18	5	B	['N']	[18]
19	mg	I-Dose	['N']	[19]
20	)	O	['N']	[20]
21	.	O	['N']	[21]
#569
0	We	O	['N']	[0]
1	conclude	O	['N']	[1]
2	that	O	['N']	[2]
3	vincristine	O	['N']	[3]
4	and	O	['N']	[4]
5	actinomycin	B	['N']	[5]
6	D	I-Drug	['Causes']	[15]
7	were	O	['N']	[7]
8	the	O	['N']	[8]
9	cause	O	['N']	[9]
10	of	O	['N']	[10]
11	this	O	['N']	[11]
12	rare	O	['N']	[12]
13	from	O	['N']	[13]
14	of	O	['N']	[14]
15	hepatotoxicity	B-Adverse_Effect	['N']	[15]
16	and	O	['N']	[16]
17	that	O	['N']	[17]
18	chemotherapy	O	['N']	[18]
19	for	O	['N']	[19]
20	the	O	['N']	[20]
21	underlying	O	['N']	[21]
22	malignant	O	['N']	[22]
23	disease	O	['N']	[23]
24	could	O	['N']	[24]
25	be	O	['N']	[25]
26	given	O	['N']	[26]
27	safely	O	['N']	[27]
28	after	O	['N']	[28]
29	clinical	O	['N']	[29]
30	recovery	O	['N']	[30]
31	.	O	['N']	[31]
#570
0	A	O	['N']	[0]
1	small	O	['N']	[1]
2	initial	O	['N']	[2]
3	dose	O	['N']	[3]
4	of	O	['N']	[4]
5	prazosin	B-Drug	['Causes']	[31]
6	ranging	O	['N']	[6]
7	from	O	['N']	[7]
8	0.5	O	['N']	[8]
9	to	O	['N']	[9]
10	1	O	['N']	[10]
11	mg	O	['N']	[11]
12	has	O	['N']	[12]
13	been	O	['N']	[13]
14	recommended	O	['N']	[14]
15	to	O	['N']	[15]
16	avoid	O	['N']	[16]
17	the	O	['N']	[17]
18	first	O	['N']	[18]
19	-	O	['N']	[19]
20	dose	O	['N']	[20]
21	phenomenon	O	['N']	[21]
22	characterized	O	['N']	[22]
23	by	O	['N']	[23]
24	a	O	['N']	[24]
25	sudden	O	['N']	[25]
26	and	O	['N']	[26]
27	severe	B	['N']	[27]
28	drop	I	['N']	[28]
29	in	I	['N']	[29]
30	blood	I	['N']	[30]
31	pressure	I-Adverse_Effect	['N']	[31]
32	after	O	['N']	[32]
33	the	O	['N']	[33]
34	administration	O	['N']	[34]
35	of	O	['N']	[35]
36	the	O	['N']	[36]
37	first	O	['N']	[37]
38	dose	O	['N']	[38]
39	of	O	['N']	[39]
40	prazosin	O	['N']	[40]
41	.	O	['N']	[41]
#571
0	OBJECTIVE	O	['N']	[0]
1	:	O	['N']	[1]
2	1	O	['N']	[2]
3	)	O	['N']	[3]
4	To	O	['N']	[4]
5	describe	O	['N']	[5]
6	a	O	['N']	[6]
7	patient	O	['N']	[7]
8	with	O	['N']	[8]
9	rheumatoid	O	['N']	[9]
10	arthritis	O	['N']	[10]
11	receiving	O	['N']	[11]
12	adalimumab	B-Drug	['Causes']	[17]
13	who	O	['N']	[13]
14	developed	O	['N']	[14]
15	fever	O	['N']	[15]
16	,	O	['N']	[16]
17	pancytopenia	B-Adverse_Effect	['N']	[17]
18	,	O	['N']	[18]
19	splenomegaly	O	['N']	[19]
20	,	O	['N']	[20]
21	and	O	['N']	[21]
22	extreme	O	['N']	[22]
23	hyperferritinemia	O	['N']	[23]
24	.	O	['N']	[24]
#572
0	A	O	['N']	[0]
1	patient	O	['N']	[1]
2	with	O	['N']	[2]
3	chronic	O	['N']	[3]
4	myeloid	O	['N']	[4]
5	leukaemia	O	['N']	[5]
6	treated	O	['N']	[6]
7	with	O	['N']	[7]
8	busulphan	B-Drug	['Causes']	[22]
9	for	O	['N']	[9]
10	4	O	['N']	[10]
11	-	O	['N']	[11]
12	5	O	['N']	[12]
13	years	O	['N']	[13]
14	,	O	['N']	[14]
15	developed	O	['N']	[15]
16	signs	O	['N']	[16]
17	of	O	['N']	[17]
18	busulphan	O	['N']	[18]
19	toxicity	O	['N']	[19]
20	and	O	['N']	[20]
21	portal	B	['N']	[21]
22	hypertension	I-Adverse_Effect	['N']	[22]
23	with	O	['N']	[23]
24	ascites	O	['N']	[24]
25	,	O	['N']	[25]
26	oesophageal	O	['N']	[26]
27	varices	O	['N']	[27]
28	and	O	['N']	[28]
29	jaundice	O	['N']	[29]
30	.	O	['N']	[30]
#573
0	A	O	['N']	[0]
1	57-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	woman	O	['N']	[4]
5	with	O	['N']	[5]
6	right	O	['N']	[6]
7	bundle	O	['N']	[7]
8	branch	O	['N']	[8]
9	block	O	['N']	[9]
10	+	O	['N']	[10]
11	LPH	O	['N']	[11]
12	and	O	['N']	[12]
13	ventricular	O	['N']	[13]
14	premature	O	['N']	[14]
15	contractions	O	['N']	[15]
16	developed	O	['N']	[16]
17	complete	O	['N']	[17]
18	heart	O	['N']	[18]
19	block	O	['N']	[19]
20	(	O	['N']	[20]
21	CHB	B-Adverse_Effect	['N']	[21]
22	)	O	['N']	[22]
23	following	O	['N']	[23]
24	administration	O	['N']	[24]
25	of	O	['N']	[25]
26	disopyramide	O	['N']	[26]
27	phosphate	O	['N']	[27]
28	(	O	['N']	[28]
29	Norpace	B-Drug	['Causes']	[21]
30	)	O	['N']	[30]
31	.	O	['N']	[31]
#574
0	A	O	['N']	[0]
1	16-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	boy	O	['N']	[4]
5	developed	O	['N']	[5]
6	fever	O	['N']	[6]
7	,	O	['N']	[7]
8	generalized	O	['N']	[8]
9	rigidity	O	['N']	[9]
10	,	O	['N']	[10]
11	leukocytosis	O	['N']	[11]
12	,	O	['N']	[12]
13	and	O	['N']	[13]
14	increased	B	['N']	[14]
15	serum	I	['N']	[15]
16	transaminase	I	['N']	[16]
17	and	I	['N']	[17]
18	creatine	I	['N']	[18]
19	kinase	I-Adverse_Effect	['N']	[19]
20	levels	O	['N']	[20]
21	while	O	['N']	[21]
22	receiving	O	['N']	[22]
23	treatment	O	['N']	[23]
24	with	O	['N']	[24]
25	olanzapine	B-Drug	['Causes']	[19]
26	and	O	['N']	[26]
27	lithium	O	['N']	[27]
28	.	O	['N']	[28]
#575
0	Although	O	['N']	[0]
1	praziquantel	B-Drug	['Causes']	[23]
2	administration	O	['N']	[2]
3	may	O	['N']	[3]
4	have	O	['N']	[4]
5	been	O	['N']	[5]
6	effective	O	['N']	[6]
7	in	O	['N']	[7]
8	killing	O	['N']	[8]
9	the	O	['N']	[9]
10	parasite	O	['N']	[10]
11	in	O	['N']	[11]
12	both	O	['N']	[12]
13	patients	O	['N']	[13]
14	,	O	['N']	[14]
15	we	O	['N']	[15]
16	are	O	['N']	[16]
17	concerned	O	['N']	[17]
18	about	O	['N']	[18]
19	the	O	['N']	[19]
20	production	O	['N']	[20]
21	of	O	['N']	[21]
22	marked	O	['N']	[22]
23	inflammation	B-Adverse_Effect	['N']	[23]
24	as	O	['N']	[24]
25	a	O	['N']	[25]
26	result	O	['N']	[26]
27	of	O	['N']	[27]
28	treatment	O	['N']	[28]
29	.	O	['N']	[29]
#576
0	The	O	['N']	[0]
1	principle	O	['N']	[1]
2	treatment	O	['N']	[2]
3	for	O	['N']	[3]
4	DPD	O	['N']	[4]
5	-	O	['N']	[5]
6	deficient	O	['N']	[6]
7	patients	O	['N']	[7]
8	with	O	['N']	[8]
9	severe	O	['N']	[9]
10	acute	O	['N']	[10]
11	5-FU	B-Drug	['Causes']	[34]
12	reactions	O	['N']	[12]
13	is	O	['N']	[13]
14	supportive	O	['N']	[14]
15	care	O	['N']	[15]
16	;	O	['N']	[16]
17	however	O	['N']	[17]
18	,	O	['N']	[18]
19	the	O	['N']	[19]
20	administration	O	['N']	[20]
21	of	O	['N']	[21]
22	thymidine	O	['N']	[22]
23	potentially	O	['N']	[23]
24	may	O	['N']	[24]
25	reverse	O	['N']	[25]
26	severe	O	['N']	[26]
27	5-FU	O	['N']	[27]
28	-	O	['N']	[28]
29	induced	O	['N']	[29]
30	neurologic	O	['N']	[30]
31	symptoms	O	['N']	[31]
32	such	O	['N']	[32]
33	as	O	['N']	[33]
34	encephalopathy	B-Adverse_Effect	['N']	[34]
35	and	O	['N']	[35]
36	coma	O	['N']	[36]
37	.	O	['N']	[37]
#577
0	RESULTS	O	['N']	[0]
1	:	O	['N']	[1]
2	Our	O	['N']	[2]
3	patient	O	['N']	[3]
4	developed	O	['N']	[4]
5	Crohn	O	['N']	[5]
6	's	O	['N']	[6]
7	disease	O	['N']	[7]
8	while	O	['N']	[8]
9	on	O	['N']	[9]
10	Copaxone	B-Drug	['Causes']	[19]
11	treatment	O	['N']	[11]
12	as	O	['N']	[12]
13	a	O	['N']	[13]
14	consequence	O	['N']	[14]
15	of	O	['N']	[15]
16	long	B	['N']	[16]
17	-	I	['N']	[17]
18	term	I	['N']	[18]
19	immunosuppression	I-Adverse_Effect	['N']	[19]
20	.	O	['N']	[20]
#578
0	The	O	['N']	[0]
1	pulmonary	B	['N']	[1]
2	toxicity	I-Adverse_Effect	['N']	[2]
3	of	O	['N']	[3]
4	gold	B-Drug	['Causes']	[2]
5	salts	O	['N']	[5]
6	is	O	['N']	[6]
7	an	O	['N']	[7]
8	uncommon	O	['N']	[8]
9	cause	O	['N']	[9]
10	of	O	['N']	[10]
11	life	O	['N']	[11]
12	-	O	['N']	[12]
13	threatening	O	['N']	[13]
14	respiratory	O	['N']	[14]
15	failure	O	['N']	[15]
16	.	O	['N']	[16]
#579
0	A	O	['N']	[0]
1	21-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	man	O	['N']	[4]
5	with	O	['N']	[5]
6	Tourette	O	['N']	[6]
7	's	O	['N']	[7]
8	syndrome	O	['N']	[8]
9	,	O	['N']	[9]
10	pedophilia	O	['N']	[10]
11	,	O	['N']	[11]
12	Asperger	O	['N']	[12]
13	's	O	['N']	[13]
14	syndrome	O	['N']	[14]
15	,	O	['N']	[15]
16	and	O	['N']	[16]
17	multiple	O	['N']	[17]
18	sclerosis	O	['N']	[18]
19	experienced	O	['N']	[19]
20	seizures	B-Adverse_Effect	['N']	[20]
21	after	O	['N']	[21]
22	receiving	O	['N']	[22]
23	therapy	O	['N']	[23]
24	with	O	['N']	[24]
25	interferon	B	['N']	[25]
26	beta-1a	I-Drug	['Causes']	[20]
27	.	O	['N']	[27]
#580
0	An	O	['N']	[0]
1	11-day	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	infant	O	['N']	[4]
5	became	O	['N']	[5]
6	lethargic	O	['N']	[6]
7	and	O	['N']	[7]
8	apneic	B-Adverse_Effect	['N']	[8]
9	after	O	['N']	[9]
10	a	O	['N']	[10]
11	single	O	['N']	[11]
12	drop	O	['N']	[12]
13	of	O	['N']	[13]
14	brimonidine	B-Drug	['Causes']	[8]
15	.	O	['N']	[15]
#581
0	INTRODUCTION	O	['N']	[0]
1	:	O	['N']	[1]
2	Although	O	['N']	[2]
3	gefitinib	B-Drug	['Causes']	[27]
4	used	O	['N']	[4]
5	for	O	['N']	[5]
6	the	O	['N']	[6]
7	treatment	O	['N']	[7]
8	of	O	['N']	[8]
9	non	O	['N']	[9]
10	-	O	['N']	[10]
11	small	O	['N']	[11]
12	-	O	['N']	[12]
13	cell	O	['N']	[13]
14	lung	O	['N']	[14]
15	cancer	O	['N']	[15]
16	is	O	['N']	[16]
17	a	O	['N']	[17]
18	well	O	['N']	[18]
19	-	O	['N']	[19]
20	known	O	['N']	[20]
21	cause	O	['N']	[21]
22	of	O	['N']	[22]
23	interstitial	O	['N']	[23]
24	lung	O	['N']	[24]
25	disease	O	['N']	[25]
26	(	O	['N']	[26]
27	ILD	B-Adverse_Effect	['N']	[27]
28	)	O	['N']	[28]
29	,	O	['N']	[29]
30	few	O	['N']	[30]
31	case	O	['N']	[31]
32	reports	O	['N']	[32]
33	on	O	['N']	[33]
34	erlotinib	O	['N']	[34]
35	-	O	['N']	[35]
36	induced	O	['N']	[36]
37	ILD	O	['N']	[37]
38	have	O	['N']	[38]
39	been	O	['N']	[39]
40	issued	O	['N']	[40]
41	.	O	['N']	[41]
#582
0	Hepatotoxicity	B-Adverse_Effect	['N']	[0]
1	of	O	['N']	[1]
2	paracetamol	B-Drug	['Causes']	[0]
3	enhanced	O	['N']	[3]
4	by	O	['N']	[4]
5	ingestion	O	['N']	[5]
6	of	O	['N']	[6]
7	alcohol	O	['N']	[7]
8	:	O	['N']	[8]
9	report	O	['N']	[9]
10	of	O	['N']	[10]
11	two	O	['N']	[11]
12	cases	O	['N']	[12]
13	.	O	['N']	[13]
#583
0	We	O	['N']	[0]
1	describe	O	['N']	[1]
2	a	O	['N']	[2]
3	patient	O	['N']	[3]
4	who	O	['N']	[4]
5	developed	O	['N']	[5]
6	granulocytopenia	B-Adverse_Effect	['N']	[6]
7	and	O	['N']	[7]
8	fever	O	['N']	[8]
9	after	O	['N']	[9]
10	taking	O	['N']	[10]
11	dipyrone	B-Drug	['Causes']	[6]
12	and	O	['N']	[12]
13	discuss	O	['N']	[13]
14	the	O	['N']	[14]
15	available	O	['N']	[15]
16	literature	O	['N']	[16]
17	.	O	['N']	[17]
#584
0	The	O	['N']	[0]
1	patient	O	['N']	[1]
2	's	O	['N']	[2]
3	previous	O	['N']	[3]
4	rash	O	['N']	[4]
5	and	O	['N']	[5]
6	the	O	['N']	[6]
7	temporal	O	['N']	[7]
8	relation	O	['N']	[8]
9	of	O	['N']	[9]
10	this	O	['N']	[10]
11	event	O	['N']	[11]
12	and	O	['N']	[12]
13	the	O	['N']	[13]
14	ingestion	O	['N']	[14]
15	of	O	['N']	[15]
16	phenolphthalein	B-Drug	['Causes']	[37]
17	,	O	['N']	[17]
18	as	O	['N']	[18]
19	well	O	['N']	[19]
20	as	O	['N']	[20]
21	the	O	['N']	[21]
22	similarity	O	['N']	[22]
23	of	O	['N']	[23]
24	this	O	['N']	[24]
25	case	O	['N']	[25]
26	to	O	['N']	[26]
27	other	O	['N']	[27]
28	reports	O	['N']	[28]
29	,	O	['N']	[29]
30	point	O	['N']	[30]
31	to	O	['N']	[31]
32	phenolphthalein	O	['N']	[32]
33	as	O	['N']	[33]
34	the	O	['N']	[34]
35	cause	O	['N']	[35]
36	of	O	['N']	[36]
37	TEN	B-Adverse_Effect	['N']	[37]
38	in	O	['N']	[38]
39	this	O	['N']	[39]
40	patient	O	['N']	[40]
41	.	O	['N']	[41]
#585
0	A	O	['N']	[0]
1	fatal	B	['N']	[1]
2	pancytopenia	I-Adverse_Effect	['N']	[2]
3	occurred	O	['N']	[3]
4	in	O	['N']	[4]
5	a	O	['N']	[5]
6	patient	O	['N']	[6]
7	with	O	['N']	[7]
8	an	O	['N']	[8]
9	history	O	['N']	[9]
10	of	O	['N']	[10]
11	depression	O	['N']	[11]
12	with	O	['N']	[12]
13	hypomanic	O	['N']	[13]
14	rebounds	O	['N']	[14]
15	,	O	['N']	[15]
16	admitted	O	['N']	[16]
17	for	O	['N']	[17]
18	a	O	['N']	[18]
19	manic	O	['N']	[19]
20	episode	O	['N']	[20]
21	and	O	['N']	[21]
22	treated	O	['N']	[22]
23	with	O	['N']	[23]
24	levomepromazine	O	['N']	[24]
25	,	O	['N']	[25]
26	diazepam	B-Drug	['Causes']	[2]
27	and	O	['N']	[27]
28	lithium	O	['N']	[28]
29	carbonate	O	['N']	[29]
30	.	O	['N']	[30]
#586
0	Diarrhoea	B-Adverse_Effect	['N']	[0]
1	,	O	['N']	[1]
2	T	O	['N']	[2]
3	-	O	['N']	[3]
4	CD4	O	['N']	[4]
5	+	O	['N']	[5]
6	lymphopenia	O	['N']	[6]
7	and	O	['N']	[7]
8	bilateral	O	['N']	[8]
9	patchy	O	['N']	[9]
10	pulmonary	O	['N']	[10]
11	infiltrates	O	['N']	[11]
12	developed	O	['N']	[12]
13	in	O	['N']	[13]
14	a	O	['N']	[14]
15	male	O	['N']	[15]
16	60	O	['N']	[16]
17	yrs	O	['N']	[17]
18	of	O	['N']	[18]
19	age	O	['N']	[19]
20	,	O	['N']	[20]
21	who	O	['N']	[21]
22	was	O	['N']	[22]
23	treated	O	['N']	[23]
24	with	O	['N']	[24]
25	oxaliplatinum	B-Drug	['Causes']	[0]
26	and	O	['N']	[26]
27	5-fluorouracil	O	['N']	[27]
28	for	O	['N']	[28]
29	unresectable	O	['N']	[29]
30	rectum	O	['N']	[30]
31	carcinoma	O	['N']	[31]
32	.	O	['N']	[32]
#587
0	CONCLUSION	O	['N']	[0]
1	:	O	['N']	[1]
2	Healthcare	O	['N']	[2]
3	professionals	O	['N']	[3]
4	should	O	['N']	[4]
5	be	O	['N']	[5]
6	aware	O	['N']	[6]
7	of	O	['N']	[7]
8	the	O	['N']	[8]
9	possible	O	['N']	[9]
10	development	O	['N']	[10]
11	of	O	['N']	[11]
12	serotonin	B	['N']	[12]
13	syndrome	I-Adverse_Effect	['N']	[13]
14	as	O	['N']	[14]
15	a	O	['N']	[15]
16	complication	O	['N']	[16]
17	of	O	['N']	[17]
18	initiation	O	['N']	[18]
19	of	O	['N']	[19]
20	fentanyl	B-Drug	['Causes']	[13]
21	and	O	['N']	[21]
22	other	O	['N']	[22]
23	phenylpiperidine	O	['N']	[23]
24	opioids	O	['N']	[24]
25	in	O	['N']	[25]
26	patients	O	['N']	[26]
27	treated	O	['N']	[27]
28	with	O	['N']	[28]
29	SSRIs	O	['N']	[29]
30	.	O	['N']	[30]
#588
0	Moreover	O	['N']	[0]
1	,	O	['N']	[1]
2	these	O	['N']	[2]
3	findings	O	['N']	[3]
4	suggest	O	['N']	[4]
5	that	O	['N']	[5]
6	the	O	['N']	[6]
7	incidence	O	['N']	[7]
8	of	O	['N']	[8]
9	BOOP	B-Adverse_Effect	['N']	[9]
10	following	O	['N']	[10]
11	rituximab	B-Drug	['Causes']	[9]
12	therapy	O	['N']	[12]
13	may	O	['N']	[13]
14	be	O	['N']	[14]
15	higher	O	['N']	[15]
16	than	O	['N']	[16]
17	has	O	['N']	[17]
18	been	O	['N']	[18]
19	previously	O	['N']	[19]
20	appreciated	O	['N']	[20]
21	.	O	['N']	[21]
#589
0	A	O	['N']	[0]
1	further	O	['N']	[1]
2	case	O	['N']	[2]
3	of	O	['N']	[3]
4	anaphylactoid	B	['N']	[4]
5	reaction	I-Adverse_Effect	['N']	[5]
6	to	O	['N']	[6]
7	methylprednisolone	B-Drug	['Causes']	[5]
8	is	O	['N']	[8]
9	reported	O	['N']	[9]
10	.	O	['N']	[10]
#590
0	Fatal	B	['N']	[0]
1	interstitial	I	['N']	[1]
2	pneumonitis	I-Adverse_Effect	['N']	[2]
3	associated	O	['N']	[3]
4	with	O	['N']	[4]
5	docetaxel	B-Drug	['Causes']	[2]
6	administration	O	['N']	[6]
7	in	O	['N']	[7]
8	a	O	['N']	[8]
9	patient	O	['N']	[9]
10	with	O	['N']	[10]
11	hormone	O	['N']	[11]
12	-	O	['N']	[12]
13	refractory	O	['N']	[13]
14	prostate	O	['N']	[14]
15	cancer	O	['N']	[15]
16	.	O	['N']	[16]
#591
0	A	O	['N']	[0]
1	14-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	female	O	['N']	[4]
5	developed	O	['N']	[5]
6	systemic	B	['N']	[6]
7	lupus	I	['N']	[7]
8	erythematosus	I	['N']	[8]
9	(	I	['N']	[9]
10	SLE)-like	I	['N']	[10]
11	symptoms	I-Adverse_Effect	['N']	[11]
12	,	O	['N']	[12]
13	rash	O	['N']	[13]
14	,	O	['N']	[14]
15	fever	O	['N']	[15]
16	,	O	['N']	[16]
17	leukopenia	O	['N']	[17]
18	and	O	['N']	[18]
19	positive	O	['N']	[19]
20	anti	O	['N']	[20]
21	-	O	['N']	[21]
22	nuclear	O	['N']	[22]
23	antibody	O	['N']	[23]
24	(	O	['N']	[24]
25	ANA	O	['N']	[25]
26	)	O	['N']	[26]
27	two	O	['N']	[27]
28	weeks	O	['N']	[28]
29	after	O	['N']	[29]
30	administration	O	['N']	[30]
31	of	O	['N']	[31]
32	carbamazepine	O	['N']	[32]
33	(	O	['N']	[33]
34	CBZ	O	['N']	[34]
35	;	O	['N']	[35]
36	Tegretol	B-Drug	['Causes']	[11]
37	)	O	['N']	[37]
38	used	O	['N']	[38]
39	against	O	['N']	[39]
40	benign	O	['N']	[40]
41	Rolandic	O	['N']	[41]
42	epilepsy	O	['N']	[42]
43	.	O	['N']	[43]
#592
0	The	O	['N']	[0]
1	second	O	['N']	[1]
2	was	O	['N']	[2]
3	an	O	['N']	[3]
4	82-year	O	['N']	[4]
5	-	O	['N']	[5]
6	old	O	['N']	[6]
7	man	O	['N']	[7]
8	receiving	O	['N']	[8]
9	ticlopidine	B-Drug	['Causes']	[26]
10	for	O	['N']	[10]
11	2	O	['N']	[11]
12	years	O	['N']	[12]
13	when	O	['N']	[13]
14	,	O	['N']	[14]
15	during	O	['N']	[15]
16	a	O	['N']	[16]
17	febrile	O	['N']	[17]
18	episode	O	['N']	[18]
19	,	O	['N']	[19]
20	he	O	['N']	[20]
21	was	O	['N']	[21]
22	found	O	['N']	[22]
23	neutropenic	O	['N']	[23]
24	with	O	['N']	[24]
25	marrow	B	['N']	[25]
26	aplasia	I-Adverse_Effect	['N']	[26]
27	.	O	['N']	[27]
#593
0	It	O	['N']	[0]
1	is	O	['N']	[1]
2	presumed	O	['N']	[2]
3	that	O	['N']	[3]
4	her	O	['N']	[4]
5	hyperchloremic	B	['N']	[5]
6	metabolic	I	['N']	[6]
7	acidosis	I-Adverse_Effect	['N']	[7]
8	was	O	['N']	[8]
9	secondary	O	['N']	[9]
10	to	O	['N']	[10]
11	cholestyramine	B-Drug	['Causes']	[7]
12	because	O	['N']	[12]
13	of	O	['N']	[13]
14	the	O	['N']	[14]
15	similarity	O	['N']	[15]
16	to	O	['N']	[16]
17	pediatric	O	['N']	[17]
18	reports	O	['N']	[18]
19	;	O	['N']	[19]
20	the	O	['N']	[20]
21	rapid	O	['N']	[21]
22	and	O	['N']	[22]
23	lasting	O	['N']	[23]
24	response	O	['N']	[24]
25	to	O	['N']	[25]
26	intravenous	O	['N']	[26]
27	sodium	O	['N']	[27]
28	bicarbonate	O	['N']	[28]
29	;	O	['N']	[29]
30	the	O	['N']	[30]
31	absence	O	['N']	[31]
32	of	O	['N']	[32]
33	another	O	['N']	[33]
34	etiology	O	['N']	[34]
35	;	O	['N']	[35]
36	normal	O	['N']	[36]
37	serum	O	['N']	[37]
38	potassium	O	['N']	[38]
39	,	O	['N']	[39]
40	chloride	O	['N']	[40]
41	and	O	['N']	[41]
42	bicarbonate	O	['N']	[42]
43	despite	O	['N']	[43]
44	continued	O	['N']	[44]
45	spironolactone	O	['N']	[45]
46	therapy	O	['N']	[46]
47	after	O	['N']	[47]
48	recovery	O	['N']	[48]
49	.	O	['N']	[49]
#594
0	Massive	B	['N']	[0]
1	pulmonary	I	['N']	[1]
2	embolism	I-Adverse_Effect	['N']	[2]
3	complicating	O	['N']	[3]
4	streptokinase	B-Drug	['Causes']	[2]
5	treatment	O	['N']	[5]
6	for	O	['N']	[6]
7	deep	O	['N']	[7]
8	vein	O	['N']	[8]
9	thrombosis	O	['N']	[9]
10	.	O	['N']	[10]
#595
0	Our	O	['N']	[0]
1	patient	O	['N']	[1]
2	had	O	['N']	[2]
3	headache	O	['N']	[3]
4	,	O	['N']	[4]
5	mild	O	['N']	[5]
6	fever	O	['N']	[6]
7	,	O	['N']	[7]
8	nausea	O	['N']	[8]
9	,	O	['N']	[9]
10	vomiting	O	['N']	[10]
11	,	O	['N']	[11]
12	rash	O	['N']	[12]
13	,	O	['N']	[13]
14	and	O	['N']	[14]
15	eosinophilia	B-Adverse_Effect	['N']	[15]
16	after	O	['N']	[16]
17	3	O	['N']	[17]
18	weeks	O	['N']	[18]
19	of	O	['N']	[19]
20	disulfiram	B-Drug	['Causes']	[15]
21	therapy	O	['N']	[21]
22	.	O	['N']	[22]
#596
0	Inadvertent	O	['N']	[0]
1	and	O	['N']	[1]
2	accidental	O	['N']	[2]
3	epinephrine	B-Drug	['Dosage']	[4]
4	overdose	B-Dose	['N']	[4]
5	might	O	['N']	[5]
6	result	O	['N']	[6]
7	in	O	['N']	[7]
8	potentially	O	['N']	[8]
9	lethal	O	['N']	[9]
10	complications	O	['N']	[10]
11	.	O	['N']	[11]
#597
0	Drug	O	['N']	[0]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	psychosis	O	['N']	[3]
4	resulted	O	['N']	[4]
5	from	O	['N']	[5]
6	the	O	['N']	[6]
7	administration	O	['N']	[7]
8	of	O	['N']	[8]
9	quinacrine	B	['N']	[9]
10	hydrochloride	I-Drug	['Dosage']	[16]
11	at	O	['N']	[11]
12	a	O	['N']	[12]
13	dosage	O	['N']	[13]
14	of	O	['N']	[14]
15	100	B	['N']	[15]
16	mg	I-Dose	['N']	[16]
17	twice	O	['N']	[17]
18	daily	O	['N']	[18]
19	for	O	['N']	[19]
20	the	O	['N']	[20]
21	treatment	O	['N']	[21]
22	of	O	['N']	[22]
23	discoid	O	['N']	[23]
24	lupus	O	['N']	[24]
25	.	O	['N']	[25]
#598
0	FK506	B-Drug	['Causes']	[35]
1	,	O	['N']	[1]
2	which	O	['N']	[2]
3	began	O	['N']	[3]
4	to	O	['N']	[4]
5	be	O	['N']	[5]
6	administered	O	['N']	[6]
7	12	O	['N']	[7]
8	days	O	['N']	[8]
9	earlier	O	['N']	[9]
10	,	O	['N']	[10]
11	rose	O	['N']	[11]
12	to	O	['N']	[12]
13	a	O	['N']	[13]
14	level	O	['N']	[14]
15	of	O	['N']	[15]
16	44	O	['N']	[16]
17	ng	O	['N']	[17]
18	/	O	['N']	[18]
19	mL	O	['N']	[19]
20	(	O	['N']	[20]
21	normal	O	['N']	[21]
22	range	O	['N']	[22]
23	,	O	['N']	[23]
24	10	O	['N']	[24]
25	-	O	['N']	[25]
26	20	O	['N']	[26]
27	ng	O	['N']	[27]
28	/	O	['N']	[28]
29	mL	O	['N']	[29]
30	)	O	['N']	[30]
31	1	O	['N']	[31]
32	day	O	['N']	[32]
33	before	O	['N']	[33]
34	neurologic	B	['N']	[34]
35	abnormalities	I-Adverse_Effect	['N']	[35]
36	began	O	['N']	[36]
37	.	O	['N']	[37]
#599
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	the	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	a	O	['N']	[5]
6	patient	O	['N']	[6]
7	with	O	['N']	[7]
8	multiple	O	['N']	[8]
9	myeloma	O	['N']	[9]
10	who	O	['N']	[10]
11	developed	O	['N']	[11]
12	acute	O	['N']	[12]
13	life	O	['N']	[13]
14	-	O	['N']	[14]
15	threatening	O	['N']	[15]
16	water	O	['N']	[16]
17	intoxication	O	['N']	[17]
18	following	O	['N']	[18]
19	treatment	O	['N']	[19]
20	with	O	['N']	[20]
21	oral	O	['N']	[21]
22	indomethacin	B-Drug	['Dosage']	[25]
23	and	O	['N']	[23]
24	low	B	['N']	[24]
25	dose	I-Dose	['N']	[25]
26	intravenous	O	['N']	[26]
27	cyclophosphamide	O	['N']	[27]
28	.	O	['N']	[28]
#600
0	Two	O	['N']	[0]
1	children	O	['N']	[1]
2	with	O	['N']	[2]
3	rheumatic	O	['N']	[3]
4	fever	O	['N']	[4]
5	developed	O	['N']	[5]
6	anicteric	B	['N']	[6]
7	hepatitis	I-Adverse_Effect	['N']	[7]
8	while	O	['N']	[8]
9	on	O	['N']	[9]
10	high	O	['N']	[10]
11	-	O	['N']	[11]
12	dose	O	['N']	[12]
13	aspirin	B-Drug	['Causes']	[7]
14	therapy	O	['N']	[14]
15	.	O	['N']	[15]
#601
0	However	O	['N']	[0]
1	,	O	['N']	[1]
2	the	O	['N']	[2]
3	occurrence	O	['N']	[3]
4	and	O	['N']	[4]
5	management	O	['N']	[5]
6	of	O	['N']	[6]
7	akathisia	B-Adverse_Effect	['N']	[7]
8	induced	O	['N']	[8]
9	by	O	['N']	[9]
10	fluvoxamine	B-Drug	['Causes']	[7]
11	have	O	['N']	[11]
12	not	O	['N']	[12]
13	been	O	['N']	[13]
14	described	O	['N']	[14]
15	.	O	['N']	[15]
#602
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	interstitial	B	['N']	[5]
6	pulmonary	I	['N']	[6]
7	disease	I-Adverse_Effect	['N']	[7]
8	that	O	['N']	[8]
9	occurred	O	['N']	[9]
10	together	O	['N']	[10]
11	with	O	['N']	[11]
12	lymphocytic	O	['N']	[12]
13	colitis	O	['N']	[13]
14	during	O	['N']	[14]
15	treatment	O	['N']	[15]
16	with	O	['N']	[16]
17	ticlopidine	B-Drug	['Causes']	[7]
18	.	O	['N']	[18]
#603
0	DISCUSSION	O	['N']	[0]
1	:	O	['N']	[1]
2	After	O	['N']	[2]
3	exclusion	O	['N']	[3]
4	of	O	['N']	[4]
5	other	O	['N']	[5]
6	causes	O	['N']	[6]
7	,	O	['N']	[7]
8	the	O	['N']	[8]
9	onset	O	['N']	[9]
10	of	O	['N']	[10]
11	thrombocytopenia	O	['N']	[11]
12	after	O	['N']	[12]
13	administration	O	['N']	[13]
14	of	O	['N']	[14]
15	lansoprazole	B-Drug	['Causes']	[53]
16	,	O	['N']	[16]
17	the	O	['N']	[17]
18	resolution	O	['N']	[18]
19	of	O	['N']	[19]
20	the	O	['N']	[20]
21	adverse	O	['N']	[21]
22	reaction	O	['N']	[22]
23	after	O	['N']	[23]
24	discontinuation	O	['N']	[24]
25	of	O	['N']	[25]
26	the	O	['N']	[26]
27	drug	O	['N']	[27]
28	,	O	['N']	[28]
29	and	O	['N']	[29]
30	the	O	['N']	[30]
31	fact	O	['N']	[31]
32	that	O	['N']	[32]
33	no	O	['N']	[33]
34	other	O	['N']	[34]
35	medicines	O	['N']	[35]
36	were	O	['N']	[36]
37	introduced	O	['N']	[37]
38	during	O	['N']	[38]
39	this	O	['N']	[39]
40	time	O	['N']	[40]
41	frame	O	['N']	[41]
42	lead	O	['N']	[42]
43	us	O	['N']	[43]
44	to	O	['N']	[44]
45	believe	O	['N']	[45]
46	that	O	['N']	[46]
47	this	O	['N']	[47]
48	was	O	['N']	[48]
49	most	O	['N']	[49]
50	likely	O	['N']	[50]
51	an	O	['N']	[51]
52	idiosyncratic	O	['N']	[52]
53	thrombocytopenic	B-Adverse_Effect	['N']	[53]
54	response	O	['N']	[54]
55	to	O	['N']	[55]
56	lansoprazole	O	['N']	[56]
57	.	O	['N']	[57]
#604
0	Thus	O	['N']	[0]
1	,	O	['N']	[1]
2	tardive	B	['N']	[2]
3	seizures	I-Adverse_Effect	['N']	[3]
4	in	O	['N']	[4]
5	our	O	['N']	[5]
6	cases	O	['N']	[6]
7	are	O	['N']	[7]
8	thought	O	['N']	[8]
9	to	O	['N']	[9]
10	be	O	['N']	[10]
11	related	O	['N']	[11]
12	to	O	['N']	[12]
13	piperacillin	B-Drug	['Causes']	[3]
14	and	O	['N']	[14]
15	cefotiam	O	['N']	[15]
16	.	O	['N']	[16]
#605
0	Aplastic	B	['N']	[0]
1	anemia	I-Adverse_Effect	['N']	[1]
2	and	O	['N']	[2]
3	agranulocytosis	O	['N']	[3]
4	in	O	['N']	[4]
5	patients	O	['N']	[5]
6	using	O	['N']	[6]
7	methazolamide	B-Drug	['Causes']	[1]
8	for	O	['N']	[8]
9	glaucoma	O	['N']	[9]
10	.	O	['N']	[10]
#606
0	Both	O	['N']	[0]
1	colchicine	B-Drug	['Causes']	[9]
2	and	O	['N']	[2]
3	statin	O	['N']	[3]
4	therapy	O	['N']	[4]
5	may	O	['N']	[5]
6	be	O	['N']	[6]
7	associated	O	['N']	[7]
8	with	O	['N']	[8]
9	myopathy	B-Adverse_Effect	['N']	[9]
10	,	O	['N']	[10]
11	which	O	['N']	[11]
12	usually	O	['N']	[12]
13	occurs	O	['N']	[13]
14	after	O	['N']	[14]
15	several	O	['N']	[15]
16	months	O	['N']	[16]
17	of	O	['N']	[17]
18	therapy	O	['N']	[18]
19	.	O	['N']	[19]
#607
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	4	O	['N']	[2]
3	patients	O	['N']	[3]
4	,	O	['N']	[4]
5	2	O	['N']	[5]
6	on	O	['N']	[6]
7	methylphenidate	O	['N']	[7]
8	and	O	['N']	[8]
9	2	O	['N']	[9]
10	on	O	['N']	[10]
11	dextroamphetamine	B-Drug	['Causes']	[19]
12	who	O	['N']	[12]
13	presented	O	['N']	[13]
14	with	O	['N']	[14]
15	acral	O	['N']	[15]
16	cyanosis	O	['N']	[16]
17	,	O	['N']	[17]
18	livedo	B	['N']	[18]
19	reticularis	I-Adverse_Effect	['N']	[19]
20	,	O	['N']	[20]
21	or	O	['N']	[21]
22	Raynaud	O	['N']	[22]
23	phenomenon	O	['N']	[23]
24	.	O	['N']	[24]
#608
0	Schneiderian	B	['N']	[0]
1	first	I	['N']	[1]
2	-	I	['N']	[2]
3	rank	I	['N']	[3]
4	symptoms	I-Adverse_Effect	['N']	[4]
5	associated	O	['N']	[5]
6	with	O	['N']	[6]
7	fluvoxamine	B-Drug	['Causes']	[4]
8	treatment	O	['N']	[8]
9	:	O	['N']	[9]
10	a	O	['N']	[10]
11	case	O	['N']	[11]
12	report	O	['N']	[12]
13	.	O	['N']	[13]
#609
0	Our	O	['N']	[0]
1	patient	O	['N']	[1]
2	had	O	['N']	[2]
3	headache	O	['N']	[3]
4	,	O	['N']	[4]
5	mild	O	['N']	[5]
6	fever	O	['N']	[6]
7	,	O	['N']	[7]
8	nausea	O	['N']	[8]
9	,	O	['N']	[9]
10	vomiting	O	['N']	[10]
11	,	O	['N']	[11]
12	rash	B-Adverse_Effect	['N']	[12]
13	,	O	['N']	[13]
14	and	O	['N']	[14]
15	eosinophilia	O	['N']	[15]
16	after	O	['N']	[16]
17	3	O	['N']	[17]
18	weeks	O	['N']	[18]
19	of	O	['N']	[19]
20	disulfiram	B-Drug	['Causes']	[12]
21	therapy	O	['N']	[21]
22	.	O	['N']	[22]
#610
0	Ticlopidine	B-Drug	['Causes']	[4]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	aplastic	B	['N']	[3]
4	anemia	I-Adverse_Effect	['N']	[4]
5	(	O	['N']	[5]
6	TIAA	O	['N']	[6]
7	)	O	['N']	[7]
8	is	O	['N']	[8]
9	considered	O	['N']	[9]
10	very	O	['N']	[10]
11	uncommon	O	['N']	[11]
12	.	O	['N']	[12]
#611
0	A	O	['N']	[0]
1	71-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	man	O	['N']	[4]
5	with	O	['N']	[5]
6	paroxysmal	O	['N']	[6]
7	atrial	O	['N']	[7]
8	fibrillation	O	['N']	[8]
9	who	O	['N']	[9]
10	had	O	['N']	[10]
11	a	O	['N']	[11]
12	previous	O	['N']	[12]
13	anterior	O	['N']	[13]
14	myocardial	O	['N']	[14]
15	infarction	O	['N']	[15]
16	exhibited	O	['N']	[16]
17	granulocytopenia	O	['N']	[17]
18	8	O	['N']	[18]
19	days	O	['N']	[19]
20	following	O	['N']	[20]
21	the	O	['N']	[21]
22	administration	O	['N']	[22]
23	of	O	['N']	[23]
24	oral	O	['N']	[24]
25	sustained	O	['N']	[25]
26	-	O	['N']	[26]
27	release	O	['N']	[27]
28	procainamide	B-Drug	['Dosage']	[33]
29	(	O	['N']	[29]
30	750	B	['N']	[30]
31	mg	I	['N']	[31]
32	/	I	['N']	[32]
33	day	I-Dose	['N']	[33]
34	)	O	['N']	[34]
35	.	O	['N']	[35]
#612
0	Neutropenia	O	['N']	[0]
1	and	O	['N']	[1]
2	agranulocytosis	B-Adverse_Effect	['N']	[2]
3	are	O	['N']	[3]
4	risks	O	['N']	[4]
5	known	O	['N']	[5]
6	to	O	['N']	[6]
7	occur	O	['N']	[7]
8	with	O	['N']	[8]
9	phenothiazines	B-Drug	['Causes']	[2]
10	and	O	['N']	[10]
11	clozapine	O	['N']	[11]
12	.	O	['N']	[12]
#613
0	We	O	['N']	[0]
1	postulate	O	['N']	[1]
2	that	O	['N']	[2]
3	cyclosporin	O	['N']	[3]
4	,	O	['N']	[4]
5	possibly	O	['N']	[5]
6	together	O	['N']	[6]
7	with	O	['N']	[7]
8	ganciclovir	B-Drug	['Causes']	[21]
9	,	O	['N']	[9]
10	can	O	['N']	[10]
11	produce	O	['N']	[11]
12	transient	O	['N']	[12]
13	brain	O	['N']	[13]
14	stem	O	['N']	[14]
15	or	O	['N']	[15]
16	neuromuscular	O	['N']	[16]
17	dysfunction	O	['N']	[17]
18	with	O	['N']	[18]
19	eye	B	['N']	[19]
20	movement	I	['N']	[20]
21	abnormality	I-Adverse_Effect	['N']	[21]
22	in	O	['N']	[22]
23	occasional	O	['N']	[23]
24	patients	O	['N']	[24]
25	.	O	['N']	[25]
#614
0	Methamphetamine	B-Drug	['Causes']	[22]
1	's	O	['N']	[1]
2	extensive	O	['N']	[2]
3	physiologic	O	['N']	[3]
4	effects	O	['N']	[4]
5	,	O	['N']	[5]
6	inconsistent	O	['N']	[6]
7	street	O	['N']	[7]
8	purity	O	['N']	[8]
9	,	O	['N']	[9]
10	and	O	['N']	[10]
11	multiple	O	['N']	[11]
12	routes	O	['N']	[12]
13	of	O	['N']	[13]
14	administration	O	['N']	[14]
15	offer	O	['N']	[15]
16	many	O	['N']	[16]
17	possibilities	O	['N']	[17]
18	for	O	['N']	[18]
19	injury	B	['N']	[19]
20	to	I	['N']	[20]
21	the	I	['N']	[21]
22	cornea	I-Adverse_Effect	['N']	[22]
23	.	O	['N']	[23]
#615
0	Toxic	O	['N']	[0]
1	epidermal	O	['N']	[1]
2	necrolysis	O	['N']	[2]
3	after	O	['N']	[3]
4	the	O	['N']	[4]
5	use	O	['N']	[5]
6	of	O	['N']	[6]
7	high	B-Dose	['N']	[7]
8	-	O	['N']	[8]
9	dose	O	['N']	[9]
10	cytosine	B	['N']	[10]
11	arabinoside	I-Drug	['Dosage']	[7]
12	.	O	['N']	[12]
#616
0	It	O	['N']	[0]
1	was	O	['N']	[1]
2	concluded	O	['N']	[2]
3	that	O	['N']	[3]
4	potassium	O	['N']	[4]
5	loss	O	['N']	[5]
6	occurred	O	['N']	[6]
7	by	O	['N']	[7]
8	a	O	['N']	[8]
9	non	O	['N']	[9]
10	-	O	['N']	[10]
11	renal	O	['N']	[11]
12	(	O	['N']	[12]
13	intestinal	O	['N']	[13]
14	)	O	['N']	[14]
15	route	O	['N']	[15]
16	in	O	['N']	[16]
17	phosphate	B-Drug	['Causes']	[20]
18	-	O	['N']	[18]
19	induced	O	['N']	[19]
20	hypokalemia	B-Adverse_Effect	['N']	[20]
21	.	O	['N']	[21]
#617
0	Due	O	['N']	[0]
1	to	O	['N']	[1]
2	the	O	['N']	[2]
3	increasing	O	['N']	[3]
4	use	O	['N']	[4]
5	of	O	['N']	[5]
6	TMP	B	['N']	[6]
7	-	I	['N']	[7]
8	SMX	I-Drug	['Causes']	[25]
9	in	O	['N']	[9]
10	children	O	['N']	[10]
11	,	O	['N']	[11]
12	clinicians	O	['N']	[12]
13	should	O	['N']	[13]
14	be	O	['N']	[14]
15	aware	O	['N']	[15]
16	of	O	['N']	[16]
17	this	O	['N']	[17]
18	potentially	O	['N']	[18]
19	life	O	['N']	[19]
20	-	O	['N']	[20]
21	threatening	O	['N']	[21]
22	,	O	['N']	[22]
23	immunemediated	B	['N']	[23]
24	hypersensitivity	I	['N']	[24]
25	reaction	I-Adverse_Effect	['N']	[25]
26	.	O	['N']	[26]
#618
0	Postoperatively	O	['N']	[0]
1	,	O	['N']	[1]
2	the	O	['N']	[2]
3	first	O	['N']	[3]
4	two	O	['N']	[4]
5	patients	O	['N']	[5]
6	treated	O	['N']	[6]
7	with	O	['N']	[7]
8	1	O	['N']	[8]
9	to	O	['N']	[9]
10	2	O	['N']	[10]
11	cc	O	['N']	[11]
12	of	O	['N']	[12]
13	thrombin	B-Drug	['Causes']	[31]
14	were	O	['N']	[14]
15	slow	O	['N']	[15]
16	to	O	['N']	[16]
17	awaken	O	['N']	[17]
18	;	O	['N']	[18]
19	one	O	['N']	[19]
20	had	O	['N']	[20]
21	evidence	O	['N']	[21]
22	of	O	['N']	[22]
23	vasospasm	O	['N']	[23]
24	by	O	['N']	[24]
25	transcranial	O	['N']	[25]
26	Doppler	O	['N']	[26]
27	ultrasound	O	['N']	[27]
28	studies	O	['N']	[28]
29	and	O	['N']	[29]
30	multiple	B	['N']	[30]
31	infarcts	I-Adverse_Effect	['N']	[31]
32	on	O	['N']	[32]
33	cranial	O	['N']	[33]
34	computerized	O	['N']	[34]
35	tomography	O	['N']	[35]
36	,	O	['N']	[36]
37	while	O	['N']	[37]
38	the	O	['N']	[38]
39	other	O	['N']	[39]
40	had	O	['N']	[40]
41	a	O	['N']	[41]
42	moderate	O	['N']	[42]
43	-	O	['N']	[43]
44	sized	O	['N']	[44]
45	frontal	O	['N']	[45]
46	hematoma	O	['N']	[46]
47	with	O	['N']	[47]
48	intracranial	O	['N']	[48]
49	hypertension	O	['N']	[49]
50	.	O	['N']	[50]
#619
0	In	O	['N']	[0]
1	both	O	['N']	[1]
2	cases	O	['N']	[2]
3	,	O	['N']	[3]
4	high	O	['N']	[4]
5	fever	O	['N']	[5]
6	,	O	['N']	[6]
7	skin	O	['N']	[7]
8	rash	O	['N']	[8]
9	,	O	['N']	[9]
10	liver	O	['N']	[10]
11	dysfunction	O	['N']	[11]
12	and	O	['N']	[12]
13	atypical	B	['N']	[13]
14	lymphocytosis	I-Adverse_Effect	['N']	[14]
15	developed	O	['N']	[15]
16	3	O	['N']	[16]
17	weeks	O	['N']	[17]
18	after	O	['N']	[18]
19	initiating	O	['N']	[19]
20	treatment	O	['N']	[20]
21	with	O	['N']	[21]
22	SASP	B-Drug	['Causes']	[14]
23	.	O	['N']	[23]
#620
0	Though	O	['N']	[0]
1	they	O	['N']	[1]
2	are	O	['N']	[2]
3	generally	O	['N']	[3]
4	considered	O	['N']	[4]
5	safe	O	['N']	[5]
6	,	O	['N']	[6]
7	there	O	['N']	[7]
8	have	O	['N']	[8]
9	been	O	['N']	[9]
10	a	O	['N']	[10]
11	few	O	['N']	[11]
12	reports	O	['N']	[12]
13	of	O	['N']	[13]
14	myocardial	B	['N']	[14]
15	infarction	I-Adverse_Effect	['N']	[15]
16	and	O	['N']	[16]
17	stroke	O	['N']	[17]
18	associated	O	['N']	[18]
19	with	O	['N']	[19]
20	triptan	B-Drug	['Causes']	[15]
21	use	O	['N']	[21]
22	.	O	['N']	[22]
#621
0	However	O	['N']	[0]
1	,	O	['N']	[1]
2	one	O	['N']	[2]
3	patient	O	['N']	[3]
4	exhibited	O	['N']	[4]
5	severe	B	['N']	[5]
6	hypersensitivity	I	['N']	[6]
7	reactions	I-Adverse_Effect	['N']	[7]
8	including	O	['N']	[8]
9	cardiac	O	['N']	[9]
10	arrest	O	['N']	[10]
11	and	O	['N']	[11]
12	apnea	O	['N']	[12]
13	,	O	['N']	[13]
14	and	O	['N']	[14]
15	another	O	['N']	[15]
16	four	O	['N']	[16]
17	patients	O	['N']	[17]
18	developed	O	['N']	[18]
19	eruptions	O	['N']	[19]
20	,	O	['N']	[20]
21	hypotension	O	['N']	[21]
22	,	O	['N']	[22]
23	and	O	['N']	[23]
24	tachycardia	O	['N']	[24]
25	soon	O	['N']	[25]
26	after	O	['N']	[26]
27	administration	O	['N']	[27]
28	of	O	['N']	[28]
29	CBDCA	B-Drug	['Causes']	[7]
30	.	O	['N']	[30]
#622
0	We	O	['N']	[0]
1	conjectured	O	['N']	[1]
2	that	O	['N']	[2]
3	the	O	['N']	[3]
4	side	O	['N']	[4]
5	effects	O	['N']	[5]
6	of	O	['N']	[6]
7	insulin	B-Drug	['Causes']	[34]
8	,	O	['N']	[8]
9	such	O	['N']	[9]
10	as	O	['N']	[10]
11	anti	O	['N']	[11]
12	-	O	['N']	[12]
13	natriuresis	O	['N']	[13]
14	and	O	['N']	[14]
15	increased	O	['N']	[15]
16	vascular	O	['N']	[16]
17	permeability	O	['N']	[17]
18	,	O	['N']	[18]
19	might	O	['N']	[19]
20	be	O	['N']	[20]
21	pronounced	O	['N']	[21]
22	in	O	['N']	[22]
23	the	O	['N']	[23]
24	presence	O	['N']	[24]
25	of	O	['N']	[25]
26	the	O	['N']	[26]
27	hepatic	O	['N']	[27]
28	dysfunction	O	['N']	[28]
29	that	O	['N']	[29]
30	accompanies	O	['N']	[30]
31	insulin	O	['N']	[31]
32	insensitivity	O	['N']	[32]
33	,	O	['N']	[33]
34	hyperinsulinaemia	B-Adverse_Effect	['N']	[34]
35	and	O	['N']	[35]
36	hypoalbuminaemia	O	['N']	[36]
37	.	O	['N']	[37]
#623
0	CONCLUSIONS	O	['N']	[0]
1	:	O	['N']	[1]
2	Clinicians	O	['N']	[2]
3	should	O	['N']	[3]
4	be	O	['N']	[4]
5	aware	O	['N']	[5]
6	of	O	['N']	[6]
7	a	O	['N']	[7]
8	risk	O	['N']	[8]
9	of	O	['N']	[9]
10	serotonin	O	['N']	[10]
11	syndrome	O	['N']	[11]
12	with	O	['N']	[12]
13	serious	O	['N']	[13]
14	extrapyramidal	O	['N']	[14]
15	reactions	O	['N']	[15]
16	in	O	['N']	[16]
17	patients	O	['N']	[17]
18	receiving	O	['N']	[18]
19	sertraline	O	['N']	[19]
20	or	O	['N']	[20]
21	venlafaxine	O	['N']	[21]
22	when	O	['N']	[22]
23	metoclopramide	B-Drug	['Dosage']	[31]
24	is	O	['N']	[24]
25	coadministered	O	['N']	[25]
26	even	O	['N']	[26]
27	in	O	['N']	[27]
28	a	O	['N']	[28]
29	single	O	['N']	[29]
30	,	O	['N']	[30]
31	conventional	B-Dose	['N']	[31]
32	dose	O	['N']	[32]
33	.	O	['N']	[33]
#624
0	Retrospectively	O	['N']	[0]
1	,	O	['N']	[1]
2	bucillamine	B-Drug	['Causes']	[12]
3	was	O	['N']	[3]
4	believed	O	['N']	[4]
5	to	O	['N']	[5]
6	be	O	['N']	[6]
7	the	O	['N']	[7]
8	cause	O	['N']	[8]
9	of	O	['N']	[9]
10	the	O	['N']	[10]
11	giant	B	['N']	[11]
12	hypertrophy	I-Adverse_Effect	['N']	[12]
13	because	O	['N']	[13]
14	of	O	['N']	[14]
15	its	O	['N']	[15]
16	structural	O	['N']	[16]
17	similarity	O	['N']	[17]
18	to	O	['N']	[18]
19	D	O	['N']	[19]
20	-	O	['N']	[20]
21	penicillamine	O	['N']	[21]
22	,	O	['N']	[22]
23	which	O	['N']	[23]
24	was	O	['N']	[24]
25	the	O	['N']	[25]
26	subject	O	['N']	[26]
27	of	O	['N']	[27]
28	an	O	['N']	[28]
29	abundance	O	['N']	[29]
30	of	O	['N']	[30]
31	reports	O	['N']	[31]
32	of	O	['N']	[32]
33	mammary	O	['N']	[33]
34	hyperplasia	O	['N']	[34]
35	.	O	['N']	[35]
#625
0	The	O	['N']	[0]
1	clinical	O	['N']	[1]
2	aspect	O	['N']	[2]
3	closely	O	['N']	[3]
4	resembled	O	['N']	[4]
5	classical	O	['N']	[5]
6	transient	B	['N']	[6]
7	global	I	['N']	[7]
8	amnesia	I-Adverse_Effect	['N']	[8]
9	but	O	['N']	[9]
10	the	O	['N']	[10]
11	episode	O	['N']	[11]
12	after	O	['N']	[12]
13	clioquinol	B-Drug	['Causes']	[8]
14	lasted	O	['N']	[14]
15	longer	O	['N']	[15]
16	(	O	['N']	[16]
17	24	O	['N']	[17]
18	hours	O	['N']	[18]
19	to	O	['N']	[19]
20	three	O	['N']	[20]
21	days	O	['N']	[21]
22	)	O	['N']	[22]
23	and	O	['N']	[23]
24	a	O	['N']	[24]
25	more	O	['N']	[25]
26	or	O	['N']	[26]
27	less	O	['N']	[27]
28	extensive	O	['N']	[28]
29	retrograde	O	['N']	[29]
30	amnesia	O	['N']	[30]
31	persisted	O	['N']	[31]
32	permanently	O	['N']	[32]
33	.	O	['N']	[33]
#626
0	Four	O	['N']	[0]
1	days	O	['N']	[1]
2	after	O	['N']	[2]
3	the	O	['N']	[3]
4	initial	O	['N']	[4]
5	injection	O	['N']	[5]
6	of	O	['N']	[6]
7	3.6	O	['N']	[7]
8	mg	O	['N']	[8]
9	of	O	['N']	[9]
10	goserelin	B	['N']	[10]
11	acetate	I-Drug	['Causes']	[29]
12	,	O	['N']	[12]
13	severe	O	['N']	[13]
14	dyspnea	O	['N']	[14]
15	developed	O	['N']	[15]
16	due	O	['N']	[16]
17	to	O	['N']	[17]
18	worsening	O	['N']	[18]
19	pleuritis	O	['N']	[19]
20	carcinomatosa	O	['N']	[20]
21	,	O	['N']	[21]
22	which	O	['N']	[22]
23	was	O	['N']	[23]
24	considered	O	['N']	[24]
25	as	O	['N']	[25]
26	a	O	['N']	[26]
27	flare	B	['N']	[27]
28	-	I	['N']	[28]
29	up	I-Adverse_Effect	['N']	[29]
30	.	O	['N']	[30]
#627
0	Three	O	['N']	[0]
1	cases	O	['N']	[1]
2	of	O	['N']	[2]
3	acute	B	['N']	[3]
4	renal	I	['N']	[4]
5	toxicity	I-Adverse_Effect	['N']	[5]
6	in	O	['N']	[6]
7	patients	O	['N']	[7]
8	receiving	O	['N']	[8]
9	long	O	['N']	[9]
10	-	O	['N']	[10]
11	term	O	['N']	[11]
12	therapy	O	['N']	[12]
13	with	O	['N']	[13]
14	mitomycin	B	['N']	[14]
15	C	I-Drug	['Causes']	[5]
16	and	O	['N']	[16]
17	5-fluorouracil	O	['N']	[17]
18	are	O	['N']	[18]
19	reported	O	['N']	[19]
20	.	O	['N']	[20]
#628
0	OBJECTIVE	O	['N']	[0]
1	:	O	['N']	[1]
2	To	O	['N']	[2]
3	report	O	['N']	[3]
4	the	O	['N']	[4]
5	occurrence	O	['N']	[5]
6	of	O	['N']	[6]
7	acute	B	['N']	[7]
8	cytolytic	I	['N']	[8]
9	hepatitis	I-Adverse_Effect	['N']	[9]
10	in	O	['N']	[10]
11	a	O	['N']	[11]
12	patient	O	['N']	[12]
13	exposed	O	['N']	[13]
14	to	O	['N']	[14]
15	pulse	O	['N']	[15]
16	itraconazole	B-Drug	['Causes']	[9]
17	therapy	O	['N']	[17]
18	for	O	['N']	[18]
19	24	O	['N']	[19]
20	weeks	O	['N']	[20]
21	and	O	['N']	[21]
22	provide	O	['N']	[22]
23	a	O	['N']	[23]
24	concise	O	['N']	[24]
25	review	O	['N']	[25]
26	of	O	['N']	[26]
27	the	O	['N']	[27]
28	literature	O	['N']	[28]
29	on	O	['N']	[29]
30	cases	O	['N']	[30]
31	of	O	['N']	[31]
32	itraconazole	O	['N']	[32]
33	-	O	['N']	[33]
34	induced	O	['N']	[34]
35	hepatitis	O	['N']	[35]
36	.	O	['N']	[36]
#629
0	Severe	B	['N']	[0]
1	hepatotoxicity	I-Adverse_Effect	['N']	[1]
2	related	O	['N']	[2]
3	to	O	['N']	[3]
4	benzarone	B-Drug	['Causes']	[1]
5	:	O	['N']	[5]
6	a	O	['N']	[6]
7	report	O	['N']	[7]
8	of	O	['N']	[8]
9	three	O	['N']	[9]
10	cases	O	['N']	[10]
11	with	O	['N']	[11]
12	two	O	['N']	[12]
13	fatalities	O	['N']	[13]
14	.	O	['N']	[14]
#630
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	patient	O	['N']	[3]
4	with	O	['N']	[4]
5	pulmonary	O	['N']	[5]
6	adenocarcinoma	O	['N']	[6]
7	complicated	O	['N']	[7]
8	by	O	['N']	[8]
9	the	O	['N']	[9]
10	syndrome	B	['N']	[10]
11	of	I	['N']	[11]
12	inappropriate	I	['N']	[12]
13	secretion	I	['N']	[13]
14	of	I	['N']	[14]
15	antidiuretic	I	['N']	[15]
16	hormone	I-Adverse_Effect	['N']	[16]
17	(	O	['N']	[17]
18	SIADH	O	['N']	[18]
19	)	O	['N']	[19]
20	following	O	['N']	[20]
21	systemic	O	['N']	[21]
22	chemotherapy	O	['N']	[22]
23	with	O	['N']	[23]
24	cisplatin	O	['N']	[24]
25	(	O	['N']	[25]
26	CDDP	O	['N']	[26]
27	)	O	['N']	[27]
28	and	O	['N']	[28]
29	vindesine	B-Drug	['Causes']	[16]
30	(	O	['N']	[30]
31	VDS	O	['N']	[31]
32	)	O	['N']	[32]
33	.	O	['N']	[33]
#631
0	In	O	['N']	[0]
1	addition	O	['N']	[1]
2	,	O	['N']	[2]
3	there	O	['N']	[3]
4	is	O	['N']	[4]
5	a	O	['N']	[5]
6	report	O	['N']	[6]
7	on	O	['N']	[7]
8	prolonged	B	['N']	[8]
9	ECT	I	['N']	[9]
10	seizure	I-Adverse_Effect	['N']	[10]
11	related	O	['N']	[11]
12	to	O	['N']	[12]
13	ciprofloxacin	B-Drug	['Causes']	[10]
14	,	O	['N']	[14]
15	which	O	['N']	[15]
16	has	O	['N']	[16]
17	an	O	['N']	[17]
18	epileptogenic	O	['N']	[18]
19	property	O	['N']	[19]
20	with	O	['N']	[20]
21	a	O	['N']	[21]
22	similar	O	['N']	[22]
23	action	O	['N']	[23]
24	to	O	['N']	[24]
25	beta	O	['N']	[25]
26	-	O	['N']	[26]
27	lactam	O	['N']	[27]
28	antibiotics	O	['N']	[28]
29	.	O	['N']	[29]
#632
0	Toxicity	B-Adverse_Effect	['N']	[0]
1	,	O	['N']	[1]
2	pharmacokinetics	O	['N']	[2]
3	,	O	['N']	[3]
4	and	O	['N']	[4]
5	in	O	['N']	[5]
6	vitro	O	['N']	[6]
7	hemodialysis	O	['N']	[7]
8	clearance	O	['N']	[8]
9	of	O	['N']	[9]
10	ifosfamide	B-Drug	['Causes']	[0]
11	and	O	['N']	[11]
12	metabolites	O	['N']	[12]
13	in	O	['N']	[13]
14	an	O	['N']	[14]
15	anephric	O	['N']	[15]
16	pediatric	O	['N']	[16]
17	patient	O	['N']	[17]
18	with	O	['N']	[18]
19	Wilms	O	['N']	[19]
20	'	O	['N']	[20]
21	tumor	O	['N']	[21]
22	.	O	['N']	[22]
#633
0	Colonic	B	['N']	[0]
1	necrosis	I-Adverse_Effect	['N']	[1]
2	is	O	['N']	[2]
3	known	O	['N']	[3]
4	as	O	['N']	[4]
5	a	O	['N']	[5]
6	rare	O	['N']	[6]
7	complication	O	['N']	[7]
8	following	O	['N']	[8]
9	the	O	['N']	[9]
10	administration	O	['N']	[10]
11	of	O	['N']	[11]
12	Kayexalate	B-Drug	['Causes']	[1]
13	(	O	['N']	[13]
14	sodium	O	['N']	[14]
15	polystryrene	O	['N']	[15]
16	sulfonate	O	['N']	[16]
17	)	O	['N']	[17]
18	in	O	['N']	[18]
19	sorbitol	O	['N']	[19]
20	.	O	['N']	[20]
#634
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	fatal	B	['N']	[5]
6	fulminant	I	['N']	[6]
7	hepatitis	I-Adverse_Effect	['N']	[7]
8	caused	O	['N']	[8]
9	by	O	['N']	[9]
10	the	O	['N']	[10]
11	use	O	['N']	[11]
12	of	O	['N']	[12]
13	disulfiram	B-Drug	['Causes']	[7]
14	in	O	['N']	[14]
15	a	O	['N']	[15]
16	man	O	['N']	[16]
17	with	O	['N']	[17]
18	previously	O	['N']	[18]
19	normal	O	['N']	[19]
20	hepatocellular	O	['N']	[20]
21	function	O	['N']	[21]
22	.	O	['N']	[22]
#635
0	A	O	['N']	[0]
1	case	O	['N']	[1]
2	of	O	['N']	[2]
3	mania	B-Adverse_Effect	['N']	[3]
4	associated	O	['N']	[4]
5	with	O	['N']	[5]
6	fluoxetine	B-Drug	['Causes']	[3]
7	.	O	['N']	[7]
#636
0	DATA	O	['N']	[0]
1	SYNTHESIS	O	['N']	[1]
2	:	O	['N']	[2]
3	Genetic	O	['N']	[3]
4	deficiencies	O	['N']	[4]
5	in	O	['N']	[5]
6	DPD	O	['N']	[6]
7	,	O	['N']	[7]
8	the	O	['N']	[8]
9	rate	O	['N']	[9]
10	-	O	['N']	[10]
11	limiting	O	['N']	[11]
12	enzyme	O	['N']	[12]
13	responsible	O	['N']	[13]
14	for	O	['N']	[14]
15	5-FU	B-Drug	['Causes']	[44]
16	catabolism	O	['N']	[16]
17	,	O	['N']	[17]
18	may	O	['N']	[18]
19	occur	O	['N']	[19]
20	in	O	['N']	[20]
21	3	O	['N']	[21]
22	%	O	['N']	[22]
23	or	O	['N']	[23]
24	more	O	['N']	[24]
25	of	O	['N']	[25]
26	patients	O	['N']	[26]
27	with	O	['N']	[27]
28	cancer	O	['N']	[28]
29	putting	O	['N']	[29]
30	them	O	['N']	[30]
31	at	O	['N']	[31]
32	increased	O	['N']	[32]
33	risk	O	['N']	[33]
34	for	O	['N']	[34]
35	unusually	O	['N']	[35]
36	severe	O	['N']	[36]
37	adverse	O	['N']	[37]
38	reactions	O	['N']	[38]
39	(	O	['N']	[39]
40	e.g.	O	['N']	[40]
41	,	O	['N']	[41]
42	diarrhea	O	['N']	[42]
43	,	O	['N']	[43]
44	stomatitis	B-Adverse_Effect	['N']	[44]
45	,	O	['N']	[45]
46	mucositis	O	['N']	[46]
47	,	O	['N']	[47]
48	myelosuppression	O	['N']	[48]
49	,	O	['N']	[49]
50	neurotoxicity	O	['N']	[50]
51	)	O	['N']	[51]
52	to	O	['N']	[52]
53	standard	O	['N']	[53]
54	doses	O	['N']	[54]
55	of	O	['N']	[55]
56	5-FU	O	['N']	[56]
57	.	O	['N']	[57]
#637
0	This	O	['N']	[0]
1	report	O	['N']	[1]
2	describes	O	['N']	[2]
3	a	O	['N']	[3]
4	case	O	['N']	[4]
5	of	O	['N']	[5]
6	paradoxical	O	['N']	[6]
7	,	O	['N']	[7]
8	intravenous	O	['N']	[8]
9	valproic	B	['N']	[9]
10	acid	I-Drug	['Causes']	[14]
11	-	O	['N']	[11]
12	induced	O	['N']	[12]
13	seizure	B	['N']	[13]
14	exacerbation	I-Adverse_Effect	['N']	[14]
15	in	O	['N']	[15]
16	a	O	['N']	[16]
17	child	O	['N']	[17]
18	with	O	['N']	[18]
19	juvenile	O	['N']	[19]
20	absence	O	['N']	[20]
21	epilepsy	O	['N']	[21]
22	,	O	['N']	[22]
23	documented	O	['N']	[23]
24	by	O	['N']	[24]
25	video	O	['N']	[25]
26	-	O	['N']	[26]
27	electroencephalography	O	['N']	[27]
28	.	O	['N']	[28]
#638
0	ARDS	B-Adverse_Effect	['N']	[0]
1	has	O	['N']	[1]
2	been	O	['N']	[2]
3	associated	O	['N']	[3]
4	with	O	['N']	[4]
5	the	O	['N']	[5]
6	administration	O	['N']	[6]
7	of	O	['N']	[7]
8	other	O	['N']	[8]
9	monoclonal	O	['N']	[9]
10	antibodies	O	['N']	[10]
11	,	O	['N']	[11]
12	such	O	['N']	[12]
13	as	O	['N']	[13]
14	infliximab	B-Drug	['Causes']	[0]
15	,	O	['N']	[15]
16	gemtuzumab	O	['N']	[16]
17	ozogamicin	O	['N']	[17]
18	,	O	['N']	[18]
19	and	O	['N']	[19]
20	OKT3	O	['N']	[20]
21	and	O	['N']	[21]
22	is	O	['N']	[22]
23	believed	O	['N']	[23]
24	to	O	['N']	[24]
25	be	O	['N']	[25]
26	directly	O	['N']	[26]
27	mediated	O	['N']	[27]
28	by	O	['N']	[28]
29	release	O	['N']	[29]
30	of	O	['N']	[30]
31	proinflammatory	O	['N']	[31]
32	cytokines	O	['N']	[32]
33	.	O	['N']	[33]
#639
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	3	O	['N']	[2]
3	patients	O	['N']	[3]
4	with	O	['N']	[4]
5	severe	O	['N']	[5]
6	hepatocellular	O	['N']	[6]
7	damage	O	['N']	[7]
8	due	O	['N']	[8]
9	to	O	['N']	[9]
10	CPA	B-Drug	['Causes']	[17]
11	therapy	O	['N']	[11]
12	,	O	['N']	[12]
13	2	O	['N']	[13]
14	with	O	['N']	[14]
15	fatal	B	['N']	[15]
16	fulminant	I	['N']	[16]
17	hepatitis	I-Adverse_Effect	['N']	[17]
18	.	O	['N']	[18]
#640
0	Severe	B	['N']	[0]
1	apnea	I-Adverse_Effect	['N']	[1]
2	in	O	['N']	[2]
3	an	O	['N']	[3]
4	infant	O	['N']	[4]
5	exposed	O	['N']	[5]
6	to	O	['N']	[6]
7	lamotrigine	B-Drug	['Causes']	[1]
8	in	O	['N']	[8]
9	breast	O	['N']	[9]
10	milk	O	['N']	[10]
11	.	O	['N']	[11]
#641
0	This	O	['N']	[0]
1	report	O	['N']	[1]
2	describes	O	['N']	[2]
3	two	O	['N']	[3]
4	patients	O	['N']	[4]
5	who	O	['N']	[5]
6	developed	O	['N']	[6]
7	acute	B	['N']	[7]
8	myelocytic	I	['N']	[8]
9	leukemia	I-Adverse_Effect	['N']	[9]
10	only	O	['N']	[10]
11	after	O	['N']	[11]
12	exposure	O	['N']	[12]
13	to	O	['N']	[13]
14	cyclophosphamide	B-Drug	['Causes']	[9]
15	,	O	['N']	[15]
16	methotrexate	O	['N']	[16]
17	,	O	['N']	[17]
18	and	O	['N']	[18]
19	5-fluorouracil	O	['N']	[19]
20	adjuvant	O	['N']	[20]
21	therapy	O	['N']	[21]
22	.	O	['N']	[22]
#642
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	Stevens	O	['N']	[5]
6	-	O	['N']	[6]
7	Johnson	O	['N']	[7]
8	syndrome	O	['N']	[8]
9	/	O	['N']	[9]
10	toxic	O	['N']	[10]
11	epidermal	O	['N']	[11]
12	necrolysis	O	['N']	[12]
13	(	O	['N']	[13]
14	SJS	O	['N']	[14]
15	/	O	['N']	[15]
16	TEN	B-Adverse_Effect	['N']	[16]
17	)	O	['N']	[17]
18	secondary	O	['N']	[18]
19	to	O	['N']	[19]
20	trimethoprim	B	['N']	[20]
21	-	I	['N']	[21]
22	sulfamethoxazole	I-Drug	['Causes']	[16]
23	(	O	['N']	[23]
24	TMP	O	['N']	[24]
25	-	O	['N']	[25]
26	Sx	O	['N']	[26]
27	)	O	['N']	[27]
28	therapy	O	['N']	[28]
29	for	O	['N']	[29]
30	presumed	O	['N']	[30]
31	community	O	['N']	[31]
32	-	O	['N']	[32]
33	associated	O	['N']	[33]
34	methicillin	O	['N']	[34]
35	-	O	['N']	[35]
36	resistant	O	['N']	[36]
37	Staphylococcus	O	['N']	[37]
38	aureus	O	['N']	[38]
39	(	O	['N']	[39]
40	CA	O	['N']	[40]
41	-	O	['N']	[41]
42	MRSA	O	['N']	[42]
43	)	O	['N']	[43]
44	infection	O	['N']	[44]
45	.	O	['N']	[45]
#643
0	Intravenous	O	['N']	[0]
1	verapamil	O	['N']	[1]
2	therapy	O	['N']	[2]
3	in	O	['N']	[3]
4	babies	O	['N']	[4]
5	may	O	['N']	[5]
6	cause	O	['N']	[6]
7	apnea	B-Adverse_Effect	['N']	[7]
8	,	O	['N']	[8]
9	hypotension	O	['N']	[9]
10	,	O	['N']	[10]
11	and	O	['N']	[11]
12	bradycardia	O	['N']	[12]
13	;	O	['N']	[13]
14	continued	O	['N']	[14]
15	episodes	O	['N']	[15]
16	of	O	['N']	[16]
17	atrial	O	['N']	[17]
18	flutter	O	['N']	[18]
19	in	O	['N']	[19]
20	a	O	['N']	[20]
21	child	O	['N']	[21]
22	may	O	['N']	[22]
23	cause	O	['N']	[23]
24	sudden	O	['N']	[24]
25	death	O	['N']	[25]
26	;	O	['N']	[26]
27	quinidine	B-Drug	['Causes']	[7]
28	may	O	['N']	[28]
29	be	O	['N']	[29]
30	related	O	['N']	[30]
31	to	O	['N']	[31]
32	the	O	['N']	[32]
33	death	O	['N']	[33]
34	;	O	['N']	[34]
35	children	O	['N']	[35]
36	with	O	['N']	[36]
37	"	O	['N']	[37]
38	familial	O	['N']	[38]
39	seizure	O	['N']	[39]
40	disorders	O	['N']	[40]
41	"	O	['N']	[41]
42	may	O	['N']	[42]
43	in	O	['N']	[43]
44	fact	O	['N']	[44]
45	have	O	['N']	[45]
46	the	O	['N']	[46]
47	long	O	['N']	[47]
48	QT	O	['N']	[48]
49	interval	O	['N']	[49]
50	syndrome	O	['N']	[50]
51	.	O	['N']	[51]
#644
0	Late	O	['N']	[0]
1	lethal	O	['N']	[1]
2	hepatitis	B	['N']	[2]
3	B	I	['N']	[3]
4	virus	I	['N']	[4]
5	reactivation	I-Adverse_Effect	['N']	[5]
6	after	O	['N']	[6]
7	rituximab	B-Drug	['Causes']	[5]
8	treatment	O	['N']	[8]
9	of	O	['N']	[9]
10	low	O	['N']	[10]
11	-	O	['N']	[11]
12	grade	O	['N']	[12]
13	cutaneous	O	['N']	[13]
14	B	O	['N']	[14]
15	-	O	['N']	[15]
16	cell	O	['N']	[16]
17	lymphoma	O	['N']	[17]
18	.	O	['N']	[18]
#645
0	Infliximab	B-Drug	['Causes']	[8]
1	therapy	O	['N']	[1]
2	may	O	['N']	[2]
3	cause	O	['N']	[3]
4	a	O	['N']	[4]
5	lupus	B	['N']	[5]
6	-	I	['N']	[6]
7	like	I	['N']	[7]
8	syndrome	I-Adverse_Effect	['N']	[8]
9	that	O	['N']	[9]
10	is	O	['N']	[10]
11	reversible	O	['N']	[11]
12	upon	O	['N']	[12]
13	discontinuing	O	['N']	[13]
14	this	O	['N']	[14]
15	agent	O	['N']	[15]
16	.	O	['N']	[16]
#646
0	Lamotrigine	B	['N']	[0]
1	toxicity	I-Adverse_Effect	['N']	[1]
2	secondary	O	['N']	[2]
3	to	O	['N']	[3]
4	sertraline	B-Drug	['Causes']	[1]
5	.	O	['N']	[5]
#647
0	Use	O	['N']	[0]
1	of	O	['N']	[1]
2	the	O	['N']	[2]
3	Naranjo	O	['N']	[3]
4	adverse	O	['N']	[4]
5	drug	O	['N']	[5]
6	reaction	O	['N']	[6]
7	probability	O	['N']	[7]
8	scale	O	['N']	[8]
9	indicated	O	['N']	[9]
10	a	O	['N']	[10]
11	probable	O	['N']	[11]
12	relationship	O	['N']	[12]
13	(	O	['N']	[13]
14	score	O	['N']	[14]
15	of	O	['N']	[15]
16	5	O	['N']	[16]
17	)	O	['N']	[17]
18	between	O	['N']	[18]
19	the	O	['N']	[19]
20	patient	O	['N']	[20]
21	's	O	['N']	[21]
22	development	O	['N']	[22]
23	of	O	['N']	[23]
24	hepatotoxicity	B-Adverse_Effect	['N']	[24]
25	and	O	['N']	[25]
26	the	O	['N']	[26]
27	TMP	B	['N']	[27]
28	-	I	['N']	[28]
29	SMX	I-Drug	['Causes']	[24]
30	therapy	O	['N']	[30]
31	.	O	['N']	[31]
#648
0	After	O	['N']	[0]
1	1	O	['N']	[1]
2	week	O	['N']	[2]
3	of	O	['N']	[3]
4	nefazodone	B-Drug	['Causes']	[16]
5	therapy	O	['N']	[5]
6	the	O	['N']	[6]
7	patient	O	['N']	[7]
8	experienced	O	['N']	[8]
9	headache	O	['N']	[9]
10	,	O	['N']	[10]
11	confusion	O	['N']	[11]
12	,	O	['N']	[12]
13	and	O	['N']	[13]
14	"	O	['N']	[14]
15	gray	B	['N']	[15]
16	areas	I-Adverse_Effect	['N']	[16]
17	"	O	['N']	[17]
18	in	O	['N']	[18]
19	her	O	['N']	[19]
20	vision	O	['N']	[20]
21	,	O	['N']	[21]
22	without	O	['N']	[22]
23	abnormal	O	['N']	[23]
24	ophthalmologic	O	['N']	[24]
25	findings	O	['N']	[25]
26	.	O	['N']	[26]
#649
0	Ofloxacin	B-Drug	['Causes']	[8]
1	:	O	['N']	[1]
2	a	O	['N']	[2]
3	probable	O	['N']	[3]
4	cause	O	['N']	[4]
5	of	O	['N']	[5]
6	toxic	B	['N']	[6]
7	epidermal	I	['N']	[7]
8	necrolysis	I-Adverse_Effect	['N']	[8]
9	.	O	['N']	[9]
#650
0	She	O	['N']	[0]
1	was	O	['N']	[1]
2	receiving	O	['N']	[2]
3	phenytoin	B	['N']	[3]
4	sodium	I-Drug	['Dosage']	[8]
5	300	B	['N']	[5]
6	mg	I	['N']	[6]
7	/	I	['N']	[7]
8	day	I-Dose	['N']	[8]
9	;	O	['N']	[9]
10	carbamazepine	O	['N']	[10]
11	200	O	['N']	[11]
12	mg	O	['N']	[12]
13	four	O	['N']	[13]
14	times	O	['N']	[14]
15	daily	O	['N']	[15]
16	had	O	['N']	[16]
17	been	O	['N']	[17]
18	discontinued	O	['N']	[18]
19	four	O	['N']	[19]
20	days	O	['N']	[20]
21	before	O	['N']	[21]
22	admission	O	['N']	[22]
23	because	O	['N']	[23]
24	of	O	['N']	[24]
25	leukopenia	O	['N']	[25]
26	.	O	['N']	[26]
#651
0	Exacerbations	B	['N']	[0]
1	of	I	['N']	[1]
2	the	I	['N']	[2]
3	heart	I	['N']	[3]
4	failure	I-Adverse_Effect	['N']	[4]
5	were	O	['N']	[5]
6	temporally	O	['N']	[6]
7	related	O	['N']	[7]
8	to	O	['N']	[8]
9	the	O	['N']	[9]
10	administration	O	['N']	[10]
11	of	O	['N']	[11]
12	the	O	['N']	[12]
13	antitumor	O	['N']	[13]
14	antibiotics	O	['N']	[14]
15	actinomycin	B	['N']	[15]
16	-	I	['N']	[16]
17	D	I-Drug	['Causes']	[4]
18	(	O	['N']	[18]
19	NSC-3053	O	['N']	[19]
20	)	O	['N']	[20]
21	and	O	['N']	[21]
22	mithramycin	O	['N']	[22]
23	(	O	['N']	[23]
24	NSC-24559	O	['N']	[24]
25	)	O	['N']	[25]
26	.	O	['N']	[26]
#652
0	A	O	['N']	[0]
1	12	O	['N']	[1]
2	year	O	['N']	[2]
3	old	O	['N']	[3]
4	patient	O	['N']	[4]
5	with	O	['N']	[5]
6	atrial	O	['N']	[6]
7	flutter	O	['N']	[7]
8	is	O	['N']	[8]
9	presented	O	['N']	[9]
10	,	O	['N']	[10]
11	in	O	['N']	[11]
12	whom	O	['N']	[12]
13	intravenous	O	['N']	[13]
14	adenosine	B-Drug	['Causes']	[22]
15	was	O	['N']	[15]
16	followed	O	['N']	[16]
17	by	O	['N']	[17]
18	acceleration	B	['N']	[18]
19	of	I	['N']	[19]
20	the	I	['N']	[20]
21	heart	I	['N']	[21]
22	rate	I-Adverse_Effect	['N']	[22]
23	to	O	['N']	[23]
24	a	O	['N']	[24]
25	potentially	O	['N']	[25]
26	dangerous	O	['N']	[26]
27	arrhythmia	O	['N']	[27]
28	.	O	['N']	[28]
#653
0	Thirty	O	['N']	[0]
1	-	O	['N']	[1]
2	six	O	['N']	[2]
3	patients	O	['N']	[3]
4	with	O	['N']	[4]
5	AL	O	['N']	[5]
6	received	O	['N']	[6]
7	,	O	['N']	[7]
8	in	O	['N']	[8]
9	a	O	['N']	[9]
10	three	O	['N']	[10]
11	-	O	['N']	[11]
12	month	O	['N']	[12]
13	period	O	['N']	[13]
14	,	O	['N']	[14]
15	51	O	['N']	[15]
16	cycles	O	['N']	[16]
17	of	O	['N']	[17]
18	combined	O	['N']	[18]
19	chemotherapy	O	['N']	[19]
20	which	O	['N']	[20]
21	included	O	['N']	[21]
22	,	O	['N']	[22]
23	in	O	['N']	[23]
24	all	O	['N']	[24]
25	of	O	['N']	[25]
26	them	O	['N']	[26]
27	,	O	['N']	[27]
28	cytosine	B	['N']	[28]
29	arabinoside	I-Drug	['Causes']	[52]
30	(	O	['N']	[30]
31	ARA	O	['N']	[31]
32	-	O	['N']	[32]
33	C	O	['N']	[33]
34	)	O	['N']	[34]
35	;	O	['N']	[35]
36	among	O	['N']	[36]
37	them	O	['N']	[37]
38	,	O	['N']	[38]
39	along	O	['N']	[39]
40	with	O	['N']	[40]
41	myelosuppression	O	['N']	[41]
42	,	O	['N']	[42]
43	five	O	['N']	[43]
44	experienced	O	['N']	[44]
45	fever	O	['N']	[45]
46	,	O	['N']	[46]
47	infectious	O	['N']	[47]
48	complications	O	['N']	[48]
49	,	O	['N']	[49]
50	gastrointestinal	B	['N']	[50]
51	tract	I	['N']	[51]
52	symptoms	I-Adverse_Effect	['N']	[52]
53	and	O	['N']	[53]
54	severe	O	['N']	[54]
55	myalgias	O	['N']	[55]
56	.	O	['N']	[56]
#654
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	the	O	['N']	[2]
3	case	O	['N']	[3]
4	histories	O	['N']	[4]
5	of	O	['N']	[5]
6	two	O	['N']	[6]
7	patients	O	['N']	[7]
8	with	O	['N']	[8]
9	histologically	O	['N']	[9]
10	confirmed	O	['N']	[10]
11	adenocarcinoma	O	['N']	[11]
12	of	O	['N']	[12]
13	the	O	['N']	[13]
14	prostate	O	['N']	[14]
15	,	O	['N']	[15]
16	both	O	['N']	[16]
17	of	O	['N']	[17]
18	whom	O	['N']	[18]
19	had	O	['N']	[19]
20	been	O	['N']	[20]
21	treated	O	['N']	[21]
22	with	O	['N']	[22]
23	steroidal	O	['N']	[23]
24	anti	O	['N']	[24]
25	-	O	['N']	[25]
26	androgen	O	['N']	[26]
27	therapy	O	['N']	[27]
28	in	O	['N']	[28]
29	the	O	['N']	[29]
30	form	O	['N']	[30]
31	of	O	['N']	[31]
32	cyproterone	B	['N']	[32]
33	acetate	I-Drug	['Causes']	[49]
34	prior	O	['N']	[34]
35	to	O	['N']	[35]
36	radical	O	['N']	[36]
37	or	O	['N']	[37]
38	palliative	O	['N']	[38]
39	pelvic	O	['N']	[39]
40	irradiation	O	['N']	[40]
41	,	O	['N']	[41]
42	and	O	['N']	[42]
43	who	O	['N']	[43]
44	subsequently	O	['N']	[44]
45	developed	O	['N']	[45]
46	femoral	B	['N']	[46]
47	head	I	['N']	[47]
48	avascular	I	['N']	[48]
49	necrosis	I-Adverse_Effect	['N']	[49]
50	.	O	['N']	[50]
#655
0	A	O	['N']	[0]
1	78-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	man	O	['N']	[4]
5	with	O	['N']	[5]
6	a	O	['N']	[6]
7	transvenous	O	['N']	[7]
8	cardioverter	O	['N']	[8]
9	defibrillator	O	['N']	[9]
10	system	O	['N']	[10]
11	developed	O	['N']	[11]
12	frequent	O	['N']	[12]
13	shocks	B-Adverse_Effect	['N']	[13]
14	during	O	['N']	[14]
15	oral	O	['N']	[15]
16	procainamide	B-Drug	['Causes']	[13]
17	therapy	O	['N']	[17]
18	.	O	['N']	[18]
#656
0	Cardiac	O	['N']	[0]
1	hypersensitivity	O	['N']	[1]
2	and	O	['N']	[2]
3	myopericarditis	B-Adverse_Effect	['N']	[3]
4	have	O	['N']	[4]
5	been	O	['N']	[5]
6	reported	O	['N']	[6]
7	during	O	['N']	[7]
8	long	O	['N']	[8]
9	-	O	['N']	[9]
10	term	O	['N']	[10]
11	treatment	O	['N']	[11]
12	with	O	['N']	[12]
13	mesalazine	B-Drug	['Causes']	[3]
14	.	O	['N']	[14]
#657
0	The	O	['N']	[0]
1	spectrum	O	['N']	[1]
2	of	O	['N']	[2]
3	nitrofurantoin	B-Drug	['Causes']	[5]
4	lung	B	['N']	[4]
5	injury	I-Adverse_Effect	['N']	[5]
6	continues	O	['N']	[6]
7	to	O	['N']	[7]
8	widen	O	['N']	[8]
9	.	O	['N']	[9]
#658
0	We	O	['N']	[0]
1	describe	O	['N']	[1]
2	a	O	['N']	[2]
3	patient	O	['N']	[3]
4	who	O	['N']	[4]
5	presented	O	['N']	[5]
6	with	O	['N']	[6]
7	bloody	B	['N']	[7]
8	diarrhoea	I-Adverse_Effect	['N']	[8]
9	after	O	['N']	[9]
10	15	O	['N']	[10]
11	mg	O	['N']	[11]
12	meloxicam	B-Drug	['Causes']	[8]
13	daily	O	['N']	[13]
14	for	O	['N']	[14]
15	10	O	['N']	[15]
16	days	O	['N']	[16]
17	for	O	['N']	[17]
18	osteoarthritis	O	['N']	[18]
19	.	O	['N']	[19]
#659
0	A	O	['N']	[0]
1	review	O	['N']	[1]
2	of	O	['N']	[2]
3	the	O	['N']	[3]
4	literature	O	['N']	[4]
5	found	O	['N']	[5]
6	11	O	['N']	[6]
7	children	O	['N']	[7]
8	and	O	['N']	[8]
9	2	O	['N']	[9]
10	adults	O	['N']	[10]
11	in	O	['N']	[11]
12	whom	O	['N']	[12]
13	intranasal	O	['N']	[13]
14	desmopressin	B-Drug	['Causes']	[28]
15	was	O	['N']	[15]
16	associated	O	['N']	[16]
17	with	O	['N']	[17]
18	hyponatremia	O	['N']	[18]
19	,	O	['N']	[19]
20	all	O	['N']	[20]
21	of	O	['N']	[21]
22	whom	O	['N']	[22]
23	experienced	O	['N']	[23]
24	seizures	O	['N']	[24]
25	or	O	['N']	[25]
26	altered	B	['N']	[26]
27	mental	I	['N']	[27]
28	status	I-Adverse_Effect	['N']	[28]
29	.	O	['N']	[29]
#660
0	Increasing	O	['N']	[0]
1	the	O	['N']	[1]
2	olanzapine	B-Drug	['Causes']	[9]
3	dosage	O	['N']	[3]
4	severely	O	['N']	[4]
5	aggravated	O	['N']	[5]
6	the	O	['N']	[6]
7	symptoms	O	['N']	[7]
8	of	O	['N']	[8]
9	RLS	B-Adverse_Effect	['N']	[9]
10	.	O	['N']	[10]
#661
0	The	O	['N']	[0]
1	main	O	['N']	[1]
2	clinical	O	['N']	[2]
3	features	O	['N']	[3]
4	of	O	['N']	[4]
5	this	O	['N']	[5]
6	58-year	O	['N']	[6]
7	-	O	['N']	[7]
8	old	O	['N']	[8]
9	female	O	['N']	[9]
10	patient	O	['N']	[10]
11	were	O	['N']	[11]
12	laboratory	O	['N']	[12]
13	evidence	O	['N']	[13]
14	of	O	['N']	[14]
15	leucopenia	O	['N']	[15]
16	and	O	['N']	[16]
17	cholestasis	O	['N']	[17]
18	,	O	['N']	[18]
19	and	O	['N']	[19]
20	biopsy	O	['N']	[20]
21	features	O	['N']	[21]
22	of	O	['N']	[22]
23	fatty	O	['N']	[23]
24	liver	O	['N']	[24]
25	parenchyma	O	['N']	[25]
26	degeneration	O	['N']	[26]
27	with	O	['N']	[27]
28	granulocytic	O	['N']	[28]
29	portal	O	['N']	[29]
30	infiltration	O	['N']	[30]
31	and	O	['N']	[31]
32	bile	B	['N']	[32]
33	stasis	I-Adverse_Effect	['N']	[33]
34	,	O	['N']	[34]
35	demonstrated	O	['N']	[35]
36	20	O	['N']	[36]
37	days	O	['N']	[37]
38	after	O	['N']	[38]
39	the	O	['N']	[39]
40	initiation	O	['N']	[40]
41	of	O	['N']	[41]
42	antithyroid	O	['N']	[42]
43	therapy	O	['N']	[43]
44	with	O	['N']	[44]
45	20	O	['N']	[45]
46	mg	O	['N']	[46]
47	methimazole	B-Drug	['Causes']	[33]
48	daily	O	['N']	[48]
49	.	O	['N']	[49]
#662
0	This	O	['N']	[0]
1	entity	O	['N']	[1]
2	is	O	['N']	[2]
3	probably	O	['N']	[3]
4	related	O	['N']	[4]
5	to	O	['N']	[5]
6	a	O	['N']	[6]
7	combination	O	['N']	[7]
8	of	O	['N']	[8]
9	high	O	['N']	[9]
10	doses	O	['N']	[10]
11	of	O	['N']	[11]
12	corticosteroids	O	['N']	[12]
13	,	O	['N']	[13]
14	vecuronium	B-Drug	['Causes']	[22]
15	administration	O	['N']	[15]
16	and	O	['N']	[16]
17	metabolic	O	['N']	[17]
18	abnormalities	O	['N']	[18]
19	associated	O	['N']	[19]
20	with	O	['N']	[20]
21	respiratory	B	['N']	[21]
22	failure	I-Adverse_Effect	['N']	[22]
23	.	O	['N']	[23]
#663
0	With	O	['N']	[0]
1	the	O	['N']	[1]
2	use	O	['N']	[2]
3	of	O	['N']	[3]
4	optical	O	['N']	[4]
5	coherence	O	['N']	[5]
6	tomography	O	['N']	[6]
7	(	O	['N']	[7]
8	OCT	O	['N']	[8]
9	)	O	['N']	[9]
10	,	O	['N']	[10]
11	two	O	['N']	[11]
12	patients	O	['N']	[12]
13	with	O	['N']	[13]
14	IFN	B-Drug	['Causes']	[17]
15	-	O	['N']	[15]
16	associated	O	['N']	[16]
17	retinopathy	B-Adverse_Effect	['N']	[17]
18	who	O	['N']	[18]
19	had	O	['N']	[19]
20	developed	O	['N']	[20]
21	macular	O	['N']	[21]
22	edema	O	['N']	[22]
23	and	O	['N']	[23]
24	reduced	O	['N']	[24]
25	visual	O	['N']	[25]
26	acuity	O	['N']	[26]
27	during	O	['N']	[27]
28	the	O	['N']	[28]
29	clinical	O	['N']	[29]
30	course	O	['N']	[30]
31	of	O	['N']	[31]
32	IFN	O	['N']	[32]
33	therapy	O	['N']	[33]
34	were	O	['N']	[34]
35	observed	O	['N']	[35]
36	.	O	['N']	[36]
#664
0	A	O	['N']	[0]
1	case	O	['N']	[1]
2	of	O	['N']	[2]
3	polymyositis	O	['N']	[3]
4	with	O	['N']	[4]
5	dilated	B	['N']	[5]
6	cardiomyopathy	I-Adverse_Effect	['N']	[6]
7	associated	O	['N']	[7]
8	with	O	['N']	[8]
9	interferon	B	['N']	[9]
10	alpha	I-Drug	['Causes']	[6]
11	treatment	O	['N']	[11]
12	for	O	['N']	[12]
13	hepatitis	O	['N']	[13]
14	B.	O	['N']	[14]
#665
0	A	O	['N']	[0]
1	40-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	man	O	['N']	[4]
5	with	O	['N']	[5]
6	advanced	O	['N']	[6]
7	HIV	O	['N']	[7]
8	infection	O	['N']	[8]
9	and	O	['N']	[9]
10	Mycobacterium	O	['N']	[10]
11	avium	O	['N']	[11]
12	complex	O	['N']	[12]
13	infection	O	['N']	[13]
14	experienced	O	['N']	[14]
15	rapid	B	['N']	[15]
16	cognitive	I	['N']	[16]
17	decline	I-Adverse_Effect	['N']	[17]
18	after	O	['N']	[18]
19	commencement	O	['N']	[19]
20	of	O	['N']	[20]
21	ethambutol	B-Drug	['Causes']	[17]
22	,	O	['N']	[22]
23	and	O	['N']	[23]
24	symptoms	O	['N']	[24]
25	fully	O	['N']	[25]
26	resolved	O	['N']	[26]
27	with	O	['N']	[27]
28	cessation	O	['N']	[28]
29	.	O	['N']	[29]
#666
0	The	O	['N']	[0]
1	reported	O	['N']	[1]
2	cases	O	['N']	[2]
3	of	O	['N']	[3]
4	in	O	['N']	[4]
5	utero	O	['N']	[5]
6	exposure	O	['N']	[6]
7	to	O	['N']	[7]
8	cyclosposphamide	B-Drug	['Causes']	[23]
9	shared	O	['N']	[9]
10	the	O	['N']	[10]
11	following	O	['N']	[11]
12	manifestations	O	['N']	[12]
13	with	O	['N']	[13]
14	our	O	['N']	[14]
15	patient	O	['N']	[15]
16	:	O	['N']	[16]
17	growth	O	['N']	[17]
18	deficiency	O	['N']	[18]
19	,	O	['N']	[19]
20	developmental	O	['N']	[20]
21	delay	O	['N']	[21]
22	,	O	['N']	[22]
23	craniosynostosis	B-Adverse_Effect	['N']	[23]
24	,	O	['N']	[24]
25	blepharophimosis	O	['N']	[25]
26	,	O	['N']	[26]
27	flat	O	['N']	[27]
28	nasal	O	['N']	[28]
29	bridge	O	['N']	[29]
30	,	O	['N']	[30]
31	abnormal	O	['N']	[31]
32	ears	O	['N']	[32]
33	,	O	['N']	[33]
34	and	O	['N']	[34]
35	distal	O	['N']	[35]
36	limb	O	['N']	[36]
37	defects	O	['N']	[37]
38	including	O	['N']	[38]
39	hypoplastic	O	['N']	[39]
40	thumbs	O	['N']	[40]
41	and	O	['N']	[41]
42	oligodactyly	O	['N']	[42]
43	.	O	['N']	[43]
#667
0	Mitomycin	O	['N']	[0]
1	C	O	['N']	[1]
2	(	O	['N']	[2]
3	MMC	B-Drug	['Causes']	[19]
4	)	O	['N']	[4]
5	is	O	['N']	[5]
6	an	O	['N']	[6]
7	alkylating	O	['N']	[7]
8	agent	O	['N']	[8]
9	that	O	['N']	[9]
10	has	O	['N']	[10]
11	been	O	['N']	[11]
12	recently	O	['N']	[12]
13	associated	O	['N']	[13]
14	with	O	['N']	[14]
15	the	O	['N']	[15]
16	hemolytic	B	['N']	[16]
17	-	I	['N']	[17]
18	uremic	I	['N']	[18]
19	syndrome	I-Adverse_Effect	['N']	[19]
20	(	O	['N']	[20]
21	HUS	O	['N']	[21]
22	)	O	['N']	[22]
23	.	O	['N']	[23]
#668
0	Eosinophilia	B-Adverse_Effect	['N']	[0]
1	caused	O	['N']	[1]
2	by	O	['N']	[2]
3	clozapine	B-Drug	['Causes']	[0]
4	was	O	['N']	[4]
5	observed	O	['N']	[5]
6	in	O	['N']	[6]
7	challenge	O	['N']	[7]
8	,	O	['N']	[8]
9	preceded	O	['N']	[9]
10	by	O	['N']	[10]
11	a	O	['N']	[11]
12	faster	O	['N']	[12]
13	neutrophil	O	['N']	[13]
14	production	O	['N']	[14]
15	and	O	['N']	[15]
16	consecutive	O	['N']	[16]
17	decrease	O	['N']	[17]
18	(	O	['N']	[18]
19	z	O	['N']	[19]
20	=	O	['N']	[20]
21	2.27	O	['N']	[21]
22	,	O	['N']	[22]
23	p	O	['N']	[23]
24	=	O	['N']	[24]
25	0.01	O	['N']	[25]
26	)	O	['N']	[26]
27	.	O	['N']	[27]
#669
0	Atypical	B	['N']	[0]
1	ventricular	I	['N']	[1]
2	tachycardia	I-Adverse_Effect	['N']	[2]
3	(	O	['N']	[3]
4	torsade	O	['N']	[4]
5	de	O	['N']	[5]
6	pointes	O	['N']	[6]
7	)	O	['N']	[7]
8	induced	O	['N']	[8]
9	by	O	['N']	[9]
10	amiodarone	B-Drug	['Causes']	[2]
11	:	O	['N']	[11]
12	arrhythmia	O	['N']	[12]
13	previously	O	['N']	[13]
14	induced	O	['N']	[14]
15	by	O	['N']	[15]
16	quinidine	O	['N']	[16]
17	and	O	['N']	[17]
18	disopyramide	O	['N']	[18]
19	.	O	['N']	[19]
#670
0	In	O	['N']	[0]
1	case	O	['N']	[1]
2	1	O	['N']	[2]
3	,	O	['N']	[3]
4	a	O	['N']	[4]
5	total	O	['N']	[5]
6	daily	O	['N']	[6]
7	dose	O	['N']	[7]
8	of	O	['N']	[8]
9	25	O	['N']	[9]
10	mg	O	['N']	[10]
11	sertraline	O	['N']	[11]
12	,	O	['N']	[12]
13	with	O	['N']	[13]
14	nondetectable	O	['N']	[14]
15	sertraline	O	['N']	[15]
16	and	O	['N']	[16]
17	desmethylsertraline	O	['N']	[17]
18	blood	O	['N']	[18]
19	levels	O	['N']	[19]
20	,	O	['N']	[20]
21	resulted	O	['N']	[21]
22	in	O	['N']	[22]
23	a	O	['N']	[23]
24	doubling	O	['N']	[24]
25	of	O	['N']	[25]
26	the	O	['N']	[26]
27	lamotrigine	B-Drug	['Causes']	[33]
28	blood	O	['N']	[28]
29	level	O	['N']	[29]
30	with	O	['N']	[30]
31	symptoms	B	['N']	[31]
32	of	I	['N']	[32]
33	toxicity	I-Adverse_Effect	['N']	[33]
34	.	O	['N']	[34]
#671
0	We	O	['N']	[0]
1	consider	O	['N']	[1]
2	asterixis	B-Adverse_Effect	['N']	[2]
3	to	O	['N']	[3]
4	be	O	['N']	[4]
5	an	O	['N']	[5]
6	easily	O	['N']	[6]
7	overlooked	O	['N']	[7]
8	sign	O	['N']	[8]
9	of	O	['N']	[9]
10	neurotoxicity	O	['N']	[10]
11	,	O	['N']	[11]
12	which	O	['N']	[12]
13	may	O	['N']	[13]
14	occur	O	['N']	[14]
15	even	O	['N']	[15]
16	at	O	['N']	[16]
17	low	O	['N']	[17]
18	or	O	['N']	[18]
19	moderate	O	['N']	[19]
20	dosage	O	['N']	[20]
21	levels	O	['N']	[21]
22	,	O	['N']	[22]
23	if	O	['N']	[23]
24	certain	O	['N']	[24]
25	drugs	O	['N']	[25]
26	as	O	['N']	[26]
27	lithium	O	['N']	[27]
28	or	O	['N']	[28]
29	clozapine	O	['N']	[29]
30	are	O	['N']	[30]
31	used	O	['N']	[31]
32	in	O	['N']	[32]
33	combination	O	['N']	[33]
34	with	O	['N']	[34]
35	CBZ	B-Drug	['Causes']	[2]
36	.	O	['N']	[36]
#672
0	However	O	['N']	[0]
1	,	O	['N']	[1]
2	each	O	['N']	[2]
3	infant	O	['N']	[3]
4	demonstrated	O	['N']	[4]
5	hemodynamic	B	['N']	[5]
6	decompensation	I-Adverse_Effect	['N']	[6]
7	shortly	O	['N']	[7]
8	after	O	['N']	[8]
9	verapamil	B-Drug	['Causes']	[6]
10	administration	O	['N']	[10]
11	and	O	['N']	[11]
12	required	O	['N']	[12]
13	cardiopulmonary	O	['N']	[13]
14	resuscitation	O	['N']	[14]
15	.	O	['N']	[15]
#673
0	OBJECTIVE	O	['N']	[0]
1	:	O	['N']	[1]
2	The	O	['N']	[2]
3	aim	O	['N']	[3]
4	of	O	['N']	[4]
5	this	O	['N']	[5]
6	paper	O	['N']	[6]
7	is	O	['N']	[7]
8	to	O	['N']	[8]
9	describe	O	['N']	[9]
10	a	O	['N']	[10]
11	case	O	['N']	[11]
12	of	O	['N']	[12]
13	increased	B	['N']	[13]
14	libido	I-Adverse_Effect	['N']	[14]
15	during	O	['N']	[15]
16	fluvoxamine	B-Drug	['Causes']	[14]
17	therapy	O	['N']	[17]
18	.	O	['N']	[18]
#674
0	Two	O	['N']	[0]
1	65-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	white	O	['N']	[4]
5	men	O	['N']	[5]
6	with	O	['N']	[6]
7	coronary	O	['N']	[7]
8	heart	O	['N']	[8]
9	disease	O	['N']	[9]
10	,	O	['N']	[10]
11	given	O	['N']	[11]
12	niacin	B-Drug	['Causes']	[25]
13	therapy	O	['N']	[13]
14	for	O	['N']	[14]
15	dyslipidemia	O	['N']	[15]
16	for	O	['N']	[16]
17	5	O	['N']	[17]
18	months	O	['N']	[18]
19	,	O	['N']	[19]
20	developed	O	['N']	[20]
21	intense	B	['N']	[21]
22	dental	I	['N']	[22]
23	and	I	['N']	[23]
24	gingival	I	['N']	[24]
25	pain	I-Adverse_Effect	['N']	[25]
26	that	O	['N']	[26]
27	was	O	['N']	[27]
28	associated	O	['N']	[28]
29	with	O	['N']	[29]
30	increases	O	['N']	[30]
31	in	O	['N']	[31]
32	dose	O	['N']	[32]
33	and	O	['N']	[33]
34	that	O	['N']	[34]
35	was	O	['N']	[35]
36	relieved	O	['N']	[36]
37	with	O	['N']	[37]
38	discontinuance	O	['N']	[38]
39	of	O	['N']	[39]
40	niacin	O	['N']	[40]
41	treatment	O	['N']	[41]
42	.	O	['N']	[42]
#675
0	Methotrexate	O	['N']	[0]
1	(	O	['N']	[1]
2	MTX	B-Drug	['Causes']	[32]
3	)	O	['N']	[3]
4	is	O	['N']	[4]
5	a	O	['N']	[5]
6	commonly	O	['N']	[6]
7	used	O	['N']	[7]
8	second	O	['N']	[8]
9	line	O	['N']	[9]
10	agent	O	['N']	[10]
11	for	O	['N']	[11]
12	RA	O	['N']	[12]
13	,	O	['N']	[13]
14	and	O	['N']	[14]
15	there	O	['N']	[15]
16	have	O	['N']	[16]
17	been	O	['N']	[17]
18	several	O	['N']	[18]
19	recent	O	['N']	[19]
20	reports	O	['N']	[20]
21	of	O	['N']	[21]
22	Epstein	B	['N']	[22]
23	-	I	['N']	[23]
24	Barr	I	['N']	[24]
25	virus	I	['N']	[25]
26	(	I	['N']	[26]
27	EBV)-associated	I	['N']	[27]
28	polyclonal	I	['N']	[28]
29	B	I	['N']	[29]
30	cell	I	['N']	[30]
31	lymphoproliferative	I	['N']	[31]
32	disorder	I-Adverse_Effect	['N']	[32]
33	in	O	['N']	[33]
34	MTX	O	['N']	[34]
35	-	O	['N']	[35]
36	treated	O	['N']	[36]
37	RA	O	['N']	[37]
38	patients	O	['N']	[38]
39	.	O	['N']	[39]
#676
0	Of	O	['N']	[0]
1	the	O	['N']	[1]
2	four	O	['N']	[2]
3	patients	O	['N']	[3]
4	who	O	['N']	[4]
5	responded	O	['N']	[5]
6	to	O	['N']	[6]
7	HU	B-Drug	['Causes']	[13]
8	with	O	['N']	[8]
9	an	O	['N']	[9]
10	increase	B	['N']	[10]
11	in	I	['N']	[11]
12	total	I	['N']	[12]
13	Hb	I-Adverse_Effect	['N']	[13]
14	,	O	['N']	[14]
15	all	O	['N']	[15]
16	reported	O	['N']	[16]
17	symptomatic	O	['N']	[17]
18	improvement	O	['N']	[18]
19	and	O	['N']	[19]
20	three	O	['N']	[20]
21	have	O	['N']	[21]
22	not	O	['N']	[22]
23	required	O	['N']	[23]
24	further	O	['N']	[24]
25	transfusions	O	['N']	[25]
26	.	O	['N']	[26]
#677
0	METHODS	O	['N']	[0]
1	:	O	['N']	[1]
2	A	O	['N']	[2]
3	68-year	O	['N']	[3]
4	-	O	['N']	[4]
5	old	O	['N']	[5]
6	man	O	['N']	[6]
7	developed	O	['N']	[7]
8	intense	O	['N']	[8]
9	conjunctival	O	['N']	[9]
10	hyperemia	O	['N']	[10]
11	and	O	['N']	[11]
12	cystoid	O	['N']	[12]
13	macula	O	['N']	[13]
14	edema	O	['N']	[14]
15	after	O	['N']	[15]
16	switching	O	['N']	[16]
17	from	O	['N']	[17]
18	latanoprost	B-Drug	['Causes']	[37]
19	to	O	['N']	[19]
20	bimatoprost	O	['N']	[20]
21	9	O	['N']	[21]
22	months	O	['N']	[22]
23	after	O	['N']	[23]
24	cataract	O	['N']	[24]
25	surgery	O	['N']	[25]
26	in	O	['N']	[26]
27	an	O	['N']	[27]
28	eye	O	['N']	[28]
29	at	O	['N']	[29]
30	low	O	['N']	[30]
31	-	O	['N']	[31]
32	risk	O	['N']	[32]
33	for	O	['N']	[33]
34	this	O	['N']	[34]
35	cystoid	B	['N']	[35]
36	macular	I	['N']	[36]
37	edema	I-Adverse_Effect	['N']	[37]
38	.	O	['N']	[38]
#678
0	The	O	['N']	[0]
1	most	O	['N']	[1]
2	common	O	['N']	[2]
3	side	O	['N']	[3]
4	effects	O	['N']	[4]
5	associated	O	['N']	[5]
6	with	O	['N']	[6]
7	amifostine	B-Drug	['Causes']	[18]
8	are	O	['N']	[8]
9	nausea	O	['N']	[9]
10	,	O	['N']	[10]
11	vomiting	O	['N']	[11]
12	,	O	['N']	[12]
13	hypotension	O	['N']	[13]
14	,	O	['N']	[14]
15	hypocalcemia	O	['N']	[15]
16	and	O	['N']	[16]
17	allergic	B	['N']	[17]
18	reactions	I-Adverse_Effect	['N']	[18]
19	.	O	['N']	[19]
#679
0	Cephalexin	B-Drug	['Causes']	[1]
1	rash	I-Adverse_Effect	['N']	[1]
2	in	O	['N']	[2]
3	infectious	O	['N']	[3]
4	mononucleosis	O	['N']	[4]
5	.	O	['N']	[5]
#680
0	OBJECTIVE	O	['N']	[0]
1	:	O	['N']	[1]
2	To	O	['N']	[2]
3	report	O	['N']	[3]
4	a	O	['N']	[4]
5	case	O	['N']	[5]
6	of	O	['N']	[6]
7	toxin	B	['N']	[7]
8	-	I	['N']	[8]
9	positive	I	['N']	[9]
10	Clostridium	I	['N']	[10]
11	difficile	I	['N']	[11]
12	-	I	['N']	[12]
13	induced	I	['N']	[13]
14	colitis	I-Adverse_Effect	['N']	[14]
15	(	O	['N']	[15]
16	CDIC	O	['N']	[16]
17	)	O	['N']	[17]
18	after	O	['N']	[18]
19	use	O	['N']	[19]
20	of	O	['N']	[20]
21	clindamycin	B	['N']	[21]
22	phosphate	I-Drug	['Causes']	[14]
23	vaginal	O	['N']	[23]
24	cream	O	['N']	[24]
25	.	O	['N']	[25]
#681
0	Angioedema	B-Adverse_Effect	['N']	[0]
1	and	O	['N']	[1]
2	maculopapular	O	['N']	[2]
3	eruptions	O	['N']	[3]
4	associated	O	['N']	[4]
5	with	O	['N']	[5]
6	carbamazepine	B-Drug	['Causes']	[0]
7	administration	O	['N']	[7]
8	.	O	['N']	[8]
#682
0	Putaminal	B	['N']	[0]
1	infarct	I-Adverse_Effect	['N']	[1]
2	in	O	['N']	[2]
3	methanol	B-Drug	['Causes']	[1]
4	intoxication	O	['N']	[4]
5	:	O	['N']	[5]
6	case	O	['N']	[6]
7	report	O	['N']	[7]
8	and	O	['N']	[8]
9	role	O	['N']	[9]
10	of	O	['N']	[10]
11	brain	O	['N']	[11]
12	imaging	O	['N']	[12]
13	studies	O	['N']	[13]
14	.	O	['N']	[14]
#683
0	Children	O	['N']	[0]
1	with	O	['N']	[1]
2	acute	O	['N']	[2]
3	lymphoblastic	O	['N']	[3]
4	leukemia	O	['N']	[4]
5	(	O	['N']	[5]
6	ALL	O	['N']	[6]
7	)	O	['N']	[7]
8	,	O	['N']	[8]
9	treated	O	['N']	[9]
10	with	O	['N']	[10]
11	L	B	['N']	[11]
12	-	I	['N']	[12]
13	asparaginase	I-Drug	['Causes']	[21]
14	are	O	['N']	[14]
15	at	O	['N']	[15]
16	risk	O	['N']	[16]
17	for	O	['N']	[17]
18	cerebral	O	['N']	[18]
19	thrombosis	O	['N']	[19]
20	or	O	['N']	[20]
21	hemorrhage	B-Adverse_Effect	['N']	[21]
22	because	O	['N']	[22]
23	of	O	['N']	[23]
24	coagulation	O	['N']	[24]
25	protein	O	['N']	[25]
26	deficiencies	O	['N']	[26]
27	.	O	['N']	[27]
#684
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	Ritalin	B-Drug	['Causes']	[8]
6	-	O	['N']	[6]
7	associated	O	['N']	[7]
8	cataract	B-Adverse_Effect	['N']	[8]
9	and	O	['N']	[9]
10	glaucoma	O	['N']	[10]
11	.	O	['N']	[11]
#685
0	Phenylpropanolamine	B-Drug	['Causes']	[13]
1	(	O	['N']	[1]
2	PPA	O	['N']	[2]
3	)	O	['N']	[3]
4	recently	O	['N']	[4]
5	has	O	['N']	[5]
6	been	O	['N']	[6]
7	publicly	O	['N']	[7]
8	implicated	O	['N']	[8]
9	as	O	['N']	[9]
10	a	O	['N']	[10]
11	cause	O	['N']	[11]
12	of	O	['N']	[12]
13	stroke	B-Adverse_Effect	['N']	[13]
14	and	O	['N']	[14]
15	other	O	['N']	[15]
16	neurologic	O	['N']	[16]
17	events	O	['N']	[17]
18	.	O	['N']	[18]
#686
0	Hypersensitivity	B-Adverse_Effect	['N']	[0]
1	to	O	['N']	[1]
2	zonisamide	B-Drug	['Causes']	[0]
3	was	O	['N']	[3]
4	confirmed	O	['N']	[4]
5	by	O	['N']	[5]
6	the	O	['N']	[6]
7	skin	O	['N']	[7]
8	patch	O	['N']	[8]
9	test	O	['N']	[9]
10	.	O	['N']	[10]
#687
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	2	O	['N']	[2]
3	cases	O	['N']	[3]
4	of	O	['N']	[4]
5	maculopapular	B	['N']	[5]
6	eruption	I-Adverse_Effect	['N']	[6]
7	and	O	['N']	[7]
8	fever	O	['N']	[8]
9	in	O	['N']	[9]
10	patients	O	['N']	[10]
11	infected	O	['N']	[11]
12	with	O	['N']	[12]
13	human	O	['N']	[13]
14	immunodeficiency	O	['N']	[14]
15	virus	O	['N']	[15]
16	(	O	['N']	[16]
17	HIV	O	['N']	[17]
18	)	O	['N']	[18]
19	on	O	['N']	[19]
20	the	O	['N']	[20]
21	2nd	O	['N']	[21]
22	day	O	['N']	[22]
23	of	O	['N']	[23]
24	first	O	['N']	[24]
25	administration	O	['N']	[25]
26	of	O	['N']	[26]
27	ritonavir	B-Drug	['Causes']	[6]
28	,	O	['N']	[28]
29	a	O	['N']	[29]
30	protease	O	['N']	[30]
31	inhibitor	O	['N']	[31]
32	.	O	['N']	[32]
#688
0	Since	O	['N']	[0]
1	recent	O	['N']	[1]
2	studies	O	['N']	[2]
3	have	O	['N']	[3]
4	reported	O	['N']	[4]
5	no	O	['N']	[5]
6	negative	O	['N']	[6]
7	interactions	O	['N']	[7]
8	with	O	['N']	[8]
9	concurrent	O	['N']	[9]
10	use	O	['N']	[10]
11	,	O	['N']	[11]
12	we	O	['N']	[12]
13	here	O	['N']	[13]
14	report	O	['N']	[14]
15	three	O	['N']	[15]
16	cases	O	['N']	[16]
17	(	O	['N']	[17]
18	one	O	['N']	[18]
19	case	O	['N']	[19]
20	of	O	['N']	[20]
21	a	O	['N']	[21]
22	prolonged	O	['N']	[22]
23	seizure	O	['N']	[23]
24	,	O	['N']	[24]
25	a	O	['N']	[25]
26	serotonin	O	['N']	[26]
27	syndrome	O	['N']	[27]
28	and	O	['N']	[28]
29	a	O	['N']	[29]
30	focal	B	['N']	[30]
31	seizure	I-Adverse_Effect	['N']	[31]
32	)	O	['N']	[32]
33	of	O	['N']	[33]
34	severe	O	['N']	[34]
35	lithium	B-Drug	['Causes']	[31]
36	-	O	['N']	[36]
37	induced	O	['N']	[37]
38	side	O	['N']	[38]
39	effects	O	['N']	[39]
40	while	O	['N']	[40]
41	patients	O	['N']	[41]
42	underwent	O	['N']	[42]
43	ECT	O	['N']	[43]
44	without	O	['N']	[44]
45	complications	O	['N']	[45]
46	and	O	['N']	[46]
47	lithium	O	['N']	[47]
48	serum	O	['N']	[48]
49	levels	O	['N']	[49]
50	were	O	['N']	[50]
51	still	O	['N']	[51]
52	subtherapeutic	O	['N']	[52]
53	.	O	['N']	[53]
#689
0	Clofazimine	B-Drug	['Causes']	[1]
1	enteropathy	B-Adverse_Effect	['N']	[1]
2	in	O	['N']	[2]
3	a	O	['N']	[3]
4	pediatric	O	['N']	[4]
5	bone	O	['N']	[5]
6	marrow	O	['N']	[6]
7	transplant	O	['N']	[7]
8	recipient	O	['N']	[8]
9	.	O	['N']	[9]
#690
0	Response	O	['N']	[0]
1	of	O	['N']	[1]
2	a	O	['N']	[2]
3	promethazine	B-Drug	['Causes']	[6]
4	-	O	['N']	[4]
5	induced	O	['N']	[5]
6	coma	B-Adverse_Effect	['N']	[6]
7	to	O	['N']	[7]
8	flumazenil	O	['N']	[8]
9	.	O	['N']	[9]
#691
0	This	O	['N']	[0]
1	therapy	O	['N']	[1]
2	was	O	['N']	[2]
3	also	O	['N']	[3]
4	complicated	O	['N']	[4]
5	by	O	['N']	[5]
6	Warfarin	B-Drug	['Causes']	[10]
7	-	O	['N']	[7]
8	induced	O	['N']	[8]
9	skin	B	['N']	[9]
10	necrosis	I-Adverse_Effect	['N']	[10]
11	.	O	['N']	[11]
#692
0	We	O	['N']	[0]
1	describe	O	['N']	[1]
2	a	O	['N']	[2]
3	patient	O	['N']	[3]
4	who	O	['N']	[4]
5	developed	O	['N']	[5]
6	HUS	O	['N']	[6]
7	after	O	['N']	[7]
8	treatment	O	['N']	[8]
9	with	O	['N']	[9]
10	mitomycin	B	['N']	[10]
11	C	I-Drug	['Dosage']	[18]
12	(	O	['N']	[12]
13	total	O	['N']	[13]
14	dose	O	['N']	[14]
15	144	B	['N']	[15]
16	mg	I	['N']	[16]
17	/	I	['N']	[17]
18	m2	I-Dose	['N']	[18]
19	)	O	['N']	[19]
20	due	O	['N']	[20]
21	to	O	['N']	[21]
22	a	O	['N']	[22]
23	carcinoma	O	['N']	[23]
24	of	O	['N']	[24]
25	the	O	['N']	[25]
26	ascending	O	['N']	[26]
27	colon	O	['N']	[27]
28	.	O	['N']	[28]
#693
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	an	O	['N']	[2]
3	additional	O	['N']	[3]
4	case	O	['N']	[4]
5	of	O	['N']	[5]
6	isotretinoin	B-Drug	['Causes']	[17]
7	teratogenicity	O	['N']	[7]
8	in	O	['N']	[8]
9	which	O	['N']	[9]
10	the	O	['N']	[10]
11	patient	O	['N']	[11]
12	had	O	['N']	[12]
13	agenesis	B	['N']	[13]
14	of	I	['N']	[14]
15	the	I	['N']	[15]
16	cerebellar	I	['N']	[16]
17	vermis	I-Adverse_Effect	['N']	[17]
18	,	O	['N']	[18]
19	multiple	O	['N']	[19]
20	leptomeningeal	O	['N']	[20]
21	neuroglial	O	['N']	[21]
22	heterotopias	O	['N']	[22]
23	,	O	['N']	[23]
24	hydrocephalus	O	['N']	[24]
25	,	O	['N']	[25]
26	and	O	['N']	[26]
27	abnormalities	O	['N']	[27]
28	of	O	['N']	[28]
29	the	O	['N']	[29]
30	corticospinal	O	['N']	[30]
31	tracts	O	['N']	[31]
32	.	O	['N']	[32]
#694
0	Hydroxyurea	B-Drug	['Causes']	[5]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	acute	B	['N']	[3]
4	interstitial	I	['N']	[4]
5	pneumonitis	I-Adverse_Effect	['N']	[5]
6	in	O	['N']	[6]
7	a	O	['N']	[7]
8	patient	O	['N']	[8]
9	with	O	['N']	[9]
10	essential	O	['N']	[10]
11	thrombocythemia	O	['N']	[11]
12	.	O	['N']	[12]
#695
0	Favorable	O	['N']	[0]
1	outcome	O	['N']	[1]
2	of	O	['N']	[2]
3	de	O	['N']	[3]
4	novo	O	['N']	[4]
5	hepatitis	B	['N']	[5]
6	B	I	['N']	[6]
7	infection	I-Adverse_Effect	['N']	[7]
8	after	O	['N']	[8]
9	liver	O	['N']	[9]
10	transplantation	O	['N']	[10]
11	with	O	['N']	[11]
12	lamivudine	B-Drug	['Causes']	[7]
13	and	O	['N']	[13]
14	adefovir	O	['N']	[14]
15	therapy	O	['N']	[15]
16	.	O	['N']	[16]
#696
0	Thrombocytosis	B-Adverse_Effect	['N']	[0]
1	under	O	['N']	[1]
2	ciprofloxacin	O	['N']	[2]
3	and	O	['N']	[3]
4	tazobactam	B-Drug	['Causes']	[0]
5	/	O	['N']	[5]
6	piperacillin	O	['N']	[6]
7	.	O	['N']	[7]
#697
0	In	O	['N']	[0]
1	this	O	['N']	[1]
2	report	O	['N']	[2]
3	,	O	['N']	[3]
4	one	O	['N']	[4]
5	patient	O	['N']	[5]
6	who	O	['N']	[6]
7	developed	O	['N']	[7]
8	gangrene	O	['N']	[8]
9	after	O	['N']	[9]
10	bleomycin	O	['N']	[10]
11	and	O	['N']	[11]
12	vincristine	O	['N']	[12]
13	/	O	['N']	[13]
14	vinblastine	B-Drug	['Causes']	[36]
15	chemotherapy	O	['N']	[15]
16	for	O	['N']	[16]
17	AIDS	O	['N']	[17]
18	-	O	['N']	[18]
19	related	O	['N']	[19]
20	Kaposi	O	['N']	[20]
21	's	O	['N']	[21]
22	sarcoma	O	['N']	[22]
23	and	O	['N']	[23]
24	another	O	['N']	[24]
25	HIV	O	['N']	[25]
26	-	O	['N']	[26]
27	infected	O	['N']	[27]
28	patient	O	['N']	[28]
29	who	O	['N']	[29]
30	exhibited	O	['N']	[30]
31	symptoms	O	['N']	[31]
32	of	O	['N']	[32]
33	severe	B	['N']	[33]
34	Raynaud	I	['N']	[34]
35	's	I	['N']	[35]
36	phenomenon	I-Adverse_Effect	['N']	[36]
37	related	O	['N']	[37]
38	to	O	['N']	[38]
39	the	O	['N']	[39]
40	same	O	['N']	[40]
41	regimen	O	['N']	[41]
42	are	O	['N']	[42]
43	presented	O	['N']	[43]
44	.	O	['N']	[44]
#698
0	A	O	['N']	[0]
1	60	O	['N']	[1]
2	year	O	['N']	[2]
3	-	O	['N']	[3]
4	old	O	['N']	[4]
5	woman	O	['N']	[5]
6	with	O	['N']	[6]
7	chronic	O	['N']	[7]
8	renal	O	['N']	[8]
9	failure	O	['N']	[9]
10	developed	O	['N']	[10]
11	acute	O	['N']	[11]
12	proximal	O	['N']	[12]
13	muscle	O	['N']	[13]
14	weakness	O	['N']	[14]
15	after	O	['N']	[15]
16	receiving	O	['N']	[16]
17	a	O	['N']	[17]
18	regular	B-Dose	['N']	[18]
19	dosage	O	['N']	[19]
20	of	O	['N']	[20]
21	colchicine	B-Drug	['Dosage']	[18]
22	.	O	['N']	[22]
#699
0	Possible	O	['N']	[0]
1	serotonin	B	['N']	[1]
2	syndrome	I-Adverse_Effect	['N']	[2]
3	associated	O	['N']	[3]
4	with	O	['N']	[4]
5	clomipramine	O	['N']	[5]
6	after	O	['N']	[6]
7	withdrawal	O	['N']	[7]
8	of	O	['N']	[8]
9	clozapine	B-Drug	['Causes']	[2]
10	.	O	['N']	[10]
#700
0	Penicillin	B-Drug	['Causes']	[6]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	Jarisch	B	['N']	[3]
4	-	I	['N']	[4]
5	Herxheimer	I	['N']	[5]
6	reaction	I-Adverse_Effect	['N']	[6]
7	.	O	['N']	[7]
#701
0	Nephrogenic	B	['N']	[0]
1	diabetes	I	['N']	[1]
2	insipidus	I-Adverse_Effect	['N']	[2]
3	and	O	['N']	[3]
4	renal	O	['N']	[4]
5	tubular	O	['N']	[5]
6	acidosis	O	['N']	[6]
7	secondary	O	['N']	[7]
8	to	O	['N']	[8]
9	foscarnet	B-Drug	['Causes']	[2]
10	therapy	O	['N']	[10]
11	.	O	['N']	[11]
#702
0	A	O	['N']	[0]
1	72-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	woman	O	['N']	[4]
5	with	O	['N']	[5]
6	a	O	['N']	[6]
7	history	O	['N']	[7]
8	of	O	['N']	[8]
9	thyrotoxicosis	O	['N']	[9]
10	presented	O	['N']	[10]
11	with	O	['N']	[11]
12	sore	O	['N']	[12]
13	throat	O	['N']	[13]
14	and	O	['N']	[14]
15	fever	B-Adverse_Effect	['N']	[15]
16	two	O	['N']	[16]
17	weeks	O	['N']	[17]
18	after	O	['N']	[18]
19	starting	O	['N']	[19]
20	carbimazole	B-Drug	['Causes']	[15]
21	.	O	['N']	[21]
#703
0	Gastric	B	['N']	[0]
1	tumor	I-Adverse_Effect	['N']	[1]
2	,	O	['N']	[2]
3	endometrial	O	['N']	[3]
4	carcinoma	O	['N']	[4]
5	and	O	['N']	[5]
6	cervical	O	['N']	[6]
7	adenocarcinoma	O	['N']	[7]
8	in	O	['N']	[8]
9	situ	O	['N']	[9]
10	were	O	['N']	[10]
11	detected	O	['N']	[11]
12	after	O	['N']	[12]
13	treatment	O	['N']	[13]
14	with	O	['N']	[14]
15	tamoxifen	B-Drug	['Causes']	[1]
16	for	O	['N']	[16]
17	breast	O	['N']	[17]
18	cancer	O	['N']	[18]
19	.	O	['N']	[19]
#704
0	Bisphosphonate	B-Drug	['Causes']	[6]
1	-	O	['N']	[1]
2	related	O	['N']	[2]
3	osteonecrosis	B	['N']	[3]
4	of	I	['N']	[4]
5	the	I	['N']	[5]
6	jaw	I-Adverse_Effect	['N']	[6]
7	(	O	['N']	[7]
8	BRONJ	O	['N']	[8]
9	)	O	['N']	[9]
10	is	O	['N']	[10]
11	reported	O	['N']	[11]
12	in	O	['N']	[12]
13	up	O	['N']	[13]
14	to	O	['N']	[14]
15	18.6	O	['N']	[15]
16	%	O	['N']	[16]
17	of	O	['N']	[17]
18	patients	O	['N']	[18]
19	treated	O	['N']	[19]
20	with	O	['N']	[20]
21	intravenous	O	['N']	[21]
22	bisphosphonates	O	['N']	[22]
23	and	O	['N']	[23]
24	can	O	['N']	[24]
25	result	O	['N']	[25]
26	in	O	['N']	[26]
27	significant	O	['N']	[27]
28	morbidity	O	['N']	[28]
29	.	O	['N']	[29]
#705
0	Ifosfamide	B-Drug	['Causes']	[8]
1	is	O	['N']	[1]
2	a	O	['N']	[2]
3	known	O	['N']	[3]
4	nephrotoxic	O	['N']	[4]
5	drug	O	['N']	[5]
6	with	O	['N']	[6]
7	demonstrated	O	['N']	[7]
8	tubulopathies	B-Adverse_Effect	['N']	[8]
9	.	O	['N']	[9]
#706
0	Hypersensitivity	B	['N']	[0]
1	reaction	I-Adverse_Effect	['N']	[1]
2	following	O	['N']	[2]
3	chloramphenicol	B-Drug	['Causes']	[1]
4	administration	O	['N']	[4]
5	in	O	['N']	[5]
6	a	O	['N']	[6]
7	patient	O	['N']	[7]
8	with	O	['N']	[8]
9	typhoid	O	['N']	[9]
10	fever	O	['N']	[10]
11	.	O	['N']	[11]
#707
0	Anterior	B	['N']	[0]
1	lumbosacral	I	['N']	[1]
2	radiculopathy	I-Adverse_Effect	['N']	[2]
3	after	O	['N']	[3]
4	intrathecal	O	['N']	[4]
5	methotrexate	B-Drug	['Causes']	[2]
6	treatment	O	['N']	[6]
7	.	O	['N']	[7]
#708
0	Patients	O	['N']	[0]
1	receiving	O	['N']	[1]
2	amifostine	B-Drug	['Causes']	[24]
3	who	O	['N']	[3]
4	develop	O	['N']	[4]
5	only	O	['N']	[5]
6	fever	O	['N']	[6]
7	should	O	['N']	[7]
8	be	O	['N']	[8]
9	evaluated	O	['N']	[9]
10	for	O	['N']	[10]
11	an	O	['N']	[11]
12	adverse	O	['N']	[12]
13	drug	O	['N']	[13]
14	reaction	O	['N']	[14]
15	,	O	['N']	[15]
16	as	O	['N']	[16]
17	well	O	['N']	[17]
18	as	O	['N']	[18]
19	for	O	['N']	[19]
20	sepsis	O	['N']	[20]
21	and	O	['N']	[21]
22	fevers	B	['N']	[22]
23	of	I	['N']	[23]
24	neutropenia	I-Adverse_Effect	['N']	[24]
25	,	O	['N']	[25]
26	and	O	['N']	[26]
27	it	O	['N']	[27]
28	may	O	['N']	[28]
29	be	O	['N']	[29]
30	necessary	O	['N']	[30]
31	to	O	['N']	[31]
32	discontinue	O	['N']	[32]
33	the	O	['N']	[33]
34	drug	O	['N']	[34]
35	.	O	['N']	[35]
#709
0	The	O	['N']	[0]
1	clinical	O	['N']	[1]
2	course	O	['N']	[2]
3	suggested	O	['N']	[3]
4	that	O	['N']	[4]
5	recombinant	B	['N']	[5]
6	alpha-2b	I	['N']	[6]
7	peginterferon	I-Drug	['Causes']	[14]
8	plus	O	['N']	[8]
9	ribavirin	O	['N']	[9]
10	provoked	O	['N']	[10]
11	type	B	['N']	[11]
12	1	I	['N']	[12]
13	diabetes	I	['N']	[13]
14	mellitus	I-Adverse_Effect	['N']	[14]
15	,	O	['N']	[15]
16	therefore	O	['N']	[16]
17	,	O	['N']	[17]
18	in	O	['N']	[18]
19	patients	O	['N']	[19]
20	who	O	['N']	[20]
21	are	O	['N']	[21]
22	candidates	O	['N']	[22]
23	for	O	['N']	[23]
24	interferon	O	['N']	[24]
25	therapy	O	['N']	[25]
26	the	O	['N']	[26]
27	presence	O	['N']	[27]
28	of	O	['N']	[28]
29	pancreatic	O	['N']	[29]
30	autoantibodies	O	['N']	[30]
31	and	O	['N']	[31]
32	the	O	['N']	[32]
33	fasting	O	['N']	[33]
34	plasma	O	['N']	[34]
35	glucose	O	['N']	[35]
36	level	O	['N']	[36]
37	should	O	['N']	[37]
38	be	O	['N']	[38]
39	investigated	O	['N']	[39]
40	before	O	['N']	[40]
41	and	O	['N']	[41]
42	during	O	['N']	[42]
43	treatment	O	['N']	[43]
44	.	O	['N']	[44]
#710
0	Sensory	O	['N']	[0]
1	neuropathy	O	['N']	[1]
2	revealing	O	['N']	[2]
3	necrotizing	B	['N']	[3]
4	vasculitis	I-Adverse_Effect	['N']	[4]
5	during	O	['N']	[5]
6	infliximab	B-Drug	['Causes']	[4]
7	therapy	O	['N']	[7]
8	for	O	['N']	[8]
9	rheumatoid	O	['N']	[9]
10	arthritis	O	['N']	[10]
11	.	O	['N']	[11]
#711
0	Multiple	B	['N']	[0]
1	sclerosis	I	['N']	[1]
2	-	I	['N']	[2]
3	like	I	['N']	[3]
4	disease	I-Adverse_Effect	['N']	[4]
5	secondary	O	['N']	[5]
6	to	O	['N']	[6]
7	alpha	B	['N']	[7]
8	interferon	I-Drug	['Causes']	[4]
9	.	O	['N']	[9]
#712
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	seizure	B-Adverse_Effect	['N']	[5]
6	associated	O	['N']	[6]
7	with	O	['N']	[7]
8	L	B	['N']	[8]
9	-	I	['N']	[9]
10	asparaginase	I-Drug	['Causes']	[5]
11	therapy	O	['N']	[11]
12	but	O	['N']	[12]
13	no	O	['N']	[13]
14	evidence	O	['N']	[14]
15	of	O	['N']	[15]
16	hemorrhagic	O	['N']	[16]
17	or	O	['N']	[17]
18	thrombotic	O	['N']	[18]
19	cerebrovascular	O	['N']	[19]
20	events	O	['N']	[20]
21	.	O	['N']	[21]
#713
0	We	O	['N']	[0]
1	speculate	O	['N']	[1]
2	that	O	['N']	[2]
3	platelet	O	['N']	[3]
4	activation	O	['N']	[4]
5	induced	O	['N']	[5]
6	by	O	['N']	[6]
7	pFVIII	B-Drug	['Causes']	[12]
8	may	O	['N']	[8]
9	have	O	['N']	[9]
10	contributed	O	['N']	[10]
11	to	O	['N']	[11]
12	thrombosis	B-Adverse_Effect	['N']	[12]
13	and	O	['N']	[13]
14	suggest	O	['N']	[14]
15	that	O	['N']	[15]
16	pFVIII	O	['N']	[16]
17	be	O	['N']	[17]
18	used	O	['N']	[18]
19	with	O	['N']	[19]
20	caution	O	['N']	[20]
21	in	O	['N']	[21]
22	elderly	O	['N']	[22]
23	patients	O	['N']	[23]
24	with	O	['N']	[24]
25	pre	O	['N']	[25]
26	-	O	['N']	[26]
27	existing	O	['N']	[27]
28	cardiovascular	O	['N']	[28]
29	risk	O	['N']	[29]
30	factors	O	['N']	[30]
31	.	O	['N']	[31]
#714
0	Based	O	['N']	[0]
1	on	O	['N']	[1]
2	the	O	['N']	[2]
3	Naranjo	O	['N']	[3]
4	probability	O	['N']	[4]
5	scale	O	['N']	[5]
6	,	O	['N']	[6]
7	serotonin	B	['N']	[7]
8	syndrome	I-Adverse_Effect	['N']	[8]
9	was	O	['N']	[9]
10	a	O	['N']	[10]
11	probable	O	['N']	[11]
12	adverse	O	['N']	[12]
13	reaction	O	['N']	[13]
14	associated	O	['N']	[14]
15	with	O	['N']	[15]
16	co	O	['N']	[16]
17	-	O	['N']	[17]
18	administration	O	['N']	[18]
19	of	O	['N']	[19]
20	citalopram	O	['N']	[20]
21	and	O	['N']	[21]
22	fentanyl	B-Drug	['Causes']	[8]
23	.	O	['N']	[23]
#715
0	CONCLUSIONS	O	['N']	[0]
1	:	O	['N']	[1]
2	The	O	['N']	[2]
3	fundus	O	['N']	[3]
4	picture	O	['N']	[4]
5	shown	O	['N']	[5]
6	in	O	['N']	[6]
7	these	O	['N']	[7]
8	cases	O	['N']	[8]
9	may	O	['N']	[9]
10	be	O	['N']	[10]
11	typical	O	['N']	[11]
12	of	O	['N']	[12]
13	ASPPC	B-Adverse_Effect	['N']	[13]
14	after	O	['N']	[14]
15	IVTA	B-Drug	['Causes']	[13]
16	injection	O	['N']	[16]
17	.	O	['N']	[17]
#716
0	In	O	['N']	[0]
1	the	O	['N']	[1]
2	second	O	['N']	[2]
3	case	O	['N']	[3]
4	,	O	['N']	[4]
5	five	O	['N']	[5]
6	cardiac	O	['N']	[6]
7	arrests	O	['N']	[7]
8	due	O	['N']	[8]
9	to	O	['N']	[9]
10	ventricular	O	['N']	[10]
11	tachycardia	O	['N']	[11]
12	and	O	['N']	[12]
13	fibrillation	B-Adverse_Effect	['N']	[13]
14	occurred	O	['N']	[14]
15	during	O	['N']	[15]
16	several	O	['N']	[16]
17	hours	O	['N']	[17]
18	after	O	['N']	[18]
19	beginning	O	['N']	[19]
20	a	O	['N']	[20]
21	trial	O	['N']	[21]
22	of	O	['N']	[22]
23	bretylium	B-Drug	['Causes']	[13]
24	maintenance	O	['N']	[24]
25	therapy	O	['N']	[25]
26	for	O	['N']	[26]
27	complex	O	['N']	[27]
28	ventricular	O	['N']	[28]
29	ectopy	O	['N']	[29]
30	.	O	['N']	[30]
#717
0	A	O	['N']	[0]
1	toxic	O	['N']	[1]
2	encephalopathy	O	['N']	[2]
3	characterized	O	['N']	[3]
4	by	O	['N']	[4]
5	depressed	O	['N']	[5]
6	level	O	['N']	[6]
7	of	O	['N']	[7]
8	consciousness	O	['N']	[8]
9	,	O	['N']	[9]
10	marked	O	['N']	[10]
11	irritability	O	['N']	[11]
12	,	O	['N']	[12]
13	and	O	['N']	[13]
14	ataxia	B-Adverse_Effect	['N']	[14]
15	developed	O	['N']	[15]
16	in	O	['N']	[16]
17	seven	O	['N']	[17]
18	children	O	['N']	[18]
19	,	O	['N']	[19]
20	5	O	['N']	[20]
21	years	O	['N']	[21]
22	of	O	['N']	[22]
23	age	O	['N']	[23]
24	and	O	['N']	[24]
25	younger	O	['N']	[25]
26	,	O	['N']	[26]
27	following	O	['N']	[27]
28	administration	O	['N']	[28]
29	of	O	['N']	[29]
30	an	O	['N']	[30]
31	antiemetic	O	['N']	[31]
32	combination	O	['N']	[32]
33	of	O	['N']	[33]
34	pentobarbital	O	['N']	[34]
35	and	O	['N']	[35]
36	pyrilamine	B	['N']	[36]
37	maleate	I-Drug	['Causes']	[14]
38	.	O	['N']	[38]
#718
0	A	O	['N']	[0]
1	48-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	woman	O	['N']	[4]
5	who	O	['N']	[5]
6	was	O	['N']	[6]
7	treated	O	['N']	[7]
8	for	O	['N']	[8]
9	thyrotoxicosis	O	['N']	[9]
10	with	O	['N']	[10]
11	methimazole	B-Drug	['Causes']	[13]
12	developed	O	['N']	[12]
13	agranulocytosis	B-Adverse_Effect	['N']	[13]
14	.	O	['N']	[14]
#719
0	Thrombotic	B	['N']	[0]
1	stroke	I-Adverse_Effect	['N']	[1]
2	associated	O	['N']	[2]
3	with	O	['N']	[3]
4	the	O	['N']	[4]
5	use	O	['N']	[5]
6	of	O	['N']	[6]
7	porcine	B	['N']	[7]
8	factor	I	['N']	[8]
9	VIII	I-Drug	['Causes']	[1]
10	in	O	['N']	[10]
11	a	O	['N']	[11]
12	patient	O	['N']	[12]
13	with	O	['N']	[13]
14	acquired	O	['N']	[14]
15	haemophilia	O	['N']	[15]
16	.	O	['N']	[16]
#720
0	PVT	B-Adverse_Effect	['N']	[0]
1	during	O	['N']	[1]
2	chemotherapy	O	['N']	[2]
3	in	O	['N']	[3]
4	children	O	['N']	[4]
5	is	O	['N']	[5]
6	a	O	['N']	[6]
7	rare	O	['N']	[7]
8	event	O	['N']	[8]
9	and	O	['N']	[9]
10	appears	O	['N']	[10]
11	to	O	['N']	[11]
12	be	O	['N']	[12]
13	closely	O	['N']	[13]
14	related	O	['N']	[14]
15	to	O	['N']	[15]
16	intensive	O	['N']	[16]
17	chemotherapy	O	['N']	[17]
18	containing	O	['N']	[18]
19	busulfan	B-Drug	['Causes']	[0]
20	and	O	['N']	[20]
21	to	O	['N']	[21]
22	be	O	['N']	[22]
23	associated	O	['N']	[23]
24	with	O	['N']	[24]
25	HVOD	O	['N']	[25]
26	.	O	['N']	[26]
#721
0	An	O	['N']	[0]
1	apparent	O	['N']	[1]
2	link	O	['N']	[2]
3	is	O	['N']	[3]
4	described	O	['N']	[4]
5	between	O	['N']	[5]
6	the	O	['N']	[6]
7	use	O	['N']	[7]
8	of	O	['N']	[8]
9	MMF	O	['N']	[9]
10	with	O	['N']	[10]
11	prednisone	B-Drug	['Causes']	[23]
12	to	O	['N']	[12]
13	treat	O	['N']	[13]
14	pemphigus	O	['N']	[14]
15	vulgaris	O	['N']	[15]
16	and	O	['N']	[16]
17	the	O	['N']	[17]
18	development	O	['N']	[18]
19	of	O	['N']	[19]
20	red	B	['N']	[20]
21	blood	I	['N']	[21]
22	cell	I	['N']	[22]
23	anemia	I-Adverse_Effect	['N']	[23]
24	.	O	['N']	[24]
#722
0	Skin	O	['N']	[0]
1	manifestations	O	['N']	[1]
2	of	O	['N']	[2]
3	a	O	['N']	[3]
4	case	O	['N']	[4]
5	of	O	['N']	[5]
6	phenylbutazone	B-Drug	['Causes']	[13]
7	-	O	['N']	[7]
8	induced	O	['N']	[8]
9	serum	B	['N']	[9]
10	sickness	I	['N']	[10]
11	-	I	['N']	[11]
12	like	I	['N']	[12]
13	reactions	I-Adverse_Effect	['N']	[13]
14	.	O	['N']	[14]
#723
0	Inappropriate	O	['N']	[0]
1	antidiuretic	O	['N']	[1]
2	hormone	O	['N']	[2]
3	secretion	O	['N']	[3]
4	after	O	['N']	[4]
5	high	B	['N']	[5]
6	dose	I-Dose	['N']	[6]
7	vinblastine	B-Drug	['Dosage']	[6]
8	.	O	['N']	[8]
#724
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	the	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	a	O	['N']	[5]
6	17-year	O	['N']	[6]
7	-	O	['N']	[7]
8	old	O	['N']	[8]
9	male	O	['N']	[9]
10	who	O	['N']	[10]
11	developed	O	['N']	[11]
12	chest	O	['N']	[12]
13	pain	O	['N']	[13]
14	,	O	['N']	[14]
15	elevated	B	['N']	[15]
16	cardiac	I	['N']	[16]
17	biomarkers	I-Adverse_Effect	['N']	[17]
18	,	O	['N']	[18]
19	and	O	['N']	[19]
20	acute	O	['N']	[20]
21	left	O	['N']	[21]
22	ventricular	O	['N']	[22]
23	dysfunction	O	['N']	[23]
24	following	O	['N']	[24]
25	a	O	['N']	[25]
26	single	O	['N']	[26]
27	dose	O	['N']	[27]
28	of	O	['N']	[28]
29	methylphenidate	B-Drug	['Causes']	[17]
30	.	O	['N']	[30]
#725
0	Life	O	['N']	[0]
1	-	O	['N']	[1]
2	threatening	O	['N']	[2]
3	acute	B	['N']	[3]
4	hyponatraemia	I-Adverse_Effect	['N']	[4]
5	induced	O	['N']	[5]
6	by	O	['N']	[6]
7	low	O	['N']	[7]
8	dose	O	['N']	[8]
9	cyclophosphamide	O	['N']	[9]
10	and	O	['N']	[10]
11	indomethacin	B-Drug	['Causes']	[4]
12	.	O	['N']	[12]
#726
0	The	O	['N']	[0]
1	possibility	O	['N']	[1]
2	can	O	['N']	[2]
3	be	O	['N']	[3]
4	raised	O	['N']	[4]
5	that	O	['N']	[5]
6	M	B	['N']	[6]
7	-	I	['N']	[7]
8	CSF	I-Drug	['Causes']	[31]
9	accelerated	O	['N']	[9]
10	the	O	['N']	[10]
11	underlying	O	['N']	[11]
12	renal	O	['N']	[12]
13	disease	O	['N']	[13]
14	in	O	['N']	[14]
15	this	O	['N']	[15]
16	case	O	['N']	[16]
17	through	O	['N']	[17]
18	enhancing	O	['N']	[18]
19	macrophage	O	['N']	[19]
20	accumulation	O	['N']	[20]
21	into	O	['N']	[21]
22	the	O	['N']	[22]
23	glomerulus	O	['N']	[23]
24	,	O	['N']	[24]
25	leading	O	['N']	[25]
26	to	O	['N']	[26]
27	the	O	['N']	[27]
28	development	O	['N']	[28]
29	of	O	['N']	[29]
30	nephrotic	B	['N']	[30]
31	syndrome	I-Adverse_Effect	['N']	[31]
32	.	O	['N']	[32]
#727
0	Captopril	B-Drug	['Causes']	[16]
1	is	O	['N']	[1]
2	an	O	['N']	[2]
3	angiotensin	O	['N']	[3]
4	-	O	['N']	[4]
5	converting	O	['N']	[5]
6	enzyme	O	['N']	[6]
7	(	O	['N']	[7]
8	ACE	O	['N']	[8]
9	)	O	['N']	[9]
10	inhibitor	O	['N']	[10]
11	and	O	['N']	[11]
12	their	O	['N']	[12]
13	cutaneous	B	['N']	[13]
14	side	I	['N']	[14]
15	-	I	['N']	[15]
16	effects	I-Adverse_Effect	['N']	[16]
17	are	O	['N']	[17]
18	documented	O	['N']	[18]
19	,	O	['N']	[19]
20	but	O	['N']	[20]
21	little	O	['N']	[21]
22	has	O	['N']	[22]
23	been	O	['N']	[23]
24	published	O	['N']	[24]
25	concerning	O	['N']	[25]
26	the	O	['N']	[26]
27	usefulness	O	['N']	[27]
28	of	O	['N']	[28]
29	patch	O	['N']	[29]
30	test	O	['N']	[30]
31	when	O	['N']	[31]
32	they	O	['N']	[32]
33	occur	O	['N']	[33]
34	.	O	['N']	[34]
#728
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	two	O	['N']	[2]
3	cases	O	['N']	[3]
4	of	O	['N']	[4]
5	tenofovir	B-Drug	['Causes']	[8]
6	(	O	['N']	[6]
7	TDF)-associated	O	['N']	[7]
8	nephrotoxicity	B-Adverse_Effect	['N']	[8]
9	in	O	['N']	[9]
10	perinatally	O	['N']	[10]
11	HIV	O	['N']	[11]
12	-	O	['N']	[12]
13	infected	O	['N']	[13]
14	adolescents	O	['N']	[14]
15	.	O	['N']	[15]
#729
0	This	O	['N']	[0]
1	report	O	['N']	[1]
2	describes	O	['N']	[2]
3	an	O	['N']	[3]
4	individual	O	['N']	[4]
5	with	O	['N']	[5]
6	mental	O	['N']	[6]
7	retardation	O	['N']	[7]
8	who	O	['N']	[8]
9	experienced	O	['N']	[9]
10	behavioral	O	['N']	[10]
11	exacerbation	O	['N']	[11]
12	associated	O	['N']	[12]
13	with	O	['N']	[13]
14	clonazepam	B-Drug	['Dosage']	[27]
15	prescribed	O	['N']	[15]
16	at	O	['N']	[16]
17	2	O	['N']	[17]
18	mg	O	['N']	[18]
19	/	O	['N']	[19]
20	day	O	['N']	[20]
21	(	O	['N']	[21]
22	0.02	B	['N']	[22]
23	mg	I	['N']	[23]
24	/	I	['N']	[24]
25	kg	I	['N']	[25]
26	/	I	['N']	[26]
27	day	I-Dose	['N']	[27]
28	)	O	['N']	[28]
29	to	O	['N']	[29]
30	treat	O	['N']	[30]
31	aggression	O	['N']	[31]
32	,	O	['N']	[32]
33	self	O	['N']	[33]
34	-	O	['N']	[34]
35	injurious	O	['N']	[35]
36	behavior	O	['N']	[36]
37	,	O	['N']	[37]
38	property	O	['N']	[38]
39	destruction	O	['N']	[39]
40	,	O	['N']	[40]
41	and	O	['N']	[41]
42	screaming	O	['N']	[42]
43	,	O	['N']	[43]
44	which	O	['N']	[44]
45	was	O	['N']	[45]
46	measured	O	['N']	[46]
47	with	O	['N']	[47]
48	a	O	['N']	[48]
49	15-minute	O	['N']	[49]
50	partial	O	['N']	[50]
51	interval	O	['N']	[51]
52	recording	O	['N']	[52]
53	measurement	O	['N']	[53]
54	method	O	['N']	[54]
55	.	O	['N']	[55]
#730
0	Acute	B	['N']	[0]
1	generalized	I	['N']	[1]
2	exanthematous	I	['N']	[2]
3	pustulosis	I-Adverse_Effect	['N']	[3]
4	induced	O	['N']	[4]
5	by	O	['N']	[5]
6	salazosulfapyridine	B-Drug	['Causes']	[3]
7	in	O	['N']	[7]
8	a	O	['N']	[8]
9	patient	O	['N']	[9]
10	with	O	['N']	[10]
11	ulcerative	O	['N']	[11]
12	colitis	O	['N']	[12]
13	.	O	['N']	[13]
#731
0	OBJECTIVE	O	['N']	[0]
1	:	O	['N']	[1]
2	To	O	['N']	[2]
3	report	O	['N']	[3]
4	the	O	['N']	[4]
5	occurrence	O	['N']	[5]
6	of	O	['N']	[6]
7	anterior	B	['N']	[7]
8	ischemic	I	['N']	[8]
9	optic	I	['N']	[9]
10	neuropathy	I-Adverse_Effect	['N']	[10]
11	as	O	['N']	[11]
12	a	O	['N']	[12]
13	complication	O	['N']	[13]
14	of	O	['N']	[14]
15	treatment	O	['N']	[15]
16	with	O	['N']	[16]
17	interferon	B	['N']	[17]
18	alfa	I-Drug	['Causes']	[10]
19	and	O	['N']	[19]
20	to	O	['N']	[20]
21	consider	O	['N']	[21]
22	the	O	['N']	[22]
23	possible	O	['N']	[23]
24	underlying	O	['N']	[24]
25	mechanisms	O	['N']	[25]
26	for	O	['N']	[26]
27	this	O	['N']	[27]
28	association	O	['N']	[28]
29	.	O	['N']	[29]
#732
0	RESULTS	O	['N']	[0]
1	:	O	['N']	[1]
2	In	O	['N']	[2]
3	a	O	['N']	[3]
4	22-year	O	['N']	[4]
5	-	O	['N']	[5]
6	old	O	['N']	[6]
7	Thai	O	['N']	[7]
8	woman	O	['N']	[8]
9	with	O	['N']	[9]
10	Graves	O	['N']	[10]
11	'	O	['N']	[11]
12	disease	O	['N']	[12]
13	,	O	['N']	[13]
14	tinnitus	B-Adverse_Effect	['N']	[14]
15	,	O	['N']	[15]
16	hearing	O	['N']	[16]
17	impairment	O	['N']	[17]
18	in	O	['N']	[18]
19	the	O	['N']	[19]
20	left	O	['N']	[20]
21	ear	O	['N']	[21]
22	(	O	['N']	[22]
23	with	O	['N']	[23]
24	progression	O	['N']	[24]
25	to	O	['N']	[25]
26	the	O	['N']	[26]
27	right	O	['N']	[27]
28	ear	O	['N']	[28]
29	)	O	['N']	[29]
30	,	O	['N']	[30]
31	and	O	['N']	[31]
32	vertigo	O	['N']	[32]
33	developed	O	['N']	[33]
34	after	O	['N']	[34]
35	3	O	['N']	[35]
36	years	O	['N']	[36]
37	of	O	['N']	[37]
38	therapy	O	['N']	[38]
39	with	O	['N']	[39]
40	PTU	B-Drug	['Causes']	[14]
41	.	O	['N']	[41]
#733
0	However	O	['N']	[0]
1	,	O	['N']	[1]
2	there	O	['N']	[2]
3	remain	O	['N']	[3]
4	questions	O	['N']	[4]
5	concerning	O	['N']	[5]
6	whether	O	['N']	[6]
7	these	O	['N']	[7]
8	drugs	O	['N']	[8]
9	,	O	['N']	[9]
10	especially	O	['N']	[10]
11	methimazole	O	['N']	[11]
12	(	O	['N']	[12]
13	MMI	B-Drug	['Causes']	[24]
14	)	O	['N']	[14]
15	,	O	['N']	[15]
16	may	O	['N']	[16]
17	be	O	['N']	[17]
18	associated	O	['N']	[18]
19	with	O	['N']	[19]
20	aplasia	O	['N']	[20]
21	cutis	O	['N']	[21]
22	congenita	O	['N']	[22]
23	(	O	['N']	[23]
24	ACC	B-Adverse_Effect	['N']	[24]
25	)	O	['N']	[25]
26	and	O	['N']	[26]
27	how	O	['N']	[27]
28	best	O	['N']	[28]
29	to	O	['N']	[29]
30	avoid	O	['N']	[30]
31	impairment	O	['N']	[31]
32	of	O	['N']	[32]
33	fetal	O	['N']	[33]
34	thyroid	O	['N']	[34]
35	function	O	['N']	[35]
36	during	O	['N']	[36]
37	their	O	['N']	[37]
38	use	O	['N']	[38]
39	.	O	['N']	[39]
#734
0	Elevated	B	['N']	[0]
1	serum	I	['N']	[1]
2	triglycerides	I-Adverse_Effect	['N']	[2]
3	with	O	['N']	[3]
4	clozapine	B-Drug	['Causes']	[2]
5	resolved	O	['N']	[5]
6	with	O	['N']	[6]
7	risperidone	O	['N']	[7]
8	in	O	['N']	[8]
9	four	O	['N']	[9]
10	patients	O	['N']	[10]
11	.	O	['N']	[11]
#735
0	Posterior	B	['N']	[0]
1	reversible	I	['N']	[1]
2	encephalopathy	I	['N']	[2]
3	syndrome	I-Adverse_Effect	['N']	[3]
4	(	O	['N']	[4]
5	PRES	B-Drug	['Causes']	[3]
6	)	O	['N']	[6]
7	induced	O	['N']	[7]
8	by	O	['N']	[8]
9	cyclosporine	O	['N']	[9]
10	use	O	['N']	[10]
11	in	O	['N']	[11]
12	a	O	['N']	[12]
13	patient	O	['N']	[13]
14	with	O	['N']	[14]
15	collapsing	O	['N']	[15]
16	focal	O	['N']	[16]
17	glomeruloesclerosis	O	['N']	[17]
18	.	O	['N']	[18]
#736
0	In	O	['N']	[0]
1	case	O	['N']	[1]
2	1	O	['N']	[2]
3	,	O	['N']	[3]
4	a	O	['N']	[4]
5	total	O	['N']	[5]
6	daily	O	['N']	[6]
7	dose	O	['N']	[7]
8	of	O	['N']	[8]
9	25	O	['N']	[9]
10	mg	O	['N']	[10]
11	sertraline	B-Drug	['Causes']	[29]
12	,	O	['N']	[12]
13	with	O	['N']	[13]
14	nondetectable	O	['N']	[14]
15	sertraline	O	['N']	[15]
16	and	O	['N']	[16]
17	desmethylsertraline	O	['N']	[17]
18	blood	O	['N']	[18]
19	levels	O	['N']	[19]
20	,	O	['N']	[20]
21	resulted	O	['N']	[21]
22	in	O	['N']	[22]
23	a	O	['N']	[23]
24	doubling	B	['N']	[24]
25	of	I	['N']	[25]
26	the	I	['N']	[26]
27	lamotrigine	I	['N']	[27]
28	blood	I	['N']	[28]
29	level	I-Adverse_Effect	['N']	[29]
30	with	O	['N']	[30]
31	symptoms	O	['N']	[31]
32	of	O	['N']	[32]
33	toxicity	O	['N']	[33]
34	.	O	['N']	[34]
#737
0	The	O	['N']	[0]
1	hearing	B	['N']	[1]
2	impairment	I-Adverse_Effect	['N']	[2]
3	and	O	['N']	[3]
4	tinnitus	O	['N']	[4]
5	were	O	['N']	[5]
6	gradually	O	['N']	[6]
7	reduced	O	['N']	[7]
8	after	O	['N']	[8]
9	PTU	B-Drug	['Causes']	[2]
10	withdrawal	O	['N']	[10]
11	and	O	['N']	[11]
12	corticosteroid	O	['N']	[12]
13	and	O	['N']	[13]
14	azathioprine	O	['N']	[14]
15	treatment	O	['N']	[15]
16	.	O	['N']	[16]
#738
0	Sulindac	B-Drug	['Causes']	[17]
1	(	O	['N']	[1]
2	Clinoril	O	['N']	[2]
3	)	O	['N']	[3]
4	,	O	['N']	[4]
5	a	O	['N']	[5]
6	nonsteroidal	O	['N']	[6]
7	anti	O	['N']	[7]
8	-	O	['N']	[8]
9	inflammatory	O	['N']	[9]
10	agent	O	['N']	[10]
11	,	O	['N']	[11]
12	has	O	['N']	[12]
13	few	O	['N']	[13]
14	reported	O	['N']	[14]
15	neurologic	B	['N']	[15]
16	toxic	I	['N']	[16]
17	effects	I-Adverse_Effect	['N']	[17]
18	,	O	['N']	[18]
19	all	O	['N']	[19]
20	of	O	['N']	[20]
21	which	O	['N']	[21]
22	have	O	['N']	[22]
23	been	O	['N']	[23]
24	associated	O	['N']	[24]
25	with	O	['N']	[25]
26	systemic	O	['N']	[26]
27	disease	O	['N']	[27]
28	.	O	['N']	[28]
#739
0	Alternating	B	['N']	[0]
1	sinus	I	['N']	[1]
2	rhythm	I-Adverse_Effect	['N']	[2]
3	and	O	['N']	[3]
4	intermittent	O	['N']	[4]
5	sinoatrial	O	['N']	[5]
6	block	O	['N']	[6]
7	induced	O	['N']	[7]
8	by	O	['N']	[8]
9	propranolol	B-Drug	['Causes']	[2]
10	.	O	['N']	[10]
#740
0	Paraplegia	B-Adverse_Effect	['N']	[0]
1	following	O	['N']	[1]
2	intrathecal	O	['N']	[2]
3	cytosine	B	['N']	[3]
4	arabinoside	I-Drug	['Causes']	[0]
5	.	O	['N']	[5]
#741
0	CASE	O	['N']	[0]
1	REPORT	O	['N']	[1]
2	:	O	['N']	[2]
3	Soon	O	['N']	[3]
4	after	O	['N']	[4]
5	initiation	O	['N']	[5]
6	of	O	['N']	[6]
7	amiodarone	B	['N']	[7]
8	HCl	I-Drug	['Causes']	[41]
9	(	O	['N']	[9]
10	200	O	['N']	[10]
11	mg	O	['N']	[11]
12	/	O	['N']	[12]
13	day	O	['N']	[13]
14	)	O	['N']	[14]
15	,	O	['N']	[15]
16	a	O	['N']	[16]
17	76-year	O	['N']	[17]
18	-	O	['N']	[18]
19	old	O	['N']	[19]
20	man	O	['N']	[20]
21	came	O	['N']	[21]
22	to	O	['N']	[22]
23	us	O	['N']	[23]
24	with	O	['N']	[24]
25	symptoms	O	['N']	[25]
26	of	O	['N']	[26]
27	visual	O	['N']	[27]
28	"	O	['N']	[28]
29	shining	O	['N']	[29]
30	,	O	['N']	[30]
31	"	O	['N']	[31]
32	glare	O	['N']	[32]
33	,	O	['N']	[33]
34	color	O	['N']	[34]
35	vision	O	['N']	[35]
36	anomalies	O	['N']	[36]
37	,	O	['N']	[37]
38	and	O	['N']	[38]
39	gradually	O	['N']	[39]
40	decreased	B	['N']	[40]
41	vision	I-Adverse_Effect	['N']	[41]
42	.	O	['N']	[42]
#742
0	She	O	['N']	[0]
1	was	O	['N']	[1]
2	placed	O	['N']	[2]
3	on	O	['N']	[3]
4	adjuvant	O	['N']	[4]
5	Adriamycin	O	['N']	[5]
6	(	O	['N']	[6]
7	doxorubicin	B-Drug	['Causes']	[15]
8	)	O	['N']	[8]
9	chemotherapy	O	['N']	[9]
10	,	O	['N']	[10]
11	but	O	['N']	[11]
12	6	O	['N']	[12]
13	months	O	['N']	[13]
14	later	O	['N']	[14]
15	died	B-Adverse_Effect	['N']	[15]
16	of	O	['N']	[16]
17	Adriamycin	O	['N']	[17]
18	toxicity	O	['N']	[18]
19	.	O	['N']	[19]
#743
0	The	O	['N']	[0]
1	site	O	['N']	[1]
2	of	O	['N']	[2]
3	thrombosis	O	['N']	[3]
4	and	O	['N']	[4]
5	the	O	['N']	[5]
6	chronological	O	['N']	[6]
7	relationship	O	['N']	[7]
8	with	O	['N']	[8]
9	the	O	['N']	[9]
10	IIR	O	['N']	[10]
11	implicates	O	['N']	[11]
12	a	O	['N']	[12]
13	hypersensitivity	O	['N']	[13]
14	to	O	['N']	[14]
15	infliximab	B-Drug	['Causes']	[22]
16	in	O	['N']	[16]
17	the	O	['N']	[17]
18	causation	O	['N']	[18]
19	of	O	['N']	[19]
20	the	O	['N']	[20]
21	venous	B	['N']	[21]
22	thrombosis	I-Adverse_Effect	['N']	[22]
23	in	O	['N']	[23]
24	this	O	['N']	[24]
25	case	O	['N']	[25]
26	.	O	['N']	[26]
#744
0	Although	O	['N']	[0]
1	the	O	['N']	[1]
2	t	B	['N']	[2]
3	-	I	['N']	[3]
4	AML	I-Adverse_Effect	['N']	[4]
5	developed	O	['N']	[5]
6	following	O	['N']	[6]
7	oral	O	['N']	[7]
8	etoposide	B-Drug	['Causes']	[4]
9	therapy	O	['N']	[9]
10	,	O	['N']	[10]
11	the	O	['N']	[11]
12	child	O	['N']	[12]
13	had	O	['N']	[13]
14	previously	O	['N']	[14]
15	received	O	['N']	[15]
16	high	O	['N']	[16]
17	-	O	['N']	[17]
18	dose	O	['N']	[18]
19	,	O	['N']	[19]
20	multiagent	O	['N']	[20]
21	chemotherapy	O	['N']	[21]
22	,	O	['N']	[22]
23	and	O	['N']	[23]
24	rearrangement	O	['N']	[24]
25	of	O	['N']	[25]
26	the	O	['N']	[26]
27	MLL	O	['N']	[27]
28	gene	O	['N']	[28]
29	was	O	['N']	[29]
30	not	O	['N']	[30]
31	demonstrated	O	['N']	[31]
32	.	O	['N']	[32]
#745
0	Two	O	['N']	[0]
1	patients	O	['N']	[1]
2	are	O	['N']	[2]
3	described	O	['N']	[3]
4	who	O	['N']	[4]
5	developed	O	['N']	[5]
6	sensory	O	['N']	[6]
7	neuropathy	O	['N']	[7]
8	after	O	['N']	[8]
9	the	O	['N']	[9]
10	ingestion	O	['N']	[10]
11	of	O	['N']	[11]
12	30.6	O	['N']	[12]
13	and	O	['N']	[13]
14	114	B	['N']	[14]
15	g	I-Dose	['N']	[15]
16	metronidazole	B-Drug	['Dosage']	[15]
17	respectively	O	['N']	[17]
18	.	O	['N']	[18]
#746
0	CONCLUSION	O	['N']	[0]
1	:	O	['N']	[1]
2	Squamous	B	['N']	[2]
3	metaplasia	I-Adverse_Effect	['N']	[3]
4	in	O	['N']	[4]
5	these	O	['N']	[5]
6	cases	O	['N']	[6]
7	appears	O	['N']	[7]
8	to	O	['N']	[8]
9	be	O	['N']	[9]
10	a	O	['N']	[10]
11	consequence	O	['N']	[11]
12	of	O	['N']	[12]
13	progestin	B-Drug	['Causes']	[3]
14	therapy	O	['N']	[14]
15	.	O	['N']	[15]
#747
0	Acute	B	['N']	[0]
1	generalized	I	['N']	[1]
2	exanthematous	I	['N']	[2]
3	pustulosis	I-Adverse_Effect	['N']	[3]
4	induced	O	['N']	[4]
5	by	O	['N']	[5]
6	nimesulide	B-Drug	['Causes']	[3]
7	.	O	['N']	[7]
#748
0	METHOD	O	['N']	[0]
1	:	O	['N']	[1]
2	We	O	['N']	[2]
3	describe	O	['N']	[3]
4	three	O	['N']	[4]
5	case	O	['N']	[5]
6	-	O	['N']	[6]
7	reports	O	['N']	[7]
8	concerning	O	['N']	[8]
9	haematological	B	['N']	[9]
10	adverse	I	['N']	[10]
11	effects	I-Adverse_Effect	['N']	[11]
12	of	O	['N']	[12]
13	quetiapine	B-Drug	['Causes']	[11]
14	.	O	['N']	[14]
#749
0	In	O	['N']	[0]
1	rare	O	['N']	[1]
2	cases	O	['N']	[2]
3	mitomycin	O	['N']	[3]
4	C	O	['N']	[4]
5	(	O	['N']	[5]
6	MMC	B-Drug	['Causes']	[24]
7	)	O	['N']	[7]
8	may	O	['N']	[8]
9	induce	O	['N']	[9]
10	cancer	O	['N']	[10]
11	-	O	['N']	[11]
12	associated	O	['N']	[12]
13	hemolytic	O	['N']	[13]
14	uremic	O	['N']	[14]
15	syndrome	O	['N']	[15]
16	,	O	['N']	[16]
17	which	O	['N']	[17]
18	is	O	['N']	[18]
19	characterized	O	['N']	[19]
20	by	O	['N']	[20]
21	hemolytic	O	['N']	[21]
22	anemia	O	['N']	[22]
23	,	O	['N']	[23]
24	thrombocytopenia	B-Adverse_Effect	['N']	[24]
25	and	O	['N']	[25]
26	progressive	O	['N']	[26]
27	renal	O	['N']	[27]
28	failure	O	['N']	[28]
29	.	O	['N']	[29]
#750
0	CONCLUSIONS	O	['N']	[0]
1	:	O	['N']	[1]
2	Low	O	['N']	[2]
3	dosages	O	['N']	[3]
4	of	O	['N']	[4]
5	quinacrine	O	['N']	[5]
6	used	O	['N']	[6]
7	for	O	['N']	[7]
8	malaria	O	['N']	[8]
9	prophylaxis	O	['N']	[9]
10	can	O	['N']	[10]
11	be	O	['N']	[11]
12	associated	O	['N']	[12]
13	with	O	['N']	[13]
14	a	O	['N']	[14]
15	delayed	O	['N']	[15]
16	,	O	['N']	[16]
17	severe	O	['N']	[17]
18	maculopathy	B-Adverse_Effect	['N']	[18]
19	indistinguishable	O	['N']	[19]
20	from	O	['N']	[20]
21	chloroquine	B-Drug	['Causes']	[18]
22	maculopathy	O	['N']	[22]
23	in	O	['N']	[23]
24	certain	O	['N']	[24]
25	patients	O	['N']	[25]
26	.	O	['N']	[26]
#751
0	Because	O	['N']	[0]
1	nephrotic	B	['N']	[1]
2	syndrome	I-Adverse_Effect	['N']	[2]
3	may	O	['N']	[3]
4	be	O	['N']	[4]
5	induced	O	['N']	[5]
6	by	O	['N']	[6]
7	IFN	B-Drug	['Causes']	[2]
8	therapy	O	['N']	[8]
9	,	O	['N']	[9]
10	the	O	['N']	[10]
11	IFN	O	['N']	[11]
12	was	O	['N']	[12]
13	stopped	O	['N']	[13]
14	.	O	['N']	[14]
#752
0	First	O	['N']	[0]
1	,	O	['N']	[1]
2	a	O	['N']	[2]
3	review	O	['N']	[3]
4	of	O	['N']	[4]
5	the	O	['N']	[5]
6	literature	O	['N']	[6]
7	produced	O	['N']	[7]
8	41	O	['N']	[8]
9	anecdotic	O	['N']	[9]
10	cases	O	['N']	[10]
11	of	O	['N']	[11]
12	neutropenia	B-Adverse_Effect	['N']	[12]
13	or	O	['N']	[13]
14	agranulocytosis	O	['N']	[14]
15	during	O	['N']	[15]
16	treatment	O	['N']	[16]
17	with	O	['N']	[17]
18	olanzapine	O	['N']	[18]
19	(	O	['N']	[19]
20	Zyprexa	B-Drug	['Causes']	[12]
21	)	O	['N']	[21]
22	reported	O	['N']	[22]
23	in	O	['N']	[23]
24	a	O	['N']	[24]
25	total	O	['N']	[25]
26	of	O	['N']	[26]
27	24	O	['N']	[27]
28	publications	O	['N']	[28]
29	.	O	['N']	[29]
#753
0	Since	O	['N']	[0]
1	imiquimod	B-Drug	['Causes']	[9]
2	induces	O	['N']	[2]
3	large	B	['N']	[3]
4	amounts	I	['N']	[4]
5	of	I	['N']	[5]
6	type	I	['N']	[6]
7	I	I	['N']	[7]
8	interferon	I	['N']	[8]
9	production	I-Adverse_Effect	['N']	[9]
10	from	O	['N']	[10]
11	TLR7-expressing	O	['N']	[11]
12	plasmacytoid	O	['N']	[12]
13	dendritic	O	['N']	[13]
14	cell	O	['N']	[14]
15	precursors	O	['N']	[15]
16	(	O	['N']	[16]
17	PDCs	O	['N']	[17]
18	)	O	['N']	[18]
19	,	O	['N']	[19]
20	the	O	['N']	[20]
21	natural	O	['N']	[21]
22	interferon	O	['N']	[22]
23	-	O	['N']	[23]
24	producing	O	['N']	[24]
25	cells	O	['N']	[25]
26	of	O	['N']	[26]
27	the	O	['N']	[27]
28	peripheral	O	['N']	[28]
29	blood	O	['N']	[29]
30	,	O	['N']	[30]
31	we	O	['N']	[31]
32	asked	O	['N']	[32]
33	whether	O	['N']	[33]
34	PDCs	O	['N']	[34]
35	are	O	['N']	[35]
36	present	O	['N']	[36]
37	in	O	['N']	[37]
38	psoriatic	O	['N']	[38]
39	skin	O	['N']	[39]
40	.	O	['N']	[40]
#754
0	The	O	['N']	[0]
1	current	O	['N']	[1]
2	study	O	['N']	[2]
3	investigated	O	['N']	[3]
4	the	O	['N']	[4]
5	visual	O	['N']	[5]
6	fields	O	['N']	[6]
7	and	O	['N']	[7]
8	visual	O	['N']	[8]
9	electrophysiology	O	['N']	[9]
10	of	O	['N']	[10]
11	eight	O	['N']	[11]
12	patients	O	['N']	[12]
13	with	O	['N']	[13]
14	known	O	['N']	[14]
15	vigabatrin	B-Drug	['Causes']	[20]
16	-	O	['N']	[16]
17	attributed	O	['N']	[17]
18	visual	B	['N']	[18]
19	field	I	['N']	[19]
20	loss	I-Adverse_Effect	['N']	[20]
21	,	O	['N']	[21]
22	three	O	['N']	[22]
23	of	O	['N']	[23]
24	whom	O	['N']	[24]
25	were	O	['N']	[25]
26	reported	O	['N']	[26]
27	previously	O	['N']	[27]
28	.	O	['N']	[28]
#755
0	We	O	['N']	[0]
1	describe	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	advanced	O	['N']	[5]
6	ovarian	O	['N']	[6]
7	carcinoma	O	['N']	[7]
8	who	O	['N']	[8]
9	developed	O	['N']	[9]
10	difficulty	O	['N']	[10]
11	walking	O	['N']	[11]
12	because	O	['N']	[12]
13	of	O	['N']	[13]
14	marked	O	['N']	[14]
15	pain	O	['N']	[15]
16	in	O	['N']	[16]
17	the	O	['N']	[17]
18	lower	O	['N']	[18]
19	extremities	O	['N']	[19]
20	and	O	['N']	[20]
21	loss	O	['N']	[21]
22	of	O	['N']	[22]
23	proprioception	O	['N']	[23]
24	25	O	['N']	[24]
25	days	O	['N']	[25]
26	after	O	['N']	[26]
27	treatment	O	['N']	[27]
28	with	O	['N']	[28]
29	weekly	O	['N']	[29]
30	taxol	B-Drug	['Dosage']	[35]
31	(	O	['N']	[31]
32	80	B	['N']	[32]
33	mg	I	['N']	[33]
34	/	I	['N']	[34]
35	m(2)x3	I-Dose	['N']	[35]
36	)	O	['N']	[36]
37	.	O	['N']	[37]
#756
0	However	O	['N']	[0]
1	,	O	['N']	[1]
2	a	O	['N']	[2]
3	large	O	['N']	[3]
4	case	O	['N']	[4]
5	-	O	['N']	[5]
6	control	O	['N']	[6]
7	study	O	['N']	[7]
8	included	O	['N']	[8]
9	three	O	['N']	[9]
10	cases	O	['N']	[10]
11	of	O	['N']	[11]
12	either	O	['N']	[12]
13	Stevens	B	['N']	[13]
14	-	I	['N']	[14]
15	Johnson	I	['N']	[15]
16	syndrome	I-Adverse_Effect	['N']	[16]
17	or	O	['N']	[17]
18	toxic	O	['N']	[18]
19	epidermal	O	['N']	[19]
20	necrolysis	O	['N']	[20]
21	associated	O	['N']	[21]
22	with	O	['N']	[22]
23	ofloxacin	B-Drug	['Causes']	[16]
24	use	O	['N']	[24]
25	,	O	['N']	[25]
26	but	O	['N']	[26]
27	no	O	['N']	[27]
28	details	O	['N']	[28]
29	of	O	['N']	[29]
30	the	O	['N']	[30]
31	cases	O	['N']	[31]
32	were	O	['N']	[32]
33	given	O	['N']	[33]
34	.	O	['N']	[34]
#757
0	The	O	['N']	[0]
1	more	O	['N']	[1]
2	common	O	['N']	[2]
3	grade	O	['N']	[3]
4	3	O	['N']	[4]
5	or	O	['N']	[5]
6	4	O	['N']	[6]
7	adverse	O	['N']	[7]
8	effects	O	['N']	[8]
9	of	O	['N']	[9]
10	sunitinib	B-Drug	['Causes']	[22]
11	include	O	['N']	[11]
12	hypertension	O	['N']	[12]
13	,	O	['N']	[13]
14	fatigue	O	['N']	[14]
15	,	O	['N']	[15]
16	hand	O	['N']	[16]
17	-	O	['N']	[17]
18	foot	O	['N']	[18]
19	syndrome	O	['N']	[19]
20	,	O	['N']	[20]
21	elevated	B	['N']	[21]
22	lipase	I-Adverse_Effect	['N']	[22]
23	and	O	['N']	[23]
24	lymphopenia	O	['N']	[24]
25	.	O	['N']	[25]
#758
0	Early	O	['N']	[0]
1	-	O	['N']	[1]
2	onset	O	['N']	[2]
3	pentamidine	B-Drug	['Causes']	[13]
4	-	O	['N']	[4]
5	associated	O	['N']	[5]
6	second	O	['N']	[6]
7	-	O	['N']	[7]
8	degree	O	['N']	[8]
9	heart	O	['N']	[9]
10	block	O	['N']	[10]
11	and	O	['N']	[11]
12	sinus	B	['N']	[12]
13	bradycardia	I-Adverse_Effect	['N']	[13]
14	:	O	['N']	[14]
15	case	O	['N']	[15]
16	report	O	['N']	[16]
17	and	O	['N']	[17]
18	review	O	['N']	[18]
19	of	O	['N']	[19]
20	the	O	['N']	[20]
21	literature	O	['N']	[21]
22	.	O	['N']	[22]
#759
0	A	O	['N']	[0]
1	10-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	boy	O	['N']	[4]
5	with	O	['N']	[5]
6	osteosarcoma	O	['N']	[6]
7	and	O	['N']	[7]
8	normal	O	['N']	[8]
9	renal	O	['N']	[9]
10	function	O	['N']	[10]
11	manifested	O	['N']	[11]
12	laboratory	O	['N']	[12]
13	evidence	O	['N']	[13]
14	of	O	['N']	[14]
15	impending	O	['N']	[15]
16	renal	O	['N']	[16]
17	toxicity	O	['N']	[17]
18	and	O	['N']	[18]
19	extreme	O	['N']	[19]
20	elevation	B	['N']	[20]
21	of	I	['N']	[21]
22	aspartate	I	['N']	[22]
23	aminotrasferase	I-Adverse_Effect	['N']	[23]
24	and	O	['N']	[24]
25	alanine	O	['N']	[25]
26	aminotransferase	O	['N']	[26]
27	within	O	['N']	[27]
28	2	O	['N']	[28]
29	hours	O	['N']	[29]
30	after	O	['N']	[30]
31	the	O	['N']	[31]
32	completion	O	['N']	[32]
33	of	O	['N']	[33]
34	a	O	['N']	[34]
35	4-hour	O	['N']	[35]
36	infusion	O	['N']	[36]
37	of	O	['N']	[37]
38	high	O	['N']	[38]
39	-	O	['N']	[39]
40	dose	O	['N']	[40]
41	methotrexate	O	['N']	[41]
42	(	O	['N']	[42]
43	MTX	B-Drug	['Causes']	[23]
44	)	O	['N']	[44]
45	(	O	['N']	[45]
46	12	O	['N']	[46]
47	g	O	['N']	[47]
48	/	O	['N']	[48]
49	m2	O	['N']	[49]
50	)	O	['N']	[50]
51	,	O	['N']	[51]
52	and	O	['N']	[52]
53	went	O	['N']	[53]
54	on	O	['N']	[54]
55	to	O	['N']	[55]
56	develop	O	['N']	[56]
57	acute	O	['N']	[57]
58	renal	O	['N']	[58]
59	failure	O	['N']	[59]
60	with	O	['N']	[60]
61	life	O	['N']	[61]
62	-	O	['N']	[62]
63	threatening	O	['N']	[63]
64	hyperkalemia	O	['N']	[64]
65	29	O	['N']	[65]
66	hours	O	['N']	[66]
67	later	O	['N']	[67]
68	.	O	['N']	[68]
#760
0	A	O	['N']	[0]
1	36-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	man	O	['N']	[4]
5	being	O	['N']	[5]
6	treated	O	['N']	[6]
7	with	O	['N']	[7]
8	cisplatinum	B-Drug	['Causes']	[32]
9	,	O	['N']	[9]
10	vinblastine	O	['N']	[10]
11	,	O	['N']	[11]
12	and	O	['N']	[12]
13	bleomycin	O	['N']	[13]
14	for	O	['N']	[14]
15	testicular	O	['N']	[15]
16	carcinoma	O	['N']	[16]
17	developed	O	['N']	[17]
18	a	O	['N']	[18]
19	dense	O	['N']	[19]
20	left	O	['N']	[20]
21	homonymous	O	['N']	[21]
22	hemianopsia	O	['N']	[22]
23	,	O	['N']	[23]
24	encephalopathy	O	['N']	[24]
25	,	O	['N']	[25]
26	and	O	['N']	[26]
27	a	O	['N']	[27]
28	partial	B	['N']	[28]
29	nondominant	I	['N']	[29]
30	parietal	I	['N']	[30]
31	lobe	I	['N']	[31]
32	syndrome	I-Adverse_Effect	['N']	[32]
33	.	O	['N']	[33]
#761
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	on	O	['N']	[2]
3	a	O	['N']	[3]
4	patient	O	['N']	[4]
5	who	O	['N']	[5]
6	developed	O	['N']	[6]
7	hypersensitivity	B	['N']	[7]
8	pneumonitis	I-Adverse_Effect	['N']	[8]
9	during	O	['N']	[9]
10	treatment	O	['N']	[10]
11	with	O	['N']	[11]
12	the	O	['N']	[12]
13	beta	O	['N']	[13]
14	-	O	['N']	[14]
15	blocker	O	['N']	[15]
16	,	O	['N']	[16]
17	celiprolol	B-Drug	['Causes']	[8]
18	.	O	['N']	[18]
#762
0	This	O	['N']	[0]
1	communication	O	['N']	[1]
2	describes	O	['N']	[2]
3	a	O	['N']	[3]
4	patient	O	['N']	[4]
5	who	O	['N']	[5]
6	developed	O	['N']	[6]
7	Schneiderian	B	['N']	[7]
8	first	I	['N']	[8]
9	-	I	['N']	[9]
10	rank	I	['N']	[10]
11	symptoms	I-Adverse_Effect	['N']	[11]
12	in	O	['N']	[12]
13	the	O	['N']	[13]
14	course	O	['N']	[14]
15	of	O	['N']	[15]
16	treatment	O	['N']	[16]
17	with	O	['N']	[17]
18	fluvoxamine	B-Drug	['Causes']	[11]
19	.	O	['N']	[19]
#763
0	A	O	['N']	[0]
1	17-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	female	O	['N']	[4]
5	patient	O	['N']	[5]
6	who	O	['N']	[6]
7	had	O	['N']	[7]
8	been	O	['N']	[8]
9	taking	O	['N']	[9]
10	oral	O	['N']	[10]
11	minocycline	B-Drug	['Dosage']	[16]
12	(	O	['N']	[12]
13	50	B	['N']	[13]
14	mg	I	['N']	[14]
15	twice	I	['N']	[15]
16	daily	I-Dose	['N']	[16]
17	)	O	['N']	[17]
18	for	O	['N']	[18]
19	3	O	['N']	[19]
20	weeks	O	['N']	[20]
21	for	O	['N']	[21]
22	acne	O	['N']	[22]
23	developed	O	['N']	[23]
24	an	O	['N']	[24]
25	eruption	O	['N']	[25]
26	that	O	['N']	[26]
27	progressed	O	['N']	[27]
28	to	O	['N']	[28]
29	an	O	['N']	[29]
30	exfoliative	O	['N']	[30]
31	dermatitis	O	['N']	[31]
32	.	O	['N']	[32]
#764
0	In	O	['N']	[0]
1	case	O	['N']	[1]
2	no	O	['N']	[2]
3	.	O	['N']	[3]
4	2	O	['N']	[4]
5	,	O	['N']	[5]
6	the	O	['N']	[6]
7	pathogenic	O	['N']	[7]
8	mechanism	O	['N']	[8]
9	seemed	O	['N']	[9]
10	to	O	['N']	[10]
11	be	O	['N']	[11]
12	persistent	O	['N']	[12]
13	light	O	['N']	[13]
14	reaction	O	['N']	[14]
15	preceded	O	['N']	[15]
16	by	O	['N']	[16]
17	systemic	O	['N']	[17]
18	photoallergy	O	['N']	[18]
19	,	O	['N']	[19]
20	as	O	['N']	[20]
21	he	O	['N']	[21]
22	had	O	['N']	[22]
23	taken	O	['N']	[23]
24	mequitazine	O	['N']	[24]
25	for	O	['N']	[25]
26	6	O	['N']	[26]
27	months	O	['N']	[27]
28	,	O	['N']	[28]
29	and	O	['N']	[29]
30	there	O	['N']	[30]
31	were	O	['N']	[31]
32	strong	O	['N']	[32]
33	positive	O	['N']	[33]
34	photopatch	O	['N']	[34]
35	test	O	['N']	[35]
36	results	O	['N']	[36]
37	with	O	['N']	[37]
38	immediate	O	['N']	[38]
39	erythema	O	['N']	[39]
40	reaction	O	['N']	[40]
41	,	O	['N']	[41]
42	cross	O	['N']	[42]
43	-	O	['N']	[43]
44	reaction	O	['N']	[44]
45	to	O	['N']	[45]
46	promethazine	B-Drug	['Causes']	[54]
47	,	O	['N']	[47]
48	decreased	B	['N']	[48]
49	MED	I	['N']	[49]
50	to	I	['N']	[50]
51	both	I	['N']	[51]
52	UVA	I	['N']	[52]
53	and	I	['N']	[53]
54	UVB	I-Adverse_Effect	['N']	[54]
55	,	O	['N']	[55]
56	and	O	['N']	[56]
57	persistence	O	['N']	[57]
58	of	O	['N']	[58]
59	the	O	['N']	[59]
60	photosensitivity	O	['N']	[60]
61	over	O	['N']	[61]
62	a	O	['N']	[62]
63	3-year	O	['N']	[63]
64	follow	O	['N']	[64]
65	-	O	['N']	[65]
66	up	O	['N']	[66]
67	period	O	['N']	[67]
68	after	O	['N']	[68]
69	discontinuation	O	['N']	[69]
70	of	O	['N']	[70]
71	the	O	['N']	[71]
72	mequitazine	O	['N']	[72]
73	.	O	['N']	[73]
#765
0	Pheripheral	B	['N']	[0]
1	edema	I-Adverse_Effect	['N']	[1]
2	was	O	['N']	[2]
3	observed	O	['N']	[3]
4	in	O	['N']	[4]
5	five	O	['N']	[5]
6	female	O	['N']	[6]
7	patients	O	['N']	[7]
8	after	O	['N']	[8]
9	taking	O	['N']	[9]
10	proton	O	['N']	[10]
11	pump	O	['N']	[11]
12	inhibitors	O	['N']	[12]
13	omeprazole	B-Drug	['Causes']	[1]
14	,	O	['N']	[14]
15	lansoprazole	O	['N']	[15]
16	,	O	['N']	[16]
17	or	O	['N']	[17]
18	pantoprazole	O	['N']	[18]
19	for	O	['N']	[19]
20	7	O	['N']	[20]
21	-	O	['N']	[21]
22	15	O	['N']	[22]
23	days	O	['N']	[23]
24	for	O	['N']	[24]
25	peptic	O	['N']	[25]
26	acid	O	['N']	[26]
27	diseases	O	['N']	[27]
28	in	O	['N']	[28]
29	recommended	O	['N']	[29]
30	standard	O	['N']	[30]
31	doses	O	['N']	[31]
32	.	O	['N']	[32]
#766
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	torsade	O	['N']	[5]
6	de	O	['N']	[6]
7	pointes	O	['N']	[7]
8	following	O	['N']	[8]
9	a	O	['N']	[9]
10	single	O	['N']	[10]
11	oral	O	['N']	[11]
12	dose	O	['N']	[12]
13	of	O	['N']	[13]
14	amiodarone	B-Drug	['Dosage']	[21]
15	(	O	['N']	[15]
16	1400	O	['N']	[16]
17	mg	O	['N']	[17]
18	or	O	['N']	[18]
19	30	B	['N']	[19]
20	mg	I	['N']	[20]
21	kg-1	I-Dose	['N']	[21]
22	)	O	['N']	[22]
23	administered	O	['N']	[23]
24	after	O	['N']	[24]
25	short	O	['N']	[25]
26	intravenous	O	['N']	[26]
27	loading	O	['N']	[27]
28	for	O	['N']	[28]
29	prevention	O	['N']	[29]
30	of	O	['N']	[30]
31	paroxysmal	O	['N']	[31]
32	atrial	O	['N']	[32]
33	flutter	O	['N']	[33]
34	.	O	['N']	[34]
#767
0	In	O	['N']	[0]
1	patients	O	['N']	[1]
2	with	O	['N']	[2]
3	swallowing	O	['N']	[3]
4	dysfunction	O	['N']	[4]
5	and	O	['N']	[5]
6	pneumonia	O	['N']	[6]
7	,	O	['N']	[7]
8	a	O	['N']	[8]
9	history	O	['N']	[9]
10	of	O	['N']	[10]
11	mineral	B	['N']	[11]
12	oil	I-Drug	['Causes']	[21]
13	use	O	['N']	[13]
14	should	O	['N']	[14]
15	be	O	['N']	[15]
16	obtained	O	['N']	[16]
17	and	O	['N']	[17]
18	a	O	['N']	[18]
19	diagnosis	O	['N']	[19]
20	of	O	['N']	[20]
21	ELP	B-Adverse_Effect	['N']	[21]
22	should	O	['N']	[22]
23	be	O	['N']	[23]
24	considered	O	['N']	[24]
25	in	O	['N']	[25]
26	the	O	['N']	[26]
27	differential	O	['N']	[27]
28	diagnoses	O	['N']	[28]
29	if	O	['N']	[29]
30	mineral	O	['N']	[30]
31	oil	O	['N']	[31]
32	use	O	['N']	[32]
33	has	O	['N']	[33]
34	occurred	O	['N']	[34]
35	.	O	['N']	[35]
#768
0	The	O	['N']	[0]
1	risk	O	['N']	[1]
2	of	O	['N']	[2]
3	developing	O	['N']	[3]
4	sAML	B-Adverse_Effect	['N']	[4]
5	is	O	['N']	[5]
6	estimated	O	['N']	[6]
7	to	O	['N']	[7]
8	be	O	['N']	[8]
9	between	O	['N']	[9]
10	1	O	['N']	[10]
11	%	O	['N']	[11]
12	and	O	['N']	[12]
13	5	O	['N']	[13]
14	%	O	['N']	[14]
15	,	O	['N']	[15]
16	2	O	['N']	[16]
17	-	O	['N']	[17]
18	20	O	['N']	[18]
19	years	O	['N']	[19]
20	after	O	['N']	[20]
21	exposure	O	['N']	[21]
22	to	O	['N']	[22]
23	etoposide	B-Drug	['Causes']	[4]
24	but	O	['N']	[24]
25	may	O	['N']	[25]
26	also	O	['N']	[26]
27	be	O	['N']	[27]
28	related	O	['N']	[28]
29	to	O	['N']	[29]
30	cumulative	O	['N']	[30]
31	drug	O	['N']	[31]
32	doses	O	['N']	[32]
33	,	O	['N']	[33]
34	treatment	O	['N']	[34]
35	schedules	O	['N']	[35]
36	,	O	['N']	[36]
37	host	O	['N']	[37]
38	factors	O	['N']	[38]
39	and	O	['N']	[39]
40	co	O	['N']	[40]
41	-	O	['N']	[41]
42	administration	O	['N']	[42]
43	of	O	['N']	[43]
44	other	O	['N']	[44]
45	antineoplastic	O	['N']	[45]
46	agents	O	['N']	[46]
47	.	O	['N']	[47]
#769
0	High	B	['N']	[0]
1	-	I	['N']	[1]
2	grade	I	['N']	[2]
3	endometrial	I	['N']	[3]
4	stromal	I	['N']	[4]
5	sarcoma	I-Adverse_Effect	['N']	[5]
6	after	O	['N']	[6]
7	tamoxifen	B-Drug	['Causes']	[5]
8	therapy	O	['N']	[8]
9	for	O	['N']	[9]
10	breast	O	['N']	[10]
11	cancer	O	['N']	[11]
12	.	O	['N']	[12]
#770
0	Antibiotic	O	['N']	[0]
1	-	O	['N']	[1]
2	associated	O	['N']	[2]
3	colitis	B-Adverse_Effect	['N']	[3]
4	(	O	['N']	[4]
5	pseudomembranous	O	['N']	[5]
6	colitis	O	['N']	[6]
7	)	O	['N']	[7]
8	developed	O	['N']	[8]
9	in	O	['N']	[9]
10	four	O	['N']	[10]
11	patients	O	['N']	[11]
12	with	O	['N']	[12]
13	spinal	O	['N']	[13]
14	cord	O	['N']	[14]
15	injury	O	['N']	[15]
16	and	O	['N']	[16]
17	taking	O	['N']	[17]
18	oral	O	['N']	[18]
19	trimethoprim	O	['N']	[19]
20	-	O	['N']	[20]
21	sulfamethoxazole	B-Drug	['Causes']	[3]
22	.	O	['N']	[22]
#771
0	PET	O	['N']	[0]
1	scintigraphy	O	['N']	[1]
2	of	O	['N']	[2]
3	etoposide	B-Drug	['Causes']	[7]
4	-	O	['N']	[4]
5	induced	O	['N']	[5]
6	pulmonary	B	['N']	[6]
7	toxicity	I-Adverse_Effect	['N']	[7]
8	.	O	['N']	[8]
#772
0	Similar	O	['N']	[0]
1	to	O	['N']	[1]
2	reports	O	['N']	[2]
3	in	O	['N']	[3]
4	patients	O	['N']	[4]
5	receiving	O	['N']	[5]
6	gefitinib	O	['N']	[6]
7	,	O	['N']	[7]
8	those	O	['N']	[8]
9	with	O	['N']	[9]
10	pathologic	O	['N']	[10]
11	findings	O	['N']	[11]
12	of	O	['N']	[12]
13	UIP	O	['N']	[13]
14	on	O	['N']	[14]
15	resected	O	['N']	[15]
16	lung	O	['N']	[16]
17	specimens	O	['N']	[17]
18	or	O	['N']	[18]
19	known	O	['N']	[19]
20	pulmonary	B	['N']	[20]
21	fibrosis	I-Adverse_Effect	['N']	[21]
22	may	O	['N']	[22]
23	be	O	['N']	[23]
24	at	O	['N']	[24]
25	particular	O	['N']	[25]
26	risk	O	['N']	[26]
27	for	O	['N']	[27]
28	erlotinib	B-Drug	['Causes']	[21]
29	pulmonary	O	['N']	[29]
30	toxicity	O	['N']	[30]
31	.	O	['N']	[31]
#773
0	Sweet	B	['N']	[0]
1	's	I	['N']	[1]
2	syndrome	I-Adverse_Effect	['N']	[2]
3	is	O	['N']	[3]
4	an	O	['N']	[4]
5	acute	O	['N']	[5]
6	febrile	O	['N']	[6]
7	neutrophilic	O	['N']	[7]
8	dermatosis	O	['N']	[8]
9	that	O	['N']	[9]
10	is	O	['N']	[10]
11	a	O	['N']	[11]
12	known	O	['N']	[12]
13	complication	O	['N']	[13]
14	of	O	['N']	[14]
15	the	O	['N']	[15]
16	administration	O	['N']	[16]
17	of	O	['N']	[17]
18	filgrastim	B-Drug	['Causes']	[2]
19	,	O	['N']	[19]
20	a	O	['N']	[20]
21	drug	O	['N']	[21]
22	that	O	['N']	[22]
23	causes	O	['N']	[23]
24	increased	O	['N']	[24]
25	neutrophil	O	['N']	[25]
26	proliferation	O	['N']	[26]
27	and	O	['N']	[27]
28	differentiation	O	['N']	[28]
29	.	O	['N']	[29]
#774
0	Case	O	['N']	[0]
1	study	O	['N']	[1]
2	:	O	['N']	[2]
3	adverse	B	['N']	[3]
4	response	I-Adverse_Effect	['N']	[4]
5	to	O	['N']	[5]
6	clonidine	B-Drug	['Causes']	[4]
7	.	O	['N']	[7]
#775
0	Idiosyncratic	O	['N']	[0]
1	factors	O	['N']	[1]
2	involving	O	['N']	[2]
3	vasopressin	B-Drug	['Causes']	[12]
4	receptor	O	['N']	[4]
5	affinity	O	['N']	[5]
6	and	O	['N']	[6]
7	distribution	O	['N']	[7]
8	,	O	['N']	[8]
9	vasopressin	O	['N']	[9]
10	-	O	['N']	[10]
11	associated	O	['N']	[11]
12	vasodilation	B-Adverse_Effect	['N']	[12]
13	in	O	['N']	[13]
14	some	O	['N']	[14]
15	vascular	O	['N']	[15]
16	beds	O	['N']	[16]
17	,	O	['N']	[17]
18	and	O	['N']	[18]
19	the	O	['N']	[19]
20	effect	O	['N']	[20]
21	of	O	['N']	[21]
22	vasopressin	O	['N']	[22]
23	on	O	['N']	[23]
24	the	O	['N']	[24]
25	renin	O	['N']	[25]
26	-	O	['N']	[26]
27	angiotensin	O	['N']	[27]
28	system	O	['N']	[28]
29	may	O	['N']	[29]
30	further	O	['N']	[30]
31	contribute	O	['N']	[31]
32	to	O	['N']	[32]
33	impaired	O	['N']	[33]
34	tissue	O	['N']	[34]
35	perfusion	O	['N']	[35]
36	.	O	['N']	[36]
#776
0	Reversal	O	['N']	[0]
1	of	O	['N']	[1]
2	ergotamine	B-Drug	['Causes']	[5]
3	-	O	['N']	[3]
4	induced	O	['N']	[4]
5	arteriospasm	B-Adverse_Effect	['N']	[5]
6	by	O	['N']	[6]
7	mechanical	O	['N']	[7]
8	intra	O	['N']	[8]
9	-	O	['N']	[9]
10	arterial	O	['N']	[10]
11	dilatation	O	['N']	[11]
12	.	O	['N']	[12]
#777
0	A	O	['N']	[0]
1	case	O	['N']	[1]
2	of	O	['N']	[2]
3	normotensive	B	['N']	[3]
4	scleroderma	I	['N']	[4]
5	renal	I	['N']	[5]
6	crisis	I-Adverse_Effect	['N']	[6]
7	after	O	['N']	[7]
8	high	O	['N']	[8]
9	-	O	['N']	[9]
10	dose	O	['N']	[10]
11	methylprednisolone	B-Drug	['Causes']	[6]
12	treatment	O	['N']	[12]
13	.	O	['N']	[13]
#778
0	Hemorrhage	O	['N']	[0]
1	from	O	['N']	[1]
2	a	O	['N']	[2]
3	falx	O	['N']	[3]
4	meningioma	O	['N']	[4]
5	after	O	['N']	[5]
6	internal	O	['N']	[6]
7	use	O	['N']	[7]
8	of	O	['N']	[8]
9	low	B	['N']	[9]
10	-	I	['N']	[10]
11	dose	I-Dose	['N']	[11]
12	aspirin	B-Drug	['Dosage']	[11]
13	.	O	['N']	[13]
#779
0	2-Chloro	B	['N']	[0]
1	-	I	['N']	[1]
2	deoxyadenosine	I-Drug	['Causes']	[21]
3	induces	O	['N']	[3]
4	durable	O	['N']	[4]
5	complete	O	['N']	[5]
6	remission	O	['N']	[6]
7	in	O	['N']	[7]
8	Castleman	O	['N']	[8]
9	's	O	['N']	[9]
10	disease	O	['N']	[10]
11	but	O	['N']	[11]
12	may	O	['N']	[12]
13	accelerate	O	['N']	[13]
14	its	O	['N']	[14]
15	transformation	O	['N']	[15]
16	to	O	['N']	[16]
17	non	B	['N']	[17]
18	-	I	['N']	[18]
19	Hodgkin	I	['N']	[19]
20	's	I	['N']	[20]
21	lymphoma	I-Adverse_Effect	['N']	[21]
22	.	O	['N']	[22]
#780
0	CONCLUSION	O	['N']	[0]
1	:	O	['N']	[1]
2	The	O	['N']	[2]
3	present	O	['N']	[3]
4	findings	O	['N']	[4]
5	suggest	O	['N']	[5]
6	that	O	['N']	[6]
7	fluvoxamine	B-Drug	['Causes']	[11]
8	can	O	['N']	[8]
9	cause	O	['N']	[9]
10	increased	B	['N']	[10]
11	libido	I-Adverse_Effect	['N']	[11]
12	in	O	['N']	[12]
13	some	O	['N']	[13]
14	patients	O	['N']	[14]
15	.	O	['N']	[15]
#781
0	a	O	['N']	[0]
1	67-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	man	O	['N']	[4]
5	with	O	['N']	[5]
6	bipolar	O	['N']	[6]
7	disorder	O	['N']	[7]
8	developed	O	['N']	[8]
9	a	O	['N']	[9]
10	Creutzfeldt	B	['N']	[10]
11	-	I	['N']	[11]
12	Jakob	I	['N']	[12]
13	like	I	['N']	[13]
14	syndrome	I-Adverse_Effect	['N']	[14]
15	during	O	['N']	[15]
16	lithium	B	['N']	[16]
17	carbonate	I-Drug	['Causes']	[14]
18	treatment	O	['N']	[18]
19	.	O	['N']	[19]
#782
0	Three	O	['N']	[0]
1	patients	O	['N']	[1]
2	with	O	['N']	[2]
3	no	O	['N']	[3]
4	history	O	['N']	[4]
5	of	O	['N']	[5]
6	asthma	O	['N']	[6]
7	or	O	['N']	[7]
8	allergy	O	['N']	[8]
9	developed	O	['N']	[9]
10	bronchospasm	B-Adverse_Effect	['N']	[10]
11	while	O	['N']	[11]
12	taking	O	['N']	[12]
13	propranolol	B-Drug	['Causes']	[10]
14	for	O	['N']	[14]
15	hypertension	O	['N']	[15]
16	.	O	['N']	[16]
#783
0	Therefore	O	['N']	[0]
1	,	O	['N']	[1]
2	although	O	['N']	[2]
3	garenoxacin	B-Drug	['Causes']	[11]
4	reportedly	O	['N']	[4]
5	causes	O	['N']	[5]
6	fewer	O	['N']	[6]
7	adverse	O	['N']	[7]
8	reactions	O	['N']	[8]
9	for	O	['N']	[9]
10	cardiac	B	['N']	[10]
11	rhythms	I-Adverse_Effect	['N']	[11]
12	than	O	['N']	[12]
13	third	O	['N']	[13]
14	-	O	['N']	[14]
15	generation	O	['N']	[15]
16	quinolone	O	['N']	[16]
17	antibiotics	O	['N']	[17]
18	,	O	['N']	[18]
19	one	O	['N']	[19]
20	must	O	['N']	[20]
21	be	O	['N']	[21]
22	cautious	O	['N']	[22]
23	of	O	['N']	[23]
24	the	O	['N']	[24]
25	interference	O	['N']	[25]
26	of	O	['N']	[26]
27	other	O	['N']	[27]
28	drugs	O	['N']	[28]
29	during	O	['N']	[29]
30	hypokalemia	O	['N']	[30]
31	in	O	['N']	[31]
32	order	O	['N']	[32]
33	to	O	['N']	[33]
34	prevent	O	['N']	[34]
35	TdP.	O	['N']	[35]
#784
0	The	O	['N']	[0]
1	typical	O	['N']	[1]
2	fluoxetine	B-Drug	['Causes']	[18]
3	-	O	['N']	[3]
4	induced	O	['N']	[4]
5	symptoms	O	['N']	[5]
6	of	O	['N']	[6]
7	restlessness	O	['N']	[7]
8	,	O	['N']	[8]
9	constant	O	['N']	[9]
10	pacing	O	['N']	[10]
11	,	O	['N']	[11]
12	purposeless	B	['N']	[12]
13	movements	I	['N']	[13]
14	of	I	['N']	[14]
15	the	I	['N']	[15]
16	feet	I	['N']	[16]
17	and	I	['N']	[17]
18	legs	I-Adverse_Effect	['N']	[18]
19	,	O	['N']	[19]
20	and	O	['N']	[20]
21	marked	O	['N']	[21]
22	anxiety	O	['N']	[22]
23	were	O	['N']	[23]
24	indistinguishable	O	['N']	[24]
25	from	O	['N']	[25]
26	those	O	['N']	[26]
27	of	O	['N']	[27]
28	neuroleptic	O	['N']	[28]
29	-	O	['N']	[29]
30	induced	O	['N']	[30]
31	akathisia	O	['N']	[31]
32	.	O	['N']	[32]
#785
0	Reversible	B	['N']	[0]
1	heart	I	['N']	[1]
2	failure	I-Adverse_Effect	['N']	[2]
3	in	O	['N']	[3]
4	a	O	['N']	[4]
5	patient	O	['N']	[5]
6	receiving	O	['N']	[6]
7	etanercept	B-Drug	['Causes']	[2]
8	for	O	['N']	[8]
9	ankylosing	O	['N']	[9]
10	spondylitis	O	['N']	[10]
11	.	O	['N']	[11]
#786
0	A	O	['N']	[0]
1	dapsone	B-Drug	['Causes']	[3]
2	hypersensitivity	B	['N']	[2]
3	syndrome	I-Adverse_Effect	['N']	[3]
4	,	O	['N']	[4]
5	consisting	O	['N']	[5]
6	of	O	['N']	[6]
7	fever	O	['N']	[7]
8	,	O	['N']	[8]
9	headache	O	['N']	[9]
10	,	O	['N']	[10]
11	nausea	O	['N']	[11]
12	,	O	['N']	[12]
13	vomiting	O	['N']	[13]
14	,	O	['N']	[14]
15	lymphadenopathy	O	['N']	[15]
16	,	O	['N']	[16]
17	hepatitis	O	['N']	[17]
18	,	O	['N']	[18]
19	hemolysis	O	['N']	[19]
20	,	O	['N']	[20]
21	leukopenia	O	['N']	[21]
22	,	O	['N']	[22]
23	and	O	['N']	[23]
24	mononucleosis	O	['N']	[24]
25	,	O	['N']	[25]
26	has	O	['N']	[26]
27	been	O	['N']	[27]
28	described	O	['N']	[28]
29	in	O	['N']	[29]
30	patients	O	['N']	[30]
31	treated	O	['N']	[31]
32	with	O	['N']	[32]
33	the	O	['N']	[33]
34	drug	O	['N']	[34]
35	for	O	['N']	[35]
36	leprosy	O	['N']	[36]
37	.	O	['N']	[37]
#787
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	five	O	['N']	[2]
3	cases	O	['N']	[3]
4	of	O	['N']	[4]
5	carboplatin	B-Drug	['Causes']	[9]
6	(	O	['N']	[6]
7	CBDCA	O	['N']	[7]
8	)	O	['N']	[8]
9	hypersensitivity	B-Adverse_Effect	['N']	[9]
10	after	O	['N']	[10]
11	weekly	O	['N']	[11]
12	low	O	['N']	[12]
13	-	O	['N']	[13]
14	dose	O	['N']	[14]
15	paclitaxel	O	['N']	[15]
16	(	O	['N']	[16]
17	60	O	['N']	[17]
18	mg	O	['N']	[18]
19	/	O	['N']	[19]
20	m2)/CBDCA	O	['N']	[20]
21	(	O	['N']	[21]
22	area	O	['N']	[22]
23	under	O	['N']	[23]
24	the	O	['N']	[24]
25	concentration	O	['N']	[25]
26	curve	O	['N']	[26]
27	=	O	['N']	[27]
28	2	O	['N']	[28]
29	)	O	['N']	[29]
30	therapy	O	['N']	[30]
31	in	O	['N']	[31]
32	patients	O	['N']	[32]
33	with	O	['N']	[33]
34	recurrent	O	['N']	[34]
35	ovarian	O	['N']	[35]
36	cancer	O	['N']	[36]
37	receiving	O	['N']	[37]
38	multiple	O	['N']	[38]
39	platinum	O	['N']	[39]
40	-	O	['N']	[40]
41	based	O	['N']	[41]
42	chemotherapy	O	['N']	[42]
43	.	O	['N']	[43]
#788
0	DATA	O	['N']	[0]
1	SYNTHESIS	O	['N']	[1]
2	:	O	['N']	[2]
3	Genetic	O	['N']	[3]
4	deficiencies	O	['N']	[4]
5	in	O	['N']	[5]
6	DPD	O	['N']	[6]
7	,	O	['N']	[7]
8	the	O	['N']	[8]
9	rate	O	['N']	[9]
10	-	O	['N']	[10]
11	limiting	O	['N']	[11]
12	enzyme	O	['N']	[12]
13	responsible	O	['N']	[13]
14	for	O	['N']	[14]
15	5-FU	B-Drug	['Causes']	[42]
16	catabolism	O	['N']	[16]
17	,	O	['N']	[17]
18	may	O	['N']	[18]
19	occur	O	['N']	[19]
20	in	O	['N']	[20]
21	3	O	['N']	[21]
22	%	O	['N']	[22]
23	or	O	['N']	[23]
24	more	O	['N']	[24]
25	of	O	['N']	[25]
26	patients	O	['N']	[26]
27	with	O	['N']	[27]
28	cancer	O	['N']	[28]
29	putting	O	['N']	[29]
30	them	O	['N']	[30]
31	at	O	['N']	[31]
32	increased	O	['N']	[32]
33	risk	O	['N']	[33]
34	for	O	['N']	[34]
35	unusually	O	['N']	[35]
36	severe	O	['N']	[36]
37	adverse	O	['N']	[37]
38	reactions	O	['N']	[38]
39	(	O	['N']	[39]
40	e.g.	O	['N']	[40]
41	,	O	['N']	[41]
42	diarrhea	B-Adverse_Effect	['N']	[42]
43	,	O	['N']	[43]
44	stomatitis	O	['N']	[44]
45	,	O	['N']	[45]
46	mucositis	O	['N']	[46]
47	,	O	['N']	[47]
48	myelosuppression	O	['N']	[48]
49	,	O	['N']	[49]
50	neurotoxicity	O	['N']	[50]
51	)	O	['N']	[51]
52	to	O	['N']	[52]
53	standard	O	['N']	[53]
54	doses	O	['N']	[54]
55	of	O	['N']	[55]
56	5-FU	O	['N']	[56]
57	.	O	['N']	[57]
#789
0	Two	O	['N']	[0]
1	patients	O	['N']	[1]
2	with	O	['N']	[2]
3	ovarian	O	['N']	[3]
4	cancer	O	['N']	[4]
5	who	O	['N']	[5]
6	had	O	['N']	[6]
7	received	O	['N']	[7]
8	multiple	O	['N']	[8]
9	courses	O	['N']	[9]
10	of	O	['N']	[10]
11	cisplatin	B-Drug	['Causes']	[29]
12	without	O	['N']	[12]
13	complications	O	['N']	[13]
14	experienced	O	['N']	[14]
15	hypersensitivity	O	['N']	[15]
16	reactions	O	['N']	[16]
17	to	O	['N']	[17]
18	cisplatin	O	['N']	[18]
19	:	O	['N']	[19]
20	one	O	['N']	[20]
21	,	O	['N']	[21]
22	involving	O	['N']	[22]
23	intrahepatic	O	['N']	[23]
24	artery	O	['N']	[24]
25	infusion	O	['N']	[25]
26	,	O	['N']	[26]
27	manifested	O	['N']	[27]
28	general	B	['N']	[28]
29	erythema	I-Adverse_Effect	['N']	[29]
30	,	O	['N']	[30]
31	dyspnea	O	['N']	[31]
32	,	O	['N']	[32]
33	and	O	['N']	[33]
34	hypotension	O	['N']	[34]
35	;	O	['N']	[35]
36	the	O	['N']	[36]
37	other	O	['N']	[37]
38	,	O	['N']	[38]
39	involving	O	['N']	[39]
40	intravenous	O	['N']	[40]
41	infusion	O	['N']	[41]
42	,	O	['N']	[42]
43	manifested	O	['N']	[43]
44	abdominal	O	['N']	[44]
45	pain	O	['N']	[45]
46	,	O	['N']	[46]
47	general	O	['N']	[47]
48	erythema	O	['N']	[48]
49	,	O	['N']	[49]
50	and	O	['N']	[50]
51	fever	O	['N']	[51]
52	.	O	['N']	[52]
#790
0	Risperidone	B-Drug	['Causes']	[3]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	psychosis	B-Adverse_Effect	['N']	[3]
4	and	O	['N']	[4]
5	depression	O	['N']	[5]
6	in	O	['N']	[6]
7	a	O	['N']	[7]
8	child	O	['N']	[8]
9	with	O	['N']	[9]
10	a	O	['N']	[10]
11	mitochondrial	O	['N']	[11]
12	disorder	O	['N']	[12]
13	.	O	['N']	[13]
#791
0	On	O	['N']	[0]
1	day	O	['N']	[1]
2	7	O	['N']	[2]
3	of	O	['N']	[3]
4	linezolid	B-Drug	['Causes']	[30]
5	treatment	O	['N']	[5]
6	,	O	['N']	[6]
7	the	O	['N']	[7]
8	patient	O	['N']	[8]
9	developed	O	['N']	[9]
10	severe	O	['N']	[10]
11	pruritus	O	['N']	[11]
12	,	O	['N']	[12]
13	macular	O	['N']	[13]
14	rash	O	['N']	[14]
15	,	O	['N']	[15]
16	facial	O	['N']	[16]
17	edema	O	['N']	[17]
18	,	O	['N']	[18]
19	eosinophilia	O	['N']	[19]
20	,	O	['N']	[20]
21	marked	O	['N']	[21]
22	increase	O	['N']	[22]
23	in	O	['N']	[23]
24	serum	O	['N']	[24]
25	creatinine	O	['N']	[25]
26	level	O	['N']	[26]
27	,	O	['N']	[27]
28	and	O	['N']	[28]
29	mild	B	['N']	[29]
30	hepatitis	I-Adverse_Effect	['N']	[30]
31	.	O	['N']	[31]
#792
0	A	O	['N']	[0]
1	14-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	female	O	['N']	[4]
5	developed	O	['N']	[5]
6	systemic	O	['N']	[6]
7	lupus	O	['N']	[7]
8	erythematosus	O	['N']	[8]
9	(	O	['N']	[9]
10	SLE)-like	O	['N']	[10]
11	symptoms	O	['N']	[11]
12	,	O	['N']	[12]
13	rash	O	['N']	[13]
14	,	O	['N']	[14]
15	fever	B-Adverse_Effect	['N']	[15]
16	,	O	['N']	[16]
17	leukopenia	O	['N']	[17]
18	and	O	['N']	[18]
19	positive	O	['N']	[19]
20	anti	O	['N']	[20]
21	-	O	['N']	[21]
22	nuclear	O	['N']	[22]
23	antibody	O	['N']	[23]
24	(	O	['N']	[24]
25	ANA	O	['N']	[25]
26	)	O	['N']	[26]
27	two	O	['N']	[27]
28	weeks	O	['N']	[28]
29	after	O	['N']	[29]
30	administration	O	['N']	[30]
31	of	O	['N']	[31]
32	carbamazepine	O	['N']	[32]
33	(	O	['N']	[33]
34	CBZ	O	['N']	[34]
35	;	O	['N']	[35]
36	Tegretol	B-Drug	['Causes']	[15]
37	)	O	['N']	[37]
38	used	O	['N']	[38]
39	against	O	['N']	[39]
40	benign	O	['N']	[40]
41	Rolandic	O	['N']	[41]
42	epilepsy	O	['N']	[42]
43	.	O	['N']	[43]
#793
0	1	O	['N']	[0]
1	.	O	['N']	[1]
2	Changes	B	['N']	[2]
3	in	I	['N']	[3]
4	the	I	['N']	[4]
5	plasma	I	['N']	[5]
6	cortisol	I	['N']	[6]
7	level	I-Adverse_Effect	['N']	[7]
8	were	O	['N']	[8]
9	reported	O	['N']	[9]
10	in	O	['N']	[10]
11	a	O	['N']	[11]
12	male	O	['N']	[12]
13	patient	O	['N']	[13]
14	with	O	['N']	[14]
15	panic	O	['N']	[15]
16	disorder	O	['N']	[16]
17	during	O	['N']	[17]
18	the	O	['N']	[18]
19	period	O	['N']	[19]
20	of	O	['N']	[20]
21	low	O	['N']	[21]
22	-	O	['N']	[22]
23	dose	O	['N']	[23]
24	alprazolam	B-Drug	['Causes']	[7]
25	treatment	O	['N']	[25]
26	(	O	['N']	[26]
27	mean	O	['N']	[27]
28	0.62	O	['N']	[28]
29	+	O	['N']	[29]
30	/-	O	['N']	[30]
31	0.15	O	['N']	[31]
32	mg	O	['N']	[32]
33	/	O	['N']	[33]
34	day	O	['N']	[34]
35	)	O	['N']	[35]
36	compared	O	['N']	[36]
37	with	O	['N']	[37]
38	during	O	['N']	[38]
39	the	O	['N']	[39]
40	period	O	['N']	[40]
41	of	O	['N']	[41]
42	high	O	['N']	[42]
43	-	O	['N']	[43]
44	dose	O	['N']	[44]
45	period	O	['N']	[45]
46	(	O	['N']	[46]
47	mean	O	['N']	[47]
48	1.08	O	['N']	[48]
49	+	O	['N']	[49]
50	/-	O	['N']	[50]
51	0.28	O	['N']	[51]
52	mg	O	['N']	[52]
53	/	O	['N']	[53]
54	day	O	['N']	[54]
55	)	O	['N']	[55]
56	.	O	['N']	[56]
#794
0	After	O	['N']	[0]
1	therapy	O	['N']	[1]
2	for	O	['N']	[2]
3	diabetic	O	['N']	[3]
4	coma	O	['N']	[4]
5	with	O	['N']	[5]
6	insulin	O	['N']	[6]
7	(	O	['N']	[7]
8	containing	O	['N']	[8]
9	the	O	['N']	[9]
10	preservative	O	['N']	[10]
11	cresol	B-Drug	['Causes']	[34]
12	)	O	['N']	[12]
13	and	O	['N']	[13]
14	electrolyte	O	['N']	[14]
15	solutions	O	['N']	[15]
16	was	O	['N']	[16]
17	started	O	['N']	[17]
18	,	O	['N']	[18]
19	the	O	['N']	[19]
20	patient	O	['N']	[20]
21	complained	O	['N']	[21]
22	of	O	['N']	[22]
23	increasing	O	['N']	[23]
24	myalgia	O	['N']	[24]
25	,	O	['N']	[25]
26	developed	O	['N']	[26]
27	a	O	['N']	[27]
28	high	O	['N']	[28]
29	fever	O	['N']	[29]
30	and	O	['N']	[30]
31	respiratory	B	['N']	[31]
32	and	I	['N']	[32]
33	metabolic	I	['N']	[33]
34	acidosis	I-Adverse_Effect	['N']	[34]
35	and	O	['N']	[35]
36	lost	O	['N']	[36]
37	consciousness	O	['N']	[37]
38	.	O	['N']	[38]
#795
0	CONCLUSIONS	O	['N']	[0]
1	:	O	['N']	[1]
2	This	O	['N']	[2]
3	is	O	['N']	[3]
4	the	O	['N']	[4]
5	first	O	['N']	[5]
6	report	O	['N']	[6]
7	of	O	['N']	[7]
8	a	O	['N']	[8]
9	possible	O	['N']	[9]
10	interaction	O	['N']	[10]
11	between	O	['N']	[11]
12	propafenone	B-Drug	['Causes']	[32]
13	and	O	['N']	[13]
14	citalopram	O	['N']	[14]
15	,	O	['N']	[15]
16	which	O	['N']	[16]
17	caused	O	['N']	[17]
18	propafenone	O	['N']	[18]
19	adverse	O	['N']	[19]
20	effects	O	['N']	[20]
21	(	O	['N']	[21]
22	eg	O	['N']	[22]
23	,	O	['N']	[23]
24	dizziness	O	['N']	[24]
25	,	O	['N']	[25]
26	falls	O	['N']	[26]
27	)	O	['N']	[27]
28	and	O	['N']	[28]
29	mimicked	O	['N']	[29]
30	coronary	B	['N']	[30]
31	artery	I	['N']	[31]
32	disease	I-Adverse_Effect	['N']	[32]
33	.	O	['N']	[33]
#796
0	The	O	['N']	[0]
1	azathioprine	B-Drug	['Dosage']	[9]
2	dose	O	['N']	[2]
3	was	O	['N']	[3]
4	low	O	['N']	[4]
5	(	O	['N']	[5]
6	1	B	['N']	[6]
7	mg	I	['N']	[7]
8	/	I	['N']	[8]
9	kg	I-Dose	['N']	[9]
10	)	O	['N']	[10]
11	and	O	['N']	[11]
12	pancytopenia	O	['N']	[12]
13	occurred	O	['N']	[13]
14	after	O	['N']	[14]
15	56	O	['N']	[15]
16	days	O	['N']	[16]
17	therapy	O	['N']	[17]
18	.	O	['N']	[18]
#797
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	here	O	['N']	[2]
3	a	O	['N']	[3]
4	26-year	O	['N']	[4]
5	-	O	['N']	[5]
6	old	O	['N']	[6]
7	female	O	['N']	[7]
8	with	O	['N']	[8]
9	diffuse	O	['N']	[9]
10	large	O	['N']	[10]
11	B	O	['N']	[11]
12	-	O	['N']	[12]
13	cell	O	['N']	[13]
14	lymphoma	O	['N']	[14]
15	who	O	['N']	[15]
16	died	O	['N']	[16]
17	of	O	['N']	[17]
18	severe	O	['N']	[18]
19	pulmonary	O	['N']	[19]
20	fibrosis	O	['N']	[20]
21	81	O	['N']	[21]
22	days	O	['N']	[22]
23	after	O	['N']	[23]
24	the	O	['N']	[24]
25	administration	O	['N']	[25]
26	of	O	['N']	[26]
27	high	O	['N']	[27]
28	-	O	['N']	[28]
29	dose	O	['N']	[29]
30	BCNU	B-Drug	['Dosage']	[35]
31	(	O	['N']	[31]
32	600	B	['N']	[32]
33	mg	I	['N']	[33]
34	/	I	['N']	[34]
35	m2	I-Dose	['N']	[35]
36	)	O	['N']	[36]
37	.	O	['N']	[37]
#798
0	INTRODUCTION	O	['N']	[0]
1	:	O	['N']	[1]
2	We	O	['N']	[2]
3	describe	O	['N']	[3]
4	the	O	['N']	[4]
5	neurointensive	O	['N']	[5]
6	care	O	['N']	[6]
7	(	O	['N']	[7]
8	NIC	O	['N']	[8]
9	)	O	['N']	[9]
10	management	O	['N']	[10]
11	of	O	['N']	[11]
12	a	O	['N']	[12]
13	patient	O	['N']	[13]
14	with	O	['N']	[14]
15	severe	B	['N']	[15]
16	cerebral	I	['N']	[16]
17	swelling	I-Adverse_Effect	['N']	[17]
18	and	O	['N']	[18]
19	raised	O	['N']	[19]
20	intracranial	O	['N']	[20]
21	pressure	O	['N']	[21]
22	(	O	['N']	[22]
23	ICP	O	['N']	[23]
24	)	O	['N']	[24]
25	after	O	['N']	[25]
26	severe	O	['N']	[26]
27	sodium	O	['N']	[27]
28	valproic	O	['N']	[28]
29	acid	O	['N']	[29]
30	(	O	['N']	[30]
31	VPA	B-Drug	['Causes']	[17]
32	)	O	['N']	[32]
33	intoxication	O	['N']	[33]
34	.	O	['N']	[34]
#799
0	This	O	['N']	[0]
1	report	O	['N']	[1]
2	describes	O	['N']	[2]
3	an	O	['N']	[3]
4	individual	O	['N']	[4]
5	with	O	['N']	[5]
6	mental	O	['N']	[6]
7	retardation	O	['N']	[7]
8	who	O	['N']	[8]
9	experienced	O	['N']	[9]
10	behavioral	B	['N']	[10]
11	exacerbation	I-Adverse_Effect	['N']	[11]
12	associated	O	['N']	[12]
13	with	O	['N']	[13]
14	clonazepam	B-Drug	['Causes']	[11]
15	prescribed	O	['N']	[15]
16	at	O	['N']	[16]
17	2	O	['N']	[17]
18	mg	O	['N']	[18]
19	/	O	['N']	[19]
20	day	O	['N']	[20]
21	(	O	['N']	[21]
22	0.02	O	['N']	[22]
23	mg	O	['N']	[23]
24	/	O	['N']	[24]
25	kg	O	['N']	[25]
26	/	O	['N']	[26]
27	day	O	['N']	[27]
28	)	O	['N']	[28]
29	to	O	['N']	[29]
30	treat	O	['N']	[30]
31	aggression	O	['N']	[31]
32	,	O	['N']	[32]
33	self	O	['N']	[33]
34	-	O	['N']	[34]
35	injurious	O	['N']	[35]
36	behavior	O	['N']	[36]
37	,	O	['N']	[37]
38	property	O	['N']	[38]
39	destruction	O	['N']	[39]
40	,	O	['N']	[40]
41	and	O	['N']	[41]
42	screaming	O	['N']	[42]
43	,	O	['N']	[43]
44	which	O	['N']	[44]
45	was	O	['N']	[45]
46	measured	O	['N']	[46]
47	with	O	['N']	[47]
48	a	O	['N']	[48]
49	15-minute	O	['N']	[49]
50	partial	O	['N']	[50]
51	interval	O	['N']	[51]
52	recording	O	['N']	[52]
53	measurement	O	['N']	[53]
54	method	O	['N']	[54]
55	.	O	['N']	[55]
#800
0	While	O	['N']	[0]
1	doxorubicin	B-Drug	['Causes']	[9]
2	was	O	['N']	[2]
3	administered	O	['N']	[3]
4	,	O	['N']	[4]
5	the	O	['N']	[5]
6	patient	O	['N']	[6]
7	presented	O	['N']	[7]
8	thoracic	B	['N']	[8]
9	pain	I-Adverse_Effect	['N']	[9]
10	and	O	['N']	[10]
11	breathing	O	['N']	[11]
12	distress	O	['N']	[12]
13	due	O	['N']	[13]
14	to	O	['N']	[14]
15	superior	O	['N']	[15]
16	vena	O	['N']	[16]
17	cava	O	['N']	[17]
18	perforation	O	['N']	[18]
19	by	O	['N']	[19]
20	the	O	['N']	[20]
21	central	O	['N']	[21]
22	catheter	O	['N']	[22]
23	and	O	['N']	[23]
24	subsequent	O	['N']	[24]
25	extravasation	O	['N']	[25]
26	of	O	['N']	[26]
27	the	O	['N']	[27]
28	drug	O	['N']	[28]
29	into	O	['N']	[29]
30	the	O	['N']	[30]
31	mediastinum	O	['N']	[31]
32	.	O	['N']	[32]
#801
0	Methotrexate	B-Drug	['Causes']	[4]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	hepatic	B	['N']	[3]
4	necrosis	I-Adverse_Effect	['N']	[4]
5	requiring	O	['N']	[5]
6	liver	O	['N']	[6]
7	transplantation	O	['N']	[7]
8	in	O	['N']	[8]
9	a	O	['N']	[9]
10	patient	O	['N']	[10]
11	with	O	['N']	[11]
12	rheumatoid	O	['N']	[12]
13	arthritis	O	['N']	[13]
14	.	O	['N']	[14]
#802
0	In	O	['N']	[0]
1	patients	O	['N']	[1]
2	with	O	['N']	[2]
3	cirrhosis	O	['N']	[3]
4	,	O	['N']	[4]
5	the	O	['N']	[5]
6	metabolism	O	['N']	[6]
7	of	O	['N']	[7]
8	meperidine	B-Drug	['Causes']	[23]
9	is	O	['N']	[9]
10	decreased	O	['N']	[10]
11	,	O	['N']	[11]
12	leading	O	['N']	[12]
13	to	O	['N']	[13]
14	accumulation	O	['N']	[14]
15	of	O	['N']	[15]
16	the	O	['N']	[16]
17	parent	O	['N']	[17]
18	drug	O	['N']	[18]
19	and	O	['N']	[19]
20	possible	O	['N']	[20]
21	CNS	B	['N']	[21]
22	depressive	I	['N']	[22]
23	effects	I-Adverse_Effect	['N']	[23]
24	similar	O	['N']	[24]
25	to	O	['N']	[25]
26	hepatic	O	['N']	[26]
27	encephalopathy	O	['N']	[27]
28	.	O	['N']	[28]
#803
0	A	O	['N']	[0]
1	27-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	man	O	['N']	[4]
5	who	O	['N']	[5]
6	had	O	['N']	[6]
7	a	O	['N']	[7]
8	history	O	['N']	[8]
9	of	O	['N']	[9]
10	bronchial	O	['N']	[10]
11	asthma	O	['N']	[11]
12	,	O	['N']	[12]
13	eosinophilic	O	['N']	[13]
14	enteritis	O	['N']	[14]
15	,	O	['N']	[15]
16	and	O	['N']	[16]
17	eosinophilic	O	['N']	[17]
18	pneumonia	O	['N']	[18]
19	presented	O	['N']	[19]
20	with	O	['N']	[20]
21	fever	B-Adverse_Effect	['N']	[21]
22	,	O	['N']	[22]
23	skin	O	['N']	[23]
24	eruptions	O	['N']	[24]
25	,	O	['N']	[25]
26	cervical	O	['N']	[26]
27	lymphadenopathy	O	['N']	[27]
28	,	O	['N']	[28]
29	hepatosplenomegaly	O	['N']	[29]
30	,	O	['N']	[30]
31	atypical	O	['N']	[31]
32	lymphocytosis	O	['N']	[32]
33	,	O	['N']	[33]
34	and	O	['N']	[34]
35	eosinophilia	O	['N']	[35]
36	two	O	['N']	[36]
37	weeks	O	['N']	[37]
38	after	O	['N']	[38]
39	receiving	O	['N']	[39]
40	trimethoprim	B-Drug	['Causes']	[21]
41	(	O	['N']	[41]
42	TMP)-sulfamethoxazole	O	['N']	[42]
43	(	O	['N']	[43]
44	SMX	O	['N']	[44]
45	)	O	['N']	[45]
46	treatment	O	['N']	[46]
47	.	O	['N']	[47]
#804
0	Although	O	['N']	[0]
1	isradipine	B-Drug	['Causes']	[7]
2	has	O	['N']	[2]
3	been	O	['N']	[3]
4	associated	O	['N']	[4]
5	with	O	['N']	[5]
6	hepatocellular	B	['N']	[6]
7	injury	I-Adverse_Effect	['N']	[7]
8	,	O	['N']	[8]
9	there	O	['N']	[9]
10	are	O	['N']	[10]
11	no	O	['N']	[11]
12	reports	O	['N']	[12]
13	of	O	['N']	[13]
14	fulminant	O	['N']	[14]
15	liver	O	['N']	[15]
16	failure	O	['N']	[16]
17	with	O	['N']	[17]
18	this	O	['N']	[18]
19	agent	O	['N']	[19]
20	,	O	['N']	[20]
21	and	O	['N']	[21]
22	our	O	['N']	[22]
23	patient	O	['N']	[23]
24	had	O	['N']	[24]
25	been	O	['N']	[25]
26	treated	O	['N']	[26]
27	for	O	['N']	[27]
28	>	O	['N']	[28]
29	2	O	['N']	[29]
30	years	O	['N']	[30]
31	without	O	['N']	[31]
32	signs	O	['N']	[32]
33	of	O	['N']	[33]
34	toxicity	O	['N']	[34]
35	.	O	['N']	[35]
#805
0	Sulfasalazine	B-Drug	['Causes']	[4]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	lupus	B	['N']	[3]
4	erythematosus	I-Adverse_Effect	['N']	[4]
5	.	O	['N']	[5]
#806
0	Three	O	['N']	[0]
1	patients	O	['N']	[1]
2	with	O	['N']	[2]
3	niacin	B-Drug	['Causes']	[10]
4	-	O	['N']	[4]
5	induced	O	['N']	[5]
6	visual	O	['N']	[6]
7	symptoms	O	['N']	[7]
8	had	O	['N']	[8]
9	cystoid	B	['N']	[9]
10	maculopathy	I-Adverse_Effect	['N']	[10]
11	without	O	['N']	[11]
12	leakage	O	['N']	[12]
13	on	O	['N']	[13]
14	fluorescein	O	['N']	[14]
15	angiography	O	['N']	[15]
16	,	O	['N']	[16]
17	and	O	['N']	[17]
18	a	O	['N']	[18]
19	fourth	O	['N']	[19]
20	patient	O	['N']	[20]
21	with	O	['N']	[21]
22	no	O	['N']	[22]
23	fundus	O	['N']	[23]
24	abnormality	O	['N']	[24]
25	experienced	O	['N']	[25]
26	cessation	O	['N']	[26]
27	of	O	['N']	[27]
28	visual	O	['N']	[28]
29	symptoms	O	['N']	[29]
30	upon	O	['N']	[30]
31	discontinuation	O	['N']	[31]
32	of	O	['N']	[32]
33	niacin	O	['N']	[33]
34	.	O	['N']	[34]
#807
0	Aminophylline	B	['N']	[0]
1	hypersensitivity	I-Adverse_Effect	['N']	[1]
2	apparently	O	['N']	[2]
3	due	O	['N']	[3]
4	to	O	['N']	[4]
5	ethylenediamine	B-Drug	['Causes']	[1]
6	.	O	['N']	[6]
#808
0	Knowledge	O	['N']	[0]
1	regarding	O	['N']	[1]
2	potential	O	['N']	[2]
3	adverse	O	['N']	[3]
4	effects	O	['N']	[4]
5	of	O	['N']	[5]
6	CAP	B-Drug	['Causes']	[17]
7	is	O	['N']	[7]
8	paramount	O	['N']	[8]
9	and	O	['N']	[9]
10	dose	O	['N']	[10]
11	modification	O	['N']	[11]
12	is	O	['N']	[12]
13	indicated	O	['N']	[13]
14	with	O	['N']	[14]
15	development	O	['N']	[15]
16	of	O	['N']	[16]
17	neurotoxicity	B-Adverse_Effect	['N']	[17]
18	.	O	['N']	[18]
#809
0	Physicians	O	['N']	[0]
1	should	O	['N']	[1]
2	be	O	['N']	[2]
3	aware	O	['N']	[3]
4	of	O	['N']	[4]
5	the	O	['N']	[5]
6	potentially	O	['N']	[6]
7	lethal	B-Adverse_Effect	['N']	[7]
8	side	O	['N']	[8]
9	effects	O	['N']	[9]
10	of	O	['N']	[10]
11	dapsone	B-Drug	['Causes']	[7]
12	.	O	['N']	[12]
#810
0	The	O	['N']	[0]
1	patient	O	['N']	[1]
2	experienced	O	['N']	[2]
3	muscle	O	['N']	[3]
4	twitches	O	['N']	[4]
5	,	O	['N']	[5]
6	tremulousness	O	['N']	[6]
7	,	O	['N']	[7]
8	and	O	['N']	[8]
9	anxiety	B-Adverse_Effect	['N']	[9]
10	on	O	['N']	[10]
11	day	O	['N']	[11]
12	17	O	['N']	[12]
13	of	O	['N']	[13]
14	foscarnet	B-Drug	['Causes']	[9]
15	therapy	O	['N']	[15]
16	.	O	['N']	[16]
#811
0	DIAGNOSIS	O	['N']	[0]
1	:	O	['N']	[1]
2	Severe	O	['N']	[2]
3	temozolomide	B-Drug	['Causes']	[25]
4	-	O	['N']	[4]
5	induced	O	['N']	[5]
6	immunosuppression	O	['N']	[6]
7	,	O	['N']	[7]
8	exacerbated	O	['N']	[8]
9	by	O	['N']	[9]
10	corticosteroids	O	['N']	[10]
11	,	O	['N']	[11]
12	with	O	['N']	[12]
13	profound	O	['N']	[13]
14	T	O	['N']	[14]
15	-	O	['N']	[15]
16	cell	O	['N']	[16]
17	lymphocytopenia	O	['N']	[17]
18	and	O	['N']	[18]
19	simultaneous	O	['N']	[19]
20	opportunistic	O	['N']	[20]
21	infections	B	['N']	[21]
22	with	I	['N']	[22]
23	Pneumocystis	I	['N']	[23]
24	jiroveci	I	['N']	[24]
25	pneumonia	I-Adverse_Effect	['N']	[25]
26	,	O	['N']	[26]
27	brain	O	['N']	[27]
28	abscess	O	['N']	[28]
29	with	O	['N']	[29]
30	Listeria	O	['N']	[30]
31	monocytogenes	O	['N']	[31]
32	,	O	['N']	[32]
33	and	O	['N']	[33]
34	cutaneous	O	['N']	[34]
35	Kaposi	O	['N']	[35]
36	's	O	['N']	[36]
37	sarcoma	O	['N']	[37]
38	.	O	['N']	[38]
#812
0	Stevens	B	['N']	[0]
1	-	I	['N']	[1]
2	Johnson	I	['N']	[2]
3	syndrome	I-Adverse_Effect	['N']	[3]
4	in	O	['N']	[4]
5	a	O	['N']	[5]
6	boy	O	['N']	[6]
7	with	O	['N']	[7]
8	nephrotic	O	['N']	[8]
9	syndrome	O	['N']	[9]
10	during	O	['N']	[10]
11	prednisolone	B-Drug	['Causes']	[3]
12	therapy	O	['N']	[12]
13	.	O	['N']	[13]
#813
0	A	O	['N']	[0]
1	literature	O	['N']	[1]
2	review	O	['N']	[2]
3	revealed	O	['N']	[3]
4	83	O	['N']	[4]
5	other	O	['N']	[5]
6	reported	O	['N']	[6]
7	cases	O	['N']	[7]
8	of	O	['N']	[8]
9	rifampicin	B-Drug	['Causes']	[13]
10	-	O	['N']	[10]
11	induced	O	['N']	[11]
12	renal	B	['N']	[12]
13	insufficiency	I-Adverse_Effect	['N']	[13]
14	.	O	['N']	[14]
#814
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	hyponatremia	O	['N']	[5]
6	associated	O	['N']	[6]
7	with	O	['N']	[7]
8	a	O	['N']	[8]
9	grand	B	['N']	[9]
10	mal	I	['N']	[10]
11	seizure	I-Adverse_Effect	['N']	[11]
12	in	O	['N']	[12]
13	a	O	['N']	[13]
14	28	O	['N']	[14]
15	month	O	['N']	[15]
16	-	O	['N']	[16]
17	old	O	['N']	[17]
18	child	O	['N']	[18]
19	after	O	['N']	[19]
20	intra	O	['N']	[20]
21	-	O	['N']	[21]
22	nasal	O	['N']	[22]
23	desmopressin	B-Drug	['Causes']	[11]
24	administration	O	['N']	[24]
25	for	O	['N']	[25]
26	high	O	['N']	[26]
27	fluid	O	['N']	[27]
28	intake	O	['N']	[28]
29	with	O	['N']	[29]
30	nocturnal	O	['N']	[30]
31	enuresis	O	['N']	[31]
32	.	O	['N']	[32]
#815
0	We	O	['N']	[0]
1	present	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	respiratory	B	['N']	[5]
6	failure	I-Adverse_Effect	['N']	[6]
7	occurring	O	['N']	[7]
8	in	O	['N']	[8]
9	a	O	['N']	[9]
10	woman	O	['N']	[10]
11	at	O	['N']	[11]
12	16	O	['N']	[12]
13	weeks	O	['N']	[13]
14	'	O	['N']	[14]
15	gestation	O	['N']	[15]
16	who	O	['N']	[16]
17	was	O	['N']	[17]
18	being	O	['N']	[18]
19	treated	O	['N']	[19]
20	with	O	['N']	[20]
21	nitrofurantoin	B-Drug	['Causes']	[6]
22	for	O	['N']	[22]
23	a	O	['N']	[23]
24	urinary	O	['N']	[24]
25	tract	O	['N']	[25]
26	infection	O	['N']	[26]
27	.	O	['N']	[27]
#816
0	Metformin	O	['N']	[0]
1	-	O	['N']	[1]
2	associated	O	['N']	[2]
3	lactic	B	['N']	[3]
4	acidosis	I-Adverse_Effect	['N']	[4]
5	(	O	['N']	[5]
6	MALA	O	['N']	[6]
7	)	O	['N']	[7]
8	is	O	['N']	[8]
9	a	O	['N']	[9]
10	serious	O	['N']	[10]
11	metabolic	O	['N']	[11]
12	complication	O	['N']	[12]
13	that	O	['N']	[13]
14	occurs	O	['N']	[14]
15	because	O	['N']	[15]
16	of	O	['N']	[16]
17	metformin	B-Drug	['Causes']	[4]
18	accumulation	O	['N']	[18]
19	in	O	['N']	[19]
20	patients	O	['N']	[20]
21	who	O	['N']	[21]
22	become	O	['N']	[22]
23	dehydrated	O	['N']	[23]
24	or	O	['N']	[24]
25	developed	O	['N']	[25]
26	acute	O	['N']	[26]
27	renal	O	['N']	[27]
28	failure	O	['N']	[28]
29	.	O	['N']	[29]
#817
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	on	O	['N']	[2]
3	three	O	['N']	[3]
4	cases	O	['N']	[4]
5	wherein	O	['N']	[5]
6	treatment	O	['N']	[6]
7	of	O	['N']	[7]
8	dexmedetomidine	B-Drug	['Causes']	[11]
9	-	O	['N']	[9]
10	induced	O	['N']	[10]
11	bradycardia	B-Adverse_Effect	['N']	[11]
12	with	O	['N']	[12]
13	i.v	O	['N']	[13]
14	.	O	['N']	[14]
15	glycopyrrolate	O	['N']	[15]
16	(	O	['N']	[16]
17	5.0	O	['N']	[17]
18	microg	O	['N']	[18]
19	/	O	['N']	[19]
20	kg	O	['N']	[20]
21	)	O	['N']	[21]
22	not	O	['N']	[22]
23	only	O	['N']	[23]
24	resulting	O	['N']	[24]
25	in	O	['N']	[25]
26	resolution	O	['N']	[26]
27	of	O	['N']	[27]
28	bradycardia	O	['N']	[28]
29	but	O	['N']	[29]
30	also	O	['N']	[30]
31	resulting	O	['N']	[31]
32	in	O	['N']	[32]
33	an	O	['N']	[33]
34	exaggerated	O	['N']	[34]
35	increase	O	['N']	[35]
36	of	O	['N']	[36]
37	arterial	O	['N']	[37]
38	blood	O	['N']	[38]
39	pressure	O	['N']	[39]
40	.	O	['N']	[40]
#818
0	However	O	['N']	[0]
1	,	O	['N']	[1]
2	there	O	['N']	[2]
3	are	O	['N']	[3]
4	few	O	['N']	[4]
5	reports	O	['N']	[5]
6	in	O	['N']	[6]
7	the	O	['N']	[7]
8	literature	O	['N']	[8]
9	of	O	['N']	[9]
10	ampicillin	B-Drug	['Causes']	[17]
11	as	O	['N']	[11]
12	a	O	['N']	[12]
13	cause	O	['N']	[13]
14	of	O	['N']	[14]
15	acute	B	['N']	[15]
16	interstitial	I	['N']	[16]
17	nephritis	I-Adverse_Effect	['N']	[17]
18	.	O	['N']	[18]
#819
0	Less	O	['N']	[0]
1	common	O	['N']	[1]
2	adverse	O	['N']	[2]
3	events	O	['N']	[3]
4	to	O	['N']	[4]
5	dapsone	B-Drug	['Causes']	[53]
6	include	O	['N']	[6]
7	the	O	['N']	[7]
8	idiosyncratic	O	['N']	[8]
9	reactions	O	['N']	[9]
10	of	O	['N']	[10]
11	leukopenia	O	['N']	[11]
12	and	O	['N']	[12]
13	agranulocytosis	O	['N']	[13]
14	,	O	['N']	[14]
15	cutaneous	O	['N']	[15]
16	eruptions	O	['N']	[16]
17	,	O	['N']	[17]
18	peripheral	O	['N']	[18]
19	neuropathy	O	['N']	[19]
20	,	O	['N']	[20]
21	psychosis	O	['N']	[21]
22	,	O	['N']	[22]
23	toxic	O	['N']	[23]
24	hepatitis	O	['N']	[24]
25	,	O	['N']	[25]
26	cholestatic	O	['N']	[26]
27	jaundice	O	['N']	[27]
28	,	O	['N']	[28]
29	nephrotic	O	['N']	[29]
30	syndrome	O	['N']	[30]
31	,	O	['N']	[31]
32	renal	O	['N']	[32]
33	papillary	O	['N']	[33]
34	necrosis	O	['N']	[34]
35	,	O	['N']	[35]
36	severe	O	['N']	[36]
37	hypoalbuminemia	O	['N']	[37]
38	without	O	['N']	[38]
39	proteinuria	O	['N']	[39]
40	,	O	['N']	[40]
41	an	O	['N']	[41]
42	infectious	O	['N']	[42]
43	mononucleosis	O	['N']	[43]
44	-	O	['N']	[44]
45	like	O	['N']	[45]
46	syndrome	O	['N']	[46]
47	,	O	['N']	[47]
48	and	O	['N']	[48]
49	minor	B	['N']	[49]
50	neurological	I	['N']	[50]
51	and	I	['N']	[51]
52	gastrointestinal	I	['N']	[52]
53	complaints	I-Adverse_Effect	['N']	[53]
54	.	O	['N']	[54]
#820
0	METHODS	O	['N']	[0]
1	:	O	['N']	[1]
2	A	O	['N']	[2]
3	patient	O	['N']	[3]
4	who	O	['N']	[4]
5	developed	O	['N']	[5]
6	dramatic	O	['N']	[6]
7	,	O	['N']	[7]
8	permanent	O	['N']	[8]
9	vision	B	['N']	[9]
10	loss	I-Adverse_Effect	['N']	[10]
11	after	O	['N']	[11]
12	a	O	['N']	[12]
13	9-month	O	['N']	[13]
14	course	O	['N']	[14]
15	of	O	['N']	[15]
16	treatment	O	['N']	[16]
17	with	O	['N']	[17]
18	ethambutol	B-Drug	['Causes']	[10]
19	and	O	['N']	[19]
20	isoniazid	O	['N']	[20]
21	for	O	['N']	[21]
22	pulmonary	O	['N']	[22]
23	tuberculosis	O	['N']	[23]
24	is	O	['N']	[24]
25	presented	O	['N']	[25]
26	.	O	['N']	[26]
#821
0	Multiple	O	['N']	[0]
1	complications	O	['N']	[1]
2	of	O	['N']	[2]
3	propylthiouracil	B-Drug	['Causes']	[11]
4	treatment	O	['N']	[4]
5	:	O	['N']	[5]
6	granulocytopenia	O	['N']	[6]
7	,	O	['N']	[7]
8	eosinophilia	O	['N']	[8]
9	,	O	['N']	[9]
10	skin	B	['N']	[10]
11	reaction	I-Adverse_Effect	['N']	[11]
12	and	O	['N']	[12]
13	hepatitis	O	['N']	[13]
14	with	O	['N']	[14]
15	lymphocyte	O	['N']	[15]
16	sensitization	O	['N']	[16]
17	.	O	['N']	[17]
#822
0	The	O	['N']	[0]
1	present	O	['N']	[1]
2	observation	O	['N']	[2]
3	suggests	O	['N']	[3]
4	,	O	['N']	[4]
5	that	O	['N']	[5]
6	a	O	['N']	[6]
7	batch	O	['N']	[7]
8	of	O	['N']	[8]
9	different	O	['N']	[9]
10	testing	O	['N']	[10]
11	doses	O	['N']	[11]
12	,	O	['N']	[12]
13	including	O	['N']	[13]
14	lower	O	['N']	[14]
15	testing	O	['N']	[15]
16	doses	O	['N']	[16]
17	may	O	['N']	[17]
18	help	O	['N']	[18]
19	to	O	['N']	[19]
20	differentiate	O	['N']	[20]
21	between	O	['N']	[21]
22	an	O	['N']	[22]
23	allergic	O	['N']	[23]
24	type	O	['N']	[24]
25	of	O	['N']	[25]
26	contact	O	['N']	[26]
27	dermatitis	O	['N']	[27]
28	and	O	['N']	[28]
29	an	O	['N']	[29]
30	irritant	B	['N']	[30]
31	type	I	['N']	[31]
32	of	I	['N']	[32]
33	reaction	I-Adverse_Effect	['N']	[33]
34	after	O	['N']	[34]
35	treatment	O	['N']	[35]
36	with	O	['N']	[36]
37	calcipotriol	B-Drug	['Causes']	[33]
38	.	O	['N']	[38]
#823
0	He	O	['N']	[0]
1	was	O	['N']	[1]
2	started	O	['N']	[2]
3	on	O	['N']	[3]
4	oral	O	['N']	[4]
5	lansoprazole	B-Drug	['Dosage']	[9]
6	60	B	['N']	[6]
7	mg	I	['N']	[7]
8	twice	I	['N']	[8]
9	daily	I-Dose	['N']	[9]
10	and	O	['N']	[10]
11	,	O	['N']	[11]
12	on	O	['N']	[12]
13	hospital	O	['N']	[13]
14	day	O	['N']	[14]
15	2	O	['N']	[15]
16	,	O	['N']	[16]
17	his	O	['N']	[17]
18	platelet	O	['N']	[18]
19	count	O	['N']	[19]
20	decreased	O	['N']	[20]
21	to	O	['N']	[21]
22	102	O	['N']	[22]
23	x	O	['N']	[23]
24	10(3)/mm(3	O	['N']	[24]
25	)	O	['N']	[25]
26	;	O	['N']	[26]
27	on	O	['N']	[27]
28	hospital	O	['N']	[28]
29	day	O	['N']	[29]
30	3	O	['N']	[30]
31	,	O	['N']	[31]
32	the	O	['N']	[32]
33	platelet	O	['N']	[33]
34	count	O	['N']	[34]
35	was	O	['N']	[35]
36	36	O	['N']	[36]
37	x	O	['N']	[37]
38	10(3)/mm(3	O	['N']	[38]
39	)	O	['N']	[39]
40	.	O	['N']	[40]
#824
0	She	O	['N']	[0]
1	was	O	['N']	[1]
2	receiving	O	['N']	[2]
3	phenytoin	O	['N']	[3]
4	sodium	O	['N']	[4]
5	300	O	['N']	[5]
6	mg	O	['N']	[6]
7	/	O	['N']	[7]
8	day	O	['N']	[8]
9	;	O	['N']	[9]
10	carbamazepine	B-Drug	['Causes']	[25]
11	200	O	['N']	[11]
12	mg	O	['N']	[12]
13	four	O	['N']	[13]
14	times	O	['N']	[14]
15	daily	O	['N']	[15]
16	had	O	['N']	[16]
17	been	O	['N']	[17]
18	discontinued	O	['N']	[18]
19	four	O	['N']	[19]
20	days	O	['N']	[20]
21	before	O	['N']	[21]
22	admission	O	['N']	[22]
23	because	O	['N']	[23]
24	of	O	['N']	[24]
25	leukopenia	B-Adverse_Effect	['N']	[25]
26	.	O	['N']	[26]
#825
0	However	O	['N']	[0]
1	,	O	['N']	[1]
2	dermatologists	O	['N']	[2]
3	should	O	['N']	[3]
4	be	O	['N']	[4]
5	cautious	O	['N']	[5]
6	about	O	['N']	[6]
7	a	O	['N']	[7]
8	photosensitivity	B-Adverse_Effect	['N']	[8]
9	reaction	O	['N']	[9]
10	induced	O	['N']	[10]
11	by	O	['N']	[11]
12	mequitazine	B-Drug	['Causes']	[8]
13	or	O	['N']	[13]
14	other	O	['N']	[14]
15	phenothiazine	O	['N']	[15]
16	-	O	['N']	[16]
17	derivative	O	['N']	[17]
18	drugs	O	['N']	[18]
19	.	O	['N']	[19]
#826
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	the	O	['N']	[2]
3	syndrome	O	['N']	[3]
4	of	O	['N']	[4]
5	inappropriate	O	['N']	[5]
6	antidiuresis	B-Adverse_Effect	['N']	[6]
7	as	O	['N']	[7]
8	a	O	['N']	[8]
9	much	O	['N']	[9]
10	earlier	O	['N']	[10]
11	side	O	['N']	[11]
12	-	O	['N']	[12]
13	effect	O	['N']	[13]
14	of	O	['N']	[14]
15	carbamazepine	B-Drug	['Causes']	[6]
16	administration	O	['N']	[16]
17	in	O	['N']	[17]
18	a	O	['N']	[18]
19	29-year	O	['N']	[19]
20	Nigerian	O	['N']	[20]
21	female	O	['N']	[21]
22	patient	O	['N']	[22]
23	with	O	['N']	[23]
24	generalized	O	['N']	[24]
25	tonic	O	['N']	[25]
26	-	O	['N']	[26]
27	elonic	O	['N']	[27]
28	seizures	O	['N']	[28]
29	.	O	['N']	[29]
#827
0	PURPOSE	O	['N']	[0]
1	:	O	['N']	[1]
2	The	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	a	O	['N']	[5]
6	patient	O	['N']	[6]
7	who	O	['N']	[7]
8	developed	O	['N']	[8]
9	aseptic	O	['N']	[9]
10	meningitis	O	['N']	[10]
11	,	O	['N']	[11]
12	hemolytic	O	['N']	[12]
13	anemia	O	['N']	[13]
14	,	O	['N']	[14]
15	hepatitis	O	['N']	[15]
16	,	O	['N']	[16]
17	and	O	['N']	[17]
18	orthostatic	B	['N']	[18]
19	hypotension	I-Adverse_Effect	['N']	[19]
20	simultaneously	O	['N']	[20]
21	during	O	['N']	[21]
22	treatment	O	['N']	[22]
23	with	O	['N']	[23]
24	trimethoprim	B-Drug	['Causes']	[19]
25	-	O	['N']	[25]
26	sulfamethoxazole	O	['N']	[26]
27	is	O	['N']	[27]
28	described	O	['N']	[28]
29	.	O	['N']	[29]
#828
0	CONCLUSION	O	['N']	[0]
1	:	O	['N']	[1]
2	The	O	['N']	[2]
3	new	O	['N']	[3]
4	quinolone	O	['N']	[4]
5	derivatives	O	['N']	[5]
6	(	O	['N']	[6]
7	levofloxacin	B-Drug	['Causes']	[41]
8	,	O	['N']	[8]
9	sparfloxacin	O	['N']	[9]
10	,	O	['N']	[10]
11	grepafloxacin	O	['N']	[11]
12	,	O	['N']	[12]
13	trovafloxacin	O	['N']	[13]
14	,	O	['N']	[14]
15	gatifloxacin	O	['N']	[15]
16	and	O	['N']	[16]
17	moxifloxacin	O	['N']	[17]
18	)	O	['N']	[18]
19	,	O	['N']	[19]
20	also	O	['N']	[20]
21	called	O	['N']	[21]
22	gyrase	O	['N']	[22]
23	inhibitors	O	['N']	[23]
24	,	O	['N']	[24]
25	are	O	['N']	[25]
26	known	O	['N']	[26]
27	for	O	['N']	[27]
28	their	O	['N']	[28]
29	potential	O	['N']	[29]
30	to	O	['N']	[30]
31	cause	O	['N']	[31]
32	central	O	['N']	[32]
33	nervous	O	['N']	[33]
34	system	O	['N']	[34]
35	-	O	['N']	[35]
36	related	O	['N']	[36]
37	adverse	O	['N']	[37]
38	effects	O	['N']	[38]
39	,	O	['N']	[39]
40	including	O	['N']	[40]
41	headache	B-Adverse_Effect	['N']	[41]
42	,	O	['N']	[42]
43	dizziness	O	['N']	[43]
44	and	O	['N']	[44]
45	insomnia	O	['N']	[45]
46	.	O	['N']	[46]
#829
0	A	O	['N']	[0]
1	macrophage	O	['N']	[1]
2	activation	O	['N']	[2]
3	syndrome	O	['N']	[3]
4	,	O	['N']	[4]
5	possibly	O	['N']	[5]
6	related	O	['N']	[6]
7	to	O	['N']	[7]
8	methotrexate	B-Drug	['Causes']	[9]
9	toxicity	I-Adverse_Effect	['N']	[9]
10	,	O	['N']	[10]
11	developed	O	['N']	[11]
12	in	O	['N']	[12]
13	a	O	['N']	[13]
14	boy	O	['N']	[14]
15	with	O	['N']	[15]
16	systemic	O	['N']	[16]
17	juvenile	O	['N']	[17]
18	rheumatoid	O	['N']	[18]
19	arthritis	O	['N']	[19]
20	.	O	['N']	[20]
#830
0	Acute	O	['N']	[0]
1	renal	O	['N']	[1]
2	failure	O	['N']	[2]
3	with	O	['N']	[3]
4	severe	B	['N']	[4]
5	tubulointerstitial	I	['N']	[5]
6	changes	I-Adverse_Effect	['N']	[6]
7	in	O	['N']	[7]
8	a	O	['N']	[8]
9	patient	O	['N']	[9]
10	with	O	['N']	[10]
11	minimal	O	['N']	[11]
12	change	O	['N']	[12]
13	nephrotic	O	['N']	[13]
14	syndrome	O	['N']	[14]
15	treated	O	['N']	[15]
16	with	O	['N']	[16]
17	enalapril	B-Drug	['Causes']	[6]
18	.	O	['N']	[18]
#831
0	During	O	['N']	[0]
1	clarithromycin	B-Drug	['Causes']	[25]
2	coadministration	O	['N']	[2]
3	,	O	['N']	[3]
4	four	O	['N']	[4]
5	out	O	['N']	[5]
6	of	O	['N']	[6]
7	the	O	['N']	[7]
8	seven	O	['N']	[8]
9	patients	O	['N']	[9]
10	developed	O	['N']	[10]
11	moderate	O	['N']	[11]
12	-	O	['N']	[12]
13	to	O	['N']	[13]
14	-	O	['N']	[14]
15	severe	O	['N']	[15]
16	toxic	O	['N']	[16]
17	symptoms	O	['N']	[17]
18	of	O	['N']	[18]
19	carbamazepine	O	['N']	[19]
20	,	O	['N']	[20]
21	such	O	['N']	[21]
22	as	O	['N']	[22]
23	drowsiness	O	['N']	[23]
24	,	O	['N']	[24]
25	dizziness	B-Adverse_Effect	['N']	[25]
26	,	O	['N']	[26]
27	and	O	['N']	[27]
28	ataxia	O	['N']	[28]
29	,	O	['N']	[29]
30	which	O	['N']	[30]
31	resolved	O	['N']	[31]
32	within	O	['N']	[32]
33	5	O	['N']	[33]
34	days	O	['N']	[34]
35	after	O	['N']	[35]
36	clarithromycin	O	['N']	[36]
37	discontinuation	O	['N']	[37]
38	.	O	['N']	[38]
#832
0	Anastrozole	B-Drug	['Causes']	[4]
1	-	O	['N']	[1]
2	associated	O	['N']	[2]
3	sclerosing	B	['N']	[3]
4	glomerulonephritis	I-Adverse_Effect	['N']	[4]
5	in	O	['N']	[5]
6	a	O	['N']	[6]
7	patient	O	['N']	[7]
8	with	O	['N']	[8]
9	breast	O	['N']	[9]
10	cancer	O	['N']	[10]
11	.	O	['N']	[11]
#833
0	Incidence	O	['N']	[0]
1	of	O	['N']	[1]
2	seizures	B-Adverse_Effect	['N']	[2]
3	in	O	['N']	[3]
4	pediatric	O	['N']	[4]
5	cancer	O	['N']	[5]
6	patients	O	['N']	[6]
7	treated	O	['N']	[7]
8	with	O	['N']	[8]
9	imipenem	B-Drug	['Causes']	[2]
10	/	O	['N']	[10]
11	cilastatin	O	['N']	[11]
12	.	O	['N']	[12]
#834
0	Two	O	['N']	[0]
1	elderly	O	['N']	[1]
2	women	O	['N']	[2]
3	suffered	O	['N']	[3]
4	an	O	['N']	[4]
5	acute	B	['N']	[5]
6	deterioration	I	['N']	[6]
7	of	I	['N']	[7]
8	renal	I	['N']	[8]
9	function	I-Adverse_Effect	['N']	[9]
10	after	O	['N']	[10]
11	treatment	O	['N']	[11]
12	with	O	['N']	[12]
13	cefoxitin	B	['N']	[13]
14	sodium	I-Drug	['Causes']	[9]
15	.	O	['N']	[15]
#835
0	One	O	['N']	[0]
1	patient	O	['N']	[1]
2	developed	O	['N']	[2]
3	severe	B	['N']	[3]
4	hyponatremia	I-Adverse_Effect	['N']	[4]
5	with	O	['N']	[5]
6	serum	O	['N']	[6]
7	Na+	O	['N']	[7]
8	of	O	['N']	[8]
9	108	O	['N']	[9]
10	mEq	O	['N']	[10]
11	/	O	['N']	[11]
12	L	O	['N']	[12]
13	when	O	['N']	[13]
14	hydrochlorothiazide	B-Drug	['Causes']	[4]
15	was	O	['N']	[15]
16	given	O	['N']	[16]
17	to	O	['N']	[17]
18	control	O	['N']	[18]
19	hypertension	O	['N']	[19]
20	.	O	['N']	[20]
#836
0	It	O	['N']	[0]
1	is	O	['N']	[1]
2	thought	O	['N']	[2]
3	that	O	['N']	[3]
4	the	O	['N']	[4]
5	clinico	O	['N']	[5]
6	-	O	['N']	[6]
7	pathological	O	['N']	[7]
8	features	O	['N']	[8]
9	and	O	['N']	[9]
10	chronology	O	['N']	[10]
11	of	O	['N']	[11]
12	this	O	['N']	[12]
13	case	O	['N']	[13]
14	bore	O	['N']	[14]
15	the	O	['N']	[15]
16	hallmarks	O	['N']	[16]
17	of	O	['N']	[17]
18	the	O	['N']	[18]
19	so	O	['N']	[19]
20	-	O	['N']	[20]
21	called	O	['N']	[21]
22	"	O	['N']	[22]
23	3-week	O	['N']	[23]
24	sulphasalazine	B-Drug	['Causes']	[36]
25	syndrome	O	['N']	[25]
26	"	O	['N']	[26]
27	,	O	['N']	[27]
28	a	O	['N']	[28]
29	rare	O	['N']	[29]
30	,	O	['N']	[30]
31	but	O	['N']	[31]
32	often	O	['N']	[32]
33	fatal	O	['N']	[33]
34	,	O	['N']	[34]
35	immunoallergic	B	['N']	[35]
36	reaction	I-Adverse_Effect	['N']	[36]
37	to	O	['N']	[37]
38	sulphasalazine	O	['N']	[38]
39	.	O	['N']	[39]
#837
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	two	O	['N']	[2]
3	cases	O	['N']	[3]
4	of	O	['N']	[4]
5	fulminant	B	['N']	[5]
6	hepatic	I	['N']	[6]
7	failure	I-Adverse_Effect	['N']	[7]
8	in	O	['N']	[8]
9	HIV-1-infected	O	['N']	[9]
10	patients	O	['N']	[10]
11	treated	O	['N']	[11]
12	with	O	['N']	[12]
13	didanosine	B-Drug	['Causes']	[7]
14	(	O	['N']	[14]
15	ddI	O	['N']	[15]
16	)	O	['N']	[16]
17	.	O	['N']	[17]
#838
0	PURPOSE	O	['N']	[0]
1	:	O	['N']	[1]
2	To	O	['N']	[2]
3	report	O	['N']	[3]
4	two	O	['N']	[4]
5	cases	O	['N']	[5]
6	in	O	['N']	[6]
7	which	O	['N']	[7]
8	topical	O	['N']	[8]
9	brimonidine	B-Drug	['Causes']	[16]
10	resulted	O	['N']	[10]
11	in	O	['N']	[11]
12	apparent	O	['N']	[12]
13	central	B	['N']	[13]
14	nervous	I	['N']	[14]
15	system	I	['N']	[15]
16	depression	I-Adverse_Effect	['N']	[16]
17	and	O	['N']	[17]
18	unresponsiveness	O	['N']	[18]
19	in	O	['N']	[19]
20	an	O	['N']	[20]
21	infant	O	['N']	[21]
22	.	O	['N']	[22]
#839
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	the	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	a	O	['N']	[5]
6	60-year	O	['N']	[6]
7	-	O	['N']	[7]
8	old	O	['N']	[8]
9	woman	O	['N']	[9]
10	who	O	['N']	[10]
11	developed	O	['N']	[11]
12	erythema	B-Adverse_Effect	['N']	[12]
13	and	O	['N']	[13]
14	erosions	O	['N']	[14]
15	in	O	['N']	[15]
16	the	O	['N']	[16]
17	axilla	O	['N']	[17]
18	and	O	['N']	[18]
19	groin	O	['N']	[19]
20	while	O	['N']	[20]
21	on	O	['N']	[21]
22	PLD	B-Drug	['Causes']	[12]
23	for	O	['N']	[23]
24	breast	O	['N']	[24]
25	cancer	O	['N']	[25]
26	.	O	['N']	[26]
#840
0	INTERPRETATION	O	['N']	[0]
1	:	O	['N']	[1]
2	When	O	['N']	[2]
3	high	O	['N']	[3]
4	doses	O	['N']	[4]
5	of	O	['N']	[5]
6	fluticasone	B	['N']	[6]
7	propionate	I-Drug	['Causes']	[14]
8	are	O	['N']	[8]
9	used	O	['N']	[9]
10	,	O	['N']	[10]
11	growth	B	['N']	[11]
12	may	I	['N']	[12]
13	be	I	['N']	[13]
14	retarded	I-Adverse_Effect	['N']	[14]
15	and	O	['N']	[15]
16	adrenal	O	['N']	[16]
17	suppression	O	['N']	[17]
18	may	O	['N']	[18]
19	occur	O	['N']	[19]
20	.	O	['N']	[20]
#841
0	Vortex	B	['N']	[0]
1	keratopathy	I-Adverse_Effect	['N']	[1]
2	associated	O	['N']	[2]
3	with	O	['N']	[3]
4	atovaquone	B-Drug	['Causes']	[1]
5	.	O	['N']	[5]
#842
0	Hepatic	B	['N']	[0]
1	reactions	I-Adverse_Effect	['N']	[1]
2	to	O	['N']	[2]
3	cyclofenil	B-Drug	['Causes']	[1]
4	.	O	['N']	[4]
#843
0	We	O	['N']	[0]
1	describe	O	['N']	[1]
2	two	O	['N']	[2]
3	dark	O	['N']	[3]
4	-	O	['N']	[4]
5	skinned	O	['N']	[5]
6	patients	O	['N']	[6]
7	who	O	['N']	[7]
8	developed	O	['N']	[8]
9	hyperpigmented	O	['N']	[9]
10	skin	O	['N']	[10]
11	and	O	['N']	[11]
12	tongue	B	['N']	[12]
13	lesions	I-Adverse_Effect	['N']	[13]
14	during	O	['N']	[14]
15	combination	O	['N']	[15]
16	therapy	O	['N']	[16]
17	with	O	['N']	[17]
18	IFN	B-Drug	['Causes']	[13]
19	and	O	['N']	[19]
20	ribavirin	O	['N']	[20]
21	.	O	['N']	[21]
#844
0	Carboplatin	O	['N']	[0]
1	hypersensitivity	O	['N']	[1]
2	induced	O	['N']	[2]
3	by	O	['N']	[3]
4	low	B	['N']	[4]
5	-	I	['N']	[5]
6	dose	I-Dose	['N']	[6]
7	paclitaxel	O	['N']	[7]
8	/	O	['N']	[8]
9	carboplatin	B-Drug	['Dosage']	[6]
10	in	O	['N']	[10]
11	multiple	O	['N']	[11]
12	platinum	O	['N']	[12]
13	-	O	['N']	[13]
14	treated	O	['N']	[14]
15	patients	O	['N']	[15]
16	with	O	['N']	[16]
17	recurrent	O	['N']	[17]
18	ovarian	O	['N']	[18]
19	cancer	O	['N']	[19]
20	.	O	['N']	[20]
#845
0	Paradoxical	O	['N']	[0]
1	ventricular	O	['N']	[1]
2	tachycardia	O	['N']	[2]
3	and	O	['N']	[3]
4	fibrillation	B-Adverse_Effect	['N']	[4]
5	after	O	['N']	[5]
6	intravenous	O	['N']	[6]
7	bretylium	B-Drug	['Causes']	[4]
8	therapy	O	['N']	[8]
9	.	O	['N']	[9]
#846
0	Three	O	['N']	[0]
1	nephrotic	O	['N']	[1]
2	patients	O	['N']	[2]
3	who	O	['N']	[3]
4	had	O	['N']	[4]
5	reduced	O	['N']	[5]
6	renal	O	['N']	[6]
7	function	O	['N']	[7]
8	and	O	['N']	[8]
9	active	O	['N']	[9]
10	renal	O	['N']	[10]
11	disease	O	['N']	[11]
12	with	O	['N']	[12]
13	progressive	O	['N']	[13]
14	deterioration	O	['N']	[14]
15	of	O	['N']	[15]
16	renal	O	['N']	[16]
17	function	O	['N']	[17]
18	prior	O	['N']	[18]
19	to	O	['N']	[19]
20	the	O	['N']	[20]
21	use	O	['N']	[21]
22	of	O	['N']	[22]
23	MP	B-Drug	['Causes']	[27]
24	developed	O	['N']	[24]
25	transient	B	['N']	[25]
26	renal	I	['N']	[26]
27	failure	I-Adverse_Effect	['N']	[27]
28	following	O	['N']	[28]
29	an	O	['N']	[29]
30	MP	O	['N']	[30]
31	pulse	O	['N']	[31]
32	therapy	O	['N']	[32]
33	.	O	['N']	[33]
#847
0	One	O	['N']	[0]
1	patient	O	['N']	[1]
2	required	O	['N']	[2]
3	nursing	O	['N']	[3]
4	home	O	['N']	[4]
5	placement	O	['N']	[5]
6	and	O	['N']	[6]
7	a	O	['N']	[7]
8	feeding	O	['N']	[8]
9	gastrostomy	O	['N']	[9]
10	as	O	['N']	[10]
11	a	O	['N']	[11]
12	result	O	['N']	[12]
13	of	O	['N']	[13]
14	the	O	['N']	[14]
15	worsening	B	['N']	[15]
16	parkinsonism	I-Adverse_Effect	['N']	[16]
17	during	O	['N']	[17]
18	risperidone	B-Drug	['Causes']	[16]
19	treatment	O	['N']	[19]
20	,	O	['N']	[20]
21	but	O	['N']	[21]
22	was	O	['N']	[22]
23	able	O	['N']	[23]
24	to	O	['N']	[24]
25	return	O	['N']	[25]
26	home	O	['N']	[26]
27	and	O	['N']	[27]
28	have	O	['N']	[28]
29	the	O	['N']	[29]
30	gastrostomy	O	['N']	[30]
31	removed	O	['N']	[31]
32	after	O	['N']	[32]
33	switching	O	['N']	[33]
34	from	O	['N']	[34]
35	risperidone	O	['N']	[35]
36	to	O	['N']	[36]
37	clozapine	O	['N']	[37]
38	.	O	['N']	[38]
#848
0	Gold	B-Drug	['Causes']	[3]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	pneumonitis	B-Adverse_Effect	['N']	[3]
4	is	O	['N']	[4]
5	a	O	['N']	[5]
6	rare	O	['N']	[6]
7	complication	O	['N']	[7]
8	of	O	['N']	[8]
9	gold	O	['N']	[9]
10	salt	O	['N']	[10]
11	therapy	O	['N']	[11]
12	.	O	['N']	[12]
#849
0	We	O	['N']	[0]
1	suggest	O	['N']	[1]
2	that	O	['N']	[2]
3	itraconazole	B-Drug	['Causes']	[24]
4	should	O	['N']	[4]
5	be	O	['N']	[5]
6	added	O	['N']	[6]
7	to	O	['N']	[7]
8	the	O	['N']	[8]
9	list	O	['N']	[9]
10	of	O	['N']	[10]
11	drugs	O	['N']	[11]
12	that	O	['N']	[12]
13	may	O	['N']	[13]
14	be	O	['N']	[14]
15	responsible	O	['N']	[15]
16	for	O	['N']	[16]
17	a	O	['N']	[17]
18	drug	O	['N']	[18]
19	-	O	['N']	[19]
20	induced	O	['N']	[20]
21	vanishing	B	['N']	[21]
22	bile	I	['N']	[22]
23	duct	I	['N']	[23]
24	syndrome	I-Adverse_Effect	['N']	[24]
25	.	O	['N']	[25]
#850
0	Fatal	B	['N']	[0]
1	venous	I	['N']	[1]
2	thrombembolism	I-Adverse_Effect	['N']	[2]
3	complicating	O	['N']	[3]
4	imatinib	B-Drug	['Causes']	[2]
5	therapy	O	['N']	[5]
6	in	O	['N']	[6]
7	a	O	['N']	[7]
8	patient	O	['N']	[8]
9	with	O	['N']	[9]
10	metastatic	O	['N']	[10]
11	gastrointestinal	O	['N']	[11]
12	stromal	O	['N']	[12]
13	tumor	O	['N']	[13]
14	.	O	['N']	[14]
#851
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	two	O	['N']	[2]
3	patients	O	['N']	[3]
4	who	O	['N']	[4]
5	developed	O	['N']	[5]
6	intense	O	['N']	[6]
7	livedo	B	['N']	[7]
8	reticularis	I-Adverse_Effect	['N']	[8]
9	clearly	O	['N']	[9]
10	related	O	['N']	[10]
11	to	O	['N']	[11]
12	the	O	['N']	[12]
13	administration	O	['N']	[13]
14	of	O	['N']	[14]
15	interferon	B	['N']	[15]
16	alpha	I	['N']	[16]
17	2b	I-Drug	['Causes']	[8]
18	as	O	['N']	[18]
19	an	O	['N']	[19]
20	adjuvant	O	['N']	[20]
21	therapy	O	['N']	[21]
22	for	O	['N']	[22]
23	melanoma	O	['N']	[23]
24	.	O	['N']	[24]
#852
0	Two	O	['N']	[0]
1	patients	O	['N']	[1]
2	with	O	['N']	[2]
3	ovarian	O	['N']	[3]
4	cancer	O	['N']	[4]
5	who	O	['N']	[5]
6	had	O	['N']	[6]
7	received	O	['N']	[7]
8	multiple	O	['N']	[8]
9	courses	O	['N']	[9]
10	of	O	['N']	[10]
11	cisplatin	B-Drug	['Causes']	[34]
12	without	O	['N']	[12]
13	complications	O	['N']	[13]
14	experienced	O	['N']	[14]
15	hypersensitivity	O	['N']	[15]
16	reactions	O	['N']	[16]
17	to	O	['N']	[17]
18	cisplatin	O	['N']	[18]
19	:	O	['N']	[19]
20	one	O	['N']	[20]
21	,	O	['N']	[21]
22	involving	O	['N']	[22]
23	intrahepatic	O	['N']	[23]
24	artery	O	['N']	[24]
25	infusion	O	['N']	[25]
26	,	O	['N']	[26]
27	manifested	O	['N']	[27]
28	general	O	['N']	[28]
29	erythema	O	['N']	[29]
30	,	O	['N']	[30]
31	dyspnea	O	['N']	[31]
32	,	O	['N']	[32]
33	and	O	['N']	[33]
34	hypotension	B-Adverse_Effect	['N']	[34]
35	;	O	['N']	[35]
36	the	O	['N']	[36]
37	other	O	['N']	[37]
38	,	O	['N']	[38]
39	involving	O	['N']	[39]
40	intravenous	O	['N']	[40]
41	infusion	O	['N']	[41]
42	,	O	['N']	[42]
43	manifested	O	['N']	[43]
44	abdominal	O	['N']	[44]
45	pain	O	['N']	[45]
46	,	O	['N']	[46]
47	general	O	['N']	[47]
48	erythema	O	['N']	[48]
49	,	O	['N']	[49]
50	and	O	['N']	[50]
51	fever	O	['N']	[51]
52	.	O	['N']	[52]
#853
0	Reversible	B	['N']	[0]
1	MR	I	['N']	[1]
2	imaging	I	['N']	[2]
3	and	I	['N']	[3]
4	MR	I	['N']	[4]
5	spectroscopy	I	['N']	[5]
6	abnormalities	I-Adverse_Effect	['N']	[6]
7	in	O	['N']	[7]
8	association	O	['N']	[8]
9	with	O	['N']	[9]
10	metronidazole	B-Drug	['Causes']	[6]
11	therapy	O	['N']	[11]
12	.	O	['N']	[12]
#854
0	Acute	B	['N']	[0]
1	respiratory	I	['N']	[1]
2	distress	I	['N']	[2]
3	syndrome	I-Adverse_Effect	['N']	[3]
4	after	O	['N']	[4]
5	rituximab	B-Drug	['Causes']	[3]
6	infusion	O	['N']	[6]
7	.	O	['N']	[7]
#855
0	On	O	['N']	[0]
1	the	O	['N']	[1]
2	next	O	['N']	[2]
3	day	O	['N']	[3]
4	,	O	['N']	[4]
5	after	O	['N']	[5]
6	a	O	['N']	[6]
7	total	O	['N']	[7]
8	dose	O	['N']	[8]
9	of	O	['N']	[9]
10	only	O	['N']	[10]
11	600	B	['N']	[11]
12	mg	I-Dose	['N']	[12]
13	of	O	['N']	[13]
14	danazol	B-Drug	['Dosage']	[12]
15	,	O	['N']	[15]
16	gingival	O	['N']	[16]
17	bleeding	O	['N']	[17]
18	and	O	['N']	[18]
19	purpura	O	['N']	[19]
20	occurred	O	['N']	[20]
21	.	O	['N']	[21]
#856
0	Reversible	O	['N']	[0]
1	cholestasis	B-Adverse_Effect	['N']	[1]
2	with	O	['N']	[2]
3	bile	O	['N']	[3]
4	duct	O	['N']	[4]
5	injury	O	['N']	[5]
6	following	O	['N']	[6]
7	azathioprine	B-Drug	['Causes']	[1]
8	therapy	O	['N']	[8]
9	.	O	['N']	[9]
#857
0	Following	O	['N']	[0]
1	7	O	['N']	[1]
2	days	O	['N']	[2]
3	of	O	['N']	[3]
4	tigecycline	B-Drug	['Causes']	[13]
5	she	O	['N']	[5]
6	developed	O	['N']	[6]
7	severe	O	['N']	[7]
8	abdominal	O	['N']	[8]
9	pain	O	['N']	[9]
10	and	O	['N']	[10]
11	elevated	B	['N']	[11]
12	pancreatic	I	['N']	[12]
13	enzymes	I-Adverse_Effect	['N']	[13]
14	suggesting	O	['N']	[14]
15	acute	O	['N']	[15]
16	pancreatitis	O	['N']	[16]
17	.	O	['N']	[17]
#858
0	Retinal	B	['N']	[0]
1	abnormalities	I-Adverse_Effect	['N']	[1]
2	,	O	['N']	[2]
3	including	O	['N']	[3]
4	retinal	O	['N']	[4]
5	hemorrhage	O	['N']	[5]
6	and	O	['N']	[6]
7	"	O	['N']	[7]
8	cotton	O	['N']	[8]
9	-	O	['N']	[9]
10	wool	O	['N']	[10]
11	"	O	['N']	[11]
12	spots	O	['N']	[12]
13	,	O	['N']	[13]
14	often	O	['N']	[14]
15	occur	O	['N']	[15]
16	within	O	['N']	[16]
17	the	O	['N']	[17]
18	first	O	['N']	[18]
19	8	O	['N']	[19]
20	weeks	O	['N']	[20]
21	in	O	['N']	[21]
22	the	O	['N']	[22]
23	course	O	['N']	[23]
24	of	O	['N']	[24]
25	interferon	B-Drug	['Causes']	[1]
26	therapy	O	['N']	[26]
27	in	O	['N']	[27]
28	patients	O	['N']	[28]
29	with	O	['N']	[29]
30	chronic	O	['N']	[30]
31	hepatitis	O	['N']	[31]
32	C.	O	['N']	[32]
#859
0	Methotrexate	B-Drug	['Causes']	[4]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	papular	B	['N']	[3]
4	eruption	I-Adverse_Effect	['N']	[4]
5	following	O	['N']	[5]
6	treatment	O	['N']	[6]
7	of	O	['N']	[7]
8	psoriasis	O	['N']	[8]
9	.	O	['N']	[9]
#860
0	In	O	['N']	[0]
1	the	O	['N']	[1]
2	other	O	['N']	[2]
3	patient	O	['N']	[3]
4	,	O	['N']	[4]
5	a	O	['N']	[5]
6	78-year	O	['N']	[6]
7	-	O	['N']	[7]
8	old	O	['N']	[8]
9	woman	O	['N']	[9]
10	,	O	['N']	[10]
11	Neisseria	B	['N']	[11]
12	mucosa	I	['N']	[12]
13	knee	I	['N']	[13]
14	arthritis	I-Adverse_Effect	['N']	[14]
15	occurred	O	['N']	[15]
16	after	O	['N']	[16]
17	a	O	['N']	[17]
18	single	O	['N']	[18]
19	sodium	B	['N']	[19]
20	hyaluronate	I-Drug	['Causes']	[14]
21	injection	O	['N']	[21]
22	.	O	['N']	[22]
#861
0	A	O	['N']	[0]
1	patient	O	['N']	[1]
2	suffering	O	['N']	[2]
3	from	O	['N']	[3]
4	heparin	B-Drug	['Causes']	[9]
5	-	O	['N']	[5]
6	associated	O	['N']	[6]
7	thrombocytopenia	O	['N']	[7]
8	(	O	['N']	[8]
9	HAT	B-Adverse_Effect	['N']	[9]
10	)	O	['N']	[10]
11	,	O	['N']	[11]
12	recurrent	O	['N']	[12]
13	arteriothromboses	O	['N']	[13]
14	,	O	['N']	[14]
15	and	O	['N']	[15]
16	acute	O	['N']	[16]
17	renal	O	['N']	[17]
18	failure	O	['N']	[18]
19	after	O	['N']	[19]
20	treatment	O	['N']	[20]
21	with	O	['N']	[21]
22	standard	O	['N']	[22]
23	heparin	O	['N']	[23]
24	is	O	['N']	[24]
25	described	O	['N']	[25]
26	.	O	['N']	[26]
#862
0	Herein	O	['N']	[0]
1	,	O	['N']	[1]
2	we	O	['N']	[2]
3	describe	O	['N']	[3]
4	a	O	['N']	[4]
5	patient	O	['N']	[5]
6	with	O	['N']	[6]
7	AIDS	O	['N']	[7]
8	who	O	['N']	[8]
9	presented	O	['N']	[9]
10	to	O	['N']	[10]
11	medical	O	['N']	[11]
12	attention	O	['N']	[12]
13	with	O	['N']	[13]
14	pancytopenia	B-Adverse_Effect	['N']	[14]
15	48	O	['N']	[15]
16	months	O	['N']	[16]
17	postchemotherapy	O	['N']	[17]
18	with	O	['N']	[18]
19	etoposide	O	['N']	[19]
20	,	O	['N']	[20]
21	prednisone	B-Drug	['Causes']	[14]
22	,	O	['N']	[22]
23	vincristine	O	['N']	[23]
24	,	O	['N']	[24]
25	cyclophosphamide	O	['N']	[25]
26	,	O	['N']	[26]
27	doxorubicin	O	['N']	[27]
28	,	O	['N']	[28]
29	and	O	['N']	[29]
30	rituximab	O	['N']	[30]
31	(	O	['N']	[31]
32	R	O	['N']	[32]
33	-	O	['N']	[33]
34	EPOCH	O	['N']	[34]
35	)	O	['N']	[35]
36	for	O	['N']	[36]
37	diffuse	O	['N']	[37]
38	large	O	['N']	[38]
39	B	O	['N']	[39]
40	-	O	['N']	[40]
41	cell	O	['N']	[41]
42	lymphoma	O	['N']	[42]
43	.	O	['N']	[43]
#863
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	patient	O	['N']	[3]
4	with	O	['N']	[4]
5	chronic	O	['N']	[5]
6	renal	O	['N']	[6]
7	failure	O	['N']	[7]
8	and	O	['N']	[8]
9	ischemic	O	['N']	[9]
10	heart	O	['N']	[10]
11	disease	O	['N']	[11]
12	who	O	['N']	[12]
13	developed	O	['N']	[13]
14	clinically	O	['N']	[14]
15	significant	O	['N']	[15]
16	methemoglobinemia	B-Adverse_Effect	['N']	[16]
17	after	O	['N']	[17]
18	an	O	['N']	[18]
19	axillary	O	['N']	[19]
20	block	O	['N']	[20]
21	with	O	['N']	[21]
22	bupivacaine	O	['N']	[22]
23	and	O	['N']	[23]
24	additional	O	['N']	[24]
25	injection	O	['N']	[25]
26	of	O	['N']	[26]
27	lidocaine	B-Drug	['Causes']	[16]
28	in	O	['N']	[28]
29	the	O	['N']	[29]
30	operative	O	['N']	[30]
31	field	O	['N']	[31]
32	.	O	['N']	[32]
#864
0	CONCLUSION	O	['N']	[0]
1	:	O	['N']	[1]
2	The	O	['N']	[2]
3	chronic	O	['N']	[3]
4	use	O	['N']	[4]
5	of	O	['N']	[5]
6	HCQ	B-Drug	['Causes']	[30]
7	for	O	['N']	[7]
8	rheumatic	O	['N']	[8]
9	diseases	O	['N']	[9]
10	,	O	['N']	[10]
11	or	O	['N']	[11]
12	as	O	['N']	[12]
13	an	O	['N']	[13]
14	anti	O	['N']	[14]
15	-	O	['N']	[15]
16	malarial	O	['N']	[16]
17	drug	O	['N']	[17]
18	,	O	['N']	[18]
19	should	O	['N']	[19]
20	be	O	['N']	[20]
21	balanced	O	['N']	[21]
22	against	O	['N']	[22]
23	the	O	['N']	[23]
24	risk	O	['N']	[24]
25	of	O	['N']	[25]
26	developing	O	['N']	[26]
27	potentially	O	['N']	[27]
28	lethal	O	['N']	[28]
29	cardiac	B	['N']	[29]
30	arrhythmias	I-Adverse_Effect	['N']	[30]
31	.	O	['N']	[31]
#865
0	OBJECTIVES	O	['N']	[0]
1	:	O	['N']	[1]
2	A	O	['N']	[2]
3	delayed	O	['N']	[3]
4	stroke	B	['N']	[4]
5	-	I	['N']	[5]
6	like	I	['N']	[6]
7	leukoencephalopathy	I-Adverse_Effect	['N']	[7]
8	has	O	['N']	[8]
9	been	O	['N']	[9]
10	observed	O	['N']	[10]
11	in	O	['N']	[11]
12	patients	O	['N']	[12]
13	receiving	O	['N']	[13]
14	methotrexate	B-Drug	['Causes']	[7]
15	(	O	['N']	[15]
16	MTX	O	['N']	[16]
17	)	O	['N']	[17]
18	for	O	['N']	[18]
19	childhood	O	['N']	[19]
20	leukemia	O	['N']	[20]
21	.	O	['N']	[21]
#866
0	Pharmacokinetic	O	['N']	[0]
1	determinants	O	['N']	[1]
2	of	O	['N']	[2]
3	6-mercaptopurine	B-Drug	['Causes']	[4]
4	myelotoxicity	B-Adverse_Effect	['N']	[4]
5	and	O	['N']	[5]
6	therapeutic	O	['N']	[6]
7	failure	O	['N']	[7]
8	in	O	['N']	[8]
9	children	O	['N']	[9]
10	with	O	['N']	[10]
11	acute	O	['N']	[11]
12	lymphoblastic	O	['N']	[12]
13	leukemia	O	['N']	[13]
14	.	O	['N']	[14]
#867
0	The	O	['N']	[0]
1	authors	O	['N']	[1]
2	report	O	['N']	[2]
3	2	O	['N']	[3]
4	cases	O	['N']	[4]
5	of	O	['N']	[5]
6	renal	B	['N']	[6]
7	damage	I-Adverse_Effect	['N']	[7]
8	associated	O	['N']	[8]
9	with	O	['N']	[9]
10	lithium	B	['N']	[10]
11	carbonate	I-Drug	['Causes']	[7]
12	treatment	O	['N']	[12]
13	.	O	['N']	[13]
#868
0	Priapism	B-Adverse_Effect	['N']	[0]
1	as	O	['N']	[1]
2	a	O	['N']	[2]
3	complication	O	['N']	[3]
4	of	O	['N']	[4]
5	heparin	B-Drug	['Causes']	[0]
6	therapy	O	['N']	[6]
7	.	O	['N']	[7]
#869
0	Tiagabine	B-Drug	['Causes']	[8]
1	overdose	O	['N']	[1]
2	causes	O	['N']	[2]
3	an	O	['N']	[3]
4	unusual	B	['N']	[4]
5	array	I	['N']	[5]
6	of	I	['N']	[6]
7	neurological	I	['N']	[7]
8	symptoms	I-Adverse_Effect	['N']	[8]
9	,	O	['N']	[9]
10	many	O	['N']	[10]
11	similar	O	['N']	[11]
12	to	O	['N']	[12]
13	reported	O	['N']	[13]
14	adverse	O	['N']	[14]
15	effects	O	['N']	[15]
16	during	O	['N']	[16]
17	therapeutic	O	['N']	[17]
18	use	O	['N']	[18]
19	.	O	['N']	[19]
#870
0	As	O	['N']	[0]
1	linezolid	B-Drug	['Causes']	[9]
2	has	O	['N']	[2]
3	been	O	['N']	[3]
4	shown	O	['N']	[4]
5	to	O	['N']	[5]
6	have	O	['N']	[6]
7	hematologic	B	['N']	[7]
8	side	I	['N']	[8]
9	effects	I-Adverse_Effect	['N']	[9]
10	,	O	['N']	[10]
11	blood	O	['N']	[11]
12	count	O	['N']	[12]
13	monitoring	O	['N']	[13]
14	is	O	['N']	[14]
15	recommended	O	['N']	[15]
16	in	O	['N']	[16]
17	patients	O	['N']	[17]
18	receiving	O	['N']	[18]
19	this	O	['N']	[19]
20	drug	O	['N']	[20]
21	for	O	['N']	[21]
22	long	O	['N']	[22]
23	-	O	['N']	[23]
24	term	O	['N']	[24]
25	therapy	O	['N']	[25]
26	.	O	['N']	[26]
#871
0	This	O	['N']	[0]
1	progressed	O	['N']	[1]
2	to	O	['N']	[2]
3	tracheal	B	['N']	[3]
4	compression	I-Adverse_Effect	['N']	[4]
5	with	O	['N']	[5]
6	stridor	O	['N']	[6]
7	after	O	['N']	[7]
8	he	O	['N']	[8]
9	had	O	['N']	[9]
10	taken	O	['N']	[10]
11	some	O	['N']	[11]
12	aspirin	B-Drug	['Causes']	[4]
13	for	O	['N']	[13]
14	relief	O	['N']	[14]
15	of	O	['N']	[15]
16	the	O	['N']	[16]
17	neck	O	['N']	[17]
18	pain	O	['N']	[18]
19	.	O	['N']	[19]
#872
0	The	O	['N']	[0]
1	authors	O	['N']	[1]
2	present	O	['N']	[2]
3	a	O	['N']	[3]
4	case	O	['N']	[4]
5	study	O	['N']	[5]
6	of	O	['N']	[6]
7	a	O	['N']	[7]
8	mentally	O	['N']	[8]
9	healthy	O	['N']	[9]
10	man	O	['N']	[10]
11	who	O	['N']	[11]
12	repeatedly	O	['N']	[12]
13	experienced	O	['N']	[13]
14	short	O	['N']	[14]
15	-	O	['N']	[15]
16	lived	O	['N']	[16]
17	,	O	['N']	[17]
18	obsessional	B	['N']	[18]
19	-	I	['N']	[19]
20	like	I	['N']	[20]
21	suicidal	I	['N']	[21]
22	ideas	I	['N']	[22]
23	and	I	['N']	[23]
24	images	I-Adverse_Effect	['N']	[24]
25	after	O	['N']	[25]
26	ingestion	O	['N']	[26]
27	of	O	['N']	[27]
28	the	O	['N']	[28]
29	anti	O	['N']	[29]
30	-	O	['N']	[30]
31	fungal	O	['N']	[31]
32	drug	O	['N']	[32]
33	ketoconazole	B-Drug	['Causes']	[24]
34	.	O	['N']	[34]
#873
0	How	O	['N']	[0]
1	low	B-Dose	['N']	[1]
2	can	O	['N']	[2]
3	you	O	['N']	[3]
4	go	O	['N']	[4]
5	?	O	['N']	[5]
6	Use	O	['N']	[6]
7	of	O	['N']	[7]
8	very	O	['N']	[8]
9	low	O	['N']	[9]
10	dosage	O	['N']	[10]
11	of	O	['N']	[11]
12	gold	B-Drug	['Dosage']	[1]
13	in	O	['N']	[13]
14	patients	O	['N']	[14]
15	with	O	['N']	[15]
16	mucocutaneous	O	['N']	[16]
17	reactions	O	['N']	[17]
18	.	O	['N']	[18]
#874
0	Renal	B	['N']	[0]
1	tubular	I	['N']	[1]
2	acidosis	I-Adverse_Effect	['N']	[2]
3	secondary	O	['N']	[3]
4	to	O	['N']	[4]
5	FK506	B-Drug	['Causes']	[2]
6	in	O	['N']	[6]
7	living	O	['N']	[7]
8	donor	O	['N']	[8]
9	liver	O	['N']	[9]
10	transplantation	O	['N']	[10]
11	:	O	['N']	[11]
12	a	O	['N']	[12]
13	case	O	['N']	[13]
14	report	O	['N']	[14]
15	.	O	['N']	[15]
#875
0	We	O	['N']	[0]
1	present	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	the	O	['N']	[5]
6	syndrome	B	['N']	[6]
7	of	I	['N']	[7]
8	inappropriate	I	['N']	[8]
9	antidiuretic	I	['N']	[9]
10	hormone	I-Adverse_Effect	['N']	[10]
11	(	O	['N']	[11]
12	SIADH	O	['N']	[12]
13	)	O	['N']	[13]
14	secondary	O	['N']	[14]
15	to	O	['N']	[15]
16	cisplatin	B-Drug	['Causes']	[10]
17	therapy	O	['N']	[17]
18	in	O	['N']	[18]
19	a	O	['N']	[19]
20	patient	O	['N']	[20]
21	with	O	['N']	[21]
22	advanced	O	['N']	[22]
23	-	O	['N']	[23]
24	stage	O	['N']	[24]
25	large	O	['N']	[25]
26	cell	O	['N']	[26]
27	neuroendocrine	O	['N']	[27]
28	carcinoma	O	['N']	[28]
29	of	O	['N']	[29]
30	the	O	['N']	[30]
31	cervix	O	['N']	[31]
32	.	O	['N']	[32]
#876
0	The	O	['N']	[0]
1	pharmaceutical	O	['N']	[1]
2	company	O	['N']	[2]
3	producing	O	['N']	[3]
4	Halfan	O	['N']	[4]
5	has	O	['N']	[5]
6	reported	O	['N']	[6]
7	8	O	['N']	[7]
8	cardiac	O	['N']	[8]
9	arrests	O	['N']	[9]
10	,	O	['N']	[10]
11	leading	O	['N']	[11]
12	to	O	['N']	[12]
13	6	O	['N']	[13]
14	deaths	O	['N']	[14]
15	,	O	['N']	[15]
16	when	O	['N']	[16]
17	a	O	['N']	[17]
18	higher	B-Dose	['N']	[18]
19	dose	O	['N']	[19]
20	than	O	['N']	[20]
21	recommended	O	['N']	[21]
22	was	O	['N']	[22]
23	used	O	['N']	[23]
24	,	O	['N']	[24]
25	there	O	['N']	[25]
26	was	O	['N']	[26]
27	recent	O	['N']	[27]
28	or	O	['N']	[28]
29	concomitant	O	['N']	[29]
30	treatment	O	['N']	[30]
31	with	O	['N']	[31]
32	mefloquine	B-Drug	['Dosage']	[18]
33	,	O	['N']	[33]
34	there	O	['N']	[34]
35	was	O	['N']	[35]
36	pre	O	['N']	[36]
37	-	O	['N']	[37]
38	existing	O	['N']	[38]
39	prolongation	O	['N']	[39]
40	of	O	['N']	[40]
41	the	O	['N']	[41]
42	QT	O	['N']	[42]
43	interval	O	['N']	[43]
44	or	O	['N']	[44]
45	the	O	['N']	[45]
46	patient	O	['N']	[46]
47	had	O	['N']	[47]
48	a	O	['N']	[48]
49	thiamine	O	['N']	[49]
50	deficiency	O	['N']	[50]
51	.	O	['N']	[51]
#877
0	Treatment	O	['N']	[0]
1	-	O	['N']	[1]
2	related	O	['N']	[2]
3	myelodysplastic	B	['N']	[3]
4	syndrome	I-Adverse_Effect	['N']	[4]
5	after	O	['N']	[5]
6	temozolomide	B-Drug	['Causes']	[4]
7	for	O	['N']	[7]
8	recurrent	O	['N']	[8]
9	high	O	['N']	[9]
10	-	O	['N']	[10]
11	grade	O	['N']	[11]
12	glioma	O	['N']	[12]
13	.	O	['N']	[13]
#878
0	We	O	['N']	[0]
1	describe	O	['N']	[1]
2	a	O	['N']	[2]
3	patient	O	['N']	[3]
4	who	O	['N']	[4]
5	presented	O	['N']	[5]
6	with	O	['N']	[6]
7	bloody	O	['N']	[7]
8	diarrhoea	O	['N']	[8]
9	after	O	['N']	[9]
10	15	B	['N']	[10]
11	mg	I-Dose	['N']	[11]
12	meloxicam	B-Drug	['Dosage']	[11]
13	daily	O	['N']	[13]
14	for	O	['N']	[14]
15	10	O	['N']	[15]
16	days	O	['N']	[16]
17	for	O	['N']	[17]
18	osteoarthritis	O	['N']	[18]
19	.	O	['N']	[19]
#879
0	We	O	['N']	[0]
1	describe	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	needle	O	['N']	[5]
6	-	O	['N']	[6]
7	track	O	['N']	[7]
8	cutaneous	B	['N']	[8]
9	seeding	I-Adverse_Effect	['N']	[9]
10	of	O	['N']	[10]
11	hepatocellular	O	['N']	[11]
12	carcinoma	O	['N']	[12]
13	(	O	['N']	[13]
14	HCC	O	['N']	[14]
15	)	O	['N']	[15]
16	after	O	['N']	[16]
17	sonographically	O	['N']	[17]
18	guided	O	['N']	[18]
19	percutaneous	O	['N']	[19]
20	ethanol	B	['N']	[20]
21	injection	I-Drug	['Causes']	[9]
22	(	O	['N']	[22]
23	PEI	O	['N']	[23]
24	)	O	['N']	[24]
25	.	O	['N']	[25]
#880
0	We	O	['N']	[0]
1	discuss	O	['N']	[1]
2	a	O	['N']	[2]
3	patient	O	['N']	[3]
4	who	O	['N']	[4]
5	developed	O	['N']	[5]
6	severe	O	['N']	[6]
7	renal	O	['N']	[7]
8	tubular	O	['N']	[8]
9	dysfunction	O	['N']	[9]
10	secondary	O	['N']	[10]
11	to	O	['N']	[11]
12	short	O	['N']	[12]
13	-	O	['N']	[13]
14	term	O	['N']	[14]
15	therapy	O	['N']	[15]
16	with	O	['N']	[16]
17	Amikacin	B-Drug	['Causes']	[24]
18	,	O	['N']	[18]
19	resulting	O	['N']	[19]
20	in	O	['N']	[20]
21	refractory	O	['N']	[21]
22	hypokalemia	O	['N']	[22]
23	,	O	['N']	[23]
24	hypocalcemia	B-Adverse_Effect	['N']	[24]
25	,	O	['N']	[25]
26	hypomagnesemia	O	['N']	[26]
27	,	O	['N']	[27]
28	metabolic	O	['N']	[28]
29	alkalosis	O	['N']	[29]
30	,	O	['N']	[30]
31	and	O	['N']	[31]
32	polyuria	O	['N']	[32]
33	.	O	['N']	[33]
#881
0	DISCUSSION	O	['N']	[0]
1	:	O	['N']	[1]
2	Colchicine	B-Drug	['Causes']	[15]
3	,	O	['N']	[3]
4	the	O	['N']	[4]
5	most	O	['N']	[5]
6	important	O	['N']	[6]
7	drug	O	['N']	[7]
8	in	O	['N']	[8]
9	treatment	O	['N']	[9]
10	of	O	['N']	[10]
11	FMF	O	['N']	[11]
12	,	O	['N']	[12]
13	can	O	['N']	[13]
14	cause	O	['N']	[14]
15	myopathy	B-Adverse_Effect	['N']	[15]
16	in	O	['N']	[16]
17	patients	O	['N']	[17]
18	with	O	['N']	[18]
19	impaired	O	['N']	[19]
20	renal	O	['N']	[20]
21	and	O	['N']	[21]
22	hepatic	O	['N']	[22]
23	function	O	['N']	[23]
24	.	O	['N']	[24]
#882
0	He	O	['N']	[0]
1	had	O	['N']	[1]
2	been	O	['N']	[2]
3	taking	O	['N']	[3]
4	trimethoprim	B-Drug	['Causes']	[34]
5	-	O	['N']	[5]
6	sulfamethoxazole	O	['N']	[6]
7	for	O	['N']	[7]
8	approximately	O	['N']	[8]
9	eight	O	['N']	[9]
10	days	O	['N']	[10]
11	when	O	['N']	[11]
12	he	O	['N']	[12]
13	revisited	O	['N']	[13]
14	his	O	['N']	[14]
15	family	O	['N']	[15]
16	physician	O	['N']	[16]
17	,	O	['N']	[17]
18	complaining	O	['N']	[18]
19	of	O	['N']	[19]
20	headaches	O	['N']	[20]
21	,	O	['N']	[21]
22	dizziness	O	['N']	[22]
23	,	O	['N']	[23]
24	difficulty	O	['N']	[24]
25	with	O	['N']	[25]
26	speech	O	['N']	[26]
27	,	O	['N']	[27]
28	weakness	O	['N']	[28]
29	,	O	['N']	[29]
30	and	O	['N']	[30]
31	itching	B	['N']	[31]
32	on	I	['N']	[32]
33	the	I	['N']	[33]
34	trunk	I-Adverse_Effect	['N']	[34]
35	of	O	['N']	[35]
36	his	O	['N']	[36]
37	body	O	['N']	[37]
38	and	O	['N']	[38]
39	legs	O	['N']	[39]
40	,	O	['N']	[40]
41	where	O	['N']	[41]
42	a	O	['N']	[42]
43	maculopapular	O	['N']	[43]
44	rash	O	['N']	[44]
45	was	O	['N']	[45]
46	noted	O	['N']	[46]
47	.	O	['N']	[47]
#883
0	OBJECTIVE	O	['N']	[0]
1	:	O	['N']	[1]
2	The	O	['N']	[2]
3	authors	O	['N']	[3]
4	described	O	['N']	[4]
5	a	O	['N']	[5]
6	case	O	['N']	[6]
7	of	O	['N']	[7]
8	interferon	B-Drug	['Causes']	[11]
9	-	O	['N']	[9]
10	induced	O	['N']	[10]
11	psychosis	B-Adverse_Effect	['N']	[11]
12	as	O	['N']	[12]
13	a	O	['N']	[13]
14	framework	O	['N']	[14]
15	to	O	['N']	[15]
16	review	O	['N']	[16]
17	the	O	['N']	[17]
18	literature	O	['N']	[18]
19	and	O	['N']	[19]
20	discuss	O	['N']	[20]
21	the	O	['N']	[21]
22	decision	O	['N']	[22]
23	to	O	['N']	[23]
24	pursue	O	['N']	[24]
25	antiviral	O	['N']	[25]
26	treatment	O	['N']	[26]
27	in	O	['N']	[27]
28	psychiatrically	O	['N']	[28]
29	ill	O	['N']	[29]
30	patients	O	['N']	[30]
31	with	O	['N']	[31]
32	hepatitis	O	['N']	[32]
33	C.	O	['N']	[33]
#884
0	Physicians	O	['N']	[0]
1	using	O	['N']	[1]
2	this	O	['N']	[2]
3	"	O	['N']	[3]
4	new	O	['N']	[4]
5	"	O	['N']	[5]
6	drug	O	['N']	[6]
7	must	O	['N']	[7]
8	be	O	['N']	[8]
9	aware	O	['N']	[9]
10	of	O	['N']	[10]
11	the	O	['N']	[11]
12	potential	O	['N']	[12]
13	danger	O	['N']	[13]
14	of	O	['N']	[14]
15	sulfonamide	B-Drug	['Causes']	[22]
16	-	O	['N']	[16]
17	induced	O	['N']	[17]
18	injury	B	['N']	[18]
19	to	I	['N']	[19]
20	the	I	['N']	[20]
21	urinary	I	['N']	[21]
22	tract	I-Adverse_Effect	['N']	[22]
23	.	O	['N']	[23]
#885
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	reversible	O	['N']	[5]
6	encephalopathy	B	['N']	[6]
7	syndrome	I-Adverse_Effect	['N']	[7]
8	in	O	['N']	[8]
9	a	O	['N']	[9]
10	16-year	O	['N']	[10]
11	-	O	['N']	[11]
12	old	O	['N']	[12]
13	girl	O	['N']	[13]
14	with	O	['N']	[14]
15	acute	O	['N']	[15]
16	myelogenous	O	['N']	[16]
17	leukemia	O	['N']	[17]
18	(	O	['N']	[18]
19	AML	O	['N']	[19]
20	)	O	['N']	[20]
21	,	O	['N']	[21]
22	who	O	['N']	[22]
23	is	O	['N']	[23]
24	undergoing	O	['N']	[24]
25	during	O	['N']	[25]
26	consolidation	O	['N']	[26]
27	chemotherapy	O	['N']	[27]
28	composed	O	['N']	[28]
29	of	O	['N']	[29]
30	BH	O	['N']	[30]
31	-	O	['N']	[31]
32	AC	O	['N']	[32]
33	(	O	['N']	[33]
34	N4-behenoyl-1-beta	O	['N']	[34]
35	-	O	['N']	[35]
36	D	O	['N']	[36]
37	-	O	['N']	[37]
38	arabinofuranosyl	O	['N']	[38]
39	cytosine	O	['N']	[39]
40	)	O	['N']	[40]
41	and	O	['N']	[41]
42	idarubicin	B-Drug	['Causes']	[7]
43	.	O	['N']	[43]
#886
0	Carboplatin	O	['N']	[0]
1	hypersensitivity	O	['N']	[1]
2	induced	O	['N']	[2]
3	by	O	['N']	[3]
4	low	B	['N']	[4]
5	-	I	['N']	[5]
6	dose	I-Dose	['N']	[6]
7	paclitaxel	B-Drug	['Dosage']	[6]
8	/	O	['N']	[8]
9	carboplatin	O	['N']	[9]
10	in	O	['N']	[10]
11	multiple	O	['N']	[11]
12	platinum	O	['N']	[12]
13	-	O	['N']	[13]
14	treated	O	['N']	[14]
15	patients	O	['N']	[15]
16	with	O	['N']	[16]
17	recurrent	O	['N']	[17]
18	ovarian	O	['N']	[18]
19	cancer	O	['N']	[19]
20	.	O	['N']	[20]
#887
0	INTRODUCTION	O	['N']	[0]
1	:	O	['N']	[1]
2	Although	O	['N']	[2]
3	gefitinib	B-Drug	['Causes']	[25]
4	used	O	['N']	[4]
5	for	O	['N']	[5]
6	the	O	['N']	[6]
7	treatment	O	['N']	[7]
8	of	O	['N']	[8]
9	non	O	['N']	[9]
10	-	O	['N']	[10]
11	small	O	['N']	[11]
12	-	O	['N']	[12]
13	cell	O	['N']	[13]
14	lung	O	['N']	[14]
15	cancer	O	['N']	[15]
16	is	O	['N']	[16]
17	a	O	['N']	[17]
18	well	O	['N']	[18]
19	-	O	['N']	[19]
20	known	O	['N']	[20]
21	cause	O	['N']	[21]
22	of	O	['N']	[22]
23	interstitial	B	['N']	[23]
24	lung	I	['N']	[24]
25	disease	I-Adverse_Effect	['N']	[25]
26	(	O	['N']	[26]
27	ILD	O	['N']	[27]
28	)	O	['N']	[28]
29	,	O	['N']	[29]
30	few	O	['N']	[30]
31	case	O	['N']	[31]
32	reports	O	['N']	[32]
33	on	O	['N']	[33]
34	erlotinib	O	['N']	[34]
35	-	O	['N']	[35]
36	induced	O	['N']	[36]
37	ILD	O	['N']	[37]
38	have	O	['N']	[38]
39	been	O	['N']	[39]
40	issued	O	['N']	[40]
41	.	O	['N']	[41]
#888
0	During	O	['N']	[0]
1	dose	O	['N']	[1]
2	-	O	['N']	[2]
3	finding	O	['N']	[3]
4	studies	O	['N']	[4]
5	for	O	['N']	[5]
6	intravenous	O	['N']	[6]
7	proton	O	['N']	[7]
8	pump	O	['N']	[8]
9	inhibitors	O	['N']	[9]
10	omeprazole	O	['N']	[10]
11	and	O	['N']	[11]
12	pantoprazole	B-Drug	['Causes']	[31]
13	,	O	['N']	[13]
14	three	O	['N']	[14]
15	of	O	['N']	[15]
16	six	O	['N']	[16]
17	young	O	['N']	[17]
18	female	O	['N']	[18]
19	volunteers	O	['N']	[19]
20	receiving	O	['N']	[20]
21	omeprazole	O	['N']	[21]
22	and	O	['N']	[22]
23	two	O	['N']	[23]
24	young	O	['N']	[24]
25	female	O	['N']	[25]
26	volunteers	O	['N']	[26]
27	receiving	O	['N']	[27]
28	pantoprazole	O	['N']	[28]
29	developed	O	['N']	[29]
30	peripheral	B	['N']	[30]
31	edema	I-Adverse_Effect	['N']	[31]
32	within	O	['N']	[32]
33	8	O	['N']	[33]
34	hr	O	['N']	[34]
35	when	O	['N']	[35]
36	high	O	['N']	[36]
37	doses	O	['N']	[37]
38	of	O	['N']	[38]
39	the	O	['N']	[39]
40	proton	O	['N']	[40]
41	pump	O	['N']	[41]
42	inhibitors	O	['N']	[42]
43	were	O	['N']	[43]
44	applied	O	['N']	[44]
45	by	O	['N']	[45]
46	continuous	O	['N']	[46]
47	infusion	O	['N']	[47]
48	together	O	['N']	[48]
49	with	O	['N']	[49]
50	large	O	['N']	[50]
51	volumes	O	['N']	[51]
52	of	O	['N']	[52]
53	fluid	O	['N']	[53]
54	.	O	['N']	[54]
#889
0	CONCLUSIONS	O	['N']	[0]
1	:	O	['N']	[1]
2	Cefazolin	B-Drug	['Causes']	[11]
3	was	O	['N']	[3]
4	a	O	['N']	[4]
5	probable	O	['N']	[5]
6	cause	O	['N']	[6]
7	of	O	['N']	[7]
8	this	O	['N']	[8]
9	patient	O	['N']	[9]
10	's	O	['N']	[10]
11	leukopenia	B-Adverse_Effect	['N']	[11]
12	.	O	['N']	[12]
#890
0	After	O	['N']	[0]
1	initiation	O	['N']	[1]
2	of	O	['N']	[2]
3	topical	O	['N']	[3]
4	vitamin	B	['N']	[4]
5	D3	I-Drug	['Causes']	[36]
6	ointment	O	['N']	[6]
7	(	O	['N']	[7]
8	20	O	['N']	[8]
9	micro	O	['N']	[9]
10	g	O	['N']	[10]
11	/	O	['N']	[11]
12	g	O	['N']	[12]
13	of	O	['N']	[13]
14	tacalcitol	O	['N']	[14]
15	)	O	['N']	[15]
16	10	O	['N']	[16]
17	g	O	['N']	[17]
18	/	O	['N']	[18]
19	day	O	['N']	[19]
20	for	O	['N']	[20]
21	the	O	['N']	[21]
22	skin	O	['N']	[22]
23	lesions	O	['N']	[23]
24	,	O	['N']	[24]
25	both	O	['N']	[25]
26	the	O	['N']	[26]
27	serum	B	['N']	[27]
28	level	I	['N']	[28]
29	of	I	['N']	[29]
30	calcium	I	['N']	[30]
31	and	I	['N']	[31]
32	urinary	I	['N']	[32]
33	excretion	I	['N']	[33]
34	of	I	['N']	[34]
35	calcium	I	['N']	[35]
36	increased	I-Adverse_Effect	['N']	[36]
37	gradually	O	['N']	[37]
38	.	O	['N']	[38]
#891
0	Ifosfamide	B-Drug	['Causes']	[3]
1	-	O	['N']	[1]
2	associated	O	['N']	[2]
3	neurotoxicity	B-Adverse_Effect	['N']	[3]
4	was	O	['N']	[4]
5	noted	O	['N']	[5]
6	within	O	['N']	[6]
7	hours	O	['N']	[7]
8	of	O	['N']	[8]
9	drug	O	['N']	[9]
10	administration	O	['N']	[10]
11	and	O	['N']	[11]
12	improved	O	['N']	[12]
13	rapidly	O	['N']	[13]
14	following	O	['N']	[14]
15	hemodialysis	O	['N']	[15]
16	.	O	['N']	[16]
#892
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	acute	O	['N']	[5]
6	generalized	O	['N']	[6]
7	exanthematous	O	['N']	[7]
8	pustulosis	O	['N']	[8]
9	(	O	['N']	[9]
10	AGEP	B-Adverse_Effect	['N']	[10]
11	)	O	['N']	[11]
12	in	O	['N']	[12]
13	a	O	['N']	[13]
14	50-year	O	['N']	[14]
15	-	O	['N']	[15]
16	old	O	['N']	[16]
17	woman	O	['N']	[17]
18	that	O	['N']	[18]
19	was	O	['N']	[19]
20	attributed	O	['N']	[20]
21	to	O	['N']	[21]
22	the	O	['N']	[22]
23	ingestion	O	['N']	[23]
24	of	O	['N']	[24]
25	nimesulide	B-Drug	['Causes']	[10]
26	.	O	['N']	[26]
#893
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	31-year	O	['N']	[3]
4	-	O	['N']	[4]
5	old	O	['N']	[5]
6	women	O	['N']	[6]
7	with	O	['N']	[7]
8	recurrent	O	['N']	[8]
9	Hodgkin	O	['N']	[9]
10	's	O	['N']	[10]
11	lymphoma	O	['N']	[11]
12	and	O	['N']	[12]
13	unrecognized	O	['N']	[13]
14	HMSN-1	O	['N']	[14]
15	who	O	['N']	[15]
16	developed	O	['N']	[16]
17	severe	O	['N']	[17]
18	motor	O	['N']	[18]
19	neuropathy	O	['N']	[19]
20	3	O	['N']	[20]
21	weeks	O	['N']	[21]
22	after	O	['N']	[22]
23	the	O	['N']	[23]
24	first	O	['N']	[24]
25	cycle	O	['N']	[25]
26	of	O	['N']	[26]
27	treatment	O	['N']	[27]
28	including	O	['N']	[28]
29	2	B	['N']	[29]
30	mg	I-Dose	['N']	[30]
31	of	O	['N']	[31]
32	vincristine	B-Drug	['Dosage']	[30]
33	.	O	['N']	[33]
#894
0	Five	O	['N']	[0]
1	months	O	['N']	[1]
2	after	O	['N']	[2]
3	initiating	O	['N']	[3]
4	mirtazapine	B-Drug	['Causes']	[10]
5	therapy	O	['N']	[5]
6	,	O	['N']	[6]
7	she	O	['N']	[7]
8	developed	O	['N']	[8]
9	symptomatic	B	['N']	[9]
10	hyponatremia	I-Adverse_Effect	['N']	[10]
11	.	O	['N']	[11]
#895
0	METHODS	O	['N']	[0]
1	:	O	['N']	[1]
2	Double	O	['N']	[2]
3	-	O	['N']	[3]
4	blind	O	['N']	[4]
5	,	O	['N']	[5]
6	placebo	O	['N']	[6]
7	-	O	['N']	[7]
8	controlled	O	['N']	[8]
9	titrated	O	['N']	[9]
10	oral	O	['N']	[10]
11	challenges	O	['N']	[11]
12	with	O	['N']	[12]
13	pancreatic	O	['N']	[13]
14	enzymes	O	['N']	[14]
15	resulted	O	['N']	[15]
16	in	O	['N']	[16]
17	definite	O	['N']	[17]
18	vomiting	B-Adverse_Effect	['N']	[18]
19	within	O	['N']	[19]
20	1	O	['N']	[20]
21	to	O	['N']	[21]
22	1.5	O	['N']	[22]
23	hours	O	['N']	[23]
24	after	O	['N']	[24]
25	challenges	O	['N']	[25]
26	with	O	['N']	[26]
27	Viokase	O	['N']	[27]
28	and	O	['N']	[28]
29	Pancrease	B	['N']	[29]
30	MT	I	['N']	[30]
31	16	I-Drug	['Causes']	[18]
32	,	O	['N']	[32]
33	but	O	['N']	[33]
34	not	O	['N']	[34]
35	with	O	['N']	[35]
36	placebo	O	['N']	[36]
37	.	O	['N']	[37]
#896
0	RESULTS	O	['N']	[0]
1	:	O	['N']	[1]
2	Both	O	['N']	[2]
3	cases	O	['N']	[3]
4	presented	O	['N']	[4]
5	here	O	['N']	[5]
6	describe	O	['N']	[6]
7	corneal	B	['N']	[7]
8	ulcers	I-Adverse_Effect	['N']	[8]
9	that	O	['N']	[9]
10	persisted	O	['N']	[10]
11	and	O	['N']	[11]
12	showed	O	['N']	[12]
13	signs	O	['N']	[13]
14	of	O	['N']	[14]
15	worsening	O	['N']	[15]
16	during	O	['N']	[16]
17	weeks	O	['N']	[17]
18	of	O	['N']	[18]
19	frequent	O	['N']	[19]
20	topical	O	['N']	[20]
21	dosing	O	['N']	[21]
22	with	O	['N']	[22]
23	moxifloxacin	B-Drug	['Causes']	[8]
24	.	O	['N']	[24]
#897
0	In	O	['N']	[0]
1	four	O	['N']	[1]
2	patients	O	['N']	[2]
3	,	O	['N']	[3]
4	thrombosis	O	['N']	[4]
5	occurred	O	['N']	[5]
6	2	O	['N']	[6]
7	-	O	['N']	[7]
8	45	O	['N']	[8]
9	days	O	['N']	[9]
10	after	O	['N']	[10]
11	severe	O	['N']	[11]
12	hepatic	B	['N']	[12]
13	veno	I	['N']	[13]
14	-	I	['N']	[14]
15	occlusive	I	['N']	[15]
16	disease	I-Adverse_Effect	['N']	[16]
17	(	O	['N']	[17]
18	HVOD	O	['N']	[18]
19	)	O	['N']	[19]
20	secondary	O	['N']	[20]
21	to	O	['N']	[21]
22	intensive	O	['N']	[22]
23	chemotherapy	O	['N']	[23]
24	containing	O	['N']	[24]
25	busulfan	B-Drug	['Causes']	[16]
26	.	O	['N']	[26]
#898
0	The	O	['N']	[0]
1	latter	O	['N']	[1]
2	form	O	['N']	[2]
3	(	O	['N']	[3]
4	Macrodantin	B-Drug	['Causes']	[33]
5	)	O	['N']	[5]
6	is	O	['N']	[6]
7	reported	O	['N']	[7]
8	to	O	['N']	[8]
9	engender	O	['N']	[9]
10	less	O	['N']	[10]
11	gastrointestinal	O	['N']	[11]
12	intolerance	O	['N']	[12]
13	but	O	['N']	[13]
14	it	O	['N']	[14]
15	can	O	['N']	[15]
16	produce	O	['N']	[16]
17	the	O	['N']	[17]
18	same	O	['N']	[18]
19	adverse	O	['N']	[19]
20	effects	O	['N']	[20]
21	as	O	['N']	[21]
22	the	O	['N']	[22]
23	conventional	O	['N']	[23]
24	form	O	['N']	[24]
25	--	O	['N']	[25]
26	liver	O	['N']	[26]
27	damage	O	['N']	[27]
28	,	O	['N']	[28]
29	acute	B	['N']	[29]
30	and	I	['N']	[30]
31	chronic	I	['N']	[31]
32	pulmonary	I	['N']	[32]
33	reactions	I-Adverse_Effect	['N']	[33]
34	,	O	['N']	[34]
35	peripheral	O	['N']	[35]
36	neuropathy	O	['N']	[36]
37	,	O	['N']	[37]
38	blood	O	['N']	[38]
39	dyscrasias	O	['N']	[39]
40	and	O	['N']	[40]
41	allergic	O	['N']	[41]
42	reactions	O	['N']	[42]
43	--	O	['N']	[43]
44	and	O	['N']	[44]
45	does	O	['N']	[45]
46	so	O	['N']	[46]
47	just	O	['N']	[47]
48	as	O	['N']	[48]
49	rapidly	O	['N']	[49]
50	and	O	['N']	[50]
51	floridly	O	['N']	[51]
52	;	O	['N']	[52]
53	one	O	['N']	[53]
54	such	O	['N']	[54]
55	case	O	['N']	[55]
56	is	O	['N']	[56]
57	reported	O	['N']	[57]
58	here	O	['N']	[58]
59	.	O	['N']	[59]
#899
0	Neutrophilic	B	['N']	[0]
1	dermatoses	I-Adverse_Effect	['N']	[1]
2	in	O	['N']	[2]
3	two	O	['N']	[3]
4	children	O	['N']	[4]
5	with	O	['N']	[5]
6	idiopathic	O	['N']	[6]
7	neutropenia	O	['N']	[7]
8	:	O	['N']	[8]
9	association	O	['N']	[9]
10	with	O	['N']	[10]
11	granulocyte	B	['N']	[11]
12	colony	I	['N']	[12]
13	-	I	['N']	[13]
14	stimulating	I	['N']	[14]
15	factor	I-Drug	['Causes']	[1]
16	(	O	['N']	[16]
17	G	O	['N']	[17]
18	-	O	['N']	[18]
19	CSF	O	['N']	[19]
20	)	O	['N']	[20]
21	therapy	O	['N']	[21]
22	.	O	['N']	[22]
#900
0	According	O	['N']	[0]
1	to	O	['N']	[1]
2	the	O	['N']	[2]
3	Naranjo	O	['N']	[3]
4	probability	O	['N']	[4]
5	scale	O	['N']	[5]
6	,	O	['N']	[6]
7	the	O	['N']	[7]
8	relationship	O	['N']	[8]
9	of	O	['N']	[9]
10	gemcitabine	B-Drug	['Causes']	[14]
11	treatment	O	['N']	[11]
12	with	O	['N']	[12]
13	cutaneous	B	['N']	[13]
14	eruption	I-Adverse_Effect	['N']	[14]
15	in	O	['N']	[15]
16	our	O	['N']	[16]
17	patient	O	['N']	[17]
18	is	O	['N']	[18]
19	possible	O	['N']	[19]
20	.	O	['N']	[20]
#901
0	These	O	['N']	[0]
1	features	O	['N']	[1]
2	have	O	['N']	[2]
3	not	O	['N']	[3]
4	previously	O	['N']	[4]
5	been	O	['N']	[5]
6	reported	O	['N']	[6]
7	as	O	['N']	[7]
8	side	O	['N']	[8]
9	effects	O	['N']	[9]
10	of	O	['N']	[10]
11	glibenclamide	O	['N']	[11]
12	therapy	O	['N']	[12]
13	,	O	['N']	[13]
14	but	O	['N']	[14]
15	intrahepatic	B	['N']	[15]
16	cholestasis	I-Adverse_Effect	['N']	[16]
17	may	O	['N']	[17]
18	occur	O	['N']	[18]
19	with	O	['N']	[19]
20	chlorpropamide	B-Drug	['Causes']	[16]
21	,	O	['N']	[21]
22	a	O	['N']	[22]
23	similar	O	['N']	[23]
24	sulphonylurea	O	['N']	[24]
25	agent	O	['N']	[25]
26	.	O	['N']	[26]
#902
0	We	O	['N']	[0]
1	describe	O	['N']	[1]
2	2	O	['N']	[2]
3	children	O	['N']	[3]
4	with	O	['N']	[4]
5	cerebral	O	['N']	[5]
6	palsy	O	['N']	[6]
7	who	O	['N']	[7]
8	suffered	O	['N']	[8]
9	significant	O	['N']	[9]
10	morbidity	B-Adverse_Effect	['N']	[10]
11	immediately	O	['N']	[11]
12	after	O	['N']	[12]
13	treatment	O	['N']	[13]
14	with	O	['N']	[14]
15	hyperbaric	B	['N']	[15]
16	oxygen	I-Drug	['Causes']	[10]
17	.	O	['N']	[17]
#903
0	Only	O	['N']	[0]
1	one	O	['N']	[1]
2	case	O	['N']	[2]
3	of	O	['N']	[3]
4	a	O	['N']	[4]
5	generalized	B	['N']	[5]
6	maculopapular	I	['N']	[6]
7	rash	I-Adverse_Effect	['N']	[7]
8	with	O	['N']	[8]
9	enoxaparin	B-Drug	['Causes']	[7]
10	has	O	['N']	[10]
11	been	O	['N']	[11]
12	reported	O	['N']	[12]
13	in	O	['N']	[13]
14	Europe	O	['N']	[14]
15	.	O	['N']	[15]
#904
0	This	O	['N']	[0]
1	case	O	['N']	[1]
2	study	O	['N']	[2]
3	is	O	['N']	[3]
4	the	O	['N']	[4]
5	second	O	['N']	[5]
6	report	O	['N']	[6]
7	of	O	['N']	[7]
8	localized	B	['N']	[8]
9	purpura	I-Adverse_Effect	['N']	[9]
10	after	O	['N']	[10]
11	prolonged	O	['N']	[11]
12	lamotrigine	B-Drug	['Causes']	[9]
13	treatment	O	['N']	[13]
14	suggesting	O	['N']	[14]
15	this	O	['N']	[15]
16	may	O	['N']	[16]
17	be	O	['N']	[17]
18	an	O	['N']	[18]
19	atypical	O	['N']	[19]
20	lamotrigine	O	['N']	[20]
21	-	O	['N']	[21]
22	induced	O	['N']	[22]
23	drug	O	['N']	[23]
24	reaction	O	['N']	[24]
25	.	O	['N']	[25]
#905
0	Ten	O	['N']	[0]
1	years	O	['N']	[1]
2	of	O	['N']	[2]
3	behavioral	O	['N']	[3]
4	data	O	['N']	[4]
5	are	O	['N']	[5]
6	presented	O	['N']	[6]
7	to	O	['N']	[7]
8	support	O	['N']	[8]
9	the	O	['N']	[9]
10	hypothesis	O	['N']	[10]
11	that	O	['N']	[11]
12	phenobarbital	B-Drug	['Causes']	[16]
13	was	O	['N']	[13]
14	exacerbating	O	['N']	[14]
15	maladaptive	B	['N']	[15]
16	behaviors	I-Adverse_Effect	['N']	[16]
17	.	O	['N']	[17]
#906
0	Anaphylactoid	O	['N']	[0]
1	shock	O	['N']	[1]
2	,	O	['N']	[2]
3	disseminated	O	['N']	[3]
4	intravascular	O	['N']	[4]
5	coagulation	O	['N']	[5]
6	,	O	['N']	[6]
7	and	O	['N']	[7]
8	anuric	B	['N']	[8]
9	renal	I	['N']	[9]
10	failure	I-Adverse_Effect	['N']	[10]
11	requiring	O	['N']	[11]
12	dialysis	O	['N']	[12]
13	occurred	O	['N']	[13]
14	in	O	['N']	[14]
15	a	O	['N']	[15]
16	patient	O	['N']	[16]
17	receiving	O	['N']	[17]
18	zomepirac	B-Drug	['Causes']	[10]
19	sodium	O	['N']	[19]
20	for	O	['N']	[20]
21	toothache	O	['N']	[21]
22	.	O	['N']	[22]
#907
0	Pheripheral	O	['N']	[0]
1	edema	O	['N']	[1]
2	was	O	['N']	[2]
3	observed	O	['N']	[3]
4	in	O	['N']	[4]
5	five	O	['N']	[5]
6	female	O	['N']	[6]
7	patients	O	['N']	[7]
8	after	O	['N']	[8]
9	taking	O	['N']	[9]
10	proton	O	['N']	[10]
11	pump	O	['N']	[11]
12	inhibitors	O	['N']	[12]
13	omeprazole	O	['N']	[13]
14	,	O	['N']	[14]
15	lansoprazole	O	['N']	[15]
16	,	O	['N']	[16]
17	or	O	['N']	[17]
18	pantoprazole	B-Drug	['Dosage']	[30]
19	for	O	['N']	[19]
20	7	O	['N']	[20]
21	-	O	['N']	[21]
22	15	O	['N']	[22]
23	days	O	['N']	[23]
24	for	O	['N']	[24]
25	peptic	O	['N']	[25]
26	acid	O	['N']	[26]
27	diseases	O	['N']	[27]
28	in	O	['N']	[28]
29	recommended	O	['N']	[29]
30	standard	B-Dose	['N']	[30]
31	doses	O	['N']	[31]
32	.	O	['N']	[32]
#908
0	In	O	['N']	[0]
1	case	O	['N']	[1]
2	no	O	['N']	[2]
3	.	O	['N']	[3]
4	2	O	['N']	[4]
5	,	O	['N']	[5]
6	the	O	['N']	[6]
7	pathogenic	O	['N']	[7]
8	mechanism	O	['N']	[8]
9	seemed	O	['N']	[9]
10	to	O	['N']	[10]
11	be	O	['N']	[11]
12	persistent	O	['N']	[12]
13	light	O	['N']	[13]
14	reaction	O	['N']	[14]
15	preceded	O	['N']	[15]
16	by	O	['N']	[16]
17	systemic	O	['N']	[17]
18	photoallergy	O	['N']	[18]
19	,	O	['N']	[19]
20	as	O	['N']	[20]
21	he	O	['N']	[21]
22	had	O	['N']	[22]
23	taken	O	['N']	[23]
24	mequitazine	B-Drug	['Causes']	[60]
25	for	O	['N']	[25]
26	6	O	['N']	[26]
27	months	O	['N']	[27]
28	,	O	['N']	[28]
29	and	O	['N']	[29]
30	there	O	['N']	[30]
31	were	O	['N']	[31]
32	strong	O	['N']	[32]
33	positive	O	['N']	[33]
34	photopatch	O	['N']	[34]
35	test	O	['N']	[35]
36	results	O	['N']	[36]
37	with	O	['N']	[37]
38	immediate	O	['N']	[38]
39	erythema	O	['N']	[39]
40	reaction	O	['N']	[40]
41	,	O	['N']	[41]
42	cross	O	['N']	[42]
43	-	O	['N']	[43]
44	reaction	O	['N']	[44]
45	to	O	['N']	[45]
46	promethazine	O	['N']	[46]
47	,	O	['N']	[47]
48	decreased	O	['N']	[48]
49	MED	O	['N']	[49]
50	to	O	['N']	[50]
51	both	O	['N']	[51]
52	UVA	O	['N']	[52]
53	and	O	['N']	[53]
54	UVB	O	['N']	[54]
55	,	O	['N']	[55]
56	and	O	['N']	[56]
57	persistence	B	['N']	[57]
58	of	I	['N']	[58]
59	the	I	['N']	[59]
60	photosensitivity	I-Adverse_Effect	['N']	[60]
61	over	O	['N']	[61]
62	a	O	['N']	[62]
63	3-year	O	['N']	[63]
64	follow	O	['N']	[64]
65	-	O	['N']	[65]
66	up	O	['N']	[66]
67	period	O	['N']	[67]
68	after	O	['N']	[68]
69	discontinuation	O	['N']	[69]
70	of	O	['N']	[70]
71	the	O	['N']	[71]
72	mequitazine	O	['N']	[72]
73	.	O	['N']	[73]
#909
0	Severe	O	['N']	[0]
1	abdominal	B	['N']	[1]
2	pain	I-Adverse_Effect	['N']	[2]
3	in	O	['N']	[3]
4	low	O	['N']	[4]
5	dosage	O	['N']	[5]
6	clofazimine	B-Drug	['Causes']	[2]
7	.	O	['N']	[7]
#910
0	Fulminant	B	['N']	[0]
1	hepatic	I	['N']	[1]
2	failure	I-Adverse_Effect	['N']	[2]
3	associated	O	['N']	[3]
4	with	O	['N']	[4]
5	bicalutamide	B-Drug	['Causes']	[2]
6	.	O	['N']	[6]
#911
0	The	O	['N']	[0]
1	authors	O	['N']	[1]
2	report	O	['N']	[2]
3	on	O	['N']	[3]
4	two	O	['N']	[4]
5	patients	O	['N']	[5]
6	with	O	['N']	[6]
7	corneal	B	['N']	[7]
8	ulcers	I	['N']	[8]
9	refractory	I	['N']	[9]
10	to	I	['N']	[10]
11	conventional	I	['N']	[11]
12	treatment	I-Adverse_Effect	['N']	[12]
13	while	O	['N']	[13]
14	the	O	['N']	[14]
15	patients	O	['N']	[15]
16	were	O	['N']	[16]
17	undergoing	O	['N']	[17]
18	oral	O	['N']	[18]
19	colchicine	B-Drug	['Causes']	[12]
20	therapy	O	['N']	[20]
21	.	O	['N']	[21]
#912
0	This	O	['N']	[0]
1	case	O	['N']	[1]
2	and	O	['N']	[2]
3	other	O	['N']	[3]
4	published	O	['N']	[4]
5	evidence	O	['N']	[5]
6	should	O	['N']	[6]
7	alert	O	['N']	[7]
8	physicians	O	['N']	[8]
9	to	O	['N']	[9]
10	the	O	['N']	[10]
11	possibility	O	['N']	[11]
12	of	O	['N']	[12]
13	fatal	O	['N']	[13]
14	erlotinib	B-Drug	['Causes']	[17]
15	-	O	['N']	[15]
16	induced	O	['N']	[16]
17	ILD	B-Adverse_Effect	['N']	[17]
18	.	O	['N']	[18]
#913
0	Here	O	['N']	[0]
1	we	O	['N']	[1]
2	report	O	['N']	[2]
3	a	O	['N']	[3]
4	patient	O	['N']	[4]
5	with	O	['N']	[5]
6	newly	O	['N']	[6]
7	diagnosed	O	['N']	[7]
8	acute	O	['N']	[8]
9	promyelocytic	O	['N']	[9]
10	leukemia	O	['N']	[10]
11	who	O	['N']	[11]
12	developed	O	['N']	[12]
13	acute	O	['N']	[13]
14	focal	O	['N']	[14]
15	myositis	O	['N']	[15]
16	,	O	['N']	[16]
17	synovitis	O	['N']	[17]
18	,	O	['N']	[18]
19	and	O	['N']	[19]
20	possible	B	['N']	[20]
21	vasculitis	I-Adverse_Effect	['N']	[21]
22	,	O	['N']	[22]
23	after	O	['N']	[23]
24	receiving	O	['N']	[24]
25	all	B	['N']	[25]
26	-	I	['N']	[26]
27	trans	I	['N']	[27]
28	retinoic	I	['N']	[28]
29	acid	I-Drug	['Causes']	[21]
30	therapy	O	['N']	[30]
31	.	O	['N']	[31]
#914
0	Neutropenia	B-Adverse_Effect	['N']	[0]
1	and	O	['N']	[1]
2	agranulocytosis	O	['N']	[2]
3	are	O	['N']	[3]
4	risks	O	['N']	[4]
5	known	O	['N']	[5]
6	to	O	['N']	[6]
7	occur	O	['N']	[7]
8	with	O	['N']	[8]
9	phenothiazines	B-Drug	['Causes']	[0]
10	and	O	['N']	[10]
11	clozapine	O	['N']	[11]
12	.	O	['N']	[12]
#915
0	Management	O	['N']	[0]
1	and	O	['N']	[1]
2	successful	O	['N']	[2]
3	desensitization	O	['N']	[3]
4	in	O	['N']	[4]
5	methotrexate	B-Drug	['Causes']	[8]
6	-	O	['N']	[6]
7	induced	O	['N']	[7]
8	anaphylaxis	B-Adverse_Effect	['N']	[8]
9	.	O	['N']	[9]
#916
0	This	O	['N']	[0]
1	case	O	['N']	[1]
2	presentation	O	['N']	[2]
3	is	O	['N']	[3]
4	of	O	['N']	[4]
5	a	O	['N']	[5]
6	patient	O	['N']	[6]
7	who	O	['N']	[7]
8	had	O	['N']	[8]
9	the	O	['N']	[9]
10	clinical	O	['N']	[10]
11	appearance	O	['N']	[11]
12	of	O	['N']	[12]
13	epiglottitis	B-Adverse_Effect	['N']	[13]
14	,	O	['N']	[14]
15	but	O	['N']	[15]
16	actually	O	['N']	[16]
17	had	O	['N']	[17]
18	an	O	['N']	[18]
19	oro	O	['N']	[19]
20	-	O	['N']	[20]
21	pharyngeal	O	['N']	[21]
22	dystonic	O	['N']	[22]
23	reaction	O	['N']	[23]
24	to	O	['N']	[24]
25	prochlorperazine	B-Drug	['Causes']	[13]
26	.	O	['N']	[26]
#917
0	The	O	['N']	[0]
1	international	O	['N']	[1]
2	literature	O	['N']	[2]
3	regarding	O	['N']	[3]
4	opportunistic	B	['N']	[4]
5	infections	I-Adverse_Effect	['N']	[5]
6	after	O	['N']	[6]
7	immunosuppressive	O	['N']	[7]
8	therapy	O	['N']	[8]
9	with	O	['N']	[9]
10	alemtuzumab	B-Drug	['Causes']	[5]
11	with	O	['N']	[11]
12	particular	O	['N']	[12]
13	attention	O	['N']	[13]
14	on	O	['N']	[14]
15	fungal	O	['N']	[15]
16	infections	O	['N']	[16]
17	has	O	['N']	[17]
18	also	O	['N']	[18]
19	been	O	['N']	[19]
20	reviewed	O	['N']	[20]
21	.	O	['N']	[21]
#918
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	marked	O	['N']	[2]
3	QT	B	['N']	[3]
4	prolongation	I-Adverse_Effect	['N']	[4]
5	and	O	['N']	[5]
6	torsades	O	['N']	[6]
7	de	O	['N']	[7]
8	pointes	O	['N']	[8]
9	in	O	['N']	[9]
10	a	O	['N']	[10]
11	setting	O	['N']	[11]
12	of	O	['N']	[12]
13	flash	O	['N']	[13]
14	pulmonary	O	['N']	[14]
15	edema	O	['N']	[15]
16	resulting	O	['N']	[16]
17	from	O	['N']	[17]
18	acute	O	['N']	[18]
19	myocardial	O	['N']	[19]
20	ischemia	O	['N']	[20]
21	in	O	['N']	[21]
22	a	O	['N']	[22]
23	patient	O	['N']	[23]
24	who	O	['N']	[24]
25	was	O	['N']	[25]
26	being	O	['N']	[26]
27	treated	O	['N']	[27]
28	with	O	['N']	[28]
29	dofetilide	B-Drug	['Causes']	[4]
30	for	O	['N']	[30]
31	atrial	O	['N']	[31]
32	fibrillation	O	['N']	[32]
33	.	O	['N']	[33]
#919
0	Central	O	['N']	[0]
1	pontine	O	['N']	[1]
2	myelinolysis	O	['N']	[2]
3	manifested	O	['N']	[3]
4	by	O	['N']	[4]
5	temporary	B	['N']	[5]
6	blindness	I-Adverse_Effect	['N']	[6]
7	:	O	['N']	[7]
8	a	O	['N']	[8]
9	possible	O	['N']	[9]
10	complication	O	['N']	[10]
11	of	O	['N']	[11]
12	lithium	B-Drug	['Causes']	[6]
13	toxicity	O	['N']	[13]
14	.	O	['N']	[14]
#920
0	RESULTS	O	['N']	[0]
1	:	O	['N']	[1]
2	Three	O	['N']	[2]
3	patients	O	['N']	[3]
4	who	O	['N']	[4]
5	developed	O	['N']	[5]
6	symptoms	O	['N']	[6]
7	of	O	['N']	[7]
8	inflammatory	O	['N']	[8]
9	bowel	O	['N']	[9]
10	disease	O	['N']	[10]
11	(	O	['N']	[11]
12	IBD	B-Adverse_Effect	['N']	[12]
13	)	O	['N']	[13]
14	during	O	['N']	[14]
15	rofecoxib	B-Drug	['Causes']	[12]
16	exposure	O	['N']	[16]
17	are	O	['N']	[17]
18	described	O	['N']	[18]
19	along	O	['N']	[19]
20	with	O	['N']	[20]
21	pathology	O	['N']	[21]
22	findings	O	['N']	[22]
23	.	O	['N']	[23]
#921
0	A	O	['N']	[0]
1	case	O	['N']	[1]
2	of	O	['N']	[2]
3	congestive	B	['N']	[3]
4	heart	I	['N']	[4]
5	failure	I-Adverse_Effect	['N']	[5]
6	in	O	['N']	[6]
7	a	O	['N']	[7]
8	child	O	['N']	[8]
9	with	O	['N']	[9]
10	Wilms	O	['N']	[10]
11	'	O	['N']	[11]
12	tumor	O	['N']	[12]
13	treated	O	['N']	[13]
14	Adriamycin	B-Drug	['Causes']	[5]
15	is	O	['N']	[15]
16	presented	O	['N']	[16]
17	and	O	['N']	[17]
18	discussed	O	['N']	[18]
19	.	O	['N']	[19]
#922
0	We	O	['N']	[0]
1	have	O	['N']	[1]
2	described	O	['N']	[2]
3	three	O	['N']	[3]
4	patients	O	['N']	[4]
5	with	O	['N']	[5]
6	hepatitis	O	['N']	[6]
7	C	O	['N']	[7]
8	for	O	['N']	[8]
9	whom	O	['N']	[9]
10	IFN	O	['N']	[10]
11	-	O	['N']	[11]
12	alpha	O	['N']	[12]
13	and	O	['N']	[13]
14	ribavirin	B-Drug	['Causes']	[28]
15	were	O	['N']	[15]
16	prescribed	O	['N']	[16]
17	and	O	['N']	[17]
18	who	O	['N']	[18]
19	developed	O	['N']	[19]
20	two	O	['N']	[20]
21	successive	O	['N']	[21]
22	phases	O	['N']	[22]
23	of	O	['N']	[23]
24	silent	O	['N']	[24]
25	thyroiditis	O	['N']	[25]
26	followed	O	['N']	[26]
27	by	O	['N']	[27]
28	hyperthryroidism	B-Adverse_Effect	['N']	[28]
29	relapse	O	['N']	[29]
30	due	O	['N']	[30]
31	to	O	['N']	[31]
32	Graves	O	['N']	[32]
33	'	O	['N']	[33]
34	disease	O	['N']	[34]
35	.	O	['N']	[35]
#923
0	The	O	['N']	[0]
1	development	O	['N']	[1]
2	of	O	['N']	[2]
3	systemic	O	['N']	[3]
4	lupus	O	['N']	[4]
5	erythematosus	O	['N']	[5]
6	(	O	['N']	[6]
7	SLE	B-Adverse_Effect	['N']	[7]
8	)	O	['N']	[8]
9	after	O	['N']	[9]
10	38	O	['N']	[10]
11	months	O	['N']	[11]
12	of	O	['N']	[12]
13	therapy	O	['N']	[13]
14	with	O	['N']	[14]
15	recombinant	O	['N']	[15]
16	human	O	['N']	[16]
17	interferon	O	['N']	[17]
18	gamma	O	['N']	[18]
19	(	O	['N']	[19]
20	rIFN	B	['N']	[20]
21	-	I	['N']	[21]
22	gamma	I-Drug	['Causes']	[7]
23	)	O	['N']	[23]
24	was	O	['N']	[24]
25	observed	O	['N']	[25]
26	in	O	['N']	[26]
27	a	O	['N']	[27]
28	patient	O	['N']	[28]
29	with	O	['N']	[29]
30	rheumatoid	O	['N']	[30]
31	arthritis	O	['N']	[31]
32	.	O	['N']	[32]
#924
0	OBJECTIVE	O	['N']	[0]
1	:	O	['N']	[1]
2	To	O	['N']	[2]
3	document	O	['N']	[3]
4	a	O	['N']	[4]
5	case	O	['N']	[5]
6	of	O	['N']	[6]
7	serotonin	B	['N']	[7]
8	syndrome	I-Adverse_Effect	['N']	[8]
9	(	O	['N']	[9]
10	SS	O	['N']	[10]
11	)	O	['N']	[11]
12	associated	O	['N']	[12]
13	with	O	['N']	[13]
14	mirtazapine	B-Drug	['Causes']	[8]
15	monotherapy	O	['N']	[15]
16	,	O	['N']	[16]
17	review	O	['N']	[17]
18	the	O	['N']	[18]
19	previously	O	['N']	[19]
20	reported	O	['N']	[20]
21	cases	O	['N']	[21]
22	of	O	['N']	[22]
23	SS	O	['N']	[23]
24	associated	O	['N']	[24]
25	with	O	['N']	[25]
26	this	O	['N']	[26]
27	tetracyclic	O	['N']	[27]
28	antidepressant	O	['N']	[28]
29	,	O	['N']	[29]
30	and	O	['N']	[30]
31	discuss	O	['N']	[31]
32	the	O	['N']	[32]
33	possible	O	['N']	[33]
34	pathogenic	O	['N']	[34]
35	mechanisms	O	['N']	[35]
36	leading	O	['N']	[36]
37	to	O	['N']	[37]
38	this	O	['N']	[38]
39	serious	O	['N']	[39]
40	adverse	O	['N']	[40]
41	drug	O	['N']	[41]
42	reaction	O	['N']	[42]
43	.	O	['N']	[43]
#925
0	We	O	['N']	[0]
1	describe	O	['N']	[1]
2	2	O	['N']	[2]
3	patients	O	['N']	[3]
4	with	O	['N']	[4]
5	cutaneous	O	['N']	[5]
6	lupus	O	['N']	[6]
7	erythematosus	O	['N']	[7]
8	who	O	['N']	[8]
9	developed	O	['N']	[9]
10	severe	O	['N']	[10]
11	dapsone	B-Drug	['Causes']	[20]
12	reaction	O	['N']	[12]
13	after	O	['N']	[13]
14	low	O	['N']	[14]
15	dose	O	['N']	[15]
16	therapy	O	['N']	[16]
17	,	O	['N']	[17]
18	with	O	['N']	[18]
19	a	O	['N']	[19]
20	fatal	B-Adverse_Effect	['N']	[20]
21	outcome	O	['N']	[21]
22	in	O	['N']	[22]
23	one	O	['N']	[23]
24	.	O	['N']	[24]
#926
0	Despite	O	['N']	[0]
1	minimal	O	['N']	[1]
2	short	O	['N']	[2]
3	-	O	['N']	[3]
4	term	O	['N']	[4]
5	side	O	['N']	[5]
6	effects	O	['N']	[6]
7	and	O	['N']	[7]
8	apparent	O	['N']	[8]
9	efficacy	O	['N']	[9]
10	,	O	['N']	[10]
11	chronic	O	['N']	[11]
12	treatment	O	['N']	[12]
13	of	O	['N']	[13]
14	MG	O	['N']	[14]
15	with	O	['N']	[15]
16	MM	B-Drug	['Causes']	[25]
17	may	O	['N']	[17]
18	be	O	['N']	[18]
19	associated	O	['N']	[19]
20	with	O	['N']	[20]
21	increased	O	['N']	[21]
22	risk	O	['N']	[22]
23	of	O	['N']	[23]
24	lymphoproliferative	B	['N']	[24]
25	disorders	I-Adverse_Effect	['N']	[25]
26	.	O	['N']	[26]
#927
0	Autopsy	O	['N']	[0]
1	findings	O	['N']	[1]
2	were	O	['N']	[2]
3	consistent	O	['N']	[3]
4	with	O	['N']	[4]
5	bleomycin	B-Drug	['Causes']	[11]
6	and	O	['N']	[6]
7	oxygen	O	['N']	[7]
8	-	O	['N']	[8]
9	induced	O	['N']	[9]
10	pulmonary	B	['N']	[10]
11	damage	I-Adverse_Effect	['N']	[11]
12	.	O	['N']	[12]
#928
0	Gold	B	['N']	[0]
1	-	I	['N']	[1]
2	salt	I-Drug	['Causes']	[10]
3	therapy	O	['N']	[3]
4	may	O	['N']	[4]
5	result	O	['N']	[5]
6	in	O	['N']	[6]
7	damage	B	['N']	[7]
8	to	I	['N']	[8]
9	proximal	I	['N']	[9]
10	tubules	I-Adverse_Effect	['N']	[10]
11	that	O	['N']	[11]
12	leak	O	['N']	[12]
13	renal	O	['N']	[13]
14	tubular	O	['N']	[14]
15	antigens	O	['N']	[15]
16	,	O	['N']	[16]
17	which	O	['N']	[17]
18	in	O	['N']	[18]
19	turn	O	['N']	[19]
20	complex	O	['N']	[20]
21	with	O	['N']	[21]
22	autoantibody	O	['N']	[22]
23	and	O	['N']	[23]
24	produce	O	['N']	[24]
25	an	O	['N']	[25]
26	autoimmune	O	['N']	[26]
27	membranous	O	['N']	[27]
28	nephropathy	O	['N']	[28]
29	.	O	['N']	[29]
#929
0	The	O	['N']	[0]
1	aim	O	['N']	[1]
2	of	O	['N']	[2]
3	this	O	['N']	[3]
4	report	O	['N']	[4]
5	is	O	['N']	[5]
6	to	O	['N']	[6]
7	describe	O	['N']	[7]
8	the	O	['N']	[8]
9	clinical	O	['N']	[9]
10	and	O	['N']	[10]
11	electroencephalographic	O	['N']	[11]
12	findings	O	['N']	[12]
13	seen	O	['N']	[13]
14	in	O	['N']	[14]
15	an	O	['N']	[15]
16	elderly	O	['N']	[16]
17	woman	O	['N']	[17]
18	without	O	['N']	[18]
19	previous	O	['N']	[19]
20	history	O	['N']	[20]
21	of	O	['N']	[21]
22	seizures	O	['N']	[22]
23	who	O	['N']	[23]
24	developed	O	['N']	[24]
25	a	O	['N']	[25]
26	nonconvulsive	B	['N']	[26]
27	generalized	I	['N']	[27]
28	status	I	['N']	[28]
29	epilepticus	I-Adverse_Effect	['N']	[29]
30	following	O	['N']	[30]
31	acute	O	['N']	[31]
32	withdrawal	O	['N']	[32]
33	of	O	['N']	[33]
34	lorazepam	B-Drug	['Causes']	[29]
35	.	O	['N']	[35]
#930
0	After	O	['N']	[0]
1	having	O	['N']	[1]
2	received	O	['N']	[2]
3	gemcitabine	B-Drug	['Causes']	[19]
4	on	O	['N']	[4]
5	day	O	['N']	[5]
6	1	O	['N']	[6]
7	of	O	['N']	[7]
8	the	O	['N']	[8]
9	second	O	['N']	[9]
10	course	O	['N']	[10]
11	,	O	['N']	[11]
12	the	O	['N']	[12]
13	patient	O	['N']	[13]
14	developed	O	['N']	[14]
15	dry	O	['N']	[15]
16	cough	O	['N']	[16]
17	,	O	['N']	[17]
18	subfebrile	B	['N']	[18]
19	temperatures	I-Adverse_Effect	['N']	[19]
20	and	O	['N']	[20]
21	dyspnea	O	['N']	[21]
22	within	O	['N']	[22]
23	48	O	['N']	[23]
24	h.	O	['N']	[24]
#931
0	A	O	['N']	[0]
1	49-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	man	O	['N']	[4]
5	with	O	['N']	[5]
6	Crohn	O	['N']	[6]
7	's	O	['N']	[7]
8	disease	O	['N']	[8]
9	treated	O	['N']	[9]
10	with	O	['N']	[10]
11	prednisone	O	['N']	[11]
12	and	O	['N']	[12]
13	mesalamine	O	['N']	[13]
14	(	O	['N']	[14]
15	5-ASA	B-Drug	['Causes']	[20]
16	)	O	['N']	[16]
17	developed	O	['N']	[17]
18	worsening	B	['N']	[18]
19	respiratory	I	['N']	[19]
20	distress	I-Adverse_Effect	['N']	[20]
21	and	O	['N']	[21]
22	fever	O	['N']	[22]
23	.	O	['N']	[23]
#932
0	The	O	['N']	[0]
1	knowledge	O	['N']	[1]
2	concerning	O	['N']	[2]
3	VGB	B-Drug	['Causes']	[7]
4	-	O	['N']	[4]
5	associated	O	['N']	[5]
6	visual	B	['N']	[6]
7	dysfunction	I-Adverse_Effect	['N']	[7]
8	in	O	['N']	[8]
9	pediatric	O	['N']	[9]
10	patients	O	['N']	[10]
11	,	O	['N']	[11]
12	particularly	O	['N']	[12]
13	in	O	['N']	[13]
14	those	O	['N']	[14]
15	who	O	['N']	[15]
16	have	O	['N']	[16]
17	been	O	['N']	[17]
18	exposed	O	['N']	[18]
19	to	O	['N']	[19]
20	VGB	O	['N']	[20]
21	in	O	['N']	[21]
22	utero	O	['N']	[22]
23	is	O	['N']	[23]
24	limited	O	['N']	[24]
25	.	O	['N']	[25]
#933
0	Pseudomembranous	B	['N']	[0]
1	colitis	I-Adverse_Effect	['N']	[1]
2	readily	O	['N']	[2]
3	occurs	O	['N']	[3]
4	in	O	['N']	[4]
5	at	O	['N']	[5]
6	least	O	['N']	[6]
7	certain	O	['N']	[7]
8	population	O	['N']	[8]
9	groups	O	['N']	[9]
10	receiving	O	['N']	[10]
11	trimethoprim	O	['N']	[11]
12	-	O	['N']	[12]
13	sulfamethoxazole	B-Drug	['Causes']	[1]
14	.	O	['N']	[14]
#934
0	That	O	['N']	[0]
1	review	O	['N']	[1]
2	suggested	O	['N']	[2]
3	that	O	['N']	[3]
4	patients	O	['N']	[4]
5	receiving	O	['N']	[5]
6	anti	B	['N']	[6]
7	-	I	['N']	[7]
8	D	I	['N']	[8]
9	IGIV	I-Drug	['Causes']	[26]
10	be	O	['N']	[10]
11	monitored	O	['N']	[11]
12	for	O	['N']	[12]
13	those	O	['N']	[13]
14	and	O	['N']	[14]
15	other	O	['N']	[15]
16	potential	O	['N']	[16]
17	complications	O	['N']	[17]
18	of	O	['N']	[18]
19	hemoglobinemia	O	['N']	[19]
20	,	O	['N']	[20]
21	particularly	O	['N']	[21]
22	disseminated	O	['N']	[22]
23	intravascular	O	['N']	[23]
24	coagulation	O	['N']	[24]
25	(	O	['N']	[25]
26	DIC	B-Adverse_Effect	['N']	[26]
27	)	O	['N']	[27]
28	.	O	['N']	[28]
#935
0	The	O	['N']	[0]
1	uncomplicated	O	['N']	[1]
2	long	O	['N']	[2]
3	-	O	['N']	[3]
4	term	O	['N']	[4]
5	use	O	['N']	[5]
6	of	O	['N']	[6]
7	adequately	O	['N']	[7]
8	-	O	['N']	[8]
9	dosed	O	['N']	[9]
10	AZA	B-Drug	['Causes']	[29]
11	and	O	['N']	[11]
12	stable	O	['N']	[12]
13	non	O	['N']	[13]
14	-	O	['N']	[14]
15	toxic	O	['N']	[15]
16	metabolite	O	['N']	[16]
17	levels	O	['N']	[17]
18	could	O	['N']	[18]
19	not	O	['N']	[19]
20	acknowledge	O	['N']	[20]
21	TPMT	O	['N']	[21]
22	deficiency	O	['N']	[22]
23	as	O	['N']	[23]
24	a	O	['N']	[24]
25	primary	O	['N']	[25]
26	cause	O	['N']	[26]
27	of	O	['N']	[27]
28	the	O	['N']	[28]
29	leukopenia	B-Adverse_Effect	['N']	[29]
30	.	O	['N']	[30]
#936
0	Posthypoglycemic	O	['N']	[0]
1	hyperglycemia	O	['N']	[1]
2	(	O	['N']	[2]
3	rebound	B	['N']	[3]
4	hyperglycemia	I-Adverse_Effect	['N']	[4]
5	)	O	['N']	[5]
6	after	O	['N']	[6]
7	overdosing	O	['N']	[7]
8	of	O	['N']	[8]
9	insulin	B-Drug	['Causes']	[4]
10	was	O	['N']	[10]
11	diagnosed	O	['N']	[11]
12	in	O	['N']	[12]
13	6	O	['N']	[13]
14	cats	O	['N']	[14]
15	with	O	['N']	[15]
16	diabetes	O	['N']	[16]
17	mellitus	O	['N']	[17]
18	.	O	['N']	[18]
#937
0	Cryptococcus	B	['N']	[0]
1	neoformans	I	['N']	[1]
2	fatal	I	['N']	[2]
3	sepsis	I-Adverse_Effect	['N']	[3]
4	in	O	['N']	[4]
5	a	O	['N']	[5]
6	chronic	O	['N']	[6]
7	lymphocytic	O	['N']	[7]
8	leukemia	O	['N']	[8]
9	patient	O	['N']	[9]
10	treated	O	['N']	[10]
11	with	O	['N']	[11]
12	alemtuzumab	B-Drug	['Causes']	[3]
13	:	O	['N']	[13]
14	case	O	['N']	[14]
15	report	O	['N']	[15]
16	and	O	['N']	[16]
17	review	O	['N']	[17]
18	of	O	['N']	[18]
19	the	O	['N']	[19]
20	literature	O	['N']	[20]
21	.	O	['N']	[21]
#938
0	Symptoms	O	['N']	[0]
1	and	O	['N']	[1]
2	signs	O	['N']	[2]
3	of	O	['N']	[3]
4	augmentation	B-Adverse_Effect	['N']	[4]
5	were	O	['N']	[5]
6	related	O	['N']	[6]
7	to	O	['N']	[7]
8	low	O	['N']	[8]
9	plasma	O	['N']	[9]
10	levodopa	B-Drug	['Causes']	[4]
11	levels	O	['N']	[11]
12	,	O	['N']	[12]
13	abating	O	['N']	[13]
14	75	O	['N']	[14]
15	minutes	O	['N']	[15]
16	after	O	['N']	[16]
17	oral	O	['N']	[17]
18	levodopa	O	['N']	[18]
19	administration	O	['N']	[19]
20	and	O	['N']	[20]
21	reappearing	O	['N']	[21]
22	after	O	['N']	[22]
23	3	O	['N']	[23]
24	hours	O	['N']	[24]
25	,	O	['N']	[25]
26	closely	O	['N']	[26]
27	mirroring	O	['N']	[27]
28	the	O	['N']	[28]
29	rapid	O	['N']	[29]
30	rise	O	['N']	[30]
31	and	O	['N']	[31]
32	fall	O	['N']	[32]
33	of	O	['N']	[33]
34	plasma	O	['N']	[34]
35	levodopa	O	['N']	[35]
36	concentration	O	['N']	[36]
37	.	O	['N']	[37]
#939
0	A	O	['N']	[0]
1	22-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	drug	O	['N']	[4]
5	-	O	['N']	[5]
6	abuser	O	['N']	[6]
7	injected	O	['N']	[7]
8	flunitrazepam	B-Drug	['Causes']	[30]
9	tablets	O	['N']	[9]
10	dissolved	O	['N']	[10]
11	in	O	['N']	[11]
12	tap	O	['N']	[12]
13	water	O	['N']	[13]
14	into	O	['N']	[14]
15	her	O	['N']	[15]
16	left	O	['N']	[16]
17	femoral	O	['N']	[17]
18	artery	O	['N']	[18]
19	and	O	['N']	[19]
20	presented	O	['N']	[20]
21	with	O	['N']	[21]
22	clinical	O	['N']	[22]
23	signs	O	['N']	[23]
24	of	O	['N']	[24]
25	acute	B	['N']	[25]
26	ischaemia	I	['N']	[26]
27	of	I	['N']	[27]
28	the	I	['N']	[28]
29	left	I	['N']	[29]
30	leg	I-Adverse_Effect	['N']	[30]
31	.	O	['N']	[31]
#940
0	This	O	['N']	[0]
1	experience	O	['N']	[1]
2	supports	O	['N']	[2]
3	the	O	['N']	[3]
4	hypothesis	O	['N']	[4]
5	that	O	['N']	[5]
6	heparin	B-Drug	['Causes']	[19]
7	can	O	['N']	[7]
8	be	O	['N']	[8]
9	readministered	O	['N']	[9]
10	early	O	['N']	[10]
11	to	O	['N']	[11]
12	patients	O	['N']	[12]
13	with	O	['N']	[13]
14	heparin	O	['N']	[14]
15	-	O	['N']	[15]
16	associated	O	['N']	[16]
17	thrombocytopenia	O	['N']	[17]
18	and	O	['N']	[18]
19	thrombosis	B-Adverse_Effect	['N']	[19]
20	,	O	['N']	[20]
21	provided	O	['N']	[21]
22	antiplatelet	O	['N']	[22]
23	therapy	O	['N']	[23]
24	is	O	['N']	[24]
25	given	O	['N']	[25]
26	.	O	['N']	[26]
#941
0	Theophylline	B	['N']	[0]
1	intoxication	I-Adverse_Effect	['N']	[1]
2	following	O	['N']	[2]
3	viloxazine	B-Drug	['Causes']	[1]
4	induced	O	['N']	[4]
5	decrease	O	['N']	[5]
6	in	O	['N']	[6]
7	clearance	O	['N']	[7]
8	.	O	['N']	[8]
#942
0	Failure	O	['N']	[0]
1	of	O	['N']	[1]
2	plasmapheresis	O	['N']	[2]
3	,	O	['N']	[3]
4	corticosteroids	O	['N']	[4]
5	and	O	['N']	[5]
6	thionamides	O	['N']	[6]
7	to	O	['N']	[7]
8	ameliorate	O	['N']	[8]
9	a	O	['N']	[9]
10	case	O	['N']	[10]
11	of	O	['N']	[11]
12	protracted	O	['N']	[12]
13	amiodarone	B-Drug	['Causes']	[16]
14	-	O	['N']	[14]
15	induced	O	['N']	[15]
16	thyroiditis	B-Adverse_Effect	['N']	[16]
17	.	O	['N']	[17]
#943
0	RESULTS	O	['N']	[0]
1	:	O	['N']	[1]
2	At	O	['N']	[2]
3	our	O	['N']	[3]
4	institution	O	['N']	[4]
5	,	O	['N']	[5]
6	no	O	['N']	[6]
7	children	O	['N']	[7]
8	appeared	O	['N']	[8]
9	with	O	['N']	[9]
10	acute	O	['N']	[10]
11	INH	B-Drug	['Causes']	[12]
12	neurotoxicity	B-Adverse_Effect	['N']	[12]
13	in	O	['N']	[13]
14	the	O	['N']	[14]
15	period	O	['N']	[15]
16	1985	O	['N']	[16]
17	through	O	['N']	[17]
18	1990	O	['N']	[18]
19	,	O	['N']	[19]
20	whereas	O	['N']	[20]
21	seven	O	['N']	[21]
22	patients	O	['N']	[22]
23	were	O	['N']	[23]
24	treated	O	['N']	[24]
25	from	O	['N']	[25]
26	1991	O	['N']	[26]
27	through	O	['N']	[27]
28	1993	O	['N']	[28]
29	.	O	['N']	[29]
#944
0	A	O	['N']	[0]
1	27-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	man	O	['N']	[4]
5	who	O	['N']	[5]
6	had	O	['N']	[6]
7	a	O	['N']	[7]
8	history	O	['N']	[8]
9	of	O	['N']	[9]
10	bronchial	O	['N']	[10]
11	asthma	O	['N']	[11]
12	,	O	['N']	[12]
13	eosinophilic	O	['N']	[13]
14	enteritis	O	['N']	[14]
15	,	O	['N']	[15]
16	and	O	['N']	[16]
17	eosinophilic	O	['N']	[17]
18	pneumonia	O	['N']	[18]
19	presented	O	['N']	[19]
20	with	O	['N']	[20]
21	fever	O	['N']	[21]
22	,	O	['N']	[22]
23	skin	B	['N']	[23]
24	eruptions	I-Adverse_Effect	['N']	[24]
25	,	O	['N']	[25]
26	cervical	O	['N']	[26]
27	lymphadenopathy	O	['N']	[27]
28	,	O	['N']	[28]
29	hepatosplenomegaly	O	['N']	[29]
30	,	O	['N']	[30]
31	atypical	O	['N']	[31]
32	lymphocytosis	O	['N']	[32]
33	,	O	['N']	[33]
34	and	O	['N']	[34]
35	eosinophilia	O	['N']	[35]
36	two	O	['N']	[36]
37	weeks	O	['N']	[37]
38	after	O	['N']	[38]
39	receiving	O	['N']	[39]
40	trimethoprim	B-Drug	['Causes']	[24]
41	(	O	['N']	[41]
42	TMP)-sulfamethoxazole	O	['N']	[42]
43	(	O	['N']	[43]
44	SMX	O	['N']	[44]
45	)	O	['N']	[45]
46	treatment	O	['N']	[46]
47	.	O	['N']	[47]
#945
0	CASE	O	['N']	[0]
1	PRESENTATION	O	['N']	[1]
2	:	O	['N']	[2]
3	We	O	['N']	[3]
4	report	O	['N']	[4]
5	a	O	['N']	[5]
6	patient	O	['N']	[6]
7	with	O	['N']	[7]
8	CF	O	['N']	[8]
9	who	O	['N']	[9]
10	developed	O	['N']	[10]
11	recurrent	B	['N']	[11]
12	eosinophilia	I-Adverse_Effect	['N']	[12]
13	and	O	['N']	[13]
14	severe	O	['N']	[14]
15	persistent	O	['N']	[15]
16	bronchospasm	O	['N']	[16]
17	following	O	['N']	[17]
18	repeated	O	['N']	[18]
19	administration	O	['N']	[19]
20	of	O	['N']	[20]
21	preservative	O	['N']	[21]
22	-	O	['N']	[22]
23	free	O	['N']	[23]
24	tobramycin	B-Drug	['Causes']	[12]
25	by	O	['N']	[25]
26	inhalation	O	['N']	[26]
27	,	O	['N']	[27]
28	beginning	O	['N']	[28]
29	at	O	['N']	[29]
30	16	O	['N']	[30]
31	months	O	['N']	[31]
32	of	O	['N']	[32]
33	age	O	['N']	[33]
34	.	O	['N']	[34]
#946
0	PURPOSE	O	['N']	[0]
1	:	O	['N']	[1]
2	To	O	['N']	[2]
3	investigate	O	['N']	[3]
4	the	O	['N']	[4]
5	concentration	O	['N']	[5]
6	-	O	['N']	[6]
7	side	O	['N']	[7]
8	effect	O	['N']	[8]
9	relationship	O	['N']	[9]
10	in	O	['N']	[10]
11	a	O	['N']	[11]
12	patient	O	['N']	[12]
13	with	O	['N']	[13]
14	severe	O	['N']	[14]
15	acyclovir	B-Drug	['Causes']	[18]
16	-	O	['N']	[16]
17	induced	O	['N']	[17]
18	neurotoxicity	B-Adverse_Effect	['N']	[18]
19	and	O	['N']	[19]
20	to	O	['N']	[20]
21	summarize	O	['N']	[21]
22	the	O	['N']	[22]
23	information	O	['N']	[23]
24	available	O	['N']	[24]
25	in	O	['N']	[25]
26	the	O	['N']	[26]
27	literature	O	['N']	[27]
28	about	O	['N']	[28]
29	central	O	['N']	[29]
30	nervous	O	['N']	[30]
31	system	O	['N']	[31]
32	side	O	['N']	[32]
33	effects	O	['N']	[33]
34	due	O	['N']	[34]
35	to	O	['N']	[35]
36	acyclovir	O	['N']	[36]
37	.	O	['N']	[37]
#947
0	Severe	B	['N']	[0]
1	neurotoxicity	I-Adverse_Effect	['N']	[1]
2	with	O	['N']	[2]
3	methyl	B	['N']	[3]
4	G	I	['N']	[4]
5	:	I	['N']	[5]
6	CALGB	I-Drug	['Causes']	[1]
7	experience	O	['N']	[7]
8	.	O	['N']	[8]
#948
0	Liver	O	['N']	[0]
1	transplantation	O	['N']	[1]
2	for	O	['N']	[2]
3	fulminant	B	['N']	[3]
4	hepatitis	I-Adverse_Effect	['N']	[4]
5	related	O	['N']	[5]
6	to	O	['N']	[6]
7	nevirapine	B-Drug	['Causes']	[4]
8	therapy	O	['N']	[8]
9	.	O	['N']	[9]
#949
0	OBJECTIVE	O	['N']	[0]
1	:	O	['N']	[1]
2	To	O	['N']	[2]
3	report	O	['N']	[3]
4	the	O	['N']	[4]
5	case	O	['N']	[5]
6	of	O	['N']	[6]
7	a	O	['N']	[7]
8	young	O	['N']	[8]
9	woman	O	['N']	[9]
10	with	O	['N']	[10]
11	Graves	O	['N']	[11]
12	'	O	['N']	[12]
13	disease	O	['N']	[13]
14	in	O	['N']	[14]
15	whom	O	['N']	[15]
16	ototoxicity	B-Adverse_Effect	['N']	[16]
17	developed	O	['N']	[17]
18	because	O	['N']	[18]
19	of	O	['N']	[19]
20	propylthiouracil	O	['N']	[20]
21	(	O	['N']	[21]
22	PTU)-induced	-	['N']	[22]
23	antineutrophil	O	['N']	[23]
24	cytoplasmic	O	['N']	[24]
25	antibody	O	['N']	[25]
26	(	O	['N']	[26]
27	ANCA)-associated	O	['N']	[27]
28	vasculitis	O	['N']	[28]
29	.	O	['N']	[29]
#950
0	Allergic	B	['N']	[0]
1	contact	I	['N']	[1]
2	dermatitis	I-Adverse_Effect	['N']	[2]
3	from	O	['N']	[3]
4	4-chloro-7-nitrobenzofurazan	B-Drug	['Causes']	[2]
5	.	O	['N']	[5]
#951
0	Moreover	O	['N']	[0]
1	,	O	['N']	[1]
2	treatment	O	['N']	[2]
3	with	O	['N']	[3]
4	immunosuppressive	O	['N']	[4]
5	drugs	O	['N']	[5]
6	such	O	['N']	[6]
7	as	O	['N']	[7]
8	cyclosporine	O	['N']	[8]
9	,	O	['N']	[9]
10	cisplatin	O	['N']	[10]
11	,	O	['N']	[11]
12	tacrolimus	O	['N']	[12]
13	,	O	['N']	[13]
14	and	O	['N']	[14]
15	interferon	B	['N']	[15]
16	-	I	['N']	[16]
17	alpha	I-Drug	['Causes']	[23]
18	can	O	['N']	[18]
19	induce	O	['N']	[19]
20	a	O	['N']	[20]
21	condition	O	['N']	[21]
22	resembling	O	['N']	[22]
23	RPLS	B-Adverse_Effect	['N']	[23]
24	.	O	['N']	[24]
#952
0	Nephrotic	B	['N']	[0]
1	syndrome	I-Adverse_Effect	['N']	[1]
2	in	O	['N']	[2]
3	a	O	['N']	[3]
4	multiple	O	['N']	[4]
5	sclerosis	O	['N']	[5]
6	patient	O	['N']	[6]
7	treated	O	['N']	[7]
8	with	O	['N']	[8]
9	interferon	B	['N']	[9]
10	beta	I	['N']	[10]
11	1a	I-Drug	['Causes']	[1]
12	.	O	['N']	[12]
#953
0	OBJECTIVE	O	['N']	[0]
1	:	O	['N']	[1]
2	To	O	['N']	[2]
3	test	O	['N']	[3]
4	the	O	['N']	[4]
5	hypothesis	O	['N']	[5]
6	that	O	['N']	[6]
7	tumor	O	['N']	[7]
8	necrosis	O	['N']	[8]
9	factor	O	['N']	[9]
10	(	O	['N']	[10]
11	TNF)-alpha	O	['N']	[11]
12	may	O	['N']	[12]
13	mediate	O	['N']	[13]
14	the	O	['N']	[14]
15	loss	O	['N']	[15]
16	and	O	['N']	[16]
17	the	O	['N']	[17]
18	dedifferentiation	O	['N']	[18]
19	of	O	['N']	[19]
20	subcutaneous	O	['N']	[20]
21	fat	O	['N']	[21]
22	tissue	O	['N']	[22]
23	in	O	['N']	[23]
24	the	O	['N']	[24]
25	insulin	B-Drug	['Causes']	[28]
26	-	O	['N']	[26]
27	induced	O	['N']	[27]
28	lipoatrophies	B-Adverse_Effect	['N']	[28]
29	of	O	['N']	[29]
30	a	O	['N']	[30]
31	diabetic	O	['N']	[31]
32	patient	O	['N']	[32]
33	who	O	['N']	[33]
34	presented	O	['N']	[34]
35	extensive	O	['N']	[35]
36	lesions	O	['N']	[36]
37	.	O	['N']	[37]
#954
0	Gynecomastia	B-Adverse_Effect	['N']	[0]
1	developed	O	['N']	[1]
2	in	O	['N']	[2]
3	two	O	['N']	[3]
4	epileptic	O	['N']	[4]
5	patients	O	['N']	[5]
6	some	O	['N']	[6]
7	months	O	['N']	[7]
8	after	O	['N']	[8]
9	the	O	['N']	[9]
10	addition	O	['N']	[10]
11	of	O	['N']	[11]
12	oral	O	['N']	[12]
13	fluoresone	B-Drug	['Causes']	[0]
14	750	O	['N']	[14]
15	mg	O	['N']	[15]
16	daily	O	['N']	[16]
17	to	O	['N']	[17]
18	the	O	['N']	[18]
19	phenobarbital	O	['N']	[19]
20	and	O	['N']	[20]
21	phenytoin	O	['N']	[21]
22	already	O	['N']	[22]
23	being	O	['N']	[23]
24	administered	O	['N']	[24]
25	.	O	['N']	[25]
#955
0	Fatal	B	['N']	[0]
1	pulmonary	I	['N']	[1]
2	fibrosis	I-Adverse_Effect	['N']	[2]
3	following	O	['N']	[3]
4	1,3-bis(2-chloroethyl)-1-nitrosourea	B-Drug	['Causes']	[2]
5	(	O	['N']	[5]
6	BCNU	O	['N']	[6]
7	)	O	['N']	[7]
8	therapy	O	['N']	[8]
9	.	O	['N']	[9]
#956
0	CONCLUSION	O	['N']	[0]
1	:	O	['N']	[1]
2	The	O	['N']	[2]
3	new	O	['N']	[3]
4	quinolone	O	['N']	[4]
5	derivatives	O	['N']	[5]
6	(	O	['N']	[6]
7	levofloxacin	B-Drug	['Causes']	[43]
8	,	O	['N']	[8]
9	sparfloxacin	O	['N']	[9]
10	,	O	['N']	[10]
11	grepafloxacin	O	['N']	[11]
12	,	O	['N']	[12]
13	trovafloxacin	O	['N']	[13]
14	,	O	['N']	[14]
15	gatifloxacin	O	['N']	[15]
16	and	O	['N']	[16]
17	moxifloxacin	O	['N']	[17]
18	)	O	['N']	[18]
19	,	O	['N']	[19]
20	also	O	['N']	[20]
21	called	O	['N']	[21]
22	gyrase	O	['N']	[22]
23	inhibitors	O	['N']	[23]
24	,	O	['N']	[24]
25	are	O	['N']	[25]
26	known	O	['N']	[26]
27	for	O	['N']	[27]
28	their	O	['N']	[28]
29	potential	O	['N']	[29]
30	to	O	['N']	[30]
31	cause	O	['N']	[31]
32	central	O	['N']	[32]
33	nervous	O	['N']	[33]
34	system	O	['N']	[34]
35	-	O	['N']	[35]
36	related	O	['N']	[36]
37	adverse	O	['N']	[37]
38	effects	O	['N']	[38]
39	,	O	['N']	[39]
40	including	O	['N']	[40]
41	headache	O	['N']	[41]
42	,	O	['N']	[42]
43	dizziness	B-Adverse_Effect	['N']	[43]
44	and	O	['N']	[44]
45	insomnia	O	['N']	[45]
46	.	O	['N']	[46]
#957
0	We	O	['N']	[0]
1	present	O	['N']	[1]
2	the	O	['N']	[2]
3	first	O	['N']	[3]
4	case	O	['N']	[4]
5	of	O	['N']	[5]
6	ovarian	B	['N']	[6]
7	endometrioid	I	['N']	[7]
8	carcinoma	I-Adverse_Effect	['N']	[8]
9	and	O	['N']	[9]
10	endometriosis	O	['N']	[10]
11	in	O	['N']	[11]
12	a	O	['N']	[12]
13	postmenopausal	O	['N']	[13]
14	patient	O	['N']	[14]
15	who	O	['N']	[15]
16	was	O	['N']	[16]
17	treated	O	['N']	[17]
18	with	O	['N']	[18]
19	tamoxifen	B-Drug	['Causes']	[8]
20	for	O	['N']	[20]
21	breast	O	['N']	[21]
22	cancer	O	['N']	[22]
23	.	O	['N']	[23]
#958
0	Transient	B	['N']	[0]
1	cardiac	I	['N']	[1]
2	arrhythmias	I-Adverse_Effect	['N']	[2]
3	related	O	['N']	[3]
4	to	O	['N']	[4]
5	lopinavir	B-Drug	['Causes']	[2]
6	/	O	['N']	[6]
7	ritonavir	O	['N']	[7]
8	in	O	['N']	[8]
9	two	O	['N']	[9]
10	patients	O	['N']	[10]
11	with	O	['N']	[11]
12	HIV	O	['N']	[12]
13	infection	O	['N']	[13]
14	.	O	['N']	[14]
#959
0	The	O	['N']	[0]
1	administration	O	['N']	[1]
2	of	O	['N']	[2]
3	"	O	['N']	[3]
4	sweet	B	['N']	[4]
5	spirits	I	['N']	[5]
6	of	I	['N']	[6]
7	nitre	I-Drug	['Causes']	[30]
8	"	O	['N']	[8]
9	(	O	['N']	[9]
10	4	O	['N']	[10]
11	%	O	['N']	[11]
12	ethyl	O	['N']	[12]
13	nitrite	O	['N']	[13]
14	CH3CH2ONO	O	['N']	[14]
15	in	O	['N']	[15]
16	70	O	['N']	[16]
17	%	O	['N']	[17]
18	ethyl	O	['N']	[18]
19	alcohol	O	['N']	[19]
20	)	O	['N']	[20]
21	was	O	['N']	[21]
22	followed	O	['N']	[22]
23	by	O	['N']	[23]
24	acute	O	['N']	[24]
25	methemoglobinemia	O	['N']	[25]
26	and	O	['N']	[26]
27	severe	B	['N']	[27]
28	anoxic	I	['N']	[28]
29	metabolic	I	['N']	[29]
30	acidosis	I-Adverse_Effect	['N']	[30]
31	in	O	['N']	[31]
32	infant	O	['N']	[32]
33	twins	O	['N']	[33]
34	,	O	['N']	[34]
35	Methylene	O	['N']	[35]
36	blue	O	['N']	[36]
37	administration	O	['N']	[37]
38	reversed	O	['N']	[38]
39	methemoglobinemia	O	['N']	[39]
40	in	O	['N']	[40]
41	both	O	['N']	[41]
42	,	O	['N']	[42]
43	but	O	['N']	[43]
44	one	O	['N']	[44]
45	twin	O	['N']	[45]
46	died	O	['N']	[46]
47	from	O	['N']	[47]
48	the	O	['N']	[48]
49	consequences	O	['N']	[49]
50	of	O	['N']	[50]
51	hypoxemia	O	['N']	[51]
52	.	O	['N']	[52]
#960
0	AIM	O	['N']	[0]
1	:	O	['N']	[1]
2	Report	O	['N']	[2]
3	of	O	['N']	[3]
4	a	O	['N']	[4]
5	case	O	['N']	[5]
6	of	O	['N']	[6]
7	a	O	['N']	[7]
8	woman	O	['N']	[8]
9	patient	O	['N']	[9]
10	who	O	['N']	[10]
11	developed	O	['N']	[11]
12	celiac	B	['N']	[12]
13	disease	I-Adverse_Effect	['N']	[13]
14	after	O	['N']	[14]
15	pegylated	O	['N']	[15]
16	interferon	O	['N']	[16]
17	alpha-2a	O	['N']	[17]
18	and	O	['N']	[18]
19	ribavirin	B-Drug	['Causes']	[13]
20	use	O	['N']	[20]
21	for	O	['N']	[21]
22	chronic	O	['N']	[22]
23	hepatitis	O	['N']	[23]
24	C.	O	['N']	[24]
#961
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	five	O	['N']	[2]
3	cases	O	['N']	[3]
4	of	O	['N']	[4]
5	carboplatin	O	['N']	[5]
6	(	O	['N']	[6]
7	CBDCA	O	['N']	[7]
8	)	O	['N']	[8]
9	hypersensitivity	O	['N']	[9]
10	after	O	['N']	[10]
11	weekly	O	['N']	[11]
12	low	O	['N']	[12]
13	-	O	['N']	[13]
14	dose	O	['N']	[14]
15	paclitaxel	B-Drug	['N']	[15]
16	(	O	['N']	[16]
17	60	-	['N']	[17]
18	mg	-	['N']	[18]
19	/	-	['N']	[19]
20	m2)/CBDCA	-	['N']	[20]
21	(	O	['N']	[21]
22	area	O	['N']	[22]
23	under	O	['N']	[23]
24	the	O	['N']	[24]
25	concentration	O	['N']	[25]
26	curve	O	['N']	[26]
27	=	O	['N']	[27]
28	2	O	['N']	[28]
29	)	O	['N']	[29]
30	therapy	O	['N']	[30]
31	in	O	['N']	[31]
32	patients	O	['N']	[32]
33	with	O	['N']	[33]
34	recurrent	O	['N']	[34]
35	ovarian	O	['N']	[35]
36	cancer	O	['N']	[36]
37	receiving	O	['N']	[37]
38	multiple	O	['N']	[38]
39	platinum	O	['N']	[39]
40	-	O	['N']	[40]
41	based	O	['N']	[41]
42	chemotherapy	O	['N']	[42]
43	.	O	['N']	[43]
#962
0	Treatment	O	['N']	[0]
1	of	O	['N']	[1]
2	lithium	B-Drug	['Causes']	[6]
3	-	O	['N']	[3]
4	induced	O	['N']	[4]
5	diabetes	B	['N']	[5]
6	insipidus	I-Adverse_Effect	['N']	[6]
7	with	O	['N']	[7]
8	amiloride	O	['N']	[8]
9	.	O	['N']	[9]
#963
0	OBJECTIVE	O	['N']	[0]
1	:	O	['N']	[1]
2	To	O	['N']	[2]
3	report	O	['N']	[3]
4	a	O	['N']	[4]
5	case	O	['N']	[5]
6	of	O	['N']	[6]
7	angioedema	B-Adverse_Effect	['N']	[7]
8	associated	O	['N']	[8]
9	with	O	['N']	[9]
10	losartan	B-Drug	['Causes']	[7]
11	administration	O	['N']	[11]
12	.	O	['N']	[12]
#964
0	A	O	['N']	[0]
1	patient	O	['N']	[1]
2	with	O	['N']	[2]
3	chronic	O	['N']	[3]
4	myelomonocytic	O	['N']	[4]
5	leukemia	O	['N']	[5]
6	developed	O	['N']	[6]
7	drug	O	['N']	[7]
8	-	O	['N']	[8]
9	induced	O	['N']	[9]
10	pulmonary	B	['N']	[10]
11	toxicity	I-Adverse_Effect	['N']	[11]
12	after	O	['N']	[12]
13	using	O	['N']	[13]
14	low	O	['N']	[14]
15	dose	O	['N']	[15]
16	oral	O	['N']	[16]
17	etoposide	B-Drug	['Causes']	[11]
18	.	O	['N']	[18]
#965
0	Factors	O	['N']	[0]
1	that	O	['N']	[1]
2	suggested	O	['N']	[2]
3	an	O	['N']	[3]
4	association	O	['N']	[4]
5	between	O	['N']	[5]
6	the	O	['N']	[6]
7	severe	B	['N']	[7]
8	angioedematous	I	['N']	[8]
9	reaction	I-Adverse_Effect	['N']	[9]
10	and	O	['N']	[10]
11	BP	B-Drug	['Causes']	[9]
12	topical	O	['N']	[12]
13	application	O	['N']	[13]
14	include	O	['N']	[14]
15	the	O	['N']	[15]
16	strong	O	['N']	[16]
17	reaction	O	['N']	[17]
18	to	O	['N']	[18]
19	BP	O	['N']	[19]
20	in	O	['N']	[20]
21	the	O	['N']	[21]
22	patch	O	['N']	[22]
23	-	O	['N']	[23]
24	test	O	['N']	[24]
25	,	O	['N']	[25]
26	the	O	['N']	[26]
27	temporal	O	['N']	[27]
28	relationship	O	['N']	[28]
29	,	O	['N']	[29]
30	the	O	['N']	[30]
31	complete	O	['N']	[31]
32	resolution	O	['N']	[32]
33	of	O	['N']	[33]
34	symptoms	O	['N']	[34]
35	after	O	['N']	[35]
36	the	O	['N']	[36]
37	drug	O	['N']	[37]
38	was	O	['N']	[38]
39	withdrawn	O	['N']	[39]
40	and	O	['N']	[40]
41	the	O	['N']	[41]
42	absence	O	['N']	[42]
43	of	O	['N']	[43]
44	other	O	['N']	[44]
45	identified	O	['N']	[45]
46	explanations	O	['N']	[46]
47	.	O	['N']	[47]
#966
0	DISCUSSION	O	['N']	[0]
1	:	O	['N']	[1]
2	To	O	['N']	[2]
3	our	O	['N']	[3]
4	knowledge	O	['N']	[4]
5	,	O	['N']	[5]
6	this	O	['N']	[6]
7	is	O	['N']	[7]
8	the	O	['N']	[8]
9	first	O	['N']	[9]
10	case	O	['N']	[10]
11	report	O	['N']	[11]
12	illustrating	O	['N']	[12]
13	neuralgic	B	['N']	[13]
14	amyotrophy	I-Adverse_Effect	['N']	[14]
15	triggered	O	['N']	[15]
16	by	O	['N']	[16]
17	exposure	O	['N']	[17]
18	to	O	['N']	[18]
19	the	O	['N']	[19]
20	antibiotics	O	['N']	[20]
21	vancomycin	O	['N']	[21]
22	,	O	['N']	[22]
23	tobramycin	O	['N']	[23]
24	,	O	['N']	[24]
25	and	O	['N']	[25]
26	piperacillin	B-Drug	['Causes']	[14]
27	/	O	['N']	[27]
28	tazobactam	O	['N']	[28]
29	.	O	['N']	[29]
#967
0	The	O	['N']	[0]
1	authors	O	['N']	[1]
2	describe	O	['N']	[2]
3	a	O	['N']	[3]
4	case	O	['N']	[4]
5	of	O	['N']	[5]
6	oral	B	['N']	[6]
7	-	I	['N']	[7]
8	facial	I	['N']	[8]
9	dyskinesia	I-Adverse_Effect	['N']	[9]
10	that	O	['N']	[10]
11	occurred	O	['N']	[11]
12	after	O	['N']	[12]
13	discontinuation	O	['N']	[13]
14	of	O	['N']	[14]
15	amoxapine	B-Drug	['Causes']	[9]
16	,	O	['N']	[16]
17	and	O	['N']	[17]
18	antidepressant	O	['N']	[18]
19	which	O	['N']	[19]
20	may	O	['N']	[20]
21	also	O	['N']	[21]
22	have	O	['N']	[22]
23	neuroleptic	O	['N']	[23]
24	effects	O	['N']	[24]
25	.	O	['N']	[25]
#968
0	Ticlopidine	B-Drug	['Causes']	[4]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	marrow	B	['N']	[3]
4	aplasia	I-Adverse_Effect	['N']	[4]
5	treated	O	['N']	[5]
6	with	O	['N']	[6]
7	cyclosporine	O	['N']	[7]
8	.	O	['N']	[8]
#969
0	Multiple	B	['N']	[0]
1	pulmonary	I	['N']	[1]
2	nodules	I-Adverse_Effect	['N']	[2]
3	:	O	['N']	[3]
4	an	O	['N']	[4]
5	unusual	O	['N']	[5]
6	presentation	O	['N']	[6]
7	of	O	['N']	[7]
8	fludarabine	B-Drug	['Causes']	[2]
9	pulmonary	O	['N']	[9]
10	toxicity	O	['N']	[10]
11	:	O	['N']	[11]
12	case	O	['N']	[12]
13	report	O	['N']	[13]
14	and	O	['N']	[14]
15	review	O	['N']	[15]
16	of	O	['N']	[16]
17	literature	O	['N']	[17]
18	.	O	['N']	[18]
#970
0	Successful	O	['N']	[0]
1	recovery	O	['N']	[1]
2	from	O	['N']	[2]
3	interstitial	B	['N']	[3]
4	pneumonitis	I-Adverse_Effect	['N']	[4]
5	,	O	['N']	[5]
6	induced	O	['N']	[6]
7	by	O	['N']	[7]
8	bicalutamide	O	['N']	[8]
9	and	O	['N']	[9]
10	leuprorelin	B	['N']	[10]
11	acetate	I-Drug	['Causes']	[4]
12	given	O	['N']	[12]
13	as	O	['N']	[13]
14	treatment	O	['N']	[14]
15	for	O	['N']	[15]
16	prostate	O	['N']	[16]
17	cancer	O	['N']	[17]
18	.	O	['N']	[18]
#971
0	In	O	['N']	[0]
1	three	O	['N']	[1]
2	of	O	['N']	[2]
3	these	O	['N']	[3]
4	patients	O	['N']	[4]
5	the	O	['N']	[5]
6	infection	O	['N']	[6]
7	was	O	['N']	[7]
8	clinically	O	['N']	[8]
9	unsuspected	O	['N']	[9]
10	;	O	['N']	[10]
11	in	O	['N']	[11]
12	the	O	['N']	[12]
13	fourth	O	['N']	[13]
14	,	O	['N']	[14]
15	cutaneous	O	['N']	[15]
16	herpes	O	['N']	[16]
17	zoster	O	['N']	[17]
18	developed	O	['N']	[18]
19	after	O	['N']	[19]
20	administration	O	['N']	[20]
21	of	O	['N']	[21]
22	300	B	['N']	[22]
23	mg	I-Dose	['N']	[23]
24	of	O	['N']	[24]
25	cytarabine	B-Drug	['Dosage']	[23]
26	daily	O	['N']	[26]
27	for	O	['N']	[27]
28	the	O	['N']	[28]
29	preceding	O	['N']	[29]
30	five	O	['N']	[30]
31	days	O	['N']	[31]
32	.	O	['N']	[32]
#972
0	We	O	['N']	[0]
1	suggest	O	['N']	[1]
2	that	O	['N']	[2]
3	the	O	['N']	[3]
4	previous	O	['N']	[4]
5	classification	O	['N']	[5]
6	of	O	['N']	[6]
7	nitrofurantoin	B-Drug	['Causes']	[10]
8	induced	I	['N']	[8]
9	lung	I	['N']	[9]
10	injury	I-Adverse_Effect	['N']	[10]
11	into	O	['N']	[11]
12	"	O	['N']	[12]
13	acute	O	['N']	[13]
14	"	O	['N']	[14]
15	and	O	['N']	[15]
16	"	O	['N']	[16]
17	chronic	O	['N']	[17]
18	"	O	['N']	[18]
19	injury	O	['N']	[19]
20	is	O	['N']	[20]
21	an	O	['N']	[21]
22	oversimplification	O	['N']	[22]
23	in	O	['N']	[23]
24	view	O	['N']	[24]
25	of	O	['N']	[25]
26	the	O	['N']	[26]
27	wide	O	['N']	[27]
28	variety	O	['N']	[28]
29	of	O	['N']	[29]
30	pathological	O	['N']	[30]
31	entities	O	['N']	[31]
32	that	O	['N']	[32]
33	have	O	['N']	[33]
34	subsequently	O	['N']	[34]
35	emerged	O	['N']	[35]
36	.	O	['N']	[36]
#973
0	We	O	['N']	[0]
1	suspect	O	['N']	[1]
2	that	O	['N']	[2]
3	nefazodone	B-Drug	['Causes']	[7]
4	inhibits	B	['N']	[4]
5	metabolism	I	['N']	[5]
6	of	I	['N']	[6]
7	tacrolimus	I-Adverse_Effect	['N']	[7]
8	.	O	['N']	[8]
#974
0	She	O	['N']	[0]
1	died	O	['N']	[1]
2	within	O	['N']	[2]
3	six	O	['N']	[3]
4	weeks	O	['N']	[4]
5	of	O	['N']	[5]
6	developing	O	['N']	[6]
7	congestive	O	['N']	[7]
8	heart	O	['N']	[8]
9	failure	O	['N']	[9]
10	coupled	O	['N']	[10]
11	with	O	['N']	[11]
12	liver	O	['N']	[12]
13	failure	O	['N']	[13]
14	due	O	['N']	[14]
15	to	O	['N']	[15]
16	haemosiderosis	B-Adverse_Effect	['N']	[16]
17	despite	O	['N']	[17]
18	regular	O	['N']	[18]
19	use	O	['N']	[19]
20	of	O	['N']	[20]
21	desferrioxamine	B-Drug	['Causes']	[16]
22	.	O	['N']	[22]
#975
0	Minocycline	B-Drug	['Causes']	[4]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	autoimmune	B	['N']	[3]
4	hepatitis	I-Adverse_Effect	['N']	[4]
5	is	O	['N']	[5]
6	usually	O	['N']	[6]
7	identical	O	['N']	[7]
8	to	O	['N']	[8]
9	sporadic	O	['N']	[9]
10	autoimmune	O	['N']	[10]
11	hepatitis	O	['N']	[11]
12	.	O	['N']	[12]
#976
0	A	O	['N']	[0]
1	case	O	['N']	[1]
2	of	O	['N']	[2]
3	toxic	B	['N']	[3]
4	hepatitis	I-Adverse_Effect	['N']	[4]
5	caused	O	['N']	[5]
6	by	O	['N']	[6]
7	combination	O	['N']	[7]
8	therapy	O	['N']	[8]
9	with	O	['N']	[9]
10	methotrexate	B-Drug	['Causes']	[4]
11	and	O	['N']	[11]
12	etretinate	O	['N']	[12]
13	in	O	['N']	[13]
14	the	O	['N']	[14]
15	treatment	O	['N']	[15]
16	of	O	['N']	[16]
17	severe	O	['N']	[17]
18	psoriasis	O	['N']	[18]
19	is	O	['N']	[19]
20	presented	O	['N']	[20]
21	in	O	['N']	[21]
22	a	O	['N']	[22]
23	47-year	O	['N']	[23]
24	-	O	['N']	[24]
25	old	O	['N']	[25]
26	woman	O	['N']	[26]
27	.	O	['N']	[27]
#977
0	Digestive	B	['N']	[0]
1	hemorrhage	I-Adverse_Effect	['N']	[1]
2	caused	O	['N']	[2]
3	by	O	['N']	[3]
4	a	O	['N']	[4]
5	Meckel	O	['N']	[5]
6	's	O	['N']	[6]
7	diverticulum	O	['N']	[7]
8	in	O	['N']	[8]
9	a	O	['N']	[9]
10	metformin	B-Drug	['Causes']	[1]
11	-	O	['N']	[11]
12	treated	O	['N']	[12]
13	patient	O	['N']	[13]
14	:	O	['N']	[14]
15	is	O	['N']	[15]
16	there	O	['N']	[16]
17	any	O	['N']	[17]
18	connection	O	['N']	[18]
19	?	O	['N']	[19]
#978
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	five	O	['N']	[2]
3	cases	O	['N']	[3]
4	of	O	['N']	[4]
5	restless	O	['N']	[5]
6	legs	O	['N']	[6]
7	syndrome	O	['N']	[7]
8	(	O	['N']	[8]
9	RLS	B-Adverse_Effect	['N']	[9]
10	)	O	['N']	[10]
11	and	O	['N']	[11]
12	periodic	O	['N']	[12]
13	limb	O	['N']	[13]
14	movements	O	['N']	[14]
15	during	O	['N']	[15]
16	sleep	O	['N']	[16]
17	(	O	['N']	[17]
18	PLMS	O	['N']	[18]
19	)	O	['N']	[19]
20	that	O	['N']	[20]
21	were	O	['N']	[21]
22	probably	O	['N']	[22]
23	associated	O	['N']	[23]
24	with	O	['N']	[24]
25	olanzapine	B-Drug	['Causes']	[9]
26	.	O	['N']	[26]
#979
0	The	O	['N']	[0]
1	use	O	['N']	[1]
2	of	O	['N']	[2]
3	pamidronate	O	['N']	[3]
4	for	O	['N']	[4]
5	hypercalcemia	O	['N']	[5]
6	secondary	O	['N']	[6]
7	to	O	['N']	[7]
8	acute	O	['N']	[8]
9	vitamin	B	['N']	[9]
10	D	I-Drug	['Causes']	[11]
11	intoxication	I-Adverse_Effect	['N']	[11]
12	.	O	['N']	[12]
#980
0	An	O	['N']	[0]
1	8-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	child	O	['N']	[4]
5	with	O	['N']	[5]
6	familial	O	['N']	[6]
7	Mediterranean	O	['N']	[7]
8	fever	O	['N']	[8]
9	exhibited	O	['N']	[9]
10	signs	O	['N']	[10]
11	of	O	['N']	[11]
12	colchicine	B-Drug	['Causes']	[13]
13	intoxication	I-Adverse_Effect	['N']	[13]
14	while	O	['N']	[14]
15	receiving	O	['N']	[15]
16	prophylactic	O	['N']	[16]
17	doses	O	['N']	[17]
18	of	O	['N']	[18]
19	the	O	['N']	[19]
20	drug	O	['N']	[20]
21	.	O	['N']	[21]
#981
0	Subglottic	B	['N']	[0]
1	stenosis	I-Adverse_Effect	['N']	[1]
2	in	O	['N']	[2]
3	Wegener	O	['N']	[3]
4	's	O	['N']	[4]
5	granulomatosis	O	['N']	[5]
6	:	O	['N']	[6]
7	development	O	['N']	[7]
8	during	O	['N']	[8]
9	cyclophosphamide	B-Drug	['Causes']	[1]
10	treatment	O	['N']	[10]
11	with	O	['N']	[11]
12	response	O	['N']	[12]
13	to	O	['N']	[13]
14	carbon	O	['N']	[14]
15	dioxide	O	['N']	[15]
16	laser	O	['N']	[16]
17	therapy	O	['N']	[17]
18	.	O	['N']	[18]
#982
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	the	O	['N']	[2]
3	first	O	['N']	[3]
4	case	O	['N']	[4]
5	of	O	['N']	[5]
6	IHA	B-Adverse_Effect	['N']	[6]
7	associated	O	['N']	[7]
8	with	O	['N']	[8]
9	cefuroxime	B-Drug	['Causes']	[6]
10	administration	O	['N']	[10]
11	.	O	['N']	[11]
#983
0	CASE	O	['N']	[0]
1	SUMMARY	O	['N']	[1]
2	:	O	['N']	[2]
3	A	O	['N']	[3]
4	39-year	O	['N']	[4]
5	-	O	['N']	[5]
6	old	O	['N']	[6]
7	white	O	['N']	[7]
8	Jewish	O	['N']	[8]
9	schizophrenic	O	['N']	[9]
10	man	O	['N']	[10]
11	treated	O	['N']	[11]
12	with	O	['N']	[12]
13	olanzapine	B-Drug	['Causes']	[19]
14	developed	O	['N']	[14]
15	an	O	['N']	[15]
16	elevated	B	['N']	[16]
17	serum	I	['N']	[17]
18	CK	I	['N']	[18]
19	concentration	I-Adverse_Effect	['N']	[19]
20	with	O	['N']	[20]
21	a	O	['N']	[21]
22	peak	O	['N']	[22]
23	concentration	O	['N']	[23]
24	of	O	['N']	[24]
25	4000	O	['N']	[25]
26	IU	O	['N']	[26]
27	/	O	['N']	[27]
28	L	O	['N']	[28]
29	(	O	['N']	[29]
30	normal	O	['N']	[30]
31	<	O	['N']	[31]
32	230	O	['N']	[32]
33	)	O	['N']	[33]
34	.	O	['N']	[34]
#984
0	A	O	['N']	[0]
1	36-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	man	O	['N']	[4]
5	being	O	['N']	[5]
6	treated	O	['N']	[6]
7	with	O	['N']	[7]
8	cisplatinum	B-Drug	['Causes']	[24]
9	,	O	['N']	[9]
10	vinblastine	O	['N']	[10]
11	,	O	['N']	[11]
12	and	O	['N']	[12]
13	bleomycin	O	['N']	[13]
14	for	O	['N']	[14]
15	testicular	O	['N']	[15]
16	carcinoma	O	['N']	[16]
17	developed	O	['N']	[17]
18	a	O	['N']	[18]
19	dense	O	['N']	[19]
20	left	O	['N']	[20]
21	homonymous	O	['N']	[21]
22	hemianopsia	O	['N']	[22]
23	,	O	['N']	[23]
24	encephalopathy	B-Adverse_Effect	['N']	[24]
25	,	O	['N']	[25]
26	and	O	['N']	[26]
27	a	O	['N']	[27]
28	partial	O	['N']	[28]
29	nondominant	O	['N']	[29]
30	parietal	O	['N']	[30]
31	lobe	O	['N']	[31]
32	syndrome	O	['N']	[32]
33	.	O	['N']	[33]
#985
0	Less	O	['N']	[0]
1	common	O	['N']	[1]
2	adverse	O	['N']	[2]
3	events	O	['N']	[3]
4	to	O	['N']	[4]
5	dapsone	B-Drug	['Causes']	[16]
6	include	O	['N']	[6]
7	the	O	['N']	[7]
8	idiosyncratic	O	['N']	[8]
9	reactions	O	['N']	[9]
10	of	O	['N']	[10]
11	leukopenia	O	['N']	[11]
12	and	O	['N']	[12]
13	agranulocytosis	O	['N']	[13]
14	,	O	['N']	[14]
15	cutaneous	B	['N']	[15]
16	eruptions	I-Adverse_Effect	['N']	[16]
17	,	O	['N']	[17]
18	peripheral	O	['N']	[18]
19	neuropathy	O	['N']	[19]
20	,	O	['N']	[20]
21	psychosis	O	['N']	[21]
22	,	O	['N']	[22]
23	toxic	O	['N']	[23]
24	hepatitis	O	['N']	[24]
25	,	O	['N']	[25]
26	cholestatic	O	['N']	[26]
27	jaundice	O	['N']	[27]
28	,	O	['N']	[28]
29	nephrotic	O	['N']	[29]
30	syndrome	O	['N']	[30]
31	,	O	['N']	[31]
32	renal	O	['N']	[32]
33	papillary	O	['N']	[33]
34	necrosis	O	['N']	[34]
35	,	O	['N']	[35]
36	severe	O	['N']	[36]
37	hypoalbuminemia	O	['N']	[37]
38	without	O	['N']	[38]
39	proteinuria	O	['N']	[39]
40	,	O	['N']	[40]
41	an	O	['N']	[41]
42	infectious	O	['N']	[42]
43	mononucleosis	O	['N']	[43]
44	-	O	['N']	[44]
45	like	O	['N']	[45]
46	syndrome	O	['N']	[46]
47	,	O	['N']	[47]
48	and	O	['N']	[48]
49	minor	O	['N']	[49]
50	neurological	O	['N']	[50]
51	and	O	['N']	[51]
52	gastrointestinal	O	['N']	[52]
53	complaints	O	['N']	[53]
54	.	O	['N']	[54]
#986
0	The	O	['N']	[0]
1	authors	O	['N']	[1]
2	presented	O	['N']	[2]
3	a	O	['N']	[3]
4	case	O	['N']	[4]
5	of	O	['N']	[5]
6	pulmonary	B	['N']	[6]
7	hypertension	I-Adverse_Effect	['N']	[7]
8	during	O	['N']	[8]
9	lithium	B-Drug	['Causes']	[7]
10	therapy	O	['N']	[10]
11	,	O	['N']	[11]
12	while	O	['N']	[12]
13	she	O	['N']	[13]
14	has	O	['N']	[14]
15	been	O	['N']	[15]
16	on	O	['N']	[16]
17	lithium	O	['N']	[17]
18	for	O	['N']	[18]
19	6	O	['N']	[19]
20	years	O	['N']	[20]
21	.	O	['N']	[21]
#987
0	A	O	['N']	[0]
1	15-year	O	['N']	[1]
2	follow	O	['N']	[2]
3	-	O	['N']	[3]
4	up	O	['N']	[4]
5	of	O	['N']	[5]
6	phenytoin	B-Drug	['Causes']	[11]
7	-	O	['N']	[7]
8	induced	O	['N']	[8]
9	unilateral	B	['N']	[9]
10	gingival	I	['N']	[10]
11	hyperplasia	I-Adverse_Effect	['N']	[11]
12	:	O	['N']	[12]
13	a	O	['N']	[13]
14	case	O	['N']	[14]
15	report	O	['N']	[15]
16	.	O	['N']	[16]
#988
0	Ten	O	['N']	[0]
1	days	O	['N']	[1]
2	after	O	['N']	[2]
3	itraconazole	B-Drug	['Causes']	[10]
4	was	O	['N']	[4]
5	started	O	['N']	[5]
6	,	O	['N']	[6]
7	he	O	['N']	[7]
8	developed	O	['N']	[8]
9	paralytic	B	['N']	[9]
10	ileus	I-Adverse_Effect	['N']	[10]
11	,	O	['N']	[11]
12	neurogenic	O	['N']	[12]
13	bladder	O	['N']	[13]
14	,	O	['N']	[14]
15	mild	O	['N']	[15]
16	left	O	['N']	[16]
17	ptosis	O	['N']	[17]
18	,	O	['N']	[18]
19	and	O	['N']	[19]
20	absence	O	['N']	[20]
21	of	O	['N']	[21]
22	deep	O	['N']	[22]
23	reflexes	O	['N']	[23]
24	,	O	['N']	[24]
25	with	O	['N']	[25]
26	severe	O	['N']	[26]
27	paralysis	O	['N']	[27]
28	of	O	['N']	[28]
29	the	O	['N']	[29]
30	lower	O	['N']	[30]
31	extremities	O	['N']	[31]
32	and	O	['N']	[32]
33	mild	O	['N']	[33]
34	weakness	O	['N']	[34]
35	of	O	['N']	[35]
36	the	O	['N']	[36]
37	upper	O	['N']	[37]
38	extremities	O	['N']	[38]
39	.	O	['N']	[39]
#989
0	Diphenhydramine	B-Drug	['Causes']	[5]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	wide	O	['N']	[3]
4	complex	O	['N']	[4]
5	dysrhythmia	B-Adverse_Effect	['N']	[5]
6	responds	O	['N']	[6]
7	to	O	['N']	[7]
8	treatment	O	['N']	[8]
9	with	O	['N']	[9]
10	sodium	O	['N']	[10]
11	bicarbonate	O	['N']	[11]
12	.	O	['N']	[12]
#990
0	PATIENT	O	['N']	[0]
1	AND	O	['N']	[1]
2	METHOD	O	['N']	[2]
3	:	O	['N']	[3]
4	A	O	['N']	[4]
5	34-year	O	['N']	[5]
6	-	O	['N']	[6]
7	old	O	['N']	[7]
8	woman	O	['N']	[8]
9	with	O	['N']	[9]
10	chronic	O	['N']	[10]
11	hepatitis	O	['N']	[11]
12	C	O	['N']	[12]
13	,	O	['N']	[13]
14	genotype	O	['N']	[14]
15	3	O	['N']	[15]
16	,	O	['N']	[16]
17	receiving	O	['N']	[17]
18	pegylated	O	['N']	[18]
19	interferon	O	['N']	[19]
20	alpha-2a	O	['N']	[20]
21	and	O	['N']	[21]
22	ribavirin	B-Drug	['Causes']	[31]
23	for	O	['N']	[23]
24	6	O	['N']	[24]
25	months	O	['N']	[25]
26	,	O	['N']	[26]
27	developed	O	['N']	[27]
28	progressive	O	['N']	[28]
29	malaise	O	['N']	[29]
30	and	O	['N']	[30]
31	anemia	B-Adverse_Effect	['N']	[31]
32	6	O	['N']	[32]
33	months	O	['N']	[33]
34	after	O	['N']	[34]
35	the	O	['N']	[35]
36	end	O	['N']	[36]
37	of	O	['N']	[37]
38	treatment	O	['N']	[38]
39	.	O	['N']	[39]
#991
0	The	O	['N']	[0]
1	favourable	O	['N']	[1]
2	outcome	O	['N']	[2]
3	in	O	['N']	[3]
4	these	O	['N']	[4]
5	two	O	['N']	[5]
6	patients	O	['N']	[6]
7	contrasts	O	['N']	[7]
8	with	O	['N']	[8]
9	the	O	['N']	[9]
10	fatal	B	['N']	[10]
11	outcome	I-Adverse_Effect	['N']	[11]
12	of	O	['N']	[12]
13	the	O	['N']	[13]
14	two	O	['N']	[14]
15	other	O	['N']	[15]
16	reported	O	['N']	[16]
17	cases	O	['N']	[17]
18	of	O	['N']	[18]
19	nitrofurantoin	B-Drug	['Causes']	[11]
20	induced	O	['N']	[20]
21	BOOP	O	['N']	[21]
22	.	O	['N']	[22]
#992
0	METHODS	O	['N']	[0]
1	:	O	['N']	[1]
2	Five	O	['N']	[2]
3	cases	O	['N']	[3]
4	of	O	['N']	[4]
5	contact	B	['N']	[5]
6	dermatitis	I-Adverse_Effect	['N']	[6]
7	due	O	['N']	[7]
8	to	O	['N']	[8]
9	budesonide	B-Drug	['Causes']	[6]
10	,	O	['N']	[10]
11	a	O	['N']	[11]
12	nonhalogenated	O	['N']	[12]
13	steroid	O	['N']	[13]
14	,	O	['N']	[14]
15	are	O	['N']	[15]
16	described	O	['N']	[16]
17	.	O	['N']	[17]
#993
0	We	O	['N']	[0]
1	reported	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	disulfiram	B-Drug	['Causes']	[8]
6	-	O	['N']	[6]
7	induced	O	['N']	[7]
8	hepatitis	B-Adverse_Effect	['N']	[8]
9	with	O	['N']	[9]
10	unique	O	['N']	[10]
11	clinical	O	['N']	[11]
12	features	O	['N']	[12]
13	and	O	['N']	[13]
14	compared	O	['N']	[14]
15	our	O	['N']	[15]
16	case	O	['N']	[16]
17	with	O	['N']	[17]
18	others	O	['N']	[18]
19	in	O	['N']	[19]
20	the	O	['N']	[20]
21	literature	O	['N']	[21]
22	.	O	['N']	[22]
#994
0	The	O	['N']	[0]
1	site	O	['N']	[1]
2	of	O	['N']	[2]
3	thrombosis	O	['N']	[3]
4	and	O	['N']	[4]
5	the	O	['N']	[5]
6	chronological	O	['N']	[6]
7	relationship	O	['N']	[7]
8	with	O	['N']	[8]
9	the	O	['N']	[9]
10	IIR	O	['N']	[10]
11	implicates	O	['N']	[11]
12	a	O	['N']	[12]
13	hypersensitivity	B-Adverse_Effect	['N']	[13]
14	to	O	['N']	[14]
15	infliximab	B-Drug	['Causes']	[13]
16	in	O	['N']	[16]
17	the	O	['N']	[17]
18	causation	O	['N']	[18]
19	of	O	['N']	[19]
20	the	O	['N']	[20]
21	venous	O	['N']	[21]
22	thrombosis	O	['N']	[22]
23	in	O	['N']	[23]
24	this	O	['N']	[24]
25	case	O	['N']	[25]
26	.	O	['N']	[26]
#995
0	A	O	['N']	[0]
1	49-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	man	O	['N']	[4]
5	with	O	['N']	[5]
6	Crohn	O	['N']	[6]
7	's	O	['N']	[7]
8	disease	O	['N']	[8]
9	treated	O	['N']	[9]
10	with	O	['N']	[10]
11	prednisone	O	['N']	[11]
12	and	O	['N']	[12]
13	mesalamine	B-Drug	['Causes']	[22]
14	(	O	['N']	[14]
15	5-ASA	O	['N']	[15]
16	)	O	['N']	[16]
17	developed	O	['N']	[17]
18	worsening	O	['N']	[18]
19	respiratory	O	['N']	[19]
20	distress	O	['N']	[20]
21	and	O	['N']	[21]
22	fever	B-Adverse_Effect	['N']	[22]
23	.	O	['N']	[23]
#996
0	OBJECTIVE	O	['N']	[0]
1	:	O	['N']	[1]
2	To	O	['N']	[2]
3	describe	O	['N']	[3]
4	two	O	['N']	[4]
5	cases	O	['N']	[5]
6	of	O	['N']	[6]
7	rhabdomyolysis	B-Adverse_Effect	['N']	[7]
8	in	O	['N']	[8]
9	patients	O	['N']	[9]
10	taking	O	['N']	[10]
11	lovastatin	B-Drug	['Causes']	[7]
12	that	O	['N']	[12]
13	were	O	['N']	[13]
14	precipitated	O	['N']	[14]
15	by	O	['N']	[15]
16	the	O	['N']	[16]
17	use	O	['N']	[17]
18	of	O	['N']	[18]
19	the	O	['N']	[19]
20	newer	O	['N']	[20]
21	macrolide	O	['N']	[21]
22	antibiotics	O	['N']	[22]
23	clarithromycin	O	['N']	[23]
24	and	O	['N']	[24]
25	azithromycin	O	['N']	[25]
26	.	O	['N']	[26]
#997
0	In	O	['N']	[0]
1	case	O	['N']	[1]
2	no	O	['N']	[2]
3	.	O	['N']	[3]
4	2	O	['N']	[4]
5	,	O	['N']	[5]
6	the	O	['N']	[6]
7	pathogenic	O	['N']	[7]
8	mechanism	O	['N']	[8]
9	seemed	O	['N']	[9]
10	to	O	['N']	[10]
11	be	O	['N']	[11]
12	persistent	O	['N']	[12]
13	light	O	['N']	[13]
14	reaction	O	['N']	[14]
15	preceded	O	['N']	[15]
16	by	O	['N']	[16]
17	systemic	O	['N']	[17]
18	photoallergy	O	['N']	[18]
19	,	O	['N']	[19]
20	as	O	['N']	[20]
21	he	O	['N']	[21]
22	had	O	['N']	[22]
23	taken	O	['N']	[23]
24	mequitazine	B-Drug	['Causes']	[39]
25	for	O	['N']	[25]
26	6	O	['N']	[26]
27	months	O	['N']	[27]
28	,	O	['N']	[28]
29	and	O	['N']	[29]
30	there	O	['N']	[30]
31	were	O	['N']	[31]
32	strong	O	['N']	[32]
33	positive	O	['N']	[33]
34	photopatch	O	['N']	[34]
35	test	O	['N']	[35]
36	results	O	['N']	[36]
37	with	O	['N']	[37]
38	immediate	O	['N']	[38]
39	erythema	B-Adverse_Effect	['N']	[39]
40	reaction	O	['N']	[40]
41	,	O	['N']	[41]
42	cross	O	['N']	[42]
43	-	O	['N']	[43]
44	reaction	O	['N']	[44]
45	to	O	['N']	[45]
46	promethazine	O	['N']	[46]
47	,	O	['N']	[47]
48	decreased	O	['N']	[48]
49	MED	O	['N']	[49]
50	to	O	['N']	[50]
51	both	O	['N']	[51]
52	UVA	O	['N']	[52]
53	and	O	['N']	[53]
54	UVB	O	['N']	[54]
55	,	O	['N']	[55]
56	and	O	['N']	[56]
57	persistence	O	['N']	[57]
58	of	O	['N']	[58]
59	the	O	['N']	[59]
60	photosensitivity	O	['N']	[60]
61	over	O	['N']	[61]
62	a	O	['N']	[62]
63	3-year	O	['N']	[63]
64	follow	O	['N']	[64]
65	-	O	['N']	[65]
66	up	O	['N']	[66]
67	period	O	['N']	[67]
68	after	O	['N']	[68]
69	discontinuation	O	['N']	[69]
70	of	O	['N']	[70]
71	the	O	['N']	[71]
72	mequitazine	O	['N']	[72]
73	.	O	['N']	[73]
#998
0	Acute	B	['N']	[0]
1	dystonia	I-Adverse_Effect	['N']	[1]
2	with	O	['N']	[2]
3	thalamic	O	['N']	[3]
4	and	O	['N']	[4]
5	brainstem	O	['N']	[5]
6	lesions	O	['N']	[6]
7	after	O	['N']	[7]
8	initial	O	['N']	[8]
9	penicillamine	B-Drug	['Causes']	[1]
10	treatment	O	['N']	[10]
11	in	O	['N']	[11]
12	Wilson	O	['N']	[12]
13	's	O	['N']	[13]
14	disease	O	['N']	[14]
15	.	O	['N']	[15]
#999
0	Polymyositis	B-Adverse_Effect	['N']	[0]
1	is	O	['N']	[1]
2	a	O	['N']	[2]
3	rare	O	['N']	[3]
4	complication	O	['N']	[4]
5	of	O	['N']	[5]
6	interferon	B	['N']	[6]
7	alpha	I-Drug	['Causes']	[0]
8	treatment	O	['N']	[8]
9	as	O	['N']	[9]
10	a	O	['N']	[10]
11	result	O	['N']	[11]
12	of	O	['N']	[12]
13	immune	O	['N']	[13]
14	-	O	['N']	[14]
15	modulating	O	['N']	[15]
16	role	O	['N']	[16]
17	of	O	['N']	[17]
18	the	O	['N']	[18]
19	drug	O	['N']	[19]
20	itself	O	['N']	[20]
21	.	O	['N']	[21]
#1000
0	A	O	['N']	[0]
1	short	O	['N']	[1]
2	review	O	['N']	[2]
3	on	O	['N']	[3]
4	imatinib	B-Drug	['Causes']	[7]
5	-	O	['N']	[5]
6	related	O	['N']	[6]
7	hepatotoxicity	B-Adverse_Effect	['N']	[7]
8	is	O	['N']	[8]
9	also	O	['N']	[9]
10	presented	O	['N']	[10]
11	.	O	['N']	[11]
#1001
0	A	O	['N']	[0]
1	woman	O	['N']	[1]
2	developed	O	['N']	[2]
3	delusional	B	['N']	[3]
4	parasitosis	I-Adverse_Effect	['N']	[4]
5	when	O	['N']	[5]
6	taking	O	['N']	[6]
7	phenelzine	B-Drug	['Causes']	[4]
8	.	O	['N']	[8]
#1002
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	the	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	a	O	['N']	[5]
6	14-year	O	['N']	[6]
7	-	O	['N']	[7]
8	old	O	['N']	[8]
9	female	O	['N']	[9]
10	with	O	['N']	[10]
11	acute	O	['N']	[11]
12	promyelocytic	O	['N']	[12]
13	leukemia	O	['N']	[13]
14	who	O	['N']	[14]
15	developed	O	['N']	[15]
16	symptomatic	B	['N']	[16]
17	cardiomyopathy	I-Adverse_Effect	['N']	[17]
18	only	O	['N']	[18]
19	4	O	['N']	[19]
20	months	O	['N']	[20]
21	into	O	['N']	[21]
22	treatment	O	['N']	[22]
23	with	O	['N']	[23]
24	a	O	['N']	[24]
25	combination	O	['N']	[25]
26	of	O	['N']	[26]
27	daunomycin	B-Drug	['Causes']	[17]
28	and	O	['N']	[28]
29	all	O	['N']	[29]
30	-	O	['N']	[30]
31	trans	O	['N']	[31]
32	retinoic	O	['N']	[32]
33	acid	O	['N']	[33]
34	(	O	['N']	[34]
35	ATRA	O	['N']	[35]
36	)	O	['N']	[36]
37	.	O	['N']	[37]
#1003
0	Here	O	['N']	[0]
1	,	O	['N']	[1]
2	we	O	['N']	[2]
3	describe	O	['N']	[3]
4	levofloxacin	B-Drug	['Causes']	[10]
5	-	O	['N']	[5]
6	induced	O	['N']	[6]
7	delirium	B	['N']	[7]
8	with	I	['N']	[8]
9	psychotic	I	['N']	[9]
10	features	I-Adverse_Effect	['N']	[10]
11	in	O	['N']	[11]
12	a	O	['N']	[12]
13	relatively	O	['N']	[13]
14	young	O	['N']	[14]
15	,	O	['N']	[15]
16	otherwise	O	['N']	[16]
17	healthy	O	['N']	[17]
18	female	O	['N']	[18]
19	.	O	['N']	[19]
#1004
0	Thrombolytic	O	['N']	[0]
1	therapy	O	['N']	[1]
2	with	O	['N']	[2]
3	tissue	O	['N']	[3]
4	plasminogen	O	['N']	[4]
5	activator	O	['N']	[5]
6	(	O	['N']	[6]
7	tPA	B-Drug	['Causes']	[24]
8	)	O	['N']	[8]
9	for	O	['N']	[9]
10	acute	O	['N']	[10]
11	myocardial	O	['N']	[11]
12	infarction	O	['N']	[12]
13	may	O	['N']	[13]
14	result	O	['N']	[14]
15	in	O	['N']	[15]
16	major	O	['N']	[16]
17	bleeding	O	['N']	[17]
18	complications	O	['N']	[18]
19	such	O	['N']	[19]
20	as	O	['N']	[20]
21	gastrointestinal	B	['N']	[21]
22	or	I	['N']	[22]
23	intracranial	I	['N']	[23]
24	bleeding	I-Adverse_Effect	['N']	[24]
25	.	O	['N']	[25]
#1005
0	Type	O	['N']	[0]
1	I	O	['N']	[1]
2	second	O	['N']	[2]
3	-	O	['N']	[3]
4	degree	O	['N']	[4]
5	AV	O	['N']	[5]
6	block	O	['N']	[6]
7	(	O	['N']	[7]
8	Mobitz	O	['N']	[8]
9	type	O	['N']	[9]
10	I	O	['N']	[10]
11	,	O	['N']	[11]
12	Wenckebach	B	['N']	[12]
13	AV	I	['N']	[13]
14	block	I-Adverse_Effect	['N']	[14]
15	)	O	['N']	[15]
16	during	O	['N']	[16]
17	ritodrine	B-Drug	['Causes']	[14]
18	therapy	O	['N']	[18]
19	for	O	['N']	[19]
20	preterm	O	['N']	[20]
21	labor	O	['N']	[21]
22	.	O	['N']	[22]
#1006
0	Bradycardia	B-Adverse_Effect	['N']	[0]
1	and	O	['N']	[1]
2	congestive	O	['N']	[2]
3	heart	O	['N']	[3]
4	failure	O	['N']	[4]
5	associated	O	['N']	[5]
6	with	O	['N']	[6]
7	ocular	O	['N']	[7]
8	timolol	B	['N']	[8]
9	maleate	I-Drug	['Causes']	[0]
10	.	O	['N']	[10]
#1007
0	We	O	['N']	[0]
1	present	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	hemolytic	B	['N']	[5]
6	-	I	['N']	[6]
7	uremic	I	['N']	[7]
8	syndrome	I-Adverse_Effect	['N']	[8]
9	that	O	['N']	[9]
10	developed	O	['N']	[10]
11	during	O	['N']	[11]
12	the	O	['N']	[12]
13	4th	O	['N']	[13]
14	cycle	O	['N']	[14]
15	of	O	['N']	[15]
16	combination	O	['N']	[16]
17	chemotherapy	O	['N']	[17]
18	with	O	['N']	[18]
19	oxaliplatin	B-Drug	['Causes']	[8]
20	,	O	['N']	[20]
21	5-fluorouracil	O	['N']	[21]
22	and	O	['N']	[22]
23	leucovorin	O	['N']	[23]
24	.	O	['N']	[24]
#1008
0	In	O	['N']	[0]
1	this	O	['N']	[1]
2	report	O	['N']	[2]
3	we	O	['N']	[3]
4	described	O	['N']	[4]
5	a	O	['N']	[5]
6	case	O	['N']	[6]
7	of	O	['N']	[7]
8	juvenile	O	['N']	[8]
9	idiopathic	O	['N']	[9]
10	arthritis	O	['N']	[10]
11	patient	O	['N']	[11]
12	who	O	['N']	[12]
13	developed	O	['N']	[13]
14	thymic	O	['N']	[14]
15	enlargement	O	['N']	[15]
16	(	O	['N']	[16]
17	true	O	['N']	[17]
18	thymic	O	['N']	[18]
19	hyperplasia	O	['N']	[19]
20	)	O	['N']	[20]
21	,	O	['N']	[21]
22	mediastinal	B	['N']	[22]
23	lymphadenopathy	I-Adverse_Effect	['N']	[23]
24	and	O	['N']	[24]
25	pleurisy	O	['N']	[25]
26	associated	O	['N']	[26]
27	with	O	['N']	[27]
28	systemic	O	['N']	[28]
29	symptoms	O	['N']	[29]
30	under	O	['N']	[30]
31	Etanercept	B-Drug	['Causes']	[23]
32	treatment	O	['N']	[32]
33	.	O	['N']	[33]
#1009
0	This	O	['N']	[0]
1	case	O	['N']	[1]
2	demonstrates	O	['N']	[2]
3	an	O	['N']	[3]
4	occupational	O	['N']	[4]
5	activity	O	['N']	[5]
6	(	O	['N']	[6]
7	construction	O	['N']	[7]
8	)	O	['N']	[8]
9	that	O	['N']	[9]
10	has	O	['N']	[10]
11	now	O	['N']	[11]
12	become	O	['N']	[12]
13	the	O	['N']	[13]
14	dominant	O	['N']	[14]
15	source	O	['N']	[15]
16	of	O	['N']	[16]
17	lead	B-Drug	['Causes']	[43]
18	exposure	O	['N']	[18]
19	for	O	['N']	[19]
20	U.S.	O	['N']	[20]
21	adults	O	['N']	[21]
22	,	O	['N']	[22]
23	the	O	['N']	[23]
24	importance	O	['N']	[24]
25	of	O	['N']	[25]
26	a	O	['N']	[26]
27	good	O	['N']	[27]
28	occupational	O	['N']	[28]
29	history	O	['N']	[29]
30	to	O	['N']	[30]
31	suspecting	O	['N']	[31]
32	and	O	['N']	[32]
33	making	O	['N']	[33]
34	a	O	['N']	[34]
35	diagnosis	O	['N']	[35]
36	,	O	['N']	[36]
37	the	O	['N']	[37]
38	possible	O	['N']	[38]
39	outcomes	O	['N']	[39]
40	of	O	['N']	[40]
41	chronic	O	['N']	[41]
42	lead	B	['N']	[42]
43	toxicity	I-Adverse_Effect	['N']	[43]
44	,	O	['N']	[44]
45	and	O	['N']	[45]
46	the	O	['N']	[46]
47	importance	O	['N']	[47]
48	of	O	['N']	[48]
49	preventing	O	['N']	[49]
50	further	O	['N']	[50]
51	exposure	O	['N']	[51]
52	and	O	['N']	[52]
53	using	O	['N']	[53]
54	proper	O	['N']	[54]
55	methods	O	['N']	[55]
56	to	O	['N']	[56]
57	treat	O	['N']	[57]
58	acute	O	['N']	[58]
59	toxicity	O	['N']	[59]
60	.	O	['N']	[60]
#1010
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	on	O	['N']	[2]
3	a	O	['N']	[3]
4	patient	O	['N']	[4]
5	with	O	['N']	[5]
6	acromegaly	O	['N']	[6]
7	who	O	['N']	[7]
8	developed	O	['N']	[8]
9	severe	O	['N']	[9]
10	drug	O	['N']	[10]
11	-	O	['N']	[11]
12	induced	O	['N']	[12]
13	hepatitis	B-Adverse_Effect	['N']	[13]
14	during	O	['N']	[14]
15	combined	O	['N']	[15]
16	treatment	O	['N']	[16]
17	with	O	['N']	[17]
18	the	O	['N']	[18]
19	long	O	['N']	[19]
20	-	O	['N']	[20]
21	acting	O	['N']	[21]
22	somatostatin	O	['N']	[22]
23	-	O	['N']	[23]
24	analog	O	['N']	[24]
25	octreotide	O	['N']	[25]
26	and	O	['N']	[26]
27	the	O	['N']	[27]
28	GH	O	['N']	[28]
29	receptor	O	['N']	[29]
30	antagonist	O	['N']	[30]
31	pegvisomant	B-Drug	['Causes']	[13]
32	.	O	['N']	[32]
#1011
0	A	O	['N']	[0]
1	10-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	boy	O	['N']	[4]
5	with	O	['N']	[5]
6	osteosarcoma	O	['N']	[6]
7	and	O	['N']	[7]
8	normal	O	['N']	[8]
9	renal	O	['N']	[9]
10	function	O	['N']	[10]
11	manifested	O	['N']	[11]
12	laboratory	O	['N']	[12]
13	evidence	O	['N']	[13]
14	of	O	['N']	[14]
15	impending	O	['N']	[15]
16	renal	O	['N']	[16]
17	toxicity	O	['N']	[17]
18	and	O	['N']	[18]
19	extreme	O	['N']	[19]
20	elevation	O	['N']	[20]
21	of	O	['N']	[21]
22	aspartate	O	['N']	[22]
23	aminotrasferase	O	['N']	[23]
24	and	O	['N']	[24]
25	alanine	O	['N']	[25]
26	aminotransferase	O	['N']	[26]
27	within	O	['N']	[27]
28	2	O	['N']	[28]
29	hours	O	['N']	[29]
30	after	O	['N']	[30]
31	the	O	['N']	[31]
32	completion	O	['N']	[32]
33	of	O	['N']	[33]
34	a	O	['N']	[34]
35	4-hour	O	['N']	[35]
36	infusion	O	['N']	[36]
37	of	O	['N']	[37]
38	high	O	['N']	[38]
39	-	O	['N']	[39]
40	dose	O	['N']	[40]
41	methotrexate	B-Drug	['Dosage']	[49]
42	(	O	['N']	[42]
43	MTX	O	['N']	[43]
44	)	O	['N']	[44]
45	(	O	['N']	[45]
46	12	B	['N']	[46]
47	g	I	['N']	[47]
48	/	I	['N']	[48]
49	m2	I-Dose	['N']	[49]
50	)	O	['N']	[50]
51	,	O	['N']	[51]
52	and	O	['N']	[52]
53	went	O	['N']	[53]
54	on	O	['N']	[54]
55	to	O	['N']	[55]
56	develop	O	['N']	[56]
57	acute	O	['N']	[57]
58	renal	O	['N']	[58]
59	failure	O	['N']	[59]
60	with	O	['N']	[60]
61	life	O	['N']	[61]
62	-	O	['N']	[62]
63	threatening	O	['N']	[63]
64	hyperkalemia	O	['N']	[64]
65	29	O	['N']	[65]
66	hours	O	['N']	[66]
67	later	O	['N']	[67]
68	.	O	['N']	[68]
#1012
0	Recognizing	O	['N']	[0]
1	early	O	['N']	[1]
2	signs	O	['N']	[2]
3	of	O	['N']	[3]
4	HMSN	O	['N']	[4]
5	,	O	['N']	[5]
6	such	O	['N']	[6]
7	as	O	['N']	[7]
8	areflexia	O	['N']	[8]
9	and	O	['N']	[9]
10	pes	O	['N']	[10]
11	cavus	O	['N']	[11]
12	deformity	O	['N']	[12]
13	,	O	['N']	[13]
14	can	O	['N']	[14]
15	prevent	O	['N']	[15]
16	severe	B	['N']	[16]
17	neurotoxicity	I-Adverse_Effect	['N']	[17]
18	of	O	['N']	[18]
19	polychemotherapy	O	['N']	[19]
20	by	O	['N']	[20]
21	avoiding	O	['N']	[21]
22	vincristine	B-Drug	['Causes']	[17]
23	.	O	['N']	[23]
#1013
0	After	O	['N']	[0]
1	receiving	O	['N']	[1]
2	3	O	['N']	[2]
3	doses	O	['N']	[3]
4	of	O	['N']	[4]
5	ifosfamide	B-Drug	['Causes']	[14]
6	/	O	['N']	[6]
7	mesna	O	['N']	[7]
8	,	O	['N']	[8]
9	she	O	['N']	[9]
10	was	O	['N']	[10]
11	found	O	['N']	[11]
12	to	O	['N']	[12]
13	be	O	['N']	[13]
14	unresponsive	B-Adverse_Effect	['N']	[14]
15	.	O	['N']	[15]
#1014
0	Dihydropyrimidine	O	['N']	[0]
1	dehydrogenase	O	['N']	[1]
2	deficiency	O	['N']	[2]
3	:	O	['N']	[3]
4	a	O	['N']	[4]
5	pharmacogenetic	O	['N']	[5]
6	defect	O	['N']	[6]
7	causing	O	['N']	[7]
8	severe	B	['N']	[8]
9	adverse	I	['N']	[9]
10	reactions	I-Adverse_Effect	['N']	[10]
11	to	O	['N']	[11]
12	5-fluorouracil	B-Drug	['Causes']	[10]
13	-	O	['N']	[13]
14	based	O	['N']	[14]
15	chemotherapy	O	['N']	[15]
16	.	O	['N']	[16]
#1015
0	The	O	['N']	[0]
1	toxic	O	['N']	[1]
2	effects	O	['N']	[2]
3	of	O	['N']	[3]
4	methotrexate	B-Drug	['Causes']	[38]
5	included	O	['N']	[5]
6	elevated	O	['N']	[6]
7	liver	O	['N']	[7]
8	transaminases	O	['N']	[8]
9	(	O	['N']	[9]
10	3/4	O	['N']	[10]
11	)	O	['N']	[11]
12	,	O	['N']	[12]
13	nausea	O	['N']	[13]
14	(	O	['N']	[14]
15	2/4	O	['N']	[15]
16	)	O	['N']	[16]
17	,	O	['N']	[17]
18	abdominal	O	['N']	[18]
19	pain	O	['N']	[19]
20	(	O	['N']	[20]
21	2/4	O	['N']	[21]
22	)	O	['N']	[22]
23	,	O	['N']	[23]
24	bone	O	['N']	[24]
25	pain	O	['N']	[25]
26	(	O	['N']	[26]
27	2/4	O	['N']	[27]
28	)	O	['N']	[28]
29	,	O	['N']	[29]
30	mild	O	['N']	[30]
31	neutropenia	O	['N']	[31]
32	(	O	['N']	[32]
33	1/4	O	['N']	[33]
34	)	O	['N']	[34]
35	,	O	['N']	[35]
36	and	O	['N']	[36]
37	mild	B	['N']	[37]
38	pruritus	I-Adverse_Effect	['N']	[38]
39	(	O	['N']	[39]
40	1/4	O	['N']	[40]
41	)	O	['N']	[41]
42	.	O	['N']	[42]
#1016
0	On	O	['N']	[0]
1	day	O	['N']	[1]
2	4	O	['N']	[2]
3	,	O	['N']	[3]
4	following	O	['N']	[4]
5	3	O	['N']	[5]
6	doses	O	['N']	[6]
7	of	O	['N']	[7]
8	dalteparin	B-Drug	['Causes']	[15]
9	,	O	['N']	[9]
10	the	O	['N']	[10]
11	patient	O	['N']	[11]
12	developed	O	['N']	[12]
13	acute	B	['N']	[13]
14	respiratory	I	['N']	[14]
15	distress	I-Adverse_Effect	['N']	[15]
16	attributable	O	['N']	[16]
17	to	O	['N']	[17]
18	a	O	['N']	[18]
19	massive	O	['N']	[19]
20	right	O	['N']	[20]
21	hemothorax	O	['N']	[21]
22	confirmed	O	['N']	[22]
23	by	O	['N']	[23]
24	computed	O	['N']	[24]
25	tomography	O	['N']	[25]
26	pulmonary	O	['N']	[26]
27	angiography	O	['N']	[27]
28	(	O	['N']	[28]
29	CTPA	O	['N']	[29]
30	)	O	['N']	[30]
31	and	O	['N']	[31]
32	intercostal	O	['N']	[32]
33	drainage	O	['N']	[33]
34	of	O	['N']	[34]
35	1500	O	['N']	[35]
36	mL	O	['N']	[36]
37	of	O	['N']	[37]
38	frank	O	['N']	[38]
39	blood	O	['N']	[39]
40	.	O	['N']	[40]
#1017
0	Carbamazepine	B	['N']	[0]
1	toxicity	I-Adverse_Effect	['N']	[1]
2	following	O	['N']	[2]
3	Oxybutynin	O	['N']	[3]
4	and	O	['N']	[4]
5	Dantrolene	B-Drug	['Causes']	[1]
6	administration	O	['N']	[6]
7	:	O	['N']	[7]
8	a	O	['N']	[8]
9	case	O	['N']	[9]
10	report	O	['N']	[10]
11	.	O	['N']	[11]
#1018
0	Does	O	['N']	[0]
1	the	O	['N']	[1]
2	use	O	['N']	[2]
3	of	O	['N']	[3]
4	insulin	B-Drug	['Causes']	[21]
5	in	O	['N']	[5]
6	a	O	['N']	[6]
7	patient	O	['N']	[7]
8	with	O	['N']	[8]
9	liver	O	['N']	[9]
10	dysfunction	O	['N']	[10]
11	increase	O	['N']	[11]
12	water	O	['N']	[12]
13	retention	O	['N']	[13]
14	in	O	['N']	[14]
15	the	O	['N']	[15]
16	body	O	['N']	[16]
17	,	O	['N']	[17]
18	i.e.	O	['N']	[18]
19	cause	O	['N']	[19]
20	insulin	O	['N']	[20]
21	oedema	B-Adverse_Effect	['N']	[21]
22	?	O	['N']	[22]
#1019
0	A	O	['N']	[0]
1	patient	O	['N']	[1]
2	presented	O	['N']	[2]
3	with	O	['N']	[3]
4	a	O	['N']	[4]
5	painful	B	['N']	[5]
6	,	I	['N']	[6]
7	oedematous	I	['N']	[7]
8	,	I	['N']	[8]
9	cyanosed	I	['N']	[9]
10	hand	I-Adverse_Effect	['N']	[10]
11	having	O	['N']	[11]
12	injected	O	['N']	[12]
13	a	O	['N']	[13]
14	solution	O	['N']	[14]
15	of	O	['N']	[15]
16	diamorphine	B-Drug	['Causes']	[10]
17	and	O	['N']	[17]
18	methylphenidate	O	['N']	[18]
19	into	O	['N']	[19]
20	his	O	['N']	[20]
21	radial	O	['N']	[21]
22	artery	O	['N']	[22]
23	.	O	['N']	[23]
#1020
0	The	O	['N']	[0]
1	case	O	['N']	[1]
2	of	O	['N']	[2]
3	a	O	['N']	[3]
4	4-year	O	['N']	[4]
5	-	O	['N']	[5]
6	old	O	['N']	[6]
7	girl	O	['N']	[7]
8	with	O	['N']	[8]
9	valproate	B-Drug	['Causes']	[12]
10	-	O	['N']	[10]
11	induced	O	['N']	[11]
12	stupor	B-Adverse_Effect	['N']	[12]
13	and	O	['N']	[13]
14	electroencephalographic	O	['N']	[14]
15	pattern	O	['N']	[15]
16	of	O	['N']	[16]
17	increased	O	['N']	[17]
18	fast	O	['N']	[18]
19	activity	O	['N']	[19]
20	is	O	['N']	[20]
21	reported	O	['N']	[21]
22	.	O	['N']	[22]
#1021
0	The	O	['N']	[0]
1	patient	O	['N']	[1]
2	was	O	['N']	[2]
3	found	O	['N']	[3]
4	to	O	['N']	[4]
5	have	O	['N']	[5]
6	no	B	['N']	[6]
7	motile	I	['N']	[7]
8	sperm	I-Adverse_Effect	['N']	[8]
9	with	O	['N']	[9]
10	a	O	['N']	[10]
11	normal	O	['N']	[11]
12	sperm	O	['N']	[12]
13	count	O	['N']	[13]
14	,	O	['N']	[14]
15	while	O	['N']	[15]
16	taking	O	['N']	[16]
17	a	O	['N']	[17]
18	dose	O	['N']	[18]
19	of	O	['N']	[19]
20	400	O	['N']	[20]
21	mg	O	['N']	[21]
22	/	O	['N']	[22]
23	day	O	['N']	[23]
24	of	O	['N']	[24]
25	carbamazepine	B-Drug	['Causes']	[8]
26	.	O	['N']	[26]
#1022
0	Visual	O	['N']	[0]
1	loss	O	['N']	[1]
2	after	O	['N']	[2]
3	a	O	['N']	[3]
4	single	B	['N']	[4]
5	small	I	['N']	[5]
6	dose	I-Dose	['N']	[6]
7	of	O	['N']	[7]
8	vincristine	B-Drug	['Dosage']	[6]
9	has	O	['N']	[9]
10	never	O	['N']	[10]
11	been	O	['N']	[11]
12	reported	O	['N']	[12]
13	.	O	['N']	[13]
#1023
0	Reversible	B	['N']	[0]
1	posterior	I	['N']	[1]
2	leukoencephalopathy	I	['N']	[2]
3	syndrome	I-Adverse_Effect	['N']	[3]
4	in	O	['N']	[4]
5	systemic	O	['N']	[5]
6	lupus	O	['N']	[6]
7	erythematosus	O	['N']	[7]
8	with	O	['N']	[8]
9	thrombocytopenia	O	['N']	[9]
10	treated	O	['N']	[10]
11	with	O	['N']	[11]
12	cyclosporine	B-Drug	['Causes']	[3]
13	.	O	['N']	[13]
#1024
0	DATA	O	['N']	[0]
1	SYNTHESIS	O	['N']	[1]
2	:	O	['N']	[2]
3	Genetic	O	['N']	[3]
4	deficiencies	O	['N']	[4]
5	in	O	['N']	[5]
6	DPD	O	['N']	[6]
7	,	O	['N']	[7]
8	the	O	['N']	[8]
9	rate	O	['N']	[9]
10	-	O	['N']	[10]
11	limiting	O	['N']	[11]
12	enzyme	O	['N']	[12]
13	responsible	O	['N']	[13]
14	for	O	['N']	[14]
15	5-FU	B-Drug	['Causes']	[46]
16	catabolism	O	['N']	[16]
17	,	O	['N']	[17]
18	may	O	['N']	[18]
19	occur	O	['N']	[19]
20	in	O	['N']	[20]
21	3	O	['N']	[21]
22	%	O	['N']	[22]
23	or	O	['N']	[23]
24	more	O	['N']	[24]
25	of	O	['N']	[25]
26	patients	O	['N']	[26]
27	with	O	['N']	[27]
28	cancer	O	['N']	[28]
29	putting	O	['N']	[29]
30	them	O	['N']	[30]
31	at	O	['N']	[31]
32	increased	O	['N']	[32]
33	risk	O	['N']	[33]
34	for	O	['N']	[34]
35	unusually	O	['N']	[35]
36	severe	O	['N']	[36]
37	adverse	O	['N']	[37]
38	reactions	O	['N']	[38]
39	(	O	['N']	[39]
40	e.g.	O	['N']	[40]
41	,	O	['N']	[41]
42	diarrhea	O	['N']	[42]
43	,	O	['N']	[43]
44	stomatitis	O	['N']	[44]
45	,	O	['N']	[45]
46	mucositis	B-Adverse_Effect	['N']	[46]
47	,	O	['N']	[47]
48	myelosuppression	O	['N']	[48]
49	,	O	['N']	[49]
50	neurotoxicity	O	['N']	[50]
51	)	O	['N']	[51]
52	to	O	['N']	[52]
53	standard	O	['N']	[53]
54	doses	O	['N']	[54]
55	of	O	['N']	[55]
56	5-FU	O	['N']	[56]
57	.	O	['N']	[57]
#1025
0	We	O	['N']	[0]
1	present	O	['N']	[1]
2	a	O	['N']	[2]
3	patient	O	['N']	[3]
4	with	O	['N']	[4]
5	human	O	['N']	[5]
6	immunodeficiency	O	['N']	[6]
7	virus	O	['N']	[7]
8	infection	O	['N']	[8]
9	under	O	['N']	[9]
10	treatment	O	['N']	[10]
11	with	O	['N']	[11]
12	foscarnet	B-Drug	['Causes']	[19]
13	for	O	['N']	[13]
14	CMV	O	['N']	[14]
15	retinitis	O	['N']	[15]
16	who	O	['N']	[16]
17	complained	O	['N']	[17]
18	of	O	['N']	[18]
19	thirst	B-Adverse_Effect	['N']	[19]
20	and	O	['N']	[20]
21	polyuria	O	['N']	[21]
22	.	O	['N']	[22]
#1026
0	Clinicians	O	['N']	[0]
1	should	O	['N']	[1]
2	be	O	['N']	[2]
3	aware	O	['N']	[3]
4	of	O	['N']	[4]
5	fasting	B	['N']	[5]
6	hypoglycemia	I-Adverse_Effect	['N']	[6]
7	as	O	['N']	[7]
8	an	O	['N']	[8]
9	unusual	O	['N']	[9]
10	but	O	['N']	[10]
11	potentially	O	['N']	[11]
12	serious	O	['N']	[12]
13	complication	O	['N']	[13]
14	of	O	['N']	[14]
15	disopyramide	B-Drug	['Causes']	[6]
16	therapy	O	['N']	[16]
17	.	O	['N']	[17]
#1027
0	Mechanisms	O	['N']	[0]
1	and	O	['N']	[1]
2	triggering	O	['N']	[2]
3	factors	O	['N']	[3]
4	of	O	['N']	[4]
5	hypoglycaemia	B-Adverse_Effect	['N']	[5]
6	induced	O	['N']	[6]
7	by	O	['N']	[7]
8	mefloquine	B-Drug	['Causes']	[5]
9	and	O	['N']	[9]
10	some	O	['N']	[10]
11	other	O	['N']	[11]
12	anti	O	['N']	[12]
13	-	O	['N']	[13]
14	malarial	O	['N']	[14]
15	quinine	O	['N']	[15]
16	analogues	O	['N']	[16]
17	are	O	['N']	[17]
18	discussed	O	['N']	[18]
19	.	O	['N']	[19]
#1028
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	girl	O	['N']	[3]
4	with	O	['N']	[4]
5	the	O	['N']	[5]
6	Rett	O	['N']	[6]
7	syndrome	O	['N']	[7]
8	who	O	['N']	[8]
9	had	O	['N']	[9]
10	acute	B	['N']	[10]
11	encephalopathy	I-Adverse_Effect	['N']	[11]
12	probably	O	['N']	[12]
13	induced	O	['N']	[13]
14	by	O	['N']	[14]
15	calcium	B	['N']	[15]
16	hopantenate	I-Drug	['Causes']	[11]
17	(	O	['N']	[17]
18	HOPA	O	['N']	[18]
19	)	O	['N']	[19]
20	.	O	['N']	[20]
#1029
0	Moreover	O	['N']	[0]
1	,	O	['N']	[1]
2	treatment	O	['N']	[2]
3	with	O	['N']	[3]
4	immunosuppressive	O	['N']	[4]
5	drugs	O	['N']	[5]
6	such	O	['N']	[6]
7	as	O	['N']	[7]
8	cyclosporine	O	['N']	[8]
9	,	O	['N']	[9]
10	cisplatin	B-Drug	['Causes']	[23]
11	,	O	['N']	[11]
12	tacrolimus	O	['N']	[12]
13	,	O	['N']	[13]
14	and	O	['N']	[14]
15	interferon	O	['N']	[15]
16	-	O	['N']	[16]
17	alpha	O	['N']	[17]
18	can	O	['N']	[18]
19	induce	O	['N']	[19]
20	a	O	['N']	[20]
21	condition	O	['N']	[21]
22	resembling	O	['N']	[22]
23	RPLS	B-Adverse_Effect	['N']	[23]
24	.	O	['N']	[24]
#1030
0	Although	O	['N']	[0]
1	risk	O	['N']	[1]
2	factors	O	['N']	[2]
3	for	O	['N']	[3]
4	MTX	B-Drug	['Causes']	[68]
5	-	O	['N']	[5]
6	induced	O	['N']	[6]
7	pulmonary	O	['N']	[7]
8	toxicity	O	['N']	[8]
9	are	O	['N']	[9]
10	poorly	O	['N']	[10]
11	understood	O	['N']	[11]
12	,	O	['N']	[12]
13	the	O	['N']	[13]
14	presence	O	['N']	[14]
15	in	O	['N']	[15]
16	3	O	['N']	[16]
17	out	O	['N']	[17]
18	of	O	['N']	[18]
19	5	O	['N']	[19]
20	of	O	['N']	[20]
21	our	O	['N']	[21]
22	patients	O	['N']	[22]
23	of	O	['N']	[23]
24	pre	O	['N']	[24]
25	-	O	['N']	[25]
26	existing	O	['N']	[26]
27	lung	O	['N']	[27]
28	disease	O	['N']	[28]
29	,	O	['N']	[29]
30	represented	O	['N']	[30]
31	by	O	['N']	[31]
32	diffuse	O	['N']	[32]
33	interstitial	O	['N']	[33]
34	changes	O	['N']	[34]
35	on	O	['N']	[35]
36	chest	O	['N']	[36]
37	X	O	['N']	[37]
38	-	O	['N']	[38]
39	ray	O	['N']	[39]
40	,	O	['N']	[40]
41	and	O	['N']	[41]
42	mild	O	['N']	[42]
43	bronchial	O	['N']	[43]
44	asthma	O	['N']	[44]
45	in	O	['N']	[45]
46	two	O	['N']	[46]
47	RA	O	['N']	[47]
48	patients	O	['N']	[48]
49	and	O	['N']	[49]
50	by	O	['N']	[50]
51	pulmonary	O	['N']	[51]
52	silicosis	O	['N']	[52]
53	in	O	['N']	[53]
54	the	O	['N']	[54]
55	patient	O	['N']	[55]
56	with	O	['N']	[56]
57	PsA	O	['N']	[57]
58	may	O	['N']	[58]
59	account	O	['N']	[59]
60	for	O	['N']	[60]
61	a	O	['N']	[61]
62	predisposition	O	['N']	[62]
63	to	O	['N']	[63]
64	the	O	['N']	[64]
65	development	O	['N']	[65]
66	of	O	['N']	[66]
67	MTX	O	['N']	[67]
68	pneumonitis	B-Adverse_Effect	['N']	[68]
69	.	O	['N']	[69]
#1031
0	One	O	['N']	[0]
1	patient	O	['N']	[1]
2	who	O	['N']	[2]
3	received	O	['N']	[3]
4	clindamycin	B-Drug	['Causes']	[11]
5	had	O	['N']	[5]
6	liver	O	['N']	[6]
7	biopsy	O	['N']	[7]
8	findings	O	['N']	[8]
9	of	O	['N']	[9]
10	marked	B	['N']	[10]
11	cholestasis	I-Adverse_Effect	['N']	[11]
12	,	O	['N']	[12]
13	portal	O	['N']	[13]
14	inflammation	O	['N']	[14]
15	,	O	['N']	[15]
16	bile	O	['N']	[16]
17	duct	O	['N']	[17]
18	injury	O	['N']	[18]
19	and	O	['N']	[19]
20	bile	O	['N']	[20]
21	duct	O	['N']	[21]
22	paucity	O	['N']	[22]
23	(	O	['N']	[23]
24	ductopenia	O	['N']	[24]
25	)	O	['N']	[25]
26	.	O	['N']	[26]
#1032
0	His	O	['N']	[0]
1	symptoms	O	['N']	[1]
2	of	O	['N']	[2]
3	brain	O	['N']	[3]
4	stem	O	['N']	[4]
5	compression	O	['N']	[5]
6	were	O	['N']	[6]
7	alleviated	O	['N']	[7]
8	and	O	['N']	[8]
9	the	O	['N']	[9]
10	role	O	['N']	[10]
11	of	O	['N']	[11]
12	phenytoin	B-Drug	['Causes']	[19]
13	in	O	['N']	[13]
14	the	O	['N']	[14]
15	production	O	['N']	[15]
16	of	O	['N']	[16]
17	his	O	['N']	[17]
18	craniocervical	B	['N']	[18]
19	abnormality	I-Adverse_Effect	['N']	[19]
20	is	O	['N']	[20]
21	discussed	O	['N']	[21]
22	.	O	['N']	[22]
#1033
0	A	O	['N']	[0]
1	rare	O	['N']	[1]
2	case	O	['N']	[2]
3	of	O	['N']	[3]
4	advanced	O	['N']	[4]
5	ovarian	O	['N']	[5]
6	carcinoma	O	['N']	[6]
7	who	O	['N']	[7]
8	developed	O	['N']	[8]
9	difficulty	B	['N']	[9]
10	walking	I-Adverse_Effect	['N']	[10]
11	25	O	['N']	[11]
12	days	O	['N']	[12]
13	after	O	['N']	[13]
14	treatment	O	['N']	[14]
15	with	O	['N']	[15]
16	weekly	O	['N']	[16]
17	paclitaxel	B-Drug	['Causes']	[10]
18	.	O	['N']	[18]
#1034
0	Capecitabine	B-Drug	['Causes']	[6]
1	was	O	['N']	[1]
2	discontinued	O	['N']	[2]
3	and	O	['N']	[3]
4	the	O	['N']	[4]
5	allergic	B	['N']	[5]
6	reactions	I-Adverse_Effect	['N']	[6]
7	resolved	O	['N']	[7]
8	after	O	['N']	[8]
9	the	O	['N']	[9]
10	woman	O	['N']	[10]
11	took	O	['N']	[11]
12	diphenhydramine	O	['N']	[12]
13	for	O	['N']	[13]
14	1	O	['N']	[14]
15	week	O	['N']	[15]
16	.	O	['N']	[16]
#1035
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	the	O	['N']	[2]
3	first	O	['N']	[3]
4	histopathologically	O	['N']	[4]
5	documented	O	['N']	[5]
6	case	O	['N']	[6]
7	of	O	['N']	[7]
8	oral	B	['N']	[8]
9	mucosa	I	['N']	[9]
10	pigmentation	I-Adverse_Effect	['N']	[10]
11	after	O	['N']	[11]
12	OLP	O	['N']	[12]
13	treatment	O	['N']	[13]
14	with	O	['N']	[14]
15	topical	O	['N']	[15]
16	tacrolimus	B-Drug	['Causes']	[10]
17	.	O	['N']	[17]
#1036
0	Less	O	['N']	[0]
1	common	O	['N']	[1]
2	adverse	O	['N']	[2]
3	events	O	['N']	[3]
4	to	O	['N']	[4]
5	dapsone	B-Drug	['Causes']	[46]
6	include	O	['N']	[6]
7	the	O	['N']	[7]
8	idiosyncratic	O	['N']	[8]
9	reactions	O	['N']	[9]
10	of	O	['N']	[10]
11	leukopenia	O	['N']	[11]
12	and	O	['N']	[12]
13	agranulocytosis	O	['N']	[13]
14	,	O	['N']	[14]
15	cutaneous	O	['N']	[15]
16	eruptions	O	['N']	[16]
17	,	O	['N']	[17]
18	peripheral	O	['N']	[18]
19	neuropathy	O	['N']	[19]
20	,	O	['N']	[20]
21	psychosis	O	['N']	[21]
22	,	O	['N']	[22]
23	toxic	O	['N']	[23]
24	hepatitis	O	['N']	[24]
25	,	O	['N']	[25]
26	cholestatic	O	['N']	[26]
27	jaundice	O	['N']	[27]
28	,	O	['N']	[28]
29	nephrotic	O	['N']	[29]
30	syndrome	O	['N']	[30]
31	,	O	['N']	[31]
32	renal	O	['N']	[32]
33	papillary	O	['N']	[33]
34	necrosis	O	['N']	[34]
35	,	O	['N']	[35]
36	severe	O	['N']	[36]
37	hypoalbuminemia	O	['N']	[37]
38	without	O	['N']	[38]
39	proteinuria	O	['N']	[39]
40	,	O	['N']	[40]
41	an	B	['N']	[41]
42	infectious	I	['N']	[42]
43	mononucleosis	I	['N']	[43]
44	-	I	['N']	[44]
45	like	I	['N']	[45]
46	syndrome	I-Adverse_Effect	['N']	[46]
47	,	O	['N']	[47]
48	and	O	['N']	[48]
49	minor	O	['N']	[49]
50	neurological	O	['N']	[50]
51	and	O	['N']	[51]
52	gastrointestinal	O	['N']	[52]
53	complaints	O	['N']	[53]
54	.	O	['N']	[54]
#1037
0	We	O	['N']	[0]
1	describe	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	disseminated	O	['N']	[5]
6	muscular	O	['N']	[6]
7	cysticercosis	O	['N']	[7]
8	followed	O	['N']	[8]
9	by	O	['N']	[9]
10	myositis	O	['N']	[10]
11	(	O	['N']	[11]
12	fever	O	['N']	[12]
13	,	O	['N']	[13]
14	diffuse	O	['N']	[14]
15	myalgia	O	['N']	[15]
16	,	O	['N']	[16]
17	weakness	O	['N']	[17]
18	of	O	['N']	[18]
19	the	O	['N']	[19]
20	lower	O	['N']	[20]
21	limbs	O	['N']	[21]
22	,	O	['N']	[22]
23	and	O	['N']	[23]
24	inflammatory	B	['N']	[24]
25	reaction	I	['N']	[25]
26	around	I	['N']	[26]
27	dying	I	['N']	[27]
28	cysticerci	I-Adverse_Effect	['N']	[28]
29	)	O	['N']	[29]
30	induced	O	['N']	[30]
31	by	O	['N']	[31]
32	praziquantel	B-Drug	['Causes']	[28]
33	therapy	O	['N']	[33]
34	,	O	['N']	[34]
35	an	O	['N']	[35]
36	event	O	['N']	[36]
37	not	O	['N']	[37]
38	described	O	['N']	[38]
39	previously	O	['N']	[39]
40	.	O	['N']	[40]
#1038
0	A	O	['N']	[0]
1	52-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	Black	O	['N']	[4]
5	woman	O	['N']	[5]
6	on	O	['N']	[6]
7	phenytoin	B-Drug	['Causes']	[16]
8	therapy	O	['N']	[8]
9	for	O	['N']	[9]
10	post	O	['N']	[10]
11	-	O	['N']	[11]
12	traumatic	O	['N']	[12]
13	epilepsy	O	['N']	[13]
14	developed	O	['N']	[14]
15	transient	B	['N']	[15]
16	hemiparesis	I-Adverse_Effect	['N']	[16]
17	contralateral	O	['N']	[17]
18	to	O	['N']	[18]
19	the	O	['N']	[19]
20	injury	O	['N']	[20]
21	.	O	['N']	[21]
#1039
0	Early	O	['N']	[0]
1	peritoneal	O	['N']	[1]
2	dialysis	O	['N']	[2]
3	has	O	['N']	[3]
4	not	O	['N']	[4]
5	previously	O	['N']	[5]
6	been	O	['N']	[6]
7	reported	O	['N']	[7]
8	for	O	['N']	[8]
9	lisinopril	B-Drug	['Causes']	[12]
10	induced	O	['N']	[10]
11	multiorgan	B	['N']	[11]
12	failure	I-Adverse_Effect	['N']	[12]
13	.	O	['N']	[13]
#1040
0	The	O	['N']	[0]
1	authors	O	['N']	[1]
2	present	O	['N']	[2]
3	an	O	['N']	[3]
4	elderly	O	['N']	[4]
5	patient	O	['N']	[5]
6	with	O	['N']	[6]
7	mixed	O	['N']	[7]
8	dementia	O	['N']	[8]
9	who	O	['N']	[9]
10	developed	O	['N']	[10]
11	TD	B-Adverse_Effect	['N']	[11]
12	at	O	['N']	[12]
13	multiple	O	['N']	[13]
14	sites	O	['N']	[14]
15	,	O	['N']	[15]
16	(	O	['N']	[16]
17	including	O	['N']	[17]
18	respiratory	O	['N']	[18]
19	dyskinesia	O	['N']	[19]
20	[	O	['N']	[20]
21	RD	O	['N']	[21]
22	]	O	['N']	[22]
23	,	O	['N']	[23]
24	limb	O	['N']	[24]
25	dyskinesia	O	['N']	[25]
26	,	O	['N']	[26]
27	and	O	['N']	[27]
28	orofacial	O	['N']	[28]
29	dyskinesia	O	['N']	[29]
30	)	O	['N']	[30]
31	following	O	['N']	[31]
32	abrupt	O	['N']	[32]
33	withdrawal	O	['N']	[33]
34	of	O	['N']	[34]
35	risperidone	B-Drug	['Causes']	[11]
36	therapy	O	['N']	[36]
37	.	O	['N']	[37]
#1041
0	We	O	['N']	[0]
1	describe	O	['N']	[1]
2	two	O	['N']	[2]
3	dark	O	['N']	[3]
4	-	O	['N']	[4]
5	skinned	O	['N']	[5]
6	patients	O	['N']	[6]
7	who	O	['N']	[7]
8	developed	O	['N']	[8]
9	hyperpigmented	B	['N']	[9]
10	skin	I-Adverse_Effect	['N']	[10]
11	and	O	['N']	[11]
12	tongue	O	['N']	[12]
13	lesions	O	['N']	[13]
14	during	O	['N']	[14]
15	combination	O	['N']	[15]
16	therapy	O	['N']	[16]
17	with	O	['N']	[17]
18	IFN	B-Drug	['Causes']	[10]
19	and	O	['N']	[19]
20	ribavirin	O	['N']	[20]
21	.	O	['N']	[21]
#1042
0	Cytarabine	B-Drug	['Causes']	[4]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	cerebellar	B	['N']	[3]
4	syndrome	I-Adverse_Effect	['N']	[4]
5	:	O	['N']	[5]
6	case	O	['N']	[6]
7	report	O	['N']	[7]
8	and	O	['N']	[8]
9	literature	O	['N']	[9]
10	review	O	['N']	[10]
11	.	O	['N']	[11]
#1043
0	Pheripheral	O	['N']	[0]
1	edema	O	['N']	[1]
2	was	O	['N']	[2]
3	observed	O	['N']	[3]
4	in	O	['N']	[4]
5	five	O	['N']	[5]
6	female	O	['N']	[6]
7	patients	O	['N']	[7]
8	after	O	['N']	[8]
9	taking	O	['N']	[9]
10	proton	O	['N']	[10]
11	pump	O	['N']	[11]
12	inhibitors	O	['N']	[12]
13	omeprazole	B-Drug	['Dosage']	[30]
14	,	O	['N']	[14]
15	lansoprazole	O	['N']	[15]
16	,	O	['N']	[16]
17	or	O	['N']	[17]
18	pantoprazole	O	['N']	[18]
19	for	O	['N']	[19]
20	7	O	['N']	[20]
21	-	O	['N']	[21]
22	15	O	['N']	[22]
23	days	O	['N']	[23]
24	for	O	['N']	[24]
25	peptic	O	['N']	[25]
26	acid	O	['N']	[26]
27	diseases	O	['N']	[27]
28	in	O	['N']	[28]
29	recommended	O	['N']	[29]
30	standard	B-Dose	['N']	[30]
31	doses	O	['N']	[31]
32	.	O	['N']	[32]
#1044
0	When	O	['N']	[0]
1	the	O	['N']	[1]
2	disease	O	['N']	[2]
3	recurred	O	['N']	[3]
4	conventional	O	['N']	[4]
5	amphotericin	B	['N']	[5]
6	B	I-Drug	['Causes']	[20]
7	was	O	['N']	[7]
8	used	O	['N']	[8]
9	again	O	['N']	[9]
10	,	O	['N']	[10]
11	but	O	['N']	[11]
12	had	O	['N']	[12]
13	to	O	['N']	[13]
14	be	O	['N']	[14]
15	stopped	O	['N']	[15]
16	because	O	['N']	[16]
17	of	O	['N']	[17]
18	severe	B	['N']	[18]
19	side	I	['N']	[19]
20	effects	I-Adverse_Effect	['N']	[20]
21	.	O	['N']	[21]
#1045
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	acute	O	['N']	[5]
6	hyperphosphatemia	B-Adverse_Effect	['N']	[6]
7	secondary	O	['N']	[7]
8	to	O	['N']	[8]
9	rectal	O	['N']	[9]
10	administration	O	['N']	[10]
11	of	O	['N']	[11]
12	sodium	B	['N']	[12]
13	phosphate	I-Drug	['Causes']	[6]
14	and	O	['N']	[14]
15	sodium	O	['N']	[15]
16	biphosphate	O	['N']	[16]
17	(	O	['N']	[17]
18	Fleet	O	['N']	[18]
19	enema	O	['N']	[19]
20	)	O	['N']	[20]
21	.	O	['N']	[21]
#1046
0	Two	O	['N']	[0]
1	patients	O	['N']	[1]
2	are	O	['N']	[2]
3	described	O	['N']	[3]
4	who	O	['N']	[4]
5	developed	O	['N']	[5]
6	sensory	O	['N']	[6]
7	neuropathy	O	['N']	[7]
8	after	O	['N']	[8]
9	the	O	['N']	[9]
10	ingestion	O	['N']	[10]
11	of	O	['N']	[11]
12	30.6	B-Dose	['N']	[12]
13	and	O	['N']	[13]
14	114	O	['N']	[14]
15	g	O	['N']	[15]
16	metronidazole	B-Drug	['Dosage']	[12]
17	respectively	O	['N']	[17]
18	.	O	['N']	[18]
#1047
0	Systemic	B	['N']	[0]
1	vasculitis	I-Adverse_Effect	['N']	[1]
2	complicating	O	['N']	[2]
3	hairy	O	['N']	[3]
4	cell	O	['N']	[4]
5	leukaemia	O	['N']	[5]
6	treatment	O	['N']	[6]
7	with	O	['N']	[7]
8	cladribine	B-Drug	['Causes']	[1]
9	.	O	['N']	[9]
#1048
0	This	O	['N']	[0]
1	case	O	['N']	[1]
2	study	O	['N']	[2]
3	describes	O	['N']	[3]
4	an	O	['N']	[4]
5	atypical	O	['N']	[5]
6	case	O	['N']	[6]
7	of	O	['N']	[7]
8	refractory	O	['N']	[8]
9	,	O	['N']	[9]
10	sodium	B	['N']	[10]
11	warfarin	I-Drug	['Causes']	[15]
12	-	O	['N']	[12]
13	induced	O	['N']	[13]
14	necrotizing	B	['N']	[14]
15	fasciitis	I-Adverse_Effect	['N']	[15]
16	and	O	['N']	[16]
17	myonecrosis	O	['N']	[17]
18	.	O	['N']	[18]
#1049
0	Our	O	['N']	[0]
1	findings	O	['N']	[1]
2	suggest	O	['N']	[2]
3	that	O	['N']	[3]
4	hyperkalemia	B-Adverse_Effect	['N']	[4]
5	can	O	['N']	[5]
6	develop	O	['N']	[6]
7	with	O	['N']	[7]
8	the	O	['N']	[8]
9	use	O	['N']	[9]
10	of	O	['N']	[10]
11	low	O	['N']	[11]
12	-	O	['N']	[12]
13	dose	O	['N']	[13]
14	heparin	B-Drug	['Causes']	[4]
15	,	O	['N']	[15]
16	within	O	['N']	[16]
17	seven	O	['N']	[17]
18	days	O	['N']	[18]
19	of	O	['N']	[19]
20	initiating	O	['N']	[20]
21	heparin	O	['N']	[21]
22	therapy	O	['N']	[22]
23	,	O	['N']	[23]
24	and	O	['N']	[24]
25	that	O	['N']	[25]
26	patients	O	['N']	[26]
27	with	O	['N']	[27]
28	diabetes	O	['N']	[28]
29	mellitus	O	['N']	[29]
30	or	O	['N']	[30]
31	chronic	O	['N']	[31]
32	renal	O	['N']	[32]
33	insufficiency	O	['N']	[33]
34	are	O	['N']	[34]
35	especially	O	['N']	[35]
36	predisposed	O	['N']	[36]
37	to	O	['N']	[37]
38	this	O	['N']	[38]
39	complication	O	['N']	[39]
40	.	O	['N']	[40]
#1050
0	The	O	['N']	[0]
1	administration	O	['N']	[1]
2	of	O	['N']	[2]
3	"	O	['N']	[3]
4	sweet	B	['N']	[4]
5	spirits	I	['N']	[5]
6	of	I	['N']	[6]
7	nitre	I-Drug	['Causes']	[51]
8	"	O	['N']	[8]
9	(	O	['N']	[9]
10	4	O	['N']	[10]
11	%	O	['N']	[11]
12	ethyl	O	['N']	[12]
13	nitrite	O	['N']	[13]
14	CH3CH2ONO	O	['N']	[14]
15	in	O	['N']	[15]
16	70	O	['N']	[16]
17	%	O	['N']	[17]
18	ethyl	O	['N']	[18]
19	alcohol	O	['N']	[19]
20	)	O	['N']	[20]
21	was	O	['N']	[21]
22	followed	O	['N']	[22]
23	by	O	['N']	[23]
24	acute	O	['N']	[24]
25	methemoglobinemia	O	['N']	[25]
26	and	O	['N']	[26]
27	severe	O	['N']	[27]
28	anoxic	O	['N']	[28]
29	metabolic	O	['N']	[29]
30	acidosis	O	['N']	[30]
31	in	O	['N']	[31]
32	infant	O	['N']	[32]
33	twins	O	['N']	[33]
34	,	O	['N']	[34]
35	Methylene	O	['N']	[35]
36	blue	O	['N']	[36]
37	administration	O	['N']	[37]
38	reversed	O	['N']	[38]
39	methemoglobinemia	O	['N']	[39]
40	in	O	['N']	[40]
41	both	O	['N']	[41]
42	,	O	['N']	[42]
43	but	O	['N']	[43]
44	one	O	['N']	[44]
45	twin	O	['N']	[45]
46	died	O	['N']	[46]
47	from	O	['N']	[47]
48	the	O	['N']	[48]
49	consequences	O	['N']	[49]
50	of	O	['N']	[50]
51	hypoxemia	B-Adverse_Effect	['N']	[51]
52	.	O	['N']	[52]
#1051
0	A	O	['N']	[0]
1	young	O	['N']	[1]
2	diamond	O	['N']	[2]
3	dealer	O	['N']	[3]
4	developed	O	['N']	[4]
5	visual	O	['N']	[5]
6	impairment	O	['N']	[6]
7	attributed	O	['N']	[7]
8	to	O	['N']	[8]
9	bilateral	B	['N']	[9]
10	posterior	I	['N']	[10]
11	subcapsular	I	['N']	[11]
12	cataracts	I-Adverse_Effect	['N']	[12]
13	following	O	['N']	[13]
14	only	O	['N']	[14]
15	four	O	['N']	[15]
16	courses	O	['N']	[16]
17	of	O	['N']	[17]
18	intermittent	O	['N']	[18]
19	Decadron	B-Drug	['Causes']	[12]
20	used	O	['N']	[20]
21	as	O	['N']	[21]
22	part	O	['N']	[22]
23	of	O	['N']	[23]
24	a	O	['N']	[24]
25	five	O	['N']	[25]
26	-	O	['N']	[26]
27	drug	O	['N']	[27]
28	antiemetic	O	['N']	[28]
29	regimen	O	['N']	[29]
30	for	O	['N']	[30]
31	cisplatin	O	['N']	[31]
32	-	O	['N']	[32]
33	associated	O	['N']	[33]
34	nausea	O	['N']	[34]
35	.	O	['N']	[35]
#1052
0	Painful	O	['N']	[0]
1	neutrophilic	B	['N']	[1]
2	skin	I	['N']	[2]
3	lesions	I-Adverse_Effect	['N']	[3]
4	were	O	['N']	[4]
5	observed	O	['N']	[5]
6	in	O	['N']	[6]
7	two	O	['N']	[7]
8	children	O	['N']	[8]
9	receiving	O	['N']	[9]
10	granulocyte	B	['N']	[10]
11	colony	I	['N']	[11]
12	-	I	['N']	[12]
13	stimulating	I	['N']	[13]
14	factor	I-Drug	['Causes']	[3]
15	(	O	['N']	[15]
16	G	O	['N']	[16]
17	-	O	['N']	[17]
18	CSF	O	['N']	[18]
19	)	O	['N']	[19]
20	for	O	['N']	[20]
21	treatment	O	['N']	[21]
22	of	O	['N']	[22]
23	idiopathic	O	['N']	[23]
24	neutropenia	O	['N']	[24]
25	.	O	['N']	[25]
#1053
0	Bone	O	['N']	[0]
1	marrow	O	['N']	[1]
2	aplasia	O	['N']	[2]
3	and	O	['N']	[3]
4	severe	B	['N']	[4]
5	skin	I	['N']	[5]
6	rash	I-Adverse_Effect	['N']	[6]
7	after	O	['N']	[7]
8	a	O	['N']	[8]
9	single	O	['N']	[9]
10	low	O	['N']	[10]
11	dose	O	['N']	[11]
12	of	O	['N']	[12]
13	methotrexate	B-Drug	['Causes']	[6]
14	.	O	['N']	[14]
#1054
0	Prazosin	B-Drug	['Causes']	[11]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	first	O	['N']	[3]
4	-	O	['N']	[4]
5	dose	O	['N']	[5]
6	phenomenon	O	['N']	[6]
7	possibly	O	['N']	[7]
8	associated	O	['N']	[8]
9	with	O	['N']	[9]
10	hemorrhagic	B	['N']	[10]
11	stroke	I-Adverse_Effect	['N']	[11]
12	:	O	['N']	[12]
13	a	O	['N']	[13]
14	report	O	['N']	[14]
15	of	O	['N']	[15]
16	three	O	['N']	[16]
17	cases	O	['N']	[17]
18	.	O	['N']	[18]
#1055
0	The	O	['N']	[0]
1	Center	O	['N']	[1]
2	for	O	['N']	[2]
3	Disease	O	['N']	[3]
4	Control	O	['N']	[4]
5	has	O	['N']	[5]
6	received	O	['N']	[6]
7	numerous	O	['N']	[7]
8	reports	O	['N']	[8]
9	of	O	['N']	[9]
10	an	O	['N']	[10]
11	eosinophilia	B	['N']	[11]
12	-	I	['N']	[12]
13	myalgia	I	['N']	[13]
14	syndrome	I-Adverse_Effect	['N']	[14]
15	related	O	['N']	[15]
16	to	O	['N']	[16]
17	products	O	['N']	[17]
18	containing	O	['N']	[18]
19	L	B	['N']	[19]
20	-	I	['N']	[20]
21	tryptophan	I-Drug	['Causes']	[14]
22	.	O	['N']	[22]
#1056
0	Overdose	B-Dose	['N']	[0]
1	of	O	['N']	[1]
2	magnesium	B-Drug	['Dosage']	[0]
3	sulfate	O	['N']	[3]
4	in	O	['N']	[4]
5	combination	O	['N']	[5]
6	with	O	['N']	[6]
7	renal	O	['N']	[7]
8	insufficiency	O	['N']	[8]
9	,	O	['N']	[9]
10	hypocalcemia	O	['N']	[10]
11	,	O	['N']	[11]
12	or	O	['N']	[12]
13	compromise	O	['N']	[13]
14	of	O	['N']	[14]
15	intestinal	O	['N']	[15]
16	integrity	O	['N']	[16]
17	may	O	['N']	[17]
18	predispose	O	['N']	[18]
19	horses	O	['N']	[19]
20	to	O	['N']	[20]
21	magnesium	O	['N']	[21]
22	toxicosis	O	['N']	[22]
23	.	O	['N']	[23]
#1057
0	A	O	['N']	[0]
1	small	O	['N']	[1]
2	initial	O	['N']	[2]
3	dose	O	['N']	[3]
4	of	O	['N']	[4]
5	prazosin	B-Drug	['Dosage']	[11]
6	ranging	O	['N']	[6]
7	from	O	['N']	[7]
8	0.5	B	['N']	[8]
9	to	I	['N']	[9]
10	1	I	['N']	[10]
11	mg	I-Dose	['N']	[11]
12	has	O	['N']	[12]
13	been	O	['N']	[13]
14	recommended	O	['N']	[14]
15	to	O	['N']	[15]
16	avoid	O	['N']	[16]
17	the	O	['N']	[17]
18	first	O	['N']	[18]
19	-	O	['N']	[19]
20	dose	O	['N']	[20]
21	phenomenon	O	['N']	[21]
22	characterized	O	['N']	[22]
23	by	O	['N']	[23]
24	a	O	['N']	[24]
25	sudden	O	['N']	[25]
26	and	O	['N']	[26]
27	severe	O	['N']	[27]
28	drop	O	['N']	[28]
29	in	O	['N']	[29]
30	blood	O	['N']	[30]
31	pressure	O	['N']	[31]
32	after	O	['N']	[32]
33	the	O	['N']	[33]
34	administration	O	['N']	[34]
35	of	O	['N']	[35]
36	the	O	['N']	[36]
37	first	O	['N']	[37]
38	dose	O	['N']	[38]
39	of	O	['N']	[39]
40	prazosin	O	['N']	[40]
41	.	O	['N']	[41]
#1058
0	This	O	['N']	[0]
1	selective	O	['N']	[1]
2	closure	O	['N']	[2]
3	of	O	['N']	[3]
4	the	O	['N']	[4]
5	ductus	O	['N']	[5]
6	arteriosus	O	['N']	[6]
7	suggests	O	['N']	[7]
8	that	O	['N']	[8]
9	the	O	['N']	[9]
10	affected	O	['N']	[10]
11	twin	O	['N']	[11]
12	was	O	['N']	[12]
13	predisposed	O	['N']	[13]
14	to	O	['N']	[14]
15	hypoxia	B-Adverse_Effect	['N']	[15]
16	and	O	['N']	[16]
17	thus	O	['N']	[17]
18	was	O	['N']	[18]
19	more	O	['N']	[19]
20	susceptible	O	['N']	[20]
21	to	O	['N']	[21]
22	ductal	O	['N']	[22]
23	closure	O	['N']	[23]
24	in	O	['N']	[24]
25	response	O	['N']	[25]
26	to	O	['N']	[26]
27	indomethacin	B-Drug	['Causes']	[15]
28	exposure	O	['N']	[28]
29	.	O	['N']	[29]
#1059
0	The	O	['N']	[0]
1	responsibility	O	['N']	[1]
2	of	O	['N']	[2]
3	CCNU	B-Drug	['Causes']	[9]
4	in	O	['N']	[4]
5	the	O	['N']	[5]
6	pathogenesis	O	['N']	[6]
7	of	O	['N']	[7]
8	pulmonary	B	['N']	[8]
9	fibrosis	I-Adverse_Effect	['N']	[9]
10	seems	O	['N']	[10]
11	very	O	['N']	[11]
12	likely	O	['N']	[12]
13	.	O	['N']	[13]
#1060
0	The	O	['N']	[0]
1	allopurinol	B-Drug	['Causes']	[3]
2	hypersensitivity	B	['N']	[2]
3	syndrome	I-Adverse_Effect	['N']	[3]
4	is	O	['N']	[4]
5	a	O	['N']	[5]
6	rare	O	['N']	[6]
7	adverse	O	['N']	[7]
8	drug	O	['N']	[8]
9	reaction	O	['N']	[9]
10	.	O	['N']	[10]
#1061
0	Acyclovir	B-Drug	['Causes']	[3]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	neurotoxicity	B-Adverse_Effect	['N']	[3]
4	:	O	['N']	[4]
5	concentration	O	['N']	[5]
6	-	O	['N']	[6]
7	side	O	['N']	[7]
8	effect	O	['N']	[8]
9	relationship	O	['N']	[9]
10	in	O	['N']	[10]
11	acyclovir	O	['N']	[11]
12	overdose	O	['N']	[12]
13	.	O	['N']	[13]
#1062
0	Cimetidine	B-Drug	['Causes']	[3]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	fever	B-Adverse_Effect	['N']	[3]
4	.	O	['N']	[4]
#1063
0	A	O	['N']	[0]
1	56-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	woman	O	['N']	[4]
5	with	O	['N']	[5]
6	scleroderma	O	['N']	[6]
7	developed	O	['N']	[7]
8	rapidly	O	['N']	[8]
9	progressive	O	['N']	[9]
10	glomerulonephritis	O	['N']	[10]
11	with	O	['N']	[11]
12	epithelial	O	['N']	[12]
13	crescents	O	['N']	[13]
14	associated	O	['N']	[14]
15	with	O	['N']	[15]
16	hemoptysis	B-Adverse_Effect	['N']	[16]
17	after	O	['N']	[17]
18	27	O	['N']	[18]
19	months	O	['N']	[19]
20	of	O	['N']	[20]
21	D	B	['N']	[21]
22	-	I	['N']	[22]
23	penicillamine	I-Drug	['Causes']	[16]
24	therapy	O	['N']	[24]
25	and	O	['N']	[25]
26	a	O	['N']	[26]
27	cumulative	O	['N']	[27]
28	dose	O	['N']	[28]
29	of	O	['N']	[29]
30	1,200	O	['N']	[30]
31	g.	O	['N']	[31]
#1064
0	Discontinuation	O	['N']	[0]
1	of	O	['N']	[1]
2	simvastatin	B-Drug	['Causes']	[9]
3	and	O	['N']	[3]
4	cyclosporine	O	['N']	[4]
5	resulted	O	['N']	[5]
6	in	O	['N']	[6]
7	resolution	O	['N']	[7]
8	of	O	['N']	[8]
9	rhabdomyolysis	B-Adverse_Effect	['N']	[9]
10	and	O	['N']	[10]
11	normalization	O	['N']	[11]
12	of	O	['N']	[12]
13	renal	O	['N']	[13]
14	function	O	['N']	[14]
15	.	O	['N']	[15]
#1065
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	the	O	['N']	[2]
3	first	O	['N']	[3]
4	case	O	['N']	[4]
5	of	O	['N']	[5]
6	polymorphic	B	['N']	[6]
7	ventricular	I	['N']	[7]
8	tachycardia	I-Adverse_Effect	['N']	[8]
9	with	O	['N']	[9]
10	normal	O	['N']	[10]
11	QT	O	['N']	[11]
12	interval	O	['N']	[12]
13	associated	O	['N']	[13]
14	with	O	['N']	[14]
15	the	O	['N']	[15]
16	oral	O	['N']	[16]
17	use	O	['N']	[17]
18	of	O	['N']	[18]
19	levofloxacin	B-Drug	['Causes']	[8]
20	in	O	['N']	[20]
21	the	O	['N']	[21]
22	absence	O	['N']	[22]
23	of	O	['N']	[23]
24	other	O	['N']	[24]
25	etiologies	O	['N']	[25]
26	known	O	['N']	[26]
27	to	O	['N']	[27]
28	cause	O	['N']	[28]
29	these	O	['N']	[29]
30	arrhythmias	O	['N']	[30]
31	.	O	['N']	[31]
#1066
0	He	O	['N']	[0]
1	was	O	['N']	[1]
2	started	O	['N']	[2]
3	on	O	['N']	[3]
4	digoxin	B-Drug	['Causes']	[16]
5	,	O	['N']	[5]
6	0.25	O	['N']	[6]
7	mg	O	['N']	[7]
8	daily	O	['N']	[8]
9	,	O	['N']	[9]
10	because	O	['N']	[10]
11	of	O	['N']	[11]
12	echocardiographically	O	['N']	[12]
13	demonstrated	O	['N']	[13]
14	left	B	['N']	[14]
15	ventricular	I	['N']	[15]
16	dilatation	I-Adverse_Effect	['N']	[16]
17	and	O	['N']	[17]
18	functional	O	['N']	[18]
19	impairment	O	['N']	[19]
20	;	O	['N']	[20]
21	he	O	['N']	[21]
22	died	O	['N']	[22]
23	of	O	['N']	[23]
24	ventricular	O	['N']	[24]
25	fibrillation	O	['N']	[25]
26	15	O	['N']	[26]
27	days	O	['N']	[27]
28	later	O	['N']	[28]
29	.	O	['N']	[29]
#1067
0	Administration	O	['N']	[0]
1	of	O	['N']	[1]
2	cisplatin	O	['N']	[2]
3	in	O	['N']	[3]
4	three	O	['N']	[4]
5	patients	O	['N']	[5]
6	with	O	['N']	[6]
7	carboplatin	B-Drug	['Causes']	[8]
8	hypersensitivity	B-Adverse_Effect	['N']	[8]
9	:	O	['N']	[9]
10	is	O	['N']	[10]
11	skin	O	['N']	[11]
12	testing	O	['N']	[12]
13	useful	O	['N']	[13]
14	?	O	['N']	[14]
#1068
0	OBJECTIVE	O	['N']	[0]
1	:	O	['N']	[1]
2	1	O	['N']	[2]
3	)	O	['N']	[3]
4	To	O	['N']	[4]
5	describe	O	['N']	[5]
6	a	O	['N']	[6]
7	patient	O	['N']	[7]
8	with	O	['N']	[8]
9	rheumatoid	O	['N']	[9]
10	arthritis	O	['N']	[10]
11	receiving	O	['N']	[11]
12	adalimumab	B-Drug	['Causes']	[23]
13	who	O	['N']	[13]
14	developed	O	['N']	[14]
15	fever	O	['N']	[15]
16	,	O	['N']	[16]
17	pancytopenia	O	['N']	[17]
18	,	O	['N']	[18]
19	splenomegaly	O	['N']	[19]
20	,	O	['N']	[20]
21	and	O	['N']	[21]
22	extreme	B	['N']	[22]
23	hyperferritinemia	I-Adverse_Effect	['N']	[23]
24	.	O	['N']	[24]
#1069
0	Hepatocellular	B	['N']	[0]
1	damage	I-Adverse_Effect	['N']	[1]
2	following	O	['N']	[2]
3	therapeutic	O	['N']	[3]
4	intravenous	O	['N']	[4]
5	iron	B	['N']	[5]
6	sucrose	I-Drug	['Causes']	[1]
7	infusion	O	['N']	[7]
8	in	O	['N']	[8]
9	a	O	['N']	[9]
10	child	O	['N']	[10]
11	.	O	['N']	[11]
#1070
0	The	O	['N']	[0]
1	addition	O	['N']	[1]
2	of	O	['N']	[2]
3	intrathecal	O	['N']	[3]
4	methotrexate	B-Drug	['Causes']	[26]
5	to	O	['N']	[5]
6	treatment	O	['N']	[6]
7	protocols	O	['N']	[7]
8	has	O	['N']	[8]
9	increased	O	['N']	[9]
10	survival	O	['N']	[10]
11	rates	O	['N']	[11]
12	in	O	['N']	[12]
13	children	O	['N']	[13]
14	with	O	['N']	[14]
15	acute	O	['N']	[15]
16	lymphoblastic	O	['N']	[16]
17	leukemia	O	['N']	[17]
18	but	O	['N']	[18]
19	is	O	['N']	[19]
20	also	O	['N']	[20]
21	associated	O	['N']	[21]
22	with	O	['N']	[22]
23	varying	O	['N']	[23]
24	degrees	O	['N']	[24]
25	of	O	['N']	[25]
26	neurotoxicity	B-Adverse_Effect	['N']	[26]
27	.	O	['N']	[27]
#1071
0	We	O	['N']	[0]
1	describe	O	['N']	[1]
2	2	O	['N']	[2]
3	patients	O	['N']	[3]
4	with	O	['N']	[4]
5	cutaneous	O	['N']	[5]
6	lupus	O	['N']	[6]
7	erythematosus	O	['N']	[7]
8	who	O	['N']	[8]
9	developed	O	['N']	[9]
10	severe	O	['N']	[10]
11	dapsone	B-Drug	['Dosage']	[14]
12	reaction	O	['N']	[12]
13	after	O	['N']	[13]
14	low	B-Dose	['N']	[14]
15	dose	O	['N']	[15]
16	therapy	O	['N']	[16]
17	,	O	['N']	[17]
18	with	O	['N']	[18]
19	a	O	['N']	[19]
20	fatal	O	['N']	[20]
21	outcome	O	['N']	[21]
22	in	O	['N']	[22]
23	one	O	['N']	[23]
24	.	O	['N']	[24]
#1072
0	A	O	['N']	[0]
1	57-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	man	O	['N']	[4]
5	developed	O	['N']	[5]
6	chronic	B	['N']	[6]
7	,	I	['N']	[7]
8	watery	I	['N']	[8]
9	diarrhea	I-Adverse_Effect	['N']	[9]
10	four	O	['N']	[10]
11	weeks	O	['N']	[11]
12	after	O	['N']	[12]
13	Helicobacter	O	['N']	[13]
14	pylori	O	['N']	[14]
15	eradication	O	['N']	[15]
16	therapy	O	['N']	[16]
17	including	O	['N']	[17]
18	lansoprazole	B-Drug	['Causes']	[9]
19	followed	O	['N']	[19]
20	by	O	['N']	[20]
21	lansoprazole	O	['N']	[21]
22	monotherapy	O	['N']	[22]
23	for	O	['N']	[23]
24	gastroesophageal	O	['N']	[24]
25	reflux	O	['N']	[25]
26	disease	O	['N']	[26]
27	.	O	['N']	[27]
#1073
0	The	O	['N']	[0]
1	goal	O	['N']	[1]
2	of	O	['N']	[2]
3	this	O	['N']	[3]
4	study	O	['N']	[4]
5	is	O	['N']	[5]
6	to	O	['N']	[6]
7	describe	O	['N']	[7]
8	three	O	['N']	[8]
9	patients	O	['N']	[9]
10	diagnosed	O	['N']	[10]
11	with	O	['N']	[11]
12	migraine	O	['N']	[12]
13	and	O	['N']	[13]
14	epilepsy	O	['N']	[14]
15	(	O	['N']	[15]
16	both	O	['N']	[16]
17	under	O	['N']	[17]
18	control	O	['N']	[18]
19	)	O	['N']	[19]
20	who	O	['N']	[20]
21	evolved	O	['N']	[21]
22	into	O	['N']	[22]
23	status	B	['N']	[23]
24	migrainosus	I-Adverse_Effect	['N']	[24]
25	after	O	['N']	[25]
26	the	O	['N']	[26]
27	introduction	O	['N']	[27]
28	of	O	['N']	[28]
29	oxcarbazepine	O	['N']	[29]
30	(	O	['N']	[30]
31	OXC	O	['N']	[31]
32	)	O	['N']	[32]
33	,	O	['N']	[33]
34	as	O	['N']	[34]
35	part	O	['N']	[35]
36	of	O	['N']	[36]
37	a	O	['N']	[37]
38	switch	O	['N']	[38]
39	off	O	['N']	[39]
40	from	O	['N']	[40]
41	carbamazepine	B-Drug	['Causes']	[24]
42	(	O	['N']	[42]
43	CBZ	O	['N']	[43]
44	)	O	['N']	[44]
45	.	O	['N']	[45]
#1074
0	Spinal	B	['N']	[0]
1	cord	I	['N']	[1]
2	infarction	I-Adverse_Effect	['N']	[2]
3	during	O	['N']	[3]
4	use	O	['N']	[4]
5	of	O	['N']	[5]
6	zolmitriptan	B-Drug	['Causes']	[2]
7	:	O	['N']	[7]
8	a	O	['N']	[8]
9	case	O	['N']	[9]
10	report	O	['N']	[10]
11	.	O	['N']	[11]
#1075
0	We	O	['N']	[0]
1	believe	O	['N']	[1]
2	that	O	['N']	[2]
3	the	O	['N']	[3]
4	acute	B	['N']	[4]
5	renal	I	['N']	[5]
6	failure	I-Adverse_Effect	['N']	[6]
7	in	O	['N']	[7]
8	our	O	['N']	[8]
9	patient	O	['N']	[9]
10	was	O	['N']	[10]
11	associated	O	['N']	[11]
12	with	O	['N']	[12]
13	anastrozole	B-Drug	['Causes']	[6]
14	.	O	['N']	[14]
#1076
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	the	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	a	O	['N']	[5]
6	43-year	O	['N']	[6]
7	-	O	['N']	[7]
8	old	O	['N']	[8]
9	man	O	['N']	[9]
10	with	O	['N']	[10]
11	ITP	O	['N']	[11]
12	refractory	O	['N']	[12]
13	to	O	['N']	[13]
14	steroids	O	['N']	[14]
15	and	O	['N']	[15]
16	intravenous	O	['N']	[16]
17	immunoglobulin	O	['N']	[17]
18	who	O	['N']	[18]
19	developed	O	['N']	[19]
20	acute	O	['N']	[20]
21	respiratory	O	['N']	[21]
22	distress	O	['N']	[22]
23	syndrome	O	['N']	[23]
24	(	O	['N']	[24]
25	ARDS	B-Adverse_Effect	['N']	[25]
26	)	O	['N']	[26]
27	after	O	['N']	[27]
28	a	O	['N']	[28]
29	single	O	['N']	[29]
30	infusion	O	['N']	[30]
31	of	O	['N']	[31]
32	rituximab	B-Drug	['Causes']	[25]
33	.	O	['N']	[33]
#1077
0	Thirty	O	['N']	[0]
1	-	O	['N']	[1]
2	six	O	['N']	[2]
3	patients	O	['N']	[3]
4	with	O	['N']	[4]
5	AL	O	['N']	[5]
6	received	O	['N']	[6]
7	,	O	['N']	[7]
8	in	O	['N']	[8]
9	a	O	['N']	[9]
10	three	O	['N']	[10]
11	-	O	['N']	[11]
12	month	O	['N']	[12]
13	period	O	['N']	[13]
14	,	O	['N']	[14]
15	51	O	['N']	[15]
16	cycles	O	['N']	[16]
17	of	O	['N']	[17]
18	combined	O	['N']	[18]
19	chemotherapy	O	['N']	[19]
20	which	O	['N']	[20]
21	included	O	['N']	[21]
22	,	O	['N']	[22]
23	in	O	['N']	[23]
24	all	O	['N']	[24]
25	of	O	['N']	[25]
26	them	O	['N']	[26]
27	,	O	['N']	[27]
28	cytosine	B	['N']	[28]
29	arabinoside	I-Drug	['Causes']	[55]
30	(	O	['N']	[30]
31	ARA	O	['N']	[31]
32	-	O	['N']	[32]
33	C	O	['N']	[33]
34	)	O	['N']	[34]
35	;	O	['N']	[35]
36	among	O	['N']	[36]
37	them	O	['N']	[37]
38	,	O	['N']	[38]
39	along	O	['N']	[39]
40	with	O	['N']	[40]
41	myelosuppression	O	['N']	[41]
42	,	O	['N']	[42]
43	five	O	['N']	[43]
44	experienced	O	['N']	[44]
45	fever	O	['N']	[45]
46	,	O	['N']	[46]
47	infectious	O	['N']	[47]
48	complications	O	['N']	[48]
49	,	O	['N']	[49]
50	gastrointestinal	O	['N']	[50]
51	tract	O	['N']	[51]
52	symptoms	O	['N']	[52]
53	and	O	['N']	[53]
54	severe	B	['N']	[54]
55	myalgias	I-Adverse_Effect	['N']	[55]
56	.	O	['N']	[56]
#1078
0	These	O	['N']	[0]
1	skin	B	['N']	[1]
2	lesions	I-Adverse_Effect	['N']	[2]
3	may	O	['N']	[3]
4	be	O	['N']	[4]
5	induced	O	['N']	[5]
6	or	O	['N']	[6]
7	worsened	O	['N']	[7]
8	during	O	['N']	[8]
9	antiviral	O	['N']	[9]
10	therapy	O	['N']	[10]
11	with	O	['N']	[11]
12	interferon	O	['N']	[12]
13	-	O	['N']	[13]
14	alpha	O	['N']	[14]
15	(	O	['N']	[15]
16	IFN	B-Drug	['Causes']	[2]
17	)	O	['N']	[17]
18	.	O	['N']	[18]
#1079
0	Severe	O	['N']	[0]
1	rhabdomyolysis	O	['N']	[1]
2	following	O	['N']	[2]
3	massive	O	['N']	[3]
4	ingestion	O	['N']	[4]
5	of	O	['N']	[5]
6	oolong	O	['N']	[6]
7	tea	O	['N']	[7]
8	:	O	['N']	[8]
9	caffeine	B-Drug	['Causes']	[10]
10	intoxication	I-Adverse_Effect	['N']	[10]
11	with	O	['N']	[11]
12	coexisting	O	['N']	[12]
13	hyponatremia	O	['N']	[13]
14	.	O	['N']	[14]
#1080
0	Fatal	B	['N']	[0]
1	lung	I	['N']	[1]
2	fibrosis	I-Adverse_Effect	['N']	[2]
3	caused	O	['N']	[3]
4	by	O	['N']	[4]
5	paclitaxel	B-Drug	['Causes']	[2]
6	toxicity	O	['N']	[6]
7	has	O	['N']	[7]
8	not	O	['N']	[8]
9	been	O	['N']	[9]
10	reported	O	['N']	[10]
11	In	O	['N']	[11]
12	this	O	['N']	[12]
13	report	O	['N']	[13]
14	,	O	['N']	[14]
15	we	O	['N']	[15]
16	describe	O	['N']	[16]
17	the	O	['N']	[17]
18	case	O	['N']	[18]
19	of	O	['N']	[19]
20	a	O	['N']	[20]
21	62-year	O	['N']	[21]
22	-	O	['N']	[22]
23	old	O	['N']	[23]
24	woman	O	['N']	[24]
25	who	O	['N']	[25]
26	received	O	['N']	[26]
27	six	O	['N']	[27]
28	cycles	O	['N']	[28]
29	of	O	['N']	[29]
30	paclitaxel	O	['N']	[30]
31	and	O	['N']	[31]
32	carboplatin	O	['N']	[32]
33	as	O	['N']	[33]
34	combination	O	['N']	[34]
35	chemotherapy	O	['N']	[35]
36	for	O	['N']	[36]
37	advanced	O	['N']	[37]
38	ovarian	O	['N']	[38]
39	cancer	O	['N']	[39]
40	.	O	['N']	[40]
#1081
0	It	O	['N']	[0]
1	is	O	['N']	[1]
2	hoped	O	['N']	[2]
3	that	O	['N']	[3]
4	this	O	['N']	[4]
5	case	O	['N']	[5]
6	report	O	['N']	[6]
7	creates	O	['N']	[7]
8	awareness	O	['N']	[8]
9	that	O	['N']	[9]
10	ofloxacin	B-Drug	['Causes']	[15]
11	-	O	['N']	[11]
12	induced	O	['N']	[12]
13	toxic	B	['N']	[13]
14	epidermal	I	['N']	[14]
15	necrolysis	I-Adverse_Effect	['N']	[15]
16	is	O	['N']	[16]
17	possible	O	['N']	[17]
18	.	O	['N']	[18]
#1082
0	A	O	['N']	[0]
1	patient	O	['N']	[1]
2	with	O	['N']	[2]
3	rheumatoid	O	['N']	[3]
4	arthritis	O	['N']	[4]
5	developed	O	['N']	[5]
6	an	O	['N']	[6]
7	acute	O	['N']	[7]
8	intrahepatic	O	['N']	[8]
9	cholestasis	O	['N']	[9]
10	after	O	['N']	[10]
11	100	B	['N']	[11]
12	mg	I-Dose	['N']	[12]
13	of	O	['N']	[13]
14	sodium	B	['N']	[14]
15	aurothiomalate	I-Drug	['Dosage']	[12]
16	.	O	['N']	[16]
#1083
0	METHODS	O	['N']	[0]
1	:	O	['N']	[1]
2	A	O	['N']	[2]
3	68-year	O	['N']	[3]
4	-	O	['N']	[4]
5	old	O	['N']	[5]
6	man	O	['N']	[6]
7	developed	O	['N']	[7]
8	intense	B	['N']	[8]
9	conjunctival	I	['N']	[9]
10	hyperemia	I-Adverse_Effect	['N']	[10]
11	and	O	['N']	[11]
12	cystoid	O	['N']	[12]
13	macula	O	['N']	[13]
14	edema	O	['N']	[14]
15	after	O	['N']	[15]
16	switching	O	['N']	[16]
17	from	O	['N']	[17]
18	latanoprost	B-Drug	['Causes']	[10]
19	to	O	['N']	[19]
20	bimatoprost	O	['N']	[20]
21	9	O	['N']	[21]
22	months	O	['N']	[22]
23	after	O	['N']	[23]
24	cataract	O	['N']	[24]
25	surgery	O	['N']	[25]
26	in	O	['N']	[26]
27	an	O	['N']	[27]
28	eye	O	['N']	[28]
29	at	O	['N']	[29]
30	low	O	['N']	[30]
31	-	O	['N']	[31]
32	risk	O	['N']	[32]
33	for	O	['N']	[33]
34	this	O	['N']	[34]
35	cystoid	O	['N']	[35]
36	macular	O	['N']	[36]
37	edema	O	['N']	[37]
38	.	O	['N']	[38]
#1084
0	CONCLUSIONS	O	['N']	[0]
1	:	O	['N']	[1]
2	Cicatrization	O	['N']	[2]
3	in	O	['N']	[3]
4	the	O	['N']	[4]
5	substantia	O	['N']	[5]
6	propria	O	['N']	[6]
7	of	O	['N']	[7]
8	the	O	['N']	[8]
9	conjunctiva	O	['N']	[9]
10	by	O	['N']	[10]
11	excessive	O	['N']	[11]
12	lymphocytic	O	['N']	[12]
13	infiltration	O	['N']	[13]
14	after	O	['N']	[14]
15	topically	O	['N']	[15]
16	administered	O	['N']	[16]
17	antiglaucoma	O	['N']	[17]
18	drugs	O	['N']	[18]
19	including	O	['N']	[19]
20	dipivefrin	B-Drug	['Causes']	[28]
21	is	O	['N']	[21]
22	a	O	['N']	[22]
23	possible	O	['N']	[23]
24	mechanism	O	['N']	[24]
25	of	O	['N']	[25]
26	action	O	['N']	[26]
27	for	O	['N']	[27]
28	entropion	B-Adverse_Effect	['N']	[28]
29	.	O	['N']	[29]
#1085
0	Case	O	['N']	[0]
1	report	O	['N']	[1]
2	:	O	['N']	[2]
3	acute	B	['N']	[3]
4	renal	I	['N']	[4]
5	failure	I-Adverse_Effect	['N']	[5]
6	after	O	['N']	[6]
7	administering	O	['N']	[7]
8	intravenous	O	['N']	[8]
9	immunoglobulin	B-Drug	['Causes']	[5]
10	.	O	['N']	[10]
#1086
0	Heparin	O	['N']	[0]
1	-	O	['N']	[1]
2	associated	O	['N']	[2]
3	thrombocytopenia	B-Adverse_Effect	['N']	[3]
4	and	O	['N']	[4]
5	thrombosis	O	['N']	[5]
6	is	O	['N']	[6]
7	a	O	['N']	[7]
8	severe	O	['N']	[8]
9	complication	O	['N']	[9]
10	of	O	['N']	[10]
11	systemic	O	['N']	[11]
12	heparin	B-Drug	['Causes']	[3]
13	therapy	O	['N']	[13]
14	.	O	['N']	[14]
#1087
0	CONCLUSIONS	O	['N']	[0]
1	:	O	['N']	[1]
2	We	O	['N']	[2]
3	conclude	O	['N']	[3]
4	that	O	['N']	[4]
5	a	O	['N']	[5]
6	high	O	['N']	[6]
7	dose	O	['N']	[7]
8	combined	O	['N']	[8]
9	with	O	['N']	[9]
10	a	O	['N']	[10]
11	short	O	['N']	[11]
12	infusion	O	['N']	[12]
13	time	O	['N']	[13]
14	increases	O	['N']	[14]
15	the	O	['N']	[15]
16	risk	O	['N']	[16]
17	of	O	['N']	[17]
18	anaphylactoid	B	['N']	[18]
19	reactions	I-Adverse_Effect	['N']	[19]
20	with	O	['N']	[20]
21	the	O	['N']	[21]
22	administration	O	['N']	[22]
23	of	O	['N']	[23]
24	intraperitoneal	O	['N']	[24]
25	cisplatin	B-Drug	['Causes']	[19]
26	.	O	['N']	[26]
#1088
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	the	O	['N']	[2]
3	first	O	['N']	[3]
4	case	O	['N']	[4]
5	of	O	['N']	[5]
6	doxycycline	B-Drug	['Causes']	[9]
7	-	O	['N']	[7]
8	induced	O	['N']	[8]
9	hypoglycemia	B-Adverse_Effect	['N']	[9]
10	in	O	['N']	[10]
11	a	O	['N']	[11]
12	young	O	['N']	[12]
13	nondiabetic	O	['N']	[13]
14	man	O	['N']	[14]
15	.	O	['N']	[15]
#1089
0	Prolonged	B	['N']	[0]
1	prostate	I	['N']	[1]
2	-	I	['N']	[2]
3	specific	I	['N']	[3]
4	antigen	I	['N']	[4]
5	response	I-Adverse_Effect	['N']	[5]
6	in	O	['N']	[6]
7	flutamide	B-Drug	['Causes']	[5]
8	withdrawal	O	['N']	[8]
9	syndrome	O	['N']	[9]
10	despite	O	['N']	[10]
11	disease	O	['N']	[11]
12	progression	O	['N']	[12]
13	.	O	['N']	[13]
#1090
0	Cisplatin	B-Drug	['Causes']	[7]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	syndrome	B	['N']	[3]
4	of	I	['N']	[4]
5	inappropriate	I	['N']	[5]
6	antidiuretic	I	['N']	[6]
7	hormone	I-Adverse_Effect	['N']	[7]
8	(	O	['N']	[8]
9	SIADH	O	['N']	[9]
10	)	O	['N']	[10]
11	in	O	['N']	[11]
12	a	O	['N']	[12]
13	patient	O	['N']	[13]
14	with	O	['N']	[14]
15	neuroendocrine	O	['N']	[15]
16	tumor	O	['N']	[16]
17	of	O	['N']	[17]
18	the	O	['N']	[18]
19	cervix	O	['N']	[19]
20	:	O	['N']	[20]
21	a	O	['N']	[21]
22	case	O	['N']	[22]
23	report	O	['N']	[23]
24	and	O	['N']	[24]
25	review	O	['N']	[25]
26	of	O	['N']	[26]
27	the	O	['N']	[27]
28	literature	O	['N']	[28]
29	.	O	['N']	[29]
#1091
0	Early	O	['N']	[0]
1	overanticoagulation	B-Adverse_Effect	['N']	[1]
2	with	O	['N']	[2]
3	acenocoumarol	B-Drug	['Causes']	[1]
4	due	O	['N']	[4]
5	to	O	['N']	[5]
6	a	O	['N']	[6]
7	genetic	O	['N']	[7]
8	polymorphism	O	['N']	[8]
9	of	O	['N']	[9]
10	cytochrome	O	['N']	[10]
11	P450	O	['N']	[11]
12	CYP2C9	O	['N']	[12]
13	.	O	['N']	[13]
#1092
0	In	O	['N']	[0]
1	one	O	['N']	[1]
2	instance	O	['N']	[2]
3	a	O	['N']	[3]
4	systemic	B	['N']	[4]
5	hypoglycemic	I	['N']	[5]
6	reaction	I-Adverse_Effect	['N']	[6]
7	resulting	O	['N']	[7]
8	in	O	['N']	[8]
9	head	O	['N']	[9]
10	trauma	O	['N']	[10]
11	and	O	['N']	[11]
12	confusion	O	['N']	[12]
13	ended	O	['N']	[13]
14	in	O	['N']	[14]
15	an	O	['N']	[15]
16	emegency	O	['N']	[16]
17	hospital	O	['N']	[17]
18	admission	O	['N']	[18]
19	following	O	['N']	[19]
20	the	O	['N']	[20]
21	substitution	O	['N']	[21]
22	of	O	['N']	[22]
23	acetohexamide	B-Drug	['Causes']	[6]
24	for	O	['N']	[24]
25	acetazolamide	O	['N']	[25]
26	.	O	['N']	[26]
#1093
0	The	O	['N']	[0]
1	cause	O	['N']	[1]
2	of	O	['N']	[2]
3	his	O	['N']	[3]
4	bleeding	O	['N']	[4]
5	was	O	['N']	[5]
6	a	O	['N']	[6]
7	severe	B	['N']	[7]
8	thrombocytopoaenia	I-Adverse_Effect	['N']	[8]
9	,	O	['N']	[9]
10	induced	O	['N']	[10]
11	by	O	['N']	[11]
12	chronic	O	['N']	[12]
13	ingestion	O	['N']	[13]
14	of	O	['N']	[14]
15	quinine	B-Drug	['Causes']	[8]
16	.	O	['N']	[16]
#1094
0	We	O	['N']	[0]
1	describe	O	['N']	[1]
2	the	O	['N']	[2]
3	development	O	['N']	[3]
4	of	O	['N']	[4]
5	cutaneous	B	['N']	[5]
6	scleroderma	I-Adverse_Effect	['N']	[6]
7	in	O	['N']	[7]
8	3	O	['N']	[8]
9	patients	O	['N']	[9]
10	coincident	O	['N']	[10]
11	with	O	['N']	[11]
12	the	O	['N']	[12]
13	use	O	['N']	[13]
14	of	O	['N']	[14]
15	bleomycin	B-Drug	['Causes']	[6]
16	in	O	['N']	[16]
17	low	O	['N']	[17]
18	cumulative	O	['N']	[18]
19	doses	O	['N']	[19]
20	of	O	['N']	[20]
21	less	O	['N']	[21]
22	than	O	['N']	[22]
23	100	O	['N']	[23]
24	U.	O	['N']	[24]
#1095
0	A	O	['N']	[0]
1	female	O	['N']	[1]
2	patient	O	['N']	[2]
3	with	O	['N']	[3]
4	HER2	O	['N']	[4]
5	positive	O	['N']	[5]
6	,	O	['N']	[6]
7	metastatic	O	['N']	[7]
8	breast	O	['N']	[8]
9	cancer	O	['N']	[9]
10	presented	O	['N']	[10]
11	with	O	['N']	[11]
12	pulmonary	B	['N']	[12]
13	infiltrates	I-Adverse_Effect	['N']	[13]
14	,	O	['N']	[14]
15	and	O	['N']	[15]
16	a	O	['N']	[16]
17	plural	O	['N']	[17]
18	effusion	O	['N']	[18]
19	dyspnoea	O	['N']	[19]
20	after	O	['N']	[20]
21	several	O	['N']	[21]
22	months	O	['N']	[22]
23	of	O	['N']	[23]
24	trastuzumab	B-Drug	['Causes']	[13]
25	treatment	O	['N']	[25]
26	.	O	['N']	[26]
#1096
0	This	O	['N']	[0]
1	case	O	['N']	[1]
2	report	O	['N']	[2]
3	describes	O	['N']	[3]
4	a	O	['N']	[4]
5	patient	O	['N']	[5]
6	who	O	['N']	[6]
7	was	O	['N']	[7]
8	previously	O	['N']	[8]
9	prescribed	O	['N']	[9]
10	alendronate	O	['N']	[10]
11	(	O	['N']	[11]
12	Fosamax	O	['N']	[12]
13	)	O	['N']	[13]
14	and	O	['N']	[14]
15	presented	O	['N']	[15]
16	with	O	['N']	[16]
17	postoperative	O	['N']	[17]
18	hypophosphatemia	O	['N']	[18]
19	and	O	['N']	[19]
20	hypocalcemic	B	['N']	[20]
21	tetany	I-Adverse_Effect	['N']	[21]
22	after	O	['N']	[22]
23	bowel	O	['N']	[23]
24	preparation	O	['N']	[24]
25	with	O	['N']	[25]
26	Fleet	B	['N']	[26]
27	Phospho	I	['N']	[27]
28	-	I	['N']	[28]
29	Soda	I-Drug	['Causes']	[21]
30	.	O	['N']	[30]
#1097
0	Tacrolimus	B-Drug	['Causes']	[11]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	HUS	O	['N']	[3]
4	:	O	['N']	[4]
5	an	O	['N']	[5]
6	unusual	O	['N']	[6]
7	cause	O	['N']	[7]
8	of	O	['N']	[8]
9	acute	B	['N']	[9]
10	renal	I	['N']	[10]
11	failure	I-Adverse_Effect	['N']	[11]
12	in	O	['N']	[12]
13	nephrotic	O	['N']	[13]
14	syndrome	O	['N']	[14]
15	.	O	['N']	[15]
#1098
0	Recent	O	['N']	[0]
1	studies	O	['N']	[1]
2	have	O	['N']	[2]
3	shown	O	['N']	[3]
4	that	O	['N']	[4]
5	under	O	['N']	[5]
6	experimental	O	['N']	[6]
7	conditions	O	['N']	[7]
8	ferrous	B	['N']	[8]
9	sulfate	I-Drug	['Causes']	[19]
10	may	O	['N']	[10]
11	reduce	B	['N']	[11]
12	the	I	['N']	[12]
13	gastrointestinal	I	['N']	[13]
14	absorption	I	['N']	[14]
15	of	I	['N']	[15]
16	orally	I	['N']	[16]
17	administered	I	['N']	[17]
18	levothyroxine	I	['N']	[18]
19	sodium	I-Adverse_Effect	['N']	[19]
20	in	O	['N']	[20]
21	patients	O	['N']	[21]
22	with	O	['N']	[22]
23	primary	O	['N']	[23]
24	hypothyroidism	O	['N']	[24]
25	.	O	['N']	[25]
#1099
0	Vision	B	['N']	[0]
1	declined	I-Adverse_Effect	['N']	[1]
2	after	O	['N']	[2]
3	treatment	O	['N']	[3]
4	with	O	['N']	[4]
5	methylprednisolone	B-Drug	['Causes']	[1]
6	,	O	['N']	[6]
7	after	O	['N']	[7]
8	which	O	['N']	[8]
9	fundus	O	['N']	[9]
10	examination	O	['N']	[10]
11	became	O	['N']	[11]
12	consistent	O	['N']	[12]
13	with	O	['N']	[13]
14	progressive	O	['N']	[14]
15	outer	O	['N']	[15]
16	retinal	O	['N']	[16]
17	necrosis	O	['N']	[17]
18	.	O	['N']	[18]
#1100
0	In	O	['N']	[0]
1	keeping	O	['N']	[1]
2	with	O	['N']	[2]
3	findings	O	['N']	[3]
4	in	O	['N']	[4]
5	the	O	['N']	[5]
6	literature	O	['N']	[6]
7	,	O	['N']	[7]
8	the	O	['N']	[8]
9	aortic	B	['N']	[9]
10	wall	I	['N']	[10]
11	in	I	['N']	[11]
12	this	I	['N']	[12]
13	case	I	['N']	[13]
14	was	I	['N']	[14]
15	damaged	I-Adverse_Effect	['N']	[15]
16	by	O	['N']	[16]
17	secondary	O	['N']	[17]
18	changes	O	['N']	[18]
19	following	O	['N']	[19]
20	irradiation	O	['N']	[20]
21	and	O	['N']	[21]
22	Bleomycin	B-Drug	['Causes']	[15]
23	treatment	O	['N']	[23]
24	.	O	['N']	[24]
#1101
0	Ocular	B	['N']	[0]
1	hypertension	I-Adverse_Effect	['N']	[1]
2	occurred	O	['N']	[2]
3	1	O	['N']	[3]
4	month	O	['N']	[4]
5	after	O	['N']	[5]
6	the	O	['N']	[6]
7	second	O	['N']	[7]
8	ranibizumab	B-Drug	['Causes']	[1]
9	injection	O	['N']	[9]
10	in	O	['N']	[10]
11	patients	O	['N']	[11]
12	1	O	['N']	[12]
13	and	O	['N']	[13]
14	3	O	['N']	[14]
15	,	O	['N']	[15]
16	and	O	['N']	[16]
17	1	O	['N']	[17]
18	month	O	['N']	[18]
19	after	O	['N']	[19]
20	the	O	['N']	[20]
21	first	O	['N']	[21]
22	ranibizumab	O	['N']	[22]
23	in	O	['N']	[23]
24	patient	O	['N']	[24]
25	2	O	['N']	[25]
26	.	O	['N']	[26]
#1102
0	A	O	['N']	[0]
1	16-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	boy	O	['N']	[4]
5	developed	O	['N']	[5]
6	fever	O	['N']	[6]
7	,	O	['N']	[7]
8	generalized	O	['N']	[8]
9	rigidity	O	['N']	[9]
10	,	O	['N']	[10]
11	leukocytosis	B-Adverse_Effect	['N']	[11]
12	,	O	['N']	[12]
13	and	O	['N']	[13]
14	increased	O	['N']	[14]
15	serum	O	['N']	[15]
16	transaminase	O	['N']	[16]
17	and	O	['N']	[17]
18	creatine	O	['N']	[18]
19	kinase	O	['N']	[19]
20	levels	O	['N']	[20]
21	while	O	['N']	[21]
22	receiving	O	['N']	[22]
23	treatment	O	['N']	[23]
24	with	O	['N']	[24]
25	olanzapine	B-Drug	['Causes']	[11]
26	and	O	['N']	[26]
27	lithium	O	['N']	[27]
28	.	O	['N']	[28]
#1103
0	Five	O	['N']	[0]
1	and	O	['N']	[1]
2	one	O	['N']	[2]
3	-	O	['N']	[3]
4	half	O	['N']	[4]
5	years	O	['N']	[5]
6	after	O	['N']	[6]
7	the	O	['N']	[7]
8	diagnosis	O	['N']	[8]
9	of	O	['N']	[9]
10	myeloma	O	['N']	[10]
11	,	O	['N']	[11]
12	while	O	['N']	[12]
13	in	O	['N']	[13]
14	remission	O	['N']	[14]
15	on	O	['N']	[15]
16	cyclophosphamide	B-Drug	['Causes']	[33]
17	therapy	O	['N']	[17]
18	,	O	['N']	[18]
19	the	O	['N']	[19]
20	patient	O	['N']	[20]
21	experienced	O	['N']	[21]
22	severe	O	['N']	[22]
23	abdominal	O	['N']	[23]
24	right	O	['N']	[24]
25	lower	O	['N']	[25]
26	quadrant	O	['N']	[26]
27	pain	O	['N']	[27]
28	due	O	['N']	[28]
29	to	O	['N']	[29]
30	a	O	['N']	[30]
31	large	O	['N']	[31]
32	cecal	B	['N']	[32]
33	lymphoma	I-Adverse_Effect	['N']	[33]
34	.	O	['N']	[34]
#1104
0	After	O	['N']	[0]
1	the	O	['N']	[1]
2	patient	O	['N']	[2]
3	discontinued	O	['N']	[3]
4	rifampicin	B-Drug	['Causes']	[8]
5	,	O	['N']	[5]
6	the	O	['N']	[6]
7	skin	B	['N']	[7]
8	lesions	I-Adverse_Effect	['N']	[8]
9	cleared	O	['N']	[9]
10	completely	O	['N']	[10]
11	within	O	['N']	[11]
12	5	O	['N']	[12]
13	weeks	O	['N']	[13]
14	without	O	['N']	[14]
15	any	O	['N']	[15]
16	systemic	O	['N']	[16]
17	medication	O	['N']	[17]
18	.	O	['N']	[18]
#1105
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	intrathecal	O	['N']	[5]
6	methotrexate	B-Drug	['Causes']	[14]
7	neurotoxicity	O	['N']	[7]
8	manifesting	O	['N']	[8]
9	as	O	['N']	[9]
10	left	O	['N']	[10]
11	arm	O	['N']	[11]
12	weakness	O	['N']	[12]
13	and	O	['N']	[13]
14	aphasia	B-Adverse_Effect	['N']	[14]
15	.	O	['N']	[15]
#1106
0	Growth	O	['N']	[0]
1	and	O	['N']	[1]
2	adrenal	O	['N']	[2]
3	suppression	O	['N']	[3]
4	in	O	['N']	[4]
5	asthmatic	O	['N']	[5]
6	children	O	['N']	[6]
7	treated	O	['N']	[7]
8	with	O	['N']	[8]
9	high	B-Dose	['N']	[9]
10	-	O	['N']	[10]
11	dose	O	['N']	[11]
12	fluticasone	B	['N']	[12]
13	propionate	I-Drug	['Dosage']	[9]
14	.	O	['N']	[14]
